

**Dossier zur Nutzenbewertung
gemäß § 35a SGB V**

Loncastuximab tesirin (Zynlonta®)

Swedish Orphan Biovitrum GmbH

Anhang 4-G2

3. Datenschnitt vom 01.03.2021

Stand: 12.05.2023

Inhaltsverzeichnis

1	Endpunktkategorie: Mortalität.....	13
1.1	Subgruppenanalysen zum Gesamtüberleben (OS).....	13
1.1.1	Merkmal Alter.....	13
1.1.2	Merkmal: Geschlecht.....	16
1.1.3	Merkmal: Ethnie.....	18
1.1.4	Merkmal: Region-1.....	20
1.1.5	Merkmal: Region-2.....	23
1.1.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	25
1.1.7	Merkmal: Bulky Erkrankung.....	29
1.1.8	Merkmal: Double/Triple-Hit.....	30
1.1.9	Merkmal: Transformation des DLBCL.....	32
1.1.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	34
1.1.11	Merkmal: Maximaler längster Durchmesser.....	36
1.1.12	Merkmal: Primärdiagnose.....	40
1.1.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	42
1.1.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie.....	45
1.1.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	47
1.1.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie.....	49
1.1.17	Merkmal: Vorherige CAR-T-Therapie.....	51
1.1.18	Merkmal: Arzneimittelformulierung.....	53
2	Endpunktkategorie: Morbidität.....	55
2.1	Subgruppenanalysen zum Ansprechen – Gesamtansprechrage.....	55
2.1.1	Merkmal Alter.....	55
2.1.2	Merkmal: Geschlecht.....	58
2.1.3	Merkmal: Ethnie.....	60
2.1.4	Merkmal: Region-1.....	62
2.1.5	Merkmal: Region-2.....	65
2.1.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	67
2.1.7	Merkmal: Bulky Erkrankung.....	71
2.1.8	Merkmal: Double/Triple-Hit.....	72
2.1.9	Merkmal: Transformation des DLBCL.....	74
2.1.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	76
2.1.11	Merkmal: Maximaler längster Durchmesser.....	78
2.1.12	Merkmal: Primärdiagnose.....	82
2.1.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	84
2.1.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie.....	87
2.1.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	89
2.1.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie.....	91
2.1.17	Merkmal: Vorherige CAR-T-Therapie.....	93
2.1.18	Merkmal: Arzneimittelformulierung.....	95
2.2	Subgruppenanalysen zum Ansprechen – Vollständige Ansprechrage.....	97
2.2.1	Merkmal Alter.....	97
2.2.2	Merkmal: Geschlecht.....	100
2.2.3	Merkmal: Ethnie.....	102
2.2.4	Merkmal: Region-1.....	104
2.2.5	Merkmal: Region-2.....	107
2.2.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	109
2.2.7	Merkmal: Bulky Erkrankung.....	113
2.2.8	Merkmal: Double/Triple-Hit.....	114
2.2.9	Merkmal: Transformation des DLBCL.....	116
2.2.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	118
2.2.11	Merkmal: Maximaler längster Durchmesser.....	120
2.2.12	Merkmal: Primärdiagnose.....	124
2.2.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	126
2.2.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie.....	129
2.2.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	131
2.2.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie.....	133
2.2.17	Merkmal: Vorherige CAR-T-Therapie.....	135
2.2.18	Merkmal: Arzneimittelformulierung.....	137
2.3	Subgruppenanalysen zum Ansprechen – Dauer des Ansprechens.....	139
2.3.1	Merkmal Alter.....	139

2.3.2	Merkmal: Geschlecht.....	142
2.3.3	Merkmal: Ethnie.....	144
2.3.4	Merkmal: Region-1	146
2.3.5	Merkmal: Region-2	149
2.3.6	Merkmal: Krankheitsstadium nach Ann-Arbor	151
2.3.7	Merkmal: Bulky Erkrankung.....	155
2.3.8	Merkmal: Double/Triple-Hit	156
2.3.9	Merkmal: Transformation des DLBCL	158
2.3.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	160
2.3.11	Merkmal: Maximaler längster Durchmesser	162
2.3.12	Merkmal: Primärdiagnose.....	166
2.3.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	168
2.3.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	171
2.3.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	173
2.3.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	175
2.3.17	Merkmal: Vorherige CAR-T-Therapie	177
2.3.18	Merkmal: Arzneimittelformulierung.....	179
2.4	Subgruppenanalysen zum progressionsfreien Überleben	181
2.4.1	Merkmal Alter	181
2.4.2	Merkmal: Geschlecht.....	184
2.4.3	Merkmal: Ethnie.....	186
2.4.4	Merkmal: Region-1	188
2.4.5	Merkmal: Region-2	191
2.4.6	Merkmal: Krankheitsstadium nach Ann-Arbor	193
2.4.7	Merkmal: Bulky Erkrankung.....	197
2.4.8	Merkmal: Double/Triple-Hit	198
2.4.9	Merkmal: Transformation des DLBCL	200
2.4.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	202
2.4.11	Merkmal: Maximaler längster Durchmesser	204
2.4.12	Merkmal: Primärdiagnose.....	208
2.4.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	210
2.4.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	213
2.4.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	215
2.4.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	217
2.4.17	Merkmal: Vorherige CAR-T-Therapie	219
2.4.18	Merkmal: Arzneimittelformulierung.....	221
2.5	Subgruppenanalysen zum rezidivfreien Überleben.....	223
2.5.1	Merkmal Alter.....	223
2.5.2	Merkmal: Geschlecht.....	226
2.5.3	Merkmal: Ethnie.....	228
2.5.4	Merkmal: Region-1	230
2.5.5	Merkmal: Region-2	233
2.5.6	Merkmal: Krankheitsstadium nach Ann-Arbor	235
2.5.7	Merkmal: Bulky Erkrankung.....	239
2.5.8	Merkmal: Double/Triple-Hit	240
2.5.9	Merkmal: Transformation des DLBCL	242
2.5.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	244
2.5.11	Merkmal: Maximaler längster Durchmesser	246
2.5.12	Merkmal: Primärdiagnose.....	250
2.5.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	252
2.5.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	255
2.5.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	257
2.5.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	259
2.5.17	Merkmal: Vorherige CAR-T-Therapie	261
2.5.18	Merkmal: Arzneimittelformulierung.....	263
2.6	Subgruppenanalysen zum EQ-5D VAS (Zeit bis zur Verschlechterung)	265
2.6.1	Merkmal Alter.....	265
2.6.2	Merkmal: Geschlecht.....	268
2.6.3	Merkmal: Ethnie.....	270
2.6.4	Merkmal: Region-1	272
2.6.5	Merkmal: Region-2	275
2.6.6	Merkmal: Krankheitsstadium nach Ann-Arbor	277
2.6.7	Merkmal: Bulky Erkrankung.....	281

2.6.8	Merkmal: Double/Triple-Hit	282
2.6.9	Merkmal: Transformation des DLBCL	284
2.6.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	286
2.6.11	Merkmal: Maximaler längster Durchmesser	288
2.6.12	Merkmal: Primärdiagnose	292
2.6.13	Merkmal: Anzahl der vorherigen systemischen Therapien	294
2.6.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	297
2.6.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	299
2.6.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	301
2.6.17	Merkmal: Vorherige CAR-T-Therapie	303
2.6.18	Merkmal: Arzneimittelformulierung	305
2.7	Subgruppenanalysen zum EQ-5D VAS (Veränderung gegenüber Studienbeginn)	307
2.7.1	Merkmal Alter	307
2.7.2	Merkmal: Geschlecht	323
2.7.3	Merkmal: Ethnie	333
2.7.4	Merkmal: Region-1	343
2.7.5	Merkmal: Region-2	358
2.7.6	Merkmal: Krankheitsstadium nach Ann-Arbor	368
2.7.7	Merkmal: Bulky Erkrankung	387
2.7.8	Merkmal: Double/Triple-Hit	394
2.7.9	Merkmal: Transformation des DLBCL	404
2.7.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	416
2.7.11	Merkmal: Maximaler längster Durchmesser	424
2.7.12	Merkmal: Primärdiagnose	439
2.7.13	Merkmal: Anzahl der vorherigen systemischen Therapien	449
2.7.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	462
2.7.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	474
2.7.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	486
2.7.17	Merkmal: Vorherige CAR-T-Therapie	498
2.7.18	Merkmal: Arzneimittelformulierung	508
3	Endpunktkategorie: Gesundheitsbezogene Lebensqualität	518
3.1	Subgruppenanalysen zum FACT-Lym – körperliches Wohlbefinden (Zeit bis zur Verschlechterung)	518
3.1.1	Merkmal Alter	518
3.1.2	Merkmal: Geschlecht	521
3.1.3	Merkmal: Ethnie	523
3.1.4	Merkmal: Region-1	525
3.1.5	Merkmal: Region-2	528
3.1.6	Merkmal: Krankheitsstadium nach Ann-Arbor	530
3.1.7	Merkmal: Bulky Erkrankung	534
3.1.8	Merkmal: Double/Triple-Hit	535
3.1.9	Merkmal: Transformation des DLBCL	537
3.1.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	539
3.1.11	Merkmal: Maximaler längster Durchmesser	541
3.1.12	Merkmal: Primärdiagnose	545
3.1.13	Merkmal: Anzahl der vorherigen systemischen Therapien	547
3.1.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	550
3.1.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	552
3.1.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	554
3.1.17	Merkmal: Vorherige CAR-T-Therapie	556
3.1.18	Merkmal: Arzneimittelformulierung	558
3.2	Subgruppenanalysen zum FACT-Lym – körperliches Wohlbefinden (Veränderung gegenüber Studienbeginn)	560
3.2.1	Merkmal Alter	560
3.2.2	Merkmal: Geschlecht	576
3.2.3	Merkmal: Ethnie	586
3.2.4	Merkmal: Region-1	596
3.2.5	Merkmal: Region-2	611
3.2.6	Merkmal: Krankheitsstadium nach Ann-Arbor	621
3.2.7	Merkmal: Bulky Erkrankung	640
3.2.8	Merkmal: Double/Triple-Hit	647
3.2.9	Merkmal: Transformation des DLBCL	657
3.2.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	669
3.2.11	Merkmal: Maximaler längster Durchmesser	677
3.2.12	Merkmal: Primärdiagnose	692

3.2.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	702
3.2.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	715
3.2.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	727
3.2.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	739
3.2.17	Merkmal: Vorherige CAR-T-Therapie	751
3.2.18	Merkmal: Arzneimittelformulierung.....	761
3.3	Subgruppenanalysen zum FACT-Lym – soziales/familiäres Wohlbefinden (Zeit bis zur Verschlechterung)	771
3.3.1	Merkmal Alter	771
3.3.2	Merkmal: Geschlecht.....	774
3.3.3	Merkmal: Ethnie.....	776
3.3.4	Merkmal: Region-1	778
3.3.5	Merkmal: Region-2	781
3.3.6	Merkmal: Krankheitsstadium nach Ann-Arbor	783
3.3.7	Merkmal: Bulky Erkrankung.....	787
3.3.8	Merkmal: Double/Triple-Hit	788
3.3.9	Merkmal: Transformation des DLBCL	790
3.3.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	792
3.3.11	Merkmal: Maximaler längster Durchmesser.....	794
3.3.12	Merkmal: Primärdiagnose.....	798
3.3.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	800
3.3.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	803
3.3.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	805
3.3.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	807
3.3.17	Merkmal: Vorherige CAR-T-Therapie	809
3.3.18	Merkmal: Arzneimittelformulierung.....	811
3.4	Subgruppenanalysen zum FACT-Lym – soziales/familiäres Wohlbefinden (Veränderung gegenüber Studienbeginn) 813	
3.4.1	Merkmal Alter.....	813
3.4.2	Merkmal: Geschlecht.....	829
3.4.3	Merkmal: Ethnie.....	839
3.4.4	Merkmal: Region-1	849
3.4.5	Merkmal: Region-2	864
3.4.6	Merkmal: Krankheitsstadium nach Ann-Arbor	874
3.4.7	Merkmal: Bulky Erkrankung.....	893
3.4.8	Merkmal: Double/Triple-Hit	900
3.4.9	Merkmal: Transformation des DLBCL	910
3.4.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	922
3.4.11	Merkmal: Maximaler längster Durchmesser.....	930
3.4.12	Merkmal: Primärdiagnose.....	945
3.4.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	955
3.4.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	968
3.4.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	980
3.4.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	992
3.4.17	Merkmal: Vorherige CAR-T-Therapie	1004
3.4.18	Merkmal: Arzneimittelformulierung.....	1014
3.5	Subgruppenanalysen zum FACT-Lym – emotionales Wohlbefinden (Zeit bis zur Verschlechterung).....	1024
3.5.1	Merkmal Alter.....	1024
3.5.2	Merkmal: Geschlecht.....	1027
3.5.3	Merkmal: Ethnie.....	1029
3.5.4	Merkmal: Region-1	1031
3.5.5	Merkmal: Region-2	1034
3.5.6	Merkmal: Krankheitsstadium nach Ann-Arbor	1036
3.5.7	Merkmal: Bulky Erkrankung.....	1040
3.5.8	Merkmal: Double/Triple-Hit	1041
3.5.9	Merkmal: Transformation des DLBCL	1043
3.5.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen.....	1045
3.5.11	Merkmal: Maximaler längster Durchmesser.....	1047
3.5.12	Merkmal: Primärdiagnose.....	1051
3.5.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	1053
3.5.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1056
3.5.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	1058
3.5.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1060
3.5.17	Merkmal: Vorherige CAR-T-Therapie	1062

3.5.18	Merkmal: Arzneimittelformulierung.....	1064
3.6	Subgruppenanalysen zum FACT-Lym – emotionales Wohlbefinden (Veränderung gegenüber Studienbeginn)...	1066
3.6.1	Merkmal Alter	1066
3.6.2	Merkmal: Geschlecht.....	1081
3.6.3	Merkmal: Ethnie.....	1091
3.6.4	Merkmal: Region-1	1101
3.6.5	Merkmal: Region-2	1115
3.6.6	Merkmal: Krankheitsstadium nach Ann-Arbor	1125
3.6.7	Merkmal: Bulky Erkrankung.....	1143
3.6.8	Merkmal: Double/Triple-Hit	1150
3.6.9	Merkmal: Transformation des DLBCL	1160
3.6.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1171
3.6.11	Merkmal: Maximaler längster Durchmesser	1179
3.6.12	Merkmal: Primärdiagnose.....	1194
3.6.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	1204
3.6.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1217
3.6.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	1228
3.6.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1239
3.6.17	Merkmal: Vorherige CAR-T-Therapie	1250
3.6.18	Merkmal: Arzneimittelformulierung.....	1260
3.7	Subgruppenanalysen zum FACT-Lym – funktionelles Wohlbefinden (Zeit bis zur Verschlechterung)	1270
3.7.1	Merkmal Alter	1270
3.7.2	Merkmal: Geschlecht.....	1273
3.7.3	Merkmal: Ethnie.....	1275
3.7.4	Merkmal: Region-1	1277
3.7.5	Merkmal: Region-2	1280
3.7.6	Merkmal: Krankheitsstadium nach Ann-Arbor	1282
3.7.7	Merkmal: Bulky Erkrankung.....	1286
3.7.8	Merkmal: Double/Triple-Hit	1287
3.7.9	Merkmal: Transformation des DLBCL	1289
3.7.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1291
3.7.11	Merkmal: Maximaler längster Durchmesser	1293
3.7.12	Merkmal: Primärdiagnose.....	1297
3.7.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	1299
3.7.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1302
3.7.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	1304
3.7.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1306
3.7.17	Merkmal: Vorherige CAR-T-Therapie	1308
3.7.18	Merkmal: Arzneimittelformulierung.....	1310
3.8	Subgruppenanalysen zum FACT-Lym – funktionelles Wohlbefinden (Veränderung gegenüber Studienbeginn)	1312
3.8.1	Merkmal Alter	1312
3.8.2	Merkmal: Geschlecht.....	1327
3.8.3	Merkmal: Ethnie.....	1337
3.8.4	Merkmal: Region-1	1347
3.8.5	Merkmal: Region-2	1361
3.8.6	Merkmal: Krankheitsstadium nach Ann-Arbor	1371
3.8.7	Merkmal: Bulky Erkrankung.....	1389
3.8.8	Merkmal: Double/Triple-Hit	1396
3.8.9	Merkmal: Transformation des DLBCL	1406
3.8.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1417
3.8.11	Merkmal: Maximaler längster Durchmesser	1425
3.8.12	Merkmal: Primärdiagnose.....	1440
3.8.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	1450
3.8.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1463
3.8.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	1474
3.8.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1485
3.8.17	Merkmal: Vorherige CAR-T-Therapie	1496
3.8.18	Merkmal: Arzneimittelformulierung.....	1506
3.9	Subgruppenanalysen zum FACT-Lym – Lymphom Subskala (Zeit bis zur Verschlechterung).....	1516
3.9.1	Merkmal Alter	1516
3.9.2	Merkmal: Geschlecht.....	1519
3.9.3	Merkmal: Ethnie.....	1521
3.9.4	Merkmal: Region-1	1523

3.9.5	Merkmal: Region-2	1526
3.9.6	Merkmal: Krankheitsstadium nach Ann-Arbor	1528
3.9.7	Merkmal: Bulky Erkrankung	1532
3.9.8	Merkmal: Double/Triple-Hit	1533
3.9.9	Merkmal: Transformation des DLBCL	1535
3.9.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1537
3.9.11	Merkmal: Maximaler längster Durchmesser	1539
3.9.12	Merkmal: Primärdiagnose	1543
3.9.13	Merkmal: Anzahl der vorherigen systemischen Therapien	1545
3.9.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1548
3.9.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	1550
3.9.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1552
3.9.17	Merkmal: Vorherige CAR-T-Therapie	1554
3.9.18	Merkmal: Arzneimittelformulierung	1556
3.10	Subgruppenanalysen zum FACT-Lym – Lymphom Subskala (Veränderung gegenüber Studienbeginn).....	1558
3.10.1	Merkmal Alter	1558
3.10.2	Merkmal: Geschlecht	1573
3.10.3	Merkmal: Ethnie	1582
3.10.4	Merkmal: Region-1	1591
3.10.5	Merkmal: Region-2	1605
3.10.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	1614
3.10.7	Merkmal: Bulky Erkrankung	1632
3.10.8	Merkmal: Double/Triple-Hit.....	1638
3.10.9	Merkmal: Transformation des DLBCL.....	1647
3.10.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1658
3.10.11	Merkmal: Maximaler längster Durchmesser	1666
3.10.12	Merkmal: Primärdiagnose	1680
3.10.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	1689
3.10.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1701
3.10.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	1712
3.10.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1723
3.10.17	Merkmal: Vorherige CAR-T-Therapie	1734
3.10.18	Merkmal: Arzneimittelformulierung.....	1743
3.11	Subgruppenanalysen zum FACT-Lym – TOI (Zeit bis zur Verschlechterung)	1752
3.11.1	Merkmal Alter.....	1752
3.11.2	Merkmal: Geschlecht	1755
3.11.3	Merkmal: Ethnie	1757
3.11.4	Merkmal: Region-1	1766
3.11.5	Merkmal: Region-2	1769
3.11.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	1771
3.11.7	Merkmal: Bulky Erkrankung	1775
3.11.8	Merkmal: Double/Triple-Hit.....	1776
3.11.9	Merkmal: Transformation des DLBCL.....	1778
3.11.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1780
3.11.11	Merkmal: Maximaler längster Durchmesser	1782
3.11.12	Merkmal: Primärdiagnose.....	1786
3.11.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	1788
3.11.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1791
3.11.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	1793
3.11.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1795
3.11.17	Merkmal: Vorherige CAR-T-Therapie	1797
3.11.18	Merkmal: Arzneimittelformulierung.....	1799
3.12	Subgruppenanalysen zum FACT-Lym – TOI (Veränderung gegenüber Studienbeginn).....	1801
3.12.1	Merkmal Alter.....	1801
3.12.2	Merkmal: Geschlecht	1816
3.12.3	Merkmal: Ethnie	1825
3.12.4	Merkmal: Region-1	1834
3.12.5	Merkmal: Region-2	1848
3.12.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	1857
3.12.7	Merkmal: Bulky Erkrankung	1875
3.12.8	Merkmal: Double/Triple-Hit.....	1881
3.12.9	Merkmal: Transformation des DLBCL.....	1890
3.12.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	1901

3.12.11	Merkmal: Maximaler längster Durchmesser	1909
3.12.12	Merkmal: Primärdiagnose	1923
3.12.13	Merkmal: Anzahl der vorherigen systemischen Therapien	1932
3.12.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	1944
3.12.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	1955
3.12.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	1966
3.12.17	Merkmal: Vorherige CAR-T-Therapie	1977
3.12.18	Merkmal: Arzneimittelformulierung	1986
3.13	Subgruppenanalysen zum FACT-Lym – FACT-G Gesamtscore (Zeit bis zur Verschlechterung).....	1995
3.13.1	Merkmal Alter	1995
3.13.2	Merkmal: Geschlecht	1998
3.13.3	Merkmal: Ethnie	2000
3.13.4	Merkmal: Region-1	2002
3.13.5	Merkmal: Region-2	2005
3.13.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	2007
3.13.7	Merkmal: Bulky Erkrankung	2011
3.13.8	Merkmal: Double/Triple-Hit.....	2012
3.13.9	Merkmal: Transformation des DLBCL.....	2014
3.13.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2016
3.13.11	Merkmal: Maximaler längster Durchmesser	2018
3.13.12	Merkmal: Primärdiagnose	2022
3.13.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	2024
3.13.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2027
3.13.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	2029
3.13.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2031
3.13.17	Merkmal: Vorherige CAR-T-Therapie	2033
3.13.18	Merkmal: Arzneimittelformulierung.....	2035
3.14	Subgruppenanalysen zum FACT-Lym – FACT-G Gesamtscore (Veränderung gegenüber Studienbeginn).....	2037
3.14.1	Merkmal Alter	2037
3.14.2	Merkmal: Geschlecht	2052
3.14.3	Merkmal: Ethnie	2062
3.14.4	Merkmal: Region-1	2072
3.14.5	Merkmal: Region-2	2086
3.14.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	2096
3.14.7	Merkmal: Bulky Erkrankung	2113
3.14.8	Merkmal: Double/Triple-Hit.....	2120
3.14.9	Merkmal: Transformation des DLBCL.....	2130
3.14.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2141
3.14.11	Merkmal: Maximaler längster Durchmesser	2148
3.14.12	Merkmal: Primärdiagnose	2163
3.14.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	2173
3.14.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2186
3.14.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	2197
3.14.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2208
3.14.17	Merkmal: Vorherige CAR-T-Therapie	2219
3.14.18	Merkmal: Arzneimittelformulierung.....	2229
3.15	Subgruppenanalysen zum FACT-Lym – Gesamtscore (Zeit bis zur Verschlechterung)	2239
3.15.1	Merkmal Alter	2239
3.15.2	Merkmal: Geschlecht	2242
3.15.3	Merkmal: Ethnie	2244
3.15.4	Merkmal: Region-1	2246
3.15.5	Merkmal: Region-2	2249
3.15.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	2251
3.15.7	Merkmal: Bulky Erkrankung	2255
3.15.8	Merkmal: Double/Triple-Hit.....	2256
3.15.9	Merkmal: Transformation des DLBCL.....	2258
3.15.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2260
3.15.11	Merkmal: Maximaler längster Durchmesser	2262
3.15.12	Merkmal: Primärdiagnose	2266
3.15.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	2268
3.15.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2271
3.15.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	2273
3.15.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2275

3.15.17	Merkmal: Vorherige CAR-T-Therapie	2277
3.15.18	Merkmal: Arzneimittelformulierung	2279
3.16	Subgruppenanalysen zum FACT-Lym – Gesamtscore (Veränderung gegenüber Studienbeginn)	2281
3.16.1	Merkmal Alter	2281
3.16.2	Merkmal: Geschlecht	2296
3.16.3	Merkmal: Ethnie	2305
3.16.4	Merkmal: Region-1	2314
3.16.5	Merkmal: Region-2	2328
3.16.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2337
3.16.7	Merkmal: Bulky Erkrankung	2355
3.16.8	Merkmal: Double/Triple-Hit	2361
3.16.9	Merkmal: Transformation des DLBCL	2370
3.16.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2381
3.16.11	Merkmal: Maximaler längster Durchmesser	2389
3.16.12	Merkmal: Primärdiagnose	2403
3.16.13	Merkmal: Anzahl der vorherigen systemischen Therapien	2412
3.16.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2424
3.16.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	2435
3.16.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2446
3.16.17	Merkmal: Vorherige CAR-T-Therapie	2457
3.16.18	Merkmal: Arzneimittelformulierung	2466
4	Endpunktkategorie: Sicherheit	2475
4.1	Subgruppenanalysen zu den UE	2475
4.1.1	Merkmal Alter	2475
4.1.2	Merkmal: Geschlecht	2478
4.1.3	Merkmal: Ethnie	2480
4.1.4	Merkmal: Region-1	2482
4.1.5	Merkmal: Region-2	2485
4.1.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2487
4.1.7	Merkmal: Bulky Erkrankung	2491
4.1.8	Merkmal: Double/Triple-Hit	2492
4.1.9	Merkmal: Transformation des DLBCL	2494
4.1.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2496
4.1.11	Merkmal: Maximaler längster Durchmesser	2498
4.1.12	Merkmal: Primärdiagnose	2502
4.1.13	Merkmal: Anzahl der vorherigen systemischen Therapien	2504
4.1.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2507
4.1.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	2509
4.1.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2511
4.1.17	Merkmal: Vorherige CAR-T-Therapie	2513
4.1.18	Merkmal: Arzneimittelformulierung	2515
4.2	Subgruppenanalysen zu den nicht schweren UE	2517
4.2.1	Merkmal Alter	2517
4.2.2	Merkmal: Geschlecht	2520
4.2.3	Merkmal: Ethnie	2522
4.2.4	Merkmal: Region-1	2524
4.2.5	Merkmal: Region-2	2527
4.2.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2529
4.2.7	Merkmal: Bulky Erkrankung	2533
4.2.8	Merkmal: Double/Triple-Hit	2534
4.2.9	Merkmal: Transformation des DLBCL	2536
4.2.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2538
4.2.11	Merkmal: Maximaler längster Durchmesser	2540
4.2.12	Merkmal: Primärdiagnose	2544
4.2.13	Merkmal: Anzahl der vorherigen systemischen Therapien	2546
4.2.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2549
4.2.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	2551
4.2.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2553
4.2.17	Merkmal: Vorherige CAR-T-Therapie	2555
4.2.18	Merkmal: Arzneimittelformulierung	2557
4.3	Subgruppenanalysen zu den schweren UE	2559
4.3.1	Merkmal Alter	2559
4.3.2	Merkmal: Geschlecht	2562

4.3.3	Merkmal: Ethnie.....	2564
4.3.4	Merkmal: Region-1	2566
4.3.5	Merkmal: Region-2	2569
4.3.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2571
4.3.7	Merkmal: Bulky Erkrankung.....	2575
4.3.8	Merkmal: Double/Triple-Hit	2576
4.3.9	Merkmal: Transformation des DLBCL	2578
4.3.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2580
4.3.11	Merkmal: Maximaler längster Durchmesser	2582
4.3.12	Merkmal: Primärdiagnose	2586
4.3.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	2588
4.3.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2591
4.3.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	2593
4.3.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2595
4.3.17	Merkmal: Vorherige CAR-T-Therapie	2597
4.3.18	Merkmal: Arzneimittelformulierung.....	2599
4.4	Subgruppenanalysen zu den schwerwiegenden UE	2601
4.4.1	Merkmal Alter	2601
4.4.2	Merkmal: Geschlecht.....	2604
4.4.3	Merkmal: Ethnie.....	2606
4.4.4	Merkmal: Region-1	2608
4.4.5	Merkmal: Region-2	2611
4.4.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2613
4.4.7	Merkmal: Bulky Erkrankung.....	2617
4.4.8	Merkmal: Double/Triple-Hit	2618
4.4.9	Merkmal: Transformation des DLBCL	2620
4.4.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2622
4.4.11	Merkmal: Maximaler längster Durchmesser	2624
4.4.12	Merkmal: Primärdiagnose	2628
4.4.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	2630
4.4.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2633
4.4.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	2635
4.4.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2637
4.4.17	Merkmal: Vorherige CAR-T-Therapie	2639
4.4.18	Merkmal: Arzneimittelformulierung.....	2641
4.5	Subgruppenanalysen zu den Abbrüchen der Studienmedikation aufgrund von UE	2643
4.5.1	Merkmal Alter	2643
4.5.2	Merkmal: Geschlecht.....	2646
4.5.3	Merkmal: Ethnie.....	2648
4.5.4	Merkmal: Region-1	2650
4.5.5	Merkmal: Region-2	2653
4.5.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2655
4.5.7	Merkmal: Bulky Erkrankung.....	2659
4.5.8	Merkmal: Double/Triple-Hit	2660
4.5.9	Merkmal: Transformation des DLBCL	2662
4.5.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2664
4.5.11	Merkmal: Maximaler längster Durchmesser	2666
4.5.12	Merkmal: Primärdiagnose	2670
4.5.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	2672
4.5.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2675
4.5.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie.....	2677
4.5.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2679
4.5.17	Merkmal: Vorherige CAR-T-Therapie	2681
4.5.18	Merkmal: Arzneimittelformulierung.....	2683
4.6	Subgruppenanalysen zum AESI – infusionsbedingte Reaktion	2685
4.6.1	Merkmal Alter	2685
4.6.2	Merkmal: Geschlecht.....	2688
4.6.3	Merkmal: Ethnie.....	2690
4.6.4	Merkmal: Region-1	2692
4.6.5	Merkmal: Region-2	2695
4.6.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2697
4.6.7	Merkmal: Bulky Erkrankung.....	2701
4.6.8	Merkmal: Double/Triple-Hit	2702

4.6.9	Merkmal: Transformation des DLBCL	2704
4.6.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2706
4.6.11	Merkmal: Maximaler längster Durchmesser	2708
4.6.12	Merkmal: Primärdiagnose	2712
4.6.13	Merkmal: Anzahl der vorherigen systemischen Therapien	2714
4.6.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2717
4.6.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	2719
4.6.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2721
4.6.17	Merkmal: Vorherige CAR-T-Therapie	2723
4.6.18	Merkmal: Arzneimittelformulierung	2725
4.7	Subgruppenanalysen zum nicht schweren AESI – infusionsbedingte Reaktion	2727
4.7.1	Merkmal Alter	2727
4.7.2	Merkmal: Geschlecht	2730
4.7.3	Merkmal: Ethnie	2732
4.7.4	Merkmal: Region-1	2734
4.7.5	Merkmal: Region-2	2737
4.7.6	Merkmal: Krankheitsstadium nach Ann-Arbor	2739
4.7.7	Merkmal: Bulky Erkrankung	2743
4.7.8	Merkmal: Double/Triple-Hit	2744
4.7.9	Merkmal: Transformation des DLBCL	2746
4.7.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	2748
4.7.11	Merkmal: Maximaler längster Durchmesser	2750
4.7.12	Merkmal: Primärdiagnose	2754
4.7.13	Merkmal: Anzahl der vorherigen systemischen Therapien	2756
4.7.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	2759
4.7.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	2761
4.7.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	2763
4.7.17	Merkmal: Vorherige CAR-T-Therapie	2765
4.7.18	Merkmal: Arzneimittelformulierung	2767
4.8	Subgruppenanalysen zum schweren AESI – infusionsbedingte Reaktion	2769
4.9	Subgruppenanalysen zum schwerwiegenden AESI – infusionsbedingte Reaktion	2770
4.10	Subgruppenanalysen zu den UE nach SOC und PT	2771
4.10.1	Merkmal Alter	2771
4.10.2	Merkmal: Geschlecht	2933
4.10.3	Merkmal: Ethnie	3041
4.10.4	Merkmal: Region-1	3149
4.10.5	Merkmal: Region-2	3311
4.10.6	Merkmal: Krankheitsstadium nach Ann-Arbor	3419
4.10.7	Merkmal: Bulky Erkrankung	3635
4.10.8	Merkmal: Double/Triple-Hit	3689
4.10.9	Merkmal: Transformation des DLBCL	3797
4.10.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	3905
4.10.11	Merkmal: Maximaler längster Durchmesser	4013
4.10.12	Merkmal: Primärdiagnose	4229
4.10.13	Merkmal: Anzahl der vorherigen systemischen Therapien	4337
4.10.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	4499
4.10.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	4607
4.10.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	4715
4.10.17	Merkmal: Vorherige CAR-T-Therapie	4823
4.10.18	Merkmal: Arzneimittelformulierung	4931
4.11	Subgruppenanalysen zum Endpunkt: Schwere unerwünschte Ereignisse nach SOC und PT	5039
4.11.1	Merkmal Alter	5039
4.11.2	Merkmal: Geschlecht	5081
4.11.3	Merkmal: Ethnie	5109
4.11.4	Merkmal: Region-1	5137
4.11.5	Merkmal: Region-2	5179
4.11.6	Merkmal: Krankheitsstadium nach Ann-Arbor	5207
4.11.7	Merkmal: Bulky Erkrankung	5263
4.11.8	Merkmal: Double/Triple-Hit	5277
4.11.9	Merkmal: Transformation des DLBCL	5305
4.11.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	5333
4.11.11	Merkmal: Maximaler längster Durchmesser	5361
4.11.12	Merkmal: Primärdiagnose	5417

4.11.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	5445
4.11.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	5487
4.11.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	5515
4.11.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	5543
4.11.17	Merkmal: Vorherige CAR-T-Therapie	5571
4.11.18	Merkmal: Arzneimittelformulierung.....	5599
4.12	Subgruppenanalysen zum Endpunkt: Schwerwiegende unerwünschte Ereignisse nach SOC und PT	5627
4.12.1	Merkmal Alter.....	5627
4.12.2	Merkmal: Geschlecht	5642
4.12.3	Merkmal: Ethnie	5652
4.12.4	Merkmal: Region-1	5662
4.12.5	Merkmal: Region 2	5677
4.12.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	5687
4.12.7	Merkmal: Bulky Erkrankung	5707
4.12.8	Merkmal: Double/Triple-Hit.....	5712
4.12.9	Merkmal: Transformation des DLBCL.....	5722
4.12.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	5732
4.12.11	Merkmal: Maximaler längster Durchmesser	5742
4.12.12	Merkmal: Primärdiagnose	5762
4.12.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	5772
4.12.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	5787
4.12.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	5797
4.12.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	5807
4.12.17	Merkmal: Vorherige CAR-T-Therapie	5817
4.12.18	Merkmal: Arzneimittelformulierung.....	5827
4.13	Subgruppenanalysen zum FACT-G GP5 (Zeit bis zur Verschlechterung)	5837
4.13.1	Merkmal Alter.....	5837
4.13.2	Merkmal: Geschlecht	5840
4.13.3	Merkmal: Ethnie	5842
4.13.4	Merkmal: Region-1	5844
4.13.5	Merkmal: Region-2	5847
4.13.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	5849
4.13.7	Merkmal: Bulky Erkrankung	5853
4.13.8	Merkmal: Double/Triple-Hit.....	5854
4.13.9	Merkmal: Transformation des DLBCL.....	5856
4.13.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	5858
4.13.11	Merkmal: Maximaler längster Durchmesser	5860
4.13.12	Merkmal: Primärdiagnose	5864
4.13.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	5866
4.13.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	5869
4.13.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	5871
4.13.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	5873
4.13.17	Merkmal: Vorherige CAR-T-Therapie	5875
4.13.18	Merkmal: Arzneimittelformulierung.....	5877
4.14	Subgruppenanalysen zum FACT-G GP5 (Veränderung gegenüber Studienbeginn)	5879
4.14.1	Merkmal Alter.....	5879
4.14.2	Merkmal: Geschlecht	5906
4.14.3	Merkmal: Ethnie	5922
4.14.4	Merkmal: Region-1	5938
4.14.5	Merkmal: Region-2	5964
4.14.6	Merkmal: Krankheitsstadium nach Ann-Arbor.....	5981
4.14.7	Merkmal: Bulky Erkrankung	6013
4.14.8	Merkmal: Double/Triple-Hit.....	6024
4.14.9	Merkmal: Transformation des DLBCL.....	6041
4.14.10	Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen	6061
4.14.11	Merkmal: Maximaler längster Durchmesser	6073
4.14.12	Merkmal: Primärdiagnose.....	6097
4.14.13	Merkmal: Anzahl der vorherigen systemischen Therapien.....	6114
4.14.14	Merkmal: Ansprechategorie auf die vorherige systemische Erstlinientherapie	6136
4.14.15	Merkmal: Ansprechategorie auf die letzte vorherige systemische Therapie	6156
4.14.16	Merkmal: Ansprechategorie auf eine beliebige vorherige systemische Therapie	6176
4.14.17	Merkmal: Vorherige CAR-T-Therapie	6196
4.14.18	Merkmal: Arzneimittelformulierung.....	6212

Table LT3OS_TSTS01: Overall survival by subgroup: Age group
 ITT set

1 Endpunktkategorie: Mortalität

1.1 Subgruppenanalysen zum Gesamtüberleben (OS)

1.1.1 Merkmal Alter

Overall survival by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	43 (66,2)
95%-CI	[53,4-77,4]
Overall survival in months [95%-CI]	
Median	10,58 [6,34-16,20]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [73,0-91,3]
Month 6	65,1 [51,9-75,4]
Month 12	41,5 [29,0-53,5]
Month 18	34,2 [22,5-46,3]
Month 24	27,0 [15,8-39,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS01: Overall survival by subgroup: Age group
 ITT set

Overall survival by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	41 (69,5)
95%-CI	[56,1-80,8]
Overall survival in months [95%-CI]	
Median	7,46[6,14-11,56]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,3 [63,3-85,2]
Month 6	63,9 [50,2-74,8]
Month 12	36,8 [24,4-49,2]
Month 18	30,7 [19,1-43,1]
Month 24	25,1 [14,0-37,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS01: Overall survival by subgroup: Age group
 ITT set

Overall survival by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	12 (57,1)
95%-CI	[34,0-78,2]
Overall survival in months [95%-CI]	
Median	8,08 [4,63-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [60,4-94,9]
Month 6	70,0 [45,1-85,3]
Month 12	37,7 [17,1-58,3]
Month 18	37,7 [17,1-58,3]
Month 24	37,7 [17,1-58,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS02: Overall survival by subgroup: Sex
 ITT set

1.1.2 Merkmal: Geschlecht

Overall survival by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	32 (53,3)
95%-CI	[40,0-66,3]
Overall survival in months [95%-CI]	
Median	11,93[8,08-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [78,9-95,3]
Month 6	75,6 [62,3-84,8]
Month 12	49,5 [35,7-61,8]
Month 18	43,1 [29,6-55,9]
Month 24	40,3 [26,7-53,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS02: Overall survival by subgroup: Sex
 ITT set

Overall survival by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	64 (75,3)
95%-CI	[64,7-84,0]
Overall survival in months [95%-CI]	
Median	6,93[5,42-10,78]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [64,3-82,9]
Month 6	58,1 [46,8-67,8]
Month 12	31,9 [22,1-42,1]
Month 18	26,6 [17,5-36,6]
Month 24	19,9 [11,6-29,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS03: Overall survival by subgroup: Race group
 ITT set

1.1.3 *Merkmal: Ethnie*

Overall survival by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	87 (66,9)
95%-CI	[58,1-74,9]
Overall survival in months [95%-CI]	
Median	8,90 [6,34-10,97]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [71,7-85,7]
Month 6	62,7 [53,7-70,5]
Month 12	36,8 [28,3-45,3]
Month 18	31,4 [23,3-39,9]
Month 24	28,0 [20,1-36,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS03: Overall survival by subgroup: Race group
 ITT set

Overall survival by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	9 (60,0)
95%-CI	[32,3-83,7]
Overall survival in months [95%-CI]	
Median	19,15[6,34-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	86,7 [56,4-96,5]
Month 12	57,8 [29,0-78,4]
Month 18	50,6 [23,3-72,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS04: Overall survival by subgroup: Country
 ITT set

1.1.4 Merkmal: Region-1

Overall survival by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	39 (66,1)
95%-CI	[52,6-77,9]
Overall survival in months [95%-CI]	
Median	9,92 [6,60-14,23]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [72,1-91,5]
Month 6	72,0 [58,4-81,8]
Month 12	39,6 [26,9-52,0]
Month 18	33,8 [21,7-46,2]
Month 24	27,4 [15,4-40,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS04: Overall survival by subgroup: Country
 ITT set

Overall survival by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	20 (64,5)
95%-CI	[45,4-80,8]
Overall survival in months [95%-CI]	
Median	10,97 [5,82-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [61,9-90,8]
Month 6	67,3 [47,7-80,9]
Month 12	40,4 [23,1-57,1]
Month 18	33,3 [17,4-50,1]
Month 24	33,3 [17,4-50,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS04: Overall survival by subgroup: Country
 ITT set

Overall survival by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	35 (66,0)
95%-CI	[51,7-78,5]
Overall survival in months [95%-CI]	
Median	8,90 [4,76-16,43]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,3 [65,7-87,9]
Month 6	57,0 [42,3-69,3]
Month 12	39,3 [25,6-52,8]
Month 18	34,5 [21,3-48,1]
Month 24	25,9 [13,9-39,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS05: Overall survival by subgroup: Region
 ITT set

1.1.5 *Merkmal: Region-2*

Overall survival by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	39 (66,1)
95%-CI	[52,6-77,9]
Overall survival in months [95%-CI]	
Median	9,92 [6,60-14,23]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [72,1-91,5]
Month 6	72,0 [58,4-81,8]
Month 12	39,6 [26,9-52,0]
Month 18	33,8 [21,7-46,2]
Month 24	27,4 [15,4-40,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS05: Overall survival by subgroup: Region
 ITT set

Overall survival by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	57 (66,3)
95%-CI	[55,3-76,1]
Overall survival in months [95%-CI]	
Median	9,46[5,82-11,93]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [68,9-86,3]
Month 6	60,7 [49,3-70,2]
Month 12	38,6 [28,0-49,2]
Month 18	33,1 [22,9-43,6]
Month 24	27,6 [17,8-38,3]

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS06: Overall survival by subgroup: Ann Arbor stage
 ITT set

1.1.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Overall survival by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
Overall survival in months [95%-CI]	
Median	15,87[2,56-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	80,0 [40,9-94,6]
Month 12	57,1 [21,7-81,5]
Month 18	42,9 [11,4-71,9]
Month 24	42,9 [11,4-71,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS06: Overall survival by subgroup: Ann Arbor stage
 ITT set

Overall survival by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	16 (69,6)
95%-CI	[47,1-86,8]
Overall survival in months [95%-CI]	
Median	10,78 [5,09-16,20]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [64,8-95,6]
Month 6	73,2 [49,8-87,0]
Month 12	44,6 [23,4-63,9]
Month 18	29,8 [12,3-49,6]
Month 24	23,8 [8,2-43,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS06: Overall survival by subgroup: Ann Arbor stage
 ITT set

Overall survival by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	8 (42,1)
95%-CI	[20,3-66,5]
Overall survival in months [95%-CI]	
Median	NE [5,09-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [58,7-94,6]
Month 6	73,0 [46,7-87,8]
Month 12	56,1 [31,1-75,2]
Month 18	56,1 [31,1-75,2]
Month 24	56,1 [31,1-75,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS07: Overall survival by subgroup: Bulky disease
 ITT set

Overall survival by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	67 (72,0)
95%-CI	[61,8-80,9]
Overall survival in months [95%-CI]	
Median	6,93 [5,88-9,92]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [68,1-85,3]
Month 6	60,0 [49,1-69,3]
Month 12	32,0 [22,5-41,9]
Month 18	28,4 [19,3-38,1]
Month 24	20,4 [11,4-31,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS07: Overall survival by subgroup: Bulky disease
 ITT set

1.1.7 *Merkmal: Bulky Erkrankung*

Overall survival by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	88 (64,2)
95%-CI	[55,6-72,2]
Overall survival in months [95%-CI]	
Median	10,32 [7,36-11,93]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [76,4-89,0]
Month 6	69,2 [60,6-76,3]
Month 12	41,4 [32,8-49,7]
Month 18	35,4 [27,1-43,7]
Month 24	29,1 [20,7-37,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS08: Overall survival by subgroup: Double/Triple hit
 ITT set

1.1.8 *Merkmal: Double/Triple-Hit*

Overall survival by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]
Overall survival in months [95%-CI]	
Median	9,20 [1,84-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [43,6-89,1]
Month 6	58,3 [29,3-78,9]
Month 12	41,7 [16,1-65,8]
Month 18	41,7 [16,1-65,8]
Month 24	41,7 [16,1-65,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS08: Overall survival by subgroup: Double/Triple hit
 ITT set

Overall survival by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	88 (67,7)
95%-CI	[58,9-75,6]
Overall survival in months [95%-CI]	
Median	9,53[6,74-11,47]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [74,3-87,7]
Month 6	66,0 [57,0-73,6]
Month 12	38,8 [30,2-47,3]
Month 18	32,5 [24,3-41,0]
Month 24	25,9 [17,7-34,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS09: Overall survival by subgroup: Transformed DLBCL
 ITT set

1.1.9 *Merkmal: Transformation des DLBCL*

Overall survival by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	22 (75,9)
95%-CI	[56,5-89,7]
Overall survival in months [95%-CI]	
Median	8,64 [6,14-11,47]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [63,4-92,4]
Month 6	75,9 [55,9-87,7]
Month 12	30,7 [14,8-48,3]
Month 18	19,2 [7,0-35,8]
Month 24	19,2 [7,0-35,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS09: Overall survival by subgroup: Transformed DLBCL
 ITT set

Overall survival by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	74 (63,8)
95%-CI	[54,4-72,5]
Overall survival in months [95%-CI]	
Median	9,92 [6,34-12,42]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [72,3-86,9]
Month 6	62,6 [52,9-70,8]
Month 12	41,0 [31,7-50,1]
Month 18	36,9 [27,9-46,0]
Month 24	29,5 [20,4-39,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS10: Overall survival by subgroup: B-Cell type
 ITT set

1.1.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Overall survival by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	32 (66,7)
95%-CI	[51,6-79,6]
Overall survival in months [95%-CI]	
Median	11,24 [7,36-15,87]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [73,8-94,1]
Month 6	74,5 [59,5-84,6]
Month 12	42,6 [28,4-56,1]
Month 18	36,1 [22,7-49,6]
Month 24	30,9 [18,2-44,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS10: Overall survival by subgroup: B-Cell type
 ITT set

Overall survival by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	13 (56,5)
95%-CI	[34,5-76,8]
Overall survival in months [95%-CI]	
Median	10,12[5,09-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [68,8-97,7]
Month 6	72,1 [48,1-86,4]
Month 12	40,1 [18,9-60,5]
Month 18	40,1 [18,9-60,5]
Month 24	20,0 [1,7-52,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS11: Overall survival by subgroup: Maximal longest diameter
 ITT set

1.1.11 Merkmal: Maximaler längster Durchmesser

Overall survival by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	47 (57,3)
95%-CI	[45,9-68,2]
Overall survival in months [95%-CI]	
Median	11,56 [8,64-19,15]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [78,3-93,2]
Month 6	74,9 [63,9-83,0]
Month 12	49,6 [38,0-60,2]
Month 18	41,2 [30,0-52,0]
Month 24	37,5 [26,4-48,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS11: Overall survival by subgroup: Maximal longest diameter
 ITT set

Overall survival by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	27 (75,0)
95%-CI	[57,8-87,9]
Overall survival in months [95%-CI]	
Median	8,90 [5,82-11,24]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [62,6-89,9]
Month 6	62,9 [44,8-76,5]
Month 12	31,4 [17,1-46,8]
Month 18	27,9 [14,2-43,4]
Month 24	18,6 [6,9-34,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS11: Overall survival by subgroup: Maximal longest diameter
 ITT set

Overall survival by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	8 (80,0)
95%-CI	[44,4-97,5]
Overall survival in months [95%-CI]	
Median	4,70 [0,36-11,47]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [32,9-89,2]
Month 6	42,0 [10,7-71,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS11: Overall survival by subgroup: Maximal longest diameter
 ITT set

Overall survival by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	13
Patients with events - n(%)	13 (100,0)
95%-CI	[75,3-100,0]
Overall survival in months [95%-CI]	
Median	2,73 [0,76-4,76]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,2 [19,2-69,6]
Month 6	15,4 [2,5-38,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS12: Overall survival by subgroup: Primary disease diagnosis
 ITT set

1.1.12 Merkmal: Primärdiagnose

Overall survival by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	86 (67,7)
95%-CI	[58,8-75,7]
Overall survival in months [95%-CI]	
Median	9,46 [6,74-10,97]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [72,8-86,7]
Month 6	66,0 [56,9-73,6]
Month 12	36,8 [28,2-45,5]
Month 18	31,2 [23,0-39,7]
Month 24	25,3 [17,1-34,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS12: Overall survival by subgroup: Primary disease diagnosis
 ITT set

Overall survival by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	6 (54,5)
95%-CI	[23,4-83,3]
Overall survival in months [95%-CI]	
Median	8,08 [1,84-NE]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [37,1-90,3]
Month 6	54,6 [22,9-78,0]
Month 12	45,5 [16,7-70,7]
Month 18	45,5 [16,7-70,7]
Month 24	45,5 [16,7-70,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS13: Overall survival by subgroup: Number prior lines
 ITT set

1.1.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Overall survival by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	38 (60,3)
95%-CI	[47,2-72,4]
Overall survival in months [95%-CI]	
Median	11,56 [6,60-18,56]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [65,4-86,2]
Month 6	71,2 [58,2-80,8]
Month 12	49,1 [36,1-61,0]
Month 18	41,7 [29,0-53,9]
Month 24	33,4 [20,5-46,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS13: Overall survival by subgroup: Number prior lines
 ITT set

Overall survival by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	26 (74,3)
95%-CI	[56,7-87,5]
Overall survival in months [95%-CI]	
Median	8,08 [5,82-11,47]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [75,1-97,1]
Month 6	63,9 [45,2-77,7]
Month 12	27,8 [13,5-44,2]
Month 18	20,9 [8,7-36,7]
Month 24	15,7 [4,9-31,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS13: Overall survival by subgroup: Number prior lines
 ITT set

Overall survival by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	32 (68,1)
95%-CI	[52,9-80,9]
Overall survival in months [95%-CI]	
Median	7,06[4,76-10,94]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [63,5-87,7]
Month 6	58,3 [42,6-71,0]
Month 12	32,7 [19,5-46,6]
Month 18	30,4 [17,6-44,2]
Month 24	27,4 [15,0-41,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS14: Overall survival by subgroup: Response category - first line
 ITT set

1.1.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Overall survival by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	64 (64,6)
95%-CI	[54,4-74,0]
Overall survival in months [95%-CI]	
Median	9,92 [7,06-12,42]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,5 [74,5-89,6]
Month 6	69,6 [59,3-77,8]
Month 12	41,8 [31,7-51,7]
Month 18	34,8 [25,1-44,6]
Month 24	27,1 [17,4-37,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS14: Overall survival by subgroup: Response category - first line
 ITT set

Overall survival by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	23 (79,3)
95%-CI	[60,3-92,0]
Overall survival in months [95%-CI]	
Median	5,82[2,43-11,24]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,1 [42,1-76,9]
Month 6	48,3 [29,5-64,8]
Month 12	27,6 [13,1-44,3]
Month 18	23,7 [10,2-40,2]
Month 24	19,7 [7,6-36,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS15: Overall survival by subgroup: Response category - last line
 ITT set

1.1.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Overall survival by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	26 (59,1)
95%-CI	[43,2-73,7]
Overall survival in months [95%-CI]	
Median	10,84 [7,75-21,62]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [74,8-95,1]
Month 6	74,7 [59,0-85,1]
Month 12	41,8 [26,6-56,4]
Month 18	39,2 [24,3-53,8]
Month 24	32,7 [16,7-49,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS15: Overall survival by subgroup: Response category - last line
 ITT set

Overall survival by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	62 (70,5)
95%-CI	[59,8-79,7]
Overall survival in months [95%-CI]	
Median	7,06[5,88-10,94]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [66,4-84,4]
Month 6	61,0 [49,7-70,5]
Month 12	36,1 [25,9-46,4]
Month 18	29,3 [19,7-39,5]
Month 24	21,9 [13,1-32,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS16: Overall survival by subgroup: Response category - any line
 ITT set

1.1.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

Overall survival by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	19 (79,2)
95%-CI	[57,8-92,9]
Overall survival in months [95%-CI]	
Median	7,00 [4,30-11,93]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [57,0-90,8]
Month 6	58,3 [36,5-75,0]
Month 12	29,2 [13,0-47,6]
Month 18	24,3 [9,5-42,7]
Month 24	19,4 [6,5-37,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS16: Overall survival by subgroup: Response category - any line
 ITT set

Overall survival by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	73 (63,5)
95%-CI	[54,0-72,3]
Overall survival in months [95%-CI]	
Median	9,89[6,93-12,09]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [74,0-88,2]
Month 6	67,6 [58,0-75,4]
Month 12	41,6 [32,1-50,7]
Month 18	35,4 [26,4-44,6]
Month 24	28,8 [19,6-38,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS17: Overall survival by subgroup: Prior use of T-CART therapy
 ITT set

1.1.17 Merkmal: Vorherige CAR-T-Therapie

Overall survival by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	10 (76,9)
95%-CI	[46,2-95,0]
Overall survival in months [95%-CI]	
Median	8,18 [1,84-14,23]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [40,8-91,2]
Month 6	58,3 [27,0-80,1]
Month 12	33,3 [10,3-58,8]
Month 18	16,7 [2,7-41,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS17: Overall survival by subgroup: Prior use of T-CART therapy
 ITT set

Overall survival by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	86 (65,2)
95%-CI	[56,4-73,2]
Overall survival in months [95%-CI]	
Median	9,53[6,93-11,47]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [74,0-87,4]
Month 6	65,9 [57,0-73,4]
Month 12	39,5 [30,9-48,0]
Month 18	35,1 [26,7-43,6]
Month 24	28,7 [20,3-37,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS18: Overall survival by subgroup: Drug formulation
 ITT set

1.1.18 *Merkmal: Arzneimittelformulierung*

Overall survival by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	24 (68,6)
95%-CI	[50,7-83,1]
Overall survival in months [95%-CI]	
Median	6,93 [4,40-11,93]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,1 [59,5-87,9]
Month 6	53,5 [35,7-68,4]
Month 12	30,9 [16,1-47,0]
Month 18	30,9 [16,1-47,0]
Month 24	27,5 [13,4-43,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3OS_TSTS18: Overall survival by subgroup: Drug formulation
 ITT set

Overall survival by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	72 (65,5)
95%-CI	[55,8-74,3]
Overall survival in months [95%-CI]	
Median	10,12 [7,06-12,09]
Overall survival:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [73,9-88,4]
Month 6	69,1 [59,3-76,9]
Month 12	41,6 [32,0-50,9]
Month 18	34,2 [25,1-43,4]
Month 24	26,5 [16,9-37,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3ORR_TSPS01: ORR - IRC by subgroup: Age group
ITT set

2 Endpunktkategorie: Morbidität

2.1 Subgruppenanalysen zum Ansprechen – Gesamtansprechrates

2.1.1 Merkmal Alter

ORR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	32 (49,2)
95%-CI	[36,6-61,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS01: ORR - IRC by subgroup: Age group
ITT set

ORR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS01: ORR - IRC by subgroup: Age group
ITT set

ORR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	11 (52,4)
95%-CI	[29,8-74,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS02: ORR - IRC by subgroup: Sex
ITT set

2.1.2 *Merkmal: Geschlecht*

ORR - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	30 (50,0)
95%-CI	[36,8-63,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS02: ORR - IRC by subgroup: Sex
ITT set

ORR - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	40 (47,1)
95%-CI	[36,1-58,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPTS03: ORR - IRC by subgroup: Race group
ITT set

2.1.3 *Merkmal: Ethnie*

ORR - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	62 (47,7)
95%-CI	[38,9-56,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS03: ORR - IRC by subgroup: Race group
ITT set

ORR - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS04: ORR - IRC by subgroup: Country
ITT set

2.1.4 *Merkmal: Region-1*

ORR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	29 (49,2)
95%-CI	[35,9-62,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS04: ORR - IRC by subgroup: Country
ITT set

ORR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	13 (41,9)
95%-CI	[24,5-60,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS04: ORR - IRC by subgroup: Country
ITT set

ORR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	27 (50,9)
95%-CI	[36,8-64,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS05: ORR - IRC by subgroup: Region
ITT set

2.1.5 *Merkmal: Region-2*

ORR - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	29 (49,2)
95%-CI	[35,9-62,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS05: ORR - IRC by subgroup: Region
ITT set

ORR - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	41 (47,7)
95%-CI	[36,8-58,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS06: ORR - IRC by subgroup: Ann Arbor stage
ITT set

2.1.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

ORR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS06: ORR - IRC by subgroup: Ann Arbor stage
ITT set

ORR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	14 (60,9)
95%-CI	[38,5-80,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS06: ORR - IRC by subgroup: Ann Arbor stage
ITT set

ORR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	11 (57,9)
95%-CI	[33,5-79,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS06: ORR - IRC by subgroup: Ann Arbor stage
ITT set

ORR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	40 (43,0)
95%-CI	[32,8-53,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS07: ORR - IRC by subgroup: Bulky disease
ITT set

2.1.7 *Merkmal: Bulky Erkrankung*

ORR - IRC by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	68 (49,6)
95%-CI	[41,0-58,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS08: ORR - IRC by subgroup: Double/Triple hit
ITT set

2.1.8 *Merkmal: Double/Triple-Hit*

ORR - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS08: ORR - IRC by subgroup: Double/Triple hit
ITT set

ORR - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	65 (50,0)
95%-CI	[41,1-58,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS09: ORR - IRC by subgroup: Transformed DLBCL
ITT set

2.1.9 *Merkmal: Transformation des DLBCL*

ORR - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	13 (44,8)
95%-CI	[26,4-64,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set. DLBCL = Diffuse large B-Cell Lymphoma.

ORR = Overall response rate. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS09: ORR - IRC by subgroup: Transformed DLBCL
ITT set

ORR - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	57 (49,1)
95%-CI	[39,7-58,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set. DLBCL = Diffuse large B-Cell Lymphoma.

ORR = Overall response rate. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS10: ORR - IRC by subgroup: B-Cell type
ITT set

2.1.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

ORR - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	26 (54,2)
95%-CI	[39,2-68,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS10: ORR - IRC by subgroup: B-Cell type
ITT set

ORR - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS11: ORR - IRC by subgroup: Maximal longest diameter
ITT set

2.1.11 *Merkmal: Maximaler längster Durchmesser*

ORR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	48 (58,5)
95%-CI	[47,1-69,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS11: ORR - IRC by subgroup: Maximal longest diameter
ITT set

ORR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	11 (30,6)
95%-CI	[16,3-48,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS11: ORR - IRC by subgroup: Maximal longest diameter
ITT set

ORR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS11: ORR - IRC by subgroup: Maximal longest diameter
ITT set

ORR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS12: ORR - IRC by subgroup: Primary disease diagnosis
ITT set

2.1.12 *Merkmal: Primärdiagnose*

ORR - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	64 (50,4)
95%-CI	[41,4-59,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS12: ORR - IRC by subgroup: Primary disease diagnosis
ITT set

ORR - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS13: ORR - IRC by subgroup: Number prior lines
ITT set

2.1.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

ORR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines: 2 lines	
Patients in analysis set	63
Patients with events - n(%)	30 (47,6)
95%-CI	[34,9-60,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS13: ORR - IRC by subgroup: Number prior lines
ITT set

ORR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	17 (48,6)
95%-CI	[31,4-66,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS13: ORR - IRC by subgroup: Number prior lines
ITT set

ORR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	23 (48,9)
95%-CI	[34,1-63,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPTS14: ORR - IRC by subgroup: Response category - first line
ITT set

2.1.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

ORR - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	53 (53,5)
95%-CI	[43,2-63,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPTS14: ORR - IRC by subgroup: Response category - first line
ITT set

ORR - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS15: ORR - IRC by subgroup: Response category - last line
ITT set

2.1.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

ORR - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	30 (68,2)
95%-CI	[52,4-81,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS15: ORR - IRC by subgroup: Response category - last line
ITT set

ORR - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	31 (35,2)
95%-CI	[25,3-46,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS16: ORR - IRC by subgroup: Response category - any line
ITT set

2.1.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

ORR - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS16: ORR - IRC by subgroup: Response category - any line
ITT set

ORR - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	60 (52,2)
95%-CI	[42,7-61,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS17: ORR - IRC by subgroup: Prior use of T-CART therapy
ITT set

2.1.17 *Merkmal: Vorherige CAR-T-Therapie*

ORR - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS17: ORR - IRC by subgroup: Prior use of T-CART therapy
ITT set

ORR - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	64 (48,5)
95%-CI	[39,7-57,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS18: ORR - IRC by subgroup: Drug formulation
ITT set

2.1.18 *Merkmal: Arzneimittelformulierung*

ORR - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	17 (48,6)
95%-CI	[31,4-66,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3ORR_TSPS18: ORR - IRC by subgroup: Drug formulation
ITT set

ORR - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	53 (48,2)
95%-CI	[38,6-57,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
ORR = Overall response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS01: CRR - IRC by subgroup: Age group
ITT set

2.2 Subgruppenanalysen zum Ansprechen – Vollständige Ansprechrate

2.2.1 Merkmal Alter

CRR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	65
Patients with events - n(%)	13 (20,0)
95%-CI	[11,1-31,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS01: CRR - IRC by subgroup: Age group
ITT set

CRR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS01: CRR - IRC by subgroup: Age group
ITT set

CRR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	8 (38,1)
95%-CI	[18,1-61,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS02: CRR - IRC by subgroup: Sex
ITT set

2.2.2 Merkmal: Geschlecht

CRR - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	22 (36,7)
95%-CI	[24,6-50,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS02: CRR - IRC by subgroup: Sex
ITT set

CRR - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	14 (16,5)
95%-CI	[9,3-26,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPTS03: CRR - IRC by subgroup: Race group
ITT set

2.2.3 *Merkmal: Ethnie*

CRR - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	34 (26,2)
95%-CI	[18,8-34,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS03: CRR - IRC by subgroup: Race group
ITT set

CRR - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS04: CRR - IRC by subgroup: Country
ITT set

2.2.4 *Merkmal: Region-1*

CRR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS04: CRR - IRC by subgroup: Country
ITT set

CRR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS04: CRR - IRC by subgroup: Country
ITT set

CRR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	14 (26,4)
95%-CI	[15,3-40,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS05: CRR - IRC by subgroup: Region
ITT set

2.2.5 *Merkmal: Region-2*

CRR - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS05: CRR - IRC by subgroup: Region
ITT set

CRR - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	21 (24,4)
95%-CI	[15,8-34,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS06: CRR - IRC by subgroup: Ann Arbor stage
ITT set

2.2.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

CRR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS06: CRR - IRC by subgroup: Ann Arbor stage
ITT set

CRR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS06: CRR - IRC by subgroup: Ann Arbor stage
ITT set

CRR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS06: CRR - IRC by subgroup: Ann Arbor stage
ITT set

CRR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	22 (23,7)
95%-CI	[15,5-33,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS07: CRR - IRC by subgroup: Bulky disease
ITT set

2.2.7 *Merkmal: Bulky Erkrankung*

CRR - IRC by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	35 (25,5)
95%-CI	[18,5-33,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS08: CRR - IRC by subgroup: Double/Triple hit
ITT set

2.2.8 *Merkmal: Double/Triple-Hit*

CRR - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS08: CRR - IRC by subgroup: Double/Triple hit
ITT set

CRR - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	31 (23,8)
95%-CI	[16,8-32,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS09: CRR - IRC by subgroup: Transformed DLBCL
ITT set

2.2.9 Merkmal: Transformation des DLBCL

CRR - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	7 (24,1)
95%-CI	[10,3-43,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set. DLBCL = Diffuse large B-Cell Lymphoma.

CRR = Complete response rate. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS09: CRR - IRC by subgroup: Transformed DLBCL
ITT set

CRR - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	29 (25,0)
95%-CI	[17,4-33,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set. DLBCL = Diffuse large B-Cell Lymphoma.

CRR = Complete response rate. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS10: CRR - IRC by subgroup: B-Cell type
ITT set

2.2.10 *Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen*

CRR - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	13 (27,1)
95%-CI	[15,3-41,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS10: CRR - IRC by subgroup: B-Cell type
ITT set

CRR - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS11: CRR - IRC by subgroup: Maximal longest diameter
ITT set

2.2.11 *Merkmal: Maximaler längster Durchmesser*

CRR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	27 (32,9)
95%-CI	[22,9-44,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS11: CRR - IRC by subgroup: Maximal longest diameter
ITT set

CRR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS11: CRR - IRC by subgroup: Maximal longest diameter
ITT set

CRR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS11: CRR - IRC by subgroup: Maximal longest diameter
ITT set

CRR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS12: CRR - IRC by subgroup: Primary disease diagnosis
ITT set

2.2.12 *Merkmal: Primärdiagnose*

CRR - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	31 (24,4)
95%-CI	[17,2-32,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS12: CRR - IRC by subgroup: Primary disease diagnosis
ITT set

CRR - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis: HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS13: CRR - IRC by subgroup: Number prior lines
ITT set

2.2.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

CRR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	15 (23,8)
95%-CI	[14,0-36,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS13: CRR - IRC by subgroup: Number prior lines
ITT set

CRR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS13: CRR - IRC by subgroup: Number prior lines
ITT set

CRR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	16 (34,0)
95%-CI	[20,9-49,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPTS14: CRR - IRC by subgroup: Response category - first line
ITT set

2.2.14 *Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

CRR - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	27 (27,3)
95%-CI	[18,8-37,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPTS14: CRR - IRC by subgroup: Response category - first line
ITT set

CRR - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS15: CRR - IRC by subgroup: Response category - last line
ITT set

2.2.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

CRR - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	19 (43,2)
95%-CI	[28,3-59,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS15: CRR - IRC by subgroup: Response category - last line
ITT set

CRR - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	11 (12,5)
95%-CI	[6,4-21,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS16: CRR - IRC by subgroup: Response category - any line
ITT set

2.2.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

CRR - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS16: CRR - IRC by subgroup: Response category - any line
ITT set

CRR - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	31 (27,0)
95%-CI	[19,1-36,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS17: CRR - IRC by subgroup: Prior use of T-CART therapy
 ITT set

2.2.17 *Merkmal: Vorherige CAR-T-Therapie*

CRR - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
 CRR = Complete response rate. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS17: CRR - IRC by subgroup: Prior use of T-CART therapy
ITT set

CRR - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	33 (25,0)
95%-CI	[17,9-33,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS18: CRR - IRC by subgroup: Drug formulation
ITT set

2.2.18 *Merkmal: Arzneimittelformulierung*

CRR - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3CRR_TSPS18: CRR - IRC by subgroup: Drug formulation
ITT set

CRR - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation: Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	28 (25,5)
95%-CI	[17,6-34,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. ITT set = Intent to Treat set.
CRR = Complete response rate. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Source Data: ars, created on: 10JAN2023

Table LT3DOR_DSTS01: DOR - IRC by subgroup: Age group
 Responders in ITT Set (IRC)

2.3 Subgruppenanalysen zum Ansprechen – Dauer des Ansprechens

2.3.1 Merkmal Alter

DOR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	32
Patients with events - n(%)	12 (37,5)
95%-CI	[21,1-56,3]
DOR - IRC in months [95%-CI]	
Median	9,26 [3,22-18,10]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,9 [55,2-89,0]
Month 6	58,5 [33,4-76,9]
Month 12	39,0 [14,3-63,4]
Month 18	39,0 [14,3-63,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS01: DOR - IRC by subgroup: Age group
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	27
Patients with events - n(%)	8 (29,6)
95%-CI	[13,8-50,2]
DOR - IRC in months [95%-CI]	
Median	12,58[3,84-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [55,9-92,3]
Month 6	73,8 [47,4-88,4]
Month 12	57,4 [29,1-77,9]
Month 18	49,2 [22,1-71,7]
Month 24	49,2 [22,1-71,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS01: DOR - IRC by subgroup: Age group
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
DOR - IRC in months [95%-CI]	
Median	NE [5,62-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	77,8 [36,5-93,9]
Month 12	77,8 [36,5-93,9]
Month 18	64,8 [25,3-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS02: DOR - IRC by subgroup: Sex
 Responders in ITT Set (IRC)

2.3.2 *Merkmal: Geschlecht*

DOR - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	30
Patients with events - n(%)	8 (26,7)
95%-CI	[12,3-45,9]
DOR - IRC in months [95%-CI]	
Median	NE [10,25-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [75,7-99,5]
Month 6	82,8 [60,2-93,2]
Month 12	71,7 [47,0-86,4]
Month 18	60,2 [35,2-78,1]
Month 24	60,2 [35,2-78,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS02: DOR - IRC by subgroup: Sex
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	40
Patients with events - n(%)	15 (37,5)
95%-CI	[22,7-54,2]
DOR - IRC in months [95%-CI]	
Median	6,87[3,84-18,10]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,2 [51,4-84,1]
Month 6	51,9 [28,3-71,1]
Month 12	35,6 [13,5-58,7]
Month 18	35,6 [13,5-58,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS03: DOR - IRC by subgroup: Race group
 Responders in ITT Set (IRC)

2.3.3 *Merkmal: Ethnie*

DOR - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	62
Patients with events - n(%)	20 (32,3)
95%-CI	[20,9-45,3]
DOR - IRC in months [95%-CI]	
Median	13,37 [6,87-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [69,7-91,5]
Month 6	69,8 [53,2-81,5]
Month 12	56,1 [38,2-70,7]
Month 18	48,9 [31,0-64,5]
Month 24	40,7 [20,8-59,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS03: DOR - IRC by subgroup: Race group
Responders in ITT Set (IRC)

DOR - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS04: DOR - IRC by subgroup: Country
 Responders in ITT Set (IRC)

2.3.4 *Merkmal: Region-1*

DOR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]
DOR - IRC in months [95%-CI]	
Median	12,58[4,63-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [58,3-91,3]
Month 6	64,0 [39,7-80,6]
Month 12	56,0 [30,4-75,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS04: DOR - IRC by subgroup: Country
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
DOR - IRC in months [95%-CI]	
Median	NE [1,54-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	71,6 [35,0-89,9]
Month 12	51,1 [19,2-76,2]
Month 18	51,1 [19,2-76,2]
Month 24	51,1 [19,2-76,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS04: DOR - IRC by subgroup: Country
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	27
Patients with events - n(%)	7 (25,9)
95%-CI	[11,1-46,3]
DOR - IRC in months [95%-CI]	
Median	18,10[5,62-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,1 [58,3-94,6]
Month 6	67,9 [37,2-86,0]
Month 12	56,6 [24,8-79,3]
Month 18	56,6 [24,8-79,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS05: DOR - IRC by subgroup: Region
 Responders in ITT Set (IRC)

2.3.5 *Merkmal: Region-2*

DOR - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]
DOR - IRC in months [95%-CI]	
Median	12,58[4,63-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [58,3-91,3]
Month 6	64,0 [39,7-80,6]
Month 12	56,0 [30,4-75,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS05: DOR - IRC by subgroup: Region
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	41
Patients with events - n(%)	12 (29,3)
95%-CI	[16,1-45,5]
DOR - IRC in months [95%-CI]	
Median	18,10[5,68-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [66,0-93,1]
Month 6	70,3 [48,3-84,4]
Month 12	54,4 [31,6-72,5]
Month 18	54,4 [31,6-72,5]
Month 24	45,3 [21,4-66,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS06: DOR - IRC by subgroup: Ann Arbor stage
Responders in ITT Set (IRC)

2.3.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

DOR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS06: DOR - IRC by subgroup: Ann Arbor stage
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	14
Patients with events - n(%)	3 (21,4)
95%-CI	[4,7-50,8]
DOR - IRC in months [95%-CI]	
Median	18,10[1,51-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	72,0 [23,8-92,8]
Month 12	72,0 [23,8-92,8]
Month 18	72,0 [23,8-92,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS06: DOR - IRC by subgroup: Ann Arbor stage
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
DOR - IRC in months [95%-CI]	
Median	5,68 [1,74-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,3 [15,2-90,2]
Month 6	42,9 [5,8-77,7]
Month 12	42,9 [5,8-77,7]
Month 18	42,9 [5,8-77,7]
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS06: DOR - IRC by subgroup: Ann Arbor stage
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	40
Patients with events - n(%)	16 (40,0)
95%-CI	[24,9-56,7]
DOR - IRC in months [95%-CI]	
Median	12,58[5,98-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [63,0-90,1]
Month 6	66,5 [47,3-80,0]
Month 12	53,6 [33,6-70,0]
Month 18	44,2 [24,7-62,1]
Month 24	44,2 [24,7-62,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS07: DOR - IRC by subgroup: Bulky disease
 Responders in ITT Set (IRC)

2.3.7 *Merkmal: Bulky Erkrankung*

DOR - IRC by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	68
Patients with events - n(%)	22 (32,4)
95%-CI	[21,5-44,8]
DOR - IRC in months [95%-CI]	
Median	13,37 [6,87-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [69,2-90,0]
Month 6	68,9 [53,1-80,3]
Month 12	56,0 [38,8-70,1]
Month 18	49,2 [32,0-64,3]
Month 24	41,0 [21,3-59,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS08: DOR - IRC by subgroup: Double/Triple hit
Responders in ITT Set (IRC)

2.3.8 Merkmal: Double/Triple-Hit

DOR - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS08: DOR - IRC by subgroup: Double/Triple hit
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	65
Patients with events - n(%)	22 (33,8)
95%-CI	[22,6-46,6]
DOR - IRC in months [95%-CI]	
Median	10,25[5,68-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [67,0-89,2]
Month 6	63,2 [46,2-76,2]
Month 12	47,8 [29,8-63,7]
Month 18	43,8 [26,0-60,3]
Month 24	36,5 [17,9-55,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS09: DOR - IRC by subgroup: Transformed DLBCL
 Responders in ITT Set (IRC)

2.3.9 *Merkmal: Transformation des DLBCL*

DOR - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
DOR - IRC in months [95%-CI]	
Median	NE [9,26-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	73,3 [24,3-93,4]
Month 18	55,0 [12,9-84,0]
Month 24	55,0 [12,9-84,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS09: DOR - IRC by subgroup: Transformed DLBCL
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	57
Patients with events - n(%)	20 (35,1)
95%-CI	[22,9-48,9]
DOR - IRC in months [95%-CI]	
Median	13,37[5,68-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [65,9-89,5]
Month 6	62,7 [45,2-76,0]
Month 12	51,3 [33,1-66,8]
Month 18	47,3 [29,3-63,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS10: DOR - IRC by subgroup: B-Cell type
 Responders in ITT Set (IRC)

2.3.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

DOR - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	26
Patients with events - n(%)	10 (38,5)
95%-CI	[20,2-59,4]
DOR - IRC in months [95%-CI]	
Median	13,37 [5,68-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [66,3-97,5]
Month 6	67,2 [40,5-83,9]
Month 12	53,7 [27,8-74,0]
Month 18	47,0 [22,2-68,5]
Month 24	31,3 [7,1-60,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS10: DOR - IRC by subgroup: B-Cell type
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
DOR - IRC in months [95%-CI]	
Median	6,87 [1,31-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [31,5-93,1]
Month 6	75,0 [31,5-93,1]
Month 12	37,5 [1,4-79,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS11: DOR - IRC by subgroup: Maximal longest diameter
 Responders in ITT Set (IRC)

2.3.11 *Merkmal: Maximaler längster Durchmesser*

DOR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	48
Patients with events - n(%)	12 (25,0)
95%-CI	[13,6-39,6]
DOR - IRC in months [95%-CI]	
Median	NE [9,26-NE]
DOR - IRC: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [66,5-91,3]
Month 6	70,7 [51,3-83,5]
Month 12	65,6 [45,0-80,1]
Month 18	60,6 [39,3-76,4]
Month 24	60,6 [39,3-76,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS11: DOR - IRC by subgroup: Maximal longest diameter
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	11
Patients with events - n(%)	7 (63,6)
95%-CI	[30,8-89,1]
DOR - IRC in months [95%-CI]	
Median	6,87 [1,54-13,37]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	63,5 [23,8-86,6]
Month 12	31,8 [4,9-64,7]
Month 18	15,9 [0,8-49,6]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS11: DOR - IRC by subgroup: Maximal longest diameter
Responders in ITT Set (IRC)

DOR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS11: DOR - IRC by subgroup: Maximal longest diameter
Responders in ITT Set (IRC)

DOR - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS12: DOR - IRC by subgroup: Primary disease diagnosis
 Responders in ITT Set (IRC)

2.3.12 *Merkmal: Primärdiagnose*

DOR - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	64
Patients with events - n(%)	21 (32,8)
95%-CI	[21,6-45,7]
DOR - IRC in months [95%-CI]	
Median	10,25 [5,98-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [68,6-90,4]
Month 6	64,4 [47,1-77,4]
Month 12	48,7 [30,3-64,8]
Month 18	44,6 [26,5-61,3]
Month 24	37,2 [18,2-56,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS12: DOR - IRC by subgroup: Primary disease diagnosis
Responders in ITT Set (IRC)

DOR - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis: HGBL	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS13: DOR - IRC by subgroup: Number prior lines
 Responders in ITT Set (IRC)

2.3.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

DOR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	30
Patients with events - n(%)	10 (33,3)
95%-CI	[17,3-52,8]
DOR - IRC in months [95%-CI]	
Median	NE [5,68-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,8 [58,1-91,1]
Month 6	69,2 [45,4-84,2]
Month 12	57,6 [33,5-75,8]
Month 18	51,2 [27,3-70,8]
Month 24	51,2 [27,3-70,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS13: DOR - IRC by subgroup: Number prior lines
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	17
Patients with events - n(%)	7 (41,2)
95%-CI	[18,4-67,1]
DOR - IRC in months [95%-CI]	
Median	5,98[1,54-18,10]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,8 [35,7-87,3]
Month 6	44,2 [13,1-72,0]
Month 12	44,2 [13,1-72,0]
Month 18	44,2 [13,1-72,0]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS13: DOR - IRC by subgroup: Number prior lines
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
DOR - IRC in months [95%-CI]	
Median	12,58[4,63-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [66,6-99,2]
Month 6	78,5 [46,0-92,7]
Month 12	53,8 [19,4-79,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS14: DOR - IRC by subgroup: Response category - first line
 Responders in ITT Set (IRC)

2.3.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

DOR - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	53
Patients with events - n(%)	17 (32,1)
95%-CI	[19,9-46,3]
DOR - IRC in months [95%-CI]	
Median	12,58 [5,68-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [69,3-92,1]
Month 6	64,8 [45,1-79,0]
Month 12	50,9 [30,6-68,1]
Month 18	46,3 [26,3-64,1]
Month 24	34,7 [12,7-58,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS14: DOR - IRC by subgroup: Response category - first line
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
DOR - IRC in months [95%-CI]	
Median	9,63 [1,25-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	66,7 [27,2-88,2]
Month 12	44,4 [7,8-77,3]
Month 18	22,2 [1,0-60,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS15: DOR - IRC by subgroup: Response category - last line
 Responders in ITT Set (IRC)

2.3.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

DOR - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	30
Patients with events - n(%)	9 (30,0)
95%-CI	[14,7-49,4]
DOR - IRC in months [95%-CI]	
Median	NE [5,62-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [58,2-91,3]
Month 6	67,7 [42,7-83,7]
Month 12	60,2 [34,0-78,8]
Month 18	52,7 [26,7-73,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS15: DOR - IRC by subgroup: Response category - last line
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	31
Patients with events - n(%)	11 (35,5)
95%-CI	[19,2-54,6]
DOR - IRC in months [95%-CI]	
Median	9,63[5,98-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,9 [56,4-90,6]
Month 6	67,8 [43,3-83,5]
Month 12	45,8 [21,0-67,6]
Month 18	45,8 [21,0-67,6]
Month 24	34,3 [10,8-59,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS16: DOR - IRC by subgroup: Response category - any line
Responders in ITT Set (IRC)

2.3.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

DOR - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS16: DOR - IRC by subgroup: Response category - any line
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	60
Patients with events - n(%)	19 (31,7)
95%-CI	[20,3-45,0]
DOR - IRC in months [95%-CI]	
Median	18,10[5,98-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,2 [66,7-89,8]
Month 6	65,5 [47,9-78,4]
Month 12	54,1 [35,7-69,4]
Month 18	50,3 [31,8-66,2]
Month 24	40,2 [18,5-61,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS17: DOR - IRC by subgroup: Prior use of T-CART therapy
Responders in ITT Set (IRC)

2.3.17 *Merkmal: Vorherige CAR-T-Therapie*

DOR - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS17: DOR - IRC by subgroup: Prior use of T-CART therapy
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	64
Patients with events - n(%)	22 (34,4)
95%-CI	[22,9-47,3]
DOR - IRC in months [95%-CI]	
Median	13,37 [5,98-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [66,9-89,1]
Month 6	64,1 [47,5-76,7]
Month 12	50,9 [33,6-65,8]
Month 18	47,3 [30,1-62,7]
Month 24	39,4 [20,2-58,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS18: DOR - IRC by subgroup: Drug formulation
 Responders in ITT Set (IRC)

2.3.18 *Merkmal: Arzneimittelformulierung*

DOR - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	17
Patients with events - n(%)	5 (29,4)
95%-CI	[10,3-56,0]
DOR - IRC in months [95%-CI]	
Median	18,10 [1,74-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [47,3-92,5]
Month 6	69,8 [37,8-87,6]
Month 12	69,8 [37,8-87,6]
Month 18	69,8 [37,8-87,6]
Month 24	46,6 [9,0-78,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3DOR_DSTS18: DOR - IRC by subgroup: Drug formulation
 Responders in ITT Set (IRC)

DOR - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	53
Patients with events - n(%)	18 (34,0)
95%-CI	[21,5-48,3]
DOR - IRC in months [95%-CI]	
Median	12,58[6,87-NE]
DOR - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [69,0-92,0]
Month 6	68,1 [50,0-80,8]
Month 12	52,4 [33,3-68,4]
Month 18	44,0 [25,4-61,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. DOR = Duration of response. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS01: PFS - IRC by subgroup: Age group
 ITT set

2.4 Subgruppenanalysen zum progressionsfreien Überleben

2.4.1 Merkmal Alter

PFS - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	32 (49,2)
95%-CI	[36,6-61,9]
PFS - IRC in months [95%-CI]	
Median	4,93 [2,66-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,4 [43,0-69,4]
Month 6	48,7 [33,6-62,2]
Month 12	23,7 [9,1-42,2]
Month 18	23,7 [9,1-42,2]
Month 24	15,8 [3,6-36,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS01: PFS - IRC by subgroup: Age group
 ITT set

PFS - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	31 (52,5)
95%-CI	[39,1-65,7]
PFS - IRC in months [95%-CI]	
Median	2,99[2,63-14,23]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,4 [34,4-62,8]
Month 6	43,1 [27,9-57,4]
Month 12	34,8 [19,6-50,5]
Month 18	24,9 [10,8-42,0]
Month 24	24,9 [10,8-42,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS01: PFS - IRC by subgroup: Age group
 ITT set

PFS - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	10 (47,6)
95%-CI	[25,7-70,2]
PFS - IRC in months [95%-CI]	
Median	7,36[1,35-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,2 [39,6-83,2]
Month 6	59,6 [33,1-78,5]
Month 12	46,3 [21,8-67,8]
Month 18	38,6 [15,6-61,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS02: PFS - IRC by subgroup: Sex
 ITT set

2.4.2 *Merkmal: Geschlecht*

PFS - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	30 (50,0)
95%-CI	[36,8-63,2]
PFS - IRC in months [95%-CI]	
Median	10,61 [2,73-15,87]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,2 [47,6-73,8]
Month 6	55,5 [40,8-67,9]
Month 12	43,9 [28,9-58,0]
Month 18	33,8 [19,3-48,9]
Month 24	33,8 [19,3-48,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS02: PFS - IRC by subgroup: Sex
 ITT set

PFS - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	43 (50,6)
95%-CI	[39,5-61,6]
PFS - IRC in months [95%-CI]	
Median	3,81 [2,69-7,06]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,6 [38,0-61,9]
Month 6	41,4 [27,6-54,7]
Month 12	20,2 [7,9-36,6]
Month 18	20,2 [7,9-36,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS03: PFS - IRC by subgroup: Race group
 ITT set

2.4.3 *Merkmal: Ethnie*

PFS - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	64 (49,2)
95%-CI	[40,4-58,1]
PFS - IRC in months [95%-CI]	
Median	5,09 [2,89-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,4 [46,3-65,3]
Month 6	49,5 [39,0-59,1]
Month 12	34,8 [23,9-46,0]
Month 18	28,3 [17,7-39,8]
Month 24	25,2 [14,6-37,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS03: PFS - IRC by subgroup: Race group
 ITT set

PFS - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	9 (60,0)
95%-CI	[32,3-83,7]
PFS - IRC in months [95%-CI]	
Median	3,20 [1,28-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,0 [22,9-72,2]
Month 6	40,0 [14,5-64,7]
Month 12	20,0 [1,5-54,0]
Month 18	20,0 [1,5-54,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS04: PFS - IRC by subgroup: Country
 ITT set

2.4.4 *Merkmal: Region-1*

PFS - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
PFS - IRC in months [95%-CI]	
Median	5,09 [2,73-14,23]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,3 [47,7-75,4]
Month 6	48,2 [32,0-62,7]
Month 12	35,9 [19,7-52,5]
Month 18	25,7 [10,9-43,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS04: PFS - IRC by subgroup: Country
 ITT set

PFS - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	18 (58,1)
95%-CI	[39,1-75,5]
PFS - IRC in months [95%-CI]	
Median	8,08[1,54-15,87]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,5 [30,9-67,3]
Month 6	50,5 [30,9-67,3]
Month 12	33,7 [15,3-53,2]
Month 18	28,1 [11,2-47,9]
Month 24	28,1 [11,2-47,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS04: PFS - IRC by subgroup: Country
 ITT set

PFS - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	28 (52,8)
95%-CI	[38,6-66,7]
PFS - IRC in months [95%-CI]	
Median	2,99[2,66-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,2 [33,4-63,2]
Month 6	45,9 [30,1-60,4]
Month 12	29,7 [13,6-47,9]
Month 18	29,7 [13,6-47,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS05: PFS - IRC by subgroup: Region
 ITT set

2.4.5 *Merkmal: Region-2*

PFS - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
PFS - IRC in months [95%-CI]	
Median	5,09 [2,73-14,23]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,3 [47,7-75,4]
Month 6	48,2 [32,0-62,7]
Month 12	35,9 [19,7-52,5]
Month 18	25,7 [10,9-43,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS05: PFS - IRC by subgroup: Region
 ITT set

PFS - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	46 (53,5)
95%-CI	[42,4-64,3]
PFS - IRC in months [95%-CI]	
Median	4,40 [2,73-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,7 [38,5-61,6]
Month 6	48,7 [36,5-59,9]
Month 12	32,1 [19,4-45,4]
Month 18	28,8 [16,4-42,5]
Month 24	24,7 [12,5-39,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS06: PFS - IRC by subgroup: Ann Arbor stage
 ITT set

2.4.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

PFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
PFS - IRC in months [95%-CI]	
Median	11,47 [1,28-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [28,2-87,8]
Month 6	66,7 [28,2-87,8]
Month 12	44,4 [7,9-77,1]
Month 18	22,2 [1,1-60,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS06: PFS - IRC by subgroup: Ann Arbor stage
 ITT set

PFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]
PFS - IRC in months [95%-CI]	
Median	6,01[1,45-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,9 [35,6-76,2]
Month 6	58,9 [35,6-76,2]
Month 12	47,1 [20,4-70,1]
Month 18	47,1 [20,4-70,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS06: PFS - IRC by subgroup: Ann Arbor stage
 ITT set

PFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	7 (36,8)
95%-CI	[16,3-61,6]
PFS - IRC in months [95%-CI]	
Median	8,31 [2,66-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,4 [39,5-85,7]
Month 6	57,0 [25,9-79,2]
Month 12	28,5 [1,7-67,8]
Month 18	28,5 [1,7-67,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS06: PFS - IRC by subgroup: Ann Arbor stage
 ITT set

PFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	50 (53,8)
95%-CI	[43,1-64,2]
PFS - IRC in months [95%-CI]	
Median	3,65 [2,69-7,06]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,9 [38,9-61,6]
Month 6	42,2 [30,4-53,6]
Month 12	29,3 [18,1-41,5]
Month 18	24,0 [13,3-36,4]
Month 24	24,0 [13,3-36,4]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS07: PFS - IRC by subgroup: Bulky disease
 ITT set

2.4.7 *Merkmal: Bulky Erkrankung*

PFS - IRC by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	69 (50,4)
95%-CI	[41,7-59,0]
PFS - IRC in months [95%-CI]	
Median	5,09 [2,89-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,0 [46,4-64,6]
Month 6	49,8 [39,8-59,0]
Month 12	34,4 [23,9-45,2]
Month 18	28,4 [18,1-39,4]
Month 24	25,2 [14,9-36,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS08: PFS - IRC by subgroup: Double/Triple hit
 ITT set

2.4.8 *Merkmal: Double/Triple-Hit*

PFS - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]
PFS - IRC in months [95%-CI]	
Median	3,68 [1,28-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,9 [31,2-82,1]
Month 6	44,2 [17,0-68,7]
Month 12	44,2 [17,0-68,7]
Month 18	35,4 [11,3-60,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS08: PFS - IRC by subgroup: Double/Triple hit
 ITT set

PFS - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	65 (50,0)
95%-CI	[41,1-58,9]
PFS - IRC in months [95%-CI]	
Median	5,09 [2,89-8,31]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,0 [45,0-63,9]
Month 6	49,2 [38,8-58,8]
Month 12	30,7 [19,7-42,4]
Month 18	25,6 [14,9-37,7]
Month 24	22,0 [11,4-34,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS09: PFS - IRC by subgroup: Transformed DLBCL
 ITT set

2.4.9 *Merkmal: Transformation des DLBCL*

PFS - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	13 (44,8)
95%-CI	[26,4-64,3]
PFS - IRC in months [95%-CI]	
Median	10,61 [2,63-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,8 [40,3-78,8]
Month 6	50,2 [27,2-69,5]
Month 12	40,2 [16,5-63,0]
Month 18	26,8 [5,8-54,3]
Month 24	26,8 [5,8-54,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS09: PFS - IRC by subgroup: Transformed DLBCL
 ITT set

PFS - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	60 (51,7)
95%-CI	[42,3-61,1]
PFS - IRC in months [95%-CI]	
Median	4,93 [2,73-8,08]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,1 [43,5-63,5]
Month 6	48,0 [37,1-58,0]
Month 12	32,2 [21,2-43,8]
Month 18	27,6 [16,9-39,4]
Month 24	23,7 [12,8-36,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS10: PFS - IRC by subgroup: B-Cell type
 ITT set

2.4.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

PFS - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	24 (50,0)
95%-CI	[35,2-64,8]
PFS - IRC in months [95%-CI]	
Median	8,31 [3,81-15,87]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,8 [59,1-85,2]
Month 6	59,2 [41,7-73,1]
Month 12	38,8 [21,4-56,0]
Month 18	30,2 [14,3-47,8]
Month 24	24,2 [9,4-42,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS10: PFS - IRC by subgroup: B-Cell type
 ITT set

PFS - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	9 (39,1)
95%-CI	[19,7-61,5]
PFS - IRC in months [95%-CI]	
Median	7,06[2,66-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,7 [26,9-75,8]
Month 6	54,7 [26,9-75,8]
Month 12	27,4 [5,0-57,1]
Month 18	27,4 [5,0-57,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS11: PFS - IRC by subgroup: Maximal longest diameter
 ITT set

2.4.11 *Merkmal: Maximaler längster Durchmesser*

PFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	34 (41,5)
95%-CI	[30,7-52,9]
PFS - IRC in months [95%-CI]	
Median	8,31 [2,99-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [48,9-71,8]
Month 6	55,1 [41,9-66,5]
Month 12	45,6 [31,1-59,0]
Month 18	41,8 [27,0-56,0]
Month 24	41,8 [27,0-56,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS11: PFS - IRC by subgroup: Maximal longest diameter
 ITT set

PFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	26 (72,2)
95%-CI	[54,8-85,8]
PFS - IRC in months [95%-CI]	
Median	2,76 [1,38-7,00]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,9 [30,6-64,9]
Month 6	40,0 [22,2-57,3]
Month 12	16,7 [4,9-34,5]
Month 18	5,6 [0,4-21,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS11: PFS - IRC by subgroup: Maximal longest diameter
 ITT set

PFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
PFS - IRC in months [95%-CI]	
Median	2,99[0,36-11,47]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,1 [1,4-80,4]
Month 6	38,1 [1,4-80,4]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS11: PFS - IRC by subgroup: Maximal longest diameter
 ITT set

PFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
PFS - IRC in months [95%-CI]	
Median	1,31 [0,72-4,40]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,4 [9,5-66,3]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS12: PFS - IRC by subgroup: Primary disease diagnosis
 ITT set

2.4.12 *Merkmal: Primärdiagnose*

PFS - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	63 (49,6)
95%-CI	[40,6-58,6]
PFS - IRC in months [95%-CI]	
Median	6,01 [2,89-8,31]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,0 [45,9-64,9]
Month 6	50,1 [39,5-59,7]
Month 12	31,3 [20,1-43,2]
Month 18	26,1 [15,2-38,3]
Month 24	22,3 [11,6-35,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS12: PFS - IRC by subgroup: Primary disease diagnosis
 ITT set

PFS - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	6 (54,5)
95%-CI	[23,4-83,3]
PFS - IRC in months [95%-CI]	
Median	9,13[1,31-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [32,9-89,2]
Month 6	50,0 [18,4-75,3]
Month 12	50,0 [18,4-75,3]
Month 18	40,0 [12,3-67,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS13: PFS - IRC by subgroup: Number prior lines
 ITT set

2.4.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

PFS - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	32 (50,8)
95%-CI	[37,9-63,6]
PFS - IRC in months [95%-CI]	
Median	7,00 [2,43-14,59]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,6 [37,3-64,2]
Month 6	51,6 [37,3-64,2]
Month 12	38,2 [23,4-52,9]
Month 18	30,6 [16,3-46,1]
Month 24	30,6 [16,3-46,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS13: PFS - IRC by subgroup: Number prior lines
 ITT set

PFS - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	20 (57,1)
95%-CI	[39,4-73,7]
PFS - IRC in months [95%-CI]	
Median	3,68 [2,66-7,36]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,6 [38,1-72,9]
Month 6	32,9 [15,2-52,0]
Month 12	24,7 [8,2-45,8]
Month 18	24,7 [8,2-45,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS13: PFS - IRC by subgroup: Number prior lines
 ITT set

PFS - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	21 (44,7)
95%-CI	[30,2-59,9]
PFS - IRC in months [95%-CI]	
Median	7,06[2,89-14,23]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,7 [41,9-73,6]
Month 6	55,4 [37,1-70,4]
Month 12	31,7 [13,1-52,3]
Month 18	23,8 [7,2-45,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS14: PFS - IRC by subgroup: Response category - first line
 ITT set

2.4.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

PFS - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	49 (49,5)
95%-CI	[39,3-59,7]
PFS - IRC in months [95%-CI]	
Median	7,00 [2,89-11,47]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,2 [45,8-67,0]
Month 6	53,1 [41,2-63,6]
Month 12	34,6 [21,7-47,9]
Month 18	28,3 [15,9-42,1]
Month 24	23,6 [11,3-38,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS14: PFS - IRC by subgroup: Response category - first line
 ITT set

PFS - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	18 (62,1)
95%-CI	[42,3-79,3]
PFS - IRC in months [95%-CI]	
Median	2,66[1,35-11,24]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,5 [21,7-60,3]
Month 6	36,4 [17,5-55,6]
Month 12	20,2 [4,7-43,3]
Month 18	10,1 [0,8-34,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS15: PFS - IRC by subgroup: Response category - last line
 ITT set

2.4.15 Merkmal: *Ansprechkategorie auf die letzte vorherige systemische Therapie*

PFS - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	16 (36,4)
95%-CI	[22,4-52,2]
PFS - IRC in months [95%-CI]	
Median	11,47 [3,81-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [57,9-86,5]
Month 6	63,7 [44,1-78,1]
Month 12	47,9 [27,0-66,2]
Month 18	41,1 [20,3-60,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS15: PFS - IRC by subgroup: Response category - last line
 ITT set

PFS - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	52 (59,1)
95%-CI	[48,1-69,5]
PFS - IRC in months [95%-CI]	
Median	2,66 [1,54-3,68]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,1 [27,5-50,6]
Month 6	35,3 [23,9-46,9]
Month 12	21,4 [10,9-34,2]
Month 18	18,3 [8,5-31,2]
Month 24	14,7 [5,7-27,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS16: PFS - IRC by subgroup: Response category - any line
 ITT set

2.4.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

PFS - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	13 (54,2)
95%-CI	[32,8-74,4]
PFS - IRC in months [95%-CI]	
Median	2,66[1,35-11,24]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,4 [24,9-70,0]
Month 6	42,4 [19,0-64,1]
Month 12	22,6 [4,7-48,5]
Month 18	11,3 [0,8-37,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS16: PFS - IRC by subgroup: Response category - any line
 ITT set

PFS - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	56 (48,7)
95%-CI	[39,3-58,2]
PFS - IRC in months [95%-CI]	
Median	6,01[2,99-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,2 [47,6-67,4]
Month 6	50,6 [39,5-60,7]
Month 12	35,7 [24,0-47,6]
Month 18	30,6 [19,0-42,9]
Month 24	26,8 [15,1-40,0]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS17: PFS - IRC by subgroup: Prior use of T-CART therapy
 ITT set

2.4.17 *Merkmal: Vorherige CAR-T-Therapie*

PFS - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
PFS - IRC in months [95%-CI]	
Median	14,23[1,35-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [31,5-93,1]
Month 6	75,0 [31,5-93,1]
Month 12	75,0 [31,5-93,1]
Month 18	37,5 [1,4-79,8]
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS17: PFS - IRC by subgroup: Prior use of T-CART therapy
 ITT set

PFS - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	70 (53,0)
95%-CI	[44,2-61,8]
PFS - IRC in months [95%-CI]	
Median	4,40 [2,76-8,08]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,2 [44,5-63,0]
Month 6	46,6 [36,5-56,0]
Month 12	30,9 [20,7-41,7]
Month 18	26,8 [16,8-37,8]
Month 24	23,4 [13,3-35,2]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS18: PFS - IRC by subgroup: Drug formulation
 ITT set

2.4.18 *Merkmal: Arzneimittelformulierung*

PFS - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	17 (48,6)
95%-CI	[31,4-66,0]
PFS - IRC in months [95%-CI]	
Median	4,40 [1,58-NE]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,8 [33,2-69,1]
Month 6	48,0 [28,4-65,2]
Month 12	38,4 [17,0-59,7]
Month 18	38,4 [17,0-59,7]
Month 24	28,8 [9,1-52,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3PFS_TSTS18: PFS - IRC by subgroup: Drug formulation
 ITT set

PFS - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	56 (50,9)
95%-CI	[41,2-60,6]
PFS - IRC in months [95%-CI]	
Median	5,09[2,73-10,61]
PFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [45,7-66,1]
Month 6	48,6 [37,3-59,0]
Month 12	32,3 [20,9-44,2]
Month 18	24,8 [14,1-37,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. PFS = Progression-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS01: RFS - IRC by subgroup: Age group
 Complete Responders in ITT Set (IRC)

2.5 Subgruppenanalysen zum rezidivfreien Überleben

2.5.1 Merkmal Alter

RFS - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
RFS - IRC in months [95%-CI]	
Median	NE [1,81-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	78,8 [38,1-94,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS01: RFS - IRC by subgroup: Age group
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
RFS - IRC in months [95%-CI]	
Median	NE[10,25-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	87,5 [38,7-98,1]
Month 18	75,0 [31,5-93,1]
Month 24	75,0 [31,5-93,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS01: RFS - IRC by subgroup: Age group
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: >= 75 years Patients in analysis set Subgroup level is not displayed due to few patients	<10

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS02: RFS - IRC by subgroup: Sex
 Complete Responders in ITT Set (IRC)

2.5.2 *Merkmal: Geschlecht*

RFS - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	22
Patients with events - n(%)	5 (22,7)
95%-CI	[7,8-45,4]
RFS - IRC in months [95%-CI]	
Median	NE [12,58-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	89,4 [63,8-97,3]
Month 12	83,0 [55,8-94,3]
Month 18	68,5 [39,3-85,8]
Month 24	68,5 [39,3-85,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS02: RFS - IRC by subgroup: Sex
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	14
Patients with events - n(%)	1 (7,1)
95%-CI	[0,2-33,9]
RFS - IRC in months [95%-CI]	
Median	NE [2,83-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	87,5 [38,7-98,1]
Month 18	87,5 [38,7-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS03: RFS - IRC by subgroup: Race group
 Complete Responders in ITT Set (IRC)

2.5.3 *Merkmal: Ethnie*

RFS - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	34
Patients with events - n(%)	6 (17,6)
95%-CI	[6,8-34,5]
RFS - IRC in months [95%-CI]	
Median	NE [13,37-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [73,4-98,1]
Month 6	87,7 [66,1-95,9]
Month 12	82,2 [58,6-93,1]
Month 18	70,0 [43,9-85,7]
Month 24	70,0 [43,9-85,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS03: RFS - IRC by subgroup: Race group
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS04: RFS - IRC by subgroup: Country
 Complete Responders in ITT Set (IRC)

2.5.4 *Merkmal: Region-1*

RFS - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
RFS - IRC in months [95%-CI]	
Median	NE [10,25-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	79,6 [39,3-94,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS04: RFS - IRC by subgroup: Country
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS04: RFS - IRC by subgroup: Country
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	14
Patients with events - n(%)	2 (14,3)
95%-CI	[1,8-42,8]
RFS - IRC in months [95%-CI]	
Median	NE [5,62-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	75,8 [30,5-93,7]
Month 12	75,8 [30,5-93,7]
Month 18	75,8 [30,5-93,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS05: RFS - IRC by subgroup: Region
 Complete Responders in ITT Set (IRC)

2.5.5 *Merkmal: Region-2*

RFS - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
RFS - IRC in months [95%-CI]	
Median	NE [10,25-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	79,6 [39,3-94,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS05: RFS - IRC by subgroup: Region
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
RFS - IRC in months [95%-CI]	
Median	NE [NE-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [65,0-99,2]
Month 6	85,6 [52,5-96,3]
Month 12	85,6 [52,5-96,3]
Month 18	85,6 [52,5-96,3]
Month 24	85,6 [52,5-96,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS06: RFS - IRC by subgroup: Ann Arbor stage
Complete Responders in ITT Set (IRC)

2.5.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

RFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS06: RFS - IRC by subgroup: Ann Arbor stage
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS06: RFS - IRC by subgroup: Ann Arbor stage
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS06: RFS - IRC by subgroup: Ann Arbor stage
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	22
Patients with events - n(%)	4 (18,2)
95%-CI	[5,2-40,3]
RFS - IRC in months [95%-CI]	
Median	NE[13,37-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	88,7 [61,4-97,1]
Month 12	88,7 [61,4-97,1]
Month 18	71,7 [39,5-88,7]
Month 24	71,7 [39,5-88,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS07: RFS - IRC by subgroup: Bulky disease
 Complete Responders in ITT Set (IRC)

2.5.7 *Merkmal: Bulky Erkrankung*

RFS - IRC by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
RFS - IRC in months [95%-CI]	
Median	NE [13,37-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,3 [76,5-99,5]
Month 6	91,5 [69,6-97,8]
Month 12	86,1 [62,3-95,4]
Month 18	74,2 [47,9-88,6]
Month 24	74,2 [47,9-88,6]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS08: RFS - IRC by subgroup: Double/Triple hit
Complete Responders in ITT Set (IRC)

2.5.8 *Merkmal: Double/Triple-Hit*

RFS - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS08: RFS - IRC by subgroup: Double/Triple hit
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	31
Patients with events - n(%)	5 (16,1)
95%-CI	[5,5-33,7]
RFS - IRC in months [95%-CI]	
Median	NE[12,58-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [70,5-97,9]
Month 6	85,5 [60,7-95,2]
Month 12	78,4 [50,8-91,6]
Month 18	70,6 [41,4-87,1]
Month 24	70,6 [41,4-87,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS09: RFS - IRC by subgroup: Transformed DLBCL
Complete Responders in ITT Set (IRC)

2.5.9 *Merkmal: Transformation des DLBCL*

RFS - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL: Transformed Patients in analysis set Subgroup level is not displayed due to few patients	<10

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS09: RFS - IRC by subgroup: Transformed DLBCL
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
RFS - IRC in months [95%-CI]	
Median	NE[13,37-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,3-97,8]
Month 6	85,6 [61,1-95,2]
Month 12	79,0 [52,3-91,8]
Month 18	71,8 [43,8-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS10: RFS - IRC by subgroup: B-Cell type
 Complete Responders in ITT Set (IRC)

2.5.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

RFS - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
RFS - IRC in months [95%-CI]	
Median	NE [2,83-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	78,8 [38,1-94,3]
Month 18	65,6 [26,0-87,7]
Month 24	65,6 [26,0-87,7]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS10: RFS - IRC by subgroup: B-Cell type
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS11: RFS - IRC by subgroup: Maximal longest diameter
 Complete Responders in ITT Set (IRC)

2.5.11 *Merkmal: Maximaler längster Durchmesser*

RFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	27
Patients with events - n(%)	1 (3,7)
95%-CI	[0,1-19,0]
RFS - IRC in months [95%-CI]	
Median	NE [NE-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	92,3 [56,6-98,9]
Month 24	92,3 [56,6-98,9]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS11: RFS - IRC by subgroup: Maximal longest diameter
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: >5 - <= 7,5 cm	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS11: RFS - IRC by subgroup: Maximal longest diameter
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS11: RFS - IRC by subgroup: Maximal longest diameter
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS12: RFS - IRC by subgroup: Primary disease diagnosis
 Complete Responders in ITT Set (IRC)

2.5.12 *Merkmal: Primärdiagnose*

RFS - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	31
Patients with events - n(%)	5 (16,1)
95%-CI	[5,5-33,7]
RFS - IRC in months [95%-CI]	
Median	NE [12,58-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [70,5-97,9]
Month 6	85,5 [60,7-95,2]
Month 12	78,4 [50,8-91,6]
Month 18	70,6 [41,4-87,1]
Month 24	70,6 [41,4-87,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS12: RFS - IRC by subgroup: Primary disease diagnosis
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS13: RFS - IRC by subgroup: Number prior lines
 Complete Responders in ITT Set (IRC)

2.5.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

RFS - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
RFS - IRC in months [95%-CI]	
Median	NE [13,37-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	79,6 [39,3-94,5]
Month 24	79,6 [39,3-94,5]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS13: RFS - IRC by subgroup: Number prior lines
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS13: RFS - IRC by subgroup: Number prior lines
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	16
Patients with events - n(%)	3 (18,8)
95%-CI	[4,0-45,6]
RFS - IRC in months [95%-CI]	
Median	NE[10,25-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	73,3 [24,3-93,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS14: RFS - IRC by subgroup: Response category - first line
 Complete Responders in ITT Set (IRC)

2.5.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

RFS - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	27
Patients with events - n(%)	4 (14,8)
95%-CI	[4,2-33,7]
RFS - IRC in months [95%-CI]	
Median	NE [10,25-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	87,7 [58,1-96,9]
Month 12	79,7 [48,4-93,2]
Month 18	70,9 [38,5-88,3]
Month 24	70,9 [38,5-88,3]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS14: RFS - IRC by subgroup: Response category - first line
Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS15: RFS - IRC by subgroup: Response category - last line
 Complete Responders in ITT Set (IRC)

2.5.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

RFS - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
RFS - IRC in months [95%-CI]	
Median	NE [10,25-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	91,7 [53,9-98,8]
Month 12	81,5 [43,5-95,1]
Month 18	71,3 [34,4-89,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS15: RFS - IRC by subgroup: Response category - last line
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
RFS - IRC in months [95%-CI]	
Median	NE[1,81-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	87,5 [38,7-98,1]
Month 18	87,5 [38,7-98,1]
Month 24	87,5 [38,7-98,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS16: RFS - IRC by subgroup: Response category - any line
Complete Responders in ITT Set (IRC)

2.5.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

RFS - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS16: RFS - IRC by subgroup: Response category - any line
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
RFS - IRC in months [95%-CI]	
Median	NE[12,58-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [73,9-99,4]
Month 6	90,2 [65,6-97,5]
Month 12	83,8 [56,9-94,6]
Month 18	76,8 [48,4-90,8]
Month 24	76,8 [48,4-90,8]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS17: RFS - IRC by subgroup: Prior use of T-CART therapy
Complete Responders in ITT Set (IRC)

2.5.17 *Merkmal: Vorherige CAR-T-Therapie*

RFS - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS17: RFS - IRC by subgroup: Prior use of T-CART therapy
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	33
Patients with events - n(%)	5 (15,2)
95%-CI	[5,1-31,9]
RFS - IRC in months [95%-CI]	
Median	NE[13,37-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [73,4-98,1]
Month 6	87,4 [65,3-95,9]
Month 12	81,6 [57,2-92,9]
Month 18	74,8 [48,2-89,1]
Month 24	74,8 [48,2-89,1]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS18: RFS - IRC by subgroup: Drug formulation
Complete Responders in ITT Set (IRC)

2.5.18 *Merkmal: Arzneimittelformulierung*

RFS - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: atte, created on: 10JAN2023

Table LT3RFS_CSTS18: RFS - IRC by subgroup: Drug formulation
 Complete Responders in ITT Set (IRC)

RFS - IRC by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	28
Patients with events - n(%)	5 (17,9)
95%-CI	[6,1-36,9]
RFS - IRC in months [95%-CI]	
Median	NE[12,58-NE]
RFS - IRC:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	89,4 [63,8-97,3]
Month 12	83,0 [55,8-94,3]
Month 18	69,7 [41,3-86,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 ITT set = Intent to Treat set. RFS = Relapse-free survival. IRC = Independent review committee assessment.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: atte, created on: 10JAN2023

Table LT3VSD_PSTS01: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Age group
 PRO set

2.6 Subgruppenanalysen zum EQ-5D VAS (Zeit bis zur Verschlechterung)

2.6.1 Merkmal Alter

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	23 (40,4)
95%-CI	[27,6-54,2]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,76 [2,89-7,23]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,8 [43,5-74,3]
Month 6	40,3 [22,5-57,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS01: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Age group
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	24 (45,3)
95%-CI	[31,6-59,6]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	3,32 [1,64-7,16]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,7 [34,0-65,3]
Month 6	37,5 [20,5-54,4]
Month 12	32,1 [15,6-49,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS01: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Age group
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	6 (30,0)
95%-CI	[11,9-54,3]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	NE [1,15-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,3 [35,3-81,8]
Month 6	63,3 [35,3-81,8]
Month 12	63,3 [35,3-81,8]
Month 18	63,3 [35,3-81,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS02: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Sex
 PRO set

2.6.2 *Merkmal: Geschlecht*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	20 (37,7)
95%-CI	[24,8-52,1]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	6,90 [1,71-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,6 [44,6-74,8]
Month 6	53,6 [35,5-68,6]
Month 12	43,8 [25,3-61,0]
Month 18	43,8 [25,3-61,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS02: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Sex
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	33 (42,9)
95%-CI	[31,6-54,6]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,24 [2,79-5,78]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,8 [38,3-65,4]
Month 6	32,8 [18,2-48,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS03: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Race group
 PRO set

2.6.3 *Merkmal: Ethnie*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	48 (41,7)
95%-CI	[32,6-51,3]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,24 [2,79-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,6 [42,8-65,0]
Month 6	39,7 [27,3-51,9]
Month 12	30,6 [18,1-44,0]
Month 18	30,6 [18,1-44,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS03: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Race group
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	NE [2,17-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,4 [35,9-86,8]
Month 6	54,7 [20,8-79,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS04: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Country
 PRO set

2.6.4 *Merkmal: Region-1*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	18 (35,3)
95%-CI	[22,4-49,9]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,76 [2,33-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,3 [37,6-71,3]
Month 6	47,5 [28,6-64,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS04: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Country
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	13 (44,8)
95%-CI	[26,4-64,3]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,24 [1,64-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,7 [39,0-78,0]
Month 6	40,9 [18,1-62,6]
Month 12	27,3 [6,2-54,4]
Month 18	27,3 [6,2-54,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS04: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Country
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	22 (45,8)
95%-CI	[31,4-60,8]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [2,10-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,0 [33,9-67,3]
Month 6	34,7 [16,4-53,8]
Month 12	27,7 [10,6-48,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS05: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Region
 PRO set

2.6.5 *Merkmal: Region-2*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	18 (35,3)
95%-CI	[22,4-49,9]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,76 [2,33-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,3 [37,6-71,3]
Month 6	47,5 [28,6-64,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS05: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Region
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	35 (44,3)
95%-CI	[33,1-55,9]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [2,83-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [42,8-68,2]
Month 6	37,4 [22,6-52,2]
Month 12	28,1 [13,7-44,4]
Month 18	28,1 [13,7-44,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS06: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage
 PRO set

2.6.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [1,48-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	45,7 [6,9-79,5]
Month 12	22,9 [1,0-62,5]
Month 18	22,9 [1,0-62,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS06: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	2,99[0,92-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,4 [15,4-67,5]
Month 6	31,8 [8,5-58,7]
Month 12	31,8 [8,5-58,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS06: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	6 (35,3)
95%-CI	[14,2-61,7]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	6,90 [2,17-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,9 [44,2-91,9]
Month 6	51,3 [17,6-77,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS06: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	34 (41,5)
95%-CI	[30,7-52,9]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,76 [1,71-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,6 [36,8-62,9]
Month 6	41,1 [26,7-55,0]
Month 12	36,6 [21,7-51,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS07: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Bulky disease
 PRO set

2.6.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	52 (41,3)
95%-CI	[32,6-50,4]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [2,89-7,16]
EQ-5D-VAS - Time to decrease at least 15 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,7 [45,6-66,3]
Month 6	41,9 [30,1-53,2]
Month 12	33,5 [21,3-46,1]
Month 18	33,5 [21,3-46,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS08: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Double/Triple hit
 PRO set

2.6.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	4 (28,6)
95%-CI	[8,4-58,1]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	NE [1,15-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,3 [27,4-84,1]
Month 6	62,3 [27,4-84,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS08: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	49 (42,2)
95%-CI	[33,1-51,8]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,24 [2,83-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,2 [43,4-65,4]
Month 6	39,0 [26,8-51,1]
Month 12	30,0 [17,8-43,2]
Month 18	30,0 [17,8-43,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS09: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Transformed DLBCL
 PRO set

2.6.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	5,13[4,24-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,7 [50,8-89,2]
Month 6	32,5 [8,4-60,1]
Month 12	32,5 [8,4-60,1]
Month 18	32,5 [8,4-60,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. VAS = visual analogue scale.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS09: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	44 (41,5)
95%-CI	[32,0-51,5]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	3,32 [2,79-7,23]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,1 [39,9-63,0]
Month 6	43,5 [30,9-55,4]
Month 12	33,5 [20,2-47,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. VAS = visual analogue scale.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS10: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: B-Cell type
 PRO set

2.6.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	20 (46,5)
95%-CI	[31,2-62,3]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	5,13 [2,10-7,23]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,1 [40,1-72,4]
Month 6	49,0 [30,3-65,4]
Month 12	28,0 [10,3-49,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS10: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: B-Cell type
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	3,32 [1,61-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,5 [31,6-77,9]
Month 6	39,0 [13,8-63,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS11: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter
 PRO set

2.6.11 *Merkmal: Maximaler längster Durchmesser*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	28 (36,8)
95%-CI	[26,1-48,7]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	5,13[2,89-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,0 [43,6-69,9]
Month 6	49,6 [34,5-62,9]
Month 12	45,1 [29,2-59,7]
Month 18	45,1 [29,2-59,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS11: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	16 (47,1)
95%-CI	[29,8-64,9]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,24 [1,64-5,29]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [34,6-73,7]
Month 6	25,9 [7,4-49,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS11: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. VAS = visual analogue scale.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS11: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. VAS = visual analogue scale.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS12: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Primary disease diagnosis
 PRO set

2.6.12 *Merkmal: Primärdiagnose*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	48 (42,9)
95%-CI	[33,5-52,6]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [2,83-6,90]
EQ-5D-VAS - Time to decrease at least 15 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,2 [44,6-66,4]
Month 6	39,8 [27,5-51,9]
Month 12	30,7 [18,2-44,0]
Month 18	30,7 [18,2-44,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS12: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	NE [1,15-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,0 [17,0-79,7]
Month 6	53,0 [17,0-79,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS13: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Number prior lines
 PRO set

2.6.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	26 (44,1)
95%-CI	[31,2-57,6]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	3,32 [1,71-7,23]
EQ-5D-VAS - Time to decrease at least 15 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,1 [37,6-68,0]
Month 6	38,1 [21,3-54,7]
Month 12	27,2 [11,7-45,4]
Month 18	27,2 [11,7-45,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS13: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Number prior lines
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	13 (40,6)
95%-CI	[23,7-59,4]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	2,99 [1,68-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,7 [25,5-66,9]
Month 6	38,1 [15,6-60,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS13: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Number prior lines
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	14 (35,9)
95%-CI	[21,2-52,8]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	7,16[2,99-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,1 [46,8-81,1]
Month 6	50,3 [28,5-68,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS14: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - first line
 PRO set

2.6.14 *Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	40 (43,5)
95%-CI	[33,2-54,2]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [2,79-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,9 [43,2-66,8]
Month 6	39,7 [26,0-53,1]
Month 12	30,9 [16,7-46,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS14: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - first line
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	10 (45,5)
95%-CI	[24,4-67,8]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	3,02 [1,48-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,8 [28,4-76,4]
Month 6	34,9 [10,4-61,3]
Month 12	23,3 [4,2-51,2]
Month 18	23,3 [4,2-51,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PST15: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - last line
 PRO set

2.6.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	14 (35,0)
95%-CI	[20,6-51,7]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	7,16[2,99-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,3 [47,3-81,1]
Month 6	51,8 [30,4-69,5]
Month 12	44,4 [22,5-64,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PST15: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - last line
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	35 (44,3)
95%-CI	[33,1-55,9]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	2,79 [1,64-5,29]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,1 [31,8-59,4]
Month 6	31,6 [17,2-47,0]
Month 12	25,3 [10,9-42,6]
Month 18	25,3 [10,9-42,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PST16: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - any line
 PRO set

2.6.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	3,02 [1,48-NE]
EQ-5D-VAS - Time to decrease at least 15 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,2 [26,4-77,9]
Month 6	35,1 [10,0-62,2]
Month 12	17,6 [1,2-50,2]
Month 18	17,6 [1,2-50,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS16: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - any line
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	42 (40,4)
95%-CI	[30,9-50,5]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,76 [2,89-7,16]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,2 [45,1-67,6]
Month 6	42,9 [29,6-55,5]
Month 12	35,7 [22,0-49,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS17: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Prior use of T-CART therapy
PRO set

2.6.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. VAS = visual analogue scale.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS17: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	51 (41,8)
95%-CI	[32,9-51,1]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [2,83-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,3 [44,0-65,3]
Month 6	39,3 [27,2-51,2]
Month 12	30,9 [18,8-43,8]
Month 18	30,9 [18,8-43,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS18: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Drug formulation
 PRO set

2.6.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	15 (46,9)
95%-CI	[29,1-65,3]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,73 [1,71-6,90]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,8 [33,9-73,1]
Month 6	27,9 [7,9-52,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSD_PSTS18: Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Drug formulation
 PRO set

Time to first decrease in EQ-5D-VAS by at least 15 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation: Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	38 (38,8)
95%-CI	[29,1-49,2]
EQ-5D-VAS - Time to decrease at least 15 points in months [95%-CI]	
Median	4,76 [2,79-NE]
EQ-5D-VAS - Time to decrease at least 15 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [43,8-67,6]
Month 6	45,2 [31,8-57,7]
Month 12	38,3 [24,3-52,1]
Month 18	38,3 [24,3-52,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

2.7 Subgruppenanalysen zum EQ-5D VAS (Veränderung gegenüber Studienbeginn)

2.7.1 Merkmal Alter

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
EQ-5D-VAS	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	56 (98,2)
Mean (SD)	69,80 (19,38)
Median (Min - Max)	72,50 [5,00-97,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	47 (95,9)
Mean (SD)	1,30 (13,37)
Median (Min - Max)	0,00 [-30,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	34 (91,9)
Mean (SD)	3,00 (16,12)
Median (Min - Max)	0,00 [-25,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	25 (89,3)
Mean (SD)	2,32 (14,67)
Median (Min - Max)	5,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	21 (95,5)
Mean (SD)	3,62 (14,58)
Median (Min - Max)	0,00 [-25,00-30,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	3,80 (12,96)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	4,54 (12,97)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	8,30 (12,34)
Median (Min - Max)	1,50 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	6,00 (15,75)
Median (Min - Max)	2,50 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,83 (19,34)
Median (Min - Max)	5,00 [-5,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	22,50 (17,56)
Median (Min - Max)	22,50 [5,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	20,00 (21,98)
Median (Min - Max)	20,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	20,00 (21,21)
Median (Min - Max)	20,00 [5,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	20,00 (21,21)
Median (Min - Max)	20,00 [5,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	43 (75,4)
Mean (SD)	-4,86 (16,32)
Median (Min - Max)	-7,00 [-30,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
EQ-5D-VAS	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	51 (96,2)
Mean (SD)	71,45 (19,23)
Median (Min - Max)	75,00 [30,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	48
Treated patients with non-missing values - n(%)	44 (91,7)
Mean (SD)	0,11 (16,74)
Median (Min - Max)	0,00 [-46,00-55,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	29 (85,3)
Mean (SD)	-1,21 (18,84)
Median (Min - Max)	0,00 [-51,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,92 (15,53)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	3,38 (12,74)
Median (Min - Max)	0,00 [-15,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	5,58 (13,69)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	5,90 (13,69)
Median (Min - Max)	0,50 [-15,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	6,63 (14,68)
Median (Min - Max)	2,50 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	11,63 (14,53)
Median (Min - Max)	7,50 [-5,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	11,00 (15,17)
Median (Min - Max)	10,00 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,50 (16,66)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	12,00 (13,04)
Median (Min - Max)	10,00 [0,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,00 (8,16)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (11,55)
Median (Min - Max)	10,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,00 (10,00)
Median (Min - Max)	0,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,00 (10,00)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (11,55)
Median (Min - Max)	10,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	43 (81,1)
Mean (SD)	-11,28 (21,65)
Median (Min - Max)	-10,00 [-55,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
EQ-5D-VAS	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	75,50 (18,20)
Median (Min - Max)	80,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-4,71 (20,28)
Median (Min - Max)	0,00 [-50,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	2,62 (14,40)
Median (Min - Max)	0,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	9,00 (14,50)
Median (Min - Max)	10,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	-1,14 (13,04)
Median (Min - Max)	0,00 [-20,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-4,33 (31,35)
Median (Min - Max)	0,00 [-65,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,20 (12,44)
Median (Min - Max)	0,00 [-20,00-15,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	6,00 (13,93)
Median (Min - Max)	7,00 [-10,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	3,25 (20,30)
Median (Min - Max)	7,50 [-25,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	19,00 (5,66)
Median (Min - Max)	19,00 [15,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	18,00 (7,07)
Median (Min - Max)	18,00 [13,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	4,00 (26,87)
Median (Min - Max)	4,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	22,00 (NE)
Median (Min - Max)	22,00 [22,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS01: EQ-5D-VAS - Change from Baseline by subgroup: Age group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	12 (60,0)
Mean (SD)	-9,58 (24,19)
Median (Min - Max)	-3,00 [-50,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

2.7.2 Merkmal: Geschlecht

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
EQ-5D-VAS	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	53 (100,0)
Mean (SD)	69,47 (18,71)
Median (Min - Max)	75,00 [30,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	43 (93,5)
Mean (SD)	1,07 (16,11)
Median (Min - Max)	0,00 [-50,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	4,26 (19,18)
Median (Min - Max)	2,50 [-30,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	24 (85,7)
Mean (SD)	6,75 (15,72)
Median (Min - Max)	6,50 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	6,43 (12,57)
Median (Min - Max)	5,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	4,05 (19,82)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	3,58 (13,34)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	7,07 (13,01)
Median (Min - Max)	2,50 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	6,64 (15,59)
Median (Min - Max)	7,50 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	11,30 (12,92)
Median (Min - Max)	12,50 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	10,10 (16,51)
Median (Min - Max)	10,00 [-20,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	14,75 (13,17)
Median (Min - Max)	15,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	8,29 (16,45)
Median (Min - Max)	5,00 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	12,17 (15,43)
Median (Min - Max)	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	43 (81,1)
Mean (SD)	-6,49 (21,63)
Median (Min - Max)	-5,00 [-55,00-35,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
EQ-5D-VAS	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	74 (96,1)
Mean (SD)	72,72 (19,37)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	65 (92,9)
Mean (SD)	-0,92 (15,96)
Median (Min - Max)	0,00 [-46,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	42 (84,0)
Mean (SD)	-1,05 (14,51)
Median (Min - Max)	0,00 [-51,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	34 (87,2)
Mean (SD)	-0,03 (14,04)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-0,57 (13,71)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	1,50 (14,19)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	4,89 (12,67)
Median (Min - Max)	0,00 [-5,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	7,63 (13,51)
Median (Min - Max)	1,50 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,17 (17,10)
Median (Min - Max)	2,50 [-7,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	15,00 (26,46)
Median (Min - Max)	5,00 [-5,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS02: EQ-5D-VAS - Change from Baseline by subgroup: Sex
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	20,00 (28,28)
Median (Min - Max)	20,00 [0,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	22,50 (31,82)
Median (Min - Max)	22,50 [0,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	55 (71,4)
Mean (SD)	-9,64 (18,42)
Median (Min - Max)	-10,00 [-50,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

2.7.3 *Merkmal: Ethnie*

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
EQ-5D-VAS	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	112 (97,4)
Mean (SD)	70,29 (19,10)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	96 (92,3)
Mean (SD)	-0,46 (16,60)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	65 (87,8)
Mean (SD)	1,29 (17,25)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	48 (85,7)
Mean (SD)	2,63 (15,07)
Median (Min - Max)	1,50 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	37 (90,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,41 (14,27)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	2,78 (18,39)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	4,00 (13,19)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	6,58 (12,69)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	7,84 (16,10)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	12,75 (16,18)
Median (Min - Max)	12,50 [-10,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	12,82 (18,07)
Median (Min - Max)	10,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	18,11 (15,92)
Median (Min - Max)	20,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	8,29 (16,45)
Median (Min - Max)	5,00 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	12,17 (15,43)
Median (Min - Max)	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,9)
Mean (SD)	-8,66 (20,50)
Median (Min - Max)	-8,00 [-55,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
EQ-5D-VAS	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	79,33 (17,65)
Median (Min - Max)	85,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	2,50 (9,69)
Median (Min - Max)	0,00 [-10,00-20,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	1,55 (15,06)
Median (Min - Max)	0,00 [-15,00-40,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	3,50 (15,46)
Median (Min - Max)	1,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	4,71 (8,88)
Median (Min - Max)	0,00 [-2,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,83 (13,72)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	4,00 (12,94)
Median (Min - Max)	0,00 [-10,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,67 (16,07)
Median (Min - Max)	5,00 [0,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS03: EQ-5D-VAS - Change from Baseline by subgroup: Race group
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	13 (86,7)
Median (Min - Max)	-5,62 (15,34)
	-5,00 [-40,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

2.7.4 *Merkmal: Region-1*

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
EQ-5D-VAS	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	68,82 (19,98)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	42 (93,3)
Mean (SD)	-0,14 (15,84)
Median (Min - Max)	0,00 [-45,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	29 (87,9)
Mean (SD)	2,10 (14,31)
Median (Min - Max)	0,00 [-30,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	23 (85,2)
Mean (SD)	4,52 (13,89)
Median (Min - Max)	2,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	17 (85,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,12 (14,21)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,94 (22,12)
Median (Min - Max)	0,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	4,91 (16,16)
Median (Min - Max)	0,00 [-15,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	9,33 (14,54)
Median (Min - Max)	0,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	20,00 (13,42)
Median (Min - Max)	20,00 [5,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	20,00 (16,43)
Median (Min - Max)	20,00 [0,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,83 (23,33)
Median (Min - Max)	20,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	22,50 (16,05)
Median (Min - Max)	25,00 [0,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,33 (23,63)
Median (Min - Max)	0,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	35,00 (NE)
Median (Min - Max)	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	35 (68,6)
Mean (SD)	-5,40 (22,04)
Median (Min - Max)	-5,00 [-45,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
EQ-5D-VAS	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	28 (96,6)
Mean (SD)	81,75 (11,05)
Median (Min - Max)	82,50 [60,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	21 (87,5)
Mean (SD)	1,05 (10,99)
Median (Min - Max)	0,00 [-25,00-23,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	11 (68,8)
Mean (SD)	-4,91 (12,54)
Median (Min - Max)	-5,00 [-25,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,91 (17,27)
Median (Min - Max)	0,00 [-25,00-27,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	2,78 (15,33)
Median (Min - Max)	0,00 [-20,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	8,00 (13,70)
Median (Min - Max)	6,50 [-10,00-27,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,00 (16,61)
Median (Min - Max)	0,00 [-20,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	16,00 (14,42)
Median (Min - Max)	20,00 [0,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	4,20 (21,65)
Median (Min - Max)	0,00 [-25,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	4,00 (26,87)
Median (Min - Max)	4,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	22,00 (NE)
Median (Min - Max)	22,00 [22,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	-7,58 (18,00)
Median (Min - Max)	-5,00 [-50,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
EQ-5D-VAS	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	47 (97,9)
Mean (SD)	68,36 (19,91)
Median (Min - Max)	70,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	44 (95,7)
Mean (SD)	-1,02 (18,24)
Median (Min - Max)	0,00 [-50,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	35 (97,2)
Mean (SD)	2,26 (19,81)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	1,96 (15,44)
Median (Min - Max)	2,50 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	4,00 (12,75)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	7,36 (8,44)
Median (Min - Max)	5,00 [-5,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	3,64 (7,00)
Median (Min - Max)	0,00 [-5,00-15,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	2,80 (10,03)
Median (Min - Max)	1,50 [-10,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,44 (8,52)
Median (Min - Max)	0,00 [-15,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	2,50 (10,37)
Median (Min - Max)	2,50 [-10,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	4,60 (7,30)
Median (Min - Max)	5,00 [-5,00-13,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	1,67 (7,64)
Median (Min - Max)	0,00 [-5,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	5,00 (5,00)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	3,75 (9,46)
Median (Min - Max)	7,50 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,50 (9,57)
Median (Min - Max)	5,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,00 (10,00)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (11,55)
Median (Min - Max)	10,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS04: EQ-5D-VAS - Change from Baseline by subgroup: Country
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	37 (77,1)
Mean (SD)	-11,84 (19,25)
Median (Min - Max)	-10,00 [-55,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

2.7.5 *Merkmal: Region-2*

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
EQ-5D-VAS	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	68,82 (19,98)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	42 (93,3)
Mean (SD)	-0,14 (15,84)
Median (Min - Max)	0,00 [-45,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	29 (87,9)
Mean (SD)	2,10 (14,31)
Median (Min - Max)	0,00 [-30,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	23 (85,2)
Mean (SD)	4,52 (13,89)
Median (Min - Max)	2,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	17 (85,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,12 (14,21)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,94 (22,12)
Median (Min - Max)	0,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	4,91 (16,16)
Median (Min - Max)	0,00 [-15,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	9,33 (14,54)
Median (Min - Max)	0,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	20,00 (13,42)
Median (Min - Max)	20,00 [5,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	20,00 (16,43)
Median (Min - Max)	20,00 [0,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,83 (23,33)
Median (Min - Max)	20,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	22,50 (16,05)
Median (Min - Max)	25,00 [0,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,33 (23,63)
Median (Min - Max)	0,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	35,00 (NE)
Median (Min - Max)	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	35 (68,6)
Mean (SD)	-5,40 (22,04)
Median (Min - Max)	-5,00 [-45,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
EQ-5D-VAS	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	77 (97,5)
Mean (SD)	73,01 (18,43)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	66 (93,0)
Mean (SD)	-0,12 (16,18)
Median (Min - Max)	0,00 [-50,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	47 (88,7)
Mean (SD)	0,85 (18,38)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	35 (87,5)
Mean (SD)	1,63 (15,79)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	3,81 (13,20)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	7,59 (10,16)
Median (Min - Max)	5,00 [-10,00-27,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	3,41 (10,82)
Median (Min - Max)	0,00 [-20,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	5,85 (11,99)
Median (Min - Max)	3,00 [-10,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	2,43 (13,81)
Median (Min - Max)	0,00 [-25,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	5,43 (12,23)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	7,67 (9,95)
Median (Min - Max)	7,50 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	7,00 (12,36)
Median (Min - Max)	5,00 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	4,60 (13,90)
Median (Min - Max)	5,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	7,60 (11,89)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS05: EQ-5D-VAS - Change from Baseline by subgroup: Region
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	63 (79,7)
Mean (SD)	-9,84 (18,52)
Median (Min - Max)	-8,00 [-55,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

2.7.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
EQ-5D-VAS	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	71,50 (5,80)
Median (Min - Max)	72,50 [60,00-80,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	6,11 (9,33)
Median (Min - Max)	5,00 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,00 (16,73)
Median (Min - Max)	0,00 [-25,00-20,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,20 (17,87)
Median (Min - Max)	0,00 [-25,00-24,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	4,50 (13,82)
Median (Min - Max)	2,50 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,33 (10,07)
Median (Min - Max)	8,00 [0,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	5,00 (8,66)
Median (Min - Max)	0,00 [0,00-15,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	7,50 (17,68)
Median (Min - Max)	7,50 [-5,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,67 (15,37)
Median (Min - Max)	20,00 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	21,50 (2,12)
Median (Min - Max)	21,50 [20,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (30,41)
Median (Min - Max)	1,50 [-20,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	21,50 (2,12)
Median (Min - Max)	21,50 [20,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	22,00 (NE)
	22,00 [22,00-22,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	23,00 (NE)
	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	23,00 (NE)
	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	23,00 (NE)
	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	23,00 (NE)
	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	-14,57 (20,89)
Median (Min - Max)	-20,00 [-40,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
EQ-5D-VAS	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	73,05 (12,97)
Median (Min - Max)	75,00 [45,00-95,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	-3,16 (15,82)
Median (Min - Max)	0,00 [-46,00-20,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-3,60 (19,42)
Median (Min - Max)	1,50 [-51,00-15,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-0,60 (17,30)
Median (Min - Max)	7,50 [-36,00-15,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-1,88 (16,46)
Median (Min - Max)	2,50 [-25,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	4,20 (20,33)
Median (Min - Max)	-4,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	5,50 (13,18)
Median (Min - Max)	0,50 [-4,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	11,25 (14,93)
Median (Min - Max)	10,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,67 (6,03)
Median (Min - Max)	0,00 [-7,00-5,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	15,00 (NE)
Median (Min - Max)	15,00 [15,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	4,00 (12,73)
Median (Min - Max)	4,00 [-5,00-13,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	15 (71,4)
Mean (SD)	-6,07 (13,06)
Median (Min - Max)	-5,00 [-31,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
EQ-5D-VAS	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	77,59 (15,66)
Median (Min - Max)	80,00 [50,00-97,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	7,50 (16,51)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	1,75 (19,20)
Median (Min - Max)	-2,50 [-30,00-40,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	5,67 (17,18)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	11,43 (15,70)
Median (Min - Max)	15,00 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	10,60 (11,67)
Median (Min - Max)	5,00 [-2,00-27,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,20 (14,67)
Median (Min - Max)	0,00 [-10,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,33 (15,37)
Median (Min - Max)	3,00 [0,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (16,26)
Median (Min - Max)	16,50 [5,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	13 (76,5)
Mean (SD)	-8,00 (22,61)
Median (Min - Max)	-5,00 [-45,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
EQ-5D-VAS	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	80 (97,6)
Mean (SD)	69,60 (21,80)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	66 (91,7)
Mean (SD)	-1,73 (16,20)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	49 (90,7)
Mean (SD)	2,27 (16,10)
Median (Min - Max)	0,00 [-30,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	34 (81,0)
Mean (SD)	3,74 (13,66)
Median (Min - Max)	1,00 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	1,56 (11,44)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	20 (90,9)
Mean (SD)	-0,20 (18,81)
Median (Min - Max)	0,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	2,75 (13,92)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	5,31 (12,53)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	7,08 (17,64)
Median (Min - Max)	7,50 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	11,11 (17,99)
Median (Min - Max)	10,00 [-10,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	17,14 (17,29)
	10,00 [0,00-40,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	15,71 (19,24)
	10,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	4,17 (17,72)
	2,50 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	15,00 (13,54)
	10,00 [5,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	6,67 (5,77)
	10,00 [0,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (0,00)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS06: EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	10,00 (NE)
	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	63 (76,8)
Median (Min - Max)	-8,13 (20,77)
	-10,00 [-55,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.

PRO = patient reported outcome. VAS = visual analogue scale.

Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
 PRO set

2.7.7 *Merkmal: Bulky Erkrankung*

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
EQ-5D-VAS	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	123 (97,6)
Mean (SD)	71,81 (19,03)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	105 (92,9)
Mean (SD)	0,06 (16,01)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	76 (89,4)
Mean (SD)	1,33 (16,85)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	57 (86,4)
Mean (SD)	3,26 (14,67)
Median (Min - Max)	2,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	44 (89,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,77 (13,50)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	33 (91,7)
Mean (SD)	2,97 (17,45)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	28 (96,6)
Mean (SD)	4,00 (12,91)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	7,27 (12,87)
Median (Min - Max)	1,50 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	7,70 (15,69)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	12,15 (15,64)
Median (Min - Max)	10,00 [-10,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	11,75 (17,62)
Median (Min - Max)	10,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	16,30 (16,06)
Median (Min - Max)	15,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	6,00 (16,54)
Median (Min - Max)	2,50 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	12,17 (15,43)
Median (Min - Max)	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS07: EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
NE	
Treated patients at visit	97 (77,0)
Treated patients with non-missing values - n(%)	-8,34 (19,94)
Mean (SD)	-8,34 (19,94)
Median (Min - Max)	-7,00 [-55,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

2.7.8 *Merkmal: Double/Triple-Hit*

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
EQ-5D-VAS	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	63,93 (20,96)
Median (Min - Max)	57,50 [40,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-1,92 (22,13)
Median (Min - Max)	0,00 [-45,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	6,29 (20,81)
Median (Min - Max)	0,00 [-25,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	11,50 (17,36)
Median (Min - Max)	10,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	3,50 (15,02)
Median (Min - Max)	-0,50 [-10,00-25,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-11,50 (36,95)
Median (Min - Max)	-0,50 [-65,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,67 (17,62)
Median (Min - Max)	0,00 [-1,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,00 (14,73)
Median (Min - Max)	0,00 [-1,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	27,50 (10,61)
Median (Min - Max)	27,50 [20,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	32,50 (17,68)
Median (Min - Max)	32,50 [20,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	37,50 (3,54)
Median (Min - Max)	37,50 [35,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	37,50 (10,61)
Median (Min - Max)	37,50 [30,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	35,00 (NE)
Median (Min - Max)	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	35,00 (NE)
Median (Min - Max)	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-2,33 (31,82)
Median (Min - Max)	-1,00 [-45,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
EQ-5D-VAS	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	113 (97,4)
Mean (SD)	72,28 (18,74)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	96 (92,3)
Mean (SD)	0,09 (15,17)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	69 (88,5)
Mean (SD)	0,83 (16,50)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	1,77 (14,56)
Median (Min - Max)	1,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)
Mean (SD)	2,70 (13,55)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	4,97 (12,94)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	3,32 (12,53)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	7,16 (13,01)
Median (Min - Max)	3,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	5,50 (14,74)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	8,45 (12,82)
Median (Min - Max)	10,00 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	6,60 (14,19)
Median (Min - Max)	7,50 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	11,00 (12,46)
Median (Min - Max)	10,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	1,86 (12,62)
Median (Min - Max)	0,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	7,60 (11,89)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS08: EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EOT	
EQ-5D-VAS - Change from baseline	NE
Treated patients at visit	89 (76,7)
Treated patients with non-missing values - n(%)	-8,85 (18,40)
Mean (SD)	-8,00 [-55,00-30,00]
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.

PRO = patient reported outcome. VAS = visual analogue scale.

Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

2.7.9 *Merkmal: Transformation des DLBCL*

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
EQ-5D-VAS	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	74,78 (18,31)
Median (Min - Max)	75,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	0,60 (13,48)
Median (Min - Max)	0,00 [-25,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	3,07 (14,56)
Median (Min - Max)	4,00 [-30,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	8,00 (11,93)
Median (Min - Max)	5,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	6,44 (11,07)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	14,40 (10,69)
Median (Min - Max)	12,00 [5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	10,00 (10,61)
Median (Min - Max)	10,00 [0,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	10,60 (15,39)
Median (Min - Max)	10,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,67 (19,14)
Median (Min - Max)	0,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,67 (17,79)
Median (Min - Max)	-5,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,67 (9,29)
Median (Min - Max)	10,00 [5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,33 (14,01)
Median (Min - Max)	10,00 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,67 (9,29)
Median (Min - Max)	10,00 [5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,67 (9,29)
Median (Min - Max)	10,00 [5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,00 (15,56)
Median (Min - Max)	11,00 [0,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	-5,30 (19,11)
Median (Min - Max)	0,00 [-50,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
EQ-5D-VAS	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	104 (98,1)
Mean (SD)	70,61 (19,26)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	88 (92,6)
Mean (SD)	-0,30 (16,55)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	62 (88,6)
Mean (SD)	0,94 (17,41)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	47 (87,0)
Mean (SD)	1,55 (15,49)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	35 (89,7)
Mean (SD)	1,83 (14,04)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	0,93 (17,76)
Median (Min - Max)	0,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	2,70 (13,19)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	17 (85,0)
Mean (SD)	6,29 (12,40)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	8,59 (15,52)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	15,00 (14,72)
Median (Min - Max)	12,50 [-5,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	11,44 (20,13)
Median (Min - Max)	10,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	19,29 (16,94)
Median (Min - Max)	20,00 [0,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	2,00 (19,56)
Median (Min - Max)	0,00 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	11,67 (22,55)
Median (Min - Max)	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (14,14)
Median (Min - Max)	0,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (14,14)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (14,14)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS09: EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	78 (73,6)
Mean (SD)	-9,01 (20,09)
Median (Min - Max)	-10,00 [-55,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

2.7.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
EQ-5D-VAS	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	74,93 (18,26)
Median (Min - Max)	77,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	38 (95,0)
Mean (SD)	-0,76 (11,49)
Median (Min - Max)	0,00 [-40,00-22,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	-0,78 (10,33)
Median (Min - Max)	0,00 [-25,00-20,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	-0,16 (13,77)
Median (Min - Max)	0,00 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,18 (11,81)
Median (Min - Max)	0,00 [-20,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	3,86 (12,64)
Median (Min - Max)	2,50 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,21 (10,23)
	0,00 [-20,00-25,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	4,20 (10,72)
	0,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-0,25 (12,95)
	2,50 [-25,00-20,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	10,00 (9,13)
	10,00 [0,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,75 (14,91)
Median (Min - Max)	5,00 [-20,00-13,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	10,00 (10,00)
	10,00 [0,00-20,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-8,33 (7,64)
	-10,00 [-15,00-0,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	35 (81,4)
Median (Min - Max)	-9,77 (14,58)
	-10,00 [-40,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
EQ-5D-VAS	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	69,55 (23,59)
Median (Min - Max)	72,50 [5,00-95,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	-2,69 (14,44)
Median (Min - Max)	0,00 [-46,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	-1,71 (23,22)
Median (Min - Max)	2,50 [-51,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	3,40 (19,32)
Median (Min - Max)	8,50 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	5,63 (11,48)
Median (Min - Max)	0,00 [-5,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,83 (12,42)
Median (Min - Max)	2,50 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,67 (18,72)
Median (Min - Max)	1,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,67 (16,07)
Median (Min - Max)	5,00 [0,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,67 (20,21)
Median (Min - Max)	0,00 [0,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	12,50 (24,75)
Median (Min - Max)	12,50 [-5,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,50 (24,75)
Median (Min - Max)	12,50 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	30,00 (NE)
Median (Min - Max)	30,00 [30,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS10: EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	15 (71,4)
Median (Min - Max)	-8,60 (20,03)
	-8,00 [-40,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

2.7.11 Merkmal: Maximaler längster Durchmesser

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
EQ-5D-VAS	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	74 (97,4)
Mean (SD)	72,74 (18,59)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	62 (89,9)
Mean (SD)	0,56 (15,93)
Median (Min - Max)	0,00 [-46,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	51 (89,5)
Mean (SD)	1,94 (18,44)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)
Mean (SD)	3,76 (13,49)
Median (Min - Max)	3,50 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	3,23 (13,69)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	23 (92,0)
Mean (SD)	2,57 (19,39)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	3,55 (12,04)
Median (Min - Max)	0,00 [-20,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	7,81 (11,53)
Median (Min - Max)	4,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	6,23 (16,22)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	8,80 (16,26)
Median (Min - Max)	7,50 [-10,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	10,67 (13,80)
Median (Min - Max)	10,00 [-5,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	11,86 (17,30)
Median (Min - Max)	10,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	2,17 (13,79)
Median (Min - Max)	2,50 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	7,60 (11,89)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	58 (76,3)
Mean (SD)	-7,43 (20,55)
Median (Min - Max)	-5,00 [-55,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
EQ-5D-VAS	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	33 (97,1)
Mean (SD)	70,15 (17,34)
Median (Min - Max)	75,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)
Mean (SD)	-0,87 (17,64)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-1,94 (11,26)
Median (Min - Max)	0,00 [-25,00-15,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-0,77 (18,53)
Median (Min - Max)	-2,00 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	0,00 (13,46)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	2,71 (13,86)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,83 (14,29)
Median (Min - Max)	-2,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	3,75 (17,97)
Median (Min - Max)	-2,50 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (17,18)
Median (Min - Max)	0,00 [-7,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	30,00 (NE)
Median (Min - Max)	30,00 [30,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	30,00 (NE)
Median (Min - Max)	30,00 [30,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	30,00 (NE)
Median (Min - Max)	30,00 [30,00-30,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	27 (79,4)
Mean (SD)	-11,19 (17,48)
Median (Min - Max)	-15,00 [-40,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
EQ-5D-VAS	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	75,78 (18,65)
Median (Min - Max)	75,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	-9,29 (13,05)
Median (Min - Max)	-5,00 [-25,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,00 (17,82)
Median (Min - Max)	0,00 [-25,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,75 (12,61)
Median (Min - Max)	-2,50 [-25,00-3,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-7,50 (3,54)
Median (Min - Max)	-7,50 [-10,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-20,00 (NE)
Median (Min - Max)	-20,00 [-20,00--20,00]
EQ-5D-VAS - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
EQ-5D-VAS - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	-19,60 (26,12)
Median (Min - Max)	-21,00 [-50,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
EQ-5D-VAS	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	56,86 (28,68)
Median (Min - Max)	70,00 [5,00-85,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	4,60 (4,28)
Median (Min - Max)	5,00 [-2,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	9,00 (1,41)
Median (Min - Max)	9,00 [8,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,50 (3,54)
Median (Min - Max)	12,50 [10,00-15,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	15,00 (NE)
Median (Min - Max)	15,00 [15,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS11: EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:	
> 10 cm	
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	1,40 (6,69)
Median (Min - Max)	0,00 [-8,00-10,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

2.7.12 *Merkmal: Primärdiagnose*

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
EQ-5D-VAS	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	109 (97,3)
Mean (SD)	72,46 (18,79)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	101
Treated patients with non-missing values - n(%)	93 (92,1)
Mean (SD)	0,90 (15,28)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	78
Treated patients with non-missing values - n(%)	69 (88,5)
Mean (SD)	1,33 (17,35)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	2,44 (14,58)
Median (Min - Max)	2,50 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,70 (13,55)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	4,97 (12,94)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	3,32 (12,53)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	7,16 (13,01)
Median (Min - Max)	3,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	5,50 (14,74)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	8,45 (12,82)
Median (Min - Max)	10,00 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	6,60 (14,19)
Median (Min - Max)	7,50 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	11,00 (12,46)
	10,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	1,86 (12,62)
	0,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	7,60 (11,89)
	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	6,60 (12,36)
	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
NE	
Treated patients at visit	85 (75,9)
Treated patients with non-missing values - n(%)	-8,74 (18,56)
Mean (SD)	-7,00 [-55,00-30,00]
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
EQ-5D-VAS	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	63,18 (22,94)
Median (Min - Max)	50,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-5,80 (22,28)
Median (Min - Max)	-2,50 [-45,00-25,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,80 (10,99)
Median (Min - Max)	0,00 [-1,00-25,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	9,80 (18,85)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	3,50 (15,02)
Median (Min - Max)	-0,50 [-10,00-25,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-11,50 (36,95)
Median (Min - Max)	-0,50 [-65,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,67 (17,62)
Median (Min - Max)	0,00 [-1,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,00 (14,73)
Median (Min - Max)	0,00 [-1,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	27,50 (10,61)
Median (Min - Max)	27,50 [20,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	32,50 (17,68)
Median (Min - Max)	32,50 [20,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS12: EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	37,50 (3,54)
	37,50 [35,00-40,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	37,50 (10,61)
	37,50 [30,00-45,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	35,00 (NE)
	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	35,00 (NE)
	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	9 (81,8)
Median (Min - Max)	-3,44 (32,10)
	-1,00 [-45,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

2.7.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
EQ-5D-VAS	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	74,29 (17,11)
Median (Min - Max)	75,00 [40,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	47 (90,4)
Mean (SD)	0,34 (12,98)
Median (Min - Max)	0,00 [-50,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	33 (86,8)
Mean (SD)	-0,42 (18,55)
Median (Min - Max)	0,00 [-30,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	23 (79,3)
Mean (SD)	6,09 (14,64)
Median (Min - Max)	10,00 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	3,58 (15,28)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	5,19 (12,48)
Median (Min - Max)	5,00 [-20,00-27,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	2,47 (11,76)
Median (Min - Max)	0,00 [-20,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	6,10 (12,34)
Median (Min - Max)	4,00 [-10,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	2,82 (15,25)
Median (Min - Max)	0,00 [-25,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	6,60 (13,79)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	7,67 (9,95)
Median (Min - Max)	7,50 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	7,00 (12,36)
Median (Min - Max)	5,00 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	4,60 (13,90)
Median (Min - Max)	5,00 [-15,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	7,60 (11,89)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	45 (76,3)
Mean (SD)	-9,11 (18,16)
Median (Min - Max)	-10,00 [-55,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
EQ-5D-VAS	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)
Mean (SD)	70,97 (17,58)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	-3,82 (15,57)
Median (Min - Max)	0,00 [-45,00-20,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	17 (81,0)
Mean (SD)	0,12 (8,53)
Median (Min - Max)	0,00 [-20,00-15,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-1,93 (15,63)
Median (Min - Max)	-1,00 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	0,00 (12,25)
Median (Min - Max)	0,00 [-20,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-4,00 (32,00)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,25 (13,91)
Median (Min - Max)	0,50 [-5,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	7,50 (15,55)
Median (Min - Max)	2,50 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,67 (6,03)
Median (Min - Max)	0,00 [-7,00-5,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (7,07)
Median (Min - Max)	0,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Number prior lines:	
3 lines	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	23 (71,9)
Mean (SD)	-10,09 (19,29)
Median (Min - Max)	-7,00 [-50,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
EQ-5D-VAS	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	67,21 (22,54)
Median (Min - Max)	70,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
	Cycle 2 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	33 (97,1)
Mean (SD)	2,33 (19,70)
Median (Min - Max)	0,00 [-46,00-55,00]
EQ-5D-VAS - Change from baseline	
	Cycle 3 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	26 (96,3)
Mean (SD)	4,35 (18,73)
Median (Min - Max)	3,50 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
	Cycle 4 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)
Mean (SD)	2,29 (14,78)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	3,38 (12,50)
Median (Min - Max)	0,00 [-15,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	3,55 (13,83)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	6,00 (15,42)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	8,63 (13,92)
Median (Min - Max)	0,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	20,83 (12,42)
Median (Min - Max)	20,00 [5,00-35,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	20,83 (15,63)
Median (Min - Max)	20,00 [0,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS13: EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	19,00 (24,60)
Median (Min - Max)	30,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	27,00 (13,04)
Median (Min - Max)	30,00 [10,00-45,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	17,50 (24,75)
Median (Min - Max)	17,50 [0,00-35,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	35,00 (NE)
Median (Min - Max)	35,00 [35,00-35,00]
EQ-5D-VAS - Change from baseline	
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (76,9)
Mean (SD)	-5,57 (22,90)
Median (Min - Max)	-3,00 [-50,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

2.7.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
EQ-5D-VAS	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	89 (96,7)
Mean (SD)	72,43 (18,55)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	
	Cycle 2 Day 1
Treated patients at visit	86
Treated patients with non-missing values - n(%)	79 (91,9)
Mean (SD)	0,19 (16,10)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	
	Cycle 3 Day 1
Treated patients at visit	66
Treated patients with non-missing values - n(%)	59 (89,4)
Mean (SD)	0,44 (17,47)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	
	Cycle 4 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	42 (85,7)
Mean (SD)	0,71 (13,95)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
	Cycle 5 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	32 (94,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,78 (12,18)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	4,92 (11,98)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	2,59 (12,77)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	5,00 (13,15)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	4,36 (15,97)
Median (Min - Max)	2,50 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	5,63 (13,74)
Median (Min - Max)	2,50 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	3,75 (14,33)
Median (Min - Max)	2,50 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	9,29 (12,39)
Median (Min - Max)	10,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,67 (9,31)
Median (Min - Max)	0,00 [-15,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	3,75 (9,46)
Median (Min - Max)	7,50 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,50 (9,57)
Median (Min - Max)	5,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,00 (10,00)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (11,55)
Median (Min - Max)	10,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	67 (72,8)
Mean (SD)	-9,63 (19,35)
Median (Min - Max)	-7,00 [-55,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
EQ-5D-VAS	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	72,14 (20,48)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-1,12 (15,13)
Median (Min - Max)	0,00 [-40,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	2,70 (17,72)
Median (Min - Max)	2,50 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	5,67 (18,49)
Median (Min - Max)	10,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	5,50 (20,96)
Median (Min - Max)	7,50 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,25 (19,31)
Median (Min - Max)	2,50 [-20,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,33 (11,55)
Median (Min - Max)	15,00 [-5,00-15,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	13,33 (11,55)
Median (Min - Max)	20,00 [0,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	22,00 (NE)
Median (Min - Max)	22,00 [22,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS14: EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	-11,56 (17,09)
Median (Min - Max)	-12,50 [-40,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.

PRO = patient reported outcome. VAS = visual analogue scale.

Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

2.7.15 Merkmal: *Ansprechkategorie auf die letzte vorherige systemische Therapie*

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
EQ-5D-VAS	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	38 (95,0)
Mean (SD)	72,26 (19,73)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	37
Treated patients with non-missing values - n(%)	33 (89,2)
Mean (SD)	-1,45 (18,09)
Median (Min - Max)	0,00 [-50,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	3,07 (17,87)
Median (Min - Max)	0,00 [-51,00-40,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	25
Treated patients with non-missing values - n(%)	20 (80,0)
Mean (SD)	3,30 (16,78)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,76 (13,40)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	2,23 (22,33)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	2,83 (11,98)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	4,40 (13,26)
Median (Min - Max)	0,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	7,00 (15,31)
Median (Min - Max)	7,50 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	9,38 (12,94)
Median (Min - Max)	10,00 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	5,50 (16,66)
Median (Min - Max)	5,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	12,00 (13,04)
Median (Min - Max)	10,00 [0,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-3,00 (9,75)
Median (Min - Max)	0,00 [-15,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	10,00 (0,00)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (0,00)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (75,0)
Mean (SD)	-11,40 (20,54)
Median (Min - Max)	-9,00 [-50,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
EQ-5D-VAS	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	78 (98,7)
Mean (SD)	71,73 (19,00)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	68
Treated patients with non-missing values - n(%)	64 (94,1)
Mean (SD)	0,11 (15,46)
Median (Min - Max)	0,00 [-40,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	40 (88,9)
Mean (SD)	-0,78 (16,97)
Median (Min - Max)	0,00 [-30,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	31 (91,2)
Mean (SD)	1,19 (14,02)
Median (Min - Max)	2,00 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	20 (87,0)
Mean (SD)	2,60 (12,53)
Median (Min - Max)	0,00 [-20,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	4,73 (12,31)
Median (Min - Max)	5,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	2,69 (13,25)
Median (Min - Max)	0,00 [-15,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	9,10 (12,54)
Median (Min - Max)	4,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	3,63 (14,79)
Median (Min - Max)	0,00 [-15,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	6,00 (14,93)
Median (Min - Max)	0,00 [-5,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (11,64)
Median (Min - Max)	7,50 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	9,33 (14,01)
Median (Min - Max)	10,00 [-5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	14,00 (12,73)
Median (Min - Max)	14,00 [5,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	6,00 (16,52)
Median (Min - Max)	5,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	7,67 (16,62)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,00 (22,63)
Median (Min - Max)	6,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,50 (23,33)
Median (Min - Max)	6,50 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS15: EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	62 (78,5)
Mean (SD)	-8,15 (18,46)
Median (Min - Max)	-5,00 [-55,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

2.7.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
EQ-5D-VAS	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	75,33 (19,98)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-0,93 (9,04)
Median (Min - Max)	0,00 [-20,00-23,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,00 (11,93)
Median (Min - Max)	0,00 [-20,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	1,38 (16,08)
Median (Min - Max)	8,50 [-20,00-24,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-2,40 (17,50)
Median (Min - Max)	0,00 [-25,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,50 (17,08)
Median (Min - Max)	-5,00 [-20,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (14,14)
Median (Min - Max)	5,00 [-5,00-15,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	22,00 (NE)
Median (Min - Max)	22,00 [22,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Response category - any line:

Relapse

EQ-5D-VAS - Change from baseline

Cycle 26 Day 1

Treated patients at visit

1

Treated patients with non-missing values - n(%)

1 (100,0)

Mean (SD)

23,00 (NE)

Median (Min - Max)

23,00 [23,00-23,00]

EQ-5D-VAS - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

18 (85,7)

Mean (SD)

-10,44 (15,54)

Median (Min - Max)

-10,00 [-40,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.

PRO = patient reported outcome. VAS = visual analogue scale.

Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
EQ-5D-VAS	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	101 (97,1)
Mean (SD)	70,85 (18,86)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	96
Treated patients with non-missing values - n(%)	89 (92,7)
Mean (SD)	0,56 (16,66)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	73
Treated patients with non-missing values - n(%)	65 (89,0)
Mean (SD)	1,78 (17,70)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	55
Treated patients with non-missing values - n(%)	48 (87,3)
Mean (SD)	3,02 (15,29)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	4,03 (13,01)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	3,86 (17,97)
Median (Min - Max)	5,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	4,08 (13,35)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	7,37 (13,36)
Median (Min - Max)	3,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	5,65 (14,93)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	8,18 (12,50)
Median (Min - Max)	10,00 [-10,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	7,80 (16,11)
Median (Min - Max)	7,50 [-20,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	11,88 (13,61)
Median (Min - Max)	10,00 [-5,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	3,57 (16,26)
Median (Min - Max)	0,00 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	10,00 (16,20)
Median (Min - Max)	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,50 (9,57)
Median (Min - Max)	5,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,00 (10,00)
Median (Min - Max)	0,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (11,55)
Median (Min - Max)	10,00 [-10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (7,07)
Median (Min - Max)	5,00 [0,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS16: EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EOT	
EQ-5D-VAS - Change from baseline	NE
Treated patients at visit	76 (73,1)
Treated patients with non-missing values - n(%)	-8,46 (20,01)
Mean (SD)	-6,00 [-55,00-35,00]
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

2.7.17 *Merkmal: Vorherige CAR-T-Therapie*

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
EQ-5D-VAS	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	72,88 (16,27)
Median (Min - Max)	72,50 [50,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-3,00 (18,71)
Median (Min - Max)	1,00 [-40,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	3,00 (7,16)
Median (Min - Max)	3,50 [-5,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	6,00 (5,23)
Median (Min - Max)	7,50 [-1,00-10,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T- CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	11,33 (10,97)
Median (Min - Max)	15,00 [-1,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:	
Yes	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,33 (16,44)
Median (Min - Max)	5,00 [-1,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,67 (18,18)
Median (Min - Max)	-1,00 [-10,00-25,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,67 (17,62)
Median (Min - Max)	0,00 [-1,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-9,83 (20,66)
Median (Min - Max)	-4,50 [-35,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy Loncastuximab tesirine
 Data-cut 3

Prior use of T-CART therapy:	
No	
Patients in analysis set	122
EQ-5D-VAS	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	119 (97,5)
Mean (SD)	71,26 (19,32)
Median (Min - Max)	75,00 [5,00-100,00]
EQ-5D-VAS - Change from baseline	Cycle 2 Day 1
Treated patients at visit	110
Treated patients with non-missing values - n(%)	102 (92,7)
Mean (SD)	0,04 (15,89)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	Cycle 3 Day 1
Treated patients at visit	82
Treated patients with non-missing values - n(%)	72 (87,8)
Mean (SD)	1,24 (17,26)
Median (Min - Max)	0,00 [-51,00-50,00]
EQ-5D-VAS - Change from baseline	Cycle 4 Day 1
Treated patients at visit	63
Treated patients with non-missing values - n(%)	54 (85,7)
Mean (SD)	2,54 (15,48)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 5 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	41 (89,1)
Mean (SD)	2,15 (13,56)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	2,13 (17,59)
Median (Min - Max)	2,50 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	3,92 (12,64)
Median (Min - Max)	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	6,89 (12,56)
Median (Min - Max)	3,00 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	7,84 (16,10)
Median (Min - Max)	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	13,17 (15,88)
Median (Min - Max)	12,50 [-10,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	11,91 (18,47)
Median (Min - Max)	10,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	17,00 (16,87)
Median (Min - Max)	20,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	6,00 (16,54)
Median (Min - Max)	2,50 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	12,17 (15,43)
Median (Min - Max)	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,60 (12,36)
Median (Min - Max)	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:	
No	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS17: EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EOT	
EQ-5D-VAS - Change from baseline	NE
Treated patients at visit	92 (75,4)
Treated patients with non-missing values - n(%)	-8,15 (19,91)
Mean (SD)	-6,00 [-55,00-45,00]
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

2.7.18 *Merkmal: Arzneimittelformulierung*

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
EQ-5D-VAS	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	70,94 (20,62)
Median (Min - Max)	72,50 [5,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	1,75 (15,72)
Median (Min - Max)	0,00 [-46,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-0,42 (18,34)
Median (Min - Max)	0,00 [-51,00-40,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-0,50 (18,55)
Median (Min - Max)	0,00 [-36,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	5,64 (16,40)
Median (Min - Max)	0,00 [-20,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. VAS = visual analogue scale.
Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	10,20 (12,24)
Median (Min - Max)	5,00 [-4,00-27,00]
EQ-5D-VAS - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,40 (14,05)
Median (Min - Max)	0,00 [-5,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	6,50 (14,71)
Median (Min - Max)	1,50 [-5,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	7,00 (18,52)
Median (Min - Max)	0,00 [-7,00-28,00]
EQ-5D-VAS - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	23 (71,9)
Mean (SD)	-11,22 (15,81)
Median (Min - Max)	-10,00 [-40,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
EQ-5D-VAS	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	95 (96,9)
Mean (SD)	71,51 (18,66)
Median (Min - Max)	75,00 [25,00-100,00]
EQ-5D-VAS - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	80 (90,9)
Mean (SD)	-0,79 (16,11)
Median (Min - Max)	0,00 [-50,00-55,00]
EQ-5D-VAS - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	57 (87,7)
Mean (SD)	1,91 (16,46)
Median (Min - Max)	0,00 [-30,00-50,00]
EQ-5D-VAS - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	42 (84,0)
Mean (SD)	4,02 (13,46)
Median (Min - Max)	2,50 [-25,00-30,00]
EQ-5D-VAS - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	33 (86,8)
Mean (SD)	1,82 (12,53)
Median (Min - Max)	0,00 [-25,00-30,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
EQ-5D-VAS - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	1,68 (18,09)
Median (Min - Max)	0,00 [-65,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	23 (95,8)
Median (Min - Max)	3,48 (12,92)
	0,00 [-20,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	21
Mean (SD)	18 (85,7)
Median (Min - Max)	7,44 (12,90)
	2,50 [-10,00-30,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	7,82 (15,79)
	5,00 [-25,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	13,58 (15,42)
	12,50 [-10,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
EQ-5D-VAS - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	11,75 (17,62)
Median (Min - Max)	10,00 [-20,00-40,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	16,30 (16,06)
	15,00 [-5,00-45,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	6,00 (16,54)
	2,50 [-15,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	12,17 (15,43)
	10,00 [-10,00-35,00]
EQ-5D-VAS - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	6,60 (12,36)
	10,00 [-10,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
EQ-5D-VAS - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,50 (13,70)
Median (Min - Max)	5,00 [-10,00-22,00]
EQ-5D-VAS - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,25 (13,62)
Median (Min - Max)	10,00 [-10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,00 (11,53)
Median (Min - Max)	10,00 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,50 (16,26)
Median (Min - Max)	11,50 [0,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
EQ-5D-VAS - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,50 (9,19)
Median (Min - Max)	16,50 [10,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3VSC_PSHS18: EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation
 PRO set

EQ-5D-VAS - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
EQ-5D-VAS - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	23,00 (NE)
Median (Min - Max)	23,00 [23,00-23,00]
EQ-5D-VAS - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	75 (76,5)
Mean (SD)	-7,35 (20,95)
Median (Min - Max)	-5,00 [-55,00-45,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. VAS = visual analogue scale.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPD_PSTS01: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Age group
 PRO set

3 Endpunktkategorie: Gesundheitsbezogene Lebensqualität

3.1 Subgruppenanalysen zum FACT-Lym – körperliches Wohlbefinden (Zeit bis zur Verschlechterung)

3.1.1 Merkmal Alter

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	18 (31,6)
95%-CI	[19,9-45,2]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,01[3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,4 [53,4-80,8]
Month 6	53,8 [32,5-71,1]
Month 12	46,1 [23,9-65,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS01: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	23 (43,4)
95%-CI	[29,8-57,7]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,71 [2,14-7,16]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,8 [50,0-79,1]
Month 6	31,8 [14,9-50,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS01: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	5 (25,0)
95%-CI	[8,7-49,1]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [52,7-91,5]
Month 6	70,0 [40,7-86,8]
Month 12	70,0 [40,7-86,8]
Month 18	70,0 [40,7-86,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS02: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Sex
 PRO set

3.1.2 Merkmal: Geschlecht

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	18 (34,0)
95%-CI	[21,5-48,3]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	7,16[3,32-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,6 [58,5-85,2]
Month 6	51,6 [32,4-67,8]
Month 12	45,9 [26,3-63,5]
Month 18	45,9 [26,3-63,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS02: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	28 (36,4)
95%-CI	[25,7-48,1]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [52,7-76,8]
Month 6	46,5 [30,1-61,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS03: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Race group
 PRO set

3.1.3 *Merkmal: Ethnie*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	41 (35,7)
95%-CI	[26,9-45,1]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [3,48-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,4 [58,5-77,9]
Month 6	46,1 [32,5-58,6]
Month 12	38,3 [23,7-52,7]
Month 18	38,3 [23,7-52,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS03: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[0,76-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,1 [39,4-88,3]
Month 6	59,3 [26,0-81,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS04: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Country
 PRO set

3.1.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	16 (31,4)
95%-CI	[19,1-45,9]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [53,7-82,5]
Month 6	51,5 [31,1-68,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS04: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	10 (34,5)
95%-CI	[17,9-54,3]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	7,16[2,10-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [49,4-87,2]
Month 6	53,4 [28,0-73,4]
Month 12	40,1 [13,4-65,9]
Month 18	40,1 [13,4-65,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS04: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	19 (39,6)
95%-CI	[25,8-54,7]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [3,25-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [50,9-80,1]
Month 6	40,6 [19,7-60,7]
Month 12	30,5 [10,2-53,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS05: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Region
 PRO set

3.1.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	16 (31,4)
95%-CI	[19,1-45,9]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [53,7-82,5]
Month 6	51,5 [31,1-68,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS05: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	30 (38,0)
95%-CI	[27,3-49,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,35-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,4 [56,4-79,2]
Month 6	46,2 [30,2-60,8]
Month 12	35,2 [18,3-52,7]
Month 18	35,2 [18,3-52,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS06: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

3.1.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [3,32-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	44,4 [6,6-78,5]
Month 12	22,2 [1,0-61,5]
Month 18	22,2 [1,0-61,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS06: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	8 (38,1)
95%-CI	[18,1-61,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,25[2,10-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,6 [40,9-86,4]
Month 6	37,3 [10,8-64,7]
Month 12	37,3 [10,8-64,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS06: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	6 (35,3)
95%-CI	[14,2-61,7]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [0,72-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,0 [41,2-88,6]
Month 6	40,0 [7,9-71,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS06: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	28 (34,1)
95%-CI	[24,0-45,4]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,01[3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,7 [51,4-75,2]
Month 6	53,5 [38,5-66,3]
Month 12	48,1 [31,5-63,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS07: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Bulky disease
 PRO set

3.1.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	45 (35,7)
95%-CI	[27,4-44,7]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,48-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [59,7-77,9]
Month 6	48,3 [35,7-59,8]
Month 12	41,2 [27,3-54,6]
Month 18	41,2 [27,3-54,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS08: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Double/Triple hit
 PRO set

3.1.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	4 (28,6)
95%-CI	[8,4-58,1]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [0,92-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [41,6-91,4]
Month 6	60,4 [22,8-84,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS08: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	42 (36,2)
95%-CI	[27,5-45,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,48-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,1 [58,4-77,6]
Month 6	46,9 [33,6-59,2]
Month 12	38,5 [23,7-53,2]
Month 18	38,5 [23,7-53,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS09: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Transformed DLBCL
 PRO set

3.1.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [2,10-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [49,4-88,9]
Month 6	44,6 [18,6-67,9]
Month 12	44,6 [18,6-67,9]
Month 18	44,6 [18,6-67,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. PWB = physical well-being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS09: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	37 (34,9)
95%-CI	[25,9-44,8]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,35-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,2 [56,9-77,2]
Month 6	49,4 [35,3-62,0]
Month 12	40,5 [24,8-55,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. PWB = physical well-being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS10: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: B-Cell type
 PRO set

3.1.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	16 (37,2)
95%-CI	[23,0-53,3]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,1 [54,0-84,1]
Month 6	47,9 [26,6-66,4]
Month 12	35,9 [12,8-60,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS10: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	7 (33,3)
95%-CI	[14,6-57,0]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,01[3,32-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,5 [57,0-94,4]
Month 6	55,7 [25,0-78,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS11: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter
 PRO set

3.1.11 *Merkmal: Maximaler längster Durchmesser*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	26 (34,2)
95%-CI	[23,7-46,0]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,01[3,71-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [56,0-78,9]
Month 6	53,2 [36,9-67,1]
Month 12	49,1 [32,3-63,9]
Month 18	49,1 [32,3-63,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS11: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	15 (44,1)
95%-CI	[27,2-62,1]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,48 [2,37-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,0 [45,6-81,5]
Month 6	39,3 [18,8-59,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS11: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. PWB = physical well-being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS11: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. PWB = physical well-being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS12: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Primary disease diagnosis
 PRO set

3.1.12 *Merkmal: Primärdiagnose*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	39 (34,8)
95%-CI	[26,1-44,4]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,71-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [60,9-79,8]
Month 6	48,7 [34,9-61,1]
Month 12	39,9 [24,5-54,9]
Month 18	39,9 [24,5-54,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS12: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,02 [0,92-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,9 [23,4-82,5]
Month 6	44,2 [12,0-73,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS13: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Number prior lines
 PRO set

3.1.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	23 (39,0)
95%-CI	[26,5-52,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [50,3-77,1]
Month 6	45,2 [27,0-61,9]
Month 12	37,7 [18,5-56,9]
Month 18	37,7 [18,5-56,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS13: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	13 (40,6)
95%-CI	[23,7-59,4]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,02 [2,10-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,1 [33,8-74,9]
Month 6	39,2 [15,4-62,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS13: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	10 (25,6)
95%-CI	[13,0-42,1]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[3,71-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [69,2-93,9]
Month 6	59,8 [36,2-77,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS14: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - first line
 PRO set

3.1.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	30 (32,6)
95%-CI	[23,2-43,2]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [3,71-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,5 [65,0-84,6]
Month 6	49,3 [33,2-63,5]
Month 12	36,9 [18,7-55,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS14: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	11 (50,0)
95%-CI	[28,2-71,8]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	2,37[1,41-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [20,7-65,7]
Month 6	35,5 [13,2-58,8]
Month 12	35,5 [13,2-58,8]
Month 18	35,5 [13,2-58,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS15: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - last line
 PRO set

3.1.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	15 (37,5)
95%-CI	[22,7-54,2]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,01[2,14-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,2 [49,9-81,0]
Month 6	51,5 [30,1-69,3]
Month 12	44,2 [22,3-64,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS15: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	28 (35,4)
95%-CI	[25,0-47,0]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,71[3,02-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,4 [51,4-76,3]
Month 6	48,8 [33,4-62,5]
Month 12	39,0 [19,0-58,7]
Month 18	39,0 [19,0-58,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS16: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - any line
 PRO set

3.1.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	11 (52,4)
95%-CI	[29,8-74,3]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	1,64 [1,41-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,7 [17,3-63,2]
Month 6	32,6 [11,3-56,2]
Month 12	32,6 [11,3-56,2]
Month 18	32,6 [11,3-56,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS16: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	34 (32,7)
95%-CI	[23,8-42,6]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,01[3,71-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [64,6-83,4]
Month 6	50,1 [35,4-63,1]
Month 12	41,1 [24,9-56,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS17: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Prior use of T-CART therapy
PRO set

3.1.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. PWB = physical well-being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS17: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	44 (36,1)
95%-CI	[27,6-45,3]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [3,48-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,7 [59,3-77,9]
Month 6	47,0 [34,0-58,9]
Month 12	39,7 [25,6-53,4]
Month 18	39,7 [25,6-53,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS18: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Drug formulation
 PRO set

3.1.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	11 (34,4)
95%-CI	[18,6-53,2]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,78 [2,37-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [47,3-83,4]
Month 6	38,4 [8,3-69,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPD_PSTS18: Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym PWB by at least 5 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	35 (35,7)
95%-CI	[26,3-46,0]
FACT-Lym PWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,24 [3,32-NE]
FACT-Lym PWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [58,1-78,8]
Month 6	48,6 [35,0-60,9]
Month 12	43,7 [28,7-57,8]
Month 18	43,7 [28,7-57,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. PWB = physical well-being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

3.2 Subgruppenanalysen zum FACT-Lym – körperliches Wohlbefinden (Veränderung gegenüber Studienbeginn)

3.2.1 Merkmal Alter

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym PWB	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	56 (98,2)
Mean (SD)	20,37 (6,12)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	46 (93,9)
Mean (SD)	0,63 (4,93)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	34 (91,9)
Mean (SD)	0,11 (5,84)
Median (Min - Max)	-0,92 [-10,00-15,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	0,40 (5,71)
Median (Min - Max)	0,00 [-9,17-16,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	-0,47 (4,98)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	0,56 (5,86)
Median (Min - Max)	0,00 [-12,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	1,18 (6,24)
Median (Min - Max)	-0,58 [-9,00-15,00]
FACT-Lym PWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,29 (6,82)
Median (Min - Max)	-1,00 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	1,65 (6,21)
Median (Min - Max)	-1,00 [-5,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,54 (7,84)
Median (Min - Max)	0,00 [-6,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	6,67 (9,09)
Median (Min - Max)	6,00 [-2,00-16,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,92 (8,02)
Median (Min - Max)	5,50 [-1,00-13,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	8,17 (11,55)
Median (Min - Max)	8,17 [0,00-16,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,75 (6,72)
Median (Min - Max)	5,75 [1,00-10,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	43 (75,4)
Mean (SD)	-0,99 (6,41)
Median (Min - Max)	-1,33 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym PWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	51 (96,2)
Mean (SD)	23,46 (3,70)
Median (Min - Max)	24,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	43 (89,6)
Mean (SD)	-1,21 (3,67)
Median (Min - Max)	-0,20 [-10,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-1,83 (3,88)
Median (Min - Max)	-1,00 [-14,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-3,16 (5,17)
Median (Min - Max)	-2,00 [-18,00-2,00]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,96 (3,74)
Median (Min - Max)	-1,00 [-11,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-2,03 (4,76)
Median (Min - Max)	0,00 [-14,00-2,50]
FACT-Lym PWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-2,40 (6,32)
Median (Min - Max)	-1,00 [-14,00-6,00]
FACT-Lym PWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	-1,11 (5,32)
Median (Min - Max)	-0,33 [-10,00-4,00]
FACT-Lym PWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-2,00 (5,91)
Median (Min - Max)	-3,33 [-10,00-5,00]
FACT-Lym PWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,50 (6,56)
Median (Min - Max)	-0,50 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,63 (5,18)
Median (Min - Max)	-4,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,75 (3,86)
Median (Min - Max)	0,50 [-3,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-4,50 (6,26)
Median (Min - Max)	-4,00 [-11,00-1,50]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-7,00 (NE)
Median (Min - Max)	-7,00 [-7,00--7,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-11,50 (2,12)
Median (Min - Max)	-11,50 [-13,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-9,67 (1,89)
Median (Min - Max)	-9,67 [-11,00--8,33]
FACT-Lym PWB - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,60 (2,26)
Median (Min - Max)	-8,60 [-10,20--7,00]
FACT-Lym PWB - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	42 (79,2)
Mean (SD)	-3,98 (4,98)
Median (Min - Max)	-3,50 [-18,00-3,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym PWB	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	22,32 (4,83)
Median (Min - Max)	23,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	-0,76 (3,17)
Median (Min - Max)	0,00 [-7,00-6,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	2,14 (3,59)
Median (Min - Max)	1,00 [-1,00-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	-0,24 (3,81)
Median (Min - Max)	-1,00 [-6,00-5,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-0,90 (5,58)
Median (Min - Max)	-1,00 [-9,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,00 (4,69)
Median (Min - Max)	-1,00 [-7,00-7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2,07 (3,88)
Median (Min - Max)	1,50 [-2,00-7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	1,00 (2,94)
Median (Min - Max)	1,00 [-2,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3,38 (3,25)
Median (Min - Max)	4,00 [-1,00-6,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1,00 (2,83)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,00 (2,83)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym PWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (2,08)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym PWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS01: FACT-Lym PWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-2,23 (4,38)
Median (Min - Max)	-1,00 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

3.2.2 Merkmal: Geschlecht

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym PWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	50 (94,3)
Mean (SD)	21,06 (5,70)
Median (Min - Max)	22,00 [9,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	40 (87,0)
Mean (SD)	-0,10 (3,85)
Median (Min - Max)	0,00 [-10,00-12,67]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	32 (88,9)
Mean (SD)	0,48 (5,48)
Median (Min - Max)	0,00 [-10,00-15,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	21 (75,0)
Mean (SD)	-0,22 (5,34)
Median (Min - Max)	-1,00 [-10,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,30 (4,36)
Median (Min - Max)	-1,00 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	-0,69 (4,91)
Median (Min - Max)	-0,50 [-14,00-7,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,80 (5,65)
Median (Min - Max)	-1,00 [-14,00-8,67]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-0,11 (5,11)
Median (Min - Max)	-1,00 [-10,00-10,67]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	-0,09 (5,74)
Median (Min - Max)	-1,00 [-10,00-9,67]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	-0,08 (5,55)
Median (Min - Max)	0,00 [-9,00-10,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	0,52 (7,03)
Median (Min - Max)	-1,00 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	1,67 (5,88)
Median (Min - Max)	-1,00 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,48 (8,29)
Median (Min - Max)	0,00 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	1,12 (7,19)
Median (Min - Max)	0,50 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	40 (75,5)
Mean (SD)	-2,69 (5,94)
Median (Min - Max)	-3,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym PWB	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	77 (100,0)
Mean (SD)	22,47 (4,86)
Median (Min - Max)	24,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	67 (95,7)
Mean (SD)	-0,49 (4,49)
Median (Min - Max)	0,00 [-10,17-12,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	44 (88,0)
Mean (SD)	-0,75 (4,57)
Median (Min - Max)	-0,92 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	37 (94,9)
Mean (SD)	-1,61 (5,49)
Median (Min - Max)	-2,00 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-0,86 (4,95)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,05 (5,88)
Median (Min - Max)	0,00 [-12,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	2,13 (6,38)
Median (Min - Max)	1,50 [-9,00-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,43 (6,68)
Median (Min - Max)	0,33 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,31 (6,00)
Median (Min - Max)	2,92 [-5,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,00 (10,00)
Median (Min - Max)	4,00 [-6,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS02: FACT-Lym PWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,92 (5,77)
Median (Min - Max)	7,92 [3,83-12,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (6,36)
Median (Min - Max)	7,50 [3,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,50 (NE)
Median (Min - Max)	1,50 [1,50-1,50]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	58 (75,3)
Mean (SD)	-2,26 (5,60)
Median (Min - Max)	-1,17 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

3.2.3 *Merkmal: Ethnie*

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym PWB	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	112 (97,4)
Mean (SD)	21,98 (5,29)
Median (Min - Max)	23,67 [7,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	95 (91,3)
Mean (SD)	-0,42 (4,07)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	65 (87,8)
Mean (SD)	-0,38 (5,11)
Median (Min - Max)	-0,33 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	48 (85,7)
Mean (SD)	-0,98 (5,00)
Median (Min - Max)	-1,00 [-11,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	38 (92,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,34 (4,53)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	-1,20 (5,09)
Median (Min - Max)	-1,00 [-14,00-7,20]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	-0,60 (5,65)
Median (Min - Max)	-1,00 [-14,00-8,67]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	-0,19 (5,43)
Median (Min - Max)	-1,00 [-10,00-10,67]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	0,48 (5,87)
Median (Min - Max)	-0,50 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	11 (78,6)
Mean (SD)	0,66 (6,88)
Median (Min - Max)	0,00 [-9,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	1,67 (7,56)
Median (Min - Max)	-0,50 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	2,96 (6,55)
Median (Min - Max)	-0,50 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,48 (8,29)
Median (Min - Max)	0,00 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	1,12 (7,19)
Median (Min - Max)	0,50 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,9)
Mean (SD)	-2,44 (5,44)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym PWB	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	21,47 (4,93)
Median (Min - Max)	21,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,31 (5,61)
Median (Min - Max)	0,08 [-7,00-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,67 (4,19)
Median (Min - Max)	0,00 [-5,00-10,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-1,73 (7,47)
Median (Min - Max)	-1,58 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	0,25 (5,25)
Median (Min - Max)	-0,58 [-9,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,17 (5,12)
Median (Min - Max)	1,42 [-1,83-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	4,17 (6,49)
	2,00 [-1,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	5,00 (6,56)
	4,00 [-1,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS03: FACT-Lym PWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,83 (NE)
Median (Min - Max)	3,83 [3,83-3,83]
FACT-Lym PWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym PWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,50 (NE)
Median (Min - Max)	1,50 [1,50-1,50]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-2,42 (7,54)
Median (Min - Max)	-1,17 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

3.2.4 *Merkmal: Region-1*

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym PWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	51 (100,0)
Mean (SD)	21,07 (5,63)
Median (Min - Max)	22,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	44 (97,8)
Mean (SD)	-0,73 (4,41)
Median (Min - Max)	-0,75 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	-0,11 (4,65)
Median (Min - Max)	-0,17 [-10,00-11,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	-1,32 (6,75)
Median (Min - Max)	-2,00 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,69 (5,71)
Median (Min - Max)	-1,92 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,10 (6,73)
Median (Min - Max)	-1,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,86 (8,33)
Median (Min - Max)	-0,17 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,74 (7,38)
Median (Min - Max)	4,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,11 (8,05)
Median (Min - Max)	4,50 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,54 (6,85)
Median (Min - Max)	4,00 [-5,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,92 (8,20)
Median (Min - Max)	3,92 [-5,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,11 (6,53)
Median (Min - Max)	4,00 [-2,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,28 (13,68)
Median (Min - Max)	1,50 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,50 (NE)
Median (Min - Max)	10,50 [10,50-10,50]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-2,81 (7,33)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym PWB	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	22,69 (4,59)
Median (Min - Max)	24,00 [12,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	0,32 (3,26)
Median (Min - Max)	0,00 [-7,00-7,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	10 (62,5)
Mean (SD)	0,81 (5,43)
Median (Min - Max)	-0,50 [-6,53-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,70 (3,85)
Median (Min - Max)	1,17 [-6,00-8,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,14 (3,82)
Median (Min - Max)	-0,30 [-9,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,78 (2,72)
Median (Min - Max)	1,42 [-1,00-6,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	2,70 (3,33)
Median (Min - Max)	2,33 [-1,17-7,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,94 (2,31)
Median (Min - Max)	0,33 [-1,00-3,50]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,30 (3,40)
Median (Min - Max)	2,33 [-3,33-5,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,00 (2,83)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	-1,00 (5,48)
Median (Min - Max)	0,00 [-11,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym PWB	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	45 (93,8)
Mean (SD)	22,35 (5,16)
Median (Min - Max)	23,33 [9,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	42 (91,3)
Mean (SD)	-0,26 (4,58)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	-0,66 (5,28)
Median (Min - Max)	-0,50 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-1,67 (4,34)
Median (Min - Max)	-1,00 [-11,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-0,82 (4,05)
Median (Min - Max)	-1,00 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-0,58 (3,79)
Median (Min - Max)	0,00 [-7,00-7,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,39 (3,59)
Median (Min - Max)	-1,00 [-9,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-1,78 (3,83)
Median (Min - Max)	-1,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-1,56 (4,62)
Median (Min - Max)	-2,50 [-8,00-6,50]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-3,00 (4,74)
Median (Min - Max)	-3,00 [-9,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,00 (4,40)
Median (Min - Max)	-2,00 [-7,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-1,33 (2,31)
Median (Min - Max)	0,00 [-4,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-3,00 (5,66)
Median (Min - Max)	-3,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,33 (7,37)
Median (Min - Max)	-10,00 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-9,67 (1,89)
	-9,67 [-11,00--8,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-8,60 (2,26)
	-8,60 [-10,20--7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS04: FACT-Lym PWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	35 (72,9)
Mean (SD)	-2,94 (3,75)
Median (Min - Max)	-3,00 [-10,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

3.2.5 *Merkmal: Region-2*

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym PWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	51 (100,0)
Mean (SD)	21,07 (5,63)
Median (Min - Max)	22,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	44 (97,8)
Mean (SD)	-0,73 (4,41)
Median (Min - Max)	-0,75 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	-0,11 (4,65)
Median (Min - Max)	-0,17 [-10,00-11,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	-1,32 (6,75)
Median (Min - Max)	-2,00 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,69 (5,71)
Median (Min - Max)	-1,92 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,10 (6,73)
Median (Min - Max)	-1,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,86 (8,33)
Median (Min - Max)	-0,17 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,74 (7,38)
Median (Min - Max)	4,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,11 (8,05)
Median (Min - Max)	4,50 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,54 (6,85)
Median (Min - Max)	4,00 [-5,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,92 (8,20)
Median (Min - Max)	3,92 [-5,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,11 (6,53)
Median (Min - Max)	4,00 [-2,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,28 (13,68)
Median (Min - Max)	1,50 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,50 (NE)
Median (Min - Max)	10,50 [10,50-10,50]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-2,81 (7,33)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym PWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	76 (96,2)
Mean (SD)	22,48 (4,90)
Median (Min - Max)	24,00 [9,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	63 (88,7)
Mean (SD)	-0,07 (4,14)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	45 (84,9)
Mean (SD)	-0,32 (5,23)
Median (Min - Max)	0,00 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	33 (82,5)
Mean (SD)	-0,95 (4,28)
Median (Min - Max)	0,00 [-11,00-8,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	28 (96,6)
Mean (SD)	-0,66 (3,86)
Median (Min - Max)	-1,00 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,25 (3,56)
Median (Min - Max)	0,00 [-7,00-7,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	-0,11 (3,92)
Median (Min - Max)	-1,00 [-9,00-7,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-1,10 (3,63)
Median (Min - Max)	-1,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	-0,46 (4,29)
Median (Min - Max)	-1,00 [-8,00-6,50]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	-2,67 (4,32)
Median (Min - Max)	-2,00 [-9,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,80 (3,83)
Median (Min - Max)	-1,00 [-7,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-1,33 (1,53)
Median (Min - Max)	-1,00 [-3,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-0,40 (2,51)
Median (Min - Max)	0,00 [-4,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-2,00 (4,36)
Median (Min - Max)	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS05: FACT-Lym PWB - Change from Baseline by subgroup: Region
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	62 (78,5)
Mean (SD)	-2,22 (4,58)
Median (Min - Max)	-2,00 [-11,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.

PRO = patient reported outcome. PWB = physical well-being.

Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.2.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym PWB	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	22,63 (4,48)
Median (Min - Max)	22,50 [13,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,09 (2,27)
Median (Min - Max)	0,00 [-4,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-0,25 (2,22)
Median (Min - Max)	-1,00 [-2,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-2,00 (1,00)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,92 (2,59)
Median (Min - Max)	-2,50 [-4,00-1,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,67 (3,01)
	-1,00 [-3,50-2,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-5,08 (5,54)
	-5,08 [-9,00--1,17]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-5,50 (6,36)
	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,78 (4,67)
	-3,33 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,00 (2,83)
	-3,00 [-5,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,00 (2,83)
	-3,00 [-5,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,00 (1,41)
	-1,00 [-2,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,00 (7,07)
	-6,00 [-11,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 26 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	7 (70,0)
Median (Min - Max)	-5,75 (7,76)
	-6,00 [-18,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym PWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	22,29 (4,79)
Median (Min - Max)	23,33 [11,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	0,19 (5,27)
Median (Min - Max)	0,00 [-10,17-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	-1,25 (6,45)
Median (Min - Max)	-1,00 [-14,00-10,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	-1,59 (6,34)
Median (Min - Max)	-2,00 [-11,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-1,44 (6,41)
Median (Min - Max)	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-1,72 (8,36)
	-3,17 [-12,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	0,53 (8,92)
	-2,33 [-9,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,60 (8,14)
	-4,00 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,33 (3,79)
	-3,00 [-4,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,50 (4,95)
	-0,50 [-4,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-7,00 (NE)
	-7,00 [-7,00--7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-13,00 (NE)
	-13,00 [-13,00--13,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-8,33 (NE)
	-8,33 [-8,33--8,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-10,20 (NE)
	-10,20 [-10,20--10,20]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	16 (76,2)
Median (Min - Max)	-1,29 (4,56)
	-0,75 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym PWB	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	22,48 (5,29)
Median (Min - Max)	25,00 [10,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,05 (4,70)
Median (Min - Max)	0,00 [-7,00-8,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-1,20 (5,57)
Median (Min - Max)	-1,50 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,07 (4,66)
Median (Min - Max)	1,00 [-8,00-8,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	0,05 (3,22)
Median (Min - Max)	0,33 [-4,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	0,27 (3,77)
	0,33 [-4,00-6,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,53 (4,05)
	0,33 [-5,00-5,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,22 (1,68)
	-1,00 [-3,00-0,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,17 (3,06)
	0,17 [-2,00-2,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	12 (70,6)
Median (Min - Max)	-2,31 (5,99)
	-1,00 [-10,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym PWB	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	80 (97,6)
Mean (SD)	21,62 (5,48)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	65 (90,3)
Mean (SD)	-0,62 (4,04)
Median (Min - Max)	0,00 [-10,00-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	50 (92,6)
Mean (SD)	0,21 (4,68)
Median (Min - Max)	0,00 [-9,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	35 (83,3)
Mean (SD)	-1,15 (5,66)
Median (Min - Max)	-1,00 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	26 (89,7)
Mean (SD)	-1,09 (4,67)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	-0,12 (5,04)
	0,00 [-14,00-7,20]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	15 (93,8)
Median (Min - Max)	1,19 (5,62)
	-0,17 [-14,00-8,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	11 (78,6)
Median (Min - Max)	2,65 (4,56)
	3,50 [-2,00-10,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	11 (91,7)
Median (Min - Max)	2,79 (6,05)
	4,00 [-8,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	1,78 (7,87)
	2,00 [-9,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	4,92 (8,44)
	3,92 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	4,94 (6,75)
	4,00 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	3,37 (7,70)
	1,50 [-4,00-16,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2 (40,0)
Median (Min - Max)	5,75 (6,72)
	5,75 [1,00-10,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-4,50 (7,78)
	-4,50 [-10,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-11,00 (NE)
	-11,00 [-11,00--11,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-7,00 (NE)
	-7,00 [-7,00--7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS06: FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	63 (76,8)
Median (Min - Max)	-2,39 (5,68)
	-3,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
 PRO set

3.2.7 *Merkmal: Bulky Erkrankung*

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym PWB	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	123 (97,6)
Mean (SD)	21,93 (5,26)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	104 (92,0)
Mean (SD)	-0,43 (4,20)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	76 (89,4)
Mean (SD)	-0,23 (4,97)
Median (Min - Max)	-0,08 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	57 (86,4)
Mean (SD)	-1,08 (5,47)
Median (Min - Max)	-1,00 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	46 (93,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,06 (4,64)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	33 (91,7)
Mean (SD)	-0,40 (5,29)
Median (Min - Max)	0,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	0,28 (5,98)
Median (Min - Max)	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	21 (84,0)
Mean (SD)	0,55 (5,73)
Median (Min - Max)	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	0,67 (5,76)
Median (Min - Max)	0,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	12 (80,0)
Mean (SD)	0,94 (6,63)
Median (Min - Max)	0,00 [-9,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	1,86 (7,20)
Median (Min - Max)	0,00 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	2,96 (6,13)
Median (Min - Max)	0,00 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,60 (7,68)
Median (Min - Max)	0,00 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	1,12 (7,19)
Median (Min - Max)	0,50 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS07: FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	97 (77,0)
Mean (SD)	-2,39 (5,72)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.2.8 Merkmal: Double/Triple-Hit

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym PWB	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	19,83 (5,74)
Median (Min - Max)	21,00 [9,33-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,55 (2,95)
Median (Min - Max)	0,00 [-6,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	2,75 (4,68)
Median (Min - Max)	2,17 [-3,00-11,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	2,22 (8,39)
Median (Min - Max)	-1,50 [-6,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,07 (8,24)
Median (Min - Max)	-2,00 [-9,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,47 (6,77)
Median (Min - Max)	2,83 [-7,00-7,20]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,89 (5,98)
Median (Min - Max)	8,00 [-2,00-8,67]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	6,22 (7,13)
Median (Min - Max)	10,00 [-2,00-10,67]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,83 (1,65)
Median (Min - Max)	10,83 [9,67-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,13 (2,64)
Median (Min - Max)	12,13 [10,27-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	14,33 (3,30)
Median (Min - Max)	14,33 [12,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,83 (1,18)
Median (Min - Max)	12,83 [12,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	16,33 (NE)
Median (Min - Max)	16,33 [16,33-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,50 (NE)
Median (Min - Max)	10,50 [10,50-10,50]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-1,62 (8,95)
Median (Min - Max)	-3,00 [-15,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym PWB	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	113 (97,4)
Mean (SD)	22,17 (5,13)
Median (Min - Max)	24,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	95 (91,3)
Mean (SD)	-0,32 (4,39)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	68 (87,2)
Mean (SD)	-0,58 (4,92)
Median (Min - Max)	-0,58 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	-1,49 (4,96)
Median (Min - Max)	-1,00 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	41 (95,3)
Mean (SD)	-1,06 (4,18)
Median (Min - Max)	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,66 (5,15)
Median (Min - Max)	0,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	-0,29 (5,85)
Median (Min - Max)	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	-0,40 (5,10)
Median (Min - Max)	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-0,53 (4,77)
Median (Min - Max)	-1,00 [-10,00-6,50]
FACT-Lym PWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-1,30 (4,42)
Median (Min - Max)	-0,50 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-0,91 (3,99)
Median (Min - Max)	-1,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	0,14 (2,85)
Median (Min - Max)	-1,00 [-3,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-1,64 (4,66)
Median (Min - Max)	0,00 [-11,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-2,00 (4,36)
Median (Min - Max)	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS08: FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	89 (76,7)
Mean (SD)	-2,52 (5,35)
Median (Min - Max)	-2,00 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.2.9 *Merkmal: Transformation des DLBCL*

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym PWB	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	21,90 (5,91)
Median (Min - Max)	24,75 [11,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	0,21 (4,19)
Median (Min - Max)	-0,10 [-9,00-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-0,59 (4,66)
Median (Min - Max)	0,00 [-9,00-10,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,65 (5,17)
Median (Min - Max)	1,00 [-10,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,60 (5,06)
Median (Min - Max)	-1,00 [-9,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,60 (5,32)
Median (Min - Max)	1,00 [-1,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,57 (7,01)
Median (Min - Max)	-1,00 [-1,17-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	2,25 (6,50)
Median (Min - Max)	-1,00 [-1,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,00 (4,36)
Median (Min - Max)	-1,00 [-8,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,33 (4,93)
Median (Min - Max)	-1,00 [-9,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,67 (3,79)
Median (Min - Max)	-1,00 [-7,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,33 (1,53)
Median (Min - Max)	-1,00 [-3,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,67 (2,08)
Median (Min - Max)	-1,00 [-4,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,33 (5,86)
Median (Min - Max)	-1,00 [-10,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,50 (6,36)
Median (Min - Max)	-6,50 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,50 (4,95)
Median (Min - Max)	-3,50 [-7,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	-1,88 (5,74)
Median (Min - Max)	-1,00 [-10,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym PWB	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	103 (97,2)
Mean (SD)	21,92 (5,09)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	87 (91,6)
Mean (SD)	-0,47 (4,27)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	61 (87,1)
Mean (SD)	-0,14 (5,08)
Median (Min - Max)	-0,33 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	47 (87,0)
Mean (SD)	-1,22 (5,54)
Median (Min - Max)	-1,00 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	36 (92,3)
Mean (SD)	-0,91 (4,58)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	-0,94 (5,20)
Median (Min - Max)	-0,83 [-14,00-7,20]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	22 (91,7)
Median (Min - Max)	-0,23 (5,78)
	-0,58 [-14,00-8,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	17 (85,0)
Median (Min - Max)	0,15 (5,68)
	-1,00 [-10,00-10,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	16 (94,1)
Median (Min - Max)	1,35 (5,84)
	2,67 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	2,36 (6,73)
	3,00 [-6,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	3,56 (7,61)
Median (Min - Max)	3,42 [-5,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	5,11 (6,53)
Median (Min - Max)	4,00 [-2,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	1,97 (9,74)
Median (Min - Max)	1,50 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,75 (12,37)
Median (Min - Max)	1,75 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-13,00 (NE)
Median (Min - Max)	-13,00 [-13,00--13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-8,33 (NE)
Median (Min - Max)	-8,33 [-8,33--8,33]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-10,20 (NE)
Median (Min - Max)	-10,20 [-10,20--10,20]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS09: FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	78 (73,6)
Mean (SD)	-2,58 (5,74)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
 PRO set

3.2.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym PWB	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	22,29 (4,64)
Median (Min - Max)	23,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	-0,05 (3,69)
Median (Min - Max)	0,00 [-7,00-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	0,23 (4,54)
Median (Min - Max)	0,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	23 (85,2)
Mean (SD)	-1,03 (5,66)
Median (Min - Max)	-1,00 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,76 (4,58)
Median (Min - Max)	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	0,32 (5,00)
Median (Min - Max)	0,00 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	13 (92,9)
Median (Min - Max)	0,29 (6,57)
	1,00 [-9,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-0,15 (6,19)
	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-0,35 (5,15)
	0,50 [-10,00-5,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	0,50 (4,04)
	1,50 [-5,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,04 (4,19)
Median (Min - Max)	0,50 [-5,00-3,83]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	0,00 (2,65)
	-1,00 [-2,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-1,63 (6,37)
	0,75 [-11,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	35 (81,4)
Median (Min - Max)	-2,77 (6,23)
	-2,00 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym PWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	22,66 (4,05)
Median (Min - Max)	23,00 [12,00-28,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-0,62 (3,74)
Median (Min - Max)	0,17 [-10,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-1,52 (4,55)
Median (Min - Max)	-0,83 [-14,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,36 (4,65)
Median (Min - Max)	0,00 [-11,00-5,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,43 (2,11)
Median (Min - Max)	-1,00 [-4,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,92 (1,99)
Median (Min - Max)	-0,83 [-4,00-2,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,83 (4,54)
Median (Min - Max)	-1,00 [-2,50-6,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,67 (4,16)
Median (Min - Max)	-2,00 [-4,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,33 (5,51)
Median (Min - Max)	-4,00 [-5,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,00 (7,07)
Median (Min - Max)	-1,00 [-6,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (5,66)
Median (Min - Max)	0,00 [-4,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-7,00 (NE)
	-7,00 [-7,00--7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-13,00 (NE)
	-13,00 [-13,00--13,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-8,33 (NE)
	-8,33 [-8,33--8,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS10: FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,20 (NE)
Median (Min - Max)	-10,20 [-10,20--10,20]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	16 (76,2)
Median (Min - Max)	-2,01 (4,16)
	-1,00 [-11,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.

PRO = patient reported outcome. PWB = physical well-being.

Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.2.11 *Merkmal: Maximaler längster Durchmesser*

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	76
FACT-Lym PWB	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	73 (96,1)
Mean (SD)	22,36 (5,57)
Median (Min - Max)	24,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	63 (91,3)
Mean (SD)	-0,53 (4,77)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	51 (89,5)
Mean (SD)	-0,56 (5,39)
Median (Min - Max)	-0,33 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	39 (90,7)
Mean (SD)	-1,42 (5,28)
Median (Min - Max)	-1,00 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,83 (4,61)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 25
Treated patients with non-missing values - n(%)	23 (92,0)
Mean (SD)	-1,08 (5,59)
Median (Min - Max)	-1,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	0,19 (5,75)
Median (Min - Max)	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 18
Treated patients with non-missing values - n(%)	15 (83,3)
Mean (SD)	0,42 (5,02)
Median (Min - Max)	-1,00 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	0,36 (5,32)
Median (Min - Max)	-0,50 [-8,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	0,22 (6,59)
Median (Min - Max)	0,00 [-9,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,60 (5,79)
Median (Min - Max)	-0,50 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	1,67 (5,43)
Median (Min - Max)	-0,50 [-3,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-0,08 (2,38)
Median (Min - Max)	0,00 [-4,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-2,00 (4,36)
Median (Min - Max)	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-7,11 (4,62)
	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-5,73 (5,22)
	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-5,50 (6,36)
	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1 2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1 2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	57 (75,0)
Mean (SD)	-2,05 (5,88)
Median (Min - Max)	-2,00 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym PWB	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	21,49 (4,48)
Median (Min - Max)	22,00 [11,00-27,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	-0,78 (3,26)
Median (Min - Max)	-0,25 [-7,00-5,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,35 (3,64)
Median (Min - Max)	-0,17 [-6,53-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-2,29 (3,99)
Median (Min - Max)	-2,00 [-9,00-2,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,25 (5,04)
Median (Min - Max)	-1,00 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	1,45 (4,36)
	2,50 [-7,00-7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	0,83 (6,00)
	2,33 [-9,00-6,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	1,13 (5,42)
	3,75 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	1,73 (4,60)
	3,50 [-3,33-6,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym PWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-3,35 (4,83)
Median (Min - Max)	-3,00 [-15,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym PWB	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	22,54 (4,25)
Median (Min - Max)	24,00 [14,00-27,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,19 (2,65)
Median (Min - Max)	0,83 [-2,00-6,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,04 (2,60)
Median (Min - Max)	0,08 [-3,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,25 (4,65)
Median (Min - Max)	-2,00 [-6,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,50 (3,54)
Median (Min - Max)	-6,50 [-9,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,50 (NE)
Median (Min - Max)	-3,50 [-3,50--3,50]
FACT-Lym PWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-9,00 (NE)
Median (Min - Max)	-9,00 [-9,00--9,00]
FACT-Lym PWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym PWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-11,00 (NE)
Median (Min - Max)	-11,00 [-11,00--11,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	-4,90 (8,25)
Median (Min - Max)	-4,00 [-18,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym PWB	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	19,71 (4,61)
Median (Min - Max)	19,00 [12,00-25,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,76 (4,00)
Median (Min - Max)	2,00 [-1,00-9,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,00 (1,41)
Median (Min - Max)	3,00 [2,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,50 (2,12)
Median (Min - Max)	3,50 [2,00-5,00]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS11: FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
> 10 cm	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-2,30 (2,99)
Median (Min - Max)	-1,50 [-7,00-1,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.2.12 *Merkmal: Primärdiagnose*

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym PWB	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	109 (97,3)
Mean (SD)	22,11 (5,04)
Median (Min - Max)	23,33 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	101
Treated patients with non-missing values - n(%)	93 (92,1)
Mean (SD)	-0,04 (4,29)
Median (Min - Max)	0,00 [-10,00-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	68 (87,2)
Mean (SD)	-0,47 (4,88)
Median (Min - Max)	-0,25 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	-1,36 (4,84)
Median (Min - Max)	-1,00 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	41 (95,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,06 (4,18)
Median (Min - Max)	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,66 (5,15)
Median (Min - Max)	0,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	24 (92,3)
Median (Min - Max)	-0,29 (5,85)
	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	18 (81,8)
Median (Min - Max)	-0,40 (5,10)
	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	17 (94,4)
Median (Min - Max)	-0,53 (4,77)
	-1,00 [-10,00-6,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	-1,30 (4,42)
	-0,50 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-0,91 (3,99)
Median (Min - Max)	-1,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	0,14 (2,85)
Median (Min - Max)	-1,00 [-3,00-5,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-1,64 (4,66)
Median (Min - Max)	0,00 [-11,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-2,00 (4,36)
Median (Min - Max)	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-5,73 (5,22)
	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-5,50 (6,36)
	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1 2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1 2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (75,9)
Mean (SD)	-2,42 (5,22)
Median (Min - Max)	-1,50 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym PWB	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	20,39 (6,14)
Median (Min - Max)	21,00 [9,33-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-1,63 (2,90)
Median (Min - Max)	-1,00 [-6,00-2,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,78 (4,76)
Median (Min - Max)	2,50 [-1,00-11,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	3,07 (9,09)
Median (Min - Max)	-1,00 [-6,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,07 (8,24)
Median (Min - Max)	-2,00 [-9,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	1,47 (6,77)
	2,83 [-7,00-7,20]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	4,89 (5,98)
	8,00 [-2,00-8,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	6,22 (7,13)
	10,00 [-2,00-10,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	10,83 (1,65)
	10,83 [9,67-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	12,13 (2,64)
	12,13 [10,27-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS12: FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	14,33 (3,30)
Median (Min - Max)	14,33 [12,00-16,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,83 (1,18)
Median (Min - Max)	12,83 [12,00-13,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	16,33 (NE)
Median (Min - Max)	16,33 [16,33-16,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,50 (NE)
Median (Min - Max)	10,50 [10,50-10,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,70 (9,08)
Median (Min - Max)	-6,00 [-15,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

3.2.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym PWB	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	57 (96,6)
Mean (SD)	22,73 (4,46)
Median (Min - Max)	24,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	46 (88,5)
Mean (SD)	-0,81 (4,02)
Median (Min - Max)	0,00 [-10,00-9,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	30 (78,9)
Mean (SD)	-0,53 (4,83)
Median (Min - Max)	-1,00 [-8,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	22 (75,9)
Mean (SD)	-0,73 (3,98)
Median (Min - Max)	0,00 [-10,00-8,00]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,70 (4,67)
Median (Min - Max)	-0,93 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-0,93 (5,67)
Median (Min - Max)	0,17 [-14,00-7,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	-0,35 (5,13)
Median (Min - Max)	-0,33 [-14,00-7,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	-0,35 (3,61)
Median (Min - Max)	-1,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,40 (4,53)
Median (Min - Max)	1,17 [-8,00-6,50]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,75 (5,12)
Median (Min - Max)	-0,50 [-9,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,80 (3,83)
Median (Min - Max)	-1,00 [-7,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-1,33 (1,53)
Median (Min - Max)	-1,00 [-3,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-0,40 (2,51)
Median (Min - Max)	0,00 [-4,00-3,00]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-2,00 (4,36)
Median (Min - Max)	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	45 (76,3)
Mean (SD)	-3,54 (5,35)
Median (Min - Max)	-4,00 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym PWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)
Mean (SD)	22,17 (4,35)
Median (Min - Max)	23,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	-0,43 (4,16)
Median (Min - Max)	0,00 [-10,17-11,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-0,25 (4,65)
Median (Min - Max)	1,17 [-9,00-10,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-3,56 (6,85)
Median (Min - Max)	-3,00 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-3,20 (5,96)
Median (Min - Max)	-1,50 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,44 (6,95)
Median (Min - Max)	-0,33 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,75 (9,98)
Median (Min - Max)	0,50 [-9,00-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,75 (8,18)
Median (Min - Max)	1,00 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,33 (4,73)
Median (Min - Max)	-3,00 [-5,00-4,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (7,07)
Median (Min - Max)	-1,00 [-6,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,83 (NE)
	3,83 [3,83-3,83]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,50 (NE)
	1,50 [1,50-1,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	22 (68,8)
Median (Min - Max)	-1,61 (5,51)
	-0,75 [-15,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym PWB	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	39 (100,0)
Mean (SD)	20,52 (6,59)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	0,36 (4,63)
Median (Min - Max)	0,00 [-10,00-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	27 (100,0)
Mean (SD)	0,12 (5,49)
Median (Min - Max)	0,00 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)
Mean (SD)	0,25 (5,29)
Median (Min - Max)	-1,00 [-11,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-0,21 (3,51)
Median (Min - Max)	-1,00 [-4,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,38 (4,02)
Median (Min - Max)	-1,00 [-6,00-7,20]
FACT-Lym PWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,61 (5,86)
Median (Min - Max)	-1,00 [-9,00-8,67]
FACT-Lym PWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	0,96 (6,94)
Median (Min - Max)	-1,00 [-10,00-10,67]
FACT-Lym PWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,11 (8,29)
Median (Min - Max)	1,50 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,38 (7,52)
Median (Min - Max)	2,00 [-5,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS13: FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,13 (9,15)
Median (Min - Max)	4,00 [-5,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,53 (7,21)
Median (Min - Max)	5,00 [-2,00-13,67]
FACT-Lym PWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,67 (19,33)
Median (Min - Max)	2,67 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,50 (NE)
Median (Min - Max)	10,50 [10,50-10,50]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	31 (79,5)
Mean (SD)	-1,42 (6,24)
Median (Min - Max)	-1,50 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

3.2.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym PWB	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	90 (97,8)
Mean (SD)	22,07 (5,15)
Median (Min - Max)	24,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 86
Treated patients with non-missing values - n(%)	78 (90,7)
Mean (SD)	-0,05 (4,70)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 66
Treated patients with non-missing values - n(%)	58 (87,9)
Mean (SD)	-0,34 (5,00)
Median (Min - Max)	-0,25 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 49
Treated patients with non-missing values - n(%)	42 (85,7)
Mean (SD)	-1,55 (5,18)
Median (Min - Max)	-1,08 [-18,00-8,83]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 34
Treated patients with non-missing values - n(%)	33 (97,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,02 (4,21)
Median (Min - Max)	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	-0,49 (5,04)
Median (Min - Max)	0,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	21 (91,3)
Median (Min - Max)	-0,51 (6,24)
	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	15 (78,9)
Median (Min - Max)	-0,91 (5,44)
	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	13 (92,9)
Median (Min - Max)	-0,96 (5,25)
	-2,00 [-10,00-6,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	7 (70,0)
Median (Min - Max)	-1,71 (5,06)
	0,00 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-1,45 (4,28)
Median (Min - Max)	-2,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	6 (66,7)
Median (Min - Max)	0,17 (3,13)
	-1,00 [-3,00-5,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	-2,10 (5,62)
	0,00 [-11,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2 (40,0)
Median (Min - Max)	-3,00 (5,66)
	-3,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-7,33 (7,37)
	-10,00 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-9,67 (1,89)
Median (Min - Max)	-9,67 [-11,00--8,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-8,60 (2,26)
	-8,60 [-10,20--7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	67 (72,8)
Mean (SD)	-2,30 (5,47)
Median (Min - Max)	-1,17 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym PWB	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	22,79 (4,55)
Median (Min - Max)	23,50 [12,00-28,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	-1,29 (2,71)
	0,00 [-7,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-2,05 (3,34)
	-1,50 [-8,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	9 (81,8)
Median (Min - Max)	-2,37 (3,66)
	-2,00 [-8,00-1,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	-2,99 (3,64)
	-1,00 [-10,00--0,93]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,63 (6,60)
Median (Min - Max)	-1,00 [-12,00-3,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,06 (1,97)
	-1,00 [-1,17-2,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,50 (2,60)
	-1,00 [-1,00-3,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,17 (2,93)
	-1,00 [-2,00-3,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,00 (1,41)
	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS14: FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-4,23 (4,80)
Median (Min - Max)	-4,00 [-15,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

3.2.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym PWB	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	22,64 (5,07)
Median (Min - Max)	25,00 [9,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	37
Treated patients with non-missing values - n(%)	33 (89,2)
Mean (SD)	-0,97 (3,65)
Median (Min - Max)	-0,50 [-10,00-7,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	28 (87,5)
Mean (SD)	-0,60 (5,66)
Median (Min - Max)	-0,92 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	25
Treated patients with non-missing values - n(%)	20 (80,0)
Mean (SD)	-2,16 (5,93)
Median (Min - Max)	-1,00 [-18,00-8,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,12 (4,47)
Median (Min - Max)	-1,83 [-9,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	0,18 (3,77)
Median (Min - Max)	0,00 [-7,00-7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	0,85 (4,53)
	0,25 [-9,00-7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	-0,78 (5,12)
	-1,00 [-10,00-4,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	-0,17 (6,22)
	3,00 [-10,00-6,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	-1,71 (5,35)
	-3,00 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-0,23 (5,32)
Median (Min - Max)	3,00 [-7,00-4,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,75 (3,86)
Median (Min - Max)	0,50 [-3,00-5,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-2,10 (5,62)
Median (Min - Max)	0,00 [-11,00-3,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-11,00 (NE)
Median (Min - Max)	-11,00 [-11,00--11,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-7,00 (NE)
Median (Min - Max)	-7,00 [-7,00--7,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (75,0)
Mean (SD)	-3,10 (5,42)
Median (Min - Max)	-3,00 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym PWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	77 (97,5)
Mean (SD)	21,60 (5,21)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	68
Mean (SD)	63 (92,6)
Median (Min - Max)	-0,14 (4,79)
	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	45
Mean (SD)	40 (88,9)
Median (Min - Max)	-0,46 (4,43)
	-0,08 [-10,00-15,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	34
Mean (SD)	31 (91,2)
Median (Min - Max)	-1,47 (4,30)
	-2,00 [-10,00-8,83]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	22 (95,7)
Median (Min - Max)	-1,43 (4,34)
	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,50 (5,58)
Median (Min - Max)	0,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	-1,18 (6,86)
	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	-0,22 (5,10)
	-1,00 [-7,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-0,94 (2,72)
	-1,50 [-4,00-3,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-0,33 (0,58)
	0,00 [-1,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,75 (1,71)
Median (Min - Max)	-1,50 [-4,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-0,67 (0,58)
	-1,00 [-1,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-0,50 (0,71)
	-0,50 [-1,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,00 (4,36)
	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,33 (7,57)
	-1,00 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,17 (4,48)
Median (Min - Max)	-5,17 [-8,33--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,10 (7,21)
Median (Min - Max)	-5,10 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS15: FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	62 (78,5)
Mean (SD)	-2,48 (5,48)
Median (Min - Max)	-1,42 [-18,00-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

3.2.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym PWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	22,87 (4,56)
Median (Min - Max)	24,00 [12,00-28,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-1,08 (2,59)
Median (Min - Max)	0,00 [-7,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-1,95 (3,60)
Median (Min - Max)	-1,00 [-8,00-3,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-2,67 (3,76)
Median (Min - Max)	-2,00 [-8,00-1,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 7
Treated patients with non-missing values - n(%)	5 (71,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-2,79 (4,03)
Median (Min - Max)	-1,00 [-10,00--0,93]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,63 (6,60)
Median (Min - Max)	-1,00 [-12,00-3,50]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,58 (2,47)
Median (Min - Max)	0,58 [-1,17-2,33]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,25 (3,18)
Median (Min - Max)	1,25 [-1,00-3,50]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,25 (3,18)
Median (Min - Max)	1,25 [-1,00-3,50]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	19 (90,5)
Median (Min - Max)	-3,86 (4,24)
	-4,00 [-11,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym PWB	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	101 (97,1)
Mean (SD)	21,88 (5,27)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	96
Treated patients with non-missing values - n(%)	87 (90,6)
Mean (SD)	-0,14 (4,52)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	73
Treated patients with non-missing values - n(%)	65 (89,0)
Mean (SD)	-0,15 (5,10)
Median (Min - Max)	-0,17 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	55
Treated patients with non-missing values - n(%)	48 (87,3)
Mean (SD)	-1,10 (5,61)
Median (Min - Max)	-1,00 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	-1,25 (4,37)
Median (Min - Max)	-1,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	-0,36 (5,05)
Median (Min - Max)	0,00 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	24 (92,3)
Median (Min - Max)	-0,06 (6,12)
	-1,00 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	18 (81,8)
Median (Min - Max)	-0,06 (5,69)
	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	16 (94,1)
Median (Min - Max)	-0,11 (5,47)
	-1,00 [-10,00-9,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	-0,17 (5,75)
	0,00 [-9,00-10,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	1,06 (7,08)
Median (Min - Max)	0,00 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	2,10 (5,85)
Median (Min - Max)	-1,00 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,83 (8,27)
Median (Min - Max)	0,00 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	1,50 (8,76)
Median (Min - Max)	1,00 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,33 (7,37)
Median (Min - Max)	-10,00 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-9,67 (1,89)
Median (Min - Max)	-9,67 [-11,00--8,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-8,60 (2,26)
	-8,60 [-10,20--7,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS16: FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym PWB - Change from baseline	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	75 (72,1)
Mean (SD)	-2,30 (5,59)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.2.17 *Merkmal: Vorherige CAR-T-Therapie*

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym PWB	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	21,13 (6,56)
Median (Min - Max)	24,00 [11,00-28,00]
FACT-Lym PWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,00 (6,29)
Median (Min - Max)	-0,50 [-6,00-11,00]
FACT-Lym PWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,25 (8,26)
Median (Min - Max)	0,50 [-10,00-10,00]
FACT-Lym PWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,71 (5,18)
Median (Min - Max)	0,50 [-3,00-8,83]
FACT-Lym PWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,33 (5,77)
Median (Min - Max)	-2,00 [-2,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,00 (7,81)
Median (Min - Max)	-1,00 [-2,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,00 (10,44)
Median (Min - Max)	-2,00 [-4,00-15,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,33 (8,39)
Median (Min - Max)	-2,00 [-3,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	6 (75,0)
Median (Min - Max)	-2,00 (7,35)
	-1,00 [-15,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym PWB	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	119 (97,5)
Mean (SD)	21,97 (5,16)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	101 (91,8)
Mean (SD)	-0,36 (4,14)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	72 (87,8)
Mean (SD)	-0,26 (4,82)
Median (Min - Max)	-0,08 [-14,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	54 (85,7)
Mean (SD)	-1,32 (5,44)
Median (Min - Max)	-1,08 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	43 (93,5)
Mean (SD)	-1,23 (4,59)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	-0,74 (5,04)
Median (Min - Max)	0,00 [-14,00-7,20]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	-0,06 (5,47)
Median (Min - Max)	-0,58 [-14,00-8,67]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	0,25 (5,45)
Median (Min - Max)	-1,00 [-10,00-10,67]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	0,81 (5,89)
Median (Min - Max)	1,17 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	11 (78,6)
Mean (SD)	1,02 (6,95)
Median (Min - Max)	0,00 [-9,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	2,25 (7,47)
Median (Min - Max)	1,50 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	3,46 (6,36)
Median (Min - Max)	1,50 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,60 (7,68)
Median (Min - Max)	0,00 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	1,12 (7,19)
Median (Min - Max)	0,50 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,75 (6,80)
Median (Min - Max)	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS17: FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	92 (75,4)
Mean (SD)	-2,47 (5,64)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

3.2.18 *Merkmal: Arzneimittelformulierung*

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym PWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	22,79 (4,43)
Median (Min - Max)	24,00 [9,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	0,23 (3,40)
Median (Min - Max)	0,83 [-10,00-9,00]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-1,26 (4,23)
Median (Min - Max)	-1,00 [-14,00-4,00]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,67 (4,39)
Median (Min - Max)	0,00 [-11,00-5,00]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,79 (3,83)
Median (Min - Max)	-1,00 [-11,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. PWB = physical well-being.
Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,93 (3,44)
Median (Min - Max)	0,00 [-7,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,73 (4,21)
Median (Min - Max)	-1,00 [-9,00-1,00]
FACT-Lym PWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,42 (3,20)
Median (Min - Max)	-1,50 [-7,00-0,33]
FACT-Lym PWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,89 (3,79)
Median (Min - Max)	-3,00 [-5,00-2,33]
FACT-Lym PWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Drug formulation:	
Frozen liquid	
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	23 (71,9)
Mean (SD)	-2,43 (4,02)
Median (Min - Max)	-3,00 [-10,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym PWB	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	95 (96,9)
Mean (SD)	21,62 (5,47)
Median (Min - Max)	23,00 [7,00-28,00]
FACT-Lym PWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	79 (89,8)
Mean (SD)	-0,55 (4,51)
Median (Min - Max)	0,00 [-10,17-12,67]
FACT-Lym PWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	57 (87,7)
Mean (SD)	0,11 (5,19)
Median (Min - Max)	0,00 [-10,00-15,67]
FACT-Lym PWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	42 (84,0)
Mean (SD)	-0,90 (5,81)
Median (Min - Max)	-1,08 [-18,00-16,67]
FACT-Lym PWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	35 (92,1)
Mean (SD)	-0,83 (4,89)
Median (Min - Max)	-1,00 [-11,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym PWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	-0,13 (5,56)
Median (Min - Max)	-0,33 [-14,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	0,97 (6,19)
Median (Min - Max)	-0,58 [-14,00-15,00]
FACT-Lym PWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	17 (81,0)
Mean (SD)	1,25 (6,03)
Median (Min - Max)	-1,00 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	1,15 (6,03)
Median (Min - Max)	1,50 [-10,00-12,00]
FACT-Lym PWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	11 (78,6)
Mean (SD)	1,57 (6,57)
Median (Min - Max)	0,00 [-9,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym PWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	1,86 (7,20)
Median (Min - Max)	0,00 [-7,00-16,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	9 (69,2)
Median (Min - Max)	2,96 (6,13)
	0,00 [-3,00-13,67]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	0,60 (7,68)
	0,00 [-11,00-16,33]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	4 (57,1)
Median (Min - Max)	1,12 (7,19)
	0,50 [-7,00-10,50]
FACT-Lym PWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-5,75 (6,80)
	-5,50 [-13,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym PWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-7,11 (4,62)
Median (Min - Max)	-8,33 [-11,00--2,00]
FACT-Lym PWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,73 (5,22)
Median (Min - Max)	-7,00 [-10,20-0,00]
FACT-Lym PWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,50 (6,36)
Median (Min - Max)	-5,50 [-10,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym PWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym PWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FPC_PSHS18: FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym PWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym PWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym PWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	75 (76,5)
Mean (SD)	-2,44 (6,16)
Median (Min - Max)	-2,00 [-18,00-12,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. PWB = physical well-being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSD_PSTS01: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Age group
 PRO set

3.3 Subgruppenanalysen zum FACT-Lym – soziales/familiäres Wohlbefinden (Zeit bis zur Verschlechterung)

3.3.1 Merkmal Alter

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	19 (33,3)
95%-CI	[21,4-47,1]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11 [2,79-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [47,8-76,5]
Month 6	52,3 [31,7-69,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS01: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	13 (24,5)
95%-CI	[13,8-38,3]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[3,94-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,3 [53,4-84,6]
Month 6	53,7 [30,4-72,3]
Month 12	53,7 [30,4-72,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS01: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	8 (40,0)
95%-CI	[19,1-63,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[1,41-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,3 [48,7-88,5]
Month 6	54,2 [24,1-76,8]
Month 12	54,2 [24,1-76,8]
Month 18	27,1 [1,7-65,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS02: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Sex
 PRO set

3.3.2 *Merkmal: Geschlecht*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	19 (35,8)
95%-CI	[23,1-50,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,82 [4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,8 [55,2-83,1]
Month 6	49,7 [30,1-66,6]
Month 12	42,6 [22,2-61,7]
Month 18	28,4 [7,1-55,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS02: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	21 (27,3)
95%-CI	[17,7-38,6]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[4,24-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,7 [53,4-78,4]
Month 6	59,5 [42,6-72,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS03: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Race group
 PRO set

3.3.3 *Merkmal: Ethnie*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	35 (30,4)
95%-CI	[22,2-39,7]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [59,5-79,2]
Month 6	52,6 [38,0-65,3]
Month 12	45,1 [26,8-61,8]
Month 18	30,1 [8,0-56,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS03: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[1,41-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,9 [30,0-82,6]
Month 6	61,9 [30,0-82,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS04: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Country
 PRO set

3.3.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	18 (35,3)
95%-CI	[22,4-49,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,13[2,56-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,5 [45,0-75,8]
Month 6	49,2 [27,9-67,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS04: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[4,24-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [60,9-95,6]
Month 6	65,6 [31,9-85,6]
Month 12	65,6 [31,9-85,6]
Month 18	65,6 [31,9-85,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS04: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	16 (33,3)
95%-CI	[20,4-48,4]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[3,94-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,8 [51,2-81,2]
Month 6	50,9 [28,7-69,3]
Month 12	50,9 [28,7-69,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS05: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Region
 PRO set

3.3.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	18 (35,3)
95%-CI	[22,4-49,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,13[2,56-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,5 [45,0-75,8]
Month 6	49,2 [27,9-67,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS05: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	22 (27,8)
95%-CI	[18,3-39,1]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[4,73-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,9 [60,4-83,4]
Month 6	55,0 [36,8-70,0]
Month 12	55,0 [36,8-70,0]
Month 18	36,7 [9,5-65,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS06: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

3.3.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [2,20-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	64,3 [15,2-90,2]
Month 12	64,3 [15,2-90,2]
Month 18	64,3 [15,2-90,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS06: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22 [3,94-12,22]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [52,0-91,5]
Month 6	68,8 [38,0-86,5]
Month 12	68,8 [38,0-86,5]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS06: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	10 (58,8)
95%-CI	[32,9-81,6]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	2,79 [0,72-8,11]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,6 [18,3-66,8]
Month 6	32,7 [9,7-58,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS06: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	22 (26,8)
95%-CI	[17,6-37,8]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[4,86-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,7 [55,4-80,2]
Month 6	51,6 [32,4-67,7]
Month 12	51,6 [32,4-67,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS07: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Bulky disease
 PRO set

3.3.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	40 (31,7)
95%-CI	[23,7-40,6]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [58,8-77,5]
Month 6	53,1 [39,6-64,9]
Month 12	45,5 [27,6-61,8]
Month 18	30,4 [8,1-56,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS08: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Double/Triple hit
 PRO set

3.3.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	5 (35,7)
95%-CI	[12,8-64,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,13[1,41-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,7 [18,0-80,9]
Month 6	27,4 [1,5-67,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS08: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	35 (30,2)
95%-CI	[22,0-39,4]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,0 [60,2-79,3]
Month 6	56,0 [41,8-68,0]
Month 12	48,0 [29,0-64,7]
Month 18	32,0 [8,4-59,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS09: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Transformed DLBCL
 PRO set

3.3.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	8 (33,3)
95%-CI	[15,6-55,3]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,82 [4,24-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [53,5-89,9]
Month 6	43,4 [13,5-70,7]
Month 12	43,4 [13,5-70,7]
Month 18	43,4 [13,5-70,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. SWB = social well being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS09: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	32 (30,2)
95%-CI	[21,7-39,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11 [4,83-12,22]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [55,6-76,9]
Month 6	55,8 [41,0-68,2]
Month 12	44,6 [22,2-64,9]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. SWB = social well being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS10: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: B-Cell type
 PRO set

3.3.10 *Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	11 (25,6)
95%-CI	[13,5-41,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,83-12,22]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,5 [61,2-89,8]
Month 6	67,1 [43,5-82,6]
Month 12	44,7 [9,8-75,7]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS10: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	5 (23,8)
95%-CI	[8,2-47,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [2,79-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [47,0-90,4]
Month 6	65,1 [32,7-84,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS11: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter
 PRO set

3.3.11 *Merkmal: Maximaler längster Durchmesser*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	31 (40,8)
95%-CI	[29,6-52,7]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,13 [3,94-12,22]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,4 [51,1-75,0]
Month 6	44,7 [28,8-59,4]
Month 12	35,8 [16,9-55,1]
Month 18	23,8 [5,9-48,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS11: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	8 (23,5)
95%-CI	[10,7-41,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [2,79-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [47,2-85,1]
Month 6	62,8 [37,0-80,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS11: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. SWB = social well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS11: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. SWB = social well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS12: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Primary disease diagnosis
 PRO set

3.3.12 *Merkmal: Primärdiagnose*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	35 (31,3)
95%-CI	[22,8-40,7]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,1 [59,2-78,7]
Month 6	55,4 [41,3-67,4]
Month 12	47,5 [28,7-64,1]
Month 18	31,6 [8,3-58,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS12: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,13[1,41-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,4 [15,5-85,7]
Month 6	29,2 [1,4-70,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS13: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Number prior lines
 PRO set

3.3.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [63,9-88,4]
Month 6	53,5 [31,2-71,4]
Month 12	53,5 [31,2-71,4]
Month 18	35,7 [8,7-64,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS13: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	9 (28,1)
95%-CI	[13,7-46,7]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[2,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,6 [45,9-83,3]
Month 6	57,2 [28,6-77,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS13: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	15 (38,5)
95%-CI	[23,4-55,4]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[2,10-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,2 [37,5-72,8]
Month 6	50,9 [30,0-68,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS14: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - first line
 PRO set

3.3.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	30 (32,6)
95%-CI	[23,2-43,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,24-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,8 [56,4-78,3]
Month 6	50,6 [34,8-64,4]
Month 12	38,0 [15,3-60,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS14: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	3 (13,6)
95%-CI	[2,9-34,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,6 [54,7-94,1]
Month 6	82,6 [54,7-94,1]
Month 12	82,6 [54,7-94,1]
Month 18	82,6 [54,7-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS15: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - last line
 PRO set

3.3.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	15 (37,5)
95%-CI	[22,7-54,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[4,24-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [50,8-82,7]
Month 6	50,8 [30,1-68,3]
Month 12	50,8 [30,1-68,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS15: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	20 (25,3)
95%-CI	[16,2-36,4]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,86-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,6 [62,8-84,5]
Month 6	60,0 [39,4-75,5]
Month 12	30,0 [2,0-69,0]
Month 18	30,0 [2,0-69,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS16: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - any line
 PRO set

3.3.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [53,7-93,9]
Month 6	82,1 [53,7-93,9]
Month 12	82,1 [53,7-93,9]
Month 18	82,1 [53,7-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS16: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	35 (33,7)
95%-CI	[24,7-43,6]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,82 [4,73-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,8 [57,2-77,8]
Month 6	50,0 [35,1-63,1]
Month 12	41,6 [22,8-59,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS17: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Prior use of T-CART therapy
PRO set

3.3.17 Merkmal: Vorherige CAR-T-Therapie

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. SWB = social well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS17: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	38 (31,1)
95%-CI	[23,1-40,2]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[4,73-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,7 [57,9-77,2]
Month 6	50,9 [36,6-63,5]
Month 12	50,9 [36,6-63,5]
Month 18	33,9 [9,4-61,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS18: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Drug formulation
 PRO set

3.3.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	8 (25,0)
95%-CI	[11,5-43,4]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE [2,79-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [42,8-83,9]
Month 6	56,6 [27,3-78,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSD_PSTS18: Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym SWB by at least 5 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation: Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	32 (32,7)
95%-CI	[23,5-42,9]
FACT-Lym SWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	8,11[4,83-NE]
FACT-Lym SWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,7 [58,0-78,8]
Month 6	52,5 [37,2-65,7]
Month 12	45,0 [26,4-62,0]
Month 18	30,0 [7,9-56,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. SWB = social well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

3.4 Subgruppenanalysen zum FACT-Lym – soziales/familiäres Wohlbefinden (Veränderung gegenüber Studienbeginn)

3.4.1 Merkmal Alter

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym SWB	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	57 (100,0)
Mean (SD)	20,92 (5,74)
Median (Min - Max)	22,17 [2,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	47 (95,9)
Mean (SD)	-0,29 (5,15)
Median (Min - Max)	0,00 [-21,50-12,60]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	35 (94,6)
Mean (SD)	-1,26 (5,17)
Median (Min - Max)	-1,00 [-13,50-11,20]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	-0,93 (5,07)
Median (Min - Max)	-1,00 [-16,33-11,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	-1,95 (3,78)
Median (Min - Max)	-1,08 [-10,50-3,50]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-0,74 (3,55)
Median (Min - Max)	0,00 [-8,50-4,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	-1,30 (5,71)
Median (Min - Max)	-1,58 [-9,50-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,72 (4,77)
Median (Min - Max)	-1,00 [-3,50-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-1,81 (5,33)
Median (Min - Max)	-2,22 [-8,40-7,35]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-4,86 (5,40)
Median (Min - Max)	-3,08 [-14,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,71 (1,89)
Median (Min - Max)	-6,42 [-7,00--3,00]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,08 (4,25)
Median (Min - Max)	-5,25 [-9,80-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,70 (0,42)
Median (Min - Max)	-1,70 [-2,00--1,40]
FACT-Lym SWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	44 (77,2)
Mean (SD)	-1,47 (4,37)
Median (Min - Max)	-1,08 [-11,00-10,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym SWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	52 (98,1)
Mean (SD)	21,96 (5,92)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	46 (95,8)
Mean (SD)	0,57 (6,30)
Median (Min - Max)	0,00 [-14,17-28,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	30 (88,2)
Mean (SD)	0,74 (6,84)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	0,08 (7,31)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-1,51 (10,29)
Median (Min - Max)	0,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,65 (3,53)
Median (Min - Max)	0,00 [-6,77-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,88 (4,94)
Median (Min - Max)	0,00 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-0,54 (5,77)
Median (Min - Max)	0,00 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-1,87 (5,33)
Median (Min - Max)	-1,10 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-2,76 (5,70)
Median (Min - Max)	-1,33 [-12,60-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,24 (6,13)
Median (Min - Max)	-1,77 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-0,99 (7,26)
Median (Min - Max)	0,00 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-1,87 (7,59)
Median (Min - Max)	0,73 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-7,58 (7,09)
Median (Min - Max)	-7,58 [-12,60--2,57]
FACT-Lym SWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,40 (5,94)
Median (Min - Max)	-8,40 [-12,60--4,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,99 (5,92)
Median (Min - Max)	-4,20 [-12,60--1,17]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-7,16 (4,72)
Median (Min - Max)	-4,67 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,90 (8,06)
Median (Min - Max)	-6,90 [-12,60--1,20]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	43 (81,1)
Mean (SD)	-0,91 (6,57)
Median (Min - Max)	0,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym SWB	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	24,27 (4,37)
Median (Min - Max)	25,43 [11,67-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	-2,13 (6,85)
Median (Min - Max)	0,00 [-28,00-2,33]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,80 (4,06)
Median (Min - Max)	0,00 [-8,40-5,83]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	0,17 (3,08)
Median (Min - Max)	0,00 [-4,67-5,50]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-0,09 (2,43)
Median (Min - Max)	0,00 [-4,67-2,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-1,17 (2,94)
Median (Min - Max)	-1,17 [-4,67-2,33]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,37 (3,22)
Median (Min - Max)	0,00 [-5,83-2,33]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,75 (3,10)
Median (Min - Max)	-0,58 [-4,67-2,83]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,46 (2,59)
Median (Min - Max)	-1,17 [-4,67-1,17]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-0,58 (0,82)
Median (Min - Max)	-0,58 [-1,17-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-0,58 (0,82)
Median (Min - Max)	-0,58 [-1,17-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,50 (6,06)
Median (Min - Max)	0,00 [-10,50-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS01: FACT-Lym SWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-2,77 (5,06)
Median (Min - Max)	-1,40 [-11,20-6,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

3.4.2 Merkmal: Geschlecht

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym SWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	52 (98,1)
Mean (SD)	22,37 (5,42)
Median (Min - Max)	23,67 [6,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	43 (93,5)
Mean (SD)	-0,28 (3,98)
Median (Min - Max)	0,00 [-8,87-15,17]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	-0,91 (4,20)
Median (Min - Max)	-0,50 [-9,00-7,47]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	23 (82,1)
Mean (SD)	-1,29 (4,95)
Median (Min - Max)	-0,70 [-16,33-9,80]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,70 (3,51)
Median (Min - Max)	-1,17 [-9,10-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-1,42 (3,35)
Median (Min - Max)	-1,17 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	-1,32 (4,15)
Median (Min - Max)	0,00 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-1,11 (4,34)
Median (Min - Max)	-1,00 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	-2,82 (4,46)
Median (Min - Max)	-2,92 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-3,38 (5,53)
Median (Min - Max)	-1,17 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-3,11 (4,88)
Median (Min - Max)	-2,67 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	-2,62 (6,12)
Median (Min - Max)	-0,93 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-3,13 (5,49)
Median (Min - Max)	-1,63 [-12,60-3,33]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-3,43 (5,25)
Median (Min - Max)	-2,00 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	42 (79,2)
Mean (SD)	-1,93 (4,62)
Median (Min - Max)	-1,00 [-12,60-8,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym SWB	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	77 (100,0)
Mean (SD)	21,52 (5,90)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	68 (97,1)
Mean (SD)	-0,20 (6,95)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	45 (90,0)
Mean (SD)	-0,05 (6,65)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	0,24 (6,37)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-1,28 (8,65)
Median (Min - Max)	0,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	0,02 (3,29)
Median (Min - Max)	1,00 [-8,50-4,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,37 (6,43)
Median (Min - Max)	-0,50 [-9,50-12,60]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,72 (4,97)
Median (Min - Max)	0,00 [-3,50-12,60]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,71 (4,62)
Median (Min - Max)	0,95 [-7,00-7,35]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,44 (3,95)
Median (Min - Max)	-1,33 [-8,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS02: FACT-Lym SWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,17 (5,42)
Median (Min - Max)	-3,17 [-7,00-0,67]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,17 (6,84)
Median (Min - Max)	-2,17 [-7,00-2,67]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,67 (NE)
Median (Min - Max)	3,67 [3,67-3,67]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	58 (75,3)
Mean (SD)	-1,01 (6,04)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

3.4.3 *Merkmal: Ethnie*

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym SWB	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	114 (99,1)
Mean (SD)	21,69 (5,57)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	99 (95,2)
Mean (SD)	0,01 (5,72)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	67 (90,5)
Mean (SD)	-0,11 (5,61)
Median (Min - Max)	-1,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	51 (91,1)
Mean (SD)	-0,04 (6,18)
Median (Min - Max)	0,00 [-16,33-28,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	39 (95,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,95 (6,38)
Median (Min - Max)	-1,00 [-19,25-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	-0,61 (3,30)
Median (Min - Max)	0,00 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	-0,81 (5,05)
Median (Min - Max)	-0,50 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,39 (4,85)
Median (Min - Max)	-1,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	-1,94 (4,75)
Median (Min - Max)	-2,20 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	-3,57 (5,24)
Median (Min - Max)	-1,17 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-3,46 (4,77)
Median (Min - Max)	-3,00 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	-3,10 (5,91)
Median (Min - Max)	-1,87 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-3,13 (5,49)
Median (Min - Max)	-1,63 [-12,60-3,33]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-3,43 (5,25)
Median (Min - Max)	-2,00 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	
87 (75,7)	
Mean (SD)	
-1,35 (5,59)	
Median (Min - Max)	
-1,00 [-14,00-28,00]	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym SWB	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	23,18 (6,66)
Median (Min - Max)	25,20 [2,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-2,24 (7,62)
Median (Min - Max)	0,00 [-21,50-8,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-2,13 (6,22)
Median (Min - Max)	-0,50 [-13,50-8,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-1,85 (3,86)
Median (Min - Max)	-0,35 [-8,50-2,33]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-4,05 (7,98)
Median (Min - Max)	-0,33 [-21,00-2,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,58 (3,79)
Median (Min - Max)	-0,17 [-8,50-2,33]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-1,90 (4,91)
	0,00 [-9,50-2,33]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,83 (2,92)
	2,67 [0,00-5,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,67 (NE)
	1,67 [1,67-1,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,33 (NE)
	-1,33 [-1,33--1,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS03: FACT-Lym SWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,67 (NE)
Median (Min - Max)	0,67 [0,67-0,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,67 (NE)
	2,67 [2,67-2,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,67 (NE)
	3,67 [3,67-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	13 (86,7)
Median (Min - Max)	-1,75 (4,86)
	0,00 [-12,83-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

3.4.4 *Merkmal: Region-1*

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym SWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	51 (100,0)
Mean (SD)	23,18 (5,73)
Median (Min - Max)	25,00 [2,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	44 (97,8)
Mean (SD)	-1,23 (5,28)
Median (Min - Max)	0,00 [-28,00-8,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	-0,81 (4,52)
Median (Min - Max)	-0,17 [-9,83-8,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	-1,35 (4,35)
Median (Min - Max)	-0,70 [-16,33-5,50]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	-2,83 (5,39)
Median (Min - Max)	-2,17 [-21,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,00 (3,26)
Median (Min - Max)	-0,17 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	-1,32 (4,15)
Median (Min - Max)	0,00 [-8,00-5,00]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,21 (3,23)
Median (Min - Max)	0,00 [-3,50-5,83]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,12 (5,46)
Median (Min - Max)	-2,33 [-8,40-5,67]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-3,75 (6,05)
Median (Min - Max)	-1,25 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,58 (5,17)
Median (Min - Max)	-4,08 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,80 (6,19)
Median (Min - Max)	-1,75 [-9,80-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,87 (2,83)
Median (Min - Max)	3,33 [-1,40-3,67]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-1,73 (4,20)
Median (Min - Max)	-1,08 [-12,83-6,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym SWB	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	22,51 (6,59)
Median (Min - Max)	24,50 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	1,13 (8,72)
Median (Min - Max)	0,00 [-21,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	2,00 (10,04)
Median (Min - Max)	0,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	2,65 (9,78)
Median (Min - Max)	0,00 [-8,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,82 (11,98)
Median (Min - Max)	-0,70 [-19,25-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,17 (3,96)
Median (Min - Max)	0,00 [-8,50-2,80]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,84 (7,54)
Median (Min - Max)	-1,17 [-9,50-12,60]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	4,20 (7,27)
Median (Min - Max)	0,00 [0,00-12,60]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,16 (4,69)
Median (Min - Max)	0,00 [-4,67-7,35]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (0,00)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	1,25 (6,63)
Median (Min - Max)	0,00 [-8,17-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym SWB	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	47 (97,9)
Mean (SD)	20,23 (4,73)
Median (Min - Max)	22,00 [6,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	44 (95,7)
Mean (SD)	0,08 (4,85)
Median (Min - Max)	-0,08 [-14,17-15,17]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	35 (97,2)
Mean (SD)	-0,69 (4,50)
Median (Min - Max)	-1,00 [-13,17-11,20]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-0,65 (4,73)
Median (Min - Max)	0,00 [-13,17-9,80]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-0,07 (2,88)
Median (Min - Max)	0,00 [-9,10-3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,30 (3,41)
Median (Min - Max)	0,00 [-6,77-4,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,77 (4,57)
Median (Min - Max)	-0,50 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,24 (4,23)
Median (Min - Max)	-1,58 [-12,60-2,00]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-2,41 (4,53)
Median (Min - Max)	-2,20 [-12,60-2,00]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-3,61 (4,72)
Median (Min - Max)	-1,52 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-4,39 (4,75)
Median (Min - Max)	-3,00 [-12,60--1,17]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-4,82 (6,80)
Median (Min - Max)	-1,87 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-6,74 (5,62)
Median (Min - Max)	-6,25 [-12,60--1,87]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,72 (5,96)
Median (Min - Max)	-2,57 [-12,60--2,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-6,60 (5,23)
Median (Min - Max)	-4,20 [-12,60--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,99 (5,92)
Median (Min - Max)	-4,20 [-12,60--1,17]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-7,16 (4,72)
Median (Min - Max)	-4,67 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,90 (8,06)
Median (Min - Max)	-6,90 [-12,60--1,20]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS04: FACT-Lym SWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	37 (77,1)
Mean (SD)	-2,60 (5,21)
Median (Min - Max)	-1,87 [-14,00-10,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

3.4.5 *Merkmal: Region-2*

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym SWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	51 (100,0)
Mean (SD)	23,18 (5,73)
Median (Min - Max)	25,00 [2,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	44 (97,8)
Mean (SD)	-1,23 (5,28)
Median (Min - Max)	0,00 [-28,00-8,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	-0,81 (4,52)
Median (Min - Max)	-0,17 [-9,83-8,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	-1,35 (4,35)
Median (Min - Max)	-0,70 [-16,33-5,50]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	-2,83 (5,39)
Median (Min - Max)	-2,17 [-21,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,00 (3,26)
Median (Min - Max)	-0,17 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	-1,32 (4,15)
Median (Min - Max)	0,00 [-8,00-5,00]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,21 (3,23)
Median (Min - Max)	0,00 [-3,50-5,83]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,12 (5,46)
Median (Min - Max)	-2,33 [-8,40-5,67]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-3,75 (6,05)
Median (Min - Max)	-1,25 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,58 (5,17)
Median (Min - Max)	-4,08 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,80 (6,19)
Median (Min - Max)	-1,75 [-9,80-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,87 (2,83)
Median (Min - Max)	3,33 [-1,40-3,67]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-1,73 (4,20)
Median (Min - Max)	-1,08 [-12,83-6,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym SWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	78 (98,7)
Mean (SD)	21,00 (5,55)
Median (Min - Max)	22,08 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	67 (94,4)
Mean (SD)	0,42 (6,31)
Median (Min - Max)	0,00 [-21,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	48 (90,6)
Mean (SD)	-0,17 (6,40)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	36 (90,0)
Mean (SD)	0,36 (6,71)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	-0,63 (7,34)
Median (Min - Max)	0,00 [-19,25-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	-0,59 (3,51)
Median (Min - Max)	0,00 [-8,50-4,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-0,80 (5,50)
Median (Min - Max)	-0,50 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-0,75 (5,50)
Median (Min - Max)	-1,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	-1,61 (4,54)
Median (Min - Max)	-1,10 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-3,09 (4,52)
Median (Min - Max)	-1,17 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-3,66 (4,61)
Median (Min - Max)	-2,10 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-3,62 (6,05)
Median (Min - Max)	-0,93 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,49 (5,57)
Median (Min - Max)	-1,93 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-4,29 (5,65)
Median (Min - Max)	-2,28 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS05: FACT-Lym SWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	64 (81,0)
Mean (SD)	-1,21 (6,11)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.4.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym SWB	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	23,50 (3,38)
Median (Min - Max)	24,00 [18,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,70 (2,92)
Median (Min - Max)	0,00 [-5,83-4,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,03 (3,30)
Median (Min - Max)	0,00 [-3,50-5,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,04 (3,82)
Median (Min - Max)	-0,67 [-3,50-5,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,17 (2,19)
Median (Min - Max)	0,00 [-2,33-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,22 (4,30)
Median (Min - Max)	0,00 [-2,33-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,89 (3,75)
Median (Min - Max)	0,00 [-2,33-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,83 (4,01)
Median (Min - Max)	2,83 [0,00-5,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,72 (4,63)
Median (Min - Max)	0,00 [-3,50-5,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	3,00 (4,24)
	3,00 [0,00-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	3,42 (4,83)
	3,42 [0,00-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	1,67 (2,36)
	1,67 [0,00-3,33]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	-1,98 (5,74)
Median (Min - Max)	0,00 [-11,67-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym SWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	19,35 (6,49)
Median (Min - Max)	19,83 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	1,14 (7,80)
Median (Min - Max)	0,50 [-14,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	0,56 (9,45)
Median (Min - Max)	-1,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,43 (10,23)
Median (Min - Max)	-1,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	3,12 (9,54)
Median (Min - Max)	1,00 [-4,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	0,03 (3,74)
	1,87 [-5,37-3,50]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,09 (3,15)
	1,63 [-4,67-2,33]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	0,14 (3,70)
	-1,17 [-3,50-5,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,86 (2,73)
	0,23 [-3,97-1,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,17 (NE)
	-1,17 [-1,17--1,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,57 (1,98)
	-2,57 [-3,97--1,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-10,50 (NE)
	-10,50 [-10,50--10,50]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,57 (NE)
	-2,57 [-2,57--2,57]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,17 (NE)
	-1,17 [-1,17--1,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,67 (NE)
	-4,67 [-4,67--4,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage II	
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	16 (76,2)
Mean (SD)	-0,97 (8,93)
Median (Min - Max)	-1,50 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym SWB	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	23,20 (4,63)
Median (Min - Max)	24,25 [14,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-2,74 (7,55)
Median (Min - Max)	-1,58 [-21,50-6,53]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-3,42 (6,44)
Median (Min - Max)	-4,00 [-13,50-11,20]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-2,07 (4,31)
Median (Min - Max)	-1,17 [-8,50-3,50]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	-1,40 (4,65)
Median (Min - Max)	-1,17 [-10,50-3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-2,17 (3,59)
	-1,17 [-8,50-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-1,87 (4,49)
	-1,00 [-9,50-2,33]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,83 (1,76)
	-2,00 [-3,50-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,33 (3,30)
	-2,33 [-4,67-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,17 (NE)
	-1,17 [-1,17--1,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,83 (NE)
	-5,83 [-5,83--5,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,50 (NE)
	-3,50 [-3,50--3,50]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	12 (70,6)
Median (Min - Max)	-1,40 (6,61)
	-0,58 [-12,83-10,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym SWB	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	82 (100,0)
Mean (SD)	22,04 (5,78)
Median (Min - Max)	23,33 [2,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	68 (94,4)
Mean (SD)	-0,06 (5,19)
Median (Min - Max)	0,00 [-28,00-15,17]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	51 (94,4)
Mean (SD)	-0,05 (4,44)
Median (Min - Max)	0,00 [-9,00-10,85]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	37 (88,1)
Mean (SD)	-0,48 (4,63)
Median (Min - Max)	0,00 [-16,33-11,20]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	-3,26 (5,87)
Median (Min - Max)	-1,40 [-21,00-2,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	20 (90,9)
Median (Min - Max)	-0,98 (3,13)
	0,00 [-7,00-4,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	16 (100,0)
Median (Min - Max)	-1,36 (5,89)
	-0,50 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	0,02 (5,75)
	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	12 (100,0)
Median (Min - Max)	-2,52 (5,40)
	-2,27 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	-4,87 (5,44)
	-1,87 [-14,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	-4,64 (4,52)
	-3,00 [-12,60-0,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	-4,09 (5,74)
	-1,87 [-12,60-2,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-2,37 (5,44)
	-1,63 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	-4,87 (6,77)
	-2,00 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-6,60 (5,23)
	-4,20 [-12,60--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,40 (5,94)
	-8,40 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,40 (5,94)
	-8,40 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,90 (8,06)
	-6,90 [-12,60--1,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS06: FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	65 (79,3)
Median (Min - Max)	-1,44 (4,13)
	-1,00 [-12,60-8,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
 PRO set

3.4.7 *Merkmal: Bulky Erkrankung*

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym SWB	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	125 (99,2)
Mean (SD)	21,99 (5,71)
Median (Min - Max)	23,00 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	108 (95,6)
Mean (SD)	-0,20 (6,03)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	79 (92,9)
Mean (SD)	-0,42 (5,71)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	60 (90,9)
Mean (SD)	-0,31 (5,92)
Median (Min - Max)	0,00 [-16,33-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	47 (95,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,47 (6,68)
Median (Min - Max)	-0,67 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	-0,78 (3,35)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	-0,99 (4,96)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	0,05 (4,71)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	-1,76 (4,69)
Median (Min - Max)	-1,10 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-3,39 (5,06)
Median (Min - Max)	-1,17 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	-3,12 (4,70)
Median (Min - Max)	-2,67 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-2,53 (5,86)
Median (Min - Max)	-0,93 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-2,37 (5,62)
Median (Min - Max)	-1,40 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-3,43 (5,25)
Median (Min - Max)	-2,00 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS07: FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	99 (78,6)
Mean (SD)	-1,40 (5,51)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.4.8 *Merkmal: Double/Triple-Hit*

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym SWB	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	24,31 (4,23)
Median (Min - Max)	26,13 [16,33-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-2,40 (8,39)
Median (Min - Max)	0,50 [-28,00-2,33]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-0,57 (3,65)
Median (Min - Max)	0,00 [-8,40-2,83]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,19 (6,65)
Median (Min - Max)	-1,75 [-16,33-1,67]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,91 (4,76)
Median (Min - Max)	0,00 [-7,00-2,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,25 (4,25)
Median (Min - Max)	-1,83 [-7,00-1,67]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,44 (5,32)
Median (Min - Max)	-7,00 [-8,00-1,67]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,48 (2,16)
Median (Min - Max)	0,00 [-1,40-2,83]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-7,70 (0,99)
Median (Min - Max)	-7,70 [-8,40--7,00]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-11,00 (4,24)
Median (Min - Max)	-11,00 [-14,00--8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-7,00 (0,00)
Median (Min - Max)	-7,00 [-7,00--7,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,40 (1,98)
Median (Min - Max)	-8,40 [-9,80--7,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,40 (NE)
Median (Min - Max)	-1,40 [-1,40--1,40]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-3,52 (3,85)
Median (Min - Max)	-1,33 [-8,17-0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym SWB	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	115 (99,1)
Mean (SD)	21,56 (5,80)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	99 (95,2)
Mean (SD)	0,03 (5,59)
Median (Min - Max)	0,00 [-21,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	71 (91,0)
Mean (SD)	-0,40 (5,92)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	55 (91,7)
Mean (SD)	0,08 (5,70)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	42 (97,7)
Mean (SD)	-1,42 (6,92)
Median (Min - Max)	-0,83 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	30 (96,8)
Mean (SD)	-0,59 (3,25)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-0,60 (4,87)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,02 (5,04)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,10 (4,47)
Median (Min - Max)	0,00 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-2,01 (3,90)
Median (Min - Max)	-1,17 [-12,60-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,34 (4,80)
Median (Min - Max)	-1,77 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	-1,06 (5,60)
Median (Min - Max)	0,00 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-2,50 (5,99)
Median (Min - Max)	-0,93 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-4,29 (5,65)
Median (Min - Max)	-2,28 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS08: FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	91 (78,4)
Mean (SD)	-1,19 (5,59)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.4.9 Merkmal: Transformation des DLBCL

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym SWB	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	21,61 (4,86)
Median (Min - Max)	22,00 [11,20-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	-1,05 (3,39)
Median (Min - Max)	0,00 [-8,87-4,83]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-0,83 (4,05)
Median (Min - Max)	-1,63 [-8,00-7,47]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,13 (3,93)
Median (Min - Max)	0,00 [-5,00-9,80]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,54 (3,54)
Median (Min - Max)	0,00 [-9,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,63 (1,96)
Median (Min - Max)	0,00 [-2,00-2,80]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,63 (1,82)
Median (Min - Max)	0,00 [-1,00-2,80]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,71 (3,51)
Median (Min - Max)	-0,50 [-2,00-5,83]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,40 (2,51)
Median (Min - Max)	-2,20 [-5,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,29 (2,53)
Median (Min - Max)	-1,87 [-5,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,40 (1,51)
Median (Min - Max)	-1,20 [-3,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,62 (1,08)
	0,00 [-1,87-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,29 (1,12)
	-1,87 [-2,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-1,00 (1,41)
	-1,00 [-2,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,40 (2,16)
	-3,00 [-4,20-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,10 (2,97)
Median (Min - Max)	-2,10 [-4,20-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,10 (2,97)
Median (Min - Max)	-2,10 [-4,20-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,60 (0,85)
Median (Min - Max)	-0,60 [-1,20-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	-2,16 (4,07)
Median (Min - Max)	-1,08 [-11,67-4,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym SWB	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	105 (99,1)
Mean (SD)	21,92 (5,90)
Median (Min - Max)	23,33 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	90 (94,7)
Mean (SD)	-0,04 (6,41)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	64 (91,4)
Mean (SD)	-0,32 (6,06)
Median (Min - Max)	-0,17 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	50 (92,6)
Mean (SD)	-0,39 (6,25)
Median (Min - Max)	0,00 [-16,33-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	37 (94,9)
Mean (SD)	-1,73 (7,33)
Median (Min - Max)	-1,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-1,03 (3,50)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	24 (100,0)
Median (Min - Max)	-1,33 (5,35)
	-0,58 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	18 (90,0)
Median (Min - Max)	-0,09 (5,02)
	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	-1,65 (5,03)
	0,00 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-3,73 (5,67)
	-1,17 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-3,69 (5,33)
Median (Min - Max)	-3,97 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	-3,34 (6,97)
Median (Min - Max)	-3,50 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-2,92 (6,99)
Median (Min - Max)	-0,70 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-5,06 (6,66)
Median (Min - Max)	-2,57 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,88 (8,08)
Median (Min - Max)	-6,88 [-12,60--1,17]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS09: FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	80 (75,5)
Mean (SD)	-1,21 (5,78)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
 PRO set

3.4.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym SWB	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	22,53 (6,45)
Median (Min - Max)	24,00 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	38 (95,0)
Mean (SD)	0,26 (8,19)
Median (Min - Max)	0,17 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	0,60 (7,05)
Median (Min - Max)	0,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	1,45 (6,56)
Median (Min - Max)	0,00 [-8,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,34 (9,14)
Median (Min - Max)	-0,33 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	0,30 (3,28)
Median (Min - Max)	0,58 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,43 (5,11)
	0,83 [-9,50-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	2,08 (4,93)
	1,33 [-3,50-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	0,41 (4,55)
	0,70 [-4,67-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-0,42 (1,61)
	-1,17 [-1,33-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,08 (4,89)
Median (Min - Max)	-0,25 [-5,83-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	2,00 (5,20)
	2,67 [-3,50-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-0,87 (6,63)
	1,67 [-10,50-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	35 (81,4)
Median (Min - Max)	0,20 (6,22)
	0,00 [-10,50-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym SWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	22,12 (3,86)
Median (Min - Max)	22,00 [15,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-0,41 (5,49)
Median (Min - Max)	0,00 [-14,17-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-1,44 (5,14)
Median (Min - Max)	-1,00 [-13,17-5,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,86 (5,18)
Median (Min - Max)	-1,00 [-13,17-5,83]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-2,42 (6,48)
Median (Min - Max)	-1,00 [-19,25-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,73 (3,42)
Median (Min - Max)	0,00 [-5,37-4,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,21 (2,55)
	1,63 [0,00-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,82 (1,73)
	1,63 [-1,17-2,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,66 (3,04)
	0,00 [-3,97-2,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-0,50 (0,71)
	-0,50 [-1,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,15 (1,15)
Median (Min - Max)	-3,15 [-3,97--2,33]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,57 (NE)
	-2,57 [-2,57--2,57]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,17 (NE)
	-1,17 [-1,17--1,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,67 (NE)
	-4,67 [-4,67--4,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS10: FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	16 (76,2)
Mean (SD)	-1,53 (5,76)
Median (Min - Max)	-0,17 [-14,00-8,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.4.11 *Merkmal: Maximaler längster Durchmesser*

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: ≤ 5 cm	
Patients in analysis set	76
FACT-Lym SWB	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	75 (98,7)
Mean (SD)	21,36 (6,28)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	65 (94,2)
Mean (SD)	-0,26 (7,04)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	53 (93,0)
Mean (SD)	-0,35 (6,24)
Median (Min - Max)	-0,17 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)
Mean (SD)	-0,16 (6,21)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,21 (7,35)
Median (Min - Max)	-0,67 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	25
Mean (SD)	24 (96,0)
Median (Min - Max)	-0,97 (3,32)
	0,00 [-8,50-4,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	21
Mean (SD)	21 (100,0)
Median (Min - Max)	-1,48 (4,54)
	0,00 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	16 (88,9)
Median (Min - Max)	-0,49 (4,02)
	0,00 [-12,60-5,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	-2,64 (4,24)
	-2,20 [-12,60-2,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-3,21 (4,13)
	-1,25 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-3,79 (4,19)
Median (Min - Max)	-3,00 [-12,60-0,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	-3,19 (5,16)
Median (Min - Max)	-1,87 [-12,60-2,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-3,33 (5,95)
Median (Min - Max)	-1,87 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-4,29 (5,65)
Median (Min - Max)	-2,28 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-4,49 (5,69)
	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-5,37 (5,26)
	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,60 (6,95)
	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,63 (5,61)
	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	59 (77,6)
Mean (SD)	-1,40 (6,54)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym SWB	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	22,58 (4,69)
Median (Min - Max)	23,00 [8,40-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)
Mean (SD)	-0,35 (4,59)
Median (Min - Max)	0,00 [-12,83-12,60]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	-0,33 (4,95)
Median (Min - Max)	-0,50 [-9,83-10,85]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	-0,05 (4,59)
Median (Min - Max)	-0,85 [-7,83-11,20]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-2,62 (5,96)
Median (Min - Max)	-1,40 [-19,25-2,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	-0,35 (2,23)
	0,00 [-3,00-2,80]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	0,69 (6,03)
	-1,05 [-4,00-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	1,17 (7,76)
	-1,63 [-4,67-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	0,35 (4,22)
	0,00 [-3,50-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,33 (NE)
Median (Min - Max)	-2,33 [-2,33--2,33]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-2,00 (3,65)
Median (Min - Max)	-1,25 [-12,83-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym SWB	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	22,50 (5,01)
Median (Min - Max)	24,00 [14,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	0,19 (2,65)
Median (Min - Max)	0,00 [-4,20-4,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,43 (3,47)
Median (Min - Max)	-0,23 [-2,80-5,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,75 (2,99)
Median (Min - Max)	0,00 [-2,00-5,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,67 (NE)
Median (Min - Max)	5,67 [5,67-5,67]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,67 (NE)
Median (Min - Max)	5,67 [5,67-5,67]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,83 (NE)
Median (Min - Max)	6,83 [6,83-6,83]
FACT-Lym SWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,33 (NE)
Median (Min - Max)	3,33 [3,33-3,33]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	1,39 (2,79)
Median (Min - Max)	1,17 [-1,40-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym SWB	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	20,48 (5,49)
Median (Min - Max)	22,00 [14,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,97 (2,68)
Median (Min - Max)	1,00 [-2,00-4,83]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (0,00)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (1,41)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS11: FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
> 10 cm	
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	0,13 (1,39)
Median (Min - Max)	0,00 [-1,33-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.4.12 Merkmal: Primärdiagnose

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym SWB	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	111 (99,1)
Mean (SD)	21,69 (5,68)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	101
Treated patients with non-missing values - n(%)	97 (96,0)
Mean (SD)	0,08 (5,66)
Median (Min - Max)	0,00 [-21,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	71 (91,0)
Mean (SD)	-0,40 (5,92)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	55 (91,7)
Mean (SD)	0,05 (5,71)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	42 (97,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,42 (6,92)
Median (Min - Max)	-0,83 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	30 (96,8)
Mean (SD)	-0,59 (3,25)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-0,60 (4,87)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,02 (5,04)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,10 (4,47)
Median (Min - Max)	0,00 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-2,01 (3,90)
Median (Min - Max)	-1,17 [-12,60-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,34 (4,80)
Median (Min - Max)	-1,77 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	-1,06 (5,60)
	0,00 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,50 (5,99)
	-0,93 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	4 (66,7)
Median (Min - Max)	-4,29 (5,65)
	-2,28 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-4,95 (5,40)
	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-5,37 (5,26)
	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,60 (6,95)
	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	87 (77,7)
Mean (SD)	-1,29 (5,74)
Median (Min - Max)	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym SWB	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	24,84 (4,05)
Median (Min - Max)	27,00 [16,33-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-2,63 (9,05)
Median (Min - Max)	0,50 [-28,00-1,67]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,49 (4,12)
Median (Min - Max)	0,00 [-8,40-2,83]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-4,47 (7,40)
Median (Min - Max)	-0,70 [-16,33-1,67]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,91 (4,76)
Median (Min - Max)	0,00 [-7,00-2,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-2,25 (4,25)
	-1,83 [-7,00-1,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,44 (5,32)
	-7,00 [-8,00-1,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,48 (2,16)
	0,00 [-1,40-2,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-7,70 (0,99)
	-7,70 [-8,40--7,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-11,00 (4,24)
	-11,00 [-14,00--8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS12: FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-7,00 (0,00)
	-7,00 [-7,00--7,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,40 (1,98)
	-8,40 [-9,80--7,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,40 (NE)
	-1,40 [-1,40--1,40]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	9 (81,8)
Median (Min - Max)	-2,76 (3,79)
	-1,33 [-8,17-0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

3.4.13 Merkmal: Anzahl der vorherigen systemischen Therapien

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym SWB	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	21,69 (6,04)
Median (Min - Max)	24,00 [2,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	48 (92,3)
Mean (SD)	-0,43 (5,74)
Median (Min - Max)	0,00 [-21,50-15,17]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	33 (86,8)
Mean (SD)	-0,93 (4,72)
Median (Min - Max)	-1,00 [-13,50-10,85]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	-0,03 (5,16)
Median (Min - Max)	0,00 [-8,50-11,20]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	20 (90,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,41 (3,71)
Median (Min - Max)	-1,08 [-10,50-3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-1,47 (3,46)
Median (Min - Max)	-1,17 [-8,50-3,50]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-1,26 (5,73)
Median (Min - Max)	-0,50 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-1,07 (6,23)
Median (Min - Max)	-1,08 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	-2,34 (4,89)
Median (Min - Max)	-2,33 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-4,13 (5,09)
Median (Min - Max)	-1,87 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-3,66 (4,61)
Median (Min - Max)	-2,10 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-3,62 (6,05)
Median (Min - Max)	-0,93 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,49 (5,57)
Median (Min - Max)	-1,93 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-4,29 (5,65)
Median (Min - Max)	-2,28 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-4,49 (5,69)
	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-5,37 (5,26)
	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,60 (6,95)
	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,63 (5,61)
	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,30 (8,91)
	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	46 (78,0)
Mean (SD)	-1,14 (4,75)
Median (Min - Max)	-0,50 [-12,83-8,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym SWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	21,93 (6,21)
Median (Min - Max)	22,75 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	0,33 (7,96)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	1,38 (7,50)
Median (Min - Max)	0,00 [-8,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	1,46 (7,51)
Median (Min - Max)	0,00 [-3,27-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	1,45 (11,64)
Median (Min - Max)	1,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,62 (2,97)
Median (Min - Max)	1,20 [-4,67-4,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,72 (2,93)
Median (Min - Max)	2,00 [-2,10-5,00]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,10 (3,26)
Median (Min - Max)	2,33 [-2,10-5,83]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,30 (0,94)
Median (Min - Max)	1,67 [0,23-2,00]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,17 (0,24)
Median (Min - Max)	-1,17 [-1,33--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,67 (NE)
	0,67 [0,67-0,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,67 (NE)
	2,67 [2,67-2,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,67 (NE)
	3,67 [3,67-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	23 (71,9)
Median (Min - Max)	0,00 (6,82)
	0,00 [-8,17-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym SWB	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	39 (100,0)
Mean (SD)	22,05 (4,82)
Median (Min - Max)	22,17 [6,00-28,00]
FACT-Lym SWB - Change from baseline	
	Cycle 2 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	-0,44 (4,13)
Median (Min - Max)	-1,00 [-14,17-9,00]
FACT-Lym SWB - Change from baseline	
	Cycle 3 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	27 (100,0)
Mean (SD)	-1,06 (5,33)
Median (Min - Max)	-1,00 [-13,17-11,20]
FACT-Lym SWB - Change from baseline	
	Cycle 4 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	-1,90 (5,19)
Median (Min - Max)	-1,00 [-16,33-5,83]
FACT-Lym SWB - Change from baseline	
	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-3,27 (5,20)
Median (Min - Max)	-2,33 [-19,25-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	-0,48 (3,38)
Median (Min - Max)	0,00 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-1,72 (4,11)
Median (Min - Max)	-1,17 [-8,00-5,00]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	0,43 (2,81)
Median (Min - Max)	0,00 [-3,50-5,67]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,23 (5,38)
Median (Min - Max)	-2,33 [-8,40-5,67]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-3,53 (6,18)
Median (Min - Max)	-0,58 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS13: FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,23 (5,50)
Median (Min - Max)	-5,83 [-7,00-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,69 (6,48)
Median (Min - Max)	-3,50 [-9,80-6,83]
FACT-Lym SWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,97 (3,35)
Median (Min - Max)	0,97 [-1,40-3,33]
FACT-Lym SWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	31 (79,5)
Mean (SD)	-2,81 (5,24)
Median (Min - Max)	-1,17 [-14,00-10,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

3.4.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym SWB	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	91 (98,9)
Mean (SD)	21,87 (5,66)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	86
Treated patients with non-missing values - n(%)	81 (94,2)
Mean (SD)	-0,20 (6,48)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	61 (92,4)
Mean (SD)	-0,32 (6,02)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)
Mean (SD)	-0,12 (5,84)
Median (Min - Max)	0,00 [-13,17-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,60 (7,64)
Median (Min - Max)	-0,67 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-0,52 (3,34)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	23 (100,0)
Median (Min - Max)	-1,16 (4,29)
	0,00 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	16 (84,2)
Median (Min - Max)	-0,62 (4,45)
	-0,50 [-12,60-5,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	-2,10 (4,32)
	-2,27 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	-2,62 (4,48)
	-1,25 [-12,60-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-2,78 (5,33)
Median (Min - Max)	-2,67 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	-1,21 (6,03)
	0,00 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	-1,58 (5,93)
	-0,93 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	-5,72 (5,96)
	-2,57 [-12,60--2,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-6,60 (5,23)
	-4,20 [-12,60--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,99 (5,92)
Median (Min - Max)	-4,20 [-12,60--1,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-7,16 (4,72)
	-4,67 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,90 (8,06)
	-6,90 [-12,60--1,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	68 (73,9)
Median (Min - Max)	-1,26 (5,92)
	-1,08 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym SWB	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	21,26 (5,78)
Median (Min - Max)	22,08 [8,40-28,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	-0,20 (5,02)
	0,00 [-12,83-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-0,37 (5,62)
	0,00 [-9,83-10,85]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	9 (81,8)
Median (Min - Max)	0,80 (5,47)
	0,00 [-7,83-11,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	-0,48 (2,44)
	-0,50 [-4,00-3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,30 (2,80)
Median (Min - Max)	0,00 [-4,00-2,80]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	3,53 (7,92)
	0,00 [-2,00-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	4,53 (7,00)
	1,00 [0,00-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,78 (3,99)
	1,00 [0,00-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,00 (0,00)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS14: FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,53 (4,16)
Median (Min - Max)	0,00 [-12,83-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

3.4.15 Merkmal: *Ansprechkategorie auf die letzte vorherige systemische Therapie*

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym SWB	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	40 (100,0)
Mean (SD)	21,92 (4,68)
Median (Min - Max)	22,58 [11,20-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	35 (94,6)
Mean (SD)	-0,77 (5,61)
Median (Min - Max)	0,00 [-21,50-7,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	-0,27 (5,19)
Median (Min - Max)	0,00 [-13,50-11,20]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	-0,22 (5,17)
Median (Min - Max)	0,00 [-13,17-9,80]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,77 (6,18)
Median (Min - Max)	0,00 [-21,00-3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,16 (4,16)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	-1,24 (5,46)
	0,00 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-0,89 (5,16)
	-0,08 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	10 (100,0)
Median (Min - Max)	-1,03 (4,96)
	0,50 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,00 (4,45)
	-1,08 [-12,60-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,77 (6,08)
Median (Min - Max)	-1,18 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	-0,99 (7,26)
	0,00 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-2,99 (6,97)
	-0,93 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1 (33,3)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,40 (5,94)
	-8,40 [-12,60--4,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,40 (5,94)
Median (Min - Max)	-8,40 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,40 (5,94)
Median (Min - Max)	-8,40 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,90 (8,06)
Median (Min - Max)	-6,90 [-12,60--1,20]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	31 (77,5)
Median (Min - Max)	-2,52 (5,74)
	-1,00 [-14,00-10,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym SWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	78 (98,7)
Mean (SD)	22,01 (5,77)
Median (Min - Max)	23,33 [2,00-28,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	68
Mean (SD)	65 (95,6)
Median (Min - Max)	-0,43 (5,53)
	0,00 [-28,00-15,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	45
Mean (SD)	41 (91,1)
Median (Min - Max)	-0,69 (4,48)
	-1,00 [-9,83-10,85]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	34
Mean (SD)	32 (94,1)
Median (Min - Max)	-0,65 (3,53)
	-1,00 [-7,83-11,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	22 (95,7)
Median (Min - Max)	-2,15 (4,63)
	-1,28 [-19,25-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,96 (2,44)
Median (Min - Max)	0,00 [-5,37-2,80]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	-0,00 (4,29)
	-1,00 [-5,00-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	1,15 (4,76)
	0,00 [-3,50-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-1,19 (4,10)
	-1,75 [-5,00-7,35]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-2,06 (2,62)
	-1,17 [-5,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,20 (2,44)
Median (Min - Max)	-3,48 [-5,83-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-1,17 (2,02)
Median (Min - Max)	0,00 [-3,50-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,52 (1,35)
Median (Min - Max)	-2,00 [-2,57-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,50 (2,12)
Median (Min - Max)	-1,50 [-3,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,58 (0,82)
Median (Min - Max)	-0,58 [-1,17-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,33 (3,30)
	-2,33 [-4,67-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS15: FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	63 (79,7)
Mean (SD)	-1,02 (3,93)
Median (Min - Max)	-1,00 [-12,83-8,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

3.4.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym SWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	21,20 (5,92)
Median (Min - Max)	22,00 [8,40-28,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	16 (100,0)
Median (Min - Max)	0,03 (5,03)
	0,00 [-12,83-12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	9 (81,8)
Median (Min - Max)	-1,35 (5,73)
	-1,00 [-9,83-10,85]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	0,34 (5,77)
	-1,00 [-7,83-11,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	7
	5 (71,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,68 (1,49)
Median (Min - Max)	-1,40 [-4,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-1,30 (3,32)
Median (Min - Max)	-2,00 [-4,00-2,80]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,30 (8,91)
Median (Min - Max)	6,30 [0,00-12,60]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,30 (8,91)
Median (Min - Max)	6,30 [0,00-12,60]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,68 (5,20)
Median (Min - Max)	3,68 [0,00-7,35]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-0,98 (4,40)
Median (Min - Max)	0,00 [-12,83-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym SWB	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	103 (99,0)
Mean (SD)	21,96 (5,51)
Median (Min - Max)	23,00 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	96
Treated patients with non-missing values - n(%)	91 (94,8)
Mean (SD)	-0,24 (6,23)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	73
Treated patients with non-missing values - n(%)	68 (93,2)
Mean (SD)	-0,29 (5,82)
Median (Min - Max)	-0,58 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	55
Treated patients with non-missing values - n(%)	51 (92,7)
Mean (SD)	-0,30 (5,98)
Median (Min - Max)	0,00 [-16,33-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	40 (100,0)
Mean (SD)	-1,32 (7,19)
Median (Min - Max)	0,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	-0,77 (3,45)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	26 (100,0)
Median (Min - Max)	-1,29 (4,25)
	-0,50 [-12,60-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	-0,60 (4,09)
	-1,00 [-12,60-5,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	-2,09 (4,35)
	-2,20 [-12,60-5,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	-3,28 (5,23)
	-1,17 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-3,04 (4,93)
Median (Min - Max)	-2,67 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	-2,28 (6,35)
	-0,93 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,67 (5,93)
	-1,63 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	4 (66,7)
Median (Min - Max)	-4,29 (5,65)
	-2,28 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-6,60 (5,23)
	-4,20 [-12,60--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,99 (5,92)
Median (Min - Max)	-4,20 [-12,60--1,17]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-7,16 (4,72)
	-4,67 [-12,60--4,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,90 (8,06)
	-6,90 [-12,60--1,20]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS16: FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,60 (NE)
Median (Min - Max)	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,60 (NE)
	-12,60 [-12,60--12,60]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	77 (74,0)
Median (Min - Max)	-1,43 (5,82)
	-1,00 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.4.17 Merkmal: Vorherige CAR-T-Therapie

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym SWB	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	24,71 (4,16)
Median (Min - Max)	26,50 [18,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-5,25 (11,30)
Median (Min - Max)	-1,33 [-28,00-1,67]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,17 (2,98)
Median (Min - Max)	0,67 [-3,50-2,83]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,46 (1,80)
Median (Min - Max)	0,33 [-1,17-2,33]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,44 (2,01)
Median (Min - Max)	-0,67 [-2,33-1,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,94 (1,86)
Median (Min - Max)	1,67 [-1,17-2,33]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,94 (1,86)
Median (Min - Max)	1,67 [-1,17-2,33]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,72 (4,76)
Median (Min - Max)	2,83 [-3,50-5,83]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,17 (NE)
Median (Min - Max)	-1,17 [-1,17--1,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,83 (NE)
Median (Min - Max)	-5,83 [-5,83--5,83]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,50 (NE)
Median (Min - Max)	-3,50 [-3,50--3,50]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,22 (1,27)
Median (Min - Max)	0,25 [-1,33-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym SWB	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	121 (99,2)
Mean (SD)	21,67 (5,75)
Median (Min - Max)	22,17 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	105 (95,5)
Mean (SD)	0,05 (5,46)
Median (Min - Max)	0,00 [-21,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	75 (91,5)
Mean (SD)	-0,45 (5,83)
Median (Min - Max)	-1,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	57 (90,5)
Mean (SD)	-0,39 (6,06)
Median (Min - Max)	0,00 [-16,33-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	44 (95,7)
Mean (SD)	-1,54 (6,89)
Median (Min - Max)	-0,83 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	-0,95 (3,43)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-1,22 (5,17)
Median (Min - Max)	-0,50 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,21 (4,78)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	-1,61 (4,77)
Median (Min - Max)	0,00 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	-3,58 (5,24)
Median (Min - Max)	-1,25 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-2,87 (4,85)
Median (Min - Max)	-2,33 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	-2,42 (6,21)
Median (Min - Max)	0,00 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-2,37 (5,62)
Median (Min - Max)	-1,40 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-3,43 (5,25)
Median (Min - Max)	-2,00 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,95 (5,40)
Median (Min - Max)	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS17: FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
EOT	
FACT-Lym SWB - Change from baseline	NE
Treated patients at visit	94 (77,0)
Treated patients with non-missing values - n(%)	
Mean (SD)	-1,50 (5,63)
Median (Min - Max)	-1,08 [-14,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

3.4.18 *Merkmal: Arzneimittelformulierung*

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym SWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	20,82 (4,62)
Median (Min - Max)	22,00 [6,00-28,00]
FACT-Lym SWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	-0,37 (4,42)
Median (Min - Max)	0,00 [-14,17-9,00]
FACT-Lym SWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-2,08 (4,31)
Median (Min - Max)	-1,00 [-13,17-6,00]
FACT-Lym SWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-0,95 (3,80)
Median (Min - Max)	0,00 [-13,17-3,50]
FACT-Lym SWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,21 (3,30)
Median (Min - Max)	0,00 [-9,00-3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. SWB = social well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,85 (1,98)
Median (Min - Max)	0,00 [-1,17-4,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	0,85 (2,84)
	0,00 [-2,10-5,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-0,53 (1,94)
	-1,00 [-2,10-2,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,74 (1,09)
	0,23 [0,00-2,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Drug formulation:

Frozen liquid

FACT-Lym SWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

23 (71,9)

Mean (SD)

-2,63 (4,87)

Median (Min - Max)

-0,33 [-14,00-4,83]

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym SWB	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	97 (99,0)
Mean (SD)	22,20 (6,00)
Median (Min - Max)	24,00 [0,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	83 (94,3)
Mean (SD)	-0,19 (6,41)
Median (Min - Max)	0,00 [-28,00-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	60 (92,3)
Mean (SD)	0,11 (6,02)
Median (Min - Max)	0,00 [-13,50-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	45 (90,0)
Mean (SD)	-0,12 (6,48)
Median (Min - Max)	0,00 [-16,33-28,00]
FACT-Lym SWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	36 (94,7)
Mean (SD)	-1,86 (7,41)
Median (Min - Max)	-1,28 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym SWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-1,06 (3,48)
Median (Min - Max)	0,00 [-8,50-6,00]
FACT-Lym SWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	-1,38 (5,26)
Median (Min - Max)	-0,50 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	0,18 (5,17)
Median (Min - Max)	0,00 [-12,60-12,60]
FACT-Lym SWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-2,20 (4,96)
Median (Min - Max)	-2,33 [-12,60-7,35]
FACT-Lym SWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	-3,59 (5,23)
Median (Min - Max)	-1,25 [-14,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym SWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	-3,12 (4,70)
Median (Min - Max)	-2,67 [-12,60-6,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	-2,53 (5,86)
	-0,93 [-12,60-6,83]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	-2,37 (5,62)
	-1,40 [-12,60-3,67]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	-3,43 (5,25)
	-2,00 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-4,95 (5,40)
	-3,60 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym SWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,49 (5,69)
Median (Min - Max)	-2,68 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-5,37 (5,26)
Median (Min - Max)	-4,43 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,60 (6,95)
Median (Min - Max)	-1,20 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym SWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,63 (5,61)
Median (Min - Max)	-8,63 [-12,60--4,67]
FACT-Lym SWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,30 (8,91)
Median (Min - Max)	-6,30 [-12,60-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FSC_PSHS18: FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym SWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym SWB - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym SWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	77 (78,6)
Mean (SD)	-1,03 (5,63)
Median (Min - Max)	-1,00 [-12,83-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. SWB = social well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FED_PSTS01: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Age group
 PRO set

3.5 Subgruppenanalysen zum FACT-Lym – emotionales Wohlbefinden (Zeit bis zur Verschlechterung)

3.5.1 Merkmal Alter

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	13 (22,8)
95%-CI	[12,7-35,8]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,06 [5,13-12,06]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,8 [68,6-92,1]
Month 6	63,2 [39,9-79,5]
Month 12	54,2 [28,5-74,1]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS01: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	22 (41,5)
95%-CI	[28,1-55,9]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	3,71[2,17-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,5 [41,3-72,3]
Month 6	40,5 [21,7-58,5]
Month 12	27,0 [7,0-52,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS01: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	4 (20,0)
95%-CI	[5,7-43,7]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,22[4,44-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [65,0-99,2]
Month 6	82,4 [42,6-95,7]
Month 12	54,9 [8,4-86,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS02: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Sex
 PRO set

3.5.2 Merkmal: Geschlecht

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	15 (28,3)
95%-CI	[16,8-42,3]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	9,69[4,44-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [70,9-94,5]
Month 6	67,6 [47,0-81,6]
Month 12	46,9 [22,8-67,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS02: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	24 (31,2)
95%-CI	[21,1-42,7]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,78 [3,71-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,2 [53,3-77,7]
Month 6	47,6 [28,1-64,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS03: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Race group
 PRO set

3.5.3 Merkmal: Ethnie

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	37 (32,2)
95%-CI	[23,8-41,5]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93 [5,13-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,3 [63,5-82,3]
Month 6	54,5 [40,3-66,6]
Month 12	40,0 [22,6-56,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS03: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	NE[2,83-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [43,5-95,1]
Month 6	81,5 [43,5-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS04: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Country
 PRO set

3.5.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	8 (15,7)
95%-CI	[7,0-28,6]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	NE [4,44-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [68,1-94,0]
Month 6	71,2 [48,8-85,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS04: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93 [2,17-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,8 [49,6-87,6]
Month 6	59,0 [25,2-81,7]
Month 12	44,3 [12,6-72,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS04: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	21 (43,8)
95%-CI	[29,5-58,8]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,90 [3,02-12,06]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [50,5-79,8]
Month 6	50,0 [30,5-66,7]
Month 12	31,3 [10,6-54,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS05: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Region
 PRO set

3.5.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	8 (15,7)
95%-CI	[7,0-28,6]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	NE [4,44-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [68,1-94,0]
Month 6	71,2 [48,8-85,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS05: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	31 (39,2)
95%-CI	[28,4-50,9]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,90 [3,65-12,06]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [56,1-79,1]
Month 6	50,7 [34,3-65,0]
Month 12	32,5 [14,2-52,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS06: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage
 PRO set

3.5.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93 [0,72-6,93]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,3 [18,6-85,0]
Month 6	59,3 [18,6-85,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS06: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	5 (23,8)
95%-CI	[8,2-47,2]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	9,69 [2,83-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [46,6-92,8]
Month 6	78,8 [46,6-92,8]
Month 12	39,4 [1,4-81,5]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS06: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	4 (23,5)
95%-CI	[6,8-49,9]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,90 [2,17-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [48,2-95,6]
Month 6	66,7 [24,4-89,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS06: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	26 (31,7)
95%-CI	[21,9-42,9]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,06[3,71-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [63,0-84,0]
Month 6	52,5 [36,1-66,5]
Month 12	52,5 [36,1-66,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS07: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Bulky disease
 PRO set

3.5.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	38 (30,2)
95%-CI	[22,3-39,0]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	9,69[5,29-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,6 [65,5-83,1]
Month 6	57,9 [44,5-69,2]
Month 12	44,4 [27,1-60,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS08: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Double/Triple hit
 PRO set

3.5.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	4 (28,6)
95%-CI	[8,4-58,1]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	NE [1,41-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [37,9-90,6]
Month 6	55,0 [16,1-82,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS08: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	35 (30,2)
95%-CI	[22,0-39,4]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93[5,29-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,2 [64,4-83,1]
Month 6	57,4 [43,0-69,4]
Month 12	41,0 [21,8-59,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS09: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Transformed DLBCL
 PRO set

3.5.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	8 (33,3)
95%-CI	[15,6-55,3]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93[3,02-12,06]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [58,7-94,7]
Month 6	55,2 [22,1-79,2]
Month 12	27,6 [1,7-66,8]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. EWB = emotional well being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS09: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	31 (29,2)
95%-CI	[20,8-38,9]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	9,69[5,29-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [61,9-81,7]
Month 6	58,6 [44,1-70,5]
Month 12	46,6 [27,3-63,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. EWB = emotional well being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS10: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: B-Cell type
 PRO set

3.5.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	13 (30,2)
95%-CI	[17,2-46,1]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,22 [3,71-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [58,2-87,9]
Month 6	61,8 [39,2-78,1]
Month 12	53,0 [28,1-72,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS10: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,78 [2,17-9,69]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,2 [35,0-81,8]
Month 6	42,1 [14,9-67,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS11: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter
 PRO set

3.5.11 *Merkmal: Maximaler längster Durchmesser*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	18 (23,7)
95%-CI	[14,7-34,8]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,06[6,90-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [78,6-94,7]
Month 6	71,9 [55,0-83,3]
Month 12	52,1 [28,4-71,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS11: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	15 (44,1)
95%-CI	[27,2-62,1]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	3,65 [1,64-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,7 [33,4-71,8]
Month 6	29,6 [9,0-53,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS11: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. EWB = emotional well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS11: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. EWB = emotional well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS12: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Primary disease diagnosis
 PRO set

3.5.12 *Merkmal: Primärdiagnose*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	36 (32,1)
95%-CI	[23,6-41,6]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93 [5,13-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,3 [63,5-82,3]
Month 6	56,7 [42,5-68,6]
Month 12	40,5 [21,6-58,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS12: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	NE[0,92-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	59,1 [16,0-86,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS13: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Number prior lines
 PRO set

3.5.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	19 (32,2)
95%-CI	[20,6-45,6]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93 [5,13-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,5 [61,1-86,5]
Month 6	63,7 [43,9-78,1]
Month 12	39,7 [16,3-62,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS13: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	8 (25,0)
95%-CI	[11,5-43,4]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,78 [3,65-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [53,7-90,6]
Month 6	42,7 [12,7-70,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS13: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	12 (30,8)
95%-CI	[17,0-47,6]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	NE [3,52-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [52,3-84,2]
Month 6	56,9 [35,1-73,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS14: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - first line
 PRO set

3.5.14 *Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	27 (29,3)
95%-CI	[20,3-39,8]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	9,69[5,13-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [63,3-83,9]
Month 6	58,6 [42,5-71,6]
Month 12	42,2 [19,7-63,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS14: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	10 (45,5)
95%-CI	[24,4-67,8]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,29[1,64-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,2 [35,9-80,3]
Month 6	40,8 [13,5-67,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS15: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - last line
 PRO set

3.5.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	9 (22,5)
95%-CI	[10,8-38,5]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,22[4,44-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [62,1-91,1]
Month 6	71,2 [49,3-85,0]
Month 12	71,2 [49,3-85,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS15: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	27 (34,2)
95%-CI	[23,9-45,7]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,78 [3,52-12,06]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,5 [56,8-80,6]
Month 6	47,0 [28,5-63,5]
Month 12	20,1 [1,8-52,7]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS16: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - any line
 PRO set

3.5.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,29[1,77-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,7 [35,3-82,3]
Month 6	41,8 [13,4-68,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS16: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	29 (27,9)
95%-CI	[19,5-37,5]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	9,69[5,13-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [66,5-85,5]
Month 6	60,5 [45,4-72,6]
Month 12	47,9 [27,7-65,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS17: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Prior use of T-CART therapy
PRO set

3.5.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. EWB = emotional well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS17: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	38 (31,1)
95%-CI	[23,1-40,2]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	6,93[5,13-12,22]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,7 [64,3-82,5]
Month 6	55,6 [41,6-67,6]
Month 12	42,2 [25,2-58,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS18: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Drug formulation
 PRO set

3.5.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	14 (43,8)
95%-CI	[26,4-62,3]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	5,13 [2,83-6,90]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,0 [45,5-81,6]
Month 6	32,2 [9,6-57,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FED_PSTS18: Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym EWB by at least 4 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation: Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	25 (25,5)
95%-CI	[17,2-35,3]
FACT-Lym EWB - Time to decrease by at least 4 points in months [95%-CI]	
Median	12,06[6,93-NE]
FACT-Lym EWB - Time to decrease by at least 4 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [66,2-86,1]
Month 6	65,7 [50,8-77,0]
Month 12	53,4 [32,8-70,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. EWB = emotional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

3.6 Subgruppenanalysen zum FACT-Lym – emotionales Wohlbefinden (Veränderung gegenüber Studienbeginn)

3.6.1 Merkmal Alter

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym EWB	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	56 (98,2)
Mean (SD)	16,40 (4,80)
Median (Min - Max)	17,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	47 (95,9)
Mean (SD)	1,00 (2,16)
Median (Min - Max)	1,00 [-5,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	35 (94,6)
Mean (SD)	0,68 (3,45)
Median (Min - Max)	1,00 [-7,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	2,08 (3,39)
Median (Min - Max)	2,00 [-8,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	21 (95,5)
Mean (SD)	1,09 (3,57)
Median (Min - Max)	1,00 [-10,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	1,68 (3,06)
Median (Min - Max)	1,50 [-2,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	1,97 (2,92)
Median (Min - Max)	1,90 [-2,00-8,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,25 (2,73)
Median (Min - Max)	2,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	2,10 (2,01)
Median (Min - Max)	1,50 [-1,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,83 (0,98)
Median (Min - Max)	1,50 [1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	3,00 (2,16)
Median (Min - Max)	2,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,85 (2,15)
Median (Min - Max)	2,70 [1,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,50 (2,12)
Median (Min - Max)	2,50 [1,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	41 (71,9)
Mean (SD)	-0,64 (3,45)
Median (Min - Max)	-1,00 [-8,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym EWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	50 (94,3)
Mean (SD)	17,37 (4,47)
Median (Min - Max)	18,50 [7,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	44 (91,7)
Mean (SD)	-0,42 (3,77)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	27 (79,4)
Mean (SD)	-0,27 (3,90)
Median (Min - Max)	0,00 [-10,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,06 (2,74)
Median (Min - Max)	0,00 [-6,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-0,53 (2,98)
Median (Min - Max)	-0,50 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,88 (3,28)
Median (Min - Max)	0,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-0,36 (4,77)
Median (Min - Max)	2,00 [-10,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,80 (2,28)
Median (Min - Max)	1,00 [-2,40-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	1,23 (3,29)
Median (Min - Max)	2,00 [-3,60-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,72 (4,28)
Median (Min - Max)	2,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,30 (2,66)
Median (Min - Max)	-0,40 [-3,60-3,00]
FACT-Lym EWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,00 (2,90)
Median (Min - Max)	-1,20 [-3,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,20 (2,84)
Median (Min - Max)	-3,30 [-4,20-2,00]
FACT-Lym EWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-3,20 (1,13)
Median (Min - Max)	-3,20 [-4,00--2,40]
FACT-Lym EWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,47 (1,50)
Median (Min - Max)	-2,40 [-4,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,40 (3,41)
Median (Min - Max)	-2,40 [-7,20--0,60]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,73 (1,14)
Median (Min - Max)	-2,40 [-4,00--1,80]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,20 (2,55)
Median (Min - Max)	-4,20 [-6,00--2,40]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	42 (79,2)
Median (Min - Max)	-1,70 (4,38)
	-2,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym EWB	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	17,21 (4,55)
Median (Min - Max)	18,00 [6,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,71 (3,79)
Median (Min - Max)	0,00 [-10,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	3,51 (3,55)
Median (Min - Max)	4,00 [-2,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	1,67 (2,50)
Median (Min - Max)	2,00 [-2,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	3,65 (3,77)
Median (Min - Max)	3,60 [-1,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,50 (4,14)
Median (Min - Max)	2,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	4,60 (4,34)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	1,75 (3,30)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	5,50 (5,45)
Median (Min - Max)	4,00 [1,00-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-2,00 (0,00)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-3,00 (4,24)
Median (Min - Max)	-3,00 [-6,00-0,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,67 (11,06)
Median (Min - Max)	6,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,80 (NE)
Median (Min - Max)	0,80 [0,80-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS01: FACT-Lym EWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-0,12 (5,13)
Median (Min - Max)	-2,00 [-6,60-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

3.6.2 *Merkmal: Geschlecht*

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym EWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	49 (92,5)
Mean (SD)	16,07 (4,68)
Median (Min - Max)	18,00 [6,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	40 (87,0)
Mean (SD)	0,99 (3,24)
Median (Min - Max)	1,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	2,10 (3,63)
Median (Min - Max)	2,00 [-3,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	22 (78,6)
Mean (SD)	2,02 (3,10)
Median (Min - Max)	2,00 [-2,40-10,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,90 (4,25)
Median (Min - Max)	3,00 [-5,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,65 (3,95)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	1,60 (4,82)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	1,97 (2,51)
Median (Min - Max)	2,00 [-2,40-6,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	2,63 (4,26)
Median (Min - Max)	2,20 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,56 (3,28)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,12 (3,60)
Median (Min - Max)	0,50 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	1,80 (3,49)
Median (Min - Max)	2,50 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,03 (7,15)
Median (Min - Max)	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	39 (73,6)
Mean (SD)	-0,95 (4,61)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym EWB	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	76 (98,7)
Mean (SD)	17,45 (4,53)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	68 (97,1)
Mean (SD)	0,01 (3,16)
Median (Min - Max)	0,00 [-10,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	44 (88,0)
Mean (SD)	-0,07 (3,73)
Median (Min - Max)	0,00 [-10,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	37 (94,9)
Mean (SD)	0,70 (3,06)
Median (Min - Max)	1,00 [-8,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,16 (2,84)
Median (Min - Max)	0,50 [-10,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	0,45 (2,78)
Median (Min - Max)	1,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	1,86 (2,43)
Median (Min - Max)	1,90 [-2,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,09 (2,41)
Median (Min - Max)	0,80 [-3,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,97 (1,02)
Median (Min - Max)	2,00 [1,00-3,80]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS02: FACT-Lym EWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (0,71)
Median (Min - Max)	1,50 [1,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (0,71)
Median (Min - Max)	1,50 [1,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	57 (74,0)
Mean (SD)	-1,09 (3,79)
Median (Min - Max)	-1,00 [-9,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

3.6.3 *Merkmal: Ethnie*

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym EWB	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	110 (95,7)
Mean (SD)	16,90 (4,60)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	96 (92,3)
Mean (SD)	0,21 (3,32)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	63 (85,1)
Mean (SD)	0,49 (3,99)
Median (Min - Max)	0,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	49 (87,5)
Mean (SD)	0,97 (3,13)
Median (Min - Max)	1,00 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	38 (92,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,75 (3,84)
Median (Min - Max)	0,50 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	0,11 (3,60)
Median (Min - Max)	0,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	1,50 (4,39)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	1,13 (2,57)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	2,45 (3,67)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	0,72 (2,99)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,20 (3,43)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	1,71 (3,27)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,03 (7,15)
Median (Min - Max)	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	84 (73,0)
Mean (SD)	-1,41 (4,07)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym EWB	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	17,00 (4,93)
Median (Min - Max)	19,00 [6,00-22,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	1,67 (1,67)
Median (Min - Max)	2,00 [-1,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	2,58 (2,07)
Median (Min - Max)	2,50 [-1,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	2,30 (2,95)
Median (Min - Max)	3,00 [-4,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	2,14 (2,04)
Median (Min - Max)	2,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,67 (1,21)
Median (Min - Max)	2,50 [1,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	2,60 (2,19)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,67 (3,21)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS03: FACT-Lym EWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	12 (80,0)
Median (Min - Max)	1,58 (3,63)
	3,00 [-6,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

3.6.4 *Merkmal: Region-1*

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym EWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	49 (96,1)
Mean (SD)	16,49 (5,03)
Median (Min - Max)	17,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	42 (93,3)
Mean (SD)	0,74 (2,51)
Median (Min - Max)	0,50 [-4,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	1,60 (2,92)
Median (Min - Max)	1,50 [-4,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	24 (88,9)
Mean (SD)	1,42 (3,22)
Median (Min - Max)	1,50 [-4,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,67 (3,22)
Median (Min - Max)	2,00 [-5,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,56 (4,23)
Median (Min - Max)	1,50 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,64 (4,54)
Median (Min - Max)	2,00 [-10,00-8,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,56 (2,24)
Median (Min - Max)	3,00 [-2,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,67 (1,86)
Median (Min - Max)	4,00 [1,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,00 (1,41)
Median (Min - Max)	3,00 [1,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,67 (1,86)
Median (Min - Max)	2,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,43 (2,57)
Median (Min - Max)	3,00 [-1,80-5,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,60 (4,28)
Median (Min - Max)	2,00 [-4,20-4,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-0,28 (3,81)
Median (Min - Max)	-1,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym EWB	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	16,87 (5,09)
Median (Min - Max)	19,00 [3,00-23,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	0,04 (3,55)
Median (Min - Max)	0,50 [-12,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	2,32 (5,15)
Median (Min - Max)	3,50 [-6,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	1,20 (2,94)
Median (Min - Max)	0,50 [-4,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	1,11 (3,47)
Median (Min - Max)	0,00 [-3,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,80 (2,26)
Median (Min - Max)	1,00 [-3,00-3,80]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,16 (4,19)
Median (Min - Max)	4,00 [1,80-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	2,27 (2,37)
Median (Min - Max)	1,00 [0,80-5,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,44 (4,51)
Median (Min - Max)	3,80 [2,00-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,50 (6,36)
Median (Min - Max)	10,50 [6,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,80 (NE)
Median (Min - Max)	0,80 [0,80-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	0,24 (4,77)
Median (Min - Max)	0,00 [-9,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym EWB	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	45 (93,8)
Mean (SD)	17,34 (3,90)
Median (Min - Max)	18,00 [6,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	43 (93,5)
Mean (SD)	0,22 (3,68)
Median (Min - Max)	0,00 [-10,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	32 (88,9)
Mean (SD)	-0,34 (3,75)
Median (Min - Max)	0,00 [-10,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	0,98 (3,20)
Median (Min - Max)	1,80 [-8,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	0,33 (4,21)
Median (Min - Max)	0,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,45 (2,95)
Median (Min - Max)	0,50 [-5,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,30 (2,84)
Median (Min - Max)	0,90 [-6,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-0,34 (2,25)
Median (Min - Max)	-0,50 [-3,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,07 (2,06)
Median (Min - Max)	1,00 [-3,60-2,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-0,90 (2,68)
Median (Min - Max)	-0,50 [-5,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,16 (2,19)
Median (Min - Max)	-1,80 [-3,60-2,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-1,07 (2,00)
Median (Min - Max)	-1,20 [-3,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-3,15 (3,28)
Median (Min - Max)	-3,30 [-7,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-1,47 (3,11)
Median (Min - Max)	-2,40 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,35 (2,55)
Median (Min - Max)	-1,70 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,40 (3,41)
Median (Min - Max)	-2,40 [-7,20--0,60]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,73 (1,14)
Median (Min - Max)	-2,40 [-4,00--1,80]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,20 (2,55)
Median (Min - Max)	-4,20 [-6,00--2,40]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS04: FACT-Lym EWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	34 (70,8)
Mean (SD)	-2,53 (3,58)
Median (Min - Max)	-2,70 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
PRO set

3.6.5 *Merkmal: Region-2*

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym EWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	49 (96,1)
Mean (SD)	16,49 (5,03)
Median (Min - Max)	17,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	42 (93,3)
Mean (SD)	0,74 (2,51)
Median (Min - Max)	0,50 [-4,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	1,60 (2,92)
Median (Min - Max)	1,50 [-4,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	24 (88,9)
Mean (SD)	1,42 (3,22)
Median (Min - Max)	1,50 [-4,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,67 (3,22)
Median (Min - Max)	2,00 [-5,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,56 (4,23)
Median (Min - Max)	1,50 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,64 (4,54)
Median (Min - Max)	2,00 [-10,00-8,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,56 (2,24)
Median (Min - Max)	3,00 [-2,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,67 (1,86)
Median (Min - Max)	4,00 [1,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,00 (1,41)
Median (Min - Max)	3,00 [1,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,67 (1,86)
Median (Min - Max)	2,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,43 (2,57)
Median (Min - Max)	3,00 [-1,80-5,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,60 (4,28)
Median (Min - Max)	2,00 [-4,20-4,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-0,28 (3,81)
Median (Min - Max)	-1,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym EWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	76 (96,2)
Mean (SD)	17,18 (4,35)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	66 (93,0)
Mean (SD)	0,14 (3,58)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	45 (84,9)
Mean (SD)	0,31 (4,27)
Median (Min - Max)	0,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	35 (87,5)
Mean (SD)	1,04 (3,09)
Median (Min - Max)	1,00 [-8,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	0,50 (3,88)
Median (Min - Max)	0,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	0,57 (2,67)
Median (Min - Max)	1,00 [-5,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	1,73 (3,89)
Median (Min - Max)	1,80 [-6,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	0,26 (2,46)
Median (Min - Max)	0,80 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	1,90 (4,04)
Median (Min - Max)	1,50 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-1,06 (2,48)
Median (Min - Max)	-2,00 [-5,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,97 (2,78)
Median (Min - Max)	-2,10 [-6,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,70 (3,89)
Median (Min - Max)	-0,10 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,40 (8,01)
Median (Min - Max)	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS05: FACT-Lym EWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	60 (75,9)
Mean (SD)	-1,49 (4,26)
Median (Min - Max)	-1,00 [-9,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.6.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym EWB	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	15,80 (4,05)
Median (Min - Max)	15,50 [7,00-21,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,78 (5,17)
Median (Min - Max)	3,00 [-12,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	3,60 (3,51)
Median (Min - Max)	4,00 [-2,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	1,67 (1,53)
Median (Min - Max)	2,00 [0,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,20 (3,47)
Median (Min - Max)	0,50 [-5,00-3,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,33 (2,31)
Median (Min - Max)	1,00 [-3,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	3,00 (1,41)
Median (Min - Max)	3,00 [2,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	3,00 (2,83)
Median (Min - Max)	3,00 [1,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,13 (1,80)
Median (Min - Max)	4,00 [2,40-6,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (4,95)
Median (Min - Max)	1,50 [-2,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,50 (4,95)
	-2,50 [-6,00-1,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	2,10 (5,52)
	2,10 [-1,80-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,90 (7,21)
	0,90 [-4,20-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,80 (NE)
	0,80 [0,80-0,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	6,00 (NE)
	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,60 (NE)
	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	7 (70,0)
Median (Min - Max)	-0,71 (4,39)
	1,00 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym EWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	16,37 (4,18)
Median (Min - Max)	17,00 [9,00-22,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	0,22 (2,39)
Median (Min - Max)	0,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,91 (3,65)
Median (Min - Max)	-1,00 [-7,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,53 (4,10)
Median (Min - Max)	1,00 [-8,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-1,00 (3,85)
Median (Min - Max)	0,00 [-10,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	0,33 (1,86)
	0,00 [-2,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	1,16 (2,06)
	1,00 [-2,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,60 (2,88)
	-2,00 [-3,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,00 (1,00)
	1,00 [0,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,90 (1,27)
	-0,90 [-1,80-0,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-7,00 (NE)
	-7,00 [-7,00--7,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,60 (NE)
	-0,60 [-0,60--0,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,80 (NE)
	-1,80 [-1,80--1,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	15 (71,4)
Median (Min - Max)	-0,64 (3,00)
	-1,00 [-6,60-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym EWB	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	17,44 (4,50)
Median (Min - Max)	18,50 [8,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	1,07 (2,37)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	1,36 (3,47)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	3,33 (3,77)
Median (Min - Max)	3,00 [-4,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	2,83 (3,06)
Median (Min - Max)	2,50 [-1,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage III	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	3,20 (3,83)
	2,00 [1,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	3,40 (3,44)
	2,00 [0,00-8,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,00 (3,61)
	1,00 [-1,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	3,00 (1,41)
	3,00 [2,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	11 (64,7)
Median (Min - Max)	-1,36 (3,93)
	0,00 [-8,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym EWB	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	80 (97,6)
Mean (SD)	17,07 (4,85)
Median (Min - Max)	18,50 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	67 (93,1)
Mean (SD)	0,21 (3,27)
Median (Min - Max)	0,00 [-10,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	48 (88,9)
Mean (SD)	0,81 (3,86)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	36 (85,7)
Mean (SD)	0,82 (2,54)
Median (Min - Max)	0,00 [-4,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	1,31 (3,58)
Median (Min - Max)	1,00 [-5,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	20 (90,9)
Median (Min - Max)	0,11 (3,71)
	1,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	16 (100,0)
Median (Min - Max)	1,16 (4,89)
	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	1,45 (2,09)
	2,00 [-2,40-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	12 (100,0)
Median (Min - Max)	2,27 (4,44)
	1,50 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	0,73 (2,78)
	1,00 [-5,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage IV	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	1,14 (3,26)
	2,00 [-3,60-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	1,17 (2,65)
	1,00 [-3,00-4,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	2,57 (6,76)
	1,50 [-3,60-15,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2 (40,0)
Median (Min - Max)	-0,20 (3,11)
	-0,20 [-2,40-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,47 (3,11)
	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,80 (3,39)
	-4,80 [-7,20--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,20 (1,13)
	-3,20 [-4,00--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,20 (2,55)
	-4,20 [-6,00--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS06: FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	63 (76,8)
Median (Min - Max)	-1,10 (4,42)
	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
 PRO set

3.6.7 *Merkmal: Bulky Erkrankung*

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym EWB	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	121 (96,0)
Mean (SD)	16,88 (4,66)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	105 (92,9)
Mean (SD)	0,37 (3,25)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	75 (88,2)
Mean (SD)	0,83 (3,82)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	58 (87,9)
Mean (SD)	1,23 (3,13)
Median (Min - Max)	1,40 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,97 (3,63)
Median (Min - Max)	1,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	0,56 (3,44)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	28 (96,6)
Mean (SD)	1,69 (4,08)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	1,20 (2,59)
Median (Min - Max)	1,50 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	2,43 (3,58)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	0,82 (2,89)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	0,35 (3,31)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	1,74 (3,09)
Median (Min - Max)	1,50 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	1,13 (6,70)
Median (Min - Max)	1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS07: FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Bulky disease:	
No	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	95 (75,4)
Mean (SD)	-0,99 (4,12)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.6.8 *Merkmal: Double/Triple-Hit*

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym EWB	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	17,50 (4,29)
Median (Min - Max)	18,50 [7,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,50 (2,15)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	1,13 (4,12)
Median (Min - Max)	2,50 [-6,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,33 (2,16)
Median (Min - Max)	0,50 [-1,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,40 (1,82)
Median (Min - Max)	3,00 [0,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-1,25 (4,11)
Median (Min - Max)	-1,50 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,00 (2,65)
Median (Min - Max)	3,00 [-1,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,00 (1,00)
Median (Min - Max)	3,00 [2,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,00 (2,83)
Median (Min - Max)	3,00 [1,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,00 (1,41)
Median (Min - Max)	2,00 [1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,50 (3,54)
Median (Min - Max)	3,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,70 (2,40)
Median (Min - Max)	2,70 [1,00-4,40]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-1,22 (4,49)
Median (Min - Max)	-2,00 [-8,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym EWB	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	111 (95,7)
Mean (SD)	16,83 (4,67)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	96 (92,3)
Mean (SD)	0,36 (3,32)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	67 (85,9)
Mean (SD)	0,79 (3,81)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	53 (88,3)
Mean (SD)	1,18 (3,22)
Median (Min - Max)	1,80 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)
Mean (SD)	0,79 (3,78)
Median (Min - Max)	0,50 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	30 (96,8)
Mean (SD)	0,81 (3,34)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	1,66 (4,26)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	0,92 (2,66)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	2,37 (3,71)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,60 (3,08)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-0,28 (3,06)
Median (Min - Max)	0,50 [-6,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	1,50 (3,33)
Median (Min - Max)	1,50 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,78 (7,07)
Median (Min - Max)	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS08: FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Double/Triple hit:	
No	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	87 (75,0)
Mean (SD)	-1,01 (4,11)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.6.9 *Merkmal: Transformation des DLBCL*

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym EWB	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	17,59 (3,36)
Median (Min - Max)	18,00 [9,00-22,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,05 (2,41)
Median (Min - Max)	0,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	1,17 (3,43)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,40 (2,22)
Median (Min - Max)	0,00 [-4,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,08 (2,59)
Median (Min - Max)	-0,50 [-5,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,40 (2,79)
Median (Min - Max)	1,00 [-5,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,80 (3,96)
Median (Min - Max)	2,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	2,25 (2,50)
Median (Min - Max)	2,50 [-1,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (4,51)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,00 (3,00)
Median (Min - Max)	-2,00 [-5,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,13 (4,01)
Median (Min - Max)	-2,40 [-6,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (4,51)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (4,51)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,00 (3,46)
Median (Min - Max)	-4,00 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,20 (5,66)
Median (Min - Max)	-3,20 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (8,49)
Median (Min - Max)	0,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (79,2)
Mean (SD)	-2,05 (3,22)
Median (Min - Max)	-2,00 [-8,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym EWB	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	103 (97,2)
Mean (SD)	16,76 (4,85)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	89 (93,7)
Mean (SD)	0,44 (3,36)
Median (Min - Max)	1,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	63 (90,0)
Mean (SD)	0,76 (3,91)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	49 (90,7)
Mean (SD)	1,36 (3,27)
Median (Min - Max)	1,80 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	35 (89,7)
Mean (SD)	1,27 (3,86)
Median (Min - Max)	1,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	0,73 (3,55)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	23 (95,8)
Median (Min - Max)	1,89 (4,16)
	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	18 (90,0)
Median (Min - Max)	0,97 (2,62)
	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	2,62 (3,52)
	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	1,66 (2,39)
	2,00 [-2,40-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	1,18 (2,82)
Median (Min - Max)	1,00 [-3,60-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	1,91 (2,72)
Median (Min - Max)	2,00 [-1,80-5,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,03 (7,98)
Median (Min - Max)	-0,80 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-3,20 (1,13)
Median (Min - Max)	-3,20 [-4,00--2,40]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,70 (0,99)
Median (Min - Max)	-1,70 [-2,40--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,50 (1,27)
Median (Min - Max)	-1,50 [-2,40--0,60]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,10 (0,42)
Median (Min - Max)	-2,10 [-2,40--1,80]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS09: FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	77 (72,6)
Mean (SD)	-0,78 (4,30)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

3.6.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym EWB	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	17,54 (4,25)
Median (Min - Max)	19,00 [8,00-23,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	38 (95,0)
Mean (SD)	0,39 (2,85)
Median (Min - Max)	0,00 [-12,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	1,79 (3,77)
Median (Min - Max)	1,00 [-7,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	24 (88,9)
Mean (SD)	1,54 (3,39)
Median (Min - Max)	2,00 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,93 (4,50)
Median (Min - Max)	0,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	1,63 (3,74)
Median (Min - Max)	2,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	13 (92,9)
Median (Min - Max)	2,98 (3,77)
	2,00 [-2,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	1,08 (3,07)
	0,90 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	4,03 (3,79)
	3,10 [1,00-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	2,00 (2,94)
	2,50 [-2,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,50 (1,29)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	1,73 (3,41)
	2,00 [-1,80-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	1,45 (9,78)
	-1,10 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	34 (79,1)
Median (Min - Max)	-0,46 (4,40)
	-1,50 [-8,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym EWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	17,81 (3,82)
Median (Min - Max)	19,00 [9,00-23,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	0,88 (3,04)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	0,47 (3,42)
Median (Min - Max)	1,00 [-6,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,16 (3,08)
Median (Min - Max)	1,00 [-6,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,13 (2,85)
Median (Min - Max)	1,00 [-3,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,17 (2,71)
Median (Min - Max)	1,00 [-3,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	4,33 (1,15)
	5,00 [3,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,33 (0,58)
	2,00 [2,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,67 (3,06)
	2,00 [0,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	3,00 (1,41)
	3,00 [2,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,60 (3,39)
	0,60 [-1,80-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,60 (NE)
	-0,60 [-0,60--0,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS10: FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,80 (NE)
Median (Min - Max)	-1,80 [-1,80--1,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	16 (76,2)
Median (Min - Max)	-1,19 (4,98)
	-1,00 [-9,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.6.11 *Merkmal: Maximaler längster Durchmesser*

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	76
FACT-Lym EWB	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	72 (94,7)
Mean (SD)	16,80 (4,53)
Median (Min - Max)	18,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	62 (89,9)
Mean (SD)	0,65 (3,12)
Median (Min - Max)	1,00 [-9,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	51 (89,5)
Mean (SD)	1,12 (3,96)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	39 (90,7)
Mean (SD)	1,68 (2,95)
Median (Min - Max)	2,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,30 (3,18)
Median (Min - Max)	1,00 [-5,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 25
Treated patients with non-missing values - n(%)	24 (96,0)
Mean (SD)	0,35 (3,73)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	1,60 (4,60)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	1,41 (2,79)
Median (Min - Max)	2,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	1,95 (4,21)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-0,14 (2,55)
Median (Min - Max)	1,00 [-5,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Maximal longest diameter:	
<= 5 cm	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-0,64 (3,00)
Median (Min - Max)	0,00 [-6,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	1,54 (3,18)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	1,49 (7,32)
Median (Min - Max)	1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
<= 5 cm	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	56 (73,7)
Mean (SD)	-0,50 (4,26)
Median (Min - Max)	-1,00 [-10,00-13,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym EWB	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	16,80 (4,89)
Median (Min - Max)	18,50 [6,00-23,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	-0,13 (3,50)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,22 (3,14)
Median (Min - Max)	1,00 [-7,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	0,31 (3,59)
Median (Min - Max)	0,00 [-8,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,71 (4,95)
Median (Min - Max)	0,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	1,11 (2,82)
Median (Min - Max)	2,00 [-3,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,76 (2,49)
Median (Min - Max)	2,00 [-2,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,05 (2,13)
Median (Min - Max)	0,40 [-3,00-2,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,84 (2,11)
Median (Min - Max)	2,40 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym EWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-2,26 (4,09)
Median (Min - Max)	-2,00 [-9,00-4,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym EWB	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	16,75 (6,43)
Median (Min - Max)	17,00 [3,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-0,50 (3,21)
Median (Min - Max)	0,00 [-6,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,67 (6,51)
Median (Min - Max)	1,00 [-6,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-0,25 (2,87)
Median (Min - Max)	0,50 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,00 (2,83)
Median (Min - Max)	-3,00 [-5,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,80 (NE)
Median (Min - Max)	-1,80 [-1,80--1,80]
FACT-Lym EWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,20 (NE)
Median (Min - Max)	-4,20 [-4,20--4,20]
FACT-Lym EWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	4 (44,4)
Mean (SD)	-1,75 (3,86)
Median (Min - Max)	-1,00 [-7,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym EWB	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	18,71 (3,04)
Median (Min - Max)	18,00 [15,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,60 (2,61)
Median (Min - Max)	0,00 [-5,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS11: FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
> 10 cm	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,20 (2,17)
Median (Min - Max)	0,00 [-5,00-0,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.6.12 *Merkmal: Primärdiagnose*

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym EWB	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	108 (96,4)
Mean (SD)	16,91 (4,67)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	101
Treated patients with non-missing values - n(%)	94 (93,1)
Mean (SD)	0,40 (3,37)
Median (Min - Max)	1,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	78
Treated patients with non-missing values - n(%)	67 (85,9)
Mean (SD)	0,67 (3,87)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	60
Treated patients with non-missing values - n(%)	53 (88,3)
Mean (SD)	1,10 (3,18)
Median (Min - Max)	1,00 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,79 (3,78)
Median (Min - Max)	0,50 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 31
Treated patients with non-missing values - n(%)	30 (96,8)
Mean (SD)	0,81 (3,34)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	1,66 (4,26)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	0,92 (2,66)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	2,37 (3,71)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,60 (3,08)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-0,28 (3,06)
Median (Min - Max)	0,50 [-6,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	1,50 (3,33)
Median (Min - Max)	1,50 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,78 (7,07)
Median (Min - Max)	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-2,35 (3,49)
	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-1,55 (2,54)
	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,80 (6,16)
	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,70 (2,40)
	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,20 (3,11)
	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,60 (NE)
	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	84 (75,0)
Mean (SD)	-0,99 (4,21)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym EWB	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	18,27 (3,41)
Median (Min - Max)	19,00 [12,00-23,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,20 (1,81)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,83 (3,37)
Median (Min - Max)	2,50 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,40 (2,41)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	2,40 (1,82)
Median (Min - Max)	3,00 [0,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Primary disease diagnosis:

HGBL

FACT-Lym EWB - Change from baseline

Cycle 6 Day 1

Treated patients at visit

5

Treated patients with non-missing values - n(%)

4 (80,0)

Mean (SD)

-1,25 (4,11)

Median (Min - Max)

-1,50 [-6,00-4,00]

FACT-Lym EWB - Change from baseline

Cycle 7 Day 1

Treated patients at visit

3

Treated patients with non-missing values - n(%)

3 (100,0)

Mean (SD)

2,00 (2,65)

Median (Min - Max)

3,00 [-1,00-4,00]

FACT-Lym EWB - Change from baseline

Cycle 8 Day 1

Treated patients at visit

3

Treated patients with non-missing values - n(%)

3 (100,0)

Mean (SD)

3,00 (1,00)

Median (Min - Max)

3,00 [2,00-4,00]

FACT-Lym EWB - Change from baseline

Cycle 9 Day 1

Treated patients at visit

2

Treated patients with non-missing values - n(%)

2 (100,0)

Mean (SD)

3,00 (2,83)

Median (Min - Max)

3,00 [1,00-5,00]

FACT-Lym EWB - Change from baseline

Cycle 10 Day 1

Treated patients at visit

2

Treated patients with non-missing values - n(%)

2 (100,0)

Mean (SD)

2,00 (1,41)

Median (Min - Max)

2,00 [1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS12: FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	3,50 (3,54)
	3,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	2,70 (2,40)
	2,70 [1,00-4,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	9 (81,8)
Median (Min - Max)	-1,56 (4,16)
	-2,00 [-8,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

3.6.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym EWB	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	16,60 (4,46)
Median (Min - Max)	17,50 [3,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	49 (94,2)
Mean (SD)	0,64 (3,38)
Median (Min - Max)	1,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	31 (81,6)
Mean (SD)	0,92 (4,31)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	23 (79,3)
Mean (SD)	1,67 (2,54)
Median (Min - Max)	2,00 [-4,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,26 (3,74)
Median (Min - Max)	1,00 [-5,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,25 (2,85)
Median (Min - Max)	1,00 [-5,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	1,23 (4,91)
Median (Min - Max)	1,80 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,24 (2,45)
Median (Min - Max)	0,40 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	2,24 (4,50)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-2,08 (2,13)
Median (Min - Max)	-2,00 [-5,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	-1,97 (2,78)
	-2,10 [-6,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	4 (57,1)
Median (Min - Max)	0,70 (3,89)
	-0,10 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	1,40 (8,01)
	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	4 (66,7)
Median (Min - Max)	-1,10 (2,64)
	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-1,88 (2,50)
	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Number prior lines:

2 lines

FACT-Lym EWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

45 (76,3)

Mean (SD)

-0,87 (4,50)

Median (Min - Max)

-1,00 [-10,00-13,00]

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym EWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	28 (87,5)
Mean (SD)	17,68 (4,72)
Median (Min - Max)	19,00 [7,00-24,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 30
Treated patients with non-missing values - n(%)	25 (83,3)
Mean (SD)	0,36 (2,75)
Median (Min - Max)	0,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 21
Treated patients with non-missing values - n(%)	17 (81,0)
Mean (SD)	1,18 (3,47)
Median (Min - Max)	2,00 [-7,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,07 (3,29)
Median (Min - Max)	0,00 [-8,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	0,00 (4,06)
Median (Min - Max)	0,00 [-10,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,00 (3,58)
Median (Min - Max)	1,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,00 (2,94)
Median (Min - Max)	2,50 [-2,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,25 (3,20)
Median (Min - Max)	0,50 [-3,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	21 (65,6)
Mean (SD)	-1,24 (3,77)
Median (Min - Max)	-1,00 [-8,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym EWB	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	39 (100,0)
Mean (SD)	16,82 (4,84)
Median (Min - Max)	17,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	0,00 (3,31)
Median (Min - Max)	0,00 [-9,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	27 (100,0)
Mean (SD)	0,50 (3,53)
Median (Min - Max)	0,00 [-7,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	1,50 (3,46)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	1,24 (3,38)
Median (Min - Max)	1,00 [-5,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,36 (4,30)
Median (Min - Max)	2,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,33 (3,12)
Median (Min - Max)	2,00 [-2,00-8,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	2,88 (1,73)
Median (Min - Max)	2,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,17 (2,64)
Median (Min - Max)	4,00 [-1,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,83 (1,60)
Median (Min - Max)	3,00 [1,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS13: FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,80 (2,05)
Median (Min - Max)	3,00 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,52 (2,87)
Median (Min - Max)	4,00 [-1,80-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,10 (5,80)
Median (Min - Max)	-0,10 [-4,20-4,00]
FACT-Lym EWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (76,9)
Mean (SD)	-1,13 (3,89)
Median (Min - Max)	-0,50 [-9,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

3.6.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym EWB	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	89 (96,7)
Mean (SD)	16,69 (4,74)
Median (Min - Max)	18,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 86
Treated patients with non-missing values - n(%)	80 (93,0)
Mean (SD)	0,47 (3,50)
Median (Min - Max)	1,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 66
Treated patients with non-missing values - n(%)	57 (86,4)
Mean (SD)	0,86 (4,10)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 49
Treated patients with non-missing values - n(%)	43 (87,8)
Mean (SD)	1,17 (3,31)
Median (Min - Max)	1,00 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 34
Treated patients with non-missing values - n(%)	32 (94,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,71 (4,11)
Median (Min - Max)	0,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	0,86 (3,52)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	22 (95,7)
Median (Min - Max)	1,85 (4,47)
	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	16 (84,2)
Median (Min - Max)	1,04 (2,73)
	1,50 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	2,27 (4,00)
	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	1,20 (3,34)
	2,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,40 (2,61)
Median (Min - Max)	1,50 [-3,60-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	0,86 (3,01)
	1,00 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	1,20 (7,22)
	-1,00 [-4,20-15,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	-1,47 (3,11)
	-2,40 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-1,35 (2,55)
	-1,70 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,40 (3,41)
Median (Min - Max)	-2,40 [-7,20--0,60]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,73 (1,14)
Median (Min - Max)	-2,40 [-4,00--1,80]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,20 (2,55)
Median (Min - Max)	-4,20 [-6,00--2,40]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	66 (71,7)
Mean (SD)	-0,66 (4,36)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym EWB	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	17,24 (4,54)
Median (Min - Max)	17,50 [3,00-23,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	0,43 (2,17)
	0,00 [-5,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	0,98 (2,81)
	0,50 [-2,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	9 (81,8)
Median (Min - Max)	1,22 (2,91)
	2,00 [-4,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	2,00 (2,44)
	3,10 [-1,20-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,70 (2,15)
Median (Min - Max)	2,00 [-1,00-3,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,27 (3,04)
	1,80 [-2,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,27 (2,37)
	1,00 [0,80-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,93 (3,58)
	3,80 [-1,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,50 (2,12)
	-0,50 [-2,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,80 (NE)
Median (Min - Max)	0,80 [0,80-0,80]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS14: FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-2,12 (3,81)
Median (Min - Max)	-1,00 [-8,00-4,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

3.6.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 1
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym EWB	Baseline
FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym EWB	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	17,32 (4,35)
Median (Min - Max)	19,00 [6,00-24,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	34 (91,9)
Mean (SD)	0,49 (3,28)
Median (Min - Max)	1,00 [-9,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	27 (84,4)
Mean (SD)	1,32 (4,27)
Median (Min - Max)	2,00 [-7,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	25

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	21 (84,0)
Mean (SD)	1,08 (3,24)
Median (Min - Max)	2,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	1,80 (4,12)
Median (Min - Max)	2,00 [-5,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	0,96 (3,43)
Median (Min - Max)	2,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	2,35 (4,37)
	2,00 [-6,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	0,16 (2,44)
	0,50 [-3,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	10 (100,0)
Median (Min - Max)	2,24 (4,79)
	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	0,58 (3,43)
	1,50 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,00 (2,56)
Median (Min - Max)	0,50 [-3,60-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	0,00 (2,90)
	-1,20 [-3,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-0,13 (7,97)
	-3,30 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1 (33,3)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,20 (1,13)
	-3,20 [-4,00--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,80 (3,39)
Median (Min - Max)	-4,80 [-7,20--2,40]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,20 (1,13)
Median (Min - Max)	-3,20 [-4,00--2,40]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,20 (2,55)
Median (Min - Max)	-4,20 [-6,00--2,40]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	29 (72,5)
Median (Min - Max)	-0,62 (4,49)
	-1,00 [-9,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym EWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	16,62 (4,86)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	68
Mean (SD)	63 (92,6)
Median (Min - Max)	0,28 (3,32)
	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	45
Mean (SD)	40 (88,9)
Median (Min - Max)	0,59 (3,78)
	1,00 [-10,00-7,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	34
Mean (SD)	31 (91,2)
Median (Min - Max)	1,25 (3,28)
	1,00 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	21 (91,3)
Median (Min - Max)	0,29 (3,62)
	0,00 [-10,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	0,92 (3,54)
Median (Min - Max)	1,00 [-4,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	1,23 (4,26)
	2,00 [-10,00-8,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	1,98 (2,72)
	2,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	2,53 (1,97)
	2,20 [0,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	0,67 (2,52)
	1,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-0,70 (4,09)
Median (Min - Max)	0,10 [-6,00-3,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	4,00 (2,65)
Median (Min - Max)	5,00 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	3,50 (3,54)
Median (Min - Max)	3,50 [1,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,67 (3,06)
Median (Min - Max)	0,00 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,00 (3,00)
Median (Min - Max)	-1,00 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,10 (0,99)
Median (Min - Max)	0,10 [-0,60-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,10 (2,69)
Median (Min - Max)	0,10 [-1,80-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS15: FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	61 (77,2)
Mean (SD)	-1,35 (4,05)
Median (Min - Max)	-1,00 [-10,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

3.6.16 Merkmal: *Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym EWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	17,30 (4,73)
Median (Min - Max)	17,00 [3,00-23,00]
FACT-Lym EWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	0,05 (1,97)
Median (Min - Max)	0,00 [-5,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	0,09 (2,48)
Median (Min - Max)	-1,00 [-2,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,13 (2,75)
Median (Min - Max)	0,00 [-4,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,00 (2,10)
Median (Min - Max)	1,00 [-1,20-3,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,20 (2,90)
Median (Min - Max)	0,00 [-3,00-3,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2,90 (1,56)
Median (Min - Max)	2,90 [1,80-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2,90 (2,97)
Median (Min - Max)	2,90 [0,80-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	4,90 (1,56)
Median (Min - Max)	4,90 [3,80-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,80 (NE)
Median (Min - Max)	0,80 [0,80-0,80]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-1,80 (3,53)
Median (Min - Max)	-1,00 [-8,00-4,80]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym EWB	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	100 (96,2)
Mean (SD)	16,78 (4,55)
Median (Min - Max)	18,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	96
Mean (SD)	89 (92,7)
Median (Min - Max)	0,44 (3,43)
	1,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	73
Mean (SD)	64 (87,7)
Median (Min - Max)	0,96 (4,02)
	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	55
Mean (SD)	49 (89,1)
Median (Min - Max)	1,40 (3,22)
	2,00 [-8,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	40
Mean (SD)	38 (95,0)
Median (Min - Max)	0,96 (3,90)
	0,50 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	0,67 (3,59)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	25 (96,2)
Median (Min - Max)	1,70 (4,26)
	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	0,98 (2,63)
	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	2,22 (3,76)
	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	1,05 (3,03)
	2,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,92 (2,92)
Median (Min - Max)	1,50 [-3,60-6,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	1,30 (3,06)
Median (Min - Max)	1,50 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,53 (6,89)
Median (Min - Max)	-1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-1,47 (3,11)
Median (Min - Max)	-2,40 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,35 (2,55)
Median (Min - Max)	-1,70 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,40 (3,41)
Median (Min - Max)	-2,40 [-7,20--0,60]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,73 (1,14)
	-2,40 [-4,00--1,80]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,20 (2,55)
	-4,20 [-6,00--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS16: FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,40 (NE)
	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	73 (70,2)
Median (Min - Max)	-0,79 (4,28)
	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.6.17 *Merkmal: Vorherige CAR-T-Therapie*

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym EWB	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	18,63 (4,78)
Median (Min - Max)	20,00 [8,00-23,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,17 (0,41)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	2,00 (3,56)
Median (Min - Max)	3,00 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,75 (5,68)
Median (Min - Max)	0,00 [-3,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	4,00 (4,00)
Median (Min - Max)	4,00 [0,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	5,33 (4,16)
Median (Min - Max)	4,00 [2,00-10,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	5,00 (2,65)
Median (Min - Max)	4,00 [3,00-8,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,33 (1,53)
Median (Min - Max)	4,00 [3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-1,33 (3,93)
Median (Min - Max)	-1,00 [-8,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym EWB	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	117 (95,9)
Mean (SD)	16,79 (4,61)
Median (Min - Max)	18,00 [3,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	102 (92,7)
Mean (SD)	0,39 (3,30)
Median (Min - Max)	0,50 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	71 (86,6)
Mean (SD)	0,76 (3,84)
Median (Min - Max)	1,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	55 (87,3)
Mean (SD)	1,15 (2,94)
Median (Min - Max)	1,80 [-8,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	42 (91,3)
Mean (SD)	0,75 (3,56)
Median (Min - Max)	1,00 [-10,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	0,10 (3,06)
Median (Min - Max)	1,00 [-6,00-4,00]
FACT-Lym EWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	1,30 (4,07)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	0,71 (2,38)
Median (Min - Max)	1,00 [-3,00-5,00]
FACT-Lym EWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	2,35 (3,66)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	0,63 (2,94)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,11 (3,36)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	1,38 (3,04)
Median (Min - Max)	1,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	1,13 (6,70)
Median (Min - Max)	1,00 [-7,00-15,00]
FACT-Lym EWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,10 (2,64)
Median (Min - Max)	-1,20 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS17: FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Prior use of T-CART therapy:

No

FACT-Lym EWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

90 (73,8)

Mean (SD)

-1,01 (4,16)

Median (Min - Max)

-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

3.6.18 *Merkmal: Arzneimittelformulierung*

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym EWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	17,91 (4,37)
Median (Min - Max)	19,00 [3,00-23,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	0,07 (3,27)
Median (Min - Max)	0,00 [-9,00-5,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-1,16 (4,13)
Median (Min - Max)	0,00 [-10,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,25 (3,28)
Median (Min - Max)	1,00 [-8,00-4,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,27 (4,03)
Median (Min - Max)	1,00 [-10,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. EWB = emotional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,40 (2,19)
Median (Min - Max)	2,00 [-2,00-4,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	1,20 (2,59)
	1,00 [-2,00-5,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	0,00 (2,58)
	0,00 [-3,00-3,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,67 (0,58)
	2,00 [1,00-2,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Drug formulation:

Frozen liquid

FACT-Lym EWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

22 (68,8)

Mean (SD)

-2,05 (3,68)

Median (Min - Max)

-1,50 [-9,00-4,00]

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym EWB	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	93 (94,9)
Mean (SD)	16,57 (4,68)
Median (Min - Max)	17,00 [4,00-24,00]
FACT-Lym EWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	80 (90,9)
Mean (SD)	0,48 (3,20)
Median (Min - Max)	0,00 [-12,00-7,00]
FACT-Lym EWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	56 (86,2)
Mean (SD)	1,50 (3,49)
Median (Min - Max)	1,00 [-6,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	43 (86,0)
Mean (SD)	1,54 (3,02)
Median (Min - Max)	1,80 [-4,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	34 (89,5)
Mean (SD)	1,19 (3,53)
Median (Min - Max)	0,50 [-5,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym EWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	0,42 (3,62)
Median (Min - Max)	1,00 [-6,00-10,00]
FACT-Lym EWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	1,80 (4,37)
Median (Min - Max)	2,00 [-10,00-12,00]
FACT-Lym EWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	1,47 (2,59)
Median (Min - Max)	2,00 [-3,00-6,00]
FACT-Lym EWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	2,56 (3,88)
Median (Min - Max)	2,00 [-3,60-13,00]
FACT-Lym EWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	0,72 (2,99)
Median (Min - Max)	1,00 [-5,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym EWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	0,35 (3,31)
Median (Min - Max)	1,00 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	1,74 (3,09)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	1,13 (6,70)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	4 (57,1)
Median (Min - Max)	-1,10 (2,64)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-1,88 (2,50)
FACT-Lym EWB - Change from baseline	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,88 (2,50)
Median (Min - Max)	-2,40 [-4,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym EWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,35 (3,49)
Median (Min - Max)	-1,50 [-7,20-0,80]
FACT-Lym EWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,55 (2,54)
Median (Min - Max)	-2,10 [-4,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,80 (6,16)
Median (Min - Max)	-2,40 [-6,00-6,00]
FACT-Lym EWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,70 (2,40)
Median (Min - Max)	-0,70 [-2,40-1,00]
FACT-Lym EWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,20 (3,11)
Median (Min - Max)	-0,20 [-2,40-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym EWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,30 (3,82)
Median (Min - Max)	0,30 [-2,40-3,00]
FACT-Lym EWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,40 (NE)
Median (Min - Max)	-2,40 [-2,40--2,40]
FACT-Lym EWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,60 (NE)
Median (Min - Max)	5,60 [5,60-5,60]
FACT-Lym EWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym EWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FEC_PSHS18: FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym EWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Drug formulation:	
Lyophilized	
FACT-Lym EWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	74 (75,5)
Mean (SD)	-0,73 (4,22)
Median (Min - Max)	-1,00 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. EWB = emotional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFD_PSTS01: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Age group
 PRO set

3.7 Subgruppenanalysen zum FACT-Lym – funktionelles Wohlbefinden (Zeit bis zur Verschlechterung)

3.7.1 Merkmal Alter

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	22 (38,6)
95%-CI	[26,0-52,4]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09 [3,25-12,06]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,7 [51,9-79,3]
Month 6	46,9 [28,3-63,5]
Month 12	39,1 [19,3-58,5]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS01: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	21 (39,6)
95%-CI	[26,5-54,0]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,93 [2,17-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [48,5-77,7]
Month 6	40,1 [19,3-60,2]
Month 12	16,1 [1,4-45,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS01: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	7 (35,0)
95%-CI	[15,4-59,2]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	12,22[3,02-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,3 [51,9-91,3]
Month 6	62,6 [33,9-81,7]
Month 12	62,6 [33,9-81,7]
Month 18	41,8 [8,9-73,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS02: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Sex
 PRO set

3.7.2 *Merkmal: Geschlecht*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	20 (37,7)
95%-CI	[24,8-52,1]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	7,39[3,25-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,2 [58,5-85,9]
Month 6	53,4 [34,5-69,2]
Month 12	40,1 [19,5-59,9]
Month 18	24,1 [7,0-46,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS02: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	30 (39,0)
95%-CI	[28,0-50,8]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73[3,52-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [51,1-74,5]
Month 6	41,7 [23,6-58,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS03: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Race group
 PRO set

3.7.3 *Merkmal: Ethnie*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	45 (39,1)
95%-CI	[30,2-48,7]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09[3,52-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,6 [55,8-75,4]
Month 6	46,9 [33,4-59,3]
Month 12	33,2 [17,5-49,9]
Month 18	20,0 [6,2-39,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS03: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,93 [0,76-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [50,0-93,1]
Month 6	44,4 [8,2-76,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS04: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Country
 PRO set

3.7.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	16 (31,4)
95%-CI	[19,1-45,9]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	10,64 [3,06-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,3 [61,8-87,1]
Month 6	50,7 [28,3-69,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS04: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	15 (51,7)
95%-CI	[32,5-70,6]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	2,17[1,71-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,2 [27,5-67,7]
Month 6	30,6 [11,7-52,0]
Month 12	30,6 [11,7-52,0]
Month 18	30,6 [11,7-52,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS04: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	17 (35,4)
95%-CI	[22,2-50,5]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,87 [4,73-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [58,9-86,0]
Month 6	58,1 [35,5-75,2]
Month 12	38,7 [14,8-62,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS05: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Region
 PRO set

3.7.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	16 (31,4)
95%-CI	[19,1-45,9]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	10,64 [3,06-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,3 [61,8-87,1]
Month 6	50,7 [28,3-69,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS05: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	34 (43,0)
95%-CI	[31,9-54,7]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09[3,25-12,06]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,3 [50,2-73,9]
Month 6	44,3 [28,6-58,9]
Month 12	34,9 [18,9-51,4]
Month 18	20,9 [6,6-40,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS06: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

3.7.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55[2,17-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	42,9 [5,8-77,7]
Month 12	21,4 [0,9-60,5]
Month 18	21,4 [0,9-60,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS06: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	7 (33,3)
95%-CI	[14,6-57,0]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,40 [2,04-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,5 [36,9-84,6]
Month 6	49,9 [16,0-76,8]
Month 12	49,9 [16,0-76,8]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS06: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	6 (35,3)
95%-CI	[14,2-61,7]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09[0,72-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,0 [41,2-88,6]
Month 6	43,2 [11,7-72,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS06: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	33 (40,2)
95%-CI	[29,6-51,7]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,93[3,06-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,2 [53,6-76,1]
Month 6	49,7 [34,6-63,1]
Month 12	38,4 [21,0-55,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS07: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Bulky disease
 PRO set

3.7.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	48 (38,1)
95%-CI	[29,6-47,2]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55[4,21-12,06]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,4 [59,4-77,4]
Month 6	47,6 [34,6-59,5]
Month 12	34,0 [18,1-50,5]
Month 18	20,4 [6,4-39,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS08: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Double/Triple hit
 PRO set

3.7.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	6 (42,9)
95%-CI	[17,7-71,1]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,06[0,92-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,2 [42,7-91,7]
Month 6	31,7 [5,2-64,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS08: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	44 (37,9)
95%-CI	[29,1-47,4]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55 [4,21-12,06]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [56,8-76,0]
Month 6	48,6 [34,7-61,1]
Month 12	34,2 [17,8-51,3]
Month 18	20,5 [6,3-40,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS09: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Transformed DLBCL
 PRO set

3.7.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	12 (50,0)
95%-CI	[29,1-70,9]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,02 [1,71-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,5 [26,8-71,6]
Month 6	37,6 [15,4-60,0]
Month 12	37,6 [15,4-60,0]
Month 18	25,0 [5,5-51,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. FWB = functional well being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS09: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	38 (35,8)
95%-CI	[26,8-45,7]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55 [4,40-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,3 [61,6-80,4]
Month 6	48,6 [33,5-62,2]
Month 12	26,4 [7,3-50,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. FWB = functional well being.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS10: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: B-Cell type
 PRO set

3.7.10 *Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	20 (46,5)
95%-CI	[31,2-62,3]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09[2,10-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [48,9-79,0]
Month 6	43,5 [24,1-61,4]
Month 12	29,0 [7,5-55,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS10: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	10 (47,6)
95%-CI	[25,7-70,2]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,52 [1,41-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,1 [30,7-75,4]
Month 6	44,9 [18,3-68,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS11: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter
 PRO set

3.7.11 *Merkmal: Maximaler längster Durchmesser*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	28 (36,8)
95%-CI	[26,1-48,7]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,87[4,40-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,8 [61,0-82,9]
Month 6	52,4 [35,8-66,5]
Month 12	43,2 [25,8-59,4]
Month 18	25,9 [8,4-47,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS11: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	12 (35,3)
95%-CI	[19,7-53,5]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55[2,17-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,2 [47,2-82,3]
Month 6	42,7 [15,4-68,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS11: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. FWB = functional well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS11: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. FWB = functional well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS12: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Primary disease diagnosis
 PRO set

3.7.12 *Merkmal: Primärdiagnose*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	44 (39,3)
95%-CI	[30,2-49,0]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55[4,21-12,06]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,3 [56,7-75,9]
Month 6	48,5 [34,7-61,0]
Month 12	34,1 [17,8-51,2]
Month 18	20,5 [6,3-40,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS12: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	6 (54,5)
95%-CI	[23,4-83,3]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,06[0,72-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [35,0-89,9]
Month 6	28,6 [4,5-60,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS13: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Number prior lines
 PRO set

3.7.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09[1,77-12,06]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,7 [43,0-71,4]
Month 6	42,3 [25,2-58,6]
Month 12	36,3 [18,8-54,1]
Month 18	21,8 [6,7-42,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS13: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	11 (34,4)
95%-CI	[18,6-53,2]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	3,52 [3,02-6,87]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [55,6-89,3]
Month 6	32,7 [6,8-62,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS13: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	12 (30,8)
95%-CI	[17,0-47,6]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	10,64 [4,40-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,0 [57,5-87,3]
Month 6	59,6 [36,7-76,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS14: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - first line
 PRO set

3.7.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	36 (39,1)
95%-CI	[29,1-49,9]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55 [3,52-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [56,0-77,2]
Month 6	46,8 [31,2-60,9]
Month 12	27,6 [10,3-48,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS14: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	8 (36,4)
95%-CI	[17,2-59,3]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	NE[1,48-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,4 [36,6-80,2]
Month 6	53,5 [26,7-74,4]
Month 12	53,5 [26,7-74,4]
Month 18	53,5 [26,7-74,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS15: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - last line
 PRO set

3.7.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	17 (42,5)
95%-CI	[27,0-59,1]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	6,87[4,21-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,1 [57,6-86,2]
Month 6	53,9 [32,1-71,5]
Month 12	30,3 [9,9-54,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS15: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	30 (38,0)
95%-CI	[27,3-49,6]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,55[2,10-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,1 [45,1-70,6]
Month 6	44,6 [27,5-60,4]
Month 12	44,6 [27,5-60,4]
Month 18	22,3 [2,0-56,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS16: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - any line
 PRO set

3.7.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,40 [1,41-NE]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,7 [29,0-74,5]
Month 6	45,6 [20,1-68,1]
Month 12	45,6 [20,1-68,1]
Month 18	45,6 [20,1-68,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS16: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	40 (38,5)
95%-CI	[29,1-48,5]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	5,09[3,52-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,0 [59,8-79,5]
Month 6	46,2 [31,6-59,6]
Month 12	30,5 [14,0-48,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS17: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Prior use of T-CART therapy
PRO set

3.7.17 Merkmal: Vorherige CAR-T-Therapie

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. FWB = functional well being.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS17: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	49 (40,2)
95%-CI	[31,4-49,4]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,93[3,52-10,64]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [57,2-75,8]
Month 6	44,1 [30,8-56,6]
Month 12	31,0 [16,1-47,3]
Month 18	18,6 [5,8-37,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS18: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Drug formulation
 PRO set

3.7.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	15 (46,9)
95%-CI	[29,1-65,3]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	4,73 [1,71-6,87]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,6 [32,6-70,7]
Month 6	35,8 [13,8-58,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFD_PSTS18: Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym FWB by at least 5 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	35 (35,7)
95%-CI	[26,3-46,0]
FACT-Lym FWB - Time to decrease by at least 5 points in months [95%-CI]	
Median	7,39[4,21-12,22]
FACT-Lym FWB - Time to decrease by at least 5 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,7 [62,7-81,9]
Month 6	51,2 [36,2-64,3]
Month 12	38,8 [20,4-56,8]
Month 18	23,3 [7,1-44,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FWB = functional well being.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

3.8 Subgruppenanalysen zum FACT-Lym – funktionelles Wohlbefinden (Veränderung gegenüber Studienbeginn)

3.8.1 Merkmal Alter

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym FWB	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	57 (100,0)
Mean (SD)	14,21 (5,61)
Median (Min - Max)	14,00 [5,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	48 (98,0)
Mean (SD)	0,14 (4,40)
Median (Min - Max)	0,00 [-15,00-10,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	35 (94,6)
Mean (SD)	-1,53 (5,22)
Median (Min - Max)	-1,00 [-19,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	0,33 (5,35)
Median (Min - Max)	1,00 [-14,00-11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	21 (95,5)
Mean (SD)	-0,57 (4,01)
Median (Min - Max)	0,00 [-9,00-8,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-0,99 (5,14)
Median (Min - Max)	-1,00 [-12,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	-1,43 (4,01)
Median (Min - Max)	-0,50 [-10,00-4,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,48 (4,75)
Median (Min - Max)	-1,00 [-6,00-9,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-1,00 (4,93)
Median (Min - Max)	-1,00 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,72 (3,15)
Median (Min - Max)	-0,50 [-7,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,75 (4,72)
Median (Min - Max)	2,00 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,75 (3,86)
Median (Min - Max)	3,50 [-4,00-4,00]
FACT-Lym FWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,00 (1,41)
Median (Min - Max)	3,00 [2,00-4,00]
FACT-Lym FWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	42 (73,7)
Mean (SD)	-2,61 (5,36)
Median (Min - Max)	-2,00 [-21,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym FWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	51 (96,2)
Mean (SD)	15,52 (6,41)
Median (Min - Max)	16,00 [0,00-26,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	45 (93,8)
Mean (SD)	-0,03 (4,64)
Median (Min - Max)	0,00 [-9,00-14,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	1,91 (7,56)
Median (Min - Max)	2,00 [-13,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	1,49 (7,64)
Median (Min - Max)	2,17 [-11,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,66 (8,63)
Median (Min - Max)	-0,25 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,46 (5,86)
Median (Min - Max)	0,00 [-9,00-9,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	0,15 (5,77)
Median (Min - Max)	0,50 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-1,57 (6,37)
Median (Min - Max)	-2,00 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-1,44 (4,12)
Median (Min - Max)	-3,00 [-6,50-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,00 (3,39)
Median (Min - Max)	-3,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,00 (4,20)
Median (Min - Max)	-2,50 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-0,20 (4,44)
Median (Min - Max)	-1,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,50 (5,45)
Median (Min - Max)	-0,50 [-5,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,67 (3,51)
Median (Min - Max)	-4,00 [-7,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,61 (4,52)
Median (Min - Max)	-3,00 [-10,83--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (5,57)
Median (Min - Max)	-3,00 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,67 (3,79)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,00 (0,00)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	42 (79,2)
Mean (SD)	-1,39 (6,57)
Median (Min - Max)	-2,00 [-11,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym FWB	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	14,36 (8,03)
Median (Min - Max)	14,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,77 (6,92)
Median (Min - Max)	0,00 [-7,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	1,59 (7,30)
Median (Min - Max)	-1,00 [-3,83-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	3,13 (8,95)
Median (Min - Max)	-1,00 [-5,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	1,25 (9,90)
Median (Min - Max)	-1,00 [-7,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	3,17 (10,83)
Median (Min - Max)	0,00 [-7,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	3,00 (11,29)
Median (Min - Max)	-1,00 [-4,00-23,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	5,00 (12,83)
Median (Min - Max)	0,00 [-4,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,75 (1,71)
Median (Min - Max)	-1,50 [-4,00-0,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,50 (0,71)
Median (Min - Max)	-1,50 [-2,00--1,00]
FACT-Lym FWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,67 (9,02)
Median (Min - Max)	-1,00 [-11,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS01: FACT-Lym FWB - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	13 (65,0)
Median (Min - Max)	0,66 (8,89)
	-1,00 [-9,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

3.8.2 *Merkmal: Geschlecht*

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym FWB	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	50 (94,3)
Mean (SD)	14,01 (6,46)
Median (Min - Max)	14,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	41 (89,1)
Mean (SD)	1,77 (5,24)
Median (Min - Max)	1,00 [-5,00-25,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	0,88 (6,13)
Median (Min - Max)	-1,00 [-9,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	23 (82,1)
Mean (SD)	2,00 (6,79)
Median (Min - Max)	2,00 [-11,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,17 (6,93)
Median (Min - Max)	-0,50 [-12,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	1,08 (7,07)
Median (Min - Max)	0,00 [-9,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	-0,08 (7,17)
Median (Min - Max)	-1,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	1,31 (7,62)
Median (Min - Max)	-1,00 [-5,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	-2,96 (2,83)
Median (Min - Max)	-2,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-1,70 (1,95)
Median (Min - Max)	-2,00 [-4,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,20 (3,12)
Median (Min - Max)	-2,00 [-7,00-2,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	-0,75 (3,11)
Median (Min - Max)	-1,00 [-5,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-0,63 (5,53)
Median (Min - Max)	-0,50 [-11,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	40 (75,5)
Mean (SD)	-1,37 (6,51)
Median (Min - Max)	-2,00 [-11,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym FWB	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	77 (100,0)
Mean (SD)	15,25 (6,22)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	69 (98,6)
Mean (SD)	-0,78 (4,48)
Median (Min - Max)	0,00 [-15,00-10,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	45 (90,0)
Mean (SD)	-0,15 (7,03)
Median (Min - Max)	1,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	0,78 (7,04)
Median (Min - Max)	1,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,21 (7,19)
Median (Min - Max)	0,00 [-9,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,79 (6,02)
Median (Min - Max)	-1,00 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,20 (4,32)
Median (Min - Max)	0,50 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,30 (6,74)
Median (Min - Max)	-2,00 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,50 (3,73)
Median (Min - Max)	3,50 [-4,00-6,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,78 (5,64)
Median (Min - Max)	0,67 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS02: FACT-Lym FWB - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,00 (0,00)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	5,50 (2,12)
Median (Min - Max)	5,50 [4,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	8,00 (NE)
Median (Min - Max)	8,00 [8,00-8,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	57 (74,0)
Mean (SD)	-1,84 (6,47)
Median (Min - Max)	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

3.8.3 *Merkmal: Ethnie*

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym FWB	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	112 (97,4)
Mean (SD)	14,53 (6,47)
Median (Min - Max)	14,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	98 (94,2)
Mean (SD)	0,32 (5,02)
Median (Min - Max)	0,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	74
Treated patients with non-missing values - n(%)	64 (86,5)
Mean (SD)	0,41 (6,76)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	56
Treated patients with non-missing values - n(%)	51 (91,1)
Mean (SD)	1,40 (7,04)
Median (Min - Max)	1,00 [-11,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	41
Treated patients with non-missing values - n(%)	38 (92,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,37 (7,31)
Median (Min - Max)	-0,25 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	0,17 (6,19)
Median (Min - Max)	-1,00 [-9,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	-0,35 (6,22)
Median (Min - Max)	-0,25 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	0,60 (6,75)
Median (Min - Max)	-1,00 [-6,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	-1,71 (3,67)
Median (Min - Max)	-2,00 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	-1,94 (2,47)
Median (Min - Max)	-2,00 [-7,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,55 (3,67)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	-0,22 (3,31)
Median (Min - Max)	-1,00 [-5,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-0,63 (5,53)
Median (Min - Max)	-0,50 [-11,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,9)
Mean (SD)	-1,78 (6,46)
Median (Min - Max)	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym FWB	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	16,47 (4,90)
Median (Min - Max)	16,00 [11,00-26,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-1,08 (3,90)
Median (Min - Max)	0,00 [-7,00-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,50 (6,32)
Median (Min - Max)	0,00 [-13,00-8,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,40 (6,55)
Median (Min - Max)	2,00 [-14,00-8,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-0,79 (5,21)
Median (Min - Max)	1,00 [-9,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,67 (8,94)
Median (Min - Max)	3,50 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	1,00 (6,96)
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,00 (11,27)
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	6,00 (NE)
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS03: FACT-Lym FWB - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	7,00 (NE)
Median (Min - Max)	7,00 [7,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	8,00 (NE)
Median (Min - Max)	8,00 [8,00-8,00]
FACT-Lym FWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	12 (80,0)
Mean (SD)	-0,67 (6,65)
Median (Min - Max)	0,00 [-15,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

3.8.4 *Merkmal: Region-1*

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym FWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	14,96 (5,87)
Median (Min - Max)	14,50 [3,00-26,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	0,57 (5,86)
Median (Min - Max)	0,00 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	1,05 (6,94)
Median (Min - Max)	0,00 [-13,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	1,41 (7,21)
Median (Min - Max)	2,00 [-14,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,17 (7,58)
Median (Min - Max)	0,00 [-12,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	1,45 (8,12)
Median (Min - Max)	0,00 [-9,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,91 (8,95)
Median (Min - Max)	1,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	3,59 (9,72)
Median (Min - Max)	2,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,83 (6,05)
Median (Min - Max)	-1,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,28 (2,65)
Median (Min - Max)	0,83 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,50 (4,42)
Median (Min - Max)	1,00 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,33 (4,08)
Median (Min - Max)	1,50 [-4,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (4,16)
Median (Min - Max)	2,00 [0,00-8,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-0,91 (7,29)
Median (Min - Max)	-1,00 [-15,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym FWB	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	17,71 (6,30)
Median (Min - Max)	18,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	-2,20 (4,87)
Median (Min - Max)	-1,00 [-15,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	0,65 (11,17)
Median (Min - Max)	1,25 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	2,20 (10,05)
Median (Min - Max)	2,33 [-7,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	1,46 (10,43)
Median (Min - Max)	-1,00 [-7,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,08 (6,68)
Median (Min - Max)	0,25 [-12,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,75 (4,73)
Median (Min - Max)	-0,75 [-10,00-3,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	3,33 (5,13)
Median (Min - Max)	2,00 [-1,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,90 (4,59)
Median (Min - Max)	-1,00 [-6,50-5,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,00 (5,66)
Median (Min - Max)	3,00 [-1,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	-1,81 (8,57)
Median (Min - Max)	-2,50 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym FWB	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	46 (95,8)
Mean (SD)	12,74 (6,30)
Median (Min - Max)	13,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	44 (95,7)
Mean (SD)	0,93 (3,52)
Median (Min - Max)	1,00 [-6,00-12,00]
FACT-Lym FWB - Change from baseline	
	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	32 (88,9)
Mean (SD)	-0,50 (3,80)
Median (Min - Max)	-0,50 [-9,00-7,00]
FACT-Lym FWB - Change from baseline	
	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	0,65 (4,97)
Median (Min - Max)	0,00 [-8,00-11,00]
FACT-Lym FWB - Change from baseline	
	Cycle 5 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	0,26 (3,92)
Median (Min - Max)	0,00 [-7,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,67 (4,05)
Median (Min - Max)	-1,00 [-7,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-1,17 (3,10)
Median (Min - Max)	-0,50 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,80 (2,30)
Median (Min - Max)	-3,00 [-6,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-1,89 (1,83)
Median (Min - Max)	-2,00 [-4,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-3,33 (2,25)
Median (Min - Max)	-3,00 [-7,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,80 (3,42)
Median (Min - Max)	-2,00 [-7,00-2,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-0,67 (4,51)
Median (Min - Max)	-1,00 [-5,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-3,25 (6,34)
Median (Min - Max)	-3,00 [-11,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,50 (5,20)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,96 (3,92)
Median (Min - Max)	-3,00 [-10,83--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (5,57)
Median (Min - Max)	-3,00 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,67 (3,79)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,00 (0,00)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS04: FACT-Lym FWB - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	35 (72,9)
Mean (SD)	-2,13 (3,49)
Median (Min - Max)	-2,00 [-11,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

3.8.5 *Merkmal: Region-2*

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym FWB	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	14,96 (5,87)
Median (Min - Max)	14,50 [3,00-26,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	0,57 (5,86)
Median (Min - Max)	0,00 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	1,05 (6,94)
Median (Min - Max)	0,00 [-13,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	1,41 (7,21)
Median (Min - Max)	2,00 [-14,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,17 (7,58)
Median (Min - Max)	0,00 [-12,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	1,45 (8,12)
Median (Min - Max)	0,00 [-9,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,91 (8,95)
Median (Min - Max)	1,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	3,59 (9,72)
Median (Min - Max)	2,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,83 (6,05)
Median (Min - Max)	-1,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,28 (2,65)
Median (Min - Max)	0,83 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,50 (4,42)
Median (Min - Max)	1,00 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,33 (4,08)
Median (Min - Max)	1,50 [-4,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (4,16)
Median (Min - Max)	2,00 [0,00-8,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-0,91 (7,29)
Median (Min - Max)	-1,00 [-15,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym FWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	77 (97,5)
Mean (SD)	14,63 (6,63)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	67 (94,4)
Mean (SD)	-0,09 (4,22)
Median (Min - Max)	0,00 [-15,00-12,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	45 (84,9)
Mean (SD)	-0,27 (6,48)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	36 (90,0)
Mean (SD)	1,12 (6,81)
Median (Min - Max)	0,50 [-8,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	0,43 (6,70)
Median (Min - Max)	-0,50 [-7,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	-0,81 (4,88)
Median (Min - Max)	-1,00 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,36 (3,59)
Median (Min - Max)	-0,75 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-1,38 (3,95)
Median (Min - Max)	-3,00 [-6,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	-1,54 (2,96)
Median (Min - Max)	-1,50 [-6,50-5,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-3,00 (2,24)
Median (Min - Max)	-3,00 [-7,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-2,50 (3,15)
Median (Min - Max)	-2,00 [-7,00-2,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-0,75 (3,69)
Median (Min - Max)	-1,00 [-5,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,17 (6,40)
Median (Min - Max)	-1,00 [-11,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS05: FACT-Lym FWB - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	61 (77,2)
Mean (SD)	-2,08 (5,94)
Median (Min - Max)	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.8.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym FWB	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	17,05 (6,44)
Median (Min - Max)	15,50 [7,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,52 (2,93)
Median (Min - Max)	1,00 [-2,33-6,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	3,10 (4,64)
Median (Min - Max)	1,50 [-1,00-11,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,50 (2,15)
Median (Min - Max)	-1,00 [-2,33-2,33]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,13 (1,44)
Median (Min - Max)	-0,75 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage I	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,50 (1,80)
Median (Min - Max)	-1,00 [-2,00-1,50]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,83 (1,89)
Median (Min - Max)	-1,00 [-4,00--0,50]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,50 (0,71)
Median (Min - Max)	-1,50 [-2,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,83 (2,75)
Median (Min - Max)	-4,00 [-6,50--1,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,50 (2,12)
Median (Min - Max)	-2,50 [-4,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,00 (1,41)
	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,50 (0,71)
	-1,50 [-2,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,50 (0,71)
	-0,50 [-1,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	7 (70,0)
Median (Min - Max)	-3,93 (4,05)
	-5,50 [-8,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym FWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	12,84 (5,30)
Median (Min - Max)	14,00 [0,00-21,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	1,67 (4,17)
Median (Min - Max)	0,50 [-5,00-14,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,82 (9,87)
Median (Min - Max)	-2,00 [-9,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	2,00 (9,90)
Median (Min - Max)	0,00 [-8,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	2,69 (10,89)
Median (Min - Max)	0,25 [-7,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-1,33 (4,84)
	-2,50 [-7,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-1,20 (2,77)
	-2,00 [-4,00-3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-2,00 (5,24)
	-4,00 [-6,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,67 (2,52)
	-2,00 [-4,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,50 (3,54)
	-4,50 [-7,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-11,00 (NE)
	-11,00 [-11,00--11,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-7,00 (NE)
	-7,00 [-7,00--7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-10,83 (NE)
	-10,83 [-10,83--10,83]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-9,00 (NE)
	-9,00 [-9,00--9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	15 (71,4)
Median (Min - Max)	0,21 (8,92)
	-1,00 [-11,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym FWB	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	16,38 (6,34)
Median (Min - Max)	17,00 [6,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,79 (5,41)
Median (Min - Max)	-0,50 [-15,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-2,82 (7,12)
Median (Min - Max)	-1,00 [-19,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,22 (5,45)
Median (Min - Max)	0,00 [-7,00-11,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,00 (4,98)
Median (Min - Max)	1,50 [-5,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-2,20 (6,72)
	0,00 [-12,00-4,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-1,80 (6,30)
	1,00 [-10,00-4,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,00 (2,65)
	1,00 [-3,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,50 (3,54)
	-0,50 [-3,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	11 (64,7)
Median (Min - Max)	-3,91 (6,33)
	-2,00 [-21,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym FWB	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	82 (100,0)
Mean (SD)	14,61 (6,46)
Median (Min - Max)	14,50 [0,00-26,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	69 (95,8)
Mean (SD)	-0,21 (5,15)
Median (Min - Max)	0,00 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	49 (90,7)
Mean (SD)	0,55 (5,78)
Median (Min - Max)	0,00 [-13,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	37 (88,1)
Mean (SD)	1,45 (6,69)
Median (Min - Max)	2,00 [-14,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	-0,68 (6,54)
Median (Min - Max)	0,00 [-12,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	20 (90,9)
Median (Min - Max)	1,46 (7,45)
	0,00 [-9,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	16 (100,0)
Median (Min - Max)	1,06 (7,51)
	0,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	2,28 (8,90)
	1,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	12 (100,0)
Median (Min - Max)	-0,75 (4,61)
	-1,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	-1,37 (3,25)
	-1,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	-0,14 (4,45)
	0,00 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	0,71 (4,46)
	0,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	2,50 (4,93)
	3,00 [-5,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	0,33 (4,51)
	0,00 [-4,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-3,00 (0,00)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,00 (2,83)
	-1,00 [-3,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,50 (0,71)
	-2,50 [-3,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,00 (0,00)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS06: FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	64 (78,0)
Median (Min - Max)	-1,44 (5,97)
	-2,00 [-15,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
 PRO set

3.8.7 *Merkmal: Bulky Erkrankung*

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym FWB	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	123 (97,6)
Mean (SD)	14,86 (6,29)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	107 (94,7)
Mean (SD)	0,17 (4,90)
Median (Min - Max)	0,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	76 (89,4)
Mean (SD)	0,27 (6,66)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	60 (90,9)
Mean (SD)	1,36 (6,91)
Median (Min - Max)	1,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,19 (6,99)
Median (Min - Max)	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	0,25 (6,60)
Median (Min - Max)	-0,50 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	-0,12 (6,25)
Median (Min - Max)	0,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	0,65 (7,15)
Median (Min - Max)	-1,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	-1,33 (3,97)
Median (Min - Max)	-1,50 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-1,49 (2,88)
Median (Min - Max)	-1,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	-1,00 (3,98)
Median (Min - Max)	-1,50 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,50 (3,87)
Median (Min - Max)	-0,50 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	0,33 (5,92)
Median (Min - Max)	0,00 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS07: FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	96 (76,2)
Mean (SD)	-1,61 (6,49)
Median (Min - Max)	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.8.8 *Merkmal: Double/Triple-Hit*

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym FWB	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	13,57 (5,96)
Median (Min - Max)	13,50 [3,00-26,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	1,90 (8,86)
Median (Min - Max)	0,50 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	2,67 (9,44)
Median (Min - Max)	-0,50 [-8,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	4,67 (10,07)
Median (Min - Max)	3,00 [-5,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,60 (12,90)
Median (Min - Max)	-2,00 [-7,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	6,29 (12,11)
Median (Min - Max)	1,58 [-2,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	5,67 (15,31)
Median (Min - Max)	0,00 [-6,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,44 (13,00)
Median (Min - Max)	5,33 [-1,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,50 (10,61)
Median (Min - Max)	-2,50 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,17 (1,18)
Median (Min - Max)	-0,17 [-1,00-0,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (7,78)
Median (Min - Max)	-0,50 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (5,66)
Median (Min - Max)	0,00 [-4,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-0,89 (10,74)
Median (Min - Max)	-5,00 [-11,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym FWB	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	113 (97,4)
Mean (SD)	14,91 (6,37)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	98 (94,2)
Mean (SD)	-0,04 (4,22)
Median (Min - Max)	0,00 [-15,00-14,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	68 (87,2)
Mean (SD)	-0,01 (6,29)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	55 (91,7)
Mean (SD)	0,86 (6,51)
Median (Min - Max)	1,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)
Mean (SD)	0,02 (6,14)
Median (Min - Max)	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	30 (96,8)
Mean (SD)	-0,55 (5,35)
Median (Min - Max)	-0,50 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-0,79 (4,53)
Median (Min - Max)	-0,25 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,74 (5,10)
Median (Min - Max)	-2,00 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,19 (3,29)
Median (Min - Max)	-1,50 [-6,50-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-1,73 (3,07)
Median (Min - Max)	-3,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-1,10 (3,54)
Median (Min - Max)	-1,50 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,63 (3,81)
Median (Min - Max)	-0,50 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,13 (6,29)
Median (Min - Max)	-0,50 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS08: FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Double/Triple hit:

No

FACT-Lym FWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

88 (75,9)

Mean (SD)

-1,72 (5,95)

Median (Min - Max)

-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.8.9 *Merkmal: Transformation des DLBCL*

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym FWB	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	15,47 (6,05)
Median (Min - Max)	15,00 [5,83-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	-0,39 (5,74)
Median (Min - Max)	0,50 [-15,00-14,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-2,14 (6,99)
Median (Min - Max)	-1,00 [-19,00-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,47 (5,55)
Median (Min - Max)	0,00 [-6,00-9,17]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,50 (4,20)
Median (Min - Max)	-0,50 [-7,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,40 (4,72)
Median (Min - Max)	0,00 [-2,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,80 (2,28)
Median (Min - Max)	1,00 [-1,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (4,32)
Median (Min - Max)	0,00 [-3,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,00 (1,73)
Median (Min - Max)	-1,00 [-4,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,33 (1,53)
Median (Min - Max)	-1,00 [-3,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,33 (2,08)
Median (Min - Max)	-1,00 [-2,00-2,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (2,89)
Median (Min - Max)	-1,00 [-1,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (2,89)
Median (Min - Max)	-1,00 [-1,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (3,21)
Median (Min - Max)	0,00 [-1,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,00 (1,73)
Median (Min - Max)	-3,00 [-3,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,50 (0,71)
Median (Min - Max)	-2,50 [-3,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (79,2)
Mean (SD)	-3,04 (6,65)
Median (Min - Max)	-4,00 [-21,00-9,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym FWB	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	104 (98,1)
Mean (SD)	14,60 (6,39)
Median (Min - Max)	14,50 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	90 (94,7)
Mean (SD)	0,29 (4,73)
Median (Min - Max)	0,00 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	63 (90,0)
Mean (SD)	0,77 (6,53)
Median (Min - Max)	0,00 [-13,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	50 (92,6)
Mean (SD)	1,41 (7,22)
Median (Min - Max)	2,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	35 (89,7)
Mean (SD)	0,67 (7,58)
Median (Min - Max)	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,11 (6,87)
Median (Min - Max)	-1,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	24 (100,0)
Median (Min - Max)	-0,52 (6,76)
	-0,75 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	18 (90,0)
Median (Min - Max)	0,57 (7,74)
	-1,50 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	-1,21 (4,27)
	-2,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-1,53 (3,25)
	-2,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-1,22 (4,52)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	0,43 (4,43)
Median (Min - Max)	0,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,17 (7,25)
Median (Min - Max)	1,00 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-5,50 (2,12)
Median (Min - Max)	-5,50 [-7,00--4,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,92 (5,54)
Median (Min - Max)	-6,92 [-10,83--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,50 (4,95)
Median (Min - Max)	-6,50 [-10,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,00 (4,24)
Median (Min - Max)	-6,00 [-9,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS09: FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	78 (73,6)
Mean (SD)	-1,31 (6,41)
Median (Min - Max)	-2,00 [-15,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

3.8.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym FWB	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	15,43 (6,20)
Median (Min - Max)	16,00 [0,00-26,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	38 (95,0)
Mean (SD)	0,02 (6,08)
Median (Min - Max)	0,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	1,14 (9,25)
Median (Min - Max)	-1,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	2,05 (9,08)
Median (Min - Max)	0,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,83 (9,34)
Median (Min - Max)	0,60 [-7,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	2,75 (8,44)
Median (Min - Max)	1,25 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,96 (8,04)
	0,25 [-10,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	2,60 (9,89)
	-0,50 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-0,94 (4,51)
	-2,50 [-6,50-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-0,50 (3,70)
	-1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,50 (3,70)
Median (Min - Max)	0,00 [-3,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	2,67 (4,51)
	3,00 [-2,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	1,00 (8,76)
	3,50 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	34 (79,1)
Median (Min - Max)	-1,32 (9,32)
	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym FWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	15,57 (5,34)
Median (Min - Max)	15,00 [7,00-26,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-1,22 (4,10)
Median (Min - Max)	-1,00 [-8,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-0,73 (5,20)
Median (Min - Max)	0,00 [-9,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,45 (4,37)
Median (Min - Max)	2,00 [-7,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-2,69 (3,65)
Median (Min - Max)	-2,00 [-9,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-4,67 (3,39)
Median (Min - Max)	-6,00 [-8,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	-2,00 (3,61)
Median (Min - Max)	-3,00 [-5,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	-2,33 (2,89)
Median (Min - Max)	-4,00 [-4,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-3,00 (5,66)
	-3,00 [-7,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,50 (4,95)
Median (Min - Max)	-3,50 [-7,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-7,00 (NE)
	-7,00 [-7,00--7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-10,83 (NE)
	-10,83 [-10,83--10,83]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-10,00 (NE)
	-10,00 [-10,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS10: FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-9,00 (NE)
Median (Min - Max)	-9,00 [-9,00--9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	16 (76,2)
Median (Min - Max)	-2,44 (4,63)
	-3,00 [-11,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.8.11 *Merkmal: Maximaler längster Durchmesser*

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: ≤ 5 cm	
Patients in analysis set	76
FACT-Lym FWB	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	74 (97,4)
Mean (SD)	14,57 (6,08)
Median (Min - Max)	14,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	64 (92,8)
Mean (SD)	0,94 (5,16)
Median (Min - Max)	0,00 [-7,00-25,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	52 (91,2)
Mean (SD)	0,34 (7,14)
Median (Min - Max)	-0,50 [-13,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)
Mean (SD)	1,33 (7,85)
Median (Min - Max)	0,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,55 (7,98)
Median (Min - Max)	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 25
Treated patients with non-missing values - n(%)	24 (96,0)
Mean (SD)	0,63 (7,40)
Median (Min - Max)	-0,50 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	0,43 (7,12)
Median (Min - Max)	0,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	0,46 (8,10)
Median (Min - Max)	-2,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	-1,00 (3,37)
Median (Min - Max)	-2,00 [-4,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-1,53 (3,11)
Median (Min - Max)	-2,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-0,33 (4,18)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	1,57 (4,08)
Median (Min - Max)	3,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	0,14 (6,79)
Median (Min - Max)	-1,00 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1 4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1 4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1 2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

<= 5 cm

FACT-Lym FWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

57 (75,0)

Mean (SD)

-0,43 (7,13)

Median (Min - Max)

-1,00 [-15,00-28,00]

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym FWB	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	15,13 (6,73)
Median (Min - Max)	15,00 [0,00-26,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	-0,98 (4,15)
Median (Min - Max)	0,00 [-15,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,21 (5,46)
Median (Min - Max)	0,00 [-19,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	1,01 (4,41)
Median (Min - Max)	1,50 [-8,00-7,83]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,63 (3,79)
Median (Min - Max)	-0,50 [-7,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	0,64 (4,05)
	0,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-0,42 (2,06)
	-0,25 [-4,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	2,50 (4,65)
	1,50 [-2,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	0,10 (4,16)
	1,00 [-6,50-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-3,16 (5,00)
Median (Min - Max)	-2,00 [-21,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym FWB	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	13,23 (7,13)
Median (Min - Max)	12,00 [5,83-26,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-0,81 (7,25)
Median (Min - Max)	-0,92 [-8,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	2,72 (9,73)
Median (Min - Max)	5,17 [-8,00-11,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,21 (7,17)
Median (Min - Max)	-4,00 [-6,00-9,17]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,50 (3,54)
Median (Min - Max)	-3,50 [-6,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	4 (44,4)
Mean (SD)	-1,17 (7,43)
Median (Min - Max)	-3,00 [-8,00-9,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym FWB	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	13,29 (6,45)
Median (Min - Max)	13,00 [5,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,53 (2,75)
Median (Min - Max)	-1,00 [-4,67-2,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	4,50 (2,12)
Median (Min - Max)	4,50 [3,00-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-0,50 (NE)
Median (Min - Max)	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS11: FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

FACT-Lym FWB - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

5 (71,4)

Mean (SD)

-3,60 (2,51)

Median (Min - Max)

-5,00 [-6,00-0,00]

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.8.12 *Merkmal: Primärdiagnose*

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym FWB	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	110 (98,2)
Mean (SD)	14,92 (6,32)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	101
Treated patients with non-missing values - n(%)	96 (95,0)
Mean (SD)	-0,19 (4,23)
Median (Min - Max)	0,00 [-15,00-14,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	68 (87,2)
Mean (SD)	-0,14 (6,36)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	55 (91,7)
Mean (SD)	0,86 (6,51)
Median (Min - Max)	1,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,02 (6,14)
Median (Min - Max)	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 31
Treated patients with non-missing values - n(%)	30 (96,8)
Mean (SD)	-0,55 (5,35)
Median (Min - Max)	-0,50 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-0,79 (4,53)
Median (Min - Max)	-0,25 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,74 (5,10)
Median (Min - Max)	-2,00 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,19 (3,29)
Median (Min - Max)	-1,50 [-6,50-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-1,73 (3,07)
Median (Min - Max)	-3,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-1,10 (3,54)
Median (Min - Max)	-1,50 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,63 (3,81)
Median (Min - Max)	-0,50 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,13 (6,29)
Median (Min - Max)	-0,50 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-3,00 (4,97)
	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-4,25 (3,20)
	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,33 (1,15)
	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,00 (1,41)
	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,00 (1,41)
	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (75,9)
Mean (SD)	-1,82 (5,99)
Median (Min - Max)	-2,00 [-21,00-28,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym FWB	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	14,27 (6,34)
Median (Min - Max)	14,00 [3,00-26,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	2,68 (9,40)
Median (Min - Max)	0,50 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,89 (9,73)
Median (Min - Max)	1,00 [-1,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,20 (11,17)
Median (Min - Max)	4,00 [-5,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,60 (12,90)
Median (Min - Max)	-2,00 [-7,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	6,29 (12,11)
	1,58 [-2,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	5,67 (15,31)
	0,00 [-6,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	9,44 (13,00)
	5,33 [-1,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,50 (10,61)
	-2,50 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-0,17 (1,18)
	-0,17 [-1,00-0,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS12: FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (7,78)
Median (Min - Max)	-0,50 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (5,66)
Median (Min - Max)	0,00 [-4,00-4,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	9 (81,8)
Median (Min - Max)	-1,33 (10,87)
	-5,00 [-11,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

3.8.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym FWB	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	15,99 (6,17)
Median (Min - Max)	16,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	49 (94,2)
Mean (SD)	-0,46 (4,79)
Median (Min - Max)	-1,00 [-15,00-14,00]
FACT-Lym FWB - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	31 (81,6)
Mean (SD)	-1,84 (5,92)
Median (Min - Max)	-1,00 [-19,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	-0,07 (5,98)
Median (Min - Max)	-0,50 [-14,00-11,00]
FACT-Lym FWB - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,44 (4,91)
Median (Min - Max)	-0,25 [-12,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-1,62 (5,57)
Median (Min - Max)	-1,00 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-1,97 (4,60)
Median (Min - Max)	-0,75 [-12,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-1,00 (4,47)
Median (Min - Max)	-2,00 [-6,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	-1,59 (3,18)
Median (Min - Max)	-2,00 [-6,50-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-3,00 [-3,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-2,50 (3,15)
Median (Min - Max)	-2,00 [-7,00-2,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-0,75 (3,69)
Median (Min - Max)	-1,00 [-5,00-4,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,17 (6,40)
Median (Min - Max)	-1,00 [-11,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,00 (1,41)
	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	45 (76,3)
Mean (SD)	-3,38 (5,54)
Median (Min - Max)	-4,00 [-21,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym FWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	14,33 (6,04)
Median (Min - Max)	13,50 [0,00-26,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	0,03 (3,84)
Median (Min - Max)	0,00 [-9,00-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	1,34 (8,02)
Median (Min - Max)	0,00 [-13,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	0,80 (9,11)
Median (Min - Max)	-1,00 [-8,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,05 (10,72)
Median (Min - Max)	-3,25 [-7,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,83 (5,74)
Median (Min - Max)	-1,50 [-5,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,00 (3,92)
Median (Min - Max)	1,50 [-4,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,50 (7,77)
Median (Min - Max)	-2,50 [-12,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,00 (5,00)
Median (Min - Max)	1,00 [-4,00-6,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,50 (7,78)
Median (Min - Max)	-1,50 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	7,00 (NE)
Median (Min - Max)	7,00 [7,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	8,00 (NE)
Median (Min - Max)	8,00 [8,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	22 (68,8)
Mean (SD)	0,65 (7,53)
Median (Min - Max)	-0,50 [-11,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym FWB	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	39 (100,0)
Mean (SD)	13,25 (6,54)
Median (Min - Max)	14,00 [2,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	1,18 (5,75)
Median (Min - Max)	0,00 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	27 (100,0)
Mean (SD)	1,98 (6,01)
Median (Min - Max)	2,00 [-7,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	2,96 (6,08)
Median (Min - Max)	2,00 [-7,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	1,00 (6,55)
Median (Min - Max)	0,00 [-6,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	2,83 (8,00)
Median (Min - Max)	0,00 [-7,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,67 (8,66)
Median (Min - Max)	0,00 [-6,00-23,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	4,29 (8,78)
Median (Min - Max)	1,50 [-3,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,00 (5,06)
Median (Min - Max)	-2,00 [-10,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,06 (2,40)
Median (Min - Max)	-0,17 [-4,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS13: FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,40 (4,28)
Median (Min - Max)	0,00 [-6,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,20 (3,35)
Median (Min - Max)	0,00 [-4,00-4,00]
FACT-Lym FWB - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym FWB - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (76,9)
Mean (SD)	-0,72 (6,40)
Median (Min - Max)	-2,00 [-9,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

3.8.14 *Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym FWB	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	90 (97,8)
Mean (SD)	14,95 (6,45)
Median (Min - Max)	15,50 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	86
Treated patients with non-missing values - n(%)	81 (94,2)
Mean (SD)	0,23 (5,26)
Median (Min - Max)	0,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	58 (87,9)
Mean (SD)	0,21 (7,37)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)
Mean (SD)	1,27 (7,62)
Median (Min - Max)	2,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	32 (94,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,53 (7,88)
Median (Min - Max)	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	0,42 (7,35)
Median (Min - Max)	0,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	23 (100,0)
Median (Min - Max)	0,24 (6,88)
	0,00 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	16 (84,2)
Median (Min - Max)	0,56 (7,92)
	-0,50 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	-1,61 (3,31)
	-2,50 [-6,50-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	-1,38 (3,50)
	-1,50 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-1,00 (4,00)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,86 (4,06)
Median (Min - Max)	0,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	2,17 (5,04)
Median (Min - Max)	2,00 [-5,00-8,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-1,50 (5,20)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,96 (3,92)
Median (Min - Max)	-3,00 [-10,83--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (5,57)
Median (Min - Max)	-3,00 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,67 (3,79)
	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,00 (0,00)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	66 (71,7)
Median (Min - Max)	-1,32 (7,22)
	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym FWB	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	15,09 (6,71)
Median (Min - Max)	14,50 [5,00-28,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-0,98 (3,41)
Median (Min - Max)	-1,00 [-9,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,60 (4,01)
Median (Min - Max)	0,50 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	1,39 (5,10)
Median (Min - Max)	1,00 [-3,00-11,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,60 (3,83)
Median (Min - Max)	-0,50 [-3,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,75 (4,65)
Median (Min - Max)	0,00 [-4,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,00 (1,73)
	-1,00 [-1,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,67 (6,43)
	-1,00 [-3,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,00 (3,46)
	-1,00 [-1,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,50 (2,12)
	-2,50 [-4,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS14: FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	19 (86,4)
Median (Min - Max)	-2,37 (4,56)
	-2,00 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

3.8.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym FWB	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	40 (100,0)
Mean (SD)	14,25 (6,64)
Median (Min - Max)	14,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 37
Treated patients with non-missing values - n(%)	35 (94,6)
Mean (SD)	0,57 (6,30)
Median (Min - Max)	1,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 32
Treated patients with non-missing values - n(%)	28 (87,5)
Mean (SD)	-0,31 (7,73)
Median (Min - Max)	-0,50 [-19,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	1,07 (7,36)
Median (Min - Max)	-0,50 [-7,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,18 (7,35)
Median (Min - Max)	1,00 [-9,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	1,36 (8,48)
Median (Min - Max)	-0,50 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	0,46 (7,85)
	-1,00 [-10,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-0,70 (9,49)
	-3,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	10 (100,0)
Median (Min - Max)	-1,40 (3,17)
	-2,00 [-4,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,38 (3,38)
	-3,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,17 (3,43)
Median (Min - Max)	-2,00 [-5,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-0,20 (4,44)
Median (Min - Max)	-1,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,33 (7,20)
Median (Min - Max)	-0,50 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-2,00 (2,83)
Median (Min - Max)	-2,00 [-4,00-0,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,00 (0,00)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,50 (0,71)
	-2,50 [-3,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,00 (0,00)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	29 (72,5)
Median (Min - Max)	-2,48 (6,74)
	-3,00 [-21,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym FWB	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	76 (96,2)
Mean (SD)	15,19 (5,99)
Median (Min - Max)	15,00 [2,00-28,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	68
Mean (SD)	64 (94,1)
Median (Min - Max)	-0,47 (4,06)
	-1,00 [-9,00-14,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	45
Mean (SD)	40 (88,9)
Median (Min - Max)	-0,03 (4,67)
	0,00 [-13,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	34
Mean (SD)	32 (94,1)
Median (Min - Max)	0,44 (5,46)
	1,00 [-14,00-9,17]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	21 (91,3)
Median (Min - Max)	-1,42 (4,51)
	-0,50 [-12,00-5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,23 (5,39)
Median (Min - Max)	0,00 [-9,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	0,27 (4,70)
	1,00 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	1,70 (4,83)
	1,00 [-5,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-0,94 (3,63)
	-1,00 [-6,50-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	0,00 (1,00)
	0,00 [-1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	0,50 [-7,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	2,00 (2,65)
	3,00 [-1,00-4,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	1,50 (3,54)
	1,50 [-1,00-4,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,00 (6,00)
	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,61 (5,59)
	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,00 (7,07)
Median (Min - Max)	-5,00 [-10,00-0,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,00 (4,24)
	-6,00 [-9,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS15: FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	62 (78,5)
Mean (SD)	-1,63 (5,36)
Median (Min - Max)	-1,00 [-15,00-9,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

3.8.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym FWB	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	15,14 (6,57)
Median (Min - Max)	14,00 [5,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-1,29 (3,05)
Median (Min - Max)	-1,00 [-7,00-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-0,11 (3,52)
Median (Min - Max)	-1,00 [-5,00-5,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-0,06 (3,87)
Median (Min - Max)	-1,67 [-3,00-7,83]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,48 (1,53)
Median (Min - Max)	-1,00 [-3,00-0,60]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-1,25 (6,02)
Median (Min - Max)	-2,50 [-7,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,50 (2,12)
	0,50 [-1,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	4,00 (7,07)
	4,00 [-1,00-9,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	2,00 (4,24)
	2,00 [-1,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-2,26 (4,21)
Median (Min - Max)	-3,00 [-8,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym FWB	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	102 (98,1)
Mean (SD)	14,72 (6,34)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	96
Mean (SD)	91 (94,8)
Median (Min - Max)	0,36 (5,00)
	0,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	73
Mean (SD)	65 (89,0)
Median (Min - Max)	0,19 (7,05)
	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	55
Mean (SD)	51 (92,7)
Median (Min - Max)	1,27 (7,36)
	1,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	40
Mean (SD)	38 (95,0)
Median (Min - Max)	0,29 (7,54)
	0,00 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	0,33 (6,82)
Median (Min - Max)	0,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	26 (100,0)
Median (Min - Max)	-0,17 (6,60)
	-0,25 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	0,05 (7,35)
	-2,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	-2,09 (3,62)
	-2,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	-1,73 (3,07)
	-3,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-1,60 (3,86)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,25 (4,13)
Median (Min - Max)	-0,50 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,50 (6,30)
Median (Min - Max)	1,00 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,50 (5,20)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,96 (3,92)
Median (Min - Max)	-3,00 [-10,83--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (5,57)
Median (Min - Max)	-3,00 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,67 (3,79)
	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,00 (0,00)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS16: FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	74 (71,2)
Mean (SD)	-1,55 (6,95)
Median (Min - Max)	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.8.17 *Merkmal: Vorherige CAR-T-Therapie*

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym FWB	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	15,63 (6,46)
Median (Min - Max)	17,00 [3,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	2,83 (11,53)
Median (Min - Max)	0,00 [-9,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	6,00 (12,33)
Median (Min - Max)	2,00 [-4,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	7,25 (11,24)
Median (Min - Max)	2,50 [0,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	9,67 (12,50)
Median (Min - Max)	4,00 [1,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,67 (10,79)
Median (Min - Max)	7,00 [4,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,00 (11,27)
Median (Min - Max)	4,00 [3,00-23,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,67 (11,93)
Median (Min - Max)	7,00 [1,00-24,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	2,83 (11,65)
Median (Min - Max)	0,50 [-11,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym FWB	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	119 (97,5)
Mean (SD)	14,70 (6,33)
Median (Min - Max)	14,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	104 (94,5)
Mean (SD)	0,01 (4,32)
Median (Min - Max)	0,00 [-15,00-14,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	72 (87,8)
Mean (SD)	-0,05 (6,20)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	57 (90,5)
Mean (SD)	0,82 (6,46)
Median (Min - Max)	1,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	42 (91,3)
Mean (SD)	-0,49 (6,14)
Median (Min - Max)	-0,50 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	-0,85 (5,08)
Median (Min - Max)	-1,00 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-1,29 (4,45)
Median (Min - Max)	-0,75 [-12,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-0,93 (4,95)
Median (Min - Max)	-2,00 [-12,00-9,00]
FACT-Lym FWB - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	-1,24 (4,06)
Median (Min - Max)	-1,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	-1,69 (2,91)
Median (Min - Max)	-2,00 [-7,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,27 (4,05)
Median (Min - Max)	-2,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	0,22 (3,99)
Median (Min - Max)	-1,00 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	0,33 (5,92)
Median (Min - Max)	0,00 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,40 (4,51)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,97 (4,05)
Median (Min - Max)	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS17: FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Prior use of T-CART therapy:	
No	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	91 (74,6)
Mean (SD)	-1,94 (5,96)
Median (Min - Max)	-2,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

3.8.18 *Merkmal: Arzneimittelformulierung*

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym FWB	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	14,53 (6,03)
Median (Min - Max)	14,00 [5,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	0,62 (3,77)
Median (Min - Max)	1,00 [-6,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-0,21 (4,02)
Median (Min - Max)	-1,00 [-7,00-7,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,29 (5,51)
Median (Min - Max)	0,00 [-8,00-11,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,05 (4,53)
Median (Min - Max)	0,00 [-7,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,40 (3,36)
Median (Min - Max)	-1,00 [-6,00-3,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,40 (4,04)
Median (Min - Max)	0,00 [-7,00-3,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,50 (2,38)
Median (Min - Max)	-2,50 [-3,00-2,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,33 (3,21)
Median (Min - Max)	1,00 [-4,00-2,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-7,00 (NE)
Median (Min - Max)	-7,00 [-7,00--7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Drug formulation:	
Frozen liquid	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	22 (68,8)
Mean (SD)	-2,45 (4,10)
Median (Min - Max)	-3,50 [-10,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym FWB	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	95 (96,9)
Mean (SD)	14,84 (6,44)
Median (Min - Max)	15,00 [0,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	82 (93,2)
Mean (SD)	0,01 (5,26)
Median (Min - Max)	0,00 [-15,00-25,00]
FACT-Lym FWB - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	57 (87,7)
Mean (SD)	0,43 (7,35)
Median (Min - Max)	0,00 [-19,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	45 (90,0)
Mean (SD)	1,57 (7,38)
Median (Min - Max)	2,00 [-14,00-28,00]
FACT-Lym FWB - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	34 (89,5)
Mean (SD)	0,24 (7,67)
Median (Min - Max)	-0,25 [-12,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FWB - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	0,54 (7,01)
Median (Min - Max)	0,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	0,15 (6,65)
Median (Min - Max)	-0,25 [-12,00-23,00]
FACT-Lym FWB - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	1,13 (7,80)
Median (Min - Max)	0,00 [-12,00-24,00]
FACT-Lym FWB - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-1,50 (4,15)
Median (Min - Max)	-2,00 [-10,00-6,00]
FACT-Lym FWB - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	-1,03 (2,46)
Median (Min - Max)	-1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FWB - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	-1,00 (3,98)
Median (Min - Max)	-1,50 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	0,50 (3,87)
	-0,50 [-5,00-7,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	0,33 (5,92)
	0,00 [-11,00-8,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	-1,40 (4,51)
	-1,00 [-7,00-5,00]
FACT-Lym FWB - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-3,97 (4,05)
	-3,00 [-10,83-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FWB - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,00 (4,97)
Median (Min - Max)	-1,50 [-10,00-1,00]
FACT-Lym FWB - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,25 (3,20)
Median (Min - Max)	-3,00 [-9,00--2,00]
FACT-Lym FWB - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (1,15)
Median (Min - Max)	-3,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,00 (1,41)
Median (Min - Max)	-2,00 [-3,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FWB - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (1,41)
Median (Min - Max)	-1,00 [-2,00-0,00]
FACT-Lym FWB - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym FWB - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FWB - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FWB = functional well being.
 Source Data: aqs, created on: 10JAN2023

Table LT3FFC_PSHS18: FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym FWB - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Drug formulation:	
Lyophilized	
FACT-Lym FWB - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	75 (76,5)
Mean (SD)	-1,41 (7,01)
Median (Min - Max)	-1,00 [-21,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FWB = functional well being.
Source Data: aqs, created on: 10JAN2023

Table LT3FLD_PSTS01: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Age group
 PRO set

3.9 Subgruppenanalysen zum FACT-Lym – Lymphom Subskala (Zeit bis zur Verschlechterung)

3.9.1 Merkmal Alter

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	57
Patients with events - n(%)	7 (12,3)
95%-CI	[5,1-23,7]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [77,2-97,6]
Month 6	78,3 [56,1-90,1]
Month 12	68,5 [39,9-85,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS01: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	12 (22,6)
95%-CI	[12,3-36,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[3,35-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [60,5-89,1]
Month 6	55,2 [30,9-74,0]
Month 12	55,2 [30,9-74,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS01: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	4 (20,0)
95%-CI	[5,7-43,7]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [3,71-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [63,8-97,3]
Month 6	80,5 [48,9-93,6]
Month 12	80,5 [48,9-93,6]
Month 18	53,7 [9,0-85,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS02: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Sex
 PRO set

3.9.2 Merkmal: Geschlecht

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	11 (20,8)
95%-CI	[10,8-34,1]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22 [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [73,8-95,1]
Month 6	72,0 [51,5-85,0]
Month 12	65,5 [42,6-81,1]
Month 18	49,1 [17,4-74,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS02: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	12 (15,6)
95%-CI	[8,3-25,6]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[4,73-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [71,0-92,5]
Month 6	69,1 [49,4-82,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS03: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Race group
 PRO set

3.9.3 *Merkmal: Ethnie*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	21 (18,3)
95%-CI	[11,7-26,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22 [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [76,4-92,1]
Month 6	69,9 [55,3-80,6]
Month 12	64,6 [47,0-77,6]
Month 18	48,4 [18,4-73,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS03: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[2,86-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	75,0 [29,8-93,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS04: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Country
 PRO set

3.9.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	6 (11,8)
95%-CI	[4,4-23,9]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [72,4-96,0]
Month 6	79,2 [57,4-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS04: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[4,17-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [60,0-97,4]
Month 6	64,3 [32,5-84,0]
Month 12	64,3 [32,5-84,0]
Month 18	64,3 [32,5-84,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS04: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	12 (25,0)
95%-CI	[13,6-39,6]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[4,73-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [65,0-91,1]
Month 6	65,9 [43,2-81,3]
Month 12	54,9 [27,4-75,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS05: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Region
 PRO set

3.9.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	6 (11,8)
95%-CI	[4,4-23,9]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [72,4-96,0]
Month 6	79,2 [57,4-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS05: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	17 (21,5)
95%-CI	[13,1-32,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[4,73-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [72,5-92,1]
Month 6	65,5 [47,5-78,7]
Month 12	58,3 [36,8-74,7]
Month 18	43,7 [16,1-68,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS06: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage
 PRO set

3.9.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	4,73[2,83-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	25,7 [1,3-65,6]
Month 12	25,7 [1,3-65,6]
Month 18	25,7 [1,3-65,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS06: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	5 (23,8)
95%-CI	[8,2-47,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22 [3,71-12,22]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,9 [53,8-93,8]
Month 6	68,3 [31,4-88,2]
Month 12	68,3 [31,4-88,2]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS06: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	4 (23,5)
95%-CI	[6,8-49,9]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	6,90 [2,86-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [45,1-95,5]
Month 6	68,8 [28,8-89,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS06: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	10 (12,2)
95%-CI	[6,0-21,3]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[NE-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [77,7-95,0]
Month 6	79,8 [63,8-89,3]
Month 12	79,8 [63,8-89,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS07: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Bulky disease
 PRO set

3.9.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	23 (18,3)
95%-CI	[11,9-26,1]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22 [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [77,2-92,0]
Month 6	70,5 [57,1-80,4]
Month 12	65,8 [49,8-77,8]
Month 18	49,3 [19,0-74,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS08: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Double/Triple hit
 PRO set

3.9.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	2 (14,3)
95%-CI	[1,8-42,8]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [1,41-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	72,0 [23,8-92,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS08: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	21 (18,1)
95%-CI	[11,6-26,3]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [76,0-92,0]
Month 6	70,2 [55,8-80,7]
Month 12	64,8 [47,4-77,8]
Month 18	48,6 [18,5-73,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS09: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Transformed DLBCL
 PRO set

3.9.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [4,24-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	59,3 [24,3-82,4]
Month 12	59,3 [24,3-82,4]
Month 18	59,3 [24,3-82,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS09: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	18 (17,0)
95%-CI	[10,4-25,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [74,4-91,8]
Month 6	73,2 [58,7-83,3]
Month 12	67,5 [49,5-80,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS10: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: B-Cell type
 PRO set

3.9.10 *Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	10 (23,3)
95%-CI	[11,8-38,6]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[4,24-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [69,9-95,3]
Month 6	69,1 [46,3-83,7]
Month 12	60,4 [34,5-78,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS10: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[3,32-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [59,4-96,9]
Month 6	77,0 [41,4-92,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS11: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter
 PRO set

3.9.11 *Merkmal: Maximaler längster Durchmesser*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	13 (17,1)
95%-CI	[9,4-27,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [71,7-91,9]
Month 6	77,5 [61,3-87,6]
Month 12	70,5 [48,9-84,3]
Month 18	52,9 [18,6-78,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS11: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	8 (23,5)
95%-CI	[10,7-41,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[3,65-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [74,7-98,2]
Month 6	55,8 [29,8-75,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS11: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS11: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS12: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Primary disease diagnosis
 PRO set

3.9.12 *Merkmal: Primärdiagnose*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	21 (18,8)
95%-CI	[12,0-27,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22 [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [75,9-91,9]
Month 6	70,2 [55,8-80,6]
Month 12	64,8 [47,3-77,7]
Month 18	48,6 [18,5-73,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS12: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[1,41-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	70,0 [22,5-91,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS13: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Number prior lines
 PRO set

3.9.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[4,24-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [69,8-92,8]
Month 6	66,3 [44,7-81,0]
Month 12	56,8 [31,1-76,0]
Month 18	42,6 [14,4-68,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS13: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	4 (12,5)
95%-CI	[3,5-29,0]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[3,71-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [75,4-98,3]
Month 6	74,6 [41,1-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS13: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	6 (15,4)
95%-CI	[5,9-30,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[4,73-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [63,9-94,1]
Month 6	73,4 [48,6-87,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS14: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - first line
 PRO set

3.9.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	16 (17,4)
95%-CI	[10,3-26,7]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [73,0-91,8]
Month 6	69,9 [53,1-81,6]
Month 12	62,1 [40,3-77,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS14: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	4 (18,2)
95%-CI	[5,2-40,3]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [3,65-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [64,8-97,3]
Month 6	67,3 [31,2-87,4]
Month 12	67,3 [31,2-87,4]
Month 18	67,3 [31,2-87,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS15: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - last line
 PRO set

3.9.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	10 (25,0)
95%-CI	[12,7-41,2]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[4,24-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,3 [55,9-88,2]
Month 6	64,6 [41,1-80,7]
Month 12	64,6 [41,1-80,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS15: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	11 (13,9)
95%-CI	[7,2-23,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [81,9-96,1]
Month 6	73,9 [55,6-85,6]
Month 12	73,9 [55,6-85,6]
Month 18	73,9 [55,6-85,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS16: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - any line
 PRO set

3.9.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE [3,65-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [64,1-97,3]
Month 6	67,1 [31,1-87,3]
Month 12	67,1 [31,1-87,3]
Month 18	67,1 [31,1-87,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS16: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	18 (17,3)
95%-CI	[10,6-26,0]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [75,7-92,7]
Month 6	71,2 [55,7-82,0]
Month 12	65,2 [46,4-78,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS17: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Prior use of T-CART therapy
PRO set

3.9.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS17: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	22 (18,0)
95%-CI	[11,7-26,0]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	12,22[6,90-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [77,2-92,4]
Month 6	69,6 [55,4-80,0]
Month 12	64,6 [47,8-77,2]
Month 18	48,4 [18,6-73,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS18: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Drug formulation
 PRO set

3.9.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	5 (15,6)
95%-CI	[5,3-32,8]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	6,90 [3,65-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [61,8-97,2]
Month 6	68,6 [33,5-87,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLD_PSTS18: Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym lymphoma scale by at least 10 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	18 (18,4)
95%-CI	[11,3-27,5]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points in months [95%-CI]	
Median	NE[12,22-NE]
FACT-Lym lymphoma scale - Time to decrease by at least 10 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [75,1-91,9]
Month 6	70,9 [56,0-81,5]
Month 12	70,9 [56,0-81,5]
Month 18	53,1 [19,9-78,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

3.10 Subgruppenanalysen zum FACT-Lym – Lymphom Subskala (Veränderung gegenüber Studienbeginn)

3.10.1 Merkmal Alter

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	57
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	56 (98,2)
Mean (SD)	40,13 (11,13)
Median (Min - Max)	41,00 [11,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	47 (95,9)
Mean (SD)	2,00 (6,89)
Median (Min - Max)	1,00 [-7,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	33 (89,2)
Mean (SD)	1,65 (8,34)
Median (Min - Max)	0,00 [-14,31-25,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	3,23 (10,08)
Median (Min - Max)	2,00 [-9,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	2,21 (8,66)
Median (Min - Max)	1,50 [-12,08-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	2,94 (11,86)
Median (Min - Max)	1,79 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	3,07 (10,43)
Median (Min - Max)	1,00 [-11,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	5,08 (11,16)
Median (Min - Max)	2,00 [-8,74-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	4,71 (9,29)
Median (Min - Max)	2,50 [-8,57-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,90 (11,83)
Median (Min - Max)	2,50 [-3,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	13,43 (17,69)
Median (Min - Max)	8,00 [-1,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	12,00 (13,24)
Median (Min - Max)	7,50 [2,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	19,50 (24,75)
Median (Min - Max)	19,50 [2,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	15,88 (25,29)
Median (Min - Max)	15,88 [-2,00-33,77]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	43 (75,4)
Mean (SD)	0,18 (8,99)
Median (Min - Max)	-1,71 [-13,64-26,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	52 (98,1)
Mean (SD)	46,97 (8,19)
Median (Min - Max)	48,50 [24,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	45 (93,8)
Mean (SD)	-0,70 (5,99)
Median (Min - Max)	-0,36 [-21,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	31 (91,2)
Mean (SD)	-1,39 (7,36)
Median (Min - Max)	1,00 [-20,00-15,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-0,97 (6,72)
Median (Min - Max)	0,00 [-19,00-14,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-3,31 (7,33)
Median (Min - Max)	-1,00 [-22,00-10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,76 (6,07)
Median (Min - Max)	0,00 [-15,00-7,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-4,42 (12,42)
Median (Min - Max)	-0,50 [-32,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-0,64 (8,91)
Median (Min - Max)	0,00 [-16,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-2,91 (8,85)
Median (Min - Max)	-0,18 [-16,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-2,00 (13,13)
Median (Min - Max)	1,00 [-18,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,86 (9,25)
Median (Min - Max)	-4,32 [-10,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	0,20 (7,98)
	0,00 [-11,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-2,23 (8,61)
	-4,82 [-9,29-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-9,90 (6,40)
	-12,36 [-14,71--2,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-7,45 (7,19)
	-8,00 [-14,36-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-11,71 (9,28)
Median (Min - Max)	-17,00 [-17,14--1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-10,51 (7,24)
Median (Min - Max)	-12,00 [-16,90--2,64]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,00 (8,49)
Median (Min - Max)	-8,00 [-14,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,50 (NE)
Median (Min - Max)	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	42 (79,2)
Mean (SD)	-2,93 (9,01)
Median (Min - Max)	-2,00 [-20,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	42,95 (10,49)
Median (Min - Max)	45,50 [13,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	2,34 (9,52)
Median (Min - Max)	1,00 [-18,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	6,63 (10,51)
Median (Min - Max)	2,50 [-2,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	8 (61,5)
Mean (SD)	8,38 (6,97)
Median (Min - Max)	10,00 [-1,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	1,88 (9,03)
Median (Min - Max)	-1,00 [-4,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	1,79 (10,21)
Median (Min - Max)	-2,00 [-4,71-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,02 (10,04)
Median (Min - Max)	2,00 [-1,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	6,00 (9,42)
Median (Min - Max)	2,00 [0,00-20,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	7,25 (8,18)
Median (Min - Max)	5,00 [0,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,00 (1,41)
Median (Min - Max)	2,00 [1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: >= 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,82 (1,67)
Median (Min - Max)	1,82 [0,64-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (18,03)
Median (Min - Max)	1,00 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,71 (NE)
Median (Min - Max)	1,71 [1,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS01: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-0,08 (9,06)
Median (Min - Max)	1,00 [-13,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

3.10.2 Merkmal: Geschlecht

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	52 (98,1)
Mean (SD)	41,81 (11,62)
Median (Min - Max)	43,50 [13,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	42 (91,3)
Mean (SD)	2,60 (8,19)
Median (Min - Max)	1,00 [-11,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	2,46 (10,64)
Median (Min - Max)	1,00 [-16,69-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	22 (78,6)
Mean (SD)	3,89 (11,18)
Median (Min - Max)	1,50 [-13,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,19 (10,63)
Median (Min - Max)	-0,75 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	1,52 (10,05)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	0,25 (12,34)
Median (Min - Max)	1,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	3,04 (11,11)
Median (Min - Max)	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	1,77 (10,68)
Median (Min - Max)	1,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	1,00 (12,24)
Median (Min - Max)	1,50 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	2,72 (13,80)
Median (Min - Max)	-0,18 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	3,50 (12,18)
Median (Min - Max)	1,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,01 (17,75)
Median (Min - Max)	-0,82 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,63 (17,44)
Median (Min - Max)	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,27 (7,69)
Median (Min - Max)	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	42 (79,2)
Mean (SD)	-0,78 (9,37)
Median (Min - Max)	-1,57 [-16,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	76 (98,7)
Mean (SD)	44,40 (9,30)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	68 (97,1)
Mean (SD)	-0,07 (6,21)
Median (Min - Max)	0,00 [-21,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	44 (88,0)
Mean (SD)	0,47 (7,00)
Median (Min - Max)	1,00 [-20,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	1,05 (7,10)
Median (Min - Max)	0,00 [-19,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	0,12 (6,31)
Median (Min - Max)	-1,00 [-12,08-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	0,68 (10,09)
Median (Min - Max)	0,50 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	2,43 (10,07)
Median (Min - Max)	0,50 [-11,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	3,99 (9,18)
Median (Min - Max)	2,00 [-8,74-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,12 (6,67)
Median (Min - Max)	5,00 [-8,57-9,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,46 (7,33)
Median (Min - Max)	14,38 [2,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS02: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,50 (0,71)
Median (Min - Max)	12,50 [12,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,50 (0,71)
Median (Min - Max)	10,50 [10,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	56 (72,7)
Mean (SD)	-1,50 (8,86)
Median (Min - Max)	-1,86 [-20,00-16,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

3.10.3 *Merkmal: Ethnie*

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	113 (98,3)
Mean (SD)	43,63 (10,14)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	98 (94,2)
Mean (SD)	0,66 (6,97)
Median (Min - Max)	0,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	66 (89,2)
Mean (SD)	0,66 (8,65)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	50 (89,3)
Mean (SD)	1,81 (8,78)
Median (Min - Max)	0,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	39 (95,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,22 (8,30)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	0,20 (9,70)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	24 (100,0)
Median (Min - Max)	-0,25 (11,09)
	0,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	2,18 (9,77)
	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	19 (100,0)
Median (Min - Max)	1,81 (9,62)
	1,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	2,20 (11,72)
	2,00 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	3,56 (13,39)
Median (Min - Max)	0,64 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	4,33 (11,66)
	2,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	1,01 (17,75)
	-0,82 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	0,63 (17,44)
	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-3,27 (7,69)
	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,9)
Mean (SD)	-1,62 (8,95)
Median (Min - Max)	-2,00 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	41,20 (11,94)
Median (Min - Max)	40,00 [15,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	3,33 (8,14)
Median (Min - Max)	0,00 [-7,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	5,08 (8,83)
Median (Min - Max)	2,00 [-5,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	3,50 (9,42)
Median (Min - Max)	3,00 [-9,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	1,99 (9,86)
Median (Min - Max)	-1,00 [-12,08-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,50 (10,60)
Median (Min - Max)	4,00 [-8,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	7,00 (12,67)
	8,00 [-11,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	11,33 (10,60)
	13,00 [0,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	9,00 (NE)
	9,00 [9,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	13,00 (NE)
Median (Min - Max)	13,00 [13,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	10,00 (NE)
	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	10,00 (NE)
	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	13 (86,7)
Median (Min - Max)	1,64 (9,50)
	1,00 [-13,64-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

3.10.4 Merkmal: Region-1

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	51 (100,0)
Mean (SD)	41,02 (10,94)
Median (Min - Max)	42,00 [11,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	44 (97,8)
Mean (SD)	2,20 (8,29)
Median (Min - Max)	1,00 [-11,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	3,18 (8,35)
Median (Min - Max)	1,00 [-12,00-25,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	4,56 (10,70)
Median (Min - Max)	3,00 [-13,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,22 (10,83)
Median (Min - Max)	-0,50 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	3,33 (11,68)
Median (Min - Max)	1,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	4,28 (15,51)
Median (Min - Max)	6,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	7,44 (12,99)
Median (Min - Max)	6,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,38 (13,00)
Median (Min - Max)	7,14 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	8,90 (13,91)
Median (Min - Max)	9,19 [-12,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,12 (16,51)
Median (Min - Max)	10,00 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	8,33 (13,62)
Median (Min - Max)	7,50 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,57 (23,25)
Median (Min - Max)	10,00 [-9,29-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	33,77 (NE)
Median (Min - Max)	33,77 [33,77-33,77]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	1,14 (9,61)
Median (Min - Max)	1,00 [-17,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	45,02 (9,97)
Median (Min - Max)	47,00 [25,71-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	21 (87,5)
Mean (SD)	-1,57 (5,63)
Median (Min - Max)	-1,00 [-21,00-8,29]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-1,18 (5,24)
Median (Min - Max)	-1,00 [-8,00-12,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,71 (7,57)
Median (Min - Max)	0,00 [-15,00-15,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-1,45 (6,12)
Median (Min - Max)	-0,29 [-12,08-10,05]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-4,21 (3,33)
Median (Min - Max)	-4,71 [-8,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-3,80 (7,28)
Median (Min - Max)	-3,32 [-12,16-7,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-1,12 (3,67)
Median (Min - Max)	1,00 [-5,36-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,70 (6,33)
Median (Min - Max)	0,00 [-9,91-5,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,64 (NE)
Median (Min - Max)	0,64 [0,64-0,64]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,00 (7,07)
Median (Min - Max)	6,00 [1,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,71 (NE)
Median (Min - Max)	1,71 [1,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	-1,96 (8,31)
Median (Min - Max)	-1,36 [-16,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	46 (95,8)
Mean (SD)	44,82 (9,74)
Median (Min - Max)	48,00 [13,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	44 (95,7)
Mean (SD)	0,83 (6,31)
Median (Min - Max)	0,79 [-18,00-14,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	34 (94,4)
Mean (SD)	0,52 (10,03)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,81 (6,60)
Median (Min - Max)	0,00 [-19,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-0,12 (7,47)
Median (Min - Max)	-1,00 [-11,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,51 (8,70)
Median (Min - Max)	1,21 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	0,39 (8,28)
Median (Min - Max)	0,50 [-11,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	1,18 (7,64)
Median (Min - Max)	0,50 [-8,74-20,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,74 (8,11)
Median (Min - Max)	2,00 [-12,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-2,17 (8,04)
Median (Min - Max)	1,50 [-18,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,83 (5,18)
Median (Min - Max)	-2,64 [-7,50-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-0,33 (2,52)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-7,91 (11,34)
Median (Min - Max)	-4,82 [-24,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-7,93 (6,55)
Median (Min - Max)	-7,50 [-14,71--2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,59 (8,20)
Median (Min - Max)	-4,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-11,71 (9,28)
Median (Min - Max)	-17,00 [-17,14--1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-10,51 (7,24)
Median (Min - Max)	-12,00 [-16,90--2,64]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,00 (8,49)
Median (Min - Max)	-8,00 [-14,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,50 (NE)
Median (Min - Max)	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS04: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (75,0)
Mean (SD)	-2,98 (8,88)
Median (Min - Max)	-5,00 [-20,00-15,07]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

3.10.5 *Merkmal: Region-2*

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	51 (100,0)
Mean (SD)	41,02 (10,94)
Median (Min - Max)	42,00 [11,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	44 (97,8)
Mean (SD)	2,20 (8,29)
Median (Min - Max)	1,00 [-11,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	3,18 (8,35)
Median (Min - Max)	1,00 [-12,00-25,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	4,56 (10,70)
Median (Min - Max)	3,00 [-13,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,22 (10,83)
Median (Min - Max)	-0,50 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	3,33 (11,68)
Median (Min - Max)	1,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	4,28 (15,51)
Median (Min - Max)	6,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	7,44 (12,99)
Median (Min - Max)	6,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,38 (13,00)
Median (Min - Max)	7,14 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	8,90 (13,91)
Median (Min - Max)	9,19 [-12,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,12 (16,51)
Median (Min - Max)	10,00 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	8,33 (13,62)
Median (Min - Max)	7,50 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,57 (23,25)
Median (Min - Max)	10,00 [-9,29-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	33,77 (NE)
Median (Min - Max)	33,77 [33,77-33,77]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	1,14 (9,61)
Median (Min - Max)	1,00 [-17,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	77 (97,5)
Mean (SD)	44,89 (9,69)
Median (Min - Max)	48,00 [13,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	66 (93,0)
Mean (SD)	0,12 (6,13)
Median (Min - Max)	0,00 [-21,00-14,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	47 (88,7)
Mean (SD)	0,12 (8,91)
Median (Min - Max)	0,86 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	35 (87,5)
Mean (SD)	0,33 (6,84)
Median (Min - Max)	0,00 [-19,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	-0,51 (6,82)
Median (Min - Max)	-1,00 [-12,08-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,88 (7,73)
Median (Min - Max)	0,00 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,01 (8,01)
Median (Min - Max)	-0,46 [-12,16-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	0,65 (6,86)
Median (Min - Max)	1,00 [-8,74-20,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	0,80 (7,75)
Median (Min - Max)	0,50 [-12,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-1,71 (7,43)
Median (Min - Max)	1,00 [-18,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,42 (4,75)
Median (Min - Max)	-1,00 [-7,50-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	4 (57,1)
Median (Min - Max)	-0,25 (2,06)
	0,00 [-3,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	-3,27 (11,78)
	-0,82 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	-6,00 (7,13)
	-2,64 [-14,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-3,27 (7,69)
	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS05: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	62 (78,5)
Mean (SD)	-2,54 (8,48)
Median (Min - Max)	-3,00 [-20,00-15,07]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.10.6 Merkmal: Krankheitsstadium nach Ann-Arbor

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	44,78 (9,94)
Median (Min - Max)	46,50 [28,93-55,91]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	2,86 (4,53)
Median (Min - Max)	1,89 [-3,00-10,07]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,42 (7,20)
Median (Min - Max)	1,00 [-7,91-12,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,75 (4,71)
Median (Min - Max)	-2,49 [-4,00-6,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-6,23 (6,44)
Median (Min - Max)	-5,45 [-14,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,78 (0,97)
Median (Min - Max)	-6,00 [-6,62--4,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-7,36 (5,79)
Median (Min - Max)	-9,00 [-12,16--0,92]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-7,50 (12,02)
Median (Min - Max)	-7,50 [-16,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-8,64 (8,08)
Median (Min - Max)	-9,91 [-16,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,50 (9,19)
Median (Min - Max)	-5,50 [-12,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,68 (7,53)
Median (Min - Max)	-4,68 [-10,00-0,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,50 (7,78)
Median (Min - Max)	-5,50 [-11,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,14 (7,27)
Median (Min - Max)	-4,14 [-9,29-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,71 (NE)
Median (Min - Max)	1,71 [1,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	-2,12 (12,45)
Median (Min - Max)	1,00 [-17,00-15,07]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	42,66 (10,06)
Median (Min - Max)	47,00 [24,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	2,51 (9,08)
Median (Min - Max)	0,50 [-8,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	-1,48 (11,02)
Median (Min - Max)	-0,07 [-20,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,03 (9,10)
Median (Min - Max)	0,00 [-19,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,63 (6,80)
Median (Min - Max)	-1,36 [-7,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-1,49 (13,86)
Median (Min - Max)	-1,96 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	3,94 (11,14)
Median (Min - Max)	1,00 [-6,31-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,41 (11,27)
Median (Min - Max)	0,00 [-8,74-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,55 (2,71)
Median (Min - Max)	3,00 [-0,36-5,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (7,42)
Median (Min - Max)	-2,25 [-7,50-3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-24,00 (NE)
Median (Min - Max)	-24,00 [-24,00--24,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,36 (NE)
Median (Min - Max)	-12,36 [-12,36--12,36]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-14,36 (NE)
Median (Min - Max)	-14,36 [-14,36--14,36]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 16 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-17,14 (NE)
Median (Min - Max)	-17,14 [-17,14--17,14]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-16,90 (NE)
Median (Min - Max)	-16,90 [-16,90--16,90]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	16 (76,2)
Mean (SD)	-1,35 (9,27)
Median (Min - Max)	-1,07 [-20,00-14,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	45,73 (7,63)
Median (Min - Max)	47,00 [30,00-56,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-2,00 (2,61)
Median (Min - Max)	-2,00 [-6,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	-2,11 (5,28)
Median (Min - Max)	-1,00 [-8,00-7,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,33 (6,98)
Median (Min - Max)	0,00 [-9,00-15,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	-1,87 (6,22)
Median (Min - Max)	-1,00 [-12,08-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-1,00 (8,72)
Median (Min - Max)	-3,00 [-8,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,20 (6,53)
Median (Min - Max)	0,00 [-11,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,00 (2,65)
Median (Min - Max)	2,00 [1,00-6,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	10 (58,8)
Median (Min - Max)	-3,66 (9,11)
	-5,00 [-13,64-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	82 (100,0)
Mean (SD)	42,91 (10,96)
Median (Min - Max)	45,50 [11,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	69 (95,8)
Mean (SD)	0,83 (7,21)
Median (Min - Max)	1,00 [-21,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	52 (96,3)
Mean (SD)	2,58 (8,71)
Median (Min - Max)	2,00 [-16,69-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	37 (88,1)
Mean (SD)	3,38 (9,48)
Median (Min - Max)	2,00 [-15,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	1,89 (9,45)
Median (Min - Max)	0,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 6 Day 1 22
Treated patients with non-missing values - n(%)	20 (90,9)
Mean (SD)	3,43 (9,32)
Median (Min - Max)	1,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1 16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	2,65 (13,18)
Median (Min - Max)	1,50 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1 14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	5,78 (10,37)
Median (Min - Max)	2,50 [-5,36-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1 12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	5,06 (10,05)
Median (Min - Max)	5,50 [-12,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1 10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	5,15 (13,19)
Median (Min - Max)	2,00 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	9,58 (14,67)
	8,00 [-6,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	8,00 (11,34)
	5,00 [-3,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	8,39 (15,67)
	6,00 [-7,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	3,60 (20,94)
	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,33 (6,11)
	0,00 [-8,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-9,00 (11,31)
	-9,00 [-17,00--1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-7,32 (6,62)
	-7,32 [-12,00--2,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,00 (8,49)
	-8,00 [-14,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,50 (NE)
	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS06: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,00 (NE)
	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	65 (79,3)
Median (Min - Max)	-0,67 (8,73)
	-2,00 [-17,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS07: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease
 PRO set

3.10.7 *Merkmal: Bulky Erkrankung*

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	124 (98,4)
Mean (SD)	43,40 (10,45)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	107 (94,7)
Mean (SD)	0,98 (7,18)
Median (Min - Max)	0,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	78 (91,8)
Mean (SD)	1,34 (8,76)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	59 (89,4)
Mean (SD)	2,18 (8,88)
Median (Min - Max)	1,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	47 (95,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS07: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,16 (8,51)
Median (Min - Max)	-1,00 [-22,00-24,00]

Table LT3FLC_PSHS07: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	33 (91,7)
Mean (SD)	1,16 (9,92)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	1,00 (11,47)
Median (Min - Max)	1,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	3,43 (10,14)
Median (Min - Max)	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	2,17 (9,50)
Median (Min - Max)	1,50 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	3,18 (11,77)
Median (Min - Max)	2,00 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS07: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	4,35 (13,05)
Median (Min - Max)	1,82 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	4,90 (11,14)
Median (Min - Max)	3,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	2,01 (16,87)
Median (Min - Max)	1,00 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,63 (17,44)
Median (Min - Max)	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,27 (7,69)
Median (Min - Max)	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS07: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Bulky disease:

No

FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]

FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]

FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]

FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]

FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Table LT3FLC_PSHS07: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	97 (77,0)
Mean (SD)	-1,15 (9,08)
Median (Min - Max)	-1,71 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.10.8 *Merkmal: Double/Triple-Hit*

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	39,21 (10,72)
Median (Min - Max)	37,00 [17,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	3,35 (7,76)
Median (Min - Max)	2,50 [-7,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	7,71 (10,28)
Median (Min - Max)	3,82 [-1,00-25,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	14,50 (14,68)
Median (Min - Max)	12,50 [-1,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	5,40 (11,74)
Median (Min - Max)	-1,00 [-4,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	9,31 (13,88)
Median (Min - Max)	7,63 [-4,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,69 (13,06)
Median (Min - Max)	8,29 [-1,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,67 (14,84)
Median (Min - Max)	9,00 [0,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,14 (11,11)
Median (Min - Max)	16,14 [8,29-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	21,69 (10,33)
Median (Min - Max)	21,69 [14,38-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	25,36 (18,89)
Median (Min - Max)	25,36 [12,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	21,00 (14,14)
Median (Min - Max)	21,00 [11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	37,00 (NE)
Median (Min - Max)	37,00 [37,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	33,77 (NE)
Median (Min - Max)	33,77 [33,77-33,77]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	0,79 (14,09)
Median (Min - Max)	-2,00 [-17,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	114 (98,3)
Mean (SD)	43,85 (10,23)
Median (Min - Max)	47,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	98 (94,2)
Mean (SD)	0,66 (7,02)
Median (Min - Max)	0,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	70 (89,7)
Mean (SD)	0,61 (8,35)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	54 (90,0)
Mean (SD)	0,71 (6,87)
Median (Min - Max)	0,00 [-19,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	42 (97,7)
Mean (SD)	-0,47 (8,00)
Median (Min - Max)	-0,79 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	0,04 (9,00)
Median (Min - Max)	0,00 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	-0,12 (11,01)
Median (Min - Max)	0,50 [-32,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	1,97 (8,89)
Median (Min - Max)	1,00 [-16,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	0,62 (8,25)
Median (Min - Max)	1,00 [-16,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,18 (8,64)
Median (Min - Max)	2,00 [-18,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,15 (7,14)
Median (Min - Max)	-0,18 [-10,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	0,88 (6,20)
	1,00 [-11,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,37 (11,34)
	-0,82 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	-6,00 (7,13)
	-2,64 [-14,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-3,27 (7,69)
	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS08: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	89 (76,7)
Mean (SD)	-1,39 (8,46)
Median (Min - Max)	-1,71 [-20,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.10.9 *Merkmal: Transformation des DLBCL*

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	43,84 (9,69)
Median (Min - Max)	48,00 [24,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	-0,77 (8,53)
Median (Min - Max)	1,00 [-21,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-0,42 (7,59)
Median (Min - Max)	0,93 [-16,69-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	1,45 (8,17)
Median (Min - Max)	2,00 [-15,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,50 (6,55)
Median (Min - Max)	-1,00 [-11,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	4,06 (10,36)
Median (Min - Max)	1,00 [-4,71-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	3,02 (12,40)
Median (Min - Max)	1,00 [-11,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	6,25 (9,84)
Median (Min - Max)	1,50 [1,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,33 (7,57)
Median (Min - Max)	0,00 [-12,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (11,27)
Median (Min - Max)	1,00 [-18,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,45 (5,09)
Median (Min - Max)	0,64 [-6,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,33 (2,52)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,33 (4,93)
Median (Min - Max)	1,00 [-7,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (8,62)
Median (Min - Max)	-2,00 [-14,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,67 (6,43)
Median (Min - Max)	2,00 [-8,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-7,00 (14,14)
Median (Min - Max)	-7,00 [-17,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,00 (11,31)
Median (Min - Max)	-4,00 [-12,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,50 (10,61)
Median (Min - Max)	-6,50 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	20 (83,3)
Median (Min - Max)	-1,89 (8,01)
	-1,07 [-17,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	104 (98,1)
Mean (SD)	43,23 (10,53)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	89 (93,7)
Mean (SD)	1,35 (6,73)
Median (Min - Max)	0,00 [-18,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	62 (88,6)
Mean (SD)	1,79 (9,04)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	49 (90,7)
Mean (SD)	2,24 (9,05)
Median (Min - Max)	0,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	37 (94,9)
Mean (SD)	0,33 (9,03)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	0,65 (9,94)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	24 (100,0)
Median (Min - Max)	0,58 (11,51)
	0,50 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	18 (90,0)
Median (Min - Max)	2,80 (10,38)
	0,50 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	3,14 (9,66)
	3,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	5,64 (11,29)
	3,00 [-12,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	5,95 (14,71)
Median (Min - Max)	3,00 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	7 (70,0)
Median (Min - Max)	7,14 (12,82)
	5,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	3,68 (20,87)
	3,68 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	6,26 (24,32)
	-2,64 [-12,36-33,77]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-7,18 (10,15)
	-7,18 [-14,36-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-9,07 (11,41)
Median (Min - Max)	-9,07 [-17,14--1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-9,77 (10,08)
Median (Min - Max)	-9,77 [-16,90--2,64]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,50 (NE)
Median (Min - Max)	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS09: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	78 (73,6)
Median (Min - Max)	-1,01 (9,33)
	-2,00 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

3.10.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	44,90 (9,61)
Median (Min - Max)	47,00 [25,71-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	-0,04 (5,96)
Median (Min - Max)	-1,00 [-7,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	0,77 (6,31)
Median (Min - Max)	1,00 [-8,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	24 (88,9)
Mean (SD)	0,93 (6,69)
Median (Min - Max)	0,00 [-9,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,72 (7,43)
Median (Min - Max)	-1,00 [-14,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 Loncastuximab tesirine
 Data-cut 3

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	1,22 (8,04)
Median (Min - Max)	1,00 [-8,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,65 (9,64)
	1,50 [-12,16-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	2,36 (9,93)
	1,00 [-16,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-1,44 (8,88)
	2,00 [-16,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	2,25 (11,06)
	3,00 [-12,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,25 (9,54)
Median (Min - Max)	1,00 [-10,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	1,00 (10,82)
	4,00 [-11,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-3,07 (16,79)
	0,36 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	35 (81,4)
Median (Min - Max)	-1,60 (8,22)
	-1,71 [-17,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	45,64 (7,67)
Median (Min - Max)	47,00 [29,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	0,75 (4,39)
Median (Min - Max)	0,00 [-8,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-0,09 (9,71)
Median (Min - Max)	1,00 [-20,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-0,21 (8,36)
Median (Min - Max)	0,00 [-19,00-15,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,33 (3,24)
Median (Min - Max)	-0,57 [-5,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 Loncastuximab tesirine
 Data-cut 3

B-cell type:	
Activated B-cell	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,38 (3,93)
Median (Min - Max)	-0,50 [-5,36-4,07]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,67 (3,79)
Median (Min - Max)	0,00 [-1,00-6,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,93 (4,48)
Median (Min - Max)	4,00 [-3,21-5,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	4,21 (3,99)
Median (Min - Max)	6,00 [-0,36-7,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	3,00 (1,41)
Median (Min - Max)	3,00 [2,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (10,96)
Median (Min - Max)	0,25 [-7,50-8,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-12,36 (NE)
	-12,36 [-12,36--12,36]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-14,36 (NE)
	-14,36 [-14,36--14,36]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-17,14 (NE)
	-17,14 [-17,14--17,14]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS10: FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-16,90 (NE)
Median (Min - Max)	-16,90 [-16,90--16,90]
FACT-Lym lymphoma scale - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	16 (76,2)
Mean (SD)	-2,55 (9,57)
Median (Min - Max)	-2,00 [-20,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.10.11 Merkmal: Maximaler längster Durchmesser

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	76
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	74 (97,4)
Mean (SD)	44,05 (10,07)
Median (Min - Max)	47,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	64 (92,8)
Mean (SD)	1,58 (7,01)
Median (Min - Max)	1,00 [-11,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	51 (89,5)
Mean (SD)	0,95 (8,67)
Median (Min - Max)	1,00 [-20,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	39 (90,7)
Mean (SD)	2,32 (7,79)
Median (Min - Max)	2,00 [-19,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,62 (6,94)
Median (Min - Max)	-0,50 [-22,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	23 (92,0)
Mean (SD)	-0,58 (8,97)
Median (Min - Max)	0,00 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	-0,33 (10,50)
Median (Min - Max)	0,00 [-32,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	2,67 (7,09)
Median (Min - Max)	1,00 [-8,74-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	1,99 (5,38)
Median (Min - Max)	1,00 [-12,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	2,04 (9,14)
Median (Min - Max)	2,00 [-18,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	1,72 (7,18)
Median (Min - Max)	0,64 [-7,50-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	3,43 (5,29)
Median (Min - Max)	2,00 [-3,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-1,38 (11,87)
Median (Min - Max)	1,00 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-6,00 (7,13)
Median (Min - Max)	-2,64 [-14,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,27 (7,69)
Median (Min - Max)	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	57 (75,0)
Mean (SD)	-0,80 (9,29)
Median (Min - Max)	0,00 [-20,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	42,60 (11,35)
Median (Min - Max)	46,00 [13,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	31 (96,9)
Mean (SD)	-0,15 (6,34)
Median (Min - Max)	-1,00 [-18,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	1,65 (9,54)
Median (Min - Max)	1,50 [-8,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	1,30 (4,55)
Median (Min - Max)	0,50 [-4,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	2,78 (9,74)
Median (Min - Max)	-0,57 [-8,91-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: >5 - <= 7,5 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	4,68 (9,55)
Median (Min - Max)	3,00 [-6,62-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,35 (12,19)
Median (Min - Max)	3,50 [-12,16-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	4,91 (10,91)
Median (Min - Max)	2,50 [-5,36-20,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,90 (11,83)
Median (Min - Max)	3,00 [-9,91-19,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	8,00 (NE)
Median (Min - Max)	8,00 [8,00-8,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-3,13 (8,30)
Median (Min - Max)	-3,50 [-17,00-15,07]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	42,02 (7,87)
Median (Min - Max)	45,00 [28,00-52,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	-2,59 (10,09)
Median (Min - Max)	-4,00 [-21,00-8,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,19 (2,24)
Median (Min - Max)	0,86 [-2,93-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,75 (7,50)
Median (Min - Max)	-3,50 [-15,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-9,50 (6,36)
Median (Min - Max)	-9,50 [-14,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-9,00 (NE)
Median (Min - Max)	-9,00 [-9,00--9,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-16,00 (NE)
Median (Min - Max)	-16,00 [-16,00--16,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-16,00 (NE)
Median (Min - Max)	-16,00 [-16,00--16,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,00 (NE)
Median (Min - Max)	-12,00 [-12,00--12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-11,00 (NE)
Median (Min - Max)	-11,00 [-11,00--11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-9,29 (NE)
Median (Min - Max)	-9,29 [-9,29--9,29]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	-1,43 (6,98)
Median (Min - Max)	-1,14 [-11,00-7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	43,43 (8,60)
Median (Min - Max)	46,00 [31,00-54,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,83 (1,10)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,00 (0,00)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,00 (4,24)
Median (Min - Max)	-3,00 [-6,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS11: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:

> 10 cm

FACT-Lym lymphoma scale - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

5 (71,4)

Mean (SD)

0,56 (6,42)

Median (Min - Max)

0,00 [-5,00-10,54]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.10.12 Merkmal: Primärdiagnose

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	110 (98,2)
Mean (SD)	43,84 (10,15)
Median (Min - Max)	47,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	101
Treated patients with non-missing values - n(%)	95 (94,1)
Mean (SD)	0,67 (6,53)
Median (Min - Max)	0,00 [-21,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	78
Treated patients with non-missing values - n(%)	70 (89,7)
Mean (SD)	1,02 (8,73)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	60
Treated patients with non-missing values - n(%)	54 (90,0)
Mean (SD)	0,99 (7,13)
Median (Min - Max)	0,00 [-19,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	42 (97,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,47 (8,00)
Median (Min - Max)	-0,79 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	0,04 (9,00)
Median (Min - Max)	0,00 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	26 (100,0)
Median (Min - Max)	-0,12 (11,01)
	0,50 [-32,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	1,97 (8,89)
	1,00 [-16,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	0,62 (8,25)
	1,00 [-16,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	-0,18 (8,64)
	2,00 [-18,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,15 (7,14)
Median (Min - Max)	-0,18 [-10,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	0,88 (6,20)
	1,00 [-11,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,37 (11,34)
	-0,82 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	-6,00 (7,13)
	-2,64 [-14,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-3,27 (7,69)
	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,00 (2,83)
	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	85 (75,9)
Median (Min - Max)	-0,99 (8,76)
	-1,14 [-20,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	42,36 (11,38)
Median (Min - Max)	42,00 [17,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	1,31 (8,52)
Median (Min - Max)	0,00 [-7,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	6,61 (9,19)
Median (Min - Max)	3,82 [0,00-25,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	14,40 (16,41)
Median (Min - Max)	12,00 [-1,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,40 (11,74)
Median (Min - Max)	-1,00 [-4,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	9,31 (13,88)
Median (Min - Max)	7,63 [-4,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,69 (13,06)
Median (Min - Max)	8,29 [-1,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	12,67 (14,84)
Median (Min - Max)	9,00 [0,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	16,14 (11,11)
Median (Min - Max)	16,14 [8,29-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	21,69 (10,33)
Median (Min - Max)	21,69 [14,38-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS12: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	25,36 (18,89)
Median (Min - Max)	25,36 [12,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	21,00 (14,14)
Median (Min - Max)	21,00 [11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	37,00 (NE)
Median (Min - Max)	37,00 [37,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	33,77 (NE)
Median (Min - Max)	33,77 [33,77-33,77]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	9 (81,8)
Median (Min - Max)	-1,78 (13,24) -5,00 [-17,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

3.10.13 Merkmal: Anzahl der vorherigen systemischen Therapien

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	44,73 (9,64)
Median (Min - Max)	47,00 [13,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	48 (92,3)
Mean (SD)	-0,27 (5,37)
Median (Min - Max)	0,00 [-18,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	32 (84,2)
Mean (SD)	0,13 (10,43)
Median (Min - Max)	-1,00 [-16,69-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	23 (79,3)
Mean (SD)	1,29 (6,95)
Median (Min - Max)	2,00 [-13,00-15,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	20 (90,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,80 (9,29)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-3,41 (8,97)
Median (Min - Max)	-3,21 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-3,19 (11,45)
Median (Min - Max)	-0,96 [-32,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,64 (7,78)
Median (Min - Max)	1,00 [-8,74-20,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,01 (8,55)
Median (Min - Max)	0,00 [-12,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-2,20 (8,87)
Median (Min - Max)	1,00 [-18,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,42 (4,75)
Median (Min - Max)	-1,00 [-7,50-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-0,25 (2,06)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-3,27 (11,78)
Median (Min - Max)	-0,82 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-6,00 (7,13)
Median (Min - Max)	-2,64 [-14,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,27 (7,69)
Median (Min - Max)	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	45 (76,3)
Mean (SD)	-2,93 (7,95)
Median (Min - Max)	-5,00 [-16,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	42,35 (9,75)
Median (Min - Max)	43,50 [27,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 30
Treated patients with non-missing values - n(%)	29 (96,7)
Mean (SD)	2,10 (9,64)
Median (Min - Max)	1,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	3,35 (6,22)
Median (Min - Max)	1,50 [-3,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	2,67 (8,73)
Median (Min - Max)	0,00 [-15,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	1,00 (6,82)
Median (Min - Max)	-1,00 [-5,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,33 (8,98)
Median (Min - Max)	3,50 [-4,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	9,00 (11,20)
Median (Min - Max)	7,00 [-1,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	9,50 (9,40)
Median (Min - Max)	8,50 [0,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	6,33 (3,06)
Median (Min - Max)	7,00 [3,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	8,50 (9,19)
Median (Min - Max)	8,50 [2,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	13,00 (NE)
Median (Min - Max)	13,00 [13,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	23 (71,9)
Mean (SD)	-0,00 (9,38)
Median (Min - Max)	-1,00 [-17,00-16,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	42,08 (11,78)
Median (Min - Max)	43,50 [11,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	33 (97,1)
Mean (SD)	1,70 (6,69)
Median (Min - Max)	0,00 [-8,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	26 (96,3)
Mean (SD)	1,27 (8,20)
Median (Min - Max)	1,00 [-20,00-25,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	2,55 (10,80)
Median (Min - Max)	0,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	1,97 (8,41)
Median (Min - Max)	0,00 [-14,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	5,54 (9,43)
Median (Min - Max)	1,57 [-6,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	4,90 (9,15)
Median (Min - Max)	4,00 [-9,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	3,88 (12,67)
Median (Min - Max)	2,50 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,05 (12,96)
Median (Min - Max)	3,50 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,90 (14,26)
Median (Min - Max)	3,50 [-12,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS13: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	9,54 (18,39)
Median (Min - Max)	8,00 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	8,00 (15,20)
Median (Min - Max)	5,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	13,86 (32,73)
Median (Min - Max)	13,86 [-9,29-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	33,77 (NE)
Median (Min - Max)	33,77 [33,77-33,77]
FACT-Lym lymphoma scale - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (76,9)
Mean (SD)	0,51 (10,10)
Median (Min - Max)	0,50 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

3.10.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	90 (97,8)
Mean (SD)	44,10 (10,59)
Median (Min - Max)	46,50 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	86
Treated patients with non-missing values - n(%)	80 (93,0)
Mean (SD)	0,58 (6,90)
Median (Min - Max)	0,00 [-21,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	66
Treated patients with non-missing values - n(%)	60 (90,9)
Mean (SD)	0,86 (9,29)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)
Mean (SD)	0,43 (7,63)
Median (Min - Max)	0,00 [-19,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,87 (8,54)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,98 (9,26)
Median (Min - Max)	0,50 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	23 (100,0)
Median (Min - Max)	-0,02 (11,67)
	0,00 [-32,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	16 (84,2)
Median (Min - Max)	2,55 (9,49)
	1,00 [-16,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,98 (8,99)
	1,50 [-16,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	-0,38 (10,18)
	2,00 [-18,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-0,27 (8,01)
Median (Min - Max)	-1,82 [-10,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	1,00 (6,68)
	2,00 [-11,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	0,68 (8,54)
	-0,32 [-9,29-11,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-7,93 (6,55)
	-7,50 [-14,71--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-4,59 (8,20)
	-4,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-11,71 (9,28)
Median (Min - Max)	-17,00 [-17,14--1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-10,51 (7,24)
	-12,00 [-16,90--2,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,00 (8,49)
	-8,00 [-14,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,50 (NE)
	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	66 (71,7)
Median (Min - Max)	-0,99 (9,10)
	-1,57 [-20,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	43,99 (8,80)
Median (Min - Max)	46,50 [25,71-55,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	0,12 (3,46)
Median (Min - Max)	0,50 [-6,00-8,29]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	1,14 (4,74)
Median (Min - Max)	0,00 [-4,29-12,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	3,02 (2,87)
Median (Min - Max)	3,00 [0,00-8,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,68 (5,63)
Median (Min - Max)	-0,50 [-7,00-10,05]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,96 (7,17)
Median (Min - Max)	-3,21 [-15,00-1,57]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,88 (3,46)
	-0,92 [-5,71-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,12 (3,18)
	-2,00 [-5,36-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,52 (5,26)
	0,00 [-8,57-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,00 (2,83)
	-1,00 [-3,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,64 (NE)
Median (Min - Max)	0,64 [0,64-0,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,71 (NE)
	1,71 [1,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS14: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	19 (86,4)
Median (Min - Max)	-2,95 (7,51)
	-2,00 [-17,00-10,54]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

3.10.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	44,80 (9,83)
Median (Min - Max)	48,00 [13,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	37
Treated patients with non-missing values - n(%)	34 (91,9)
Mean (SD)	-0,51 (6,57)
Median (Min - Max)	-0,50 [-21,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	0,49 (9,65)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	25
Treated patients with non-missing values - n(%)	21 (84,0)
Mean (SD)	0,18 (7,93)
Median (Min - Max)	0,00 [-19,00-15,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,99 (8,66)
Median (Min - Max)	-1,00 [-14,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	0,47 (8,37)
Median (Min - Max)	0,50 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	0,90 (9,76)
	-1,00 [-11,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	1,40 (10,29)
	1,50 [-16,00-20,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	10 (100,0)
Median (Min - Max)	2,40 (10,11)
	5,00 [-16,00-19,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-1,00 (10,17)
	1,50 [-18,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,89 (8,72)
Median (Min - Max)	0,18 [-10,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	0,20 (7,98)
	0,00 [-11,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-3,65 (13,11)
	-4,82 [-24,00-11,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-8,68 (8,54)
	-8,68 [-14,71--2,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,00 (5,66)
	-4,00 [-8,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-9,00 (11,31)
Median (Min - Max)	-9,00 [-17,00--1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-7,32 (6,62)
	-7,32 [-12,00--2,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,00 (8,49)
	-8,00 [-14,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,50 (NE)
	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	30 (75,0)
Median (Min - Max)	-2,96 (9,00)
	-3,50 [-20,00-15,07]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	78 (98,7)
Mean (SD)	42,51 (10,51)
Median (Min - Max)	45,50 [11,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	68
Treated patients with non-missing values - n(%)	65 (95,6)
Mean (SD)	1,52 (7,35)
Median (Min - Max)	1,00 [-18,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	45
Treated patients with non-missing values - n(%)	41 (91,1)
Mean (SD)	1,40 (8,06)
Median (Min - Max)	1,00 [-15,36-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	32 (94,1)
Mean (SD)	2,68 (6,84)
Median (Min - Max)	2,00 [-13,00-17,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	0,46 (7,70)
Median (Min - Max)	0,00 [-22,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	0,90 (9,07)
Median (Min - Max)	0,00 [-15,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	-0,68 (12,33)
	1,00 [-32,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	2,34 (7,21)
	1,00 [-5,36-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-1,60 (4,86)
	0,00 [-9,91-3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	2,00 (1,00)
	2,00 [1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-0,96 (4,83)
Median (Min - Max)	-0,18 [-7,50-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	2,00 (2,00)
	2,00 [0,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	1,50 (0,71)
	1,50 [1,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,21 (7,29)
	-2,00 [-12,36-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-2,79 (10,07)
	2,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-7,07 (14,24)
Median (Min - Max)	-7,07 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,45 (14,78)
Median (Min - Max)	-6,45 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS15: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	62 (78,5)
Median (Min - Max)	-0,73 (8,43)
	-1,00 [-17,00-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

3.10.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	43,75 (8,86)
Median (Min - Max)	47,00 [25,71-55,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	0,39 (3,42)
Median (Min - Max)	0,50 [-6,00-8,29]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	1,04 (4,96)
Median (Min - Max)	0,00 [-4,29-12,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,78 (2,97)
Median (Min - Max)	2,50 [0,00-8,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 7
Treated patients with non-missing values - n(%)	5 (71,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,41 (6,13)
Median (Min - Max)	0,00 [-7,00-10,05]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-6,36 (5,90)
Median (Min - Max)	-4,36 [-15,00--1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,32 (3,39)
	-3,32 [-5,71--0,92]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,18 (4,50)
	-2,18 [-5,36-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,29 (6,06)
	-4,29 [-8,57-0,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,64 (NE)
Median (Min - Max)	0,64 [0,64-0,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,71 (NE)
	1,71 [1,71-1,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	19 (90,5)
Median (Min - Max)	-2,06 (7,15)
	-1,71 [-13,00-10,54]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	102 (98,1)
Mean (SD)	43,49 (10,69)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 96
Treated patients with non-missing values - n(%)	90 (93,8)
Mean (SD)	0,82 (7,11)
Median (Min - Max)	0,00 [-21,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 73
Treated patients with non-missing values - n(%)	67 (91,8)
Mean (SD)	1,25 (9,28)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 55
Treated patients with non-missing values - n(%)	50 (90,9)
Mean (SD)	1,83 (9,59)
Median (Min - Max)	0,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 40
Treated patients with non-missing values - n(%)	40 (100,0)
Mean (SD)	-0,27 (8,83)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	1,74 (9,83)
Median (Min - Max)	1,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	26 (100,0)
Median (Min - Max)	1,05 (11,97)
	1,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	3,73 (10,66)
	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	2,57 (9,85)
	2,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	2,36 (12,35)
	2,00 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	3,96 (14,14)
Median (Min - Max)	1,00 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	4,75 (12,28)
	3,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	2,13 (18,03)
	-0,32 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	0,41 (19,49)
	-2,64 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-4,59 (8,20)
	-4,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-11,71 (9,28)
Median (Min - Max)	-17,00 [-17,14--1,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-10,51 (7,24)
	-12,00 [-16,90--2,64]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,00 (8,49)
	-8,00 [-14,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,50 (NE)
	-5,50 [-5,50--5,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS16: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	75 (72,1)
Median (Min - Max)	-1,03 (9,40)
	-2,00 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.10.17 Merkmal: Vorherige CAR-T-Therapie

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	44,75 (11,06)
Median (Min - Max)	45,00 [28,00-58,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,33 (9,97)
Median (Min - Max)	1,00 [-5,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	3,75 (12,04)
Median (Min - Max)	0,50 [-7,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	3,75 (8,18)
Median (Min - Max)	0,00 [-1,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	6,33 (7,51)
Median (Min - Max)	6,00 [-1,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	10,67 (11,02)
Median (Min - Max)	10,00 [0,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,67 (12,66)
Median (Min - Max)	4,00 [-1,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	9,00 (10,82)
Median (Min - Max)	6,00 [0,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-1,50 (10,01)
Median (Min - Max)	-1,00 [-17,00-14,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	120 (98,4)
Mean (SD)	43,25 (10,34)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	104 (94,5)
Mean (SD)	0,81 (6,96)
Median (Min - Max)	0,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	74 (90,2)
Mean (SD)	1,21 (8,64)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	56 (88,9)
Mean (SD)	1,97 (8,93)
Median (Min - Max)	1,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	44 (95,7)
Mean (SD)	-0,27 (8,48)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	0,21 (9,48)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	26 (100,0)
Mean (SD)	0,11 (11,26)
Median (Min - Max)	0,50 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	2,55 (10,05)
Median (Min - Max)	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	2,23 (9,75)
Median (Min - Max)	2,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	3,20 (12,29)
Median (Min - Max)	2,00 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	4,84 (13,58)
Median (Min - Max)	3,00 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	5,00 (11,81)
Median (Min - Max)	2,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	2,01 (16,87)
Median (Min - Max)	1,00 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,63 (17,44)
Median (Min - Max)	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,27 (7,69)
Median (Min - Max)	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS17: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	92 (75,4)
Mean (SD)	-1,17 (9,03)
Median (Min - Max)	-1,86 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

3.10.18 Merkmal: Arzneimittelformulierung

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	45,40 (9,25)
Median (Min - Max)	47,50 [27,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	0,90 (4,55)
Median (Min - Max)	1,00 [-8,00-10,07]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,37 (6,92)
Median (Min - Max)	2,00 [-20,00-12,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-0,50 (6,62)
Median (Min - Max)	1,00 [-19,00-7,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,09 (4,25)
Median (Min - Max)	-1,00 [-6,00-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,25 (5,56)
Median (Min - Max)	2,50 [-8,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,80 (3,77)
Median (Min - Max)	0,00 [-7,00-3,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,75 (1,71)
Median (Min - Max)	1,50 [0,00-4,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,33 (3,51)
Median (Min - Max)	3,00 [0,00-7,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Drug formulation:

Frozen liquid

FACT-Lym lymphoma scale - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

22 (68,8)

Mean (SD)

-2,55 (9,44)

Median (Min - Max)

-4,00 [-20,00-15,07]

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	96 (98,0)
Mean (SD)	42,66 (10,64)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 88
Treated patients with non-missing values - n(%)	82 (93,2)
Mean (SD)	0,97 (7,82)
Median (Min - Max)	0,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 65
Treated patients with non-missing values - n(%)	59 (90,8)
Mean (SD)	1,65 (9,31)
Median (Min - Max)	1,00 [-16,69-35,21]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 50
Treated patients with non-missing values - n(%)	44 (88,0)
Mean (SD)	3,04 (9,40)
Median (Min - Max)	0,50 [-15,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 38
Treated patients with non-missing values - n(%)	36 (94,7)
Mean (SD)	0,23 (9,48)
Median (Min - Max)	-0,79 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	1,29 (10,44)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	24 (100,0)
Mean (SD)	1,37 (12,53)
Median (Min - Max)	1,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	Cycle 8 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	3,80 (11,21)
Median (Min - Max)	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 9 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	1,97 (10,26)
Median (Min - Max)	1,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	3,28 (12,29)
Median (Min - Max)	2,50 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	4,35 (13,05)
Median (Min - Max)	1,82 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	4,90 (11,14)
Median (Min - Max)	3,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	2,01 (16,87)
Median (Min - Max)	1,00 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,63 (17,44)
Median (Min - Max)	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,27 (7,69)
Median (Min - Max)	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS18: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	76 (77,6)
Mean (SD)	-0,79 (8,95)
Median (Min - Max)	-1,07 [-17,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FOD_PSTS01: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Age group
 PRO set

3.11 Subgruppenanalysen zum FACT-Lym – TOI (Zeit bis zur Verschlechterung)

3.11.1 Merkmal Alter

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	57
Patients with events - n(%)	10 (17,5)
95%-CI	[8,7-29,9]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [64,5-89,9]
Month 6	69,4 [47,2-83,8]
Month 12	69,4 [47,2-83,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS01: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	15 (28,3)
95%-CI	[16,8-42,3]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	5,55[3,32-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,3 [54,4-84,1]
Month 6	47,7 [24,5-67,7]
Month 12	47,7 [24,5-67,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS01: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	5 (25,0)
95%-CI	[8,7-49,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[3,75-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [63,2-97,2]
Month 6	72,1 [40,0-88,9]
Month 12	72,1 [40,0-88,9]
Month 18	48,0 [9,1-79,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS02: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Sex
 PRO set

3.11.2 Merkmal: Geschlecht

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	12 (22,6)
95%-CI	[12,3-36,2]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [68,0-92,9]
Month 6	61,1 [38,6-77,5]
Month 12	61,1 [38,6-77,5]
Month 18	45,8 [16,5-71,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS02: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	18 (23,4)
95%-CI	[14,5-34,4]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[4,73-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,5 [60,7-84,1]
Month 6	63,4 [45,8-76,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

3.11.3 Merkmal: Ethnie

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	113 (98,3)
Mean (SD)	43,63 (10,14)
Median (Min - Max)	46,00 [11,00-60,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	98 (94,2)
Mean (SD)	0,66 (6,97)
Median (Min - Max)	0,00 [-21,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	66 (89,2)
Mean (SD)	0,66 (8,65)
Median (Min - Max)	1,00 [-20,00-35,21]
FACT-Lym lymphoma scale - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	50 (89,3)
Mean (SD)	1,81 (8,78)
Median (Min - Max)	0,00 [-19,00-42,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	39 (95,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,22 (8,30)
Median (Min - Max)	-1,00 [-22,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	0,20 (9,70)
Median (Min - Max)	0,00 [-15,00-26,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	24 (100,0)
Median (Min - Max)	-0,25 (11,09)
	0,00 [-32,00-24,79]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	2,18 (9,77)
	1,00 [-16,00-29,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	19 (100,0)
Median (Min - Max)	1,81 (9,62)
	1,00 [-16,00-24,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	2,20 (11,72)
	2,00 [-18,00-29,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	3,56 (13,39)
Median (Min - Max)	0,64 [-10,00-38,71]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	4,33 (11,66)
	2,00 [-11,00-31,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	1,01 (17,75)
	-0,82 [-24,00-37,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	0,63 (17,44)
	-2,32 [-14,71-33,77]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-3,27 (7,69)
	0,00 [-14,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-8,04 (10,56)
Median (Min - Max)	-9,00 [-17,14-3,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,88 (9,36)
Median (Min - Max)	-7,32 [-16,90-4,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (7,94)
Median (Min - Max)	-2,00 [-14,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (4,24)
Median (Min - Max)	-1,00 [-4,00-2,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-2,25 (4,60)
Median (Min - Max)	-2,25 [-5,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym lymphoma scale - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (2,12)
Median (Min - Max)	-0,50 [-2,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,00 (2,83)
Median (Min - Max)	-1,00 [-3,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,9)
Mean (SD)	-1,62 (8,95)
Median (Min - Max)	-2,00 [-20,00-26,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym lymphoma scale	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	41,20 (11,94)
Median (Min - Max)	40,00 [15,00-57,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	3,33 (8,14)
Median (Min - Max)	0,00 [-7,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	5,08 (8,83)
Median (Min - Max)	2,00 [-5,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	3,50 (9,42)
Median (Min - Max)	3,00 [-9,00-16,00]
FACT-Lym lymphoma scale - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	1,99 (9,86)
Median (Min - Max)	-1,00 [-12,08-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FLC_PSHS03: FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym lymphoma scale - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,50 (10,60)
Median (Min - Max)	4,00 [-8,00-22,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	7,00 (12,67)
	8,00 [-11,00-23,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	11,33 (10,60)
	13,00 [0,00-21,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	9,00 (NE)
	9,00 [9,00-9,00]
FACT-Lym lymphoma scale - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FOD_PSTS03: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Race group
 PRO set

FACT-Lym lymphoma scale - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym lymphoma scale - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	13,00 (NE)
Median (Min - Max)	13,00 [13,00-13,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
FACT-Lym lymphoma scale - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	1,64 (9,50)
Median (Min - Max)	1,00 [-13,64-14,00]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS04: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Country
 PRO set

3.11.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	10 (19,6)
95%-CI	[9,8-33,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [3,75-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [64,0-90,9]
Month 6	67,1 [45,6-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS04: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	7 (24,1)
95%-CI	[10,3-43,5]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[3,32-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,9 [57,9-91,2]
Month 6	60,5 [29,2-81,5]
Month 12	60,5 [29,2-81,5]
Month 18	60,5 [29,2-81,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS04: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	13 (27,1)
95%-CI	[15,3-41,8]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[4,73-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,2 [57,2-86,5]
Month 6	57,5 [34,3-75,0]
Month 12	57,5 [34,3-75,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS05: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Region
 PRO set

3.11.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	10 (19,6)
95%-CI	[9,8-33,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [3,75-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [64,0-90,9]
Month 6	67,1 [45,6-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS05: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	20 (25,3)
95%-CI	[16,2-36,4]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [63,9-85,9]
Month 6	57,7 [38,7-72,7]
Month 12	57,7 [38,7-72,7]
Month 18	43,3 [16,5-67,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS06: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage
 PRO set

3.11.6 Merkmal: Krankheitsstadium nach Ann-Arbor

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	4,73[2,83-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	22,9 [1,0-62,5]
Month 12	22,9 [1,0-62,5]
Month 18	22,9 [1,0-62,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS06: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [2,10-12,22]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,1 [42,7-89,1]
Month 6	58,5 [23,1-82,2]
Month 12	58,5 [23,1-82,2]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS06: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	5 (29,4)
95%-CI	[10,3-56,0]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[1,48-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,6 [35,9-87,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS06: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	15 (18,3)
95%-CI	[10,6-28,4]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [68,9-89,3]
Month 6	72,8 [57,5-83,3]
Month 12	72,8 [57,5-83,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS07: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Bulky disease
 PRO set

3.11.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	30 (23,8)
95%-CI	[16,7-32,2]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,3 [68,3-85,4]
Month 6	61,1 [46,9-72,5]
Month 12	61,1 [46,9-72,5]
Month 18	45,8 [18,4-69,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS08: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Double/Triple hit
 PRO set

3.11.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	3 (21,4)
95%-CI	[4,7-50,8]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [3,02-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	57,7 [14,7-85,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS08: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	27 (23,3)
95%-CI	[15,9-32,0]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,1 [66,4-84,8]
Month 6	61,5 [46,2-73,7]
Month 12	61,5 [46,2-73,7]
Month 18	46,1 [18,3-70,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS09: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Transformed DLBCL
 PRO set

3.11.9 Merkmal: Transformation des DLBCL

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [3,02-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [55,9-92,3]
Month 6	60,5 [28,1-81,9]
Month 12	60,5 [28,1-81,9]
Month 18	60,5 [28,1-81,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. TOI = trial outcome index

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS09: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	24 (22,6)
95%-CI	[15,1-31,8]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [66,8-86,0]
Month 6	61,6 [45,7-74,2]
Month 12	61,6 [45,7-74,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. TOI = trial outcome index

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS10: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: B-Cell type
 PRO set

3.11.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	13 (30,2)
95%-CI	[17,2-46,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,9 [56,8-86,2]
Month 6	55,9 [31,4-74,6]
Month 12	55,9 [31,4-74,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS10: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[3,32-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,6 [54,7-94,1]
Month 6	72,3 [39,4-89,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS11: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter
 PRO set

3.11.11 Merkmal: Maximaler längster Durchmesser

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	18 (23,7)
95%-CI	[14,7-34,8]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,3 [65,1-86,9]
Month 6	64,6 [47,3-77,6]
Month 12	64,6 [47,3-77,6]
Month 18	48,5 [18,5-73,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS11: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	10 (29,4)
95%-CI	[15,1-47,5]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	5,55[3,32-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [57,4-89,7]
Month 6	48,7 [20,8-71,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS11: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. TOI = trial outcome index
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS11: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. TOI = trial outcome index
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PST12: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Primary disease diagnosis
 PRO set

3.11.12 Merkmal: Primärdiagnose

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	26 (23,2)
95%-CI	[15,8-32,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [67,2-85,6]
Month 6	62,2 [46,8-74,4]
Month 12	62,2 [46,8-74,4]
Month 18	46,7 [18,4-71,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS12: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	3,75 [1,41-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [35,4-94,2]
Month 6	46,8 [11,4-76,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS13: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Number prior lines
 PRO set

3.11.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	17 (28,8)
95%-CI	[17,8-42,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [60,3-85,3]
Month 6	55,2 [33,5-72,4]
Month 12	55,2 [33,5-72,4]
Month 18	41,4 [15,1-66,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS13: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	6 (18,8)
95%-CI	[7,2-36,4]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[3,02-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,8 [61,7-93,7]
Month 6	62,0 [28,5-83,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS13: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	7 (17,9)
95%-CI	[7,5-33,5]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[4,73-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [60,5-92,0]
Month 6	69,7 [44,9-85,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PST14: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - first line
 PRO set

3.11.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	20 (21,7)
95%-CI	[13,8-31,6]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,3 [65,9-86,6]
Month 6	60,0 [41,5-74,3]
Month 12	60,0 [41,5-74,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS14: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	6 (27,3)
95%-CI	[10,7-50,2]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[1,97-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,1 [44,9-87,5]
Month 6	64,1 [35,8-82,5]
Month 12	64,1 [35,8-82,5]
Month 18	64,1 [35,8-82,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS15: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - last line
 PRO set

3.11.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	12 (30,0)
95%-CI	[16,6-46,5]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22 [3,75-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,4 [51,5-84,2]
Month 6	59,9 [37,4-76,6]
Month 12	59,9 [37,4-76,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS15: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	16 (20,3)
95%-CI	[12,0-30,8]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE[5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,0 [65,3-87,7]
Month 6	62,0 [40,5-77,6]
Month 12	62,0 [40,5-77,6]
Month 18	62,0 [40,5-77,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS16: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - any line
 PRO set

3.11.16 Merkmal: *Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [1,97-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [42,3-86,7]
Month 6	62,6 [34,0-81,6]
Month 12	62,6 [34,0-81,6]
Month 18	62,6 [34,0-81,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS16: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	23 (22,1)
95%-CI	[14,6-31,3]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,09-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [69,2-88,0]
Month 6	60,4 [43,6-73,5]
Month 12	60,4 [43,6-73,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS17: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Prior use of T-CART therapy
PRO set

3.11.17 Merkmal: Vorherige CAR-T-Therapie

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. TOI = trial outcome index
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS17: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	28 (23,0)
95%-CI	[15,8-31,4]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,5 [69,4-86,6]
Month 6	60,9 [46,0-72,9]
Month 12	60,9 [46,0-72,9]
Month 18	45,7 [18,2-69,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS18: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Drug formulation
 PRO set

3.11.18 Merkmal: Arzneimittelformulierung

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	7 (21,9)
95%-CI	[9,3-40,0]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	NE [4,73-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [52,1-89,8]
Month 6	51,2 [18,7-76,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOD_PSTS18: Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym TOI by at least 18 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation: Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	23 (23,5)
95%-CI	[15,5-33,1]
FACT-Lym TOI - Time to decrease by at least 18 points in months [95%-CI]	
Median	12,22[5,55-NE]
FACT-Lym TOI - Time to decrease by at least 18 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,3 [68,2-86,9]
Month 6	63,7 [48,3-75,6]
Month 12	63,7 [48,3-75,6]
Month 18	47,8 [18,7-72,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. TOI = trial outcome index
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

3.12 Subgruppenanalysen zum FACT-Lym – TOI (Veränderung gegenüber Studienbeginn)

3.12.1 Merkmal Alter

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym TOI	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	55 (96,5)
Mean (SD)	74,55 (19,47)
Median (Min - Max)	77,00 [32,00-108,83]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)
Mean (SD)	2,67 (11,66)
Median (Min - Max)	2,00 [-21,00-35,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	33 (89,2)
Mean (SD)	-0,87 (16,97)
Median (Min - Max)	-2,00 [-31,00-36,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	3,96 (17,35)
Median (Min - Max)	3,50 [-27,00-62,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	20 (90,9)
Mean (SD)	1,14 (14,02)
Median (Min - Max)	2,50 [-23,00-24,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	0,91 (19,19)
Median (Min - Max)	1,57 [-31,00-41,00]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	2,82 (16,54)
Median (Min - Max)	0,00 [-19,00-41,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	6,86 (19,58)
Median (Min - Max)	1,00 [-21,74-40,00]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	5,36 (11,93)
Median (Min - Max)	0,46 [-4,00-25,29]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	8,72 (20,46)
Median (Min - Max)	3,00 [-11,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	20,85 (22,94)
Median (Min - Max)	17,50 [-1,00-49,38]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	19,67 (17,29)
Median (Min - Max)	16,50 [5,00-40,67]
FACT-Lym TOI - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	30,67 (34,88)
Median (Min - Max)	30,67 [6,00-55,33]
FACT-Lym TOI - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym TOI - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	40 (70,2)
Mean (SD)	-3,06 (16,77)
Median (Min - Max)	-4,58 [-43,00-32,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym TOI	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	51 (96,2)
Mean (SD)	85,46 (15,02)
Median (Min - Max)	88,00 [45,00-107,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	43 (89,6)
Mean (SD)	-2,48 (13,40)
Median (Min - Max)	-1,00 [-56,00-26,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	27 (79,4)
Mean (SD)	0,64 (16,45)
Median (Min - Max)	2,00 [-41,00-27,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	-1,64 (16,48)
Median (Min - Max)	-2,50 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	-4,62 (16,23)
Median (Min - Max)	-4,00 [-45,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,23 (17,22)
Median (Min - Max)	-2,62 [-38,00-24,50]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-5,46 (23,24)
Median (Min - Max)	-2,50 [-58,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	-2,31 (14,88)
Median (Min - Max)	4,17 [-28,00-11,00]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-3,10 (20,24)
Median (Min - Max)	-2,01 [-30,00-22,00]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,00 (24,04)
Median (Min - Max)	9,00 [-30,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-0,52 (18,55)
Median (Min - Max)	-1,50 [-18,50-21,83]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,00 (15,31)
Median (Min - Max)	10,00 [-15,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,21 (18,96)
Median (Min - Max)	-0,02 [-20,29-19,50]
FACT-Lym TOI - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-5,42 (29,61)
Median (Min - Max)	-5,42 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-13,40 (29,34)
Median (Min - Max)	-21,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-14,83 (28,74)
Median (Min - Max)	-27,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-13,58 (27,00)
Median (Min - Max)	-21,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,50 (30,41)
Median (Min - Max)	-5,50 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	15,00 (NE)
Median (Min - Max)	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	14,50 (NE)
Median (Min - Max)	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	41 (77,4)
Mean (SD)	-7,94 (17,68)
Median (Min - Max)	-8,00 [-43,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym TOI	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	80,06 (19,76)
Median (Min - Max)	78,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,92 (11,93)
Median (Min - Max)	0,00 [-30,00-25,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	7,49 (10,24)
Median (Min - Max)	4,00 [-6,17-25,33]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	8 (61,5)
Mean (SD)	11,40 (10,31)
Median (Min - Max)	12,50 [-1,00-26,00]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,23 (18,08)
Median (Min - Max)	-0,58 [-19,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	4,95 (19,28)
Median (Min - Max)	-0,64 [-13,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	11,08 (13,04)
Median (Min - Max)	10,00 [-3,09-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	12,00 (13,39)
Median (Min - Max)	12,00 [-1,00-25,00]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,88 (11,71)
Median (Min - Max)	6,00 [-2,00-25,50]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,00 (2,83)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,32 (3,79)
Median (Min - Max)	1,32 [-1,36-4,00]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-5,00 (28,21)
Median (Min - Max)	-1,00 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS01: FACT-Lym TOI - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-1,65 (17,59)
Median (Min - Max)	0,00 [-31,00-20,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

3.12.2 Merkmal: Geschlecht

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym TOI	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	49 (92,5)
Mean (SD)	76,69 (20,39)
Median (Min - Max)	80,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	38 (82,6)
Mean (SD)	3,80 (11,19)
Median (Min - Max)	2,00 [-21,00-27,50]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	30 (83,3)
Mean (SD)	4,50 (16,11)
Median (Min - Max)	4,42 [-26,36-36,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	21 (75,0)
Mean (SD)	7,24 (18,90)
Median (Min - Max)	9,00 [-34,00-62,67]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	20 (87,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,59 (17,76)
Median (Min - Max)	1,42 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	3,31 (18,29)
Median (Min - Max)	5,43 [-38,00-33,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	0,12 (19,78)
Median (Min - Max)	0,75 [-58,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	5,29 (17,66)
Median (Min - Max)	3,00 [-28,00-38,67]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	0,43 (17,25)
Median (Min - Max)	-0,50 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	1,33 (19,32)
Median (Min - Max)	2,50 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	3,20 (20,10)
Median (Min - Max)	1,50 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	6,96 (16,87)
Median (Min - Max)	5,50 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	3,25 (27,72)
Median (Min - Max)	2,50 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	39 (73,6)
Mean (SD)	-4,17 (17,80)
Median (Min - Max)	-5,00 [-40,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym TOI	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	76 (98,7)
Mean (SD)	81,87 (16,80)
Median (Min - Max)	84,00 [32,00-108,83]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	67 (95,7)
Mean (SD)	-1,72 (12,92)
Median (Min - Max)	-1,00 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	43 (86,0)
Mean (SD)	-1,14 (15,49)
Median (Min - Max)	0,00 [-41,00-33,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	37 (94,9)
Mean (SD)	0,07 (14,70)
Median (Min - Max)	0,00 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-0,73 (13,63)
Median (Min - Max)	-3,00 [-23,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-2,54 (17,90)
Median (Min - Max)	-5,67 [-31,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	4,36 (17,36)
Median (Min - Max)	0,98 [-16,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	5,12 (18,03)
Median (Min - Max)	3,33 [-21,74-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,92 (11,38)
Median (Min - Max)	2,67 [-2,00-25,29]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	13,68 (21,59)
Median (Min - Max)	23,00 [-11,00-29,05]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS02: FACT-Lym TOI - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	25,42 (5,07)
Median (Min - Max)	25,42 [21,83-29,00]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	23,50 (4,95)
Median (Min - Max)	23,50 [20,00-27,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	19,50 (NE)
Median (Min - Max)	19,50 [19,50-19,50]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	55 (71,4)
Mean (SD)	-5,58 (17,09)
Median (Min - Max)	-6,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

3.12.3 *Merkmal: Ethnie*

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym TOI	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	110 (95,7)
Mean (SD)	79,94 (18,44)
Median (Min - Max)	83,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	93 (89,4)
Mean (SD)	-0,02 (12,39)
Median (Min - Max)	0,00 [-56,00-27,50]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	61 (82,4)
Mean (SD)	0,72 (15,57)
Median (Min - Max)	1,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	48 (85,7)
Mean (SD)	2,77 (17,06)
Median (Min - Max)	2,33 [-37,00-62,67]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	36 (87,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,31 (15,62)
Median (Min - Max)	-2,29 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	26 (86,7)
Mean (SD)	-1,01 (17,41)
Median (Min - Max)	-2,31 [-38,00-33,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	-0,65 (17,94)
Median (Min - Max)	-1,00 [-58,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	3,20 (16,71)
Median (Min - Max)	1,50 [-28,00-38,67]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	1,82 (15,76)
Median (Min - Max)	1,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	2,61 (19,68)
Median (Min - Max)	2,50 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	5,55 (20,60)
Median (Min - Max)	4,00 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	9,19 (17,13)
Median (Min - Max)	6,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	3,25 (27,72)
Median (Min - Max)	2,50 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	82 (71,3)
Mean (SD)	-5,68 (16,83)
Median (Min - Max)	-6,00 [-43,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym TOI	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	79,13 (18,66)
Median (Min - Max)	82,00 [45,17-108,83]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	2,56 (14,15)
Median (Min - Max)	2,00 [-21,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	3,53 (17,94)
Median (Min - Max)	4,42 [-31,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	2,17 (14,66)
Median (Min - Max)	5,42 [-27,00-24,83]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	2,64 (15,53)
Median (Min - Max)	4,00 [-18,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	9,33 (20,14)
Median (Min - Max)	11,92 [-14,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	12,17 (20,76)
	9,00 [-16,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	17,33 (19,66)
	7,00 [5,00-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	19,00 (NE)
	19,00 [19,00-19,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	23,00 (NE)
	23,00 [23,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS03: FACT-Lym TOI - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	21,83 (NE)
Median (Min - Max)	21,83 [21,83-21,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	20,00 (NE)
	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	19,50 (NE)
	19,50 [19,50-19,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	12 (80,0)
Median (Min - Max)	-0,29 (20,44)
	2,42 [-38,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

3.12.4 Merkmal: Region-1

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym TOI	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	77,15 (18,70)
Median (Min - Max)	78,50 [32,00-108,83]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	1,47 (12,79)
Median (Min - Max)	-1,00 [-21,00-35,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	4,13 (15,56)
Median (Min - Max)	4,00 [-25,00-35,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	4,65 (18,92)
Median (Min - Max)	1,00 [-34,00-62,67]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
PRO set

<u>FACT-Lym TOI - Change from Baseline by subgroup: Country</u>	<u>Loncastuximab tesirine Data-cut 3</u>
Mean (SD)	-0,63 (19,19)
Median (Min - Max)	1,00 [-45,00-24,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	2,15 (22,16)
Median (Min - Max)	6,07 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	7,05 (26,67)
Median (Min - Max)	13,00 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	13,78 (20,79)
Median (Min - Max)	11,00 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,66 (21,30)
Median (Min - Max)	15,50 [-30,00-25,29]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	13,72 (21,19)
Median (Min - Max)	16,00 [-21,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,54 (23,57)
Median (Min - Max)	16,92 [-18,00-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	14,78 (19,15)
Median (Min - Max)	15,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	18,18 (37,83)
Median (Min - Max)	19,50 [-20,29-55,33]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-2,58 (19,53)
Median (Min - Max)	-1,50 [-43,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym TOI	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	85,42 (17,47)
Median (Min - Max)	88,00 [47,05-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	21 (87,5)
Mean (SD)	-4,74 (14,06)
Median (Min - Max)	-0,20 [-56,00-11,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	10 (62,5)
Mean (SD)	-2,18 (18,93)
Median (Min - Max)	-2,00 [-31,00-27,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	2,50 (16,75)
Median (Min - Max)	3,17 [-27,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-0,81 (13,51)
Median (Min - Max)	-2,29 [-20,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-4,04 (8,30)
Median (Min - Max)	-5,67 [-14,00-8,79]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-1,43 (9,60)
Median (Min - Max)	-1,38 [-16,00-10,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	3,16 (4,07)
Median (Min - Max)	3,33 [-1,00-7,14]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,30 (10,27)
Median (Min - Max)	-0,07 [-19,74-6,00]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,36 (NE)
Median (Min - Max)	-1,36 [-1,36--1,36]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (15,56)
Median (Min - Max)	10,00 [-1,00-21,00]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	23 (79,3)
Mean (SD)	-4,49 (18,64)
Median (Min - Max)	-5,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym TOI	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	44 (91,7)
Mean (SD)	79,20 (18,49)
Median (Min - Max)	82,00 [24,00-105,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	40 (87,0)
Mean (SD)	1,51 (11,20)
Median (Min - Max)	1,00 [-30,00-25,67]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	-0,59 (15,48)
Median (Min - Max)	0,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	0,59 (13,99)
Median (Min - Max)	3,00 [-37,00-26,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	-0,24 (12,92)
Median (Min - Max)	-0,50 [-23,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	1,48 (16,04)
Median (Min - Max)	2,29 [-19,33-33,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-2,05 (11,53)
Median (Min - Max)	-2,25 [-19,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,66 (12,80)
Median (Min - Max)	-2,00 [-21,74-25,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,13 (14,94)
Median (Min - Max)	1,00 [-24,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,50 (16,57)
Median (Min - Max)	-4,00 [-30,00-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,80 (14,27)
Median (Min - Max)	4,00 [-18,50-14,52]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	5,00 (12,00)
Median (Min - Max)	5,00 [-7,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-7,26 (21,11)
Median (Min - Max)	-3,00 [-35,00-11,96]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-2,28 (21,63)
Median (Min - Max)	4,00 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,55 (25,17)
Median (Min - Max)	-9,50 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-14,83 (28,74)
Median (Min - Max)	-27,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-13,58 (27,00)
Median (Min - Max)	-21,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,50 (30,41)
Median (Min - Max)	-5,50 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	15,00 (NE)
Median (Min - Max)	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	14,50 (NE)
Median (Min - Max)	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS04: FACT-Lym TOI - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	33 (68,8)
Mean (SD)	-7,62 (14,00)
Median (Min - Max)	-10,00 [-34,00-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

3.12.5 *Merkmal: Region-2*

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym TOI	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	77,15 (18,70)
Median (Min - Max)	78,50 [32,00-108,83]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	1,47 (12,79)
Median (Min - Max)	-1,00 [-21,00-35,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	4,13 (15,56)
Median (Min - Max)	4,00 [-25,00-35,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	4,65 (18,92)
Median (Min - Max)	1,00 [-34,00-62,67]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,63 (19,19)
Median (Min - Max)	1,00 [-45,00-24,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	2,15 (22,16)
Median (Min - Max)	6,07 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	7,05 (26,67)
Median (Min - Max)	13,00 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	13,78 (20,79)
Median (Min - Max)	11,00 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,66 (21,30)
Median (Min - Max)	15,50 [-30,00-25,29]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	13,72 (21,19)
Median (Min - Max)	16,00 [-21,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,54 (23,57)
Median (Min - Max)	16,92 [-18,00-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	14,78 (19,15)
Median (Min - Max)	15,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	18,18 (37,83)
Median (Min - Max)	19,50 [-20,29-55,33]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-2,58 (19,53)
Median (Min - Max)	-1,50 [-43,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym TOI	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	81,64 (18,08)
Median (Min - Max)	86,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	62 (87,3)
Mean (SD)	-0,55 (12,42)
Median (Min - Max)	0,50 [-56,00-25,67]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	42 (79,2)
Mean (SD)	-1,00 (15,95)
Median (Min - Max)	-0,50 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	33 (82,5)
Mean (SD)	1,17 (14,63)
Median (Min - Max)	3,00 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	-0,69 (12,62)
Median (Min - Max)	-2,57 [-23,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,14 (14,17)
Median (Min - Max)	-2,00 [-19,33-33,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-1,87 (10,70)
Median (Min - Max)	-2,00 [-19,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-1,21 (11,36)
Median (Min - Max)	-1,00 [-21,74-25,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	0,55 (13,22)
Median (Min - Max)	0,46 [-24,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-4,00 (15,19)
Median (Min - Max)	-1,00 [-30,00-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,72 (12,76)
Median (Min - Max)	1,32 [-18,50-14,52]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	3,50 (10,25)
Median (Min - Max)	2,00 [-7,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,51 (19,88)
Median (Min - Max)	2,50 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS05: FACT-Lym TOI - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	58 (73,4)
Mean (SD)	-6,49 (15,76)
Median (Min - Max)	-7,50 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.12.6 Merkmal: Krankheitsstadium nach Ann-Arbor

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym TOI	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	84,46 (19,18)
Median (Min - Max)	89,00 [55,18-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	4,95 (7,45)
Median (Min - Max)	1,89 [-4,00-14,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	7,00 (10,10)
Median (Min - Max)	6,50 [-3,00-18,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-3,11 (4,40)
Median (Min - Max)	-4,00 [-7,00-1,67]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-8,27 (7,59)
Median (Min - Max)	-6,04 [-19,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-6,95 (4,44)
Median (Min - Max)	-6,71 [-11,50--2,62]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-12,54 (13,37)
Median (Min - Max)	-12,54 [-22,00--3,09]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-14,50 (19,09)
Median (Min - Max)	-14,50 [-28,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-17,25 (14,17)
Median (Min - Max)	-19,74 [-30,00--2,00]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-11,00 (14,14)
Median (Min - Max)	-11,00 [-21,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-9,68 (11,77)
	-9,68 [-18,00--1,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,00 (9,90)
	-8,00 [-15,00--1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-10,64 (13,64)
	-10,64 [-20,29--1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,71 (NE)
	0,71 [0,71-0,71]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	7 (70,0)
Median (Min - Max)	-11,80 (21,49)
	-21,41 [-34,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym TOI	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	77,85 (15,36)
Median (Min - Max)	82,00 [45,00-96,36]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	3,42 (13,09)
Median (Min - Max)	-0,10 [-23,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-2,35 (22,47)
Median (Min - Max)	1,00 [-41,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,30 (19,98)
Median (Min - Max)	1,50 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,02 (19,33)
Median (Min - Max)	0,75 [-23,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-4,54 (25,45)
	-11,68 [-31,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	3,27 (21,74)
	-2,50 [-12,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,19 (24,01)
	-9,00 [-21,74-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,45 (7,29)
	1,00 [-8,36-6,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-7,25 (15,91)
	-7,25 [-18,50-4,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-35,00 (NE)
	-35,00 [-35,00--35,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-26,36 (NE)
	-26,36 [-26,36--26,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-38,19 (NE)
	-38,19 [-38,19--38,19]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-35,48 (NE)
	-35,48 [-35,48--35,48]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-36,10 (NE)
	-36,10 [-36,10--36,10]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	
Treated patients with non-missing values - n(%)	EOT
Mean (SD)	NE
Median (Min - Max)	15 (71,4)
	-2,49 (18,86)
	-4,17 [-30,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym TOI	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	83,44 (15,09)
Median (Min - Max)	85,00 [57,00-105,67]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-2,74 (8,75)
Median (Min - Max)	-3,00 [-21,00-11,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	-10,56 (14,22)
Median (Min - Max)	-10,00 [-31,00-9,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,48 (11,94)
Median (Min - Max)	-1,00 [-13,00-22,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-0,11 (8,27)
Median (Min - Max)	3,50 [-12,00-8,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	-4,25 (14,15)
	-5,50 [-18,00-12,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-4,53 (11,90)
	3,33 [-19,00-5,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	1,78 (3,29)
	3,33 [-2,00-4,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,17 (5,89)
	0,17 [-4,00-4,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	6,00 (NE)
	6,00 [6,00-6,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	9 (52,9)
Median (Min - Max)	-10,44 (17,63)
	-8,00 [-43,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym TOI	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	81 (98,8)
Mean (SD)	79,07 (19,58)
Median (Min - Max)	82,00 [24,00-108,83]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	66 (91,7)
Mean (SD)	-0,55 (13,39)
Median (Min - Max)	-0,50 [-56,00-27,50]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	49 (90,7)
Mean (SD)	3,65 (13,98)
Median (Min - Max)	4,00 [-25,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	36 (85,7)
Mean (SD)	4,35 (17,35)
Median (Min - Max)	4,50 [-34,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	-0,12 (16,69)
Median (Min - Max)	-2,00 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	5,00 (17,42)
	6,07 [-38,00-33,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	16 (100,0)
Median (Min - Max)	4,82 (20,12)
	7,92 [-58,00-28,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	11 (78,6)
Median (Min - Max)	12,19 (13,58)
	7,14 [-6,00-38,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	12 (100,0)
Median (Min - Max)	8,87 (15,13)
	9,00 [-24,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	7,70 (22,00)
	9,00 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	16,82 (19,97)
	14,52 [-15,00-49,38]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	16,10 (15,45)
	17,00 [-7,00-40,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	16,97 (22,27)
	15,73 [-12,00-55,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2 (40,0)
Median (Min - Max)	9,76 (8,15)
	9,76 [4,00-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,00 (20,07)
	2,00 [-21,00-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,50 (31,82)
	-4,50 [-27,00-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,32 (26,42)
	-2,32 [-21,00-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-5,50 (30,41)
	-5,50 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	14,50 (NE)
	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS06: FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	20,00 (NE)
	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	17,00 (NE)
	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	63 (76,8)
Median (Min - Max)	-4,05 (16,49)
	-5,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS07: FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease
 PRO set

3.12.7 *Merkmal: Bulky Erkrankung*

FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym TOI	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	121 (96,0)
Mean (SD)	80,02 (18,45)
Median (Min - Max)	83,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	102 (90,3)
Mean (SD)	0,21 (12,60)
Median (Min - Max)	0,00 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	73 (85,9)
Mean (SD)	1,18 (15,88)
Median (Min - Max)	1,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	57 (86,4)
Mean (SD)	2,93 (16,58)
Median (Min - Max)	3,00 [-37,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	43 (87,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS07: FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,67 (15,49)
Median (Min - Max)	-2,00 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS07: FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	32 (88,9)
Mean (SD)	0,93 (18,08)
Median (Min - Max)	-0,21 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	28 (96,6)
Mean (SD)	1,64 (18,74)
Median (Min - Max)	0,75 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	21 (84,0)
Mean (SD)	5,22 (17,37)
Median (Min - Max)	3,33 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	2,68 (15,81)
Median (Min - Max)	1,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	4,18 (19,67)
Median (Min - Max)	3,00 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS07: FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	6,91 (20,19)
Median (Min - Max)	5,00 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	10,27 (16,51)
Median (Min - Max)	8,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	5,06 (26,49)
Median (Min - Max)	6,00 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS07: FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS07: FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	93 (73,8)
Mean (SD)	-4,86 (17,35)
Median (Min - Max)	-5,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.12.8 *Merkmal: Double/Triple-Hit*

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym TOI	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	72,61 (17,03)
Median (Min - Max)	71,50 [43,33-104,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	4,70 (12,92)
Median (Min - Max)	2,50 [-20,00-27,50]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	13,12 (15,13)
Median (Min - Max)	12,67 [-12,00-35,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	21,39 (21,47)
Median (Min - Max)	16,33 [1,00-62,67]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	5,93 (22,36)
Median (Min - Max)	21,00 [-19,00-24,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	13,89 (23,69)
Median (Min - Max)	23,00 [-13,00-31,67]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	21,25 (5,69)
Median (Min - Max)	20,00 [16,29-27,45]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	28,33 (9,02)
Median (Min - Max)	24,33 [22,00-38,67]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	24,48 (1,14)
Median (Min - Max)	24,48 [23,67-25,29]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	33,66 (6,52)
Median (Min - Max)	33,66 [29,05-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	39,19 (14,41)
Median (Min - Max)	39,19 [29,00-49,38]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	33,83 (9,66)
Median (Min - Max)	33,83 [27,00-40,67]
FACT-Lym TOI - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	55,33 (NE)
Median (Min - Max)	55,33 [55,33-55,33]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-1,72 (26,50)
Median (Min - Max)	7,00 [-43,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym TOI	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	111 (95,7)
Mean (SD)	80,75 (18,42)
Median (Min - Max)	84,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	93 (89,4)
Mean (SD)	-0,29 (12,46)
Median (Min - Max)	-0,20 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	65 (83,3)
Mean (SD)	-0,29 (15,45)
Median (Min - Max)	0,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	0,51 (14,66)
Median (Min - Max)	1,33 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)
Mean (SD)	-1,53 (14,55)
Median (Min - Max)	-2,29 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,41 (17,37)
Median (Min - Max)	-2,00 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	25 (96,2)
Median (Min - Max)	-0,72 (18,40)
	-1,00 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	18 (81,8)
Median (Min - Max)	1,36 (15,34)
	1,50 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	0,26 (14,74)
	0,46 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	-1,18 (15,96)
	2,00 [-30,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,45 (14,05)
Median (Min - Max)	1,50 [-18,50-21,83]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	4,38 (11,78)
Median (Min - Max)	5,50 [-15,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-1,23 (19,89)
Median (Min - Max)	2,50 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS08: FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,3)
Mean (SD)	-5,34 (16,23)
Median (Min - Max)	-6,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.12.9 *Merkmal: Transformation des DLBCL*

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym TOI	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	80,95 (19,30)
Median (Min - Max)	87,00 [45,00-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	-2,16 (18,06)
Median (Min - Max)	-1,10 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-1,37 (15,71)
Median (Min - Max)	0,00 [-29,00-33,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	1,27 (15,62)
Median (Min - Max)	3,00 [-27,00-24,83]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-3,60 (12,27)
Median (Min - Max)	-5,50 [-20,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	9,06 (18,90)
Median (Min - Max)	3,00 [-6,71-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	7,38 (19,32)
Median (Min - Max)	1,00 [-7,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	9,50 (20,37)
Median (Min - Max)	0,00 [-2,00-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-8,33 (13,65)
Median (Min - Max)	-2,00 [-24,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,67 (17,67)
Median (Min - Max)	-1,00 [-30,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,45 (10,66)
Median (Min - Max)	-1,36 [-15,00-6,00]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-1,00 (6,00)
Median (Min - Max)	-1,00 [-7,00-5,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,33 (9,07)
Median (Min - Max)	-1,00 [-12,00-6,00]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,36 (2,32)
Median (Min - Max)	2,36 [0,71-4,00]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-6,00 (13,00)
Median (Min - Max)	1,00 [-21,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-13,00 (19,80)
Median (Min - Max)	-13,00 [-27,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-10,00 (15,56)
Median (Min - Max)	-10,00 [-21,00-1,00]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-14,00 (18,38)
Median (Min - Max)	-14,00 [-27,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (79,2)
Mean (SD)	-6,91 (18,85)
Median (Min - Max)	-7,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym TOI	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	102 (96,2)
Mean (SD)	79,59 (18,27)
Median (Min - Max)	82,00 [24,00-108,83]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	85 (89,5)
Mean (SD)	0,85 (10,94)
Median (Min - Max)	0,00 [-30,00-27,50]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	60 (85,7)
Mean (SD)	1,73 (16,00)
Median (Min - Max)	1,50 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	47 (87,0)
Mean (SD)	2,99 (16,90)
Median (Min - Max)	1,67 [-37,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	33 (84,6)
Mean (SD)	0,22 (16,41)
Median (Min - Max)	0,83 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	27 (87,1)
Mean (SD)	-0,57 (17,88)
Median (Min - Max)	-2,62 [-38,00-33,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	23 (95,8)
Median (Min - Max)	0,39 (18,81)
	0,50 [-58,00-28,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	17 (85,0)
Median (Min - Max)	4,21 (17,13)
	4,00 [-28,00-38,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	4,62 (15,71)
	4,33 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	8,33 (19,07)
	6,50 [-21,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	10,36 (21,88)
Median (Min - Max)	12,00 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	15,10 (17,50)
Median (Min - Max)	17,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	8,75 (32,26)
Median (Min - Max)	15,73 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-5,42 (29,61)
Median (Min - Max)	-5,42 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-9,60 (40,44)
Median (Min - Max)	-9,60 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,74 (37,81)
Median (Min - Max)	-8,74 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-9,87 (37,09)
	-9,87 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	16,00 (NE)
	16,00 [16,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	14,50 (NE)
	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS09: FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	75 (70,8)
Mean (SD)	-4,51 (16,99)
Median (Min - Max)	-5,00 [-43,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

3.12.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym TOI	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	82,62 (16,69)
Median (Min - Max)	86,33 [47,05-107,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	-0,01 (11,36)
Median (Min - Max)	0,00 [-21,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	1,27 (16,00)
Median (Min - Max)	2,00 [-31,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	22 (81,5)
Mean (SD)	1,94 (15,13)
Median (Min - Max)	-0,50 [-27,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,11 (15,05)
Median (Min - Max)	2,42 [-23,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	4,29 (15,89)
Median (Min - Max)	4,21 [-18,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	13 (92,9)
Median (Min - Max)	3,01 (17,87)
	4,00 [-22,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	4,81 (17,85)
	4,50 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-2,73 (15,49)
	0,46 [-30,00-19,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	2,25 (18,03)
	3,50 [-21,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,71 (16,39)
Median (Min - Max)	1,50 [-18,00-21,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	3,67 (17,62)
	6,00 [-15,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-3,70 (28,30)
	-0,39 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	34 (79,1)
Median (Min - Max)	-5,39 (18,66)
	-4,86 [-43,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym TOI	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	83,87 (14,71)
Median (Min - Max)	84,00 [50,00-108,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-1,08 (8,98)
Median (Min - Max)	1,00 [-23,00-17,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-2,35 (16,76)
Median (Min - Max)	0,00 [-41,00-25,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,12 (14,05)
Median (Min - Max)	-1,00 [-37,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-2,86 (6,75)
Median (Min - Max)	-3,25 [-14,83-6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-5,96 (8,87)
Median (Min - Max)	-8,25 [-16,36-6,07]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,83 (8,81)
	-2,00 [-2,50-13,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,74 (11,61)
	-1,00 [-12,21-11,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,55 (10,41)
	-2,00 [-8,36-12,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-1,00 (14,14)
	-1,00 [-11,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,25 (21,57)
Median (Min - Max)	-3,25 [-18,50-12,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	10,00 (NE)
	10,00 [10,00-10,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-26,36 (NE)
	-26,36 [-26,36--26,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-38,19 (NE)
	-38,19 [-38,19--38,19]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-35,48 (NE)
	-35,48 [-35,48--35,48]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS10: FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-36,10 (NE)
Median (Min - Max)	-36,10 [-36,10--36,10]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	16 (76,2)
Median (Min - Max)	-7,00 (15,50)
	-7,00 [-34,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.12.11 Merkmal: Maximaler längster Durchmesser

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
FACT-Lym TOI	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	72 (94,7)
Mean (SD)	80,78 (17,74)
Median (Min - Max)	84,00 [32,00-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	61 (88,4)
Mean (SD)	1,50 (11,96)
Median (Min - Max)	0,00 [-23,00-35,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	50 (87,7)
Mean (SD)	1,11 (17,56)
Median (Min - Max)	0,50 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	39 (90,7)
Mean (SD)	2,86 (15,83)
Median (Min - Max)	3,00 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	28 (87,5)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,53 (14,96)
Median (Min - Max)	2,50 [-45,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	-1,22 (18,72)
Median (Min - Max)	-0,21 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	0,28 (18,93)
Median (Min - Max)	0,50 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	15 (83,3)
Mean (SD)	4,31 (15,04)
Median (Min - Max)	2,00 [-21,74-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	3,17 (13,29)
Median (Min - Max)	1,00 [-24,00-25,29]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	2,81 (17,66)
Median (Min - Max)	2,50 [-30,00-29,05]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	4,39 (15,72)
Median (Min - Max)	4,00 [-18,50-29,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	9,57 (12,16)
Median (Min - Max)	6,00 [-7,00-27,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	1,49 (19,81)
Median (Min - Max)	6,00 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1 6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1 5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 16 Day 1 4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1 4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	54 (71,1)
Mean (SD)	-2,65 (18,32)
Median (Min - Max)	-3,50 [-40,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym TOI	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	79,23 (19,98)
Median (Min - Max)	82,50 [24,00-107,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	-1,86 (10,12)
Median (Min - Max)	0,00 [-30,00-13,50]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-1,23 (9,21)
Median (Min - Max)	1,00 [-29,00-9,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-0,04 (9,50)
Median (Min - Max)	1,00 [-20,00-12,71]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-1,08 (16,46)
Median (Min - Max)	-4,00 [-23,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	6,77 (14,08)
Median (Min - Max)	6,07 [-7,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	6,89 (15,07)
Median (Min - Max)	6,83 [-12,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	8,54 (13,98)
Median (Min - Max)	9,07 [-9,00-25,00]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	3,74 (16,70)
Median (Min - Max)	1,00 [-19,74-25,50]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	9,00 (NE)
Median (Min - Max)	9,00 [9,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	12,00 (NE)
Median (Min - Max)	12,00 [12,00-12,00]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	10,00 (NE)
Median (Min - Max)	10,00 [10,00-10,00]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-9,64 (15,17)
Median (Min - Max)	-7,02 [-43,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym TOI	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	76,90 (15,57)
Median (Min - Max)	72,17 [60,00-102,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-6,53 (26,05)
Median (Min - Max)	1,08 [-56,00-14,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	3,39 (13,46)
Median (Min - Max)	9,17 [-12,00-13,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-7,21 (18,34)
Median (Min - Max)	-9,50 [-27,00-17,17]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-19,50 (0,71)
Median (Min - Max)	-19,50 [-20,00--19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-11,50 (NE)
Median (Min - Max)	-11,50 [-11,50--11,50]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-22,00 (NE)
Median (Min - Max)	-22,00 [-22,00--22,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-28,00 (NE)
Median (Min - Max)	-28,00 [-28,00--28,00]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-30,00 (NE)
Median (Min - Max)	-30,00 [-30,00--30,00]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-21,00 (NE)
Median (Min - Max)	-21,00 [-21,00--21,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-18,00 (NE)
Median (Min - Max)	-18,00 [-18,00--18,00]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-15,00 (NE)
Median (Min - Max)	-15,00 [-15,00--15,00]
FACT-Lym TOI - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-20,29 (NE)
Median (Min - Max)	-20,29 [-20,29--20,29]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	4 (44,4)
Mean (SD)	-8,67 (19,77)
Median (Min - Max)	-16,00 [-23,00-20,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym TOI	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	76,43 (18,41)
Median (Min - Max)	82,00 [50,00-103,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	3,06 (5,19)
	6,00 [-4,52-7,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	6,00 (1,41)
	6,00 [5,00-7,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	5,00 (0,00)
	5,00 [5,00-5,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,50 (NE)
	-3,50 [-3,50--3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS11: FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
> 10 cm	
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-5,34 (8,46)
Median (Min - Max)	-4,71 [-17,00-4,04]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.12.12 Merkmal: Primärdiagnose

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym TOI	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	108 (96,4)
Mean (SD)	80,61 (18,15)
Median (Min - Max)	83,50 [24,00-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	101
Treated patients with non-missing values - n(%)	92 (91,1)
Mean (SD)	0,10 (12,36)
Median (Min - Max)	0,00 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	65 (83,3)
Mean (SD)	0,13 (15,80)
Median (Min - Max)	1,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	0,93 (14,76)
Median (Min - Max)	2,33 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,53 (14,55)
Median (Min - Max)	-2,29 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,41 (17,37)
Median (Min - Max)	-2,00 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	25 (96,2)
Median (Min - Max)	-0,72 (18,40)
	-1,00 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	18 (81,8)
Median (Min - Max)	1,36 (15,34)
	1,50 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	0,26 (14,74)
	0,46 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	-1,18 (15,96)
	2,00 [-30,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,45 (14,05)
Median (Min - Max)	1,50 [-18,50-21,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	4,38 (11,78)
	5,50 [-15,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-1,23 (19,89)
	2,50 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	4 (66,7)
Median (Min - Max)	-1,53 (17,73)
	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-7,44 (22,30)
	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-10,87 (24,77)
	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-9,93 (23,22)
	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-4,00 (21,66)
	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	7,50 (10,61)
	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	6,75 (10,96)
	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	82 (73,2)
Mean (SD)	-5,07 (16,45)
Median (Min - Max)	-5,50 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym TOI	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	77,03 (17,93)
Median (Min - Max)	75,00 [43,33-104,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	2,36 (15,32)
Median (Min - Max)	0,00 [-20,00-27,50]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,27 (12,61)
Median (Min - Max)	12,67 [3,64-35,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	22,67 (23,75)
Median (Min - Max)	17,67 [1,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,93 (22,36)
Median (Min - Max)	21,00 [-19,00-24,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	13,89 (23,69)
Median (Min - Max)	23,00 [-13,00-31,67]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	21,25 (5,69)
Median (Min - Max)	20,00 [16,29-27,45]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	28,33 (9,02)
Median (Min - Max)	24,33 [22,00-38,67]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	24,48 (1,14)
Median (Min - Max)	24,48 [23,67-25,29]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	33,66 (6,52)
Median (Min - Max)	33,66 [29,05-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS12: FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	39,19 (14,41)
Median (Min - Max)	39,19 [29,00-49,38]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	33,83 (9,66)
Median (Min - Max)	33,83 [27,00-40,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	55,33 (NE)
Median (Min - Max)	55,33 [55,33-55,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-5,81 (26,47)
Median (Min - Max)	-17,00 [-43,00-30,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

3.12.13 Merkmal: Anzahl der vorherigen systemischen Therapien

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym TOI	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	83,06 (17,88)
Median (Min - Max)	83,50 [24,00-110,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	46 (88,5)
Mean (SD)	-1,51 (10,62)
Median (Min - Max)	-0,60 [-30,00-26,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	29 (76,3)
Mean (SD)	-3,14 (16,19)
Median (Min - Max)	-3,00 [-31,00-27,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	22 (75,9)
Mean (SD)	1,67 (14,35)
Median (Min - Max)	3,00 [-34,00-23,70]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	16 (72,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-3,32 (17,09)
Median (Min - Max)	-0,58 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-4,63 (18,80)
Median (Min - Max)	-4,67 [-38,00-33,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-4,99 (18,39)
Median (Min - Max)	-2,50 [-58,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	0,17 (12,84)
Median (Min - Max)	1,00 [-21,74-25,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,97 (15,02)
Median (Min - Max)	1,00 [-24,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,40 (17,78)
Median (Min - Max)	2,00 [-30,00-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,72 (12,76)
Median (Min - Max)	1,32 [-18,50-14,52]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	3,50 (10,25)
Median (Min - Max)	2,00 [-7,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-1,51 (19,88)
Median (Min - Max)	2,50 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	10,00 (14,14)
	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	17,00 (NE)
	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	44 (74,6)
Median (Min - Max)	-9,25 (16,57)
	-10,50 [-43,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym TOI	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	79,40 (16,41)
Median (Min - Max)	82,00 [49,00-104,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	26 (86,7)
Mean (SD)	-0,45 (16,35)
Median (Min - Max)	-0,50 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	4,85 (14,45)
Median (Min - Max)	2,50 [-25,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,09 (17,07)
Median (Min - Max)	-3,00 [-27,00-28,00]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-2,25 (18,45)
Median (Min - Max)	-5,25 [-23,00-27,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,72 (20,00)
Median (Min - Max)	-1,33 [-13,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	11,75 (23,64)
Median (Min - Max)	9,00 [-12,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,75 (21,61)
Median (Min - Max)	2,00 [-9,00-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	6,00 (11,36)
Median (Min - Max)	1,00 [-2,00-19,00]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,00 (24,04)
Median (Min - Max)	6,00 [-11,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	21,83 (NE)
Median (Min - Max)	21,83 [21,83-21,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	19,50 (NE)
Median (Min - Max)	19,50 [19,50-19,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	21 (65,6)
Mean (SD)	-1,42 (18,01)
Median (Min - Max)	-2,00 [-43,00-28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym TOI	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	75,26 (19,98)
Median (Min - Max)	78,00 [32,00-105,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	33 (97,1)
Mean (SD)	3,35 (11,40)
Median (Min - Max)	1,00 [-23,00-27,50]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	26 (96,3)
Mean (SD)	3,45 (15,95)
Median (Min - Max)	4,42 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)
Mean (SD)	5,68 (18,55)
Median (Min - Max)	4,00 [-37,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	2,76 (11,99)
Median (Min - Max)	-2,00 [-19,00-24,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	6,96 (14,27)
Median (Min - Max)	7,54 [-12,00-31,67]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	8,17 (14,21)
Median (Min - Max)	9,00 [-22,00-27,45]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	9,13 (20,39)
Median (Min - Max)	9,00 [-28,00-38,67]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,16 (20,78)
Median (Min - Max)	5,00 [-30,00-25,29]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	8,22 (22,54)
Median (Min - Max)	6,50 [-21,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS13: FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	14,28 (26,12)
Median (Min - Max)	12,00 [-18,00-49,38]
FACT-Lym TOI - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	13,73 (21,22)
Median (Min - Max)	10,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	17,52 (53,47)
Median (Min - Max)	17,52 [-20,29-55,33]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	29 (74,4)
Mean (SD)	-1,12 (16,96)
Median (Min - Max)	-1,00 [-34,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

3.12.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym TOI	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	89 (96,7)
Mean (SD)	80,59 (18,34)
Median (Min - Max)	83,00 [24,00-108,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 86
Treated patients with non-missing values - n(%)	77 (89,5)
Mean (SD)	0,55 (13,62)
Median (Min - Max)	0,00 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 66
Treated patients with non-missing values - n(%)	55 (83,3)
Mean (SD)	0,42 (16,90)
Median (Min - Max)	1,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 49
Treated patients with non-missing values - n(%)	43 (87,8)
Mean (SD)	0,72 (16,14)
Median (Min - Max)	3,00 [-37,00-28,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 34
Treated patients with non-missing values - n(%)	31 (91,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,04 (15,99)
Median (Min - Max)	-2,57 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	1,88 (18,23)
Median (Min - Max)	0,50 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	22 (95,7)
Median (Min - Max)	0,32 (20,14)
	2,17 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	15 (78,9)
Median (Min - Max)	2,96 (17,51)
	3,33 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,20 (16,76)
	1,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	-0,63 (18,71)
	3,00 [-30,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,23 (15,85)
Median (Min - Max)	2,50 [-18,50-21,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	5,14 (12,51)
	6,00 [-15,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	4,36 (16,98)
	8,98 [-20,29-21,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	-2,28 (21,63)
	4,00 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-9,55 (25,17)
	-9,50 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-14,83 (28,74)
Median (Min - Max)	-27,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-13,58 (27,00)
	-21,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-5,50 (30,41)
	-5,50 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	14,50 (NE)
	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	17,00 (NE)
	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	64 (69,6)
Median (Min - Max)	-4,18 (17,64)
	-5,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym TOI	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	81,87 (17,95)
Median (Min - Max)	83,00 [47,05-110,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	-2,15 (8,03)
	-0,10 [-20,00-14,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	-0,32 (9,79)
	-1,50 [-17,00-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	9 (81,8)
Median (Min - Max)	2,04 (7,61)
	1,67 [-11,00-12,71]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	5 (62,5)
Median (Min - Max)	-4,00 (9,30)
	-2,00 [-20,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-6,84 (17,31)
Median (Min - Max)	-2,57 [-31,00-8,79]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,82 (1,11)
	-1,38 [-3,09--1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	0,05 (6,63)
	-1,00 [-6,00-7,14]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,36 (1,11)
	-2,00 [-2,00--0,07]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-5,50 (6,36)
	-5,50 [-10,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,36 (NE)
Median (Min - Max)	-1,36 [-1,36--1,36]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS14: FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	19 (86,4)
Median (Min - Max)	-9,55 (14,21)
	-8,00 [-43,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

3.12.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym TOI	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	80,62 (18,56)
Median (Min - Max)	86,00 [24,00-108,83]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	37
Treated patients with non-missing values - n(%)	33 (89,2)
Mean (SD)	-1,67 (14,58)
Median (Min - Max)	-1,00 [-56,00-25,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	26 (81,3)
Mean (SD)	-1,42 (17,29)
Median (Min - Max)	1,00 [-41,00-27,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	25
Treated patients with non-missing values - n(%)	20 (80,0)
Mean (SD)	0,02 (16,10)
Median (Min - Max)	3,00 [-37,00-23,70]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,52 (15,19)
Median (Min - Max)	1,42 [-20,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	3,85 (16,25)
Median (Min - Max)	4,21 [-19,33-33,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	2,14 (15,07)
	-1,00 [-22,00-28,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	0,92 (17,84)
	2,00 [-28,00-25,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	10 (100,0)
Median (Min - Max)	3,25 (18,53)
	6,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,25 (18,90)
	-3,50 [-30,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	3,23 (16,34)
Median (Min - Max)	8,00 [-18,00-21,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	5,00 (15,31)
	10,00 [-15,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-2,47 (23,27)
	-0,02 [-35,00-21,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1 (33,3)
Median (Min - Max)	15,52 (NE)
	15,52 [15,52-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,00 (28,28)
	-1,00 [-21,00-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-4,50 (31,82)
Median (Min - Max)	-4,50 [-27,00-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,32 (26,42)
	-2,32 [-21,00-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-5,50 (30,41)
	-5,50 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	14,50 (NE)
	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	17,00 (NE)
	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	28 (70,0)
Median (Min - Max)	-7,03 (16,37)
	-9,42 [-43,00-20,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym TOI	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	79,52 (18,69)
Median (Min - Max)	82,00 [32,00-110,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	68
Mean (SD)	61 (89,7)
Median (Min - Max)	0,46 (11,85)
	-0,20 [-30,00-35,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	45
Mean (SD)	39 (86,7)
Median (Min - Max)	1,08 (14,62)
	0,00 [-26,36-36,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	34
Mean (SD)	31 (91,2)
Median (Min - Max)	1,81 (13,88)
	3,00 [-34,00-26,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	20 (87,0)
Median (Min - Max)	-2,77 (14,77)
	-2,79 [-45,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,12 (17,98)
Median (Min - Max)	-2,31 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	-0,57 (22,12)
	2,17 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	3,83 (14,21)
	2,17 [-12,21-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-3,48 (7,59)
	-1,04 [-19,74-4,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	1,67 (2,52)
	2,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,71 (10,42)
Median (Min - Max)	-1,18 [-18,50-6,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	3,33 (3,79)
	5,00 [-1,00-6,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	2,50 (4,95)
	2,50 [-1,00-6,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-7,21 (16,66)
	0,71 [-26,36-4,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-11,73 (22,92)
	1,00 [-38,19-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-17,24 (25,79)
Median (Min - Max)	-17,24 [-35,48-1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-17,55 (26,23)
	-17,55 [-36,10-1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS15: FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	60 (75,9)
Mean (SD)	-5,18 (16,72)
Median (Min - Max)	-5,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

3.12.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym TOI	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	81,76 (18,16)
Median (Min - Max)	84,00 [47,05-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-1,98 (7,26)
Median (Min - Max)	-0,60 [-16,00-14,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-1,02 (9,70)
Median (Min - Max)	-2,00 [-17,00-18,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,05 (6,89)
Median (Min - Max)	0,00 [-11,00-12,71]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-7,25 (8,54)
Median (Min - Max)	-3,50 [-20,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-10,23 (16,42)
Median (Min - Max)	-9,36 [-31,00-8,79]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,24 (1,21)
	-2,24 [-3,09--1,38]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	3,07 (5,76)
	3,07 [-1,00-7,14]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-1,04 (1,36)
	-1,04 [-2,00--0,07]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,36 (NE)
Median (Min - Max)	-1,36 [-1,36--1,36]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-8,18 (12,52)
Median (Min - Max)	-6,05 [-30,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym TOI	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	100 (96,2)
Mean (SD)	79,78 (18,48)
Median (Min - Max)	82,50 [24,00-108,83]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	96
Mean (SD)	86 (89,6)
Median (Min - Max)	0,74 (13,26)
	0,00 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	73
Mean (SD)	62 (84,9)
Median (Min - Max)	1,05 (16,68)
	1,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	55
Mean (SD)	48 (87,3)
Median (Min - Max)	2,54 (17,77)
	3,50 [-37,00-62,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	40
Mean (SD)	37 (92,5)
Median (Min - Max)	-0,94 (15,81)
	-2,00 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	2,53 (18,00)
Median (Min - Max)	2,29 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	25 (96,2)
Median (Min - Max)	1,36 (19,61)
	1,00 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	18 (81,8)
Median (Min - Max)	4,39 (18,17)
	2,67 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	1,79 (16,20)
	1,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	2,39 (19,91)
	3,00 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	5,52 (20,84)
Median (Min - Max)	5,00 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	9,58 (17,08)
	8,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	5,81 (28,21)
	8,98 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	3 (50,0)
Median (Min - Max)	-2,28 (21,63)
	4,00 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-9,55 (25,17)
	-9,50 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-14,83 (28,74)
Median (Min - Max)	-27,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-13,58 (27,00)
	-21,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-5,50 (30,41)
	-5,50 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,00 (NE)
	15,00 [15,00-15,00]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	14,50 (NE)
	14,50 [14,50-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS16: FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,00 (NE)
Median (Min - Max)	20,00 [20,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	71 (68,3)
Mean (SD)	-4,49 (17,71)
Median (Min - Max)	-6,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.12.17 Merkmal: Vorherige CAR-T-Therapie

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym TOI	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	81,50 (18,95)
Median (Min - Max)	84,00 [53,00-104,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	6,17 (20,68)
Median (Min - Max)	3,00 [-20,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	10,00 (23,69)
Median (Min - Max)	14,00 [-21,00-33,00]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	12,71 (12,66)
Median (Min - Max)	13,50 [-1,00-24,83]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	17,33 (8,14)
Median (Min - Max)	21,00 [8,00-23,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	25,33 (14,64)
Median (Min - Max)	23,00 [12,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	21,67 (18,56)
Median (Min - Max)	20,00 [4,00-41,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	22,00 (18,00)
Median (Min - Max)	22,00 [4,00-40,00]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-0,67 (23,84)
Median (Min - Max)	4,00 [-43,00-22,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym TOI	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	117 (95,9)
Mean (SD)	79,73 (18,43)
Median (Min - Max)	82,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	99 (90,0)
Mean (SD)	-0,08 (11,97)
Median (Min - Max)	0,00 [-56,00-27,50]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	69 (84,1)
Mean (SD)	0,67 (15,41)
Median (Min - Max)	1,00 [-41,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	54 (85,7)
Mean (SD)	1,92 (16,65)
Median (Min - Max)	2,33 [-37,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	40 (87,0)
Mean (SD)	-2,02 (15,11)
Median (Min - Max)	-2,79 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	29 (87,9)
Mean (SD)	-1,59 (16,62)
Median (Min - Max)	-2,62 [-38,00-33,00]
FACT-Lym TOI - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-0,77 (17,61)
Median (Min - Max)	-1,00 [-58,00-28,00]
FACT-Lym TOI - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	2,42 (16,08)
Median (Min - Max)	1,50 [-28,00-38,67]
FACT-Lym TOI - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	3,03 (16,17)
Median (Min - Max)	1,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	4,19 (20,55)
Median (Min - Max)	2,50 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	7,63 (21,02)
Median (Min - Max)	6,00 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	10,74 (17,44)
Median (Min - Max)	10,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	5,06 (26,49)
Median (Min - Max)	6,00 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-1,53 (17,73)
Median (Min - Max)	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,44 (22,30)
Median (Min - Max)	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS17: FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	88 (72,1)
Mean (SD)	-5,29 (16,91)
Median (Min - Max)	-6,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

3.12.18 Merkmal: Arzneimittelformulierung

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym TOI	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	82,72 (17,30)
Median (Min - Max)	84,00 [43,00-107,00]
FACT-Lym TOI - Change from baseline	Cycle 2 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	1,75 (8,56)
Median (Min - Max)	1,17 [-23,00-17,00]
FACT-Lym TOI - Change from baseline	Cycle 3 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-1,11 (13,54)
Median (Min - Max)	0,00 [-41,00-18,00]
FACT-Lym TOI - Change from baseline	Cycle 4 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,88 (13,88)
Median (Min - Max)	2,33 [-37,00-15,00]
FACT-Lym TOI - Change from baseline	Cycle 5 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,83 (10,04)
Median (Min - Max)	-3,00 [-23,00-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,75 (10,01)
Median (Min - Max)	-2,00 [-18,00-3,00]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-4,93 (10,29)
Median (Min - Max)	-2,00 [-19,00-5,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,17 (5,11)
Median (Min - Max)	-1,50 [-9,00-3,33]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,11 (3,17)
Median (Min - Max)	1,00 [-2,00-4,33]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-11,00 (NE)
Median (Min - Max)	-11,00 [-11,00--11,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym TOI - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	21 (65,6)
Mean (SD)	-7,21 (14,68)
Median (Min - Max)	-10,00 [-34,00-15,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. TOI = trial outcome index
Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym TOI	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	93 (94,9)
Mean (SD)	78,85 (18,74)
Median (Min - Max)	82,00 [24,00-110,00]
FACT-Lym TOI - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	77 (87,5)
Mean (SD)	-0,26 (13,73)
Median (Min - Max)	-1,00 [-56,00-35,00]
FACT-Lym TOI - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	54 (83,1)
Mean (SD)	1,98 (16,67)
Median (Min - Max)	1,50 [-31,00-36,67]
FACT-Lym TOI - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	42 (84,0)
Mean (SD)	4,40 (17,30)
Median (Min - Max)	3,50 [-34,00-62,67]
FACT-Lym TOI - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	32 (84,2)
Mean (SD)	-0,26 (17,09)
Median (Min - Max)	-2,00 [-45,00-34,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym TOI - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	1,74 (18,94)
Median (Min - Max)	-0,21 [-38,00-41,00]
FACT-Lym TOI - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	3,06 (19,99)
Median (Min - Max)	1,00 [-58,00-41,00]
FACT-Lym TOI - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	17 (81,0)
Mean (SD)	6,95 (18,85)
Median (Min - Max)	5,00 [-28,00-40,00]
FACT-Lym TOI - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	2,96 (17,18)
Median (Min - Max)	1,00 [-30,00-25,50]
FACT-Lym TOI - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	5,44 (19,99)
Median (Min - Max)	3,50 [-30,00-38,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym TOI - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	6,91 (20,19)
Median (Min - Max)	5,00 [-18,50-49,38]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	10,27 (16,51)
	8,00 [-15,00-40,67]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	5,06 (26,49)
	6,00 [-35,00-55,33]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	4 (57,1)
Median (Min - Max)	-1,53 (17,73)
	2,36 [-26,36-15,52]
FACT-Lym TOI - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-7,44 (22,30)
	1,00 [-38,19-19,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym TOI - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-10,87 (24,77)
Median (Min - Max)	-13,00 [-35,48-18,00]
FACT-Lym TOI - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-9,93 (23,22)
Median (Min - Max)	-10,00 [-36,10-16,36]
FACT-Lym TOI - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-4,00 (21,66)
Median (Min - Max)	-1,00 [-27,00-16,00]
FACT-Lym TOI - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,50 (10,61)
Median (Min - Max)	7,50 [0,00-15,00]
FACT-Lym TOI - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,75 (10,96)
Median (Min - Max)	6,75 [-1,00-14,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FOC_PSHS18: FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym TOI - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym TOI - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,00 (14,14)
Median (Min - Max)	10,00 [0,00-20,00]
FACT-Lym TOI - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	17,00 (NE)
Median (Min - Max)	17,00 [17,00-17,00]
FACT-Lym TOI - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]
FACT-Lym TOI - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	73 (74,5)
Mean (SD)	-4,36 (18,03)
Median (Min - Max)	-5,00 [-43,00-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. TOI = trial outcome index
 Source Data: aqs, created on: 10JAN2023

Table LT3FGD_PSTS01: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Age group
 PRO set

3.13 Subgruppenanalysen zum FACT-Lym – FACT-G Gesamtscore (Zeit bis zur Verschlechterung)

3.13.1 Merkmal Alter

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	13 (22,8)
95%-CI	[12,7-35,8]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	12,06 [4,99-12,06]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [61,5-88,1]
Month 6	68,0 [47,4-82,0]
Month 12	60,5 [36,9-77,6]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS01: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	17 (32,1)
95%-CI	[19,9-46,3]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	5,78 [3,32-10,64]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [51,0-82,5]
Month 6	47,6 [25,7-66,7]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS01: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	6 (30,0)
95%-CI	[11,9-54,3]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	12,22[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [57,9-94,5]
Month 6	66,1 [34,7-85,0]
Month 12	66,1 [34,7-85,0]
Month 18	44,0 [8,8-75,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS02: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Sex
 PRO set

3.13.2 Merkmal: Geschlecht

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	14 (26,4)
95%-CI	[15,3-40,3]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[5,78-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,1 [67,7-92,6]
Month 6	67,9 [47,3-81,8]
Month 12	48,5 [22,0-70,7]
Month 18	24,2 [4,4-52,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS02: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	22 (28,6)
95%-CI	[18,8-40,0]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	6,05[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [55,4-80,6]
Month 6	54,0 [35,6-69,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS03: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Race group
 PRO set

3.13.3 *Merkmal: Ethnie*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	31 (27,0)
95%-CI	[19,1-36,0]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,3 [66,4-85,1]
Month 6	60,8 [46,2-72,6]
Month 12	41,0 [19,9-61,1]
Month 18	20,5 [4,1-45,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS03: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE [2,79-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,4 [33,6-86,7]
Month 6	53,9 [19,9-79,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS04: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Country
 PRO set

3.13.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	13 (25,5)
95%-CI	[14,3-39,6]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [59,9-88,5]
Month 6	64,3 [43,3-79,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS04: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	7 (24,1)
95%-CI	[10,3-43,5]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE [2,79-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,5 [47,2-87,1]
Month 6	65,2 [38,6-82,5]
Month 12	65,2 [38,6-82,5]
Month 18	65,2 [38,6-82,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS04: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	14 (29,2)
95%-CI	[17,0-44,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69 [4,73-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,4 [62,9-90,2]
Month 6	56,0 [31,2-74,9]
Month 12	37,3 [8,7-67,3]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS05: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Region
 PRO set

3.13.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	13 (25,5)
95%-CI	[14,3-39,6]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [59,9-88,5]
Month 6	64,3 [43,3-79,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS05: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	23 (29,1)
95%-CI	[19,4-40,4]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69 [4,73-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,7 [61,2-84,2]
Month 6	57,5 [39,8-71,7]
Month 12	46,0 [21,9-67,2]
Month 18	23,0 [4,4-50,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS06: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage
 PRO set

3.13.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[3,32-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	62,5 [14,2-89,3]
Month 12	31,3 [1,3-73,4]
Month 18	31,3 [1,3-73,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS06: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[3,71-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [54,0-96,3]
Month 6	53,7 [14,6-81,8]
Month 12	26,9 [1,4-66,8]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS06: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	4 (23,5)
95%-CI	[6,8-49,9]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE[0,72-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,0 [41,2-88,6]
Month 6	72,0 [41,2-88,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS06: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	23 (28,0)
95%-CI	[18,7-39,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	12,06[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [56,2-80,8]
Month 6	57,3 [40,2-71,1]
Month 12	52,1 [33,8-67,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS07: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Bulky disease
 PRO set

3.13.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	35 (27,8)
95%-CI	[20,2-36,5]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [66,0-83,9]
Month 6	60,2 [46,7-71,3]
Month 12	40,8 [20,1-60,6]
Month 18	20,4 [4,1-45,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS08: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Double/Triple hit
 PRO set

3.13.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	6 (42,9)
95%-CI	[17,7-71,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	4,44 [0,92-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,6 [39,8-91,1]
Month 6	44,8 [11,7-74,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS08: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	30 (25,9)
95%-CI	[18,2-34,8]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64 [5,78-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [64,7-83,9]
Month 6	61,6 [47,1-73,2]
Month 12	41,1 [17,3-63,7]
Month 18	20,5 [3,8-46,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS09: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Transformed DLBCL PRO set

3.13.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	5,78 [2,83-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,5 [44,9-87,9]
Month 6	41,9 [13,2-68,9]
Month 12	41,9 [13,2-68,9]
Month 18	21,0 [1,4-56,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS09: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	27 (25,5)
95%-CI	[17,5-34,9]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,6 [65,0-84,8]
Month 6	64,3 [49,8-75,6]
Month 12	36,3 [11,9-61,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS10: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: B-Cell type
 PRO set

3.13.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	13 (30,2)
95%-CI	[17,2-46,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [54,9-84,5]
Month 6	68,7 [50,0-81,6]
Month 12	45,8 [10,4-76,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS10: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69 [2,79-9,69]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [47,0-90,4]
Month 6	66,4 [35,4-85,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS11: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter PRO set

3.13.11 Merkmal: Maximaler längster Durchmesser

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	21 (27,6)
95%-CI	[18,0-39,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,7 [65,1-87,5]
Month 6	61,5 [43,6-75,3]
Month 12	45,9 [21,6-67,4]
Month 18	23,0 [4,4-50,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS11: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	11 (32,4)
95%-CI	[17,4-50,5]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE [2,79-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [47,1-83,5]
Month 6	51,3 [27,9-70,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS11: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS11: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS12: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Primary disease diagnosis
 PRO set

3.13.12 Merkmal: Primärdiagnose

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis: DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	30 (26,8)
95%-CI	[18,9-36,0]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64 [5,78-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [64,8-83,9]
Month 6	61,6 [47,2-73,2]
Month 12	41,1 [17,3-63,7]
Month 18	20,5 [3,8-46,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS12: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	6 (54,5)
95%-CI	[23,4-83,3]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	4,44[0,92-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [31,2-89,1]
Month 6	41,6 [10,4-71,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS13: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Number prior lines
 PRO set

3.13.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	19 (32,2)
95%-CI	[20,6-45,6]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[3,71-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,7 [57,8-84,4]
Month 6	56,2 [36,0-72,2]
Month 12	44,9 [20,5-66,8]
Month 18	22,5 [4,2-49,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS13: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	7 (21,9)
95%-CI	[9,3-40,0]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE[3,71-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [52,9-90,4]
Month 6	51,7 [18,9-77,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS13: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	10 (25,6)
95%-CI	[13,0-42,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[4,73-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,9 [58,5-90,0]
Month 6	68,5 [45,6-83,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS14: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - first line
 PRO set

3.13.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	25 (27,2)
95%-CI	[18,4-37,4]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-12,06]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,8 [62,0-83,8]
Month 6	59,3 [42,8-72,5]
Month 12	29,7 [6,1-59,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS14: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	6 (27,3)
95%-CI	[10,7-50,2]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE [1,64-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,1 [44,9-87,5]
Month 6	61,8 [31,5-81,8]
Month 12	61,8 [31,5-81,8]
Month 18	61,8 [31,5-81,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS15: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - last line
 PRO set

3.13.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	13 (32,5)
95%-CI	[18,6-49,1]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	10,64[4,44-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [58,0-88,9]
Month 6	53,1 [29,0-72,3]
Month 12	35,4 [8,3-64,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS15: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	21 (26,6)
95%-CI	[17,3-37,7]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[3,35-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [56,2-81,3]
Month 6	62,0 [46,0-74,6]
Month 12	41,4 [10,4-70,9]
Month 18	20,7 [1,2-56,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS16: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - any line
 PRO set

3.13.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE [1,64-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,7 [42,6-86,8]
Month 6	60,6 [30,3-81,0]
Month 12	60,6 [30,3-81,0]
Month 18	60,6 [30,3-81,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS16: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	28 (26,9)
95%-CI	[18,7-36,5]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [65,5-85,4]
Month 6	59,2 [43,8-71,7]
Month 12	39,5 [16,5-61,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS17: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Prior use of T-CART therapy
PRO set

3.13.17 Merkmal: Vorherige CAR-T-Therapie

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Prior use of T-CART therapy:
Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS17: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	34 (27,9)
95%-CI	[20,1-36,7]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[4,99-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,2 [65,5-84,0]
Month 6	58,6 [44,3-70,3]
Month 12	39,4 [19,2-59,1]
Month 18	19,7 [4,0-44,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS18: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Drug formulation
 PRO set

3.13.18 *Merkmal: Arzneimittelformulierung*

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	9 (28,1)
95%-CI	[13,7-46,7]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	NE [2,83-NE]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,6 [42,0-81,4]
Month 6	54,6 [26,9-75,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGD_PSTS18: Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym FACT-G total score by at least 17 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation: Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	27 (27,6)
95%-CI	[19,0-37,5]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points in months [95%-CI]	
Median	9,69[5,78-12,22]
FACT-Lym FACT-G total score - Time to decrease by at least 17 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [68,2-87,4]
Month 6	61,8 [46,3-74,0]
Month 12	41,6 [20,0-62,0]
Month 18	20,8 [4,1-46,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

3.14 Subgruppenanalysen zum FACT-Lym – FACT-G Gesamtscore (Veränderung gegenüber Studienbeginn)

3.14.1 Merkmal Alter

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	56 (98,2)
Mean (SD)	71,94 (15,09)
Median (Min - Max)	74,25 [35,00-99,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	46 (93,9)
Mean (SD)	1,51 (9,00)
Median (Min - Max)	1,92 [-20,67-22,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	35 (94,6)
Mean (SD)	-2,58 (13,62)
Median (Min - Max)	-3,00 [-38,50-30,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	1,88 (10,86)
Median (Min - Max)	2,92 [-28,27-20,70]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	20 (90,9)
Mean (SD)	-1,74 (9,85)
Median (Min - Max)	0,42 [-26,60-11,50]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	0,51 (11,66)
Median (Min - Max)	0,58 [-21,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	0,42 (11,09)
Median (Min - Max)	-1,17 [-17,10-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	3,75 (15,34)
Median (Min - Max)	0,50 [-19,50-27,83]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	0,94 (9,30)
Median (Min - Max)	-3,37 [-5,67-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,21 (6,88)
Median (Min - Max)	-2,87 [-12,00-7,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	4,71 (6,70)
Median (Min - Max)	5,33 [-2,83-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,44 (3,06)
Median (Min - Max)	4,13 [3,50-10,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,97 (12,68)
Median (Min - Max)	11,97 [3,00-20,93]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	6,00 (NE)
Median (Min - Max)	6,00 [6,00-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Age group:	
< 65 years	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	41 (71,9)
Mean (SD)	-5,41 (12,49)
Median (Min - Max)	-5,00 [-40,83-25,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	50 (94,3)
Mean (SD)	77,90 (15,33)
Median (Min - Max)	80,58 [46,00-103,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	43 (89,6)
Mean (SD)	-1,07 (13,15)
Median (Min - Max)	0,33 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	26 (76,5)
Mean (SD)	0,86 (17,37)
Median (Min - Max)	0,42 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-0,94 (18,05)
Median (Min - Max)	-2,00 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	-2,42 (19,48)
Median (Min - Max)	-3,00 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-2,17 (12,92)
Median (Min - Max)	1,50 [-31,00-12,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-1,13 (17,10)
Median (Min - Max)	3,73 [-41,00-12,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,52 (7,59)
Median (Min - Max)	-1,00 [-7,33-11,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-1,78 (12,42)
Median (Min - Max)	-4,33 [-17,20-13,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-0,80 (13,08)
Median (Min - Max)	3,33 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-2,84 (11,77)
Median (Min - Max)	-1,00 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	3,96 (10,22)
Median (Min - Max)	5,02 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-2,19 (15,06)
Median (Min - Max)	-9,87 [-11,87-15,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-20,57 (NE)
Median (Min - Max)	-20,57 [-20,57--20,57]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-21,20 (NE)
Median (Min - Max)	-21,20 [-21,20--21,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-20,75 (0,92)
Median (Min - Max)	-20,75 [-21,40--20,10]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-17,20 (NE)
Median (Min - Max)	-17,20 [-17,20--17,20]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-20,20 (NE)
Median (Min - Max)	-20,20 [-20,20--20,20]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	41 (77,4)
Mean (SD)	-7,78 (17,52)
Median (Min - Max)	-7,00 [-39,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	77,72 (17,06)
Median (Min - Max)	78,20 [28,67-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-1,11 (12,72)
Median (Min - Max)	1,42 [-29,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	5,43 (10,23)
Median (Min - Max)	3,67 [-7,00-29,83]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	4,72 (11,23)
Median (Min - Max)	0,50 [-12,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	3,92 (14,16)
Median (Min - Max)	3,68 [-15,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	2,50 (18,14)
Median (Min - Max)	4,17 [-19,67-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	9,30 (10,23)
Median (Min - Max)	7,00 [1,83-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	7,00 (14,85)
Median (Min - Max)	1,67 [-4,17-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	5,67 (2,50)
Median (Min - Max)	4,67 [4,00-9,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-3,58 (0,59)
Median (Min - Max)	-3,58 [-4,00--3,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-4,08 (5,54)
Median (Min - Max)	-4,08 [-8,00--0,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,17 (26,96)
Median (Min - Max)	4,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,20 (NE)
Median (Min - Max)	-1,20 [-1,20--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS01: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-4,46 (16,61)
Median (Min - Max)	-8,20 [-25,17-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

3.14.2 Merkmal: Geschlecht

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	48 (90,6)
Mean (SD)	73,19 (16,04)
Median (Min - Max)	75,25 [28,67-101,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	38 (82,6)
Mean (SD)	3,24 (8,96)
Median (Min - Max)	2,58 [-11,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	29 (80,6)
Mean (SD)	2,33 (13,08)
Median (Min - Max)	3,17 [-17,00-30,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	21 (75,0)
Mean (SD)	3,25 (11,93)
Median (Min - Max)	4,00 [-26,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	20 (87,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,13 (12,82)
Median (Min - Max)	1,02 [-31,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	0,26 (13,61)
Median (Min - Max)	2,17 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,54 (13,58)
Median (Min - Max)	1,83 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	3,82 (9,72)
Median (Min - Max)	0,75 [-5,37-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	-2,09 (8,62)
Median (Min - Max)	-3,73 [-17,20-12,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	-3,10 (7,44)
Median (Min - Max)	-3,17 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,89 (8,32)
Median (Min - Max)	-1,00 [-16,77-9,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	2,56 (5,57)
Median (Min - Max)	4,00 [-8,87-9,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,39 (18,87)
Median (Min - Max)	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	38 (71,7)
Mean (SD)	-6,60 (15,08)
Median (Min - Max)	-5,83 [-39,00-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	77 (100,0)
Mean (SD)	76,46 (15,37)
Median (Min - Max)	78,00 [42,93-103,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	68 (97,1)
Mean (SD)	-1,74 (12,27)
Median (Min - Max)	-1,42 [-41,00-28,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	45 (90,0)
Mean (SD)	-1,44 (15,59)
Median (Min - Max)	-1,83 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	37 (94,9)
Mean (SD)	0,04 (15,25)
Median (Min - Max)	-1,00 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-1,61 (16,02)
Median (Min - Max)	-4,00 [-26,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,36 (12,80)
Median (Min - Max)	-0,83 [-21,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	3,43 (12,64)
Median (Min - Max)	3,67 [-17,10-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	2,94 (17,18)
Median (Min - Max)	0,00 [-19,50-27,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,48 (9,21)
Median (Min - Max)	8,67 [-5,00-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,44 (11,65)
Median (Min - Max)	7,67 [-12,00-8,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS02: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	11,25 (0,35)
Median (Min - Max)	11,25 [11,00-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	12,33 (3,30)
Median (Min - Max)	12,33 [10,00-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	15,17 (NE)
Median (Min - Max)	15,17 [15,17-15,17]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	57 (74,0)
Mean (SD)	-6,11 (15,57)
Median (Min - Max)	-6,50 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

3.14.3 *Merkmal: Ethnie*

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	110 (95,7)
Mean (SD)	74,81 (15,94)
Median (Min - Max)	76,08 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	94 (90,4)
Mean (SD)	0,22 (11,62)
Median (Min - Max)	1,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	74
Treated patients with non-missing values - n(%)	62 (83,8)
Mean (SD)	0,26 (14,79)
Median (Min - Max)	-0,08 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	56
Treated patients with non-missing values - n(%)	48 (85,7)
Mean (SD)	1,64 (14,79)
Median (Min - Max)	1,00 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	41
Treated patients with non-missing values - n(%)	36 (87,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,65 (15,33)
Median (Min - Max)	-1,25 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	-1,12 (12,99)
Median (Min - Max)	-0,83 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	0,64 (13,30)
Median (Min - Max)	1,83 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	2,27 (12,39)
Median (Min - Max)	0,42 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	0,22 (9,46)
Median (Min - Max)	-1,88 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	11 (78,6)
Mean (SD)	-2,93 (7,99)
Median (Min - Max)	-3,17 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-1,50 (8,99)
Median (Min - Max)	-0,58 [-16,77-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	3,49 (5,79)
Median (Min - Max)	4,13 [-8,87-10,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,39 (18,87)
Median (Min - Max)	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,60 (NE)
	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-6,00 (NE)
	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Race group:	
White	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	83 (72,2)
Mean (SD)	-6,81 (15,33)
Median (Min - Max)	-6,67 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	78,11 (13,37)
Median (Min - Max)	78,20 [57,67-99,83]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-1,36 (9,96)
Median (Min - Max)	0,58 [-21,83-10,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-1,10 (14,68)
Median (Min - Max)	0,85 [-38,50-16,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-0,88 (10,62)
Median (Min - Max)	-0,75 [-16,83-13,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-2,34 (9,57)
Median (Min - Max)	0,83 [-17,00-8,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,92 (13,28)
Median (Min - Max)	6,75 [-13,50-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5,87 (12,42)
Median (Min - Max)	7,00 [-8,50-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	10,50 (17,59)
Median (Min - Max)	11,00 [-7,33-27,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	13,67 (NE)
Median (Min - Max)	13,67 [13,67-13,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	8,67 (NE)
Median (Min - Max)	8,67 [8,67-8,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS03: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	11,50 (NE)
Median (Min - Max)	11,50 [11,50-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	14,67 (NE)
	14,67 [14,67-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	15,17 (NE)
	15,17 [15,17-15,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	12 (80,0)
Median (Min - Max)	-2,84 (15,27)
	-1,00 [-25,83-25,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

3.14.4 Merkmal: Region-1

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	75,15 (15,42)
Median (Min - Max)	73,83 [35,00-101,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	-0,30 (9,41)
Median (Min - Max)	0,17 [-29,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	1,69 (11,12)
Median (Min - Max)	0,00 [-17,00-29,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	0,42 (11,25)
Median (Min - Max)	0,50 [-26,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	-3,01 (12,87)
Median (Min - Max)	-4,17 [-31,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-0,09 (16,48)
Median (Min - Max)	2,17 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	3,09 (17,98)
Median (Min - Max)	6,83 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	10,10 (13,06)
Median (Min - Max)	11,00 [-7,33-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,82 (9,26)
Median (Min - Max)	3,63 [-5,67-13,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,07 (5,11)
Median (Min - Max)	5,25 [-2,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,50 (6,26)
Median (Min - Max)	7,17 [-2,83-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,08 (5,04)
Median (Min - Max)	6,63 [1,03-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,08 (17,51)
Median (Min - Max)	15,17 [-11,87-20,93]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-5,73 (15,07)
Median (Min - Max)	-4,50 [-39,00-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	79,78 (17,16)
Median (Min - Max)	81,00 [42,93-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	21 (87,5)
Mean (SD)	-1,21 (15,07)
Median (Min - Max)	0,33 [-41,00-28,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	11 (68,8)
Mean (SD)	4,15 (25,65)
Median (Min - Max)	6,50 [-38,50-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	7,24 (20,33)
Median (Min - Max)	7,17 [-16,00-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,62 (23,63)
Median (Min - Max)	-0,15 [-24,25-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,32 (10,27)
Median (Min - Max)	-1,17 [-13,50-17,10]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,31 (9,97)
Median (Min - Max)	5,33 [-8,50-18,73]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	10,74 (13,13)
Median (Min - Max)	3,33 [3,00-25,90]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,68 (11,04)
Median (Min - Max)	6,33 [-10,93-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-4,00 (NE)
Median (Min - Max)	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-8,00 (NE)
Median (Min - Max)	-8,00 [-8,00--8,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	14,50 (14,85)
Median (Min - Max)	14,50 [4,00-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,20 (NE)
Median (Min - Max)	-1,20 [-1,20--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	24 (82,8)
Mean (SD)	-0,93 (19,84)
Median (Min - Max)	-2,00 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	44 (91,7)
Mean (SD)	72,43 (14,74)
Median (Min - Max)	75,00 [28,67-100,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	41 (89,1)
Mean (SD)	1,04 (11,54)
Median (Min - Max)	2,83 [-35,17-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	-2,58 (12,57)
Median (Min - Max)	-1,00 [-40,17-30,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-0,57 (13,72)
Median (Min - Max)	0,33 [-37,17-19,50]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	0,85 (9,92)
Median (Min - Max)	1,65 [-26,60-18,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-0,11 (9,20)
Median (Min - Max)	2,00 [-16,37-12,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-1,56 (7,78)
Median (Min - Max)	1,00 [-17,10-9,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-5,64 (7,01)
Median (Min - Max)	-4,17 [-19,50-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-4,20 (7,57)
Median (Min - Max)	-4,00 [-17,20-5,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-8,81 (6,60)
Median (Min - Max)	-6,00 [-18,87--3,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-7,13 (8,90)
Median (Min - Max)	-6,38 [-16,77-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	-2,43 (9,10)
Median (Min - Max)	-2,43 [-8,87-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-11,79 (15,84)
Median (Min - Max)	-9,87 [-28,50-3,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-7,28 (18,79)
Median (Min - Max)	-7,28 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-12,10 (12,87)
Median (Min - Max)	-12,10 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-20,75 (0,92)
Median (Min - Max)	-20,75 [-21,40--20,10]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	-17,20 (NE)
Median (Min - Max)	-17,20 [-17,20--17,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-20,20 (NE)
Median (Min - Max)	-20,20 [-20,20--20,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS04: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	33 (68,8)
Mean (SD)	-10,00 (10,38)
Median (Min - Max)	-8,17 [-31,67-9,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

3.14.5 *Merkmal: Region-2*

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	75,15 (15,42)
Median (Min - Max)	73,83 [35,00-101,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	-0,30 (9,41)
Median (Min - Max)	0,17 [-29,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	1,69 (11,12)
Median (Min - Max)	0,00 [-17,00-29,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	0,42 (11,25)
Median (Min - Max)	0,50 [-26,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	-3,01 (12,87)
Median (Min - Max)	-4,17 [-31,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-0,09 (16,48)
Median (Min - Max)	2,17 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	3,09 (17,98)
Median (Min - Max)	6,83 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	10,10 (13,06)
Median (Min - Max)	11,00 [-7,33-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	3,82 (9,26)
Median (Min - Max)	3,63 [-5,67-13,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	4,07 (5,11)
Median (Min - Max)	5,25 [-2,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,50 (6,26)
Median (Min - Max)	7,17 [-2,83-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,08 (5,04)
Median (Min - Max)	6,63 [1,03-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,08 (17,51)
Median (Min - Max)	15,17 [-11,87-20,93]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-5,73 (15,07)
Median (Min - Max)	-4,50 [-39,00-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	75,24 (15,90)
Median (Min - Max)	78,00 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	63 (88,7)
Mean (SD)	0,28 (12,66)
Median (Min - Max)	2,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	43 (81,1)
Mean (SD)	-1,15 (16,82)
Median (Min - Max)	-0,50 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	33 (82,5)
Mean (SD)	1,79 (16,09)
Median (Min - Max)	1,00 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	0,58 (15,60)
Median (Min - Max)	1,20 [-26,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	0,05 (9,26)
Median (Min - Max)	-0,83 [-16,37-17,10]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	0,59 (8,82)
Median (Min - Max)	1,83 [-17,10-18,73]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-1,55 (11,04)
Median (Min - Max)	-1,00 [-19,50-25,90]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	-0,40 (9,96)
Median (Min - Max)	-0,77 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	-8,01 (6,22)
Median (Min - Max)	-5,00 [-18,87--3,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-7,31 (7,71)
Median (Min - Max)	-8,00 [-16,77-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,04 (7,73)
Median (Min - Max)	4,00 [-8,87-5,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,27 (19,69)
Median (Min - Max)	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS05: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Region:	
Non-USA	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	59 (74,7)
Mean (SD)	-6,66 (15,55)
Median (Min - Max)	-7,00 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.14.6 Merkmal: Krankheitsstadium nach Ann-Arbor

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	78,98 (14,69)
Median (Min - Max)	83,33 [53,08-100,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	4,11 (5,70)
Median (Min - Max)	1,96 [-2,00-13,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	7,63 (9,88)
Median (Min - Max)	4,50 [-0,50-22,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-0,94 (5,28)
Median (Min - Max)	-0,33 [-6,50-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-2,07 (3,49)
Median (Min - Max)	-1,25 [-7,00-1,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,28 (1,55)
Median (Min - Max)	-1,00 [-1,33-1,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-2,08 (5,54)
Median (Min - Max)	-2,08 [-6,00-1,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,17 (5,89)
Median (Min - Max)	-1,17 [-5,33-3,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,76 (7,48)
Median (Min - Max)	-4,33 [-10,93-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-3,00 (1,41)
Median (Min - Max)	-3,00 [-4,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-4,50 (4,95)
	-4,50 [-8,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	3,02 (2,80)
	3,02 [1,03-5,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-3,93 (11,22)
	-3,93 [-11,87-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,00 (NE)
	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,20 (NE)
	-1,20 [-1,20--1,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,67 (NE)
	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,60 (NE)
	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-6,00 (NE)
	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	7 (70,0)
Median (Min - Max)	-12,37 (14,87)
	-15,83 [-31,67-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	70,01 (12,86)
Median (Min - Max)	73,00 [46,00-90,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	3,66 (12,11)
Median (Min - Max)	6,00 [-35,17-28,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,80 (24,13)
Median (Min - Max)	-1,00 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	2,37 (24,38)
Median (Min - Max)	8,33 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	4,22 (23,92)
Median (Min - Max)	4,33 [-26,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,69 (16,79)
Median (Min - Max)	-5,72 [-21,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,40 (15,09)
Median (Min - Max)	1,83 [-17,10-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,06 (18,39)
Median (Min - Max)	-5,37 [-19,50-27,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,86 (8,27)
Median (Min - Max)	-0,77 [-11,97-4,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,17 (NE)
Median (Min - Max)	-3,17 [-3,17--3,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,47 (11,74)
	-8,47 [-16,77--0,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-28,50 (NE)
	-28,50 [-28,50--28,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-20,57 (NE)
	-20,57 [-20,57--20,57]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-20,10 (NE)
	-20,10 [-20,10--20,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	15 (71,4)
Median (Min - Max)	-2,89 (21,38)
	-5,17 [-27,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	79,49 (13,87)
Median (Min - Max)	78,08 [51,00-99,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-2,50 (13,17)
Median (Min - Max)	-2,00 [-21,83-22,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-7,78 (16,95)
Median (Min - Max)	-9,00 [-38,50-15,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,41 (11,50)
Median (Min - Max)	4,00 [-16,83-19,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	3,00 (7,23)
Median (Min - Max)	5,17 [-7,33-11,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,90 (10,15)
	2,00 [-13,50-10,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,80 (7,77)
	2,00 [-9,67-6,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-1,06 (5,34)
	0,50 [-7,00-3,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	0,33 (8,49)
	0,33 [-5,67-6,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,83 (NE)
	2,83 [2,83-2,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-2,83 (NE)
	-2,83 [-2,83--2,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,50 (NE)
	3,50 [3,50-3,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	11 (64,7)
Median (Min - Max)	-8,48 (16,81)
	-8,17 [-40,83-17,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	80 (97,6)
Mean (SD)	75,11 (16,54)
Median (Min - Max)	76,58 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 72
Treated patients with non-missing values - n(%)	66 (91,7)
Mean (SD)	-0,90 (11,22)
Median (Min - Max)	-0,08 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 54
Treated patients with non-missing values - n(%)	48 (88,9)
Mean (SD)	1,39 (11,06)
Median (Min - Max)	0,92 [-20,00-30,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 42
Treated patients with non-missing values - n(%)	35 (83,3)
Mean (SD)	0,97 (11,20)
Median (Min - Max)	0,50 [-26,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	-3,33 (12,97)
Median (Min - Max)	-3,33 [-31,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	1,09 (14,04)
	3,00 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	15 (93,8)
Median (Min - Max)	3,30 (15,00)
	7,00 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	11 (78,6)
Median (Min - Max)	8,47 (11,69)
	6,83 [-7,33-28,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	11 (91,7)
Median (Min - Max)	3,35 (10,94)
	5,17 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	-2,16 (10,23)
	-2,87 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	4,21 (9,19)
	7,17 [-12,60-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	6 (75,0)
Median (Min - Max)	5,51 (8,08)
	6,63 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	10,85 (14,24)
	15,17 [-9,87-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	1 (20,0)
Median (Min - Max)	6,00 (NE)
	6,00 [6,00-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-12,10 (12,87)
	-12,10 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-21,40 (NE)
	-21,40 [-21,40--21,40]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-17,20 (NE)
	-17,20 [-17,20--17,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-20,20 (NE)
	-20,20 [-20,20--20,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS06: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	62 (75,6)
Mean (SD)	-6,06 (13,40)
Median (Min - Max)	-6,25 [-39,00-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
 PRO set

3.14.7 *Merkmal: Bulky Erkrankung*

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	121 (96,0)
Mean (SD)	75,43 (15,58)
Median (Min - Max)	77,00 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	103 (91,2)
Mean (SD)	-0,01 (11,49)
Median (Min - Max)	1,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	74 (87,1)
Mean (SD)	0,04 (14,68)
Median (Min - Max)	-0,08 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	57 (86,4)
Mean (SD)	1,43 (14,13)
Median (Min - Max)	1,00 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	43 (87,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,92 (14,47)
Median (Min - Max)	-1,00 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	33 (91,7)
Mean (SD)	-0,02 (13,05)
Median (Min - Max)	1,50 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	27 (93,1)
Mean (SD)	1,61 (13,07)
Median (Min - Max)	1,83 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	21 (84,0)
Mean (SD)	3,45 (13,05)
Median (Min - Max)	0,50 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	0,93 (9,69)
Median (Min - Max)	-0,77 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	12 (80,0)
Mean (SD)	-1,97 (8,32)
Median (Min - Max)	-2,58 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,32 (9,39)
Median (Min - Max)	-0,17 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	4,73 (6,57)
Median (Min - Max)	4,27 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,23 (18,24)
Median (Min - Max)	3,50 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS07: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Bulky disease:

No

FACT-Lym FACT-G total score - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

94 (74,6)

Mean (SD)

-6,18 (15,33)

Median (Min - Max)

-6,25 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.14.8 Merkmal: Double/Triple-Hit

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	75,21 (14,12)
Median (Min - Max)	76,60 [53,08-101,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-0,54 (13,19)
Median (Min - Max)	1,08 [-29,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	5,97 (13,05)
Median (Min - Max)	6,17 [-15,83-29,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	4,03 (12,24)
Median (Min - Max)	2,48 [-12,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,03 (16,63)
Median (Min - Max)	-3,33 [-15,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	4,26 (20,63)
Median (Min - Max)	4,02 [-19,67-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,11 (16,07)
Median (Min - Max)	-1,00 [-1,33-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	19,14 (8,92)
Median (Min - Max)	17,33 [11,27-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,63 (10,42)
Median (Min - Max)	3,63 [-3,73-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,97 (6,65)
Median (Min - Max)	2,97 [-1,73-7,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,33 (0,94)
Median (Min - Max)	10,33 [9,67-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,13 (4,05)
Median (Min - Max)	7,13 [4,27-10,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,93 (NE)
Median (Min - Max)	20,93 [20,93-20,93]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-7,25 (18,84)
Median (Min - Max)	-3,08 [-35,33-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	111 (95,7)
Mean (SD)	75,20 (15,89)
Median (Min - Max)	77,00 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	94 (90,4)
Mean (SD)	0,12 (11,24)
Median (Min - Max)	1,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	66 (84,6)
Mean (SD)	-0,68 (14,80)
Median (Min - Max)	-0,65 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	0,88 (14,38)
Median (Min - Max)	0,75 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)
Mean (SD)	-1,18 (14,40)
Median (Min - Max)	-0,50 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,61 (12,08)
Median (Min - Max)	1,50 [-31,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,79 (12,82)
Median (Min - Max)	1,92 [-41,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	0,83 (11,84)
Median (Min - Max)	0,17 [-19,50-27,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	0,61 (9,90)
Median (Min - Max)	-0,77 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-2,95 (8,56)
Median (Min - Max)	-3,58 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,69 (8,68)
Median (Min - Max)	-1,00 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	4,05 (7,24)
Median (Min - Max)	4,00 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-0,44 (17,93)
Median (Min - Max)	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,60 (NE)
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-6,00 (NE)
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS08: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Double/Triple hit:	
No	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	86 (74,1)
Mean (SD)	-6,21 (15,01)
Median (Min - Max)	-6,58 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.14.9 *Merkmal: Transformation des DLBCL*

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	75,76 (15,49)
Median (Min - Max)	75,67 [46,00-103,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	-2,22 (11,88)
Median (Min - Max)	0,67 [-41,00-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-2,63 (13,12)
Median (Min - Max)	-0,50 [-30,50-16,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,78 (11,75)
Median (Min - Max)	0,30 [-16,00-18,80]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-3,72 (9,17)
Median (Min - Max)	-0,50 [-20,00-8,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,23 (11,00)
Median (Min - Max)	2,00 [-5,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,79 (9,82)
Median (Min - Max)	1,83 [0,80-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	6,21 (15,05)
Median (Min - Max)	2,00 [-7,00-27,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-6,07 (10,64)
Median (Min - Max)	-5,00 [-17,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-8,96 (8,58)
Median (Min - Max)	-4,00 [-18,87--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-6,53 (6,92)
Median (Min - Max)	-8,00 [-12,60-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,04 (7,73)
Median (Min - Max)	4,00 [-8,87-5,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,96 (7,73)
Median (Min - Max)	3,00 [-9,87-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,50 (4,95)
Median (Min - Max)	2,50 [-1,00-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-11,30 (14,28)
Median (Min - Max)	-11,30 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (79,2)
Mean (SD)	-9,37 (15,64)
Median (Min - Max)	-8,17 [-40,83-25,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	102 (96,2)
Mean (SD)	75,08 (15,76)
Median (Min - Max)	77,00 [28,67-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 95
Treated patients with non-missing values - n(%)	86 (90,5)
Mean (SD)	0,57 (11,30)
Median (Min - Max)	1,00 [-35,17-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 70
Treated patients with non-missing values - n(%)	61 (87,1)
Mean (SD)	0,61 (15,03)
Median (Min - Max)	0,00 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 54
Treated patients with non-missing values - n(%)	47 (87,0)
Mean (SD)	1,30 (14,72)
Median (Min - Max)	1,00 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 39
Treated patients with non-missing values - n(%)	33 (84,6)
Mean (SD)	-0,08 (15,75)
Median (Min - Max)	-1,50 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	-0,96 (13,33)
Median (Min - Max)	0,33 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	22 (91,7)
Median (Min - Max)	0,65 (13,71)
	1,98 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	17 (85,0)
Median (Min - Max)	2,80 (12,96)
	0,33 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	16 (94,1)
Median (Min - Max)	2,24 (9,28)
	1,70 [-11,97-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	0,36 (7,24)
	-1,73 [-12,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,01 (9,46)
Median (Min - Max)	2,25 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	6 (60,0)
Median (Min - Max)	7,08 (5,04)
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	4,15 (23,24)
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	1 (25,0)
Median (Min - Max)	-20,57 (NE)
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-20,10 (NE)
Median (Min - Max)	-20,10 [-20,10--20,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS09: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	76 (71,7)
Mean (SD)	-5,54 (15,22)
Median (Min - Max)	-5,58 [-39,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
 PRO set

3.14.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	77,79 (14,90)
Median (Min - Max)	78,00 [42,93-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	1,12 (12,03)
Median (Min - Max)	1,42 [-29,00-28,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	3,08 (18,10)
Median (Min - Max)	2,25 [-38,50-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	23 (85,2)
Mean (SD)	3,89 (16,71)
Median (Min - Max)	4,00 [-28,27-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	3,22 (18,47)
Median (Min - Max)	1,75 [-26,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	5,00 (13,23)
Median (Min - Max)	5,67 [-13,50-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	5,00 (13,16)
Median (Min - Max)	6,83 [-17,10-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	5,61 (16,43)
Median (Min - Max)	-1,83 [-14,10-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	3,14 (10,48)
Median (Min - Max)	1,70 [-10,93-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,58 (5,39)
Median (Min - Max)	0,42 [-3,17-8,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,88 (6,51)
Median (Min - Max)	-0,58 [-2,83-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	6,40 (7,26)
	3,50 [1,03-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-0,05 (24,55)
	1,65 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	34 (79,1)
Median (Min - Max)	-4,16 (18,48)
	-5,50 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	78,16 (12,45)
Median (Min - Max)	78,67 [51,00-99,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-1,36 (12,87)
Median (Min - Max)	1,00 [-35,17-19,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-3,22 (15,00)
Median (Min - Max)	2,00 [-40,17-17,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-2,61 (14,73)
Median (Min - Max)	-1,80 [-37,17-13,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-4,11 (9,85)
Median (Min - Max)	-4,50 [-24,25-6,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-5,14 (9,54)
Median (Min - Max)	-5,25 [-16,37-7,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	7,71 (5,06)
Median (Min - Max)	9,00 [2,13-12,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	0,49 (6,11)
Median (Min - Max)	0,00 [-5,37-6,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	-1,66 (12,33)
Median (Min - Max)	-5,00 [-11,97-12,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-1,50 (14,85)
	-1,50 [-12,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS10: FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-6,05 (15,16)
Median (Min - Max)	-6,05 [-16,77-4,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	9,00 (NE)
	9,00 [9,00-9,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-20,57 (NE)
	-20,57 [-20,57--20,57]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-20,10 (NE)
	-20,10 [-20,10--20,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	16 (76,2)
Median (Min - Max)	-7,16 (14,65)
	-5,25 [-27,00-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.14.11 Merkmal: Maximaler längster Durchmesser

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	72 (94,7)
Mean (SD)	74,66 (15,03)
Median (Min - Max)	76,00 [35,00-100,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	62 (89,9)
Mean (SD)	1,19 (11,85)
Median (Min - Max)	1,63 [-35,17-34,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	51 (89,5)
Mean (SD)	0,30 (16,18)
Median (Min - Max)	-0,50 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	39 (90,7)
Mean (SD)	1,97 (14,87)
Median (Min - Max)	0,50 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	28 (87,5)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,56 (15,56)
Median (Min - Max)	2,40 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	23 (92,0)
Mean (SD)	-0,57 (14,74)
Median (Min - Max)	2,00 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	1,66 (13,71)
Median (Min - Max)	1,92 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	15 (83,3)
Mean (SD)	3,16 (13,18)
Median (Min - Max)	0,50 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	0,06 (9,53)
Median (Min - Max)	0,50 [-17,20-13,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	-3,21 (8,86)
Median (Min - Max)	-4,00 [-18,87-8,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-2,11 (10,22)
Median (Min - Max)	-1,50 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	4,72 (7,92)
Median (Min - Max)	4,50 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	1,47 (18,85)
Median (Min - Max)	3,50 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
<= 5 cm	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	55 (72,4)
Mean (SD)	-3,86 (17,56)
Median (Min - Max)	-5,00 [-39,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	76,01 (16,90)
Median (Min - Max)	77,58 [28,67-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	-1,80 (9,64)
Median (Min - Max)	0,63 [-25,50-13,40]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-1,77 (10,88)
Median (Min - Max)	1,00 [-30,50-12,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	-1,80 (13,23)
Median (Min - Max)	-0,35 [-28,27-20,70]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-4,97 (13,26)
Median (Min - Max)	-4,50 [-26,60-18,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	2,86 (9,62)
Median (Min - Max)	2,83 [-10,60-17,10]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	3,49 (14,01)
Median (Min - Max)	7,00 [-17,10-18,73]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	4,74 (16,60)
Median (Min - Max)	3,58 [-14,10-25,90]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,02 (11,73)
Median (Min - Max)	5,17 [-10,93-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	9,00 (NE)
Median (Min - Max)	9,00 [9,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	4,67 (NE)
Median (Min - Max)	4,67 [4,67-4,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	9,00 (NE)
Median (Min - Max)	9,00 [9,00-9,00]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-10,78 (11,49)
Median (Min - Max)	-7,92 [-40,83-7,47]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	75,10 (17,13)
Median (Min - Max)	70,50 [49,00-103,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,84 (19,28)
Median (Min - Max)	0,65 [-41,00-13,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	4,18 (19,01)
Median (Min - Max)	6,37 [-15,83-22,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-1,96 (14,86)
Median (Min - Max)	-4,00 [-16,00-16,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-11,50 (6,36)
Median (Min - Max)	-11,50 [-16,00--7,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,50 (NE)
Median (Min - Max)	1,50 [1,50-1,50]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,33 (NE)
Median (Min - Max)	-5,33 [-5,33--5,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,33 (NE)
Median (Min - Max)	-4,33 [-4,33--4,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,00 (NE)
Median (Min - Max)	-2,00 [-2,00--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,03 (NE)
Median (Min - Max)	1,03 [1,03-1,03]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-11,87 (NE)
Median (Min - Max)	-11,87 [-11,87--11,87]
FACT-Lym FACT-G total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	4 (44,4)
Mean (SD)	-7,48 (12,53)
Median (Min - Max)	-10,92 [-18,00-9,93]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	72,19 (18,18)
Median (Min - Max)	74,00 [51,00-100,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,59 (6,65)
Median (Min - Max)	3,63 [-8,67-8,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,00 (4,24)
Median (Min - Max)	3,00 [0,00-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,00 (8,49)
Median (Min - Max)	7,00 [1,00-13,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,50 (NE)
Median (Min - Max)	1,50 [1,50-1,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS11: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:	
> 10 cm	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-6,97 (7,58)
Median (Min - Max)	-6,50 [-18,33-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.14.12 Merkmal: Primärdiagnose

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	108 (96,4)
Mean (SD)	75,46 (15,63)
Median (Min - Max)	77,08 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	101
Treated patients with non-missing values - n(%)	93 (92,1)
Mean (SD)	0,27 (11,20)
Median (Min - Max)	1,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	66 (84,6)
Mean (SD)	-0,82 (14,92)
Median (Min - Max)	-0,65 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	52 (86,7)
Mean (SD)	0,90 (14,38)
Median (Min - Max)	0,75 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,18 (14,40)
Median (Min - Max)	-0,50 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,61 (12,08)
Median (Min - Max)	1,50 [-31,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	24 (92,3)
Median (Min - Max)	0,79 (12,82)
	1,92 [-41,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	18 (81,8)
Median (Min - Max)	0,83 (11,84)
	0,17 [-19,50-27,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	17 (94,4)
Median (Min - Max)	0,61 (9,90)
	-0,77 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	-2,95 (8,56)
	-3,58 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,69 (8,68)
Median (Min - Max)	-1,00 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	7 (63,6)
Median (Min - Max)	4,05 (7,24)
	4,00 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	-0,44 (17,93)
	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	3 (50,0)
Median (Min - Max)	-5,19 (13,77)
	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	-9,73 (9,98)
	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	2 (50,0)
Median (Min - Max)	-9,10 (11,46)
	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-8,10 (17,11)
	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	83 (74,1)
Mean (SD)	-6,32 (15,16)
Median (Min - Max)	-6,67 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	77,78 (13,00)
Median (Min - Max)	77,00 [59,67-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-1,78 (14,89)
Median (Min - Max)	1,08 [-29,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,01 (11,07)
Median (Min - Max)	9,90 [-0,73-29,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	5,19 (13,31)
Median (Min - Max)	4,67 [-12,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	1,03 (16,63)
Median (Min - Max)	-3,33 [-15,00-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	4,26 (20,63)
Median (Min - Max)	4,02 [-19,67-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,11 (16,07)
Median (Min - Max)	-1,00 [-1,33-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	19,14 (8,92)
Median (Min - Max)	17,33 [11,27-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	3,63 (10,42)
Median (Min - Max)	3,63 [-3,73-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	2,97 (6,65)
Median (Min - Max)	2,97 [-1,73-7,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS12: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	10,33 (0,94)
Median (Min - Max)	10,33 [9,67-11,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	7,13 (4,05)
Median (Min - Max)	7,13 [4,27-10,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	20,93 (NE)
Median (Min - Max)	20,93 [20,93-20,93]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-8,36 (18,85)
Median (Min - Max)	-13,00 [-35,33-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

3.14.13 Merkmal: Anzahl der vorherigen systemischen Therapien

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	57 (96,6)
Mean (SD)	76,93 (16,48)
Median (Min - Max)	78,00 [28,67-101,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	46 (88,5)
Mean (SD)	-0,69 (11,08)
Median (Min - Max)	-0,92 [-25,50-34,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	29 (76,3)
Mean (SD)	-3,62 (13,76)
Median (Min - Max)	-3,00 [-38,50-19,17]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	22 (75,9)
Mean (SD)	1,46 (11,67)
Median (Min - Max)	0,42 [-26,00-20,70]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	16 (72,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,04 (11,45)
Median (Min - Max)	1,50 [-31,00-18,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-3,24 (12,78)
Median (Min - Max)	-1,17 [-31,00-17,10]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	-1,25 (13,65)
Median (Min - Max)	1,83 [-41,00-18,73]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	-0,27 (12,08)
Median (Min - Max)	0,33 [-19,50-25,90]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,35 (11,33)
Median (Min - Max)	4,08 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-7,51 (7,58)
Median (Min - Max)	-4,00 [-18,87--3,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-7,31 (7,71)
Median (Min - Max)	-8,00 [-16,77-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,04 (7,73)
Median (Min - Max)	4,00 [-8,87-5,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-1,27 (19,69)
Median (Min - Max)	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 24 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Number prior lines:	
2 lines	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	44 (74,6)
Mean (SD)	-8,55 (14,64)
Median (Min - Max)	-7,67 [-40,83-24,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	75,25 (15,79)
Median (Min - Max)	77,00 [35,00-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 30
Treated patients with non-missing values - n(%)	26 (86,7)
Mean (SD)	-0,04 (13,60)
Median (Min - Max)	1,29 [-41,00-28,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	3,68 (16,89)
Median (Min - Max)	4,33 [-16,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,83 (19,60)
Median (Min - Max)	-3,17 [-28,27-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-1,80 (22,82)
Median (Min - Max)	-7,10 [-26,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,01 (15,63)
Median (Min - Max)	1,17 [-19,67-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	6,48 (16,97)
Median (Min - Max)	9,83 [-17,10-23,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,60 (18,41)
Median (Min - Max)	-3,67 [-14,10-27,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	2,63 (9,79)
Median (Min - Max)	-0,77 [-5,00-13,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-1,67 (14,61)
Median (Min - Max)	-1,67 [-12,00-8,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	11,50 (NE)
Median (Min - Max)	11,50 [11,50-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	14,67 (NE)
Median (Min - Max)	14,67 [14,67-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	15,17 (NE)
Median (Min - Max)	15,17 [15,17-15,17]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	21 (65,6)
Mean (SD)	-2,07 (18,12)
Median (Min - Max)	-3,08 [-35,33-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	39 (100,0)
Mean (SD)	72,64 (14,28)
Median (Min - Max)	71,00 [49,00-100,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	1,10 (10,23)
Median (Min - Max)	2,67 [-35,17-25,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	27 (100,0)
Mean (SD)	1,54 (13,73)
Median (Min - Max)	0,83 [-40,17-30,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)
Mean (SD)	2,38 (12,29)
Median (Min - Max)	4,00 [-37,17-24,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	-1,24 (11,51)
Median (Min - Max)	-3,00 [-24,25-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	4,09 (11,90)
Median (Min - Max)	3,00 [-15,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	3,89 (10,60)
Median (Min - Max)	-1,00 [-6,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	8,55 (11,17)
Median (Min - Max)	8,92 [-5,33-28,83]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,04 (8,15)
Median (Min - Max)	-3,37 [-5,67-12,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,63 (5,91)
Median (Min - Max)	0,55 [-6,00-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS13: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	4,30 (6,18)
Median (Min - Max)	4,67 [-2,83-11,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	5,56 (3,81)
Median (Min - Max)	4,27 [1,03-10,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	4,53 (23,19)
Median (Min - Max)	4,53 [-11,87-20,93]
FACT-Lym FACT-G total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	30 (76,9)
Mean (SD)	-5,97 (13,91)
Median (Min - Max)	-6,25 [-31,67-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

3.14.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	89 (96,7)
Mean (SD)	75,33 (15,50)
Median (Min - Max)	77,00 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	86
Treated patients with non-missing values - n(%)	78 (90,7)
Mean (SD)	0,43 (12,38)
Median (Min - Max)	0,96 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	56 (84,8)
Mean (SD)	-0,13 (16,14)
Median (Min - Max)	-0,65 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	42 (85,7)
Mean (SD)	1,09 (15,33)
Median (Min - Max)	0,67 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	31 (91,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,81 (16,30)
Median (Min - Max)	-1,00 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,77 (12,94)
Median (Min - Max)	1,75 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	21 (91,3)
Median (Min - Max)	1,40 (14,27)
	2,13 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	15 (78,9)
Median (Min - Max)	1,40 (13,35)
	0,33 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	13 (92,9)
Median (Min - Max)	-1,11 (9,70)
	-4,33 [-17,20-13,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	7 (70,0)
Median (Min - Max)	-2,34 (10,37)
	-2,00 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-2,29 (9,72)
Median (Min - Max)	-1,00 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	6 (66,7)
Median (Min - Max)	3,89 (7,92)
	3,75 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	4,29 (15,89)
	3,00 [-11,87-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2 (40,0)
Median (Min - Max)	-7,28 (18,79)
	-7,28 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	2 (50,0)
Median (Min - Max)	-12,10 (12,87)
	-12,10 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-20,75 (0,92)
Median (Min - Max)	-20,75 [-21,40--20,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1 (33,3)
Median (Min - Max)	-17,20 (NE)
	-17,20 [-17,20--17,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-20,20 (NE)
	-20,20 [-20,20--20,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	65 (70,7)
Mean (SD)	-5,29 (16,40)
Median (Min - Max)	-6,00 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	76,38 (16,88)
Median (Min - Max)	77,50 [42,93-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-2,04 (9,01)
Median (Min - Max)	-0,50 [-21,83-13,40]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-0,84 (9,82)
Median (Min - Max)	1,50 [-20,00-13,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	1,04 (12,97)
Median (Min - Max)	0,50 [-16,83-20,70]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 8
Treated patients with non-missing values - n(%)	5 (62,5)
Mean (SD)	-0,46 (9,40)
Median (Min - Max)	1,20 [-14,00-11,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-0,48 (15,73)
Median (Min - Max)	1,00 [-21,00-17,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	4,86 (12,64)
	1,83 [-6,00-18,73]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	8,97 (14,88)
	3,00 [-2,00-25,90]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	6,88 (11,60)
	4,00 [-3,00-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-5,00 (1,41)
	-5,00 [-6,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-8,00 (NE)
Median (Min - Max)	-8,00 [-8,00--8,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,00 (NE)
	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,20 (NE)
Median (Min - Max)	-1,20 [-1,20--1,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS14: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-9,24 (12,22)
Median (Min - Max)	-6,83 [-35,33-9,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

3.14.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	75,55 (15,90)
Median (Min - Max)	77,00 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	37
Mean (SD)	34 (91,9)
Median (Min - Max)	-1,13 (13,48)
	0,25 [-41,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	32
Mean (SD)	27 (84,4)
Median (Min - Max)	-0,94 (17,02)
	-0,50 [-40,17-29,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	25
Mean (SD)	20 (80,0)
Median (Min - Max)	0,35 (14,72)
	2,50 [-37,17-24,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	18
	16 (88,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,11 (12,45)
Median (Min - Max)	2,40 [-17,00-27,67]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	3,37 (12,12)
Median (Min - Max)	4,00 [-19,67-28,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	4,04 (10,46)
	4,42 [-8,50-26,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	9 (75,0)
Median (Min - Max)	-0,26 (13,05)
	-2,00 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	1,64 (9,91)
	4,17 [-17,20-13,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	-3,48 (10,18)
	-3,17 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	0,48 (8,84)
Median (Min - Max)	-0,17 [-12,60-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	4 (57,1)
Median (Min - Max)	3,96 (10,22)
	5,02 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	-2,01 (21,71)
	-9,87 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-21,20 (NE)
	-21,20 [-21,20--21,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-21,40 (NE)
Median (Min - Max)	-21,40 [-21,40--21,40]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-17,20 (NE)
	-17,20 [-17,20--17,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-20,20 (NE)
	-20,20 [-20,20--20,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (70,0)
Mean (SD)	-8,07 (15,42)
Median (Min - Max)	-6,50 [-40,83-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	75,32 (15,94)
Median (Min - Max)	78,00 [35,00-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	68
Treated patients with non-missing values - n(%)	61 (89,7)
Mean (SD)	-0,41 (10,14)
Median (Min - Max)	1,00 [-29,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	45
Treated patients with non-missing values - n(%)	39 (86,7)
Mean (SD)	-0,67 (11,10)
Median (Min - Max)	-0,17 [-20,00-30,33]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	31 (91,2)
Mean (SD)	-0,44 (11,40)
Median (Min - Max)	0,30 [-28,27-20,70]
FACT-Lym FACT-G total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	20 (87,0)
Mean (SD)	-4,73 (12,04)
Median (Min - Max)	-2,75 [-31,00-8,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	-0,77 (14,00)
Median (Min - Max)	-1,00 [-31,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	0,58 (16,55)
	2,07 [-41,00-23,33]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	4,61 (13,55)
	2,00 [-14,10-27,83]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-0,54 (10,42)
	-2,88 [-11,97-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	-1,72 (3,95)
	-4,00 [-4,00-2,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,65 (7,69)
Median (Min - Max)	-5,42 [-16,77-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	4,17 (0,76)
	4,00 [3,50-5,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	3,50 (0,71)
	3,50 [3,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-5,19 (13,77)
	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	-4,00 (1,41)
	-4,00 [-5,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-10,65 (13,36)
Median (Min - Max)	-10,65 [-20,10--1,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS15: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,60 (NE)
	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-6,00 (NE)
	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	61 (77,2)
Median (Min - Max)	-6,52 (13,30)
	-6,50 [-39,00-25,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

3.14.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	76,51 (17,46)
Median (Min - Max)	77,00 [42,93-101,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-2,29 (8,95)
Median (Min - Max)	-1,50 [-21,83-13,40]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-3,32 (8,96)
Median (Min - Max)	0,00 [-20,00-6,12]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	-2,27 (11,55)
Median (Min - Max)	-2,17 [-16,83-20,70]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 7
Treated patients with non-missing values - n(%)	4 (57,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-5,45 (6,31)
Median (Min - Max)	-4,50 [-14,00-1,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,98 (16,94)
Median (Min - Max)	-8,00 [-21,00-17,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	10,28 (11,95)
	10,28 [1,83-18,73]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	14,45 (16,19)
	14,45 [3,00-25,90]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	11,82 (11,07)
	11,82 [4,00-19,65]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-4,00 (NE)
	-4,00 [-4,00--4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-8,00 (NE)
Median (Min - Max)	-8,00 [-8,00--8,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,00 (NE)
	-5,00 [-5,00--5,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,20 (NE)
Median (Min - Max)	-1,20 [-1,20--1,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	4,00 (NE)
	4,00 [4,00-4,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,00 (NE)
	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,60 (NE)
	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 24 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-6,00 (NE)
	-6,00 [-6,00--6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	19 (90,5)
Median (Min - Max)	-8,91 (11,01)
	-7,00 [-25,83-9,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	100 (96,2)
Mean (SD)	75,16 (15,02)
Median (Min - Max)	76,33 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 96
Treated patients with non-missing values - n(%)	87 (90,6)
Mean (SD)	0,45 (11,83)
Median (Min - Max)	1,17 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 73
Treated patients with non-missing values - n(%)	63 (86,3)
Mean (SD)	0,23 (15,46)
Median (Min - Max)	-0,50 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 55
Treated patients with non-missing values - n(%)	48 (87,3)
Mean (SD)	1,55 (14,76)
Median (Min - Max)	1,42 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	-0,84 (15,35)
Median (Min - Max)	-1,00 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	0,28 (12,70)
Median (Min - Max)	1,75 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	0,99 (13,40)
Median (Min - Max)	1,92 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	1,45 (12,45)
Median (Min - Max)	0,17 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-1,06 (8,82)
Median (Min - Max)	-3,37 [-17,20-13,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	-2,73 (8,56)
Median (Min - Max)	-2,58 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-0,73 (9,31)
Median (Min - Max)	-0,17 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	7 (63,6)
Median (Min - Max)	3,94 (7,23)
	4,00 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	1,98 (19,69)
	3,00 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	2 (33,3)
Median (Min - Max)	-7,28 (18,79)
	-7,28 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	2 (50,0)
Median (Min - Max)	-12,10 (12,87)
	-12,10 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-20,75 (0,92)
Median (Min - Max)	-20,75 [-21,40--20,10]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1 (33,3)
Median (Min - Max)	-17,20 (NE)
	-17,20 [-17,20--17,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-20,20 (NE)
	-20,20 [-20,20--20,20]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	0 (0,0)
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS16: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	72 (69,2)
Mean (SD)	-5,78 (16,04)
Median (Min - Max)	-5,58 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.14.17 Merkmal: Vorherige CAR-T-Therapie

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	80,08 (15,15)
Median (Min - Max)	80,00 [59,00-100,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-2,25 (19,35)
Median (Min - Max)	-3,25 [-29,00-25,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	8,42 (18,53)
Median (Min - Max)	8,17 [-12,50-29,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	11,17 (9,95)
Median (Min - Max)	9,50 [1,00-24,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	14,56 (11,36)
Median (Min - Max)	8,33 [7,67-27,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	20,94 (9,15)
Median (Min - Max)	23,33 [10,83-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	18,94 (10,62)
Median (Min - Max)	23,33 [6,83-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	19,06 (16,08)
Median (Min - Max)	27,83 [0,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,67 (NE)
Median (Min - Max)	-5,67 [-5,67--5,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,83 (NE)
Median (Min - Max)	2,83 [2,83-2,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-2,83 (NE)
Median (Min - Max)	-2,83 [-2,83--2,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,50 (NE)
Median (Min - Max)	3,50 [3,50-3,50]
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-0,28 (20,05)
Median (Min - Max)	3,50 [-35,33-25,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	117 (95,9)
Mean (SD)	74,87 (15,69)
Median (Min - Max)	76,17 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 110
Treated patients with non-missing values - n(%)	100 (90,9)
Mean (SD)	0,18 (10,90)
Median (Min - Max)	1,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 82
Treated patients with non-missing values - n(%)	70 (85,4)
Mean (SD)	-0,44 (14,45)
Median (Min - Max)	-0,33 [-40,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 63
Treated patients with non-missing values - n(%)	54 (85,7)
Mean (SD)	0,46 (14,16)
Median (Min - Max)	0,32 [-37,17-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 46
Treated patients with non-missing values - n(%)	40 (87,0)
Mean (SD)	-2,08 (14,11)
Median (Min - Max)	-2,25 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	-2,12 (11,49)
Median (Min - Max)	-0,92 [-31,00-17,10]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	-0,56 (11,80)
Median (Min - Max)	1,42 [-41,00-18,73]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	0,84 (10,94)
Median (Min - Max)	0,17 [-19,50-25,90]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	1,30 (9,84)
Median (Min - Max)	1,62 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	11 (78,6)
Mean (SD)	-2,40 (8,58)
Median (Min - Max)	-3,17 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-0,07 (9,86)
Median (Min - Max)	0,42 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	4,89 (7,01)
Median (Min - Max)	4,63 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,23 (18,24)
Median (Min - Max)	3,50 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS17: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Prior use of T-CART therapy:

No

FACT-Lym FACT-G total score - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

89 (73,0)

Mean (SD)

-6,71 (14,98)

Median (Min - Max)

-6,83 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

3.14.18 Merkmal: Arzneimittelformulierung

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	76,05 (14,82)
Median (Min - Max)	78,00 [49,00-101,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	0,56 (10,30)
Median (Min - Max)	1,50 [-35,17-19,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-4,72 (13,24)
Median (Min - Max)	-3,00 [-40,17-13,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-2,08 (15,00)
Median (Min - Max)	0,67 [-37,17-19,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,68 (11,83)
Median (Min - Max)	1,50 [-26,60-11,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-1,09 (8,25)
Median (Min - Max)	2,00 [-10,60-7,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,09 (10,93)
Median (Min - Max)	2,00 [-17,10-9,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-4,44 (7,75)
Median (Min - Max)	-3,50 [-14,10-3,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,19 (5,73)
Median (Min - Max)	-0,77 [-5,00-6,33]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-12,00 (NE)
Median (Min - Max)	-12,00 [-12,00--12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Drug formulation:	
Frozen liquid	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	22 (68,8)
Mean (SD)	-9,44 (11,56)
Median (Min - Max)	-7,00 [-31,67-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym FACT-G total score	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	93 (94,9)
Mean (SD)	74,91 (15,99)
Median (Min - Max)	75,50 [28,67-103,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 88
Treated patients with non-missing values - n(%)	78 (88,6)
Mean (SD)	-0,14 (11,84)
Median (Min - Max)	1,00 [-41,00-34,17]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 65
Treated patients with non-missing values - n(%)	55 (84,6)
Mean (SD)	1,68 (14,91)
Median (Min - Max)	0,83 [-38,50-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 50
Treated patients with non-missing values - n(%)	42 (84,0)
Mean (SD)	2,45 (13,74)
Median (Min - Max)	0,75 [-26,00-56,00]
FACT-Lym FACT-G total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 38
Treated patients with non-missing values - n(%)	32 (84,2)
Mean (SD)	-0,67 (15,44)
Median (Min - Max)	-2,25 [-31,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FACT-G total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	0,17 (13,83)
Median (Min - Max)	0,33 [-31,00-28,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	22 (91,7)
Mean (SD)	2,45 (13,59)
Median (Min - Max)	1,83 [-41,00-26,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	17 (81,0)
Mean (SD)	5,30 (13,50)
Median (Min - Max)	1,00 [-19,50-28,83]
FACT-Lym FACT-G total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	1,07 (10,41)
Median (Min - Max)	0,50 [-17,20-19,65]
FACT-Lym FACT-G total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	11 (78,6)
Mean (SD)	-1,05 (8,07)
Median (Min - Max)	-2,00 [-18,87-9,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FACT-G total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-0,32 (9,39)
Median (Min - Max)	-0,17 [-16,77-11,50]
FACT-Lym FACT-G total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	4,73 (6,57)
Median (Min - Max)	4,27 [-8,87-14,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	2,23 (18,24)
Median (Min - Max)	3,50 [-28,50-25,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-5,19 (13,77)
Median (Min - Max)	-1,00 [-20,57-6,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-9,73 (9,98)
Median (Min - Max)	-5,00 [-21,20--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FACT-G total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-14,23 (11,31)
Median (Min - Max)	-20,10 [-21,40--1,20]
FACT-Lym FACT-G total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	-9,10 (11,46)
Median (Min - Max)	-9,10 [-17,20--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,10 (17,11)
Median (Min - Max)	-8,10 [-20,20-4,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym FACT-G total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-2,67 (NE)
Median (Min - Max)	-2,67 [-2,67--2,67]
FACT-Lym FACT-G total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym FACT-G total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,60 (NE)
Median (Min - Max)	1,60 [1,60-1,60]
FACT-Lym FACT-G total score - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym FACT-G total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-6,00 (NE)
Median (Min - Max)	-6,00 [-6,00--6,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FGC_PSHS18: FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym FACT-G total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Drug formulation:	
Lyophilized	
FACT-Lym FACT-G total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	73 (74,5)
Mean (SD)	-5,36 (16,21)
Median (Min - Max)	-5,17 [-40,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome. FACT-G = Functional Assessment of Cancer Therapy General.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTD_PSTS01: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Age group
 PRO set

3.15 Subgruppenanalysen zum FACT-Lym – Gesamtscore (Zeit bis zur Verschlechterung)

3.15.1 Merkmal Alter

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	57
Patients with events - n(%)	7 (12,3)
95%-CI	[5,1-23,7]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [70,5-94,4]
Month 6	75,6 [52,8-88,5]
Month 12	75,6 [52,8-88,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS01: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	12 (22,6)
95%-CI	[12,3-36,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[3,35-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [64,8-91,3]
Month 6	53,5 [29,1-72,9]
Month 12	53,5 [29,1-72,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS01: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Age group
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
Patients with events - n(%)	6 (30,0)
95%-CI	[11,9-54,3]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[3,71-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [57,9-94,5]
Month 6	64,7 [32,2-84,6]
Month 12	64,7 [32,2-84,6]
Month 18	43,1 [8,6-75,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS02: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Sex
 PRO set

3.15.2 Merkmal: Geschlecht

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	9 (17,0)
95%-CI	[8,1-29,8]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,4 [76,3-96,3]
Month 6	71,9 [49,6-85,6]
Month 12	71,9 [49,6-85,6]
Month 18	53,9 [18,6-79,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS02: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Sex
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	16 (20,8)
95%-CI	[12,4-31,5]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[4,73-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,1 [66,2-88,8]
Month 6	60,7 [41,1-75,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS03: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Race group
 PRO set

3.15.3 Merkmal: Ethnie

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	21 (18,3)
95%-CI	[11,7-26,5]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22 [12,22-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [75,0-91,1]
Month 6	66,0 [50,0-78,0]
Month 12	66,0 [50,0-78,0]
Month 18	49,5 [19,0-74,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS03: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Race group
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[2,79-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [48,0-95,7]
Month 6	59,7 [23,5-83,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS04: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Country
 PRO set

3.15.4 *Merkmal: Region-1*

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	9 (17,6)
95%-CI	[8,4-30,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [5,13-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [70,8-94,5]
Month 6	67,2 [43,7-82,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS04: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[3,32-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [61,2-93,4]
Month 6	75,0 [47,4-89,5]
Month 12	75,0 [47,4-89,5]
Month 18	75,0 [47,4-89,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS04: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Country
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	11 (22,9)
95%-CI	[12,0-37,3]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[4,73-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,2 [65,7-92,2]
Month 6	58,0 [32,2-76,9]
Month 12	58,0 [32,2-76,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS05: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Region
 PRO set

3.15.5 *Merkmal: Region-2*

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	9 (17,6)
95%-CI	[8,4-30,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [5,13-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [70,8-94,5]
Month 6	67,2 [43,7-82,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS05: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Region
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	16 (20,3)
95%-CI	[12,0-30,8]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [70,2-90,6]
Month 6	63,2 [43,3-77,8]
Month 12	63,2 [43,3-77,8]
Month 18	47,4 [17,7-72,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS06: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage
 PRO set

3.15.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	4,73[1,48-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	45,7 [6,9-79,5]
Month 12	45,7 [6,9-79,5]
Month 18	45,7 [6,9-79,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS06: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	4,99 [2,10-12,22]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,6 [48,6-93,0]
Month 6	42,4 [7,5-75,3]
Month 12	42,4 [7,5-75,3]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS06: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	4 (23,5)
95%-CI	[6,8-49,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[1,48-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,0 [42,2-91,6]
Month 6	65,1 [30,6-85,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS06: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	12 (14,6)
95%-CI	[7,8-24,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[NE-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [74,5-93,5]
Month 6	71,6 [52,3-84,2]
Month 12	71,6 [52,3-84,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS07: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Bulky disease
 PRO set

3.15.7 *Merkmal: Bulky Erkrankung*

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	25 (19,8)
95%-CI	[13,3-27,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22 [12,22-NE]
FACT-Lym total score - Time to decrease by at least 26 points:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [74,9-90,3]
Month 6	64,9 [50,4-76,1]
Month 12	64,9 [50,4-76,1]
Month 18	48,7 [19,1-73,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS08: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Double/Triple hit
 PRO set

3.15.8 *Merkmal: Double/Triple-Hit*

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	4 (28,6)
95%-CI	[8,4-58,1]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	5,13[1,41-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [44,4-95,3]
Month 6	49,2 [12,3-78,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS08: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Double/Triple hit
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	21 (18,1)
95%-CI	[11,6-26,3]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[12,22-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [74,6-90,9]
Month 6	67,4 [52,0-78,9]
Month 12	67,4 [52,0-78,9]
Month 18	50,6 [19,3-75,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS09: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Transformed DLBCL
 PRO set

3.15.9 *Merkmal: Transformation des DLBCL*

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [3,71-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [64,8-97,4]
Month 6	52,0 [15,3-79,6]
Month 12	52,0 [15,3-79,6]
Month 18	52,0 [15,3-79,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS09: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Transformed DLBCL
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	20 (18,9)
95%-CI	[11,9-27,6]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22 [12,22-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,4 [72,6-90,2]
Month 6	67,7 [52,2-79,2]
Month 12	67,7 [52,2-79,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS10: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: B-Cell type
 PRO set

3.15.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	10 (23,3)
95%-CI	[11,8-38,6]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22 [12,22-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [60,0-88,3]
Month 6	73,4 [54,3-85,5]
Month 12	73,4 [54,3-85,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS10: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: B-Cell type
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[3,02-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [64,1-97,3]
Month 6	69,6 [35,4-88,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS11: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter
 PRO set

3.15.11 Merkmal: Maximaler längster Durchmesser

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	15 (19,7)
95%-CI	[11,5-30,5]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22 [5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [72,2-91,9]
Month 6	66,6 [47,9-79,9]
Month 12	66,6 [47,9-79,9]
Month 18	50,0 [18,6-75,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS11: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	9 (26,5)
95%-CI	[12,9-44,4]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[3,32-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [59,0-91,5]
Month 6	55,4 [30,1-74,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS11: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	<10
Subgroup level is not displayed due to few patients	

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
PRO = patient reported outcome.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS11: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter
PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Maximal longest diameter:

> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS12: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Primary disease diagnosis
 PRO set

3.15.12 Merkmal: Primärdiagnose

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	21 (18,8)
95%-CI	[12,0-27,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [12,22-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [74,6-90,9]
Month 6	67,5 [52,0-78,9]
Month 12	67,5 [52,0-78,9]
Month 18	50,6 [19,3-75,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS12: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Primary disease diagnosis
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	5,13[1,41-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [35,4-94,2]
Month 6	46,8 [11,4-76,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS13: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Number prior lines
 PRO set

3.15.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	14 (23,7)
95%-CI	[13,6-36,6]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[4,99-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [66,6-90,7]
Month 6	58,3 [36,0-75,2]
Month 12	58,3 [36,0-75,2]
Month 18	43,7 [15,9-69,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS13: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	6 (18,8)
95%-CI	[7,2-36,4]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[3,71-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [62,4-93,8]
Month 6	57,6 [21,8-81,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS13: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Number prior lines
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	5 (12,8)
95%-CI	[4,3-27,4]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[NE-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [70,2-96,6]
Month 6	78,3 [53,6-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS14: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - first line
 PRO set

3.15.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	17 (18,5)
95%-CI	[11,1-27,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [70,4-89,7]
Month 6	65,6 [47,8-78,6]
Month 12	65,6 [47,8-78,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS14: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - first line
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	4 (18,2)
95%-CI	[5,2-40,3]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE[3,02-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [64,8-97,3]
Month 6	68,4 [32,8-87,8]
Month 12	68,4 [32,8-87,8]
Month 18	68,4 [32,8-87,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS15: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - last line
 PRO set

3.15.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
Patients with events - n(%)	10 (25,0)
95%-CI	[12,7-41,2]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[4,99-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [64,8-93,1]
Month 6	60,6 [35,9-78,3]
Month 12	60,6 [35,9-78,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS15: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - last line
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	14 (17,7)
95%-CI	[10,0-27,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [NE-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [69,0-90,4]
Month 6	69,4 [52,1-81,4]
Month 12	69,4 [52,1-81,4]
Month 18	69,4 [52,1-81,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS16: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - any line
 PRO set

3.15.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [3,02-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [64,1-97,3]
Month 6	68,2 [32,7-87,7]
Month 12	68,2 [32,7-87,7]
Month 18	68,2 [32,7-87,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS16: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - any line
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	20 (19,2)
95%-CI	[12,2-28,1]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [73,2-90,8]
Month 6	64,3 [47,7-76,8]
Month 12	64,3 [47,7-76,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS17: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Prior use of T-CART therapy
PRO set

3.15.17 Merkmal: Vorherige CAR-T-Therapie

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS17: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Prior use of T-CART therapy
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	23 (18,9)
95%-CI	[12,3-26,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [75,7-91,4]
Month 6	64,0 [48,4-75,9]
Month 12	64,0 [48,4-75,9]
Month 18	48,0 [18,7-72,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS18: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Drug formulation
 PRO set

3.15.18 Merkmal: Arzneimittelformulierung

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	4 (12,5)
95%-CI	[3,5-29,0]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	NE [4,73-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [58,3-95,0]
Month 6	70,6 [32,5-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTD_PSTS18: Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Drug formulation
 PRO set

Time to first decrease in FACT-Lym total score by at least 26 points by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	21 (21,4)
95%-CI	[13,8-30,9]
FACT-Lym total score - Time to decrease by at least 26 points in months [95%-CI]	
Median	12,22[5,78-NE]
FACT-Lym total score - Time to decrease by at least 26 points: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [73,7-90,8]
Month 6	63,4 [47,3-75,7]
Month 12	63,4 [47,3-75,7]
Month 18	47,5 [18,5-72,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

3.16 Subgruppenanalysen zum FACT-Lym – Gesamtscore (Veränderung gegenüber Studienbeginn)

3.16.1 Merkmal Alter

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym total score	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	55 (96,5)
Mean (SD)	111,75 (24,24)
Median (Min - Max)	116,00 [60,00-156,83]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	45 (91,8)
Mean (SD)	3,36 (13,29)
Median (Min - Max)	3,83 [-24,67-33,33]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	33 (89,2)
Mean (SD)	-1,88 (19,16)
Median (Min - Max)	-3,00 [-39,50-48,33]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	5,10 (17,31)
Median (Min - Max)	6,42 [-31,27-50,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	20 (90,9)
Mean (SD)	0,80 (15,25)
Median (Min - Max)	3,50 [-31,60-22,33]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	3,46 (20,93)
Median (Min - Max)	4,29 [-36,00-45,33]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	3,50 (17,83)
Median (Min - Max)	4,92 [-19,50-46,33]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	8,83 (23,16)
Median (Min - Max)	4,00 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	5,65 (9,96)
Median (Min - Max)	2,12 [-4,67-20,27]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,69 (15,84)
Median (Min - Max)	1,92 [-10,00-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	18,14 (23,05)
Median (Min - Max)	14,00 [-3,83-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	17,44 (13,66)
Median (Min - Max)	14,25 [6,00-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	31,47 (37,43)
Median (Min - Max)	31,47 [5,00-57,93]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	4,00 (NE)
Median (Min - Max)	4,00 [4,00-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Age group:	
< 65 years	
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	40 (70,2)
Mean (SD)	-5,27 (18,69)
Median (Min - Max)	-6,92 [-52,83-38,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym total score	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	51 (96,2)
Mean (SD)	124,49 (21,08)
Median (Min - Max)	126,00 [70,00-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	48
Treated patients with non-missing values - n(%)	44 (91,7)
Mean (SD)	-1,68 (16,97)
Median (Min - Max)	0,75 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-0,08 (22,53)
Median (Min - Max)	1,92 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-1,78 (21,82)
Median (Min - Max)	0,00 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	-6,05 (23,01)
Median (Min - Max)	-7,00 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-3,09 (18,69)
Median (Min - Max)	-4,50 [-46,00-17,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-6,54 (28,78)
Median (Min - Max)	2,13 [-73,00-23,67]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,85 (11,86)
Median (Min - Max)	4,33 [-21,33-11,83]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	-3,74 (19,46)
Median (Min - Max)	-3,26 [-29,20-22,67]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	-2,04 (23,87)
Median (Min - Max)	4,00 [-36,87-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-3,06 (18,78)
Median (Min - Max)	-6,34 [-24,27-24,50]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	4,01 (15,61)
Median (Min - Max)	3,20 [-11,87-24,67]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-4,27 (20,90)
Median (Min - Max)	-10,55 [-21,15-25,17]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-16,20 (23,65)
Median (Min - Max)	-16,20 [-32,92-0,52]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-28,85 (32,68)
Median (Min - Max)	-29,20 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-24,21 (23,58)
Median (Min - Max)	-37,24 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-23,47 (22,51)
Median (Min - Max)	-29,20 [-42,56-1,36]
FACT-Lym total score - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-16,60 (24,89)
Median (Min - Max)	-16,60 [-34,20-1,00]
FACT-Lym total score - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-0,50 (NE)
Median (Min - Max)	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	41 (77,4)
Mean (SD)	-10,69 (24,22)
Median (Min - Max)	-9,67 [-54,00-60,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym total score	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	19 (95,0)
Mean (SD)	121,35 (25,85)
Median (Min - Max)	123,00 [41,67-155,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,34 (16,86)
Median (Min - Max)	0,00 [-43,50-26,67]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	9,86 (12,28)
Median (Min - Max)	7,37 [-6,00-31,17]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	8 (61,5)
Mean (SD)	12,65 (10,92)
Median (Min - Max)	13,25 [-4,00-27,33]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	5,79 (20,04)
Median (Min - Max)	3,18 [-19,00-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	4,29 (24,43)
Median (Min - Max)	2,52 [-23,67-34,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	15,32 (12,87)
Median (Min - Max)	16,17 [0,91-30,00]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	13,00 (13,98)
Median (Min - Max)	12,17 [-1,17-28,83]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	12,92 (8,61)
Median (Min - Max)	11,75 [4,00-24,17]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-1,58 (2,00)
Median (Min - Max)	-1,58 [-3,00--0,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-2,26 (7,21)
Median (Min - Max)	-2,26 [-7,36-2,83]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-3,83 (44,91)
Median (Min - Max)	5,00 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,80 (NE)
Median (Min - Max)	1,80 [1,80-1,80]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS01: FACT-Lym total score - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,67 (NE)
Median (Min - Max)	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	13 (65,0)
Mean (SD)	-4,54 (23,36)
Median (Min - Max)	1,00 [-34,17--28,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

3.16.2 Merkmal: Geschlecht

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym total score	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	49 (92,5)
Mean (SD)	115,03 (25,72)
Median (Min - Max)	119,60 [41,67-154,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	39 (84,8)
Mean (SD)	5,04 (12,38)
Median (Min - Max)	4,00 [-22,00-38,17]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	4,24 (19,54)
Median (Min - Max)	4,64 [-31,92-48,33]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	21 (75,0)
Mean (SD)	7,74 (17,93)
Median (Min - Max)	9,00 [-39,00-50,33]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	20 (87,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,17 (20,48)
Median (Min - Max)	3,18 [-53,00-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	2,54 (20,12)
Median (Min - Max)	7,80 [-46,00-34,67]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	18 (94,7)
Mean (SD)	0,45 (23,33)
Median (Min - Max)	2,98 [-73,00-30,00]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	7,13 (16,03)
Median (Min - Max)	4,00 [-21,33-40,27]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	0,24 (16,51)
Median (Min - Max)	1,00 [-29,20-24,17]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-1,49 (16,96)
Median (Min - Max)	-1,08 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,21 (20,17)
Median (Min - Max)	-2,75 [-24,27-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	6,14 (14,67)
Median (Min - Max)	5,50 [-11,87-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,15 (34,22)
Median (Min - Max)	0,38 [-52,50-57,93]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	39 (73,6)
Mean (SD)	-7,11 (21,66)
Median (Min - Max)	-7,67 [-54,00-42,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym total score	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	76 (98,7)
Mean (SD)	120,59 (22,45)
Median (Min - Max)	123,25 [60,00-156,83]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	67 (95,7)
Mean (SD)	-1,86 (16,65)
Median (Min - Max)	-1,00 [-62,00-33,33]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	43 (86,0)
Mean (SD)	-1,57 (19,83)
Median (Min - Max)	-2,00 [-60,17-55,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	0,71 (19,51)
Median (Min - Max)	0,50 [-56,17-56,00]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	-1,39 (18,42)
Median (Min - Max)	-4,00 [-31,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,09 (21,56)
Median (Min - Max)	-5,75 [-36,00-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	5,85 (19,87)
Median (Min - Max)	6,31 [-19,50-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	6,93 (22,79)
Median (Min - Max)	4,33 [-28,24-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,60 (8,76)
Median (Min - Max)	8,71 [2,00-22,67]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	11,91 (18,99)
Median (Min - Max)	22,05 [-10,00-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS02: FACT-Lym total score - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	23,75 (1,06)
Median (Min - Max)	23,75 [23,00-24,50]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	22,83 (2,59)
Median (Min - Max)	22,83 [21,00-24,67]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	25,17 (NE)
Median (Min - Max)	25,17 [25,17-25,17]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	55 (71,4)
Mean (SD)	-7,83 (22,16)
Median (Min - Max)	-7,00 [-52,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

3.16.3 *Merkmal: Ethnie*

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym total score	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	110 (95,7)
Mean (SD)	118,28 (23,97)
Median (Min - Max)	121,25 [41,67-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	94 (90,4)
Mean (SD)	0,51 (15,57)
Median (Min - Max)	1,25 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	74
Treated patients with non-missing values - n(%)	62 (83,8)
Mean (SD)	0,26 (19,84)
Median (Min - Max)	1,00 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	56
Treated patients with non-missing values - n(%)	49 (87,5)
Mean (SD)	3,33 (19,88)
Median (Min - Max)	4,00 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	41
Treated patients with non-missing values - n(%)	36 (87,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,11 (20,19)
Median (Min - Max)	-3,50 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	27 (90,0)
Mean (SD)	-0,57 (19,78)
Median (Min - Max)	-4,50 [-46,00-34,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	23 (95,8)
Median (Min - Max)	0,10 (21,28)
	3,83 [-73,00-30,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	4,71 (17,28)
	4,00 [-28,24-40,27]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	19 (100,0)
Median (Min - Max)	2,33 (14,88)
	4,00 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	-0,24 (17,05)
	-1,08 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	2,29 (20,33)
Median (Min - Max)	-1,68 [-24,27-48,38]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	7,79 (14,59)
Median (Min - Max)	6,00 [-11,87-35,27]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	1,15 (34,22)
Median (Min - Max)	0,38 [-52,50-57,93]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	82 (71,3)
Mean (SD)	-8,65 (21,76)
Median (Min - Max)	-7,42 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym total score	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	119,31 (23,62)
Median (Min - Max)	120,00 [79,17-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	1,98 (15,71)
Median (Min - Max)	5,00 [-22,83-33,33]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	3,99 (20,08)
Median (Min - Max)	2,92 [-39,50-37,33]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	2,62 (15,64)
Median (Min - Max)	6,92 [-21,00-27,17]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	1,66 (13,82)
Median (Min - Max)	-3,50 [-12,83-22,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	10,42 (22,87)
Median (Min - Max)	13,92 [-21,50-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	12,87 (24,31)
	9,00 [-19,50-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	21,83 (23,53)
	11,00 [5,67-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	22,67 (NE)
	22,67 [22,67-22,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	23,67 (NE)
	23,67 [23,67-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS03: FACT-Lym total score - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	24,50 (NE)
Median (Min - Max)	24,50 [24,50-24,50]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	24,67 (NE)
Median (Min - Max)	24,67 [24,67-24,67]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	25,17 (NE)
Median (Min - Max)	25,17 [25,17-25,17]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	12 (80,0)
Mean (SD)	0,08 (21,79)
Median (Min - Max)	-1,50 [-32,53-38,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

3.16.4 Merkmal: Region-1

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym total score	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	116,39 (24,41)
Median (Min - Max)	116,58 [60,00-156,83]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	1,28 (13,52)
Median (Min - Max)	-1,00 [-28,00-33,33]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	4,87 (16,16)
Median (Min - Max)	2,83 [-29,00-37,33]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	4,98 (17,83)
Median (Min - Max)	6,83 [-39,00-50,33]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,79 (20,14)
Median (Min - Max)	-4,50 [-53,00-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	3,24 (25,34)
Median (Min - Max)	10,54 [-46,00-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	7,37 (30,77)
Median (Min - Max)	10,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	17,55 (21,07)
Median (Min - Max)	11,83 [-21,33-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	9,20 (17,59)
Median (Min - Max)	18,64 [-20,33-22,67]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	12,97 (15,36)
Median (Min - Max)	17,53 [-14,00-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,62 (21,46)
Median (Min - Max)	17,83 [-11,00-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,41 (15,62)
Median (Min - Max)	17,50 [-9,97-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	20,65 (39,74)
Median (Min - Max)	25,17 [-21,15-57,93]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-4,59 (22,32)
Median (Min - Max)	-6,00 [-54,00-42,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym total score	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	124,80 (24,86)
Median (Min - Max)	127,00 [68,65-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	21 (87,5)
Mean (SD)	-2,77 (19,50)
Median (Min - Max)	2,00 [-62,00-28,00]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	11 (68,8)
Mean (SD)	-0,04 (29,16)
Median (Min - Max)	3,00 [-39,50-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	6,86 (24,53)
Median (Min - Max)	6,92 [-31,00-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	1,06 (24,73)
Median (Min - Max)	-1,40 [-24,82-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-4,89 (13,20)
Median (Min - Max)	-5,71 [-21,50-15,39]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	3,19 (14,05)
Median (Min - Max)	5,33 [-19,50-16,17]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	9,63 (9,46)
Median (Min - Max)	4,33 [4,00-20,54]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	2,98 (13,91)
Median (Min - Max)	6,33 [-20,84-14,33]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-7,36 (NE)
Median (Min - Max)	-7,36 [-7,36--7,36]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	20,50 (21,92)
Median (Min - Max)	20,50 [5,00-36,00]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,80 (NE)
Median (Min - Max)	1,80 [1,80-1,80]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,67 (NE)
Median (Min - Max)	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	23 (79,3)
Mean (SD)	-2,57 (26,20)
Median (Min - Max)	-4,71 [-52,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym total score	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	44 (91,7)
Mean (SD)	116,61 (22,59)
Median (Min - Max)	121,25 [41,67-154,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	41 (89,1)
Mean (SD)	1,73 (15,56)
Median (Min - Max)	2,50 [-43,50-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	-2,37 (19,34)
Median (Min - Max)	-1,00 [-60,17-48,33]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	-0,16 (18,24)
Median (Min - Max)	3,50 [-56,17-27,33]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	0,83 (16,12)
Median (Min - Max)	-1,00 [-31,60-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	1,63 (15,97)
Median (Min - Max)	4,29 [-21,72-34,67]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	-2,53 (14,03)
Median (Min - Max)	-1,50 [-18,80-30,00]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-3,18 (12,71)
Median (Min - Max)	-2,58 [-28,24-20,33]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	-0,35 (14,69)
Median (Min - Max)	2,00 [-29,20-24,17]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-9,01 (14,65)
Median (Min - Max)	-5,50 [-36,87-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-7,34 (13,24)
Median (Min - Max)	-1,68 [-24,27-5,00]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-0,89 (9,61)
Median (Min - Max)	3,20 [-11,87-6,00]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-17,15 (25,21)
Median (Min - Max)	-10,55 [-52,50-5,00]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	-9,47 (20,39)
Median (Min - Max)	0,52 [-32,92-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-21,39 (30,57)
Median (Min - Max)	-14,10 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-24,21 (23,58)
Median (Min - Max)	-37,24 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-23,47 (22,51)
Median (Min - Max)	-29,20 [-42,56-1,36]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-16,60 (24,89)
Median (Min - Max)	-16,60 [-34,20-1,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-0,50 (NE)
Median (Min - Max)	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS04: FACT-Lym total score - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	33 (68,8)
Mean (SD)	-13,35 (17,16)
Median (Min - Max)	-11,17 [-48,67-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

3.16.5 *Merkmal: Region-2*

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym total score	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	50 (98,0)
Mean (SD)	116,39 (24,41)
Median (Min - Max)	116,58 [60,00-156,83]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	43 (95,6)
Mean (SD)	1,28 (13,52)
Median (Min - Max)	-1,00 [-28,00-33,33]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	31 (93,9)
Mean (SD)	4,87 (16,16)
Median (Min - Max)	2,83 [-29,00-37,33]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	25 (92,6)
Mean (SD)	4,98 (17,83)
Median (Min - Max)	6,83 [-39,00-50,33]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,79 (20,14)
Median (Min - Max)	-4,50 [-53,00-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	3,24 (25,34)
Median (Min - Max)	10,54 [-46,00-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	7,37 (30,77)
Median (Min - Max)	10,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	17,55 (21,07)
Median (Min - Max)	11,83 [-21,33-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	9,20 (17,59)
Median (Min - Max)	18,64 [-20,33-22,67]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	12,97 (15,36)
Median (Min - Max)	17,53 [-14,00-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,62 (21,46)
Median (Min - Max)	17,83 [-11,00-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	15,41 (15,62)
Median (Min - Max)	17,50 [-9,97-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	20,65 (39,74)
Median (Min - Max)	25,17 [-21,15-57,93]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	36 (70,6)
Mean (SD)	-4,59 (22,32)
Median (Min - Max)	-6,00 [-54,00-42,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym total score	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	119,75 (23,52)
Median (Min - Max)	123,83 [41,67-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	63 (88,7)
Mean (SD)	0,27 (16,84)
Median (Min - Max)	2,33 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	43 (81,1)
Mean (SD)	-2,02 (21,76)
Median (Min - Max)	0,00 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	34 (85,0)
Mean (SD)	1,91 (20,16)
Median (Min - Max)	4,42 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	0,15 (18,84)
Median (Min - Max)	-3,00 [-31,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-0,28 (15,11)
Median (Min - Max)	-4,67 [-21,72-34,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-0,85 (13,85)
Median (Min - Max)	2,00 [-19,50-30,00]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-0,22 (12,94)
Median (Min - Max)	2,00 [-28,24-20,54]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	0,84 (13,97)
Median (Min - Max)	3,12 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	-8,15 (13,57)
Median (Min - Max)	-3,00 [-36,87-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-7,34 (11,84)
Median (Min - Max)	-4,52 [-24,27-5,00]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,58 (8,38)
Median (Min - Max)	4,10 [-11,87-6,00]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,60 (29,25)
Median (Min - Max)	0,38 [-52,50-36,00]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS05: FACT-Lym total score - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	58 (73,4)
Mean (SD)	-9,36 (21,53)
Median (Min - Max)	-10,33 [-52,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

3.16.6 Merkmal: Krankheitsstadium nach Ann-Arbor

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym total score	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	123,76 (24,17)
Median (Min - Max)	128,00 [82,01-154,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	6,97 (8,51)
Median (Min - Max)	4,39 [-1,33-21,00]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	3,55 (20,19)
Median (Min - Max)	3,00 [-27,74-25,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	-0,61 (6,60)
Median (Min - Max)	0,00 [-7,50-5,67]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Mean (SD)	-8,30 (9,73)
Median (Min - Max)	-6,70 [-21,00-1,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-6,06 (1,75)
Median (Min - Max)	-5,71 [-7,96--4,50]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-7,04 (11,25)
Median (Min - Max)	-7,04 [-15,00-0,91]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-8,67 (17,91)
Median (Min - Max)	-8,67 [-21,33-4,00]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-12,39 (14,20)
Median (Min - Max)	-20,33 [-20,84-4,00]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-8,50 (7,78)
Median (Min - Max)	-8,50 [-14,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-9,18 (2,58)
	-9,18 [-11,00--7,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-2,48 (10,58)
	-2,48 [-9,97-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-8,08 (18,49)
	-8,08 [-21,15-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,71 (NE)
	0,71 [0,71-0,71]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,80 (NE)
Median (Min - Max)	1,80 [1,80-1,80]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 21 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-1,67 (NE)
	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,60 (NE)
	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,00 (NE)
	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	7 (70,0)
Median (Min - Max)	-14,49 (26,15)
	-15,00 [-48,67-18,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym total score	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	113,09 (19,41)
Median (Min - Max)	116,17 [70,00-141,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	5,12 (16,13)
Median (Min - Max)	5,68 [-43,17-33,33]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-2,50 (31,71)
Median (Min - Max)	-1,17 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	1,80 (31,07)
Median (Min - Max)	3,00 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	3,68 (27,37)
Median (Min - Max)	1,33 [-31,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-4,18 (28,78)
	-11,72 [-36,00-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	4,34 (25,21)
	2,13 [-16,10-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-0,65 (29,38)
	-8,58 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-0,31 (10,97)
	2,23 [-12,32-9,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-0,17 (NE)
	-0,17 [-0,17--0,17]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-10,72 (19,16)
	-10,72 [-24,27-2,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	-52,50 (NE)
	-52,50 [-52,50--52,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-32,92 (NE)
	-32,92 [-32,92--32,92]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-61,36 (NE)
	-61,36 [-61,36--61,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-37,24 (NE)
	-37,24 [-37,24--37,24]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage II	
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-42,56 (NE)
Median (Min - Max)	-42,56 [-42,56--42,56]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	
NE	
Treated patients with non-missing values - n(%)	15 (71,4)
Mean (SD)	-4,25 (27,75)
Median (Min - Max)	-6,17 [-47,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym total score	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	124,07 (19,43)
Median (Min - Max)	123,00 [81,00-154,67]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	-5,04 (14,40)
Median (Min - Max)	-4,00 [-24,67-22,00]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	-14,54 (17,65)
Median (Min - Max)	-14,00 [-39,50-16,50]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	1,74 (15,38)
Median (Min - Max)	6,00 [-16,83-24,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	2,83 (11,15)
Median (Min - Max)	7,67 [-12,33-13,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage III	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-3,46 (19,66)
Median (Min - Max)	-6,58 [-21,50-20,83]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-3,00 (14,00)
Median (Min - Max)	5,00 [-19,50-10,83]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,94 (6,11)
Median (Min - Max)	4,33 [-5,00-6,50]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,83 (7,78)
Median (Min - Max)	0,83 [-4,67-6,33]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,83 (NE)
Median (Min - Max)	5,83 [5,83-5,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage III	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,83 (NE)
Median (Min - Max)	-3,83 [-3,83--3,83]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	7,50 (NE)
Median (Min - Max)	7,50 [7,50-7,50]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (52,9)
Mean (SD)	-14,31 (24,02)
Median (Min - Max)	-16,17 [-52,83-32,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym total score	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	81 (98,8)
Mean (SD)	117,94 (25,45)
Median (Min - Max)	121,00 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	67 (93,1)
Mean (SD)	-0,16 (15,92)
Median (Min - Max)	0,00 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	49 (90,7)
Mean (SD)	4,17 (15,53)
Median (Min - Max)	3,50 [-29,00-48,33]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	37 (88,1)
Mean (SD)	4,26 (16,99)
Median (Min - Max)	4,83 [-39,00-50,33]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	-1,67 (19,17)
Median (Min - Max)	-4,00 [-53,00-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 6 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	20 (90,9)
Median (Min - Max)	5,20 (19,65)
	9,54 [-46,00-34,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	16 (100,0)
Median (Min - Max)	4,63 (24,65)
	8,50 [-73,00-30,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	12 (85,7)
Median (Min - Max)	14,15 (13,20)
	11,42 [-4,00-40,27]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	12 (100,0)
Median (Min - Max)	8,62 (15,21)
	12,71 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	3,57 (20,63)
	4,00 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	13,32 (21,45)
	12,67 [-18,60-48,38]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	7 (87,5)
Median (Min - Max)	13,18 (15,60)
	14,00 [-11,87-35,27]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	17,17 (27,73)
	15,08 [-16,87-57,93]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	2 (40,0)
Median (Min - Max)	2,26 (2,46)
	2,26 [0,52-4,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-8,07 (18,36)
	1,00 [-29,20-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-17,70 (29,27)
	-17,70 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-13,92 (21,61)
	-13,92 [-29,20-1,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-16,60 (24,89)
	-16,60 [-34,20-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,50 (NE)
	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS06: FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

Ann Arbor stage:	
Stage IV	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	63 (76,8)
Mean (SD)	-6,58 (19,63)
Median (Min - Max)	-7,17 [-54,00-42,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS07: FACT-Lym total score - Change from Baseline by subgroup: Bulky disease
 PRO set

3.16.7 *Merkmal: Bulky Erkrankung*

FACT-Lym total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym total score	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	121 (96,0)
Mean (SD)	118,68 (23,84)
Median (Min - Max)	121,50 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	103 (91,2)
Mean (SD)	0,64 (15,64)
Median (Min - Max)	1,33 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	74 (87,1)
Mean (SD)	0,86 (19,79)
Median (Min - Max)	1,00 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	58 (87,9)
Mean (SD)	3,52 (19,12)
Median (Min - Max)	5,25 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	43 (87,8)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS07: FACT-Lym total score - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Mean (SD)	-0,66 (19,18)
Median (Min - Max)	-3,50 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS07: FACT-Lym total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	33 (91,7)
Mean (SD)	1,42 (20,45)
Median (Min - Max)	4,00 [-46,00-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	28 (96,6)
Mean (SD)	2,38 (21,94)
Median (Min - Max)	4,92 [-73,00-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	7,05 (18,57)
Median (Min - Max)	4,17 [-28,24-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	20 (100,0)
Mean (SD)	3,35 (15,18)
Median (Min - Max)	4,90 [-29,20-24,17]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	13 (86,7)
Mean (SD)	1,60 (17,62)
Median (Min - Max)	-0,17 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS07: FACT-Lym total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	4,14 (20,42)
Median (Min - Max)	0,58 [-24,27-48,38]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	9,48 (14,75)
Median (Min - Max)	6,75 [-11,87-35,27]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	3,82 (33,00)
Median (Min - Max)	5,00 [-52,50-57,93]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS07: FACT-Lym total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS07: FACT-Lym total score - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	93 (73,8)
Mean (SD)	-7,36 (21,90)
Median (Min - Max)	-7,00 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

3.16.8 *Merkmal: Double/Triple-Hit*

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym total score	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	14 (100,0)
Mean (SD)	114,42 (22,26)
Median (Min - Max)	113,43 [82,01-155,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	12 (100,0)
Mean (SD)	2,80 (16,06)
Median (Min - Max)	5,17 [-28,00-26,67]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	13,68 (14,93)
Median (Min - Max)	14,58 [-16,83-29,83]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	18,53 (17,31)
Median (Min - Max)	13,25 [0,00-50,33]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Mean (SD)	6,43 (20,27)
Median (Min - Max)	15,00 [-19,00-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	13,57 (24,95)
Median (Min - Max)	24,64 [-23,67-28,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	18,80 (10,03)
Median (Min - Max)	23,45 [7,29-25,67]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	31,81 (7,43)
Median (Min - Max)	28,83 [26,33-40,27]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	19,78 (0,69)
Median (Min - Max)	19,78 [19,29-20,27]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	24,66 (3,69)
Median (Min - Max)	24,66 [22,05-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	35,69 (17,95)
Median (Min - Max)	35,69 [23,00-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	28,13 (10,09)
Median (Min - Max)	28,13 [21,00-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	57,93 (NE)
Median (Min - Max)	57,93 [57,93-57,93]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (64,3)
Mean (SD)	-6,47 (29,27)
Median (Min - Max)	5,00 [-52,33-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym total score	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	111 (95,7)
Mean (SD)	118,91 (24,08)
Median (Min - Max)	122,50 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	104
Treated patients with non-missing values - n(%)	94 (90,4)
Mean (SD)	0,40 (15,52)
Median (Min - Max)	1,25 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	78
Treated patients with non-missing values - n(%)	66 (84,6)
Mean (SD)	-0,69 (19,83)
Median (Min - Max)	-0,50 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	60
Treated patients with non-missing values - n(%)	53 (88,3)
Mean (SD)	1,47 (18,66)
Median (Min - Max)	3,00 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)
Mean (SD)	-1,60 (19,12)
Median (Min - Max)	-3,75 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,25 (19,68)
Median (Min - Max)	-4,50 [-46,00-45,33]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	0,41 (22,25)
Median (Min - Max)	3,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	3,14 (16,67)
Median (Min - Max)	4,00 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	1,52 (14,91)
Median (Min - Max)	3,12 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	-2,59 (15,67)
Median (Min - Max)	-2,00 [-36,87-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,17 (14,43)
Median (Min - Max)	-2,75 [-24,27-24,50]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	4,82 (11,87)
Median (Min - Max)	5,50 [-11,87-24,67]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-2,95 (27,82)
Median (Min - Max)	0,38 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS08: FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	85 (73,3)
Mean (SD)	-7,65 (21,13)
Median (Min - Max)	-7,17 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

3.16.9 *Merkmal: Transformation des DLBCL*

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym total score	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	119,46 (23,70)
Median (Min - Max)	120,00 [70,00-154,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	-2,77 (19,02)
Median (Min - Max)	-1,17 [-62,00-33,33]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-1,71 (18,69)
Median (Min - Max)	0,50 [-38,50-37,33]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	2,24 (17,55)
Median (Min - Max)	6,00 [-31,00-27,17]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Mean (SD)	-4,22 (13,01)
Median (Min - Max)	-6,10 [-21,00-22,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	9,28 (20,97)
Median (Min - Max)	4,00 [-5,71-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	8,81 (21,75)
Median (Min - Max)	2,00 [-10,20-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	12,46 (24,56)
Median (Min - Max)	3,00 [-5,00-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (17,50)
Median (Min - Max)	-3,00 [-29,20-4,00]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-13,96 (19,85)
Median (Min - Max)	-3,00 [-36,87--2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-6,99 (11,80)
Median (Min - Max)	-7,36 [-18,60-5,00]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,29 (10,04)
Median (Min - Max)	5,00 [-11,87-6,00]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-2,29 (12,62)
Median (Min - Max)	5,00 [-16,87-5,00]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,36 (2,32)
Median (Min - Max)	2,36 [0,71-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-10,40 (16,40)
Median (Min - Max)	-3,00 [-29,20-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-18,30 (28,43)
Median (Min - Max)	-18,30 [-38,40-1,80]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-13,10 (22,77)
Median (Min - Max)	-13,10 [-29,20-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-14,60 (27,72)
Median (Min - Max)	-14,60 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,67 (NE)
Median (Min - Max)	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (79,2)
Mean (SD)	-11,30 (22,58)
Median (Min - Max)	-16,17 [-52,83-38,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym total score	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	102 (96,2)
Mean (SD)	118,17 (23,98)
Median (Min - Max)	121,75 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	95
Treated patients with non-missing values - n(%)	86 (90,5)
Mean (SD)	1,48 (14,60)
Median (Min - Max)	2,00 [-43,50-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	70
Treated patients with non-missing values - n(%)	61 (87,1)
Mean (SD)	1,41 (20,12)
Median (Min - Max)	1,00 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	48 (88,9)
Mean (SD)	3,43 (19,62)
Median (Min - Max)	4,42 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	39
Treated patients with non-missing values - n(%)	33 (84,6)
Mean (SD)	0,42 (20,74)
Median (Min - Max)	-3,50 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	28 (90,3)
Mean (SD)	0,02 (20,42)
Median (Min - Max)	0,04 [-46,00-34,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	23 (95,8)
Median (Min - Max)	0,98 (22,21)
	5,33 [-73,00-30,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	18 (90,0)
Median (Min - Max)	5,85 (17,64)
	5,00 [-28,24-40,27]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	5,60 (14,12)
	6,33 [-20,84-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	6,27 (14,88)
	4,92 [-14,00-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	7,84 (21,83)
Median (Min - Max)	2,83 [-24,27-48,38]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	7 (70,0)
Median (Min - Max)	13,67 (14,99)
	14,00 [-9,97-35,27]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	6,87 (40,56)
	10,46 [-52,50-57,93]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	2 (50,0)
Median (Min - Max)	-16,20 (23,65)
	-16,20 [-32,92-0,52]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-28,68 (46,21)
	-28,68 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-17,12 (28,46)
Median (Min - Max)	-17,12 [-37,24-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-20,60 (31,06)
	-20,60 [-42,56-1,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,50 (NE)
	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS09: FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	75 (70,8)
Mean (SD)	-6,58 (21,70)
Median (Min - Max)	-6,83 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

3.16.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym total score	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	43 (100,0)
Mean (SD)	122,69 (22,53)
Median (Min - Max)	125,17 [68,65-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	37 (92,5)
Mean (SD)	1,08 (14,87)
Median (Min - Max)	0,00 [-28,00-33,33]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	2,61 (21,76)
Median (Min - Max)	1,75 [-39,50-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	23 (85,2)
Mean (SD)	4,03 (19,65)
Median (Min - Max)	0,00 [-31,27-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym total score - Change from Baseline by subgroup: B- Cell type	Loncastuximab tesirine Data-cut 3
Mean (SD)	2,54 (20,71)
Median (Min - Max)	0,58 [-31,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	6,22 (18,84)
Median (Min - Max)	7,38 [-21,50-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	13 (92,9)
Median (Min - Max)	6,63 (19,59)
	9,00 [-19,50-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	7,98 (20,76)
	6,08 [-21,33-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	1,70 (15,93)
	5,70 [-20,84-22,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	4 (80,0)
Median (Min - Max)	3,83 (15,61)
	2,83 [-14,00-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	3,13 (15,33)
Median (Min - Max)	-0,50 [-11,00-24,50]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	7,40 (17,32)
Median (Min - Max)	7,50 [-9,97-24,67]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-3,12 (41,21)
Median (Min - Max)	2,01 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	34 (79,1)
Mean (SD)	-5,40 (23,98)
Median (Min - Max)	-6,08 [-52,83-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym total score	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	123,80 (18,71)
Median (Min - Max)	125,00 [82,00-156,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 18
Treated patients with non-missing values - n(%)	17 (94,4)
Mean (SD)	-0,61 (15,83)
Median (Min - Max)	3,33 [-43,17-28,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-3,31 (22,95)
Median (Min - Max)	3,50 [-60,17-26,53]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	-2,82 (20,64)
Median (Min - Max)	3,00 [-56,17-16,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-4,31 (11,52)
Median (Min - Max)	-4,50 [-24,82-12,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	-5,53 (13,45)
Median (Min - Max)	-5,75 [-21,72-11,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	9,38 (8,02)
	8,00 [2,13-18,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,42 (10,30)
	4,00 [-8,58-11,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,56 (15,17)
	2,00 [-12,32-18,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	1,50 (16,26)
	1,50 [-10,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-5,80 (26,12)
Median (Min - Max)	-5,80 [-24,27-12,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	14,00 (NE)
Median (Min - Max)	14,00 [14,00-14,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	-32,92 (NE)
Median (Min - Max)	-32,92 [-32,92--32,92]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	-61,36 (NE)
Median (Min - Max)	-61,36 [-61,36--61,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 16 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	-37,24 (NE)
Median (Min - Max)	-37,24 [-37,24--37,24]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS10: FACT-Lym total score - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-42,56 (NE)
Median (Min - Max)	-42,56 [-42,56--42,56]
EOT	
FACT-Lym total score - Change from baseline	NE
Treated patients at visit	16 (76,2)
Treated patients with non-missing values - n(%)	-9,72 (22,14)
Mean (SD)	-6,08 [-47,00-42,00]
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

3.16.11 Merkmal: Maximaler längster Durchmesser

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
FACT-Lym total score	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	72 (94,7)
Mean (SD)	118,54 (22,38)
Median (Min - Max)	121,00 [60,00-155,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	62 (89,9)
Mean (SD)	2,08 (15,13)
Median (Min - Max)	1,67 [-43,17-38,17]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	50 (87,7)
Mean (SD)	1,47 (21,95)
Median (Min - Max)	0,25 [-60,17-55,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	39 (90,7)
Mean (SD)	4,40 (19,25)
Median (Min - Max)	7,83 [-56,17-56,00]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	28 (87,5)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Mean (SD)	1,37 (19,10)
Median (Min - Max)	3,18 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	23 (92,0)
Mean (SD)	-0,74 (22,35)
Median (Min - Max)	4,00 [-46,00-45,33]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	0,40 (23,13)
Median (Min - Max)	3,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	6,09 (17,30)
Median (Min - Max)	4,00 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	2,49 (13,62)
Median (Min - Max)	4,00 [-29,20-22,67]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-0,55 (17,15)
Median (Min - Max)	-1,08 [-36,87-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	-0,04 (16,46)
Median (Min - Max)	-1,68 [-24,27-24,50]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	7 (70,0)
Mean (SD)	7,93 (12,09)
Median (Min - Max)	6,00 [-11,87-24,67]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	-0,35 (28,97)
Median (Min - Max)	5,00 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	54 (71,1)
Mean (SD)	-4,67 (24,44)
Median (Min - Max)	-6,33 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym total score	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	34 (100,0)
Mean (SD)	118,61 (27,01)
Median (Min - Max)	124,58 [41,67-156,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	-1,85 (13,77)
Median (Min - Max)	0,67 [-43,50-21,69]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	17 (89,5)
Mean (SD)	-3,16 (14,01)
Median (Min - Max)	1,83 [-38,50-14,67]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	-1,07 (15,27)
Median (Min - Max)	3,00 [-31,27-23,91]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	-2,92 (21,09)
Median (Min - Max)	-7,00 [-31,60-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	7,53 (15,65)
Median (Min - Max)	8,07 [-7,96-34,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	9,95 (17,18)
Median (Min - Max)	13,02 [-16,10-30,00]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	9,65 (16,35)
Median (Min - Max)	16,08 [-14,10-20,54]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	6,93 (17,54)
Median (Min - Max)	11,08 [-20,84-24,17]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	13,00 (NE)
Median (Min - Max)	13,00 [13,00-13,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	12,67 (NE)
Median (Min - Max)	12,67 [12,67-12,67]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	14,00 (NE)
Median (Min - Max)	14,00 [14,00-14,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	-13,90 (17,47)
Median (Min - Max)	-9,33 [-52,83-14,57]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym total score	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	116,48 (23,96)
Median (Min - Max)	114,25 [77,00-152,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-7,01 (29,38)
Median (Min - Max)	0,15 [-62,00-21,00]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	5,18 (21,00)
Median (Min - Max)	7,37 [-16,83-25,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-6,71 (21,40)
Median (Min - Max)	-7,50 [-31,00-19,17]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-21,00 (0,00)
Median (Min - Max)	-21,00 [-21,00--21,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,50 (NE)
Median (Min - Max)	-4,50 [-4,50--4,50]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-15,00 (NE)
Median (Min - Max)	-15,00 [-15,00--15,00]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-21,33 (NE)
Median (Min - Max)	-21,33 [-21,33--21,33]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-20,33 (NE)
Median (Min - Max)	-20,33 [-20,33--20,33]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-14,00 (NE)
Median (Min - Max)	-14,00 [-14,00--14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-11,00 (NE)
Median (Min - Max)	-11,00 [-11,00--11,00]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-9,97 (NE)
Median (Min - Max)	-9,97 [-9,97--9,97]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-21,15 (NE)
Median (Min - Max)	-21,15 [-21,15--21,15]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	4 (44,4)
Mean (SD)	-8,98 (18,31)
Median (Min - Max)	-13,42 [-26,00-16,93]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym total score	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	115,62 (26,16)
Median (Min - Max)	126,00 [82,00-154,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	3,42 (6,28)
Median (Min - Max)	5,00 [-7,52-8,00]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	4,00 (4,24)
Median (Min - Max)	4,00 [1,00-7,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	4,00 (4,24)
Median (Min - Max)	4,00 [1,00-7,00]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,50 (NE)
Median (Min - Max)	-3,50 [-3,50--3,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS11: FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-6,40 (11,27)
Median (Min - Max)	-4,71 [-23,33-4,04]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

3.16.12 Merkmal: Primärdiagnose

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym total score	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	108 (96,4)
Mean (SD)	119,02 (23,69)
Median (Min - Max)	121,25 [41,67-156,83]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	101
Treated patients with non-missing values - n(%)	93 (92,1)
Mean (SD)	0,83 (15,46)
Median (Min - Max)	2,00 [-62,00-38,17]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	78
Treated patients with non-missing values - n(%)	66 (84,6)
Mean (SD)	-0,39 (20,18)
Median (Min - Max)	0,25 [-60,17-55,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	60
Treated patients with non-missing values - n(%)	53 (88,3)
Mean (SD)	1,78 (18,72)
Median (Min - Max)	4,00 [-56,17-56,00]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	38 (88,4)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,60 (19,12)
Median (Min - Max)	-3,75 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	-0,25 (19,68)
Median (Min - Max)	-4,50 [-46,00-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	25 (96,2)
Median (Min - Max)	0,41 (22,25)
	3,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	3,14 (16,67)
	4,00 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	18 (100,0)
Median (Min - Max)	1,52 (14,91)
	3,12 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	-2,59 (15,67)
	-2,00 [-36,87-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	-2,17 (14,43)
Median (Min - Max)	-2,75 [-24,27-24,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	4,82 (11,87)
	5,50 [-11,87-24,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-2,95 (27,82)
	0,38 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	4 (66,7)
Median (Min - Max)	-6,92 (17,41)
	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	5 (100,0)
Median (Min - Max)	-17,71 (27,73)
	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 22 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	2,00 (NE)
	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 23 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	2,60 (NE)
	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 25 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-5,00 (NE)
	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	82 (73,2)
Median (Min - Max)	-7,44 (21,48)
	-7,08 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym total score	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	120,14 (21,42)
Median (Min - Max)	122,00 [87,33-155,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,47 (18,37)
Median (Min - Max)	-2,50 [-28,00-26,67]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	16,62 (9,09)
Median (Min - Max)	14,58 [4,64-29,83]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	19,59 (19,14)
Median (Min - Max)	13,30 [0,00-50,33]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	6,43 (20,27)
Median (Min - Max)	15,00 [-19,00-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	13,57 (24,95)
Median (Min - Max)	24,64 [-23,67-28,67]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	18,80 (10,03)
Median (Min - Max)	23,45 [7,29-25,67]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	31,81 (7,43)
Median (Min - Max)	28,83 [26,33-40,27]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	19,78 (0,69)
Median (Min - Max)	19,78 [19,29-20,27]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	24,66 (3,69)
Median (Min - Max)	24,66 [22,05-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS12: FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	35,69 (17,95)
Median (Min - Max)	35,69 [23,00-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	28,13 (10,09)
Median (Min - Max)	28,13 [21,00-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	57,93 (NE)
Median (Min - Max)	57,93 [57,93-57,93]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-10,13 (28,73)
Median (Min - Max)	-21,00 [-52,33-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

3.16.13 Merkmal: Anzahl der vorherigen systemischen Therapien

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym total score	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	58 (98,3)
Mean (SD)	121,35 (24,71)
Median (Min - Max)	122,75 [41,67-156,83]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	47 (90,4)
Mean (SD)	-0,91 (14,19)
Median (Min - Max)	0,00 [-43,50-38,17]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	30 (78,9)
Mean (SD)	-4,49 (19,69)
Median (Min - Max)	-2,92 [-39,50-31,17]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	22 (75,9)
Mean (SD)	3,19 (16,14)
Median (Min - Max)	7,25 [-39,00-24,00]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	16 (72,7)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Mean (SD)	-2,06 (20,12)
Median (Min - Max)	1,10 [-53,00-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	-6,06 (20,50)
Median (Min - Max)	-6,27 [-46,00-34,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	-4,95 (23,45)
Median (Min - Max)	2,00 [-73,00-30,00]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	1,12 (14,02)
Median (Min - Max)	2,50 [-28,24-20,54]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	0,86 (15,89)
Median (Min - Max)	5,80 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	-7,61 (16,57)
Median (Min - Max)	-2,00 [-36,87-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-7,34 (11,84)
Median (Min - Max)	-4,52 [-24,27-5,00]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,58 (8,38)
Median (Min - Max)	4,10 [-11,87-6,00]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	-4,60 (29,25)
Median (Min - Max)	0,38 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
Cycle 14 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Cycle 15 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Cycle 17 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	
Cycle 18 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	
Cycle 19 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	
Cycle 20 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
Cycle 23 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	
Cycle 25 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	44 (74,6)
Mean (SD)	-11,17 (21,36)
Median (Min - Max)	-14,00 [-54,00-42,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym total score	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	118,18 (22,40)
Median (Min - Max)	123,00 [63,00-155,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 30
Treated patients with non-missing values - n(%)	26 (86,7)
Mean (SD)	0,97 (19,44)
Median (Min - Max)	1,58 [-62,00-33,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	7,51 (18,84)
Median (Min - Max)	4,33 [-19,17-55,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	1,84 (23,00)
Median (Min - Max)	-1,00 [-31,27-56,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	-0,80 (25,09)
Median (Min - Max)	-5,50 [-31,60-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	6,34 (24,03)
Median (Min - Max)	3,17 [-23,67-45,33]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	15,48 (26,28)
Median (Min - Max)	15,83 [-16,10-46,33]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	11,10 (26,70)
Median (Min - Max)	4,83 [-14,10-48,83]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	8,97 (11,87)
Median (Min - Max)	2,23 [2,00-22,67]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	6,83 (23,81)
Median (Min - Max)	6,83 [-10,00-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 11 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	24,50 (NE)
Median (Min - Max)	24,50 [24,50-24,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	24,67 (NE)
Median (Min - Max)	24,67 [24,67-24,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1 1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	25,17 (NE)
Median (Min - Max)	25,17 [25,17-25,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	EOT NE
Treated patients with non-missing values - n(%)	21 (65,6)
Mean (SD)	-2,45 (23,75)
Median (Min - Max)	-6,17 [-52,33-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym total score	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	38 (97,4)
Mean (SD)	114,09 (23,48)
Median (Min - Max)	113,42 [60,00-154,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	33 (97,1)
Mean (SD)	2,70 (14,06)
Median (Min - Max)	3,00 [-43,17-26,67]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	26 (96,3)
Mean (SD)	2,44 (19,59)
Median (Min - Max)	3,17 [-60,17-48,33]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	22 (95,7)
Mean (SD)	4,16 (19,83)
Median (Min - Max)	4,42 [-56,17-50,33]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	0,73 (15,12)
Median (Min - Max)	-3,00 [-24,82-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	9,63 (15,53)
Median (Min - Max)	13,00 [-19,00-28,67]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	8,79 (13,05)
Median (Min - Max)	9,00 [-15,00-25,67]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	12,43 (19,58)
Median (Min - Max)	11,42 [-21,33-40,27]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	5,09 (16,68)
Median (Min - Max)	8,00 [-20,33-20,27]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	7,53 (16,55)
Median (Min - Max)	9,42 [-14,00-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS13: FACT-Lym total score - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	13,84 (23,49)
Median (Min - Max)	12,67 [-11,00-48,38]
FACT-Lym total score - Change from baseline	
Cycle 12 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	13,56 (16,71)
Median (Min - Max)	14,00 [-9,97-35,27]
FACT-Lym total score - Change from baseline	
Cycle 13 Day 1	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	18,39 (55,92)
Median (Min - Max)	18,39 [-21,15-57,93]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	29 (74,4)
Mean (SD)	-5,69 (20,90)
Median (Min - Max)	-7,00 [-48,67-38,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

3.16.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym total score	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	89 (96,7)
Mean (SD)	118,97 (23,63)
Median (Min - Max)	120,00 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 86
Treated patients with non-missing values - n(%)	78 (90,7)
Mean (SD)	1,05 (16,75)
Median (Min - Max)	2,42 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 66
Treated patients with non-missing values - n(%)	56 (84,8)
Mean (SD)	0,03 (21,61)
Median (Min - Max)	-1,08 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 49
Treated patients with non-missing values - n(%)	44 (89,8)
Mean (SD)	1,53 (19,86)
Median (Min - Max)	2,50 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 34
Treated patients with non-missing values - n(%)	31 (91,2)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,32 (21,14)
Median (Min - Max)	-4,00 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	24 (92,3)
Mean (SD)	2,14 (20,32)
Median (Min - Max)	-0,25 [-46,00-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	23
Mean (SD)	22 (95,7)
Median (Min - Max)	1,05 (24,21)
	4,92 [-73,00-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	19
Mean (SD)	16 (84,2)
Median (Min - Max)	4,32 (18,73)
	4,17 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	14
Mean (SD)	14 (100,0)
Median (Min - Max)	0,37 (16,62)
	2,12 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	8 (80,0)
Median (Min - Max)	-2,05 (18,53)
	1,00 [-36,87-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	-2,15 (16,13)
Median (Min - Max)	-2,75 [-24,27-24,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	7 (77,8)
Median (Min - Max)	4,79 (12,82)
	6,00 [-11,87-24,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	6 (85,7)
Median (Min - Max)	3,98 (22,84)
	0,38 [-21,15-36,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	5
Mean (SD)	3 (60,0)
Median (Min - Max)	-9,47 (20,39)
	0,52 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-21,39 (30,57)
	-14,10 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-24,21 (23,58)
Median (Min - Max)	-37,24 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-23,47 (22,51)
	-29,20 [-42,56-1,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-16,60 (24,89)
	-16,60 [-34,20-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,50 (NE)
	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	64 (69,6)
Mean (SD)	-6,27 (22,77)
Median (Min - Max)	-7,08 [-54,00-60,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym total score	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	22 (100,0)
Mean (SD)	120,36 (25,18)
Median (Min - Max)	124,58 [68,65-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	18 (100,0)
Mean (SD)	-1,91 (11,67)
Median (Min - Max)	-1,00 [-22,83-21,69]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,30 (12,53)
Median (Min - Max)	2,42 [-24,00-17,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	4,06 (13,75)
Median (Min - Max)	5,67 [-16,83-23,91]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	5 (62,5)
Mean (SD)	-1,66 (12,25)
Median (Min - Max)	1,20 [-21,00-10,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-5,44 (22,12)
Median (Min - Max)	-0,57 [-36,00-15,39]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	2,98 (9,19)
	0,91 [-5,00-13,02]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	6,85 (12,52)
	4,00 [-4,00-20,54]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	4,36 (6,55)
	4,00 [-2,00-11,08]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-6,00 (4,24)
	-6,00 [-9,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-7,36 (NE)
Median (Min - Max)	-7,36 [-7,36--7,36]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,80 (NE)
Median (Min - Max)	1,80 [1,80-1,80]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	3,00 (NE)
	3,00 [3,00-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS14: FACT-Lym total score - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,67 (NE)
Median (Min - Max)	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	-12,19 (18,30)
Median (Min - Max)	-11,00 [-52,33-18,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

3.16.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym total score	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	39 (97,5)
Mean (SD)	119,38 (23,80)
Median (Min - Max)	122,00 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 37
Treated patients with non-missing values - n(%)	34 (91,9)
Mean (SD)	-1,81 (17,97)
Median (Min - Max)	-0,88 [-62,00-28,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 32
Treated patients with non-missing values - n(%)	26 (81,3)
Mean (SD)	-1,29 (22,24)
Median (Min - Max)	0,25 [-60,17-31,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 25
Treated patients with non-missing values - n(%)	21 (84,0)
Mean (SD)	0,03 (19,81)
Median (Min - Max)	0,00 [-56,17-24,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 18
Treated patients with non-missing values - n(%)	16 (88,9)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,78 (17,54)
Median (Min - Max)	1,08 [-21,00-42,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	4,64 (17,45)
Median (Min - Max)	7,94 [-23,67-34,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	13 (100,0)
Median (Min - Max)	3,26 (18,13)
	3,83 [-19,50-30,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	10 (83,3)
Median (Min - Max)	1,89 (17,24)
	3,50 [-28,24-28,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	10 (100,0)
Median (Min - Max)	4,46 (17,70)
	7,48 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	-3,67 (18,41)
	-4,58 [-36,87-23,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	1,45 (15,66)
Median (Min - Max)	0,58 [-18,60-24,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	7
Mean (SD)	5 (71,4)
Median (Min - Max)	4,01 (15,61)
	3,20 [-11,87-24,67]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	6 (100,0)
Median (Min - Max)	-5,60 (32,40)
	-10,55 [-52,50-36,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	1 (33,3)
Median (Min - Max)	0,52 (NE)
	0,52 [0,52-0,52]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-12,60 (23,48)
	-12,60 [-29,20-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-17,70 (29,27)
Median (Min - Max)	-17,70 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-13,92 (21,61)
	-13,92 [-29,20-1,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-16,60 (24,89)
	-16,60 [-34,20-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,50 (NE)
	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Cycle 22 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	
EOT	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	28 (70,0)
Mean (SD)	-10,59 (22,33)
Median (Min - Max)	-11,00 [-52,83-32,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym total score	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	75 (94,9)
Mean (SD)	118,07 (24,82)
Median (Min - Max)	121,00 [60,00-156,00]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	68
Treated patients with non-missing values - n(%)	61 (89,7)
Mean (SD)	0,69 (14,43)
Median (Min - Max)	2,00 [-43,50-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	45
Treated patients with non-missing values - n(%)	40 (88,9)
Mean (SD)	0,26 (17,45)
Median (Min - Max)	0,25 [-31,92-48,33]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	31 (91,2)
Mean (SD)	2,46 (16,16)
Median (Min - Max)	5,67 [-39,00-27,33]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	20 (87,0)
Mean (SD)	-4,65 (18,01)
Median (Min - Max)	-4,50 [-53,00-22,33]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	-0,31 (21,98)
Median (Min - Max)	-4,83 [-46,00-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	12 (92,3)
Median (Min - Max)	0,86 (27,27)
	4,92 [-73,00-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	10 (90,9)
Median (Min - Max)	6,95 (17,71)
	4,17 [-14,10-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	8
Mean (SD)	8 (100,0)
Median (Min - Max)	-2,15 (10,45)
	-0,38 [-20,84-11,08]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	0,28 (4,84)
	-2,00 [-3,00-5,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-7,61 (12,26)
Median (Min - Max)	-5,60 [-24,27-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	3 (75,0)
Median (Min - Max)	6,17 (1,26)
	6,00 [5,00-7,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	5,00 (0,00)
	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-9,40 (20,44)
	0,71 [-32,92-4,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-21,12 (34,90)
	-3,00 [-61,36-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-17,72 (27,61)
Median (Min - Max)	-17,72 [-37,24-1,80]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-19,78 (32,22)
	-19,78 [-42,56-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	5,00 (NE)
	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	1,00 (NE)
	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS15: FACT-Lym total score - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,67 (NE)
Median (Min - Max)	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	60 (75,9)
Mean (SD)	-7,57 (19,91)
Median (Min - Max)	-7,08 [-54,00-42,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

3.16.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym total score	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	120,26 (25,87)
Median (Min - Max)	124,00 [68,65-156,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	-1,90 (11,56)
Median (Min - Max)	-1,00 [-22,83-21,69]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	-2,28 (11,89)
Median (Min - Max)	1,83 [-24,00-17,00]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,51 (13,17)
Median (Min - Max)	1,00 [-16,83-23,91]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Mean (SD)	-7,45 (9,49)
Median (Min - Max)	-5,00 [-21,00-1,20]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-11,33 (21,70)
Median (Min - Max)	-12,36 [-36,00-15,39]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	6,96 (8,56)
	6,96 [0,91-13,02]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	12,27 (11,70)
	12,27 [4,00-20,54]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	7,54 (5,01)
	7,54 [4,00-11,08]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-3,00 (NE)
	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-7,36 (NE)
Median (Min - Max)	-7,36 [-7,36--7,36]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,71 (NE)
Median (Min - Max)	0,71 [0,71-0,71]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,00 (NE)
Median (Min - Max)	-3,00 [-3,00--3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,80 (NE)
Median (Min - Max)	1,80 [1,80-1,80]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym total score - Change from baseline	
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,67 (NE)
Median (Min - Max)	-1,67 [-1,67--1,67]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-10,96 (16,50)
Median (Min - Max)	-7,17 [-35,00-18,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym total score	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	100 (96,2)
Mean (SD)	118,33 (23,21)
Median (Min - Max)	120,33 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	96
Mean (SD)	87 (90,6)
Median (Min - Max)	1,21 (16,23)
	2,33 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	73
Mean (SD)	63 (86,3)
Median (Min - Max)	0,88 (20,86)
	0,50 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	55
Mean (SD)	49 (89,1)
Median (Min - Max)	3,26 (20,27)
	4,83 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
Treated patients with non-missing values - n(%)	40
Mean (SD)	37 (92,5)
Median (Min - Max)	-0,75 (20,10)
	-3,50 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	28 (93,3)
Mean (SD)	2,35 (19,87)
Median (Min - Max)	4,29 [-46,00-45,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	25 (96,2)
Median (Min - Max)	1,82 (23,13)
	4,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	19 (86,4)
Median (Min - Max)	5,48 (19,19)
	4,00 [-28,24-48,83]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	17 (100,0)
Median (Min - Max)	1,92 (15,87)
	2,23 [-29,20-24,17]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	11 (84,6)
Median (Min - Max)	0,16 (18,06)
	-0,17 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	3,40 (21,32)
Median (Min - Max)	0,58 [-24,27-48,38]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 12 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	6,75 [-11,87-35,27]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 13 Day 1
Treated patients with non-missing values - n(%)	9
Mean (SD)	8 (88,9)
Median (Min - Max)	3,67 (35,27)
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 14 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	3 (50,0)
Median (Min - Max)	-9,47 (20,39)
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	4 (100,0)
Median (Min - Max)	-21,39 (30,57)
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 15 Day 1
Treated patients with non-missing values - n(%)	4
Mean (SD)	-21,39 (30,57)
Median (Min - Max)	-14,10 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-24,21 (23,58)
Median (Min - Max)	-37,24 [-38,40-3,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 17 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	3 (100,0)
Median (Min - Max)	-23,47 (22,51)
	-29,20 [-42,56-1,36]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 18 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	2 (100,0)
Median (Min - Max)	-16,60 (24,89)
	-16,60 [-34,20-1,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 19 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	0,00 (NE)
	0,00 [0,00-0,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 20 Day 1
Treated patients with non-missing values - n(%)	1
Mean (SD)	1 (100,0)
Median (Min - Max)	-0,50 (NE)
	-0,50 [-0,50--0,50]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS16: FACT-Lym total score - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,00 (NE)
Median (Min - Max)	5,00 [5,00-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	71 (68,3)
Mean (SD)	-6,85 (22,65)
Median (Min - Max)	-7,17 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

3.16.17 Merkmal: Vorherige CAR-T-Therapie

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym total score	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	124,83 (24,81)
Median (Min - Max)	129,00 [89,67-155,00]
FACT-Lym total score - Change from baseline	Cycle 2 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,08 (24,97)
Median (Min - Max)	-3,25 [-28,00-33,33]
FACT-Lym total score - Change from baseline	Cycle 3 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	12,17 (26,29)
Median (Min - Max)	15,42 [-19,50-37,33]
FACT-Lym total score - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	14,92 (12,52)
Median (Min - Max)	15,75 [1,00-27,17]
FACT-Lym total score - Change from baseline	Cycle 5 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Mean (SD)	20,89 (6,62)
Median (Min - Max)	22,33 [13,67-26,67]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	31,61 (12,51)
Median (Min - Max)	28,67 [20,83-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	27,61 (17,83)
Median (Min - Max)	25,67 [10,83-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	28,06 (21,18)
Median (Min - Max)	28,83 [6,50-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-4,67 (NE)
Median (Min - Max)	-4,67 [-4,67--4,67]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	5,83 (NE)
Median (Min - Max)	5,83 [5,83-5,83]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-3,83 (NE)
Median (Min - Max)	-3,83 [-3,83--3,83]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	7,50 (NE)
Median (Min - Max)	7,50 [7,50-7,50]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	-1,78 (27,84)
Median (Min - Max)	4,00 [-52,33-23,50]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym total score	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	117 (95,9)
Mean (SD)	117,97 (23,82)
Median (Min - Max)	121,00 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	100 (90,9)
Mean (SD)	0,65 (14,97)
Median (Min - Max)	1,67 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	70 (85,4)
Mean (SD)	0,22 (19,40)
Median (Min - Max)	0,75 [-60,17-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	55 (87,3)
Mean (SD)	2,36 (19,30)
Median (Min - Max)	4,00 [-56,17-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46
Treated patients with non-missing values - n(%)	40 (87,0)
Mean (SD)	-2,28 (18,86)
Median (Min - Max)	-4,00 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	30 (90,9)
Mean (SD)	-1,59 (18,63)
Median (Min - Max)	-4,58 [-46,00-34,67]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	25 (96,2)
Mean (SD)	-0,65 (20,63)
Median (Min - Max)	3,83 [-73,00-30,00]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	19 (86,4)
Mean (SD)	3,73 (16,35)
Median (Min - Max)	4,00 [-28,24-40,27]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	19 (100,0)
Mean (SD)	3,77 (15,48)
Median (Min - Max)	5,80 [-29,20-24,17]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	1,25 (18,35)
Median (Min - Max)	-1,08 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	4,86 (21,25)
Median (Min - Max)	2,83 [-24,27-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	9,70 (15,63)
Median (Min - Max)	6,00 [-11,87-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	3,82 (33,00)
Median (Min - Max)	5,00 [-52,50-57,93]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS17: FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	88 (72,1)
Mean (SD)	-7,93 (21,52)
Median (Min - Max)	-7,17 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

3.16.18 Merkmal: Arzneimittelformulierung

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym total score	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	32 (100,0)
Mean (SD)	121,45 (22,82)
Median (Min - Max)	125,08 [77,00-156,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 2 Day 1 28
Treated patients with non-missing values - n(%)	28 (100,0)
Mean (SD)	1,46 (12,83)
Median (Min - Max)	2,00 [-43,17-28,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 3 Day 1 21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	-4,35 (18,66)
Median (Min - Max)	-2,00 [-60,17-18,00]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 4 Day 1 17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	-2,58 (19,68)
Median (Min - Max)	4,33 [-56,17-19,50]
FACT-Lym total score - Change from baseline	
Treated patients at visit	Cycle 5 Day 1 11
Treated patients with non-missing values - n(%)	11 (100,0)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Mean (SD)	-1,77 (14,16)
Median (Min - Max)	-3,00 [-31,60-14,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Drug formulation:	
Frozen liquid	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	-2,44 (12,46)
Median (Min - Max)	-1,80 [-17,17-11,00]
FACT-Lym total score - Change from baseline	
Cycle 7 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-2,89 (12,38)
Median (Min - Max)	5,00 [-16,67-8,00]
FACT-Lym total score - Change from baseline	
Cycle 8 Day 1	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-2,69 (8,75)
Median (Min - Max)	-0,50 [-14,10-4,33]
FACT-Lym total score - Change from baseline	
Cycle 9 Day 1	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	3,52 (2,44)
Median (Min - Max)	2,23 [2,00-6,33]
FACT-Lym total score - Change from baseline	
Cycle 10 Day 1	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-10,00 (NE)
Median (Min - Max)	-10,00 [-10,00--10,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Drug formulation:

Frozen liquid

FACT-Lym total score - Change from baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

21 (65,6)

Mean (SD)

-12,34 (19,51)

Median (Min - Max)

-15,00 [-48,67-18,00]

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym total score	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	93 (94,9)
Mean (SD)	117,36 (24,21)
Median (Min - Max)	119,60 [41,67-156,83]
FACT-Lym total score - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	78 (88,6)
Mean (SD)	0,39 (16,45)
Median (Min - Max)	0,75 [-62,00-38,17]
FACT-Lym total score - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	55 (84,6)
Mean (SD)	2,66 (20,01)
Median (Min - Max)	1,83 [-39,50-55,00]
FACT-Lym total score - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	43 (86,0)
Mean (SD)	5,36 (18,67)
Median (Min - Max)	4,83 [-39,00-56,00]
FACT-Lym total score - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	38
Treated patients with non-missing values - n(%)	32 (84,2)
Mean (SD)	-0,28 (20,81)
Median (Min - Max)	-4,00 [-53,00-55,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym total score - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	29 (93,5)
Mean (SD)	1,96 (21,42)
Median (Min - Max)	4,57 [-46,00-45,33]
FACT-Lym total score - Change from baseline	Cycle 7 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	3,53 (23,56)
Median (Min - Max)	4,83 [-73,00-46,33]
FACT-Lym total score - Change from baseline	Cycle 8 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	18 (85,7)
Mean (SD)	9,21 (19,62)
Median (Min - Max)	6,08 [-28,24-48,83]
FACT-Lym total score - Change from baseline	Cycle 9 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	17 (100,0)
Mean (SD)	3,32 (16,52)
Median (Min - Max)	5,80 [-29,20-24,17]
FACT-Lym total score - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	2,57 (18,04)
Median (Min - Max)	1,92 [-36,87-27,27]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym total score - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	12 (92,3)
Mean (SD)	4,14 (20,42)
Median (Min - Max)	0,58 [-24,27-48,38]
FACT-Lym total score - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	9,48 (14,75)
Median (Min - Max)	6,75 [-11,87-35,27]
FACT-Lym total score - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	3,82 (33,00)
Median (Min - Max)	5,00 [-52,50-57,93]
FACT-Lym total score - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	-6,92 (17,41)
Median (Min - Max)	0,62 [-32,92-4,00]
FACT-Lym total score - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-17,71 (27,73)
Median (Min - Max)	-3,00 [-61,36-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym total score - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-17,71 (23,23)
Median (Min - Max)	-17,72 [-38,40-3,00]
FACT-Lym total score - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	-16,85 (22,65)
Median (Min - Max)	-13,92 [-42,56-3,00]
FACT-Lym total score - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-9,40 (21,57)
Median (Min - Max)	1,00 [-34,20-5,00]
FACT-Lym total score - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym total score - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,25 (1,06)
Median (Min - Max)	0,25 [-0,50-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FTC_PSHS18: FACT-Lym total score - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym total score - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym total score - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,67 (4,71)
Median (Min - Max)	1,67 [-1,67-5,00]
FACT-Lym total score - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym total score - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,60 (NE)
Median (Min - Max)	2,60 [2,60-2,60]
FACT-Lym total score - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-5,00 (NE)
Median (Min - Max)	-5,00 [-5,00--5,00]
FACT-Lym total score - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	73 (74,5)
Mean (SD)	-6,15 (22,40)
Median (Min - Max)	-7,00 [-54,00-60,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3A_TSTS01: Time to first TEAE by subgroup: Age group
 ITT set

4 Endpunktkategorie: Sicherheit

4.1 Subgruppenanalysen zu den UE

4.1.1 Merkmal Alter

Time to first TEAE by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	65 (100,0)
95%-CI	[94,5-100,0]
TEAE in months [95%-CI]	
Median	0,10 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS01: Time to first TEAE by subgroup: Age group
 ITT set

Time to first TEAE by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	58 (98,3)
95%-CI	[90,9-100,0]
TEAE in months [95%-CI]	
Median	0,16[0,07-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS01: Time to first TEAE by subgroup: Age group
 ITT set

Time to first TEAE by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	20 (95,2)
95%-CI	[76,2-99,9]
TEAE in months [95%-CI]	
Median	0,10 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	4,8 [0,3-19,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS02: Time to first TEAE by subgroup: Sex
 ITT set

4.1.2 *Merkmal: Geschlecht*

Time to first TEAE by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	58 (96,7)
95%-CI	[88,5-99,6]
TEAE in months [95%-CI]	
Median	0,16 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	2,1 [0,2-9,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS02: Time to first TEAE by subgroup: Sex
 ITT set

Time to first TEAE by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	85 (100,0)
95%-CI	[95,8-100,0]
TEAE in months [95%-CI]	
Median	0,10 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS03: Time to first TEAE by subgroup: Race group
 ITT set

4.1.3 *Merkmal: Ethnie*

Time to first TEAE by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	130 (100,0)
95%-CI	[97,2-100,0]
TEAE in months [95%-CI]	
Median	0,13 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS03: Time to first TEAE by subgroup: Race group
 ITT set

Time to first TEAE by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	13 (86,7)
95%-CI	[59,5-98,3]
TEAE in months [95%-CI]	
Median	0,26 [0,03-0,72]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	13,3 [2,2-34,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS04: Time to first TEAE graded \geq 3 by subgroup: Country
 ITT set

4.1.4 *Merkmal: Region-1*

Time to first TEAE graded \geq 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	46 (78,0)
95%-CI	[65,3-87,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,18 [0,66-1,48]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	20,0 [9,8-32,9]
Month 6	17,2 [7,6-29,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS04: Time to first TEAE graded >= 3 by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	21 (67,7)
95%-CI	[48,6-83,3]
TEAE graded >= 3 in months [95%-CI]	
Median	2,56 [0,69-3,48]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,3 [21,7-58,2]
Month 6	18,9 [5,6-38,1]
Month 12	18,9 [5,6-38,1]
Month 18	18,9 [5,6-38,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS04: Time to first TEAE by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	40 (75,5)
95%-CI	[61,7-86,2]
TEAE graded >= 3 in months [95%-CI]	
Median	2,00 [0,92-2,96]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,1 [22,7-49,6]
Month 6	21,6 [10,4-35,4]
Month 12	11,5 [2,8-27,1]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS05: Time to first TEAE graded \geq 3 by subgroup: Region
 ITT set

4.1.5 *Merkmal: Region-2*

Time to first TEAE graded \geq 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	46 (78,0)
95%-CI	[65,3-87,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,18 [0,66-1,48]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	20,0 [9,8-32,9]
Month 6	17,2 [7,6-29,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS05: Time to first TEAE by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	61 (70,9)
95%-CI	[60,1-80,2]
TEAE graded >= 3 in months [95%-CI]	
Median	2,00 [0,99-2,96]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [27,5-49,5]
Month 6	21,4 [12,0-32,6]
Month 12	14,7 [6,1-26,9]
Month 18	7,3 [0,9-23,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS06: Time to first TEAE by subgroup: Ann Arbor stage
 ITT set

4.1.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	10 (100,0)
95%-CI	[69,2-100,0]
TEAE in months [95%-CI]	
Median	0,16 [0,03-0,43]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS06: Time to first TEAE by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	22 (95,7)
95%-CI	[78,1-99,9]
TEAE in months [95%-CI]	
Median	0,16[0,03-0,30]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS06: Time to first TEAE by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	19 (100,0)
95%-CI	[82,4-100,0]
TEAE in months [95%-CI]	
Median	0,10 [0,03-0,20]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS06: Time to first TEAE by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	92 (98,9)
95%-CI	[94,2-100,0]
TEAE in months [95%-CI]	
Median	0,13 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,1 [0,1-5,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS07: Time to first TEAE by subgroup: Bulky disease
 ITT set

4.1.7 *Merkmal: Bulky Erkrankung*

Time to first TEAE by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	135 (98,5)
95%-CI	[94,8-99,8]
TEAE in months [95%-CI]	
Median	0,13 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	0,8 [0,1-4,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS08: Time to first TEAE by subgroup: Double/Triple hit
 ITT set

4.1.8 *Merkmal: Double/Triple-Hit*

Time to first TEAE by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	14 (93,3)
95%-CI	[68,1-99,8]
TEAE in months [95%-CI]	
Median	0,07 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	6,7 [0,4-26,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS08: Time to first TEAE by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	129 (99,2)
95%-CI	[95,8-100,0]
TEAE in months [95%-CI]	
Median	0,13 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS09: Time to first TEAE by subgroup: Transformed DLBCL
 ITT set

4.1.9 *Merkmal: Transformation des DLBCL*

Time to first TEAE by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	29 (100,0)
95%-CI	[88,1-100,0]
TEAE in months [95%-CI]	
Median	0,07 [0,03-0,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS09: Time to first TEAE by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	114 (98,3)
95%-CI	[93,9-99,8]
TEAE in months [95%-CI]	
Median	0,16 [0,10-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,0 [0,1-4,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS10: Time to first TEAE by subgroup: B-Cell type
 ITT set

4.1.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first TEAE by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	48 (100,0)
95%-CI	[92,6-100,0]
TEAE in months [95%-CI]	
Median	0,10 [0,03-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS10: Time to first TEAE by subgroup: B-Cell type
 ITT set

Time to first TEAE by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	22 (95,7)
95%-CI	[78,1-99,9]
TEAE in months [95%-CI]	
Median	0,16[0,10-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	4,4 [0,3-18,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS11: Time to first TEAE by subgroup: Maximal longest diameter
 ITT set

4.1.11 Merkmal: Maximaler längster Durchmesser

Time to first TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	80 (97,6)
95%-CI	[91,5-99,7]
TEAE in months [95%-CI]	
Median	0,13 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,4 [0,1-6,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS11: Time to first TEAE by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	36 (100,0)
95%-CI	[90,3-100,0]
TEAE in months [95%-CI]	
Median	0,15 [0,07-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS11: Time to first TEAE by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	10 (100,0)
95%-CI	[69,2-100,0]
TEAE in months [95%-CI]	
Median	0,03[0,03-0,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS11: Time to first TEAE by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	13
Patients with events - n(%)	13 (100,0)
95%-CI	[75,3-100,0]
TEAE in months [95%-CI]	
Median	0,16[0,03-0,33]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS12: Time to first TEAE by subgroup: Primary disease diagnosis
 ITT set

4.1.12 *Merkmal: Primärdiagnose*

Time to first TEAE by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	125 (98,4)
95%-CI	[94,4-99,8]
TEAE in months [95%-CI]	
Median	0,13 [0,07-0,20]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	0,9 [0,1-4,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS12: Time to first TEAE by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	11 (100,0)
95%-CI	[71,5-100,0]
TEAE in months [95%-CI]	
Median	0,07 [0,03-0,49]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS13: Time to first TEAE by subgroup: Number prior lines
 ITT set

4.1.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first TEAE by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	61 (96,8)
95%-CI	[89,0-99,6]
TEAE in months [95%-CI]	
Median	0,16 [0,10-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,9 [0,2-8,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS13: Time to first TEAE by subgroup: Number prior lines
 ITT set

Time to first TEAE by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	35 (100,0)
95%-CI	[90,0-100,0]
TEAE in months [95%-CI]	
Median	0,10 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS13: Time to first TEAE by subgroup: Number prior lines
 ITT set

Time to first TEAE by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	47 (100,0)
95%-CI	[92,5-100,0]
TEAE in months [95%-CI]	
Median	0,07 [0,03-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS14: Time to first TEAE by subgroup: Response category - first line
 ITT set

4.1.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first TEAE by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	97 (98,0)
95%-CI	[92,9-99,8]
TEAE in months [95%-CI]	
Median	0,10 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,2 [0,1-5,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS14: Time to first TEAE by subgroup: Response category - first line
 ITT set

Time to first TEAE by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	29 (100,0)
95%-CI	[88,1-100,0]
TEAE in months [95%-CI]	
Median	0,16[0,03-0,33]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS15: Time to first TEAE by subgroup: Response category - last line
 ITT set

4.1.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first TEAE by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	44 (100,0)
95%-CI	[92,0-100,0]
TEAE in months [95%-CI]	
Median	0,15 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS15: Time to first TEAE by subgroup: Response category - last line
 ITT set

Time to first TEAE by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	86 (97,7)
95%-CI	[92,0-99,7]
TEAE in months [95%-CI]	
Median	0,11 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,4 [0,1-6,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS16: Time to first TEAE by subgroup: Response category - any line
 ITT set

4.1.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

Time to first TEAE by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	24 (100,0)
95%-CI	[85,8-100,0]
TEAE in months [95%-CI]	
Median	0,15 [0,03-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS16: Time to first TEAE by subgroup: Response category - any line
 ITT set

Time to first TEAE by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	113 (98,3)
95%-CI	[93,9-99,8]
TEAE in months [95%-CI]	
Median	0,10 [0,07-0,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,0 [0,1-4,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS17: Time to first TEAE by subgroup: Prior use of T-CART therapy
 ITT set

4.1.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first TEAE by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	13 (100,0)
95%-CI	[75,3-100,0]
TEAE in months [95%-CI]	
Median	0,03 [0,03-0,20]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS17: Time to first TEAE by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	130 (98,5)
95%-CI	[94,6-99,8]
TEAE in months [95%-CI]	
Median	0,13 [0,07-0,20]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	0,9 [0,1-4,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS18: Time to first TEAE by subgroup: Drug formulation
 ITT set

4.1.18 Merkmal: Arzneimittelformulierung

Time to first TEAE by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	35 (100,0)
95%-CI	[90,0-100,0]
TEAE in months [95%-CI]	
Median	0,16 [0,07-0,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSTS18: Time to first TEAE by subgroup: Drug formulation
 ITT set

Time to first TEAE by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	108 (98,2)
95%-CI	[93,6-99,8]
TEAE in months [95%-CI]	
Median	0,11 [0,07-0,20]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,0 [0,1-5,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS01: Time to first TEAE graded < 3 by subgroup: Age group
 ITT set

4.2 Subgruppenanalysen zu den nicht schweren UE

4.2.1 Merkmal Alter

Time to first TEAE graded < 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	65
Patients with events - n(%)	63 (96,9)
95%-CI	[89,3-99,6]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,07-0,16]
TEAE graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS01: Time to first TEAE graded < 3 by subgroup: Age group
 ITT set

Time to first TEAE graded < 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	58 (98,3)
95%-CI	[90,9-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,07-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS01: Time to first TEAE graded < 3 by subgroup: Age group
 ITT set

Time to first TEAE graded < 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	20 (95,2)
95%-CI	[76,2-99,9]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,03-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	4,8 [0,3-19,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS02: Time to first TEAE graded < 3 by subgroup: Sex
 ITT set

4.2.2 *Merkmal: Geschlecht*

Time to first TEAE graded < 3 by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	57 (95,0)
95%-CI	[86,1-99,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,18 [0,07-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	2,3 [0,2-10,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS02: Time to first TEAE graded < 3 by subgroup: Sex
 ITT set

Time to first TEAE graded < 3 by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	84 (98,8)
95%-CI	[93,6-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,07-0,16]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS03: Time to first TEAE graded < 3 by subgroup: Race group
 ITT set

4.2.3 *Merkmal: Ethnie*

Time to first TEAE graded < 3 by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	128 (98,5)
95%-CI	[94,6-99,8]
TEAE graded < 3 in months [95%-CI]	
Median	0,13[0,07-0,16]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS03: Time to first TEAE graded < 3 by subgroup: Race group
 ITT set

Time to first TEAE graded < 3 by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	13 (86,7)
95%-CI	[59,5-98,3]
TEAE graded < 3 in months [95%-CI]	
Median	0,26 [0,03-0,72]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	13,3 [2,2-34,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS04: Time to first TEAE graded < 3 by subgroup: Country
 ITT set

4.2.4 *Merkmal: Region-1*

Time to first TEAE graded < 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	58 (98,3)
95%-CI	[90,9-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,07 [0,03-0,10]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,7 [0,1-8,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS04: Time to first TEAE graded < 3 by subgroup: Country
 ITT set

Time to first TEAE graded < 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	28 (90,3)
95%-CI	[74,2-98,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,07-0,33]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS04: Time to first TEAE graded < 3 by subgroup: Country
 ITT set

Time to first TEAE graded < 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	53 (100,0)
95%-CI	[93,3-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,26 [0,10-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS05: Time to first TEAE graded < 3 by subgroup: Region
 ITT set

4.2.5 *Merkmal: Region-2*

Time to first TEAE graded < 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	58 (98,3)
95%-CI	[90,9-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,07 [0,03-0,10]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,7 [0,1-8,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS05: Time to first TEAE graded < 3 by subgroup: Region
 ITT set

Time to first TEAE graded < 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	83 (96,5)
95%-CI	[90,1-99,3]
TEAE graded < 3 in months [95%-CI]	
Median	0,18 [0,13-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS06: Time to first TEAE graded < 3 by subgroup: Ann Arbor stage
 ITT set

4.2.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first TEAE graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	10 (100,0)
95%-CI	[69,2-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,16 [0,03-0,43]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS06: Time to first TEAE graded < 3 by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	22 (95,7)
95%-CI	[78,1-99,9]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,03-0,30]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS06: Time to first TEAE graded < 3 by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	18 (94,7)
95%-CI	[74,0-99,9]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,03-0,46]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS06: Time to first TEAE graded < 3 by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	91 (97,8)
95%-CI	[92,4-99,7]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,07-0,20]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,3 [0,1-6,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS07: Time to first TEAE graded < 3 by subgroup: Bulky disease
 ITT set

4.2.7 *Merkmal: Bulky Erkrankung*

Time to first TEAE graded < 3 by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	134 (97,8)
95%-CI	[93,7-99,5]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,07-0,20]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	0,9 [0,1-4,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS08: Time to first TEAE graded < 3 by subgroup: Double/Triple hit
 ITT set

4.2.8 *Merkmal: Double/Triple-Hit*

Time to first TEAE graded < 3 by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	14 (93,3)
95%-CI	[68,1-99,8]
TEAE graded < 3 in months [95%-CI]	
Median	0,07 [0,03-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	6,7 [0,4-26,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS08: Time to first TEAE graded < 3 by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded < 3 by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	127 (97,7)
95%-CI	[93,4-99,5]
TEAE graded < 3 in months [95%-CI]	
Median	0,13[0,10-0,20]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS09: Time to first TEAE graded < 3 by subgroup: Transformed DLBCL
 ITT set

4.2.9 *Merkmal: Transformation des DLBCL*

Time to first TEAE graded < 3 by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	29 (100,0)
95%-CI	[88,1-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,07 [0,03-0,13]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS09: Time to first TEAE graded < 3 by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded < 3 by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	112 (96,6)
95%-CI	[91,4-99,1]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,10-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,1 [0,1-5,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS10: Time to first TEAE graded < 3 by subgroup: B-Cell type
 ITT set

4.2.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first TEAE graded < 3 by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	48 (100,0)
95%-CI	[92,6-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,03-0,16]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Time to first TEAE graded < 3 by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	20 (87,0)
95%-CI	[66,4-97,2]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,10-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	7,0 [0,5-25,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS11: Time to first TEAE graded < 3 by subgroup: Maximal longest diameter
 ITT set

4.2.11 *Merkmal: Maximaler längster Durchmesser*

Time to first TEAE graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	80 (97,6)
95%-CI	[91,5-99,7]
TEAE graded < 3 in months [95%-CI]	
Median	0,15 [0,07-0,26]
TEAE graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,4 [0,1-6,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS11: Time to first TEAE graded < 3 by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	36 (100,0)
95%-CI	[90,3-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,15 [0,07-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS11: Time to first TEAE graded < 3 by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	10 (100,0)
95%-CI	[69,2-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,05 [0,03-0,10]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS11: Time to first TEAE graded < 3 by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	11 (84,6)
95%-CI	[54,6-98,1]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,03-0,49]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS12: Time to first TEAE graded < 3 by subgroup: Primary disease diagnosis
 ITT set

4.2.12 *Merkmal: Primärdiagnose*

Time to first TEAE graded < 3 by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	123 (96,9)
95%-CI	[92,1-99,1]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,10-0,23]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,0 [0,1-4,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS12: Time to first TEAE graded < 3 by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded < 3 by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	11 (100,0)
95%-CI	[71,5-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,07 [0,03-0,49]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS13: Time to first TEAE graded < 3 by subgroup: Number prior lines
 ITT set

4.2.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first TEAE graded < 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	60 (95,2)
95%-CI	[86,7-99,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,16 [0,10-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	2,1 [0,2-9,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS13: Time to first TEAE graded < 3 by subgroup: Number prior lines
 ITT set

Time to first TEAE graded < 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	35 (100,0)
95%-CI	[90,0-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,03-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS13: Time to first TEAE graded < 3 by subgroup: Number prior lines
 ITT set

Time to first TEAE graded < 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	46 (97,9)
95%-CI	[88,7-99,9]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,03-0,16]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS14: Time to first TEAE graded < 3 by subgroup: Response category - first line
 ITT set

4.2.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first TEAE graded < 3 by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	97 (98,0)
95%-CI	[92,9-99,8]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,07-0,16]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,2 [0,1-5,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS14: Time to first TEAE graded < 3 by subgroup: Response category - first line
 ITT set

Time to first TEAE graded < 3 by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	28 (96,6)
95%-CI	[82,2-99,9]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,03-0,33]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS15: Time to first TEAE graded < 3 by subgroup: Response category - last line
 ITT set

4.2.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first TEAE graded < 3 by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	43 (97,7)
95%-CI	[88,0-99,9]
TEAE graded < 3 in months [95%-CI]	
Median	0,20 [0,03-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS15: Time to first TEAE graded < 3 by subgroup: Response category - last line
 ITT set

Time to first TEAE graded < 3 by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	86 (97,7)
95%-CI	[92,0-99,7]
TEAE graded < 3 in months [95%-CI]	
Median	0,13[0,07-0,16]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,4 [0,1-6,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS16: Time to first TEAE graded < 3 by subgroup: Response category - any line
 ITT set

4.2.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first TEAE graded < 3 by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	24 (100,0)
95%-CI	[85,8-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,15 [0,03-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS16: Time to first TEAE graded < 3 by subgroup: Response category - any line
 ITT set

Time to first TEAE graded < 3 by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	112 (97,4)
95%-CI	[92,6-99,5]
TEAE graded < 3 in months [95%-CI]	
Median	0,13[0,07-0,20]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,1 [0,1-5,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS17: Time to first TEAE graded < 3 by subgroup: Prior use of T-CART therapy
 ITT set

4.2.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first TEAE graded < 3 by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	12 (92,3)
95%-CI	[64,0-99,8]
TEAE graded < 3 in months [95%-CI]	
Median	0,10 [0,03-0,30]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS17: Time to first TEAE graded < 3 by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded < 3 by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	129 (97,7)
95%-CI	[93,5-99,5]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,07-0,20]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	0,9 [0,1-4,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS18: Time to first TEAE graded < 3 by subgroup: Drug formulation
 ITT set

4.2.18 *Merkmal: Arzneimittelformulierung*

Time to first TEAE graded < 3 by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	35 (100,0)
95%-CI	[90,0-100,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,16[0,07-0,26]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AN_TSTS18: Time to first TEAE graded < 3 by subgroup: Drug formulation
 ITT set

Time to first TEAE graded < 3 by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	106 (96,4)
95%-CI	[91,0-99,0]
TEAE graded < 3 in months [95%-CI]	
Median	0,13 [0,07-0,23]
TEAE graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	1,2 [0,1-5,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS01: Time to first TEAE graded ≥ 3 by subgroup: Age group
 ITT set

4.3 Subgruppenanalysen zu den schweren UE

4.3.1 Merkmal Alter

Time to first TEAE graded ≥ 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	51 (78,5)
95%-CI	[66,5-87,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,18 [0,72-2,00]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	23,2 [13,2-34,8]
Month 6	16,1 [7,4-27,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS01: Time to first TEAE graded >= 3 by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	43 (72,9)
95%-CI	[59,7-83,6]
TEAE graded >= 3 in months [95%-CI]	
Median	1,64 [0,95-3,15]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,7 [26,2-52,9]
Month 6	17,5 [7,1-31,7]
Month 12	5,8 [0,5-21,6]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS01: Time to first TEAE graded ≥ 3 by subgroup: Age group
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
≥ 75 years	
Patients in analysis set	21
Patients with events - n(%)	13 (61,9)
95%-CI	[38,4-81,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	2,56[0,49-10,15]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,4 [12,7-57,6]
Month 6	34,4 [12,7-57,6]
Month 12	22,9 [4,8-49,0]
Month 18	22,9 [4,8-49,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS02: Time to first TEAE graded \geq 3 by subgroup: Sex
 ITT set

4.3.2 *Merkmal: Geschlecht*

Time to first TEAE graded \geq 3 by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	40 (66,7)
95%-CI	[53,3-78,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,64 [0,66-3,29]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,0 [25,6-52,1]
Month 6	32,6 [19,3-46,5]
Month 12	18,6 [7,0-34,6]
Month 18	9,3 [1,0-29,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS02: Time to first TEAE graded \geq 3 by subgroup: Sex
 ITT set

Time to first TEAE graded \geq 3 by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	67 (78,8)
95%-CI	[68,6-86,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,41 [0,95-2,40]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	26,8 [17,2-37,3]
Month 6	10,9 [4,2-21,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS03: Time to first TEAE graded >= 3 by subgroup: Race group
 ITT set

4.3.3 *Merkmal: Ethnie*

Time to first TEAE graded >= 3 by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	94 (72,3)
95%-CI	[63,8-79,8]
TEAE graded >= 3 in months [95%-CI]	
Median	1,48 [0,95-2,43]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,4 [23,8-41,4]
Month 6	20,0 [12,3-29,1]
Month 12	11,7 [4,7-22,1]
Month 18	5,8 [0,7-19,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS03: Time to first TEAE graded >= 3 by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	13 (86,7)
95%-CI	[59,5-98,3]
TEAE graded >= 3 in months [95%-CI]	
Median	1,45 [0,26-2,86]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	22,5 [5,6-46,3]
Month 6	15,0 [2,5-37,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS04: Time to first TEAE graded >= 3 by subgroup: Country
 ITT set

4.3.4 *Merkmal: Region-1*

Time to first TEAE graded >= 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	46 (78,0)
95%-CI	[65,3-87,7]
TEAE graded >= 3 in months [95%-CI]	
Median	1,18 [0,66-1,48]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	20,0 [9,8-32,9]
Month 6	17,2 [7,6-29,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS04: Time to first TEAE graded >= 3 by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	21 (67,7)
95%-CI	[48,6-83,3]
TEAE graded >= 3 in months [95%-CI]	
Median	2,56 [0,69-3,48]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,3 [21,7-58,2]
Month 6	18,9 [5,6-38,1]
Month 12	18,9 [5,6-38,1]
Month 18	18,9 [5,6-38,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS04: Time to first TEAE graded >= 3 by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	40 (75,5)
95%-CI	[61,7-86,2]
TEAE graded >= 3 in months [95%-CI]	
Median	2,00 [0,92-2,96]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,1 [22,7-49,6]
Month 6	21,6 [10,4-35,4]
Month 12	11,5 [2,8-27,1]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS05: Time to first TEAE graded ≥ 3 by subgroup: Region
 ITT set

4.3.5 *Merkmal: Region-2*

Time to first TEAE graded ≥ 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	46 (78,0)
95%-CI	[65,3-87,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,18 [0,66-1,48]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	20,0 [9,8-32,9]
Month 6	17,2 [7,6-29,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS05: Time to first TEAE graded >= 3 by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	61 (70,9)
95%-CI	[60,1-80,2]
TEAE graded >= 3 in months [95%-CI]	
Median	2,00 [0,99-2,96]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [27,5-49,5]
Month 6	21,4 [12,0-32,6]
Month 12	14,7 [6,1-26,9]
Month 18	7,3 [0,9-23,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS06: Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage
 ITT set

4.3.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	7 (70,0)
95%-CI	[34,8-93,3]
TEAE graded >= 3 in months [95%-CI]	
Median	2,96 [0,03-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,0 [16,1-74,5]
Month 6	36,0 [9,0-64,8]
Month 12	18,0 [1,2-51,7]
Month 18	18,0 [1,2-51,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS06: Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	17 (73,9)
95%-CI	[51,6-89,8]
TEAE graded >= 3 in months [95%-CI]	
Median	2,40 [0,99-5,68]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,9 [19,3-59,8]
Month 6	24,9 [7,6-47,2]
Month 12	12,5 [1,1-38,6]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS06: Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	17 (89,5)
95%-CI	[66,9-98,7]
TEAE graded >= 3 in months [95%-CI]	
Median	1,48 [0,72-2,56]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	11,3 [1,9-30,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS06: Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	66 (71,0)
95%-CI	[60,6-79,9]
TEAE graded >= 3 in months [95%-CI]	
Median	1,18 [0,69-2,00]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,5 [22,2-43,2]
Month 6	19,3 [10,0-30,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS07: Time to first TEAE graded ≥ 3 by subgroup: Bulky disease
 ITT set

4.3.7 *Merkmal: Bulky Erkrankung*

Time to first TEAE graded ≥ 3 by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	100 (73,0)
95%-CI	[64,7-80,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,58 [1,02-2,50]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,9 [24,5-41,6]
Month 6	20,3 [12,7-29,0]
Month 12	10,5 [4,1-20,3]
Month 18	5,3 [0,6-18,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS08: Time to first TEAE graded ≥ 3 by subgroup: Double/Triple hit
 ITT set

4.3.8 *Merkmal: Double/Triple-Hit*

Time to first TEAE graded ≥ 3 by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	12 (80,0)
95%-CI	[51,9-95,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	0,92 [0,26-2,50]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	10,4 [0,7-35,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS08: Time to first TEAE graded ≥ 3 by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	95 (73,1)
95%-CI	[64,6-80,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,48 [0,95-2,56]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,6 [24,9-42,5]
Month 6	20,5 [12,8-29,5]
Month 12	10,6 [4,2-20,6]
Month 18	5,3 [0,6-18,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS09: Time to first TEAE graded ≥ 3 by subgroup: Transformed DLBCL
 ITT set

4.3.9 *Merkmal: Transformation des DLBCL*

Time to first TEAE graded ≥ 3 by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	22 (75,9)
95%-CI	[56,5-89,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,02 [0,43-2,92]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	28,6 [13,2-46,1]
Month 6	18,4 [5,8-36,5]
Month 12	18,4 [5,8-36,5]
Month 18	18,4 [5,8-36,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS09: Time to first TEAE graded \geq 3 by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	85 (73,3)
95%-CI	[64,3-81,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,48 [0,95-2,50]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	31,9 [22,7-41,5]
Month 6	19,3 [11,3-29,0]
Month 12	6,9 [1,6-18,0]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS10: Time to first TEAE graded ≥ 3 by subgroup: B-Cell type
 ITT set

4.3.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first TEAE graded ≥ 3 by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	35 (72,9)
95%-CI	[58,2-84,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,94 [0,92-2,92]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,2 [21,2-49,5]
Month 6	25,8 [13,2-40,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS10: Time to first TEAE graded \geq 3 by subgroup: B-Cell type
 ITT set

Time to first TEAE graded \geq 3 by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	17 (73,9)
95%-CI	[51,6-89,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	2,00 [0,43-3,48]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,2 [14,6-55,0]
Month 6	20,5 [5,6-42,0]
Month 12	20,5 [5,6-42,0]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS11: Time to first TEAE graded ≥ 3 by subgroup: Maximal longest diameter
 ITT set

4.3.11 *Merkmal: Maximaler längster Durchmesser*

Time to first TEAE graded ≥ 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: ≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	55 (67,1)
95%-CI	[55,8-77,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	2,83 [1,64-3,02]
TEAE graded ≥ 3 : Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,3 [27,5-50,9]
Month 6	24,7 [14,2-36,7]
Month 12	14,8 [5,9-27,6]
Month 18	7,4 [0,9-24,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS11: Time to first TEAE graded >= 3 by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	27 (75,0)
95%-CI	[57,8-87,9]
TEAE graded >= 3 in months [95%-CI]	
Median	1,00 [0,49-2,00]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	28,4 [14,3-44,2]
Month 6	17,0 [5,3-34,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS11: Time to first TEAE graded >= 3 by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	10 (100,0)
95%-CI	[69,2-100,0]
TEAE graded >= 3 in months [95%-CI]	
Median	0,57 [0,03-1,58]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	10,0 [0,6-35,8]
Month 6	10,0 [0,6-35,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS11: Time to first TEAE graded \geq 3 by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	11 (84,6)
95%-CI	[54,6-98,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	0,43 [0,26-0,99]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS12: Time to first TEAE graded ≥ 3 by subgroup: Primary disease diagnosis
 ITT set

4.3.12 *Merkmal: Primärdiagnose*

Time to first TEAE graded ≥ 3 by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	95 (74,8)
95%-CI	[66,3-82,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,45 [0,95-2,40]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,3 [24,7-42,1]
Month 6	20,5 [12,9-29,4]
Month 12	10,6 [4,2-20,6]
Month 18	5,3 [0,6-18,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS12: Time to first TEAE graded ≥ 3 by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	8 (72,7)
95%-CI	[39,0-94,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,18 [0,26-2,92]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS13: Time to first TEAE graded ≥ 3 by subgroup: Number prior lines
 ITT set

4.3.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first TEAE graded ≥ 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	40 (63,5)
95%-CI	[50,4-75,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	2,89 [1,25-3,55]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,8 [32,0-58,6]
Month 6	27,3 [14,9-41,2]
Month 12	21,8 [9,5-37,4]
Month 18	10,9 [1,2-33,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS13: Time to first TEAE graded ≥ 3 by subgroup: Number prior lines
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	26 (74,3)
95%-CI	[56,7-87,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	0,92 [0,49-1,64]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	28,1 [13,7-44,4]
Month 6	21,1 [7,4-39,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS13: Time to first TEAE graded ≥ 3 by subgroup: Number prior lines
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	41 (87,2)
95%-CI	[74,3-95,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	0,95 [0,53-2,10]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	18,8 [8,9-31,5]
Month 6	10,4 [2,7-24,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS14: Time to first TEAE graded ≥ 3 by subgroup: Response category - first line
 ITT set

4.3.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first TEAE graded ≥ 3 by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	74 (74,7)
95%-CI	[65,0-82,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,48 [0,95-2,56]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,3 [24,6-44,2]
Month 6	19,3 [10,9-29,4]
Month 12	12,0 [4,4-23,9]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS14: Time to first TEAE graded >= 3 by subgroup: Response category - first line
ITT set

Time to first TEAE graded >= 3 by subgroup: Response category
- first line

Loncastuximab tesirine
Data-cut 3

Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	21 (72,4)
95%-CI	[52,8-87,3]
TEAE graded >= 3 in months [95%-CI]	
Median	1,45 [0,43-2,89]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	24,0 [8,4-44,0]
Month 6	18,0 [4,9-37,8]
Month 12	9,0 [0,8-30,4]
Month 18	9,0 [0,8-30,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS15: Time to first TEAE graded ≥ 3 by subgroup: Response category - last line
 ITT set

4.3.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first TEAE graded ≥ 3 by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	40 (90,9)
95%-CI	[78,3-97,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,64 [0,66-2,86]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,7 [17,8-44,7]
Month 6	15,5 [6,4-28,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS15: Time to first TEAE graded ≥ 3 by subgroup: Response category - last line
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	56 (63,6)
95%-CI	[52,7-73,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,45 [0,95-2,83]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,8 [22,7-45,3]
Month 6	27,0 [16,4-38,8]
Month 12	27,0 [16,4-38,8]
Month 18	13,5 [1,6-37,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS16: Time to first TEAE graded ≥ 3 by subgroup: Response category - any line
 ITT set

4.3.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first TEAE graded ≥ 3 by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	16 (66,7)
95%-CI	[44,7-84,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,94 [0,59-2,96]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	23,1 [6,4-46,0]
Month 6	15,4 [2,7-37,9]
Month 12	15,4 [2,7-37,9]
Month 18	15,4 [2,7-37,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS16: Time to first TEAE graded ≥ 3 by subgroup: Response category - any line
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	88 (76,5)
95%-CI	[67,7-83,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,25 [0,95-2,40]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,2 [23,4-41,4]
Month 6	19,4 [11,7-28,7]
Month 12	8,7 [2,8-19,0]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS17: Time to first TEAE graded ≥ 3 by subgroup: Prior use of T-CART therapy
 ITT set

4.3.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first TEAE graded ≥ 3 by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	12 (92,3)
95%-CI	[64,0-99,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	0,72 [0,20-1,48]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS17: Time to first TEAE graded ≥ 3 by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded ≥ 3 by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	95 (72,0)
95%-CI	[63,5-79,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,64 [0,95-2,56]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,3 [25,6-43,2]
Month 6	21,1 [13,3-30,2]
Month 12	11,0 [4,3-21,1]
Month 18	5,5 [0,7-18,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS18: Time to first TEAE graded ≥ 3 by subgroup: Drug formulation
 ITT set

4.3.18 *Merkmal: Arzneimittelformulierung*

Time to first TEAE graded ≥ 3 by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	26 (74,3)
95%-CI	[56,7-87,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,97 [0,72-2,96]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,6 [15,8-46,9]
Month 6	17,9 [6,0-34,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSTS18: Time to first TEAE graded >= 3 by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	81 (73,6)
95%-CI	[64,4-81,6]
TEAE graded >= 3 in months [95%-CI]	
Median	1,41 [0,92-2,50]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	31,8 [22,4-41,6]
Month 6	19,8 [11,5-29,8]
Month 12	9,9 [3,6-20,0]
Month 18	5,0 [0,6-17,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS01: Time to first serious TEAE by subgroup: Age group
 ITT set

4.4 Subgruppenanalysen zu den schwerwiegenden UE

4.4.1 Merkmal Alter

Time to first serious TEAE by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	26 (40,0)
95%-CI	[28,0-52,9]
serious TEAE in months [95%-CI]	
Median	6,44 [2,50-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,9 [43,4-70,0]
Month 6	57,9 [43,4-70,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS01: Time to first serious TEAE by subgroup: Age group
 ITT set

Time to first serious TEAE by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	23 (39,0)
95%-CI	[26,5-52,6]
serious TEAE in months [95%-CI]	
Median	5,52 [3,29-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,4 [59,6-83,1]
Month 6	46,8 [28,5-63,2]
Month 12	39,0 [19,4-58,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS01: Time to first serious TEAE by subgroup: Age group
 ITT set

Time to first serious TEAE by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	8 (38,1)
95%-CI	[18,1-61,6]
serious TEAE in months [95%-CI]	
Median	6,47 [2,73-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [30,8-78,2]
Month 6	58,3 [30,8-78,2]
Month 12	43,8 [14,4-70,3]
Month 18	43,8 [14,4-70,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS02: Time to first serious TEAE by subgroup: Sex
 ITT set

4.4.2 Merkmal: Geschlecht

Time to first serious TEAE by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	18 (30,0)
95%-CI	[18,8-43,2]
serious TEAE in months [95%-CI]	
Median	NE [6,01-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,5 [55,2-81,4]
Month 6	67,4 [51,5-79,1]
Month 12	58,4 [40,1-72,9]
Month 18	58,4 [40,1-72,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS02: Time to first serious TEAE by subgroup: Sex
 ITT set

Time to first serious TEAE by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	39 (45,9)
95%-CI	[35,0-57,0]
serious TEAE in months [95%-CI]	
Median	3,94 [2,89-9,10]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,1 [47,9-70,3]
Month 6	41,7 [26,4-56,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS03: Time to first serious TEAE by subgroup: Race group
 ITT set

4.4.3 *Merkmal: Ethnie*

Time to first serious TEAE by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	52 (40,0)
95%-CI	[31,5-49,0]
serious TEAE in months [95%-CI]	
Median	6,01 [3,29-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,6 [53,6-71,9]
Month 6	50,8 [38,9-61,5]
Month 12	41,8 [28,6-54,4]
Month 18	41,8 [28,6-54,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS03: Time to first serious TEAE by subgroup: Race group
 ITT set

Time to first serious TEAE by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
serious TEAE in months [95%-CI]	
Median	9,10 [2,30-9,10]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,2 [41,7-88,6]
Month 6	72,2 [41,7-88,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS04: Time to first serious TEAE by subgroup: Country
 ITT set

4.4.4 *Merkmal: Region-1*

Time to first serious TEAE by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
serious TEAE in months [95%-CI]	
Median	4,73 [2,50-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,8 [36,4-65,2]
Month 6	46,6 [29,9-61,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS04: Time to first serious TEAE by subgroup: Country
 ITT set

Time to first serious TEAE by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	17 (54,8)
95%-CI	[36,0-72,7]
serious TEAE in months [95%-CI]	
Median	3,29 [0,95-6,44]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,5 [40,9-75,4]
Month 6	35,2 [14,6-56,7]
Month 12	26,4 [8,0-49,5]
Month 18	26,4 [8,0-49,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS04: Time to first serious TEAE by subgroup: Country
 ITT set

Time to first serious TEAE by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	13 (24,5)
95%-CI	[13,8-38,3]
serious TEAE in months [95%-CI]	
Median	NE [6,47-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,3 [64,5-88,4]
Month 6	71,2 [52,8-83,4]
Month 12	64,0 [41,9-79,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS05: Time to first serious TEAE by subgroup: Region
 ITT set

4.4.5 *Merkmal: Region-2*

Time to first serious TEAE by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
serious TEAE in months [95%-CI]	
Median	4,73 [2,50-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,8 [36,4-65,2]
Month 6	46,6 [29,9-61,8]
Month 12	NE
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS05: Time to first serious TEAE by subgroup: Region
 ITT set

Time to first serious TEAE by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	30 (34,9)
95%-CI	[24,9-45,9]
serious TEAE in months [95%-CI]	
Median	6,47 [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,8 [61,5-81,3]
Month 6	58,3 [43,9-70,3]
Month 12	50,0 [33,7-64,3]
Month 18	50,0 [33,7-64,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS06: Time to first serious TEAE by subgroup: Ann Arbor stage
 ITT set

4.4.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first serious TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
serious TEAE in months [95%-CI]	
Median	NE [1,64-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	66,7 [16,0-91,4]
Month 12	66,7 [16,0-91,4]
Month 18	66,7 [16,0-91,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS06: Time to first serious TEAE by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
serious TEAE in months [95%-CI]	
Median	NE [2,79-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,1 [48,6-89,3]
Month 6	67,6 [39,7-84,7]
Month 12	67,6 [39,7-84,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS06: Time to first serious TEAE by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	9 (47,4)
95%-CI	[24,4-71,1]
serious TEAE in months [95%-CI]	
Median	3,15[1,38-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,8 [27,8-74,1]
Month 6	46,1 [21,1-68,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS06: Time to first serious TEAE by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	40 (43,0)
95%-CI	[32,8-53,7]
serious TEAE in months [95%-CI]	
Median	6,01 [2,92-9,10]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,4 [49,6-71,3]
Month 6	50,3 [36,2-62,8]
Month 12	31,4 [15,4-48,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS07: Time to first serious TEAE by subgroup: Bulky disease
 ITT set

4.4.7 *Merkmal: Bulky Erkrankung*

Time to first serious TEAE by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	52 (38,0)
95%-CI	[29,8-46,6]
serious TEAE in months [95%-CI]	
Median	6,44 [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [56,8-74,1]
Month 6	55,0 [43,8-64,9]
Month 12	42,1 [27,9-55,7]
Month 18	42,1 [27,9-55,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS08: Time to first serious TEAE by subgroup: Double/Triple hit
 ITT set

4.4.8 *Merkmal: Double/Triple-Hit*

Time to first serious TEAE by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	9 (60,0)
95%-CI	[32,3-83,7]
serious TEAE in months [95%-CI]	
Median	2,76 [0,66-6,01]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,5 [11,3-61,2]
Month 6	35,5 [11,3-61,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS08: Time to first serious TEAE by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	48 (36,9)
95%-CI	[28,6-45,8]
serious TEAE in months [95%-CI]	
Median	9,10[3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,4 [59,1-76,1]
Month 6	56,2 [44,5-66,3]
Month 12	45,2 [30,3-59,0]
Month 18	45,2 [30,3-59,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS09: Time to first serious TEAE by subgroup: Transformed DLBCL
 ITT set

4.4.9 *Merkmal: Transformation des DLBCL*

Time to first serious TEAE by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]
serious TEAE in months [95%-CI]	
Median	NE [1,64-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,9 [42,7-80,2]
Month 6	51,6 [27,9-71,0]
Month 12	51,6 [27,9-71,0]
Month 18	51,6 [27,9-71,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS09: Time to first serious TEAE by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	46 (39,7)
95%-CI	[30,7-49,2]
serious TEAE in months [95%-CI]	
Median	6,44 [3,48-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,0 [53,5-72,8]
Month 6	53,8 [41,3-64,7]
Month 12	37,5 [21,5-53,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS10: Time to first serious TEAE by subgroup: B-Cell type
 ITT set

4.4.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first serious TEAE by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	18 (37,5)
95%-CI	[24,0-52,6]
serious TEAE in months [95%-CI]	
Median	9,10 [3,29-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,2 [51,8-80,0]
Month 6	59,8 [41,3-74,1]
Month 12	40,4 [15,2-64,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS10: Time to first serious TEAE by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]
serious TEAE in months [95%-CI]	
Median	5,52 [0,82-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [42,4-80,8]
Month 6	42,2 [17,5-65,2]
Month 12	42,2 [17,5-65,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS11: Time to first serious TEAE by subgroup: Maximal longest diameter
 ITT set

4.4.11 *Merkmal: Maximaler längster Durchmesser*

Time to first serious TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	28 (34,1)
95%-CI	[24,0-45,4]
serious TEAE in months [95%-CI]	
Median	9,10 [3,15-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,7 [54,6-77,7]
Month 6	55,4 [40,7-67,8]
Month 12	48,5 [30,4-64,4]
Month 18	48,5 [30,4-64,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS11: Time to first serious TEAE by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	14 (38,9)
95%-CI	[23,1-56,5]
serious TEAE in months [95%-CI]	
Median	6,44 [3,48-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [50,8-82,8]
Month 6	54,5 [29,6-73,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS11: Time to first serious TEAE by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
serious TEAE in months [95%-CI]	
Median	NE [0,20-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,0 [18,4-75,3]
Month 6	50,0 [18,4-75,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS11: Time to first serious TEAE by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	8 (61,5)
95%-CI	[31,6-86,1]
serious TEAE in months [95%-CI]	
Median	0,72 [0,36-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [14,1-62,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS12: Time to first serious TEAE by subgroup: Primary disease diagnosis
 ITT set

4.4.12 *Merkmal: Primärdiagnose*

Time to first serious TEAE by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	50 (39,4)
95%-CI	[30,8-48,4]
serious TEAE in months [95%-CI]	
Median	6,47 [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,4 [57,0-74,2]
Month 6	54,6 [43,2-64,7]
Month 12	44,0 [29,5-57,5]
Month 18	44,0 [29,5-57,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS12: Time to first serious TEAE by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	7 (63,6)
95%-CI	[30,8-89,1]
serious TEAE in months [95%-CI]	
Median	2,76[0,66-6,01]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	27,3 [4,1-58,9]
Month 6	27,3 [4,1-58,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS13: Time to first serious TEAE by subgroup: Number prior lines
 ITT set

4.4.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first serious TEAE by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	22 (34,9)
95%-CI	[23,3-48,0]
serious TEAE in months [95%-CI]	
Median	NE [3,15-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,3 [52,6-78,4]
Month 6	61,3 [45,7-73,7]
Month 12	50,2 [31,2-66,5]
Month 18	50,2 [31,2-66,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS13: Time to first serious TEAE by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
serious TEAE in months [95%-CI]	
Median	9,10 [2,73-9,10]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,5 [41,1-78,0]
Month 6	50,0 [22,5-72,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS13: Time to first serious TEAE by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	22 (46,8)
95%-CI	[32,1-61,9]
serious TEAE in months [95%-CI]	
Median	3,94 [2,50-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,0 [44,6-73,9]
Month 6	43,0 [24,5-60,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS14: Time to first serious TEAE by subgroup: Response category - first line
 ITT set

4.4.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first serious TEAE by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	36 (36,4)
95%-CI	[26,9-46,6]
serious TEAE in months [95%-CI]	
Median	9,10 [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,4 [61,0-79,5]
Month 6	56,5 [43,1-67,9]
Month 12	46,2 [28,8-61,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS14: Time to first serious TEAE by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	13 (44,8)
95%-CI	[26,4-64,3]
serious TEAE in months [95%-CI]	
Median	6,44 [0,72-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,9 [29,2-70,4]
Month 6	51,9 [29,2-70,4]
Month 12	34,6 [8,4-63,4]
Month 18	34,6 [8,4-63,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS15: Time to first serious TEAE by subgroup: Response category - last line
 ITT set

4.4.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first serious TEAE by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	18 (40,9)
95%-CI	[26,3-56,8]
serious TEAE in months [95%-CI]	
Median	9,10 [2,92-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,7 [47,4-77,6]
Month 6	57,5 [39,5-71,9]
Month 12	44,4 [23,7-63,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS15: Time to first serious TEAE by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	33 (37,5)
95%-CI	[27,4-48,5]
serious TEAE in months [95%-CI]	
Median	6,44 [3,29-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,4 [53,6-74,9]
Month 6	52,7 [37,4-65,9]
Month 12	46,1 [28,3-62,2]
Month 18	46,1 [28,3-62,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS16: Time to first serious TEAE by subgroup: Response category - any line
 ITT set

4.4.16 Merkmal: *Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first serious TEAE by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]
serious TEAE in months [95%-CI]	
Median	6,44 [0,89-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,4 [34,1-79,0]
Month 6	60,4 [34,1-79,0]
Month 12	30,2 [1,9-69,8]
Month 18	30,2 [1,9-69,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS16: Time to first serious TEAE by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	45 (39,1)
95%-CI	[30,2-48,7]
serious TEAE in months [95%-CI]	
Median	6,47 [3,48-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,5 [56,3-74,9]
Month 6	53,9 [41,7-64,5]
Month 12	42,6 [27,4-56,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS17: Time to first serious TEAE by subgroup: Prior use of T-CART therapy
 ITT set

4.4.17 Merkmal: Vorherige CAR-T-Therapie

Time to first serious TEAE by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
serious TEAE in months [95%-CI]	
Median	1,38 [0,46-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,1 [10,4-64,8]
Month 6	37,1 [10,4-64,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS17: Time to first serious TEAE by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	50 (37,9)
95%-CI	[29,6-46,7]
serious TEAE in months [95%-CI]	
Median	6,44 [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,9 [57,3-74,9]
Month 6	55,2 [43,7-65,3]
Month 12	41,8 [27,4-55,7]
Month 18	41,8 [27,4-55,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS18: Time to first serious TEAE by subgroup: Drug formulation
 ITT set

4.4.18 *Merkmal: Arzneimittelformulierung*

Time to first serious TEAE by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
serious TEAE in months [95%-CI]	
Median	3,94 [3,02-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [52,0-84,5]
Month 6	47,7 [23,6-68,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSTS18: Time to first serious TEAE by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	44 (40,0)
95%-CI	[30,8-49,8]
serious TEAE in months [95%-CI]	
Median	6,44 [3,48-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,8 [50,9-71,0]
Month 6	54,8 [42,4-65,6]
Month 12	40,6 [25,7-55,0]
Month 18	40,6 [25,7-55,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS01: Time to first TEAE leading to study drug discontinuation by subgroup: Age group
 ITT set

4.5 Subgruppenanalysen zu den Abbrüchen der Studienmedikation aufgrund von UE

4.5.1 Merkmal Alter

Time to first TEAE leading to study drug discontinuation by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	16 (24,6)
95%-CI	[14,8-36,9]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	7,56[4,86-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [74,7-93,8]
Month 6	65,3 [44,3-80,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS01: Time to first TEAE leading to study drug discontinuation by subgroup: Age group
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	14 (23,7)
95%-CI	[13,6-36,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10[3,94-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [73,0-94,1]
Month 6	63,0 [40,5-78,9]
Month 12	46,7 [21,8-68,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS01: Time to first TEAE leading to study drug discontinuation by subgroup: Age group
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	19,38 [3,48-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,6 [52,4-93,8]
Month 6	59,4 [23,6-82,9]
Month 12	59,4 [23,6-82,9]
Month 18	59,4 [23,6-82,9]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS02: Time to first TEAE leading to study drug discontinuation by subgroup: Sex
 ITT set

4.5.2 *Merkmal: Geschlecht*

Time to first TEAE leading to study drug discontinuation by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	14 (23,3)
95%-CI	[13,4-36,0]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	14,13 [6,44-19,38]
TEAEs leading to study drug discontinuation: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [70,4-92,6]
Month 6	72,5 [52,9-85,0]
Month 12	62,3 [40,6-78,0]
Month 18	41,5 [9,7-71,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS02: Time to first TEAE leading to study drug discontinuation by subgroup: Sex
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Sex	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	22 (25,9)
95%-CI	[17,0-36,5]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	6,01 [4,01-9,30]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [76,5-93,2]
Month 6	54,3 [34,8-70,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS03: Time to first TEAE leading to study drug discontinuation by subgroup: Race group
 ITT set

4.5.3 *Merkmal: Ethnie*

Time to first TEAE leading to study drug discontinuation by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	34 (26,2)
95%-CI	[18,8-34,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	7,56 [5,55-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [75,4-90,2]
Month 6	60,7 [46,3-72,4]
Month 12	43,9 [27,9-58,9]
Month 18	29,3 [8,1-54,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS03: Time to first TEAE leading to study drug discontinuation by subgroup: Race group
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,16-9,10]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	83,3 [27,3-97,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS04: Time to first TEAE leading to study drug discontinuation by subgroup: Country
 ITT set

4.5.4 *Merkmal: Region-1*

Time to first TEAE leading to study drug discontinuation by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,55-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [71,5-93,8]
Month 6	58,3 [33,3-76,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS04: Time to first TEAE leading to study drug discontinuation by subgroup: Country
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	9 (29,0)
95%-CI	[14,2-48,0]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	6,01 [3,78-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [62,1-94,0]
Month 6	60,2 [30,5-80,5]
Month 12	48,1 [18,4-73,0]
Month 18	48,1 [18,4-73,0]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS04: Time to first TEAE leading to study drug discontinuation by subgroup: Country
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	14 (26,4)
95%-CI	[15,3-40,3]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	7,56[4,01-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [72,3-93,8]
Month 6	66,5 [43,9-81,6]
Month 12	45,6 [21,9-66,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS05: Time to first TEAE leading to study drug discontinuation by subgroup: Region
 ITT set

4.5.5 *Merkmal: Region-2*

Time to first TEAE leading to study drug discontinuation by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,55-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [71,5-93,8]
Month 6	58,3 [33,3-76,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS05: Time to first TEAE leading to study drug discontinuation by subgroup: Region
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	23 (26,7)
95%-CI	[17,8-37,4]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	7,56[5,16-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [75,2-92,3]
Month 6	64,9 [47,7-77,7]
Month 12	46,1 [26,7-63,6]
Month 18	30,8 [8,0-57,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS06: Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage
 ITT set

4.5.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	19,38 [2,17-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	51,4 [11,8-81,3]
Month 12	51,4 [11,8-81,3]
Month 18	51,4 [11,8-81,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS06: Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	8 (34,8)
95%-CI	[16,4-57,3]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	4,86 [3,71-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [56,5-94,6]
Month 6	42,5 [14,0-69,0]
Month 12	31,9 [7,9-59,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS06: Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	7 (36,8)
95%-CI	[16,3-61,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	6,01[2,10-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,1 [48,0-90,4]
Month 6	63,4 [29,6-84,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS06: Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	17 (18,3)
95%-CI	[11,0-27,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,30 [7,56-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [79,4-94,7]
Month 6	70,9 [51,3-83,8]
Month 12	47,9 [23,2-69,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS07: Time to first TEAE leading to study drug discontinuation by subgroup: Bulky disease
 ITT set

4.5.7 *Merkmal: Bulky Erkrankung*

Time to first TEAE leading to study drug discontinuation by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	33 (24,1)
95%-CI	[17,2-32,1]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [6,01-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [79,7-92,8]
Month 6	64,5 [50,6-75,4]
Month 12	44,3 [27,9-59,5]
Month 18	29,6 [8,1-55,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS08: Time to first TEAE leading to study drug discontinuation by subgroup: Double/Triple hit
 ITT set

4.5.8 *Merkmal: Double/Triple-Hit*

Time to first TEAE leading to study drug discontinuation by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,30 [3,48-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [59,1-99,0]
Month 6	53,1 [8,3-85,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS08: Time to first TEAE leading to study drug discontinuation by subgroup: Double/Triple hit
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	32 (24,6)
95%-CI	[17,5-32,9]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [6,01-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [76,7-91,1]
Month 6	64,2 [50,1-75,3]
Month 12	46,2 [29,2-61,6]
Month 18	30,8 [8,4-57,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS09: Time to first TEAE leading to study drug discontinuation by subgroup: Transformed DLBCL
 ITT set

4.5.9 *Merkmal: Transformation des DLBCL*

Time to first TEAE leading to study drug discontinuation by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	14,13 [3,94-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [60,9-95,2]
Month 6	76,9 [47,4-91,2]
Month 12	76,9 [47,4-91,2]
Month 18	38,5 [1,5-80,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS09: Time to first TEAE leading to study drug discontinuation by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	30 (25,9)
95%-CI	[18,2-34,8]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	7,56[5,55-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [77,3-92,0]
Month 6	60,2 [44,7-72,6]
Month 12	37,2 [20,5-53,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS10: Time to first TEAE leading to study drug discontinuation by subgroup: B-Cell type
 ITT set

4.5.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first TEAE leading to study drug discontinuation by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	12 (25,0)
95%-CI	[13,6-39,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [4,86-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [75,4-96,2]
Month 6	60,6 [37,2-77,6]
Month 12	43,6 [18,4-66,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS10: Time to first TEAE leading to study drug discontinuation by subgroup: B-Cell type
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	NE [3,48-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [58,6-94,9]
Month 6	68,4 [38,0-86,1]
Month 12	68,4 [38,0-86,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS11: Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter
 ITT set

4.5.11 *Merkmal: Maximaler längster Durchmesser*

Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	21 (25,6)
95%-CI	[16,6-36,4]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,62-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [81,7-96,7]
Month 6	67,5 [49,3-80,4]
Month 12	40,8 [21,7-59,0]
Month 18	27,2 [7,0-52,9]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS11: Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	7 (19,4)
95%-CI	[8,2-36,0]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	NE [3,48-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [70,2-96,6]
Month 6	58,8 [29,8-79,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS11: Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	2,07[0,20-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,0 [12,0-77,6]
Month 6	48,0 [12,0-77,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS11: Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	NE [0,72-NE]
TEAEs leading to study drug discontinuation: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,3 [34,4-89,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS12: Time to first TEAE leading to study drug discontinuation by subgroup: Primary disease diagnosis
 ITT set

4.5.12 *Merkmal: Primärdiagnose*

Time to first TEAE leading to study drug discontinuation by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	33 (26,0)
95%-CI	[18,6-34,5]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,55-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [75,8-90,3]
Month 6	63,8 [49,8-74,8]
Month 12	45,9 [29,1-61,1]
Month 18	30,6 [8,3-56,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS12: Time to first TEAE leading to study drug discontinuation by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,30 [3,48-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	55,6 [7,3-87,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS13: Time to first TEAE leading to study drug discontinuation by subgroup: Number prior lines
 ITT set

4.5.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first TEAE leading to study drug discontinuation by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	17 (27,0)
95%-CI	[16,6-39,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	6,44 [5,16-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [71,1-92,9]
Month 6	64,8 [44,3-79,4]
Month 12	49,9 [28,8-67,8]
Month 18	33,3 [8,3-61,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS13: Time to first TEAE leading to study drug discontinuation by subgroup: Number prior lines
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [3,78-9,10]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [70,6-96,6]
Month 6	66,4 [29,8-87,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS13: Time to first TEAE leading to study drug discontinuation by subgroup: Number prior lines
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	13 (27,7)
95%-CI	[15,6-42,6]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	7,56[3,71-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [68,2-92,8]
Month 6	58,5 [34,6-76,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS14: Time to first TEAE leading to study drug discontinuation by subgroup: Response category - first line
 ITT set

4.5.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first TEAE leading to study drug discontinuation by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	25 (25,3)
95%-CI	[17,1-35,0]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,62-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [77,8-92,7]
Month 6	63,4 [47,1-75,9]
Month 12	46,4 [27,8-63,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS14: Time to first TEAE leading to study drug discontinuation by subgroup: Response category - first line
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	9 (31,0)
95%-CI	[15,3-50,8]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	4,27 [3,48-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [52,9-92,8]
Month 6	45,9 [15,4-72,3]
Month 12	23,0 [1,5-59,7]
Month 18	23,0 [1,5-59,7]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS15: Time to first TEAE leading to study drug discontinuation by subgroup: Response category - last line
 ITT set

4.5.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first TEAE leading to study drug discontinuation by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	11 (25,0)
95%-CI	[13,2-40,3]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,62-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [78,2-97,5]
Month 6	70,7 [45,8-85,8]
Month 12	49,0 [23,3-70,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS15: Time to first TEAE leading to study drug discontinuation by subgroup: Response category - last line
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	17 (19,3)
95%-CI	[11,7-29,1]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	19,38 [4,86-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [69,9-90,8]
Month 6	63,4 [43,6-77,8]
Month 12	56,3 [34,3-73,5]
Month 18	56,3 [34,3-73,5]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS16: Time to first TEAE leading to study drug discontinuation by subgroup: Response category - any line
 ITT set

4.5.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first TEAE leading to study drug discontinuation by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	4,27 [3,48-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [50,7-96,5]
Month 6	48,9 [15,7-75,8]
Month 12	48,9 [15,7-75,8]
Month 18	48,9 [15,7-75,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS16: Time to first TEAE leading to study drug discontinuation by subgroup: Response category - any line
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	28 (24,3)
95%-CI	[16,8-33,2]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10[6,01-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [77,9-92,1]
Month 6	65,6 [50,6-77,1]
Month 12	46,8 [29,2-62,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS17: Time to first TEAE leading to study drug discontinuation by subgroup: Prior use of T-CART therapy
 ITT set

4.5.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first TEAE leading to study drug discontinuation by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	NE [5,62-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	66,7 [5,4-94,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS17: Time to first TEAE leading to study drug discontinuation by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	35 (26,5)
95%-CI	[19,2-34,9]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,10 [5,55-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [76,7-90,7]
Month 6	63,6 [49,8-74,5]
Month 12	42,2 [25,7-57,8]
Month 18	28,1 [7,7-53,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS18: Time to first TEAE leading to study drug discontinuation by subgroup: Drug formulation
 ITT set

4.5.18 *Merkmal: Arzneimittelformulierung*

Time to first TEAE leading to study drug discontinuation by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	6,01 [3,94-NE]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [75,7-97,2]
Month 6	54,3 [22,9-77,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AT_TSTS18: Time to first TEAE leading to study drug discontinuation by subgroup: Drug formulation
 ITT set

Time to first TEAE leading to study drug discontinuation by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	27 (24,5)
95%-CI	[16,8-33,7]
TEAEs leading to study drug discontinuation in months [95%-CI]	
Median	9,30 [5,62-19,38]
TEAEs leading to study drug discontinuation:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [74,6-90,8]
Month 6	65,2 [49,9-76,8]
Month 12	48,6 [30,6-64,5]
Month 18	32,4 [8,6-59,6]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 TEAE = Treatment-emergent adverse event. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS01: Time to first AESI infusion related events by subgroup: Age group
 ITT set

4.6 Subgruppenanalysen zum AESI – infusionsbedingte Reaktion

4.6.1 Merkmal Alter

Time to first AESI infusion related events by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [82,5-96,7]
Month 6	92,3 [82,5-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS01: Time to first AESI infusion related events by subgroup: Age group
 ITT set

Time to first AESI infusion related events by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,1]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS01: Time to first AESI infusion related events by subgroup: Age group
 ITT set

Time to first AESI infusion related events by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	90,9 [50,8-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS02: Time to first AESI infusion related events by subgroup: Sex
 ITT set

4.6.2 *Merkmal: Geschlecht*

Time to first AESI infusion related events by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,7 [87,3-99,2]
Month 6	92,5 [75,8-97,8]
Month 12	92,5 [75,8-97,8]
Month 18	92,5 [75,8-97,8]
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS02: Time to first AESI infusion related events by subgroup: Sex
 ITT set

Time to first AESI infusion related events by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	3 (3,5)
95%-CI	[0,7-10,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,5 [89,5-98,9]
Month 6	96,5 [89,5-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS03: Time to first AESI infusion related events by subgroup: Race group
 ITT set

4.6.3 *Merkmal: Ethnie*

Time to first AESI infusion related events by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	5 (3,8)
95%-CI	[1,3-8,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,9 [92,0-98,8]
Month 6	94,2 [84,2-98,0]
Month 12	94,2 [84,2-98,0]
Month 18	94,2 [84,2-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS03: Time to first AESI infusion related events by subgroup: Race group
 ITT set

Time to first AESI infusion related events by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS04: Time to first AESI infusion related events by subgroup: Country
 ITT set

4.6.4 *Merkmal: Region-1*

Time to first AESI infusion related events by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [80,8-96,4]
Month 6	91,5 [80,8-96,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS04: Time to first AESI infusion related events by subgroup: Country
 ITT set

Time to first AESI infusion related events by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	90,9 [50,8-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS04: Time to first AESI infusion related events by subgroup: Country
 ITT set

Time to first AESI infusion related events by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS05: Time to first AESI infusion related events by subgroup: Region
 ITT set

4.6.5 *Merkmal: Region-2*

Time to first AESI infusion related events by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [80,8-96,4]
Month 6	91,5 [80,8-96,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS05: Time to first AESI infusion related events by subgroup: Region
 ITT set

Time to first AESI infusion related events by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	1 (1,2)
95%-CI	[0,0-6,3]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	96,2 [75,7-99,5]
Month 12	96,2 [75,7-99,5]
Month 18	96,2 [75,7-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS06: Time to first AESI infusion related events by subgroup: Ann Arbor stage
 ITT set

4.6.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first AESI infusion related events by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS06: Time to first AESI infusion related events by subgroup: Ann Arbor stage
 ITT set

Time to first AESI infusion related events by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS06: Time to first AESI infusion related events by subgroup: Ann Arbor stage
 ITT set

Time to first AESI infusion related events by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS06: Time to first AESI infusion related events by subgroup: Ann Arbor stage
 ITT set

Time to first AESI infusion related events by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	5 (5,4)
95%-CI	[1,8-12,1]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [89,0-98,4]
Month 6	92,0 [78,7-97,2]
Month 12	92,0 [78,7-97,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS07: Time to first AESI infusion related events by subgroup: Bulky disease
 ITT set

4.6.7 *Merkmal: Bulky Erkrankung*

Time to first AESI infusion related events by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	6 (4,4)
95%-CI	[1,6-9,3]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [91,5-98,5]
Month 6	94,2 [85,9-97,6]
Month 12	94,2 [85,9-97,6]
Month 18	94,2 [85,9-97,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS08: Time to first AESI infusion related events by subgroup: Double/Triple hit
 ITT set

4.6.8 *Merkmal: Double/Triple-Hit*

Time to first AESI infusion related events by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS08: Time to first AESI infusion related events by subgroup: Double/Triple hit
 ITT set

Time to first AESI infusion related events by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	4 (3,1)
95%-CI	[0,8-7,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [93,0-99,3]
Month 6	95,2 [85,4-98,5]
Month 12	95,2 [85,4-98,5]
Month 18	95,2 [85,4-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS09: Time to first AESI infusion related events by subgroup: Transformed DLBCL
 ITT set

4.6.9 *Merkmal: Transformation des DLBCL*

Time to first AESI infusion related events by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [78,0-99,5]
Month 6	96,6 [78,0-99,5]
Month 12	96,6 [78,0-99,5]
Month 18	96,6 [78,0-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

AESI = Adverse event of special interest. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS09: Time to first AESI infusion related events by subgroup: Transformed DLBCL
 ITT set

Time to first AESI infusion related events by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	5 (4,3)
95%-CI	[1,4-9,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [91,1-98,7]
Month 6	93,7 [83,1-97,7]
Month 12	93,7 [83,1-97,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

AESI = Adverse event of special interest. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS10: Time to first AESI infusion related events by subgroup: B-Cell type
 ITT set

4.6.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first AESI infusion related events by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	3 (6,3)
95%-CI	[1,3-17,2]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [84,4-98,9]
Month 6	91,0 [72,3-97,3]
Month 12	91,0 [72,3-97,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS10: Time to first AESI infusion related events by subgroup: B-Cell type
 ITT set

Time to first AESI infusion related events by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS11: Time to first AESI infusion related events by subgroup: Maximal longest diameter
 ITT set

4.6.11 *Merkmal: Maximaler längster Durchmesser*

Time to first AESI infusion related events by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	5 (6,1)
95%-CI	[2,0-13,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [87,5-98,1]
Month 6	92,1 [80,3-96,9]
Month 12	92,1 [80,3-96,9]
Month 18	92,1 [80,3-96,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS11: Time to first AESI infusion related events by subgroup: Maximal longest diameter
 ITT set

Time to first AESI infusion related events by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-9,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS11: Time to first AESI infusion related events by subgroup: Maximal longest diameter
 ITT set

Time to first AESI infusion related events by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS11: Time to first AESI infusion related events by subgroup: Maximal longest diameter
 ITT set

Time to first AESI infusion related events by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS12: Time to first AESI infusion related events by subgroup: Primary disease diagnosis
 ITT set

4.6.12 *Merkmal: Primärdiagnose*

Time to first AESI infusion related events by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	3 (2,4)
95%-CI	[0,5-6,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,4 [93,9-99,6]
Month 6	96,0 [85,7-98,9]
Month 12	96,0 [85,7-98,9]
Month 18	96,0 [85,7-98,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS12: Time to first AESI infusion related events by subgroup: Primary disease diagnosis
 ITT set

Time to first AESI infusion related events by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
AESI infusion related events in months [95%-CI]	
Median	NE[0,03-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS13: Time to first AESI infusion related events by subgroup: Number prior lines
 ITT set

4.6.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first AESI infusion related events by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	2 (3,2)
95%-CI	[0,4-11,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,4 [89,3-99,8]
Month 6	94,1 [75,6-98,7]
Month 12	94,1 [75,6-98,7]
Month 18	94,1 [75,6-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS13: Time to first AESI infusion related events by subgroup: Number prior lines
 ITT set

Time to first AESI infusion related events by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [81,4-99,6]
Month 6	97,1 [81,4-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS13: Time to first AESI infusion related events by subgroup: Number prior lines
 ITT set

Time to first AESI infusion related events by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [81,5-97,9]
Month 6	93,6 [81,5-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS14: Time to first AESI infusion related events by subgroup: Response category - first line
 ITT set

4.6.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first AESI infusion related events by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	3 (3,0)
95%-CI	[0,6-8,6]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,0 [92,2-99,5]
Month 6	95,0 [82,9-98,6]
Month 12	95,0 [82,9-98,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS14: Time to first AESI infusion related events by subgroup: Response category - first line
 ITT set

Time to first AESI infusion related events by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,9]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS15: Time to first AESI infusion related events by subgroup: Response category - last line
 ITT set

4.6.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first AESI infusion related events by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	2 (4,5)
95%-CI	[0,6-15,5]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [84,9-99,7]
Month 6	92,3 [69,7-98,2]
Month 12	92,3 [69,7-98,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS15: Time to first AESI infusion related events by subgroup: Response category - last line
 ITT set

Time to first AESI infusion related events by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	2 (2,3)
95%-CI	[0,3-8,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [91,2-99,4]
Month 6	97,7 [91,2-99,4]
Month 12	97,7 [91,2-99,4]
Month 18	97,7 [91,2-99,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS16: Time to first AESI infusion related events by subgroup: Response category - any line
 ITT set

4.6.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first AESI infusion related events by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS16: Time to first AESI infusion related events by subgroup: Response category - any line
 ITT set

Time to first AESI infusion related events by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	4 (3,5)
95%-CI	[1,0-8,7]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,4 [92,1-99,2]
Month 6	94,8 [84,5-98,3]
Month 12	94,8 [84,5-98,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS17: Time to first AESI infusion related events by subgroup: Prior use of T-CART therapy
 ITT set

4.6.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first AESI infusion related events by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS17: Time to first AESI infusion related events by subgroup: Prior use of T-CART therapy
 ITT set

Time to first AESI infusion related events by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	5 (3,8)
95%-CI	[1,2-8,6]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,0 [92,1-98,9]
Month 6	94,6 [85,6-98,0]
Month 12	94,6 [85,6-98,0]
Month 18	94,6 [85,6-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS18: Time to first AESI infusion related events by subgroup: Drug formulation
 ITT set

4.6.18 *Merkmal: Arzneimittelformulierung*

Time to first AESI infusion related events by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEI_TSTS18: Time to first AESI infusion related events by subgroup: Drug formulation
 ITT set

Time to first AESI infusion related events by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	6 (5,5)
95%-CI	[2,0-11,5]
AESI infusion related events in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [89,4-98,1]
Month 6	92,8 [82,9-97,1]
Month 12	92,8 [82,9-97,1]
Month 18	92,8 [82,9-97,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS01: Time to first AESI infusion related events graded < 3 by subgroup: Age group
 ITT set

4.7 Subgruppenanalysen zum nicht schweren AESI – infusionsbedingte Reaktion

4.7.1 Merkmal Alter

Time to first AESI infusion related events graded < 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: < 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [82,5-96,7]
Month 6	92,3 [82,5-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS01: Time to first AESI infusion related events graded < 3 by subgroup: Age group
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,1]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS01: Time to first AESI infusion related events graded < 3 by subgroup: Age group
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	90,9 [50,8-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS02: Time to first AESI infusion related events graded < 3 by subgroup: Sex
 ITT set

4.7.2 *Merkmal: Geschlecht*

Time to first AESI infusion related events graded < 3 by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,7 [87,3-99,2]
Month 6	92,5 [75,8-97,8]
Month 12	92,5 [75,8-97,8]
Month 18	92,5 [75,8-97,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS02: Time to first AESI infusion related events graded < 3 by subgroup: Sex
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	3 (3,5)
95%-CI	[0,7-10,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,5 [89,5-98,9]
Month 6	96,5 [89,5-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS03: Time to first AESI infusion related events graded < 3 by subgroup: Race group
 ITT set

4.7.3 *Merkmal: Ethnie*

Time to first AESI infusion related events graded < 3 by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	5 (3,8)
95%-CI	[1,3-8,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,9 [92,0-98,8]
Month 6	94,2 [84,2-98,0]
Month 12	94,2 [84,2-98,0]
Month 18	94,2 [84,2-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS03: Time to first AESI infusion related events graded < 3 by subgroup: Race group
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS04: Time to first AESI infusion related events graded < 3 by subgroup: Country
 ITT set

4.7.4 *Merkmal: Region-1*

Time to first AESI infusion related events graded < 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [80,8-96,4]
Month 6	91,5 [80,8-96,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS04: Time to first AESI infusion related events graded < 3 by subgroup: Country
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	90,9 [50,8-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS04: Time to first AESI infusion related events graded < 3 by subgroup: Country
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS05: Time to first AESI infusion related events graded < 3 by subgroup: Region
 ITT set

4.7.5 *Merkmal: Region-2*

Time to first AESI infusion related events graded < 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [80,8-96,4]
Month 6	91,5 [80,8-96,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS05: Time to first AESI infusion related events graded < 3 by subgroup: Region
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	1 (1,2)
95%-CI	[0,0-6,3]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	96,2 [75,7-99,5]
Month 12	96,2 [75,7-99,5]
Month 18	96,2 [75,7-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS06: Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage
 ITT set

4.7.6 *Merkmal: Krankheitsstadium nach Ann-Arbor*

Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS06: Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS06: Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS06: Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	5 (5,4)
95%-CI	[1,8-12,1]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [89,0-98,4]
Month 6	92,0 [78,7-97,2]
Month 12	92,0 [78,7-97,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS07: Time to first AESI infusion related events graded < 3 by subgroup: Bulky disease
 ITT set

4.7.7 *Merkmal: Bulky Erkrankung*

Time to first AESI infusion related events graded < 3 by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	6 (4,4)
95%-CI	[1,6-9,3]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [91,5-98,5]
Month 6	94,2 [85,9-97,6]
Month 12	94,2 [85,9-97,6]
Month 18	94,2 [85,9-97,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS08: Time to first AESI infusion related events graded < 3 by subgroup: Double/Triple hit
 ITT set

4.7.8 *Merkmal: Double/Triple-Hit*

Time to first AESI infusion related events graded < 3 by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS08: Time to first AESI infusion related events graded < 3 by subgroup: Double/Triple hit
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	4 (3,1)
95%-CI	[0,8-7,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [93,0-99,3]
Month 6	95,2 [85,4-98,5]
Month 12	95,2 [85,4-98,5]
Month 18	95,2 [85,4-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS09: Time to first AESI infusion related events graded < 3 by subgroup: Transformed DLBCL
 ITT set

4.7.9 *Merkmal: Transformation des DLBCL*

Time to first AESI infusion related events graded < 3 by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [78,0-99,5]
Month 6	96,6 [78,0-99,5]
Month 12	96,6 [78,0-99,5]
Month 18	96,6 [78,0-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

AESI = Adverse event of special interest. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS09: Time to first AESI infusion related events graded < 3 by subgroup: Transformed DLBCL
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	5 (4,3)
95%-CI	[1,4-9,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [91,1-98,7]
Month 6	93,7 [83,1-97,7]
Month 12	93,7 [83,1-97,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

AESI = Adverse event of special interest. ITT set = Intent to Treat set.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS10: Time to first AESI infusion related events graded < 3 by subgroup: B-Cell type
 ITT set

4.7.10 *Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen*

Time to first AESI infusion related events graded < 3 by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	3 (6,3)
95%-CI	[1,3-17,2]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [84,4-98,9]
Month 6	91,0 [72,3-97,3]
Month 12	91,0 [72,3-97,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS10: Time to first AESI infusion related events graded < 3 by subgroup: B-Cell type
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS11: Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter
 ITT set

4.7.11 *Merkmal: Maximaler längster Durchmesser*

Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	5 (6,1)
95%-CI	[2,0-13,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [87,5-98,1]
Month 6	92,1 [80,3-96,9]
Month 12	92,1 [80,3-96,9]
Month 18	92,1 [80,3-96,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS11: Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-9,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS11: Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS11: Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS12: Time to first AESI infusion related events graded < 3 by subgroup: Primary disease diagnosis
 ITT set

4.7.12 *Merkmal: Primärdiagnose*

Time to first AESI infusion related events graded < 3 by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	3 (2,4)
95%-CI	[0,5-6,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,4 [93,9-99,6]
Month 6	96,0 [85,7-98,9]
Month 12	96,0 [85,7-98,9]
Month 18	96,0 [85,7-98,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS12: Time to first AESI infusion related events graded < 3 by subgroup: Primary disease diagnosis
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE[0,03-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS13: Time to first AESI infusion related events graded < 3 by subgroup: Number prior lines
 ITT set

4.7.13 *Merkmal: Anzahl der vorherigen systemischen Therapien*

Time to first AESI infusion related events graded < 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	2 (3,2)
95%-CI	[0,4-11,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,4 [89,3-99,8]
Month 6	94,1 [75,6-98,7]
Month 12	94,1 [75,6-98,7]
Month 18	94,1 [75,6-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS13: Time to first AESI infusion related events graded < 3 by subgroup: Number prior lines
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [81,4-99,6]
Month 6	97,1 [81,4-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS13: Time to first AESI infusion related events graded < 3 by subgroup: Number prior lines
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [81,5-97,9]
Month 6	93,6 [81,5-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS14: Time to first AESI infusion related events graded < 3 by subgroup: Response category - first line
 ITT set

4.7.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first AESI infusion related events graded < 3 by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	3 (3,0)
95%-CI	[0,6-8,6]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,0 [92,2-99,5]
Month 6	95,0 [82,9-98,6]
Month 12	95,0 [82,9-98,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS14: Time to first AESI infusion related events graded < 3 by subgroup: Response category - first line
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,9]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS15: Time to first AESI infusion related events graded < 3 by subgroup: Response category - last line
 ITT set

4.7.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first AESI infusion related events graded < 3 by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	2 (4,5)
95%-CI	[0,6-15,5]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [84,9-99,7]
Month 6	92,3 [69,7-98,2]
Month 12	92,3 [69,7-98,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS15: Time to first AESI infusion related events graded < 3 by subgroup: Response category - last line
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	2 (2,3)
95%-CI	[0,3-8,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [91,2-99,4]
Month 6	97,7 [91,2-99,4]
Month 12	97,7 [91,2-99,4]
Month 18	97,7 [91,2-99,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS16: Time to first AESI infusion related events graded < 3 by subgroup: Response category - any line
 ITT set

4.7.16 *Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first AESI infusion related events graded < 3 by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE[NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS16: Time to first AESI infusion related events graded < 3 by subgroup: Response category - any line
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	4 (3,5)
95%-CI	[1,0-8,7]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,4 [92,1-99,2]
Month 6	94,8 [84,5-98,3]
Month 12	94,8 [84,5-98,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS17: Time to first AESI infusion related events graded < 3 by subgroup: Prior use of T-CART therapy
 ITT set

4.7.17 *Merkmal: Vorherige CAR-T-Therapie*

Time to first AESI infusion related events graded < 3 by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS17: Time to first AESI infusion related events graded < 3 by subgroup: Prior use of T-CART therapy
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	5 (3,8)
95%-CI	[1,2-8,6]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,0 [92,1-98,9]
Month 6	94,6 [85,6-98,0]
Month 12	94,6 [85,6-98,0]
Month 18	94,6 [85,6-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS18: Time to first AESI infusion related events graded < 3 by subgroup: Drug formulation
 ITT set

4.7.18 *Merkmal: Arzneimittelformulierung*

Time to first AESI infusion related events graded < 3 by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT3AEIN_TSTS18: Time to first AESI infusion related events graded < 3 by subgroup: Drug formulation
 ITT set

Time to first AESI infusion related events graded < 3 by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	6 (5,5)
95%-CI	[2,0-11,5]
AESI infusion related events graded < 3 in months [95%-CI]	
Median	NE [NE-NE]
AESI infusion related events graded < 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [89,4-98,1]
Month 6	92,8 [82,9-97,1]
Month 12	92,8 [82,9-97,1]
Month 18	92,8 [82,9-97,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 AESI = Adverse event of special interest. ITT set = Intent to Treat set.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aae_tte, created on: 10JAN2023

Table LT1AEIC_TSTS01: Time to first AESI infusion related events graded ≥ 3 by subgroup: Age group
ITT set

4.8 Subgruppenanalysen zum schweren AESI – infusionsbedingte Reaktion

Es sind keine Ereignisse einer schweren infusionsbedingten Reaktion aufgetreten, weshalb keine Subgruppenanalysen dargestellt werden.

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
AESI = Adverse event of special interest. ITT set = Intent to Treat set.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aae_tte, created on: 10JAN2023

Table LT1AEIC_TSTS18: Time to first AESI infusion related events graded ≥ 3 by subgroup: Drug formulation
ITT set

4.9 Subgruppenanalysen zum schwerwiegenden AESI – infusionsbedingte Reaktion

Es sind keine Ereignisse einer schwerwiegenden infusionsbedingten Reaktion aufgetreten, weshalb keine Subgruppenanalysen dargestellt werden.

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
AESI = Adverse event of special interest. ITT set = Intent to Treat set.
Confidence interval for event rate: exact Clopper-Pearson method.
Confidence interval for Median: Brookmeyer Crowley.
Confidence interval for time point estimates: via log-log transformation of rates.
Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

4.10 Subgruppenanalysen zu den UE nach SOC und PT

4.10.1 Merkmal Alter

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	42 (64,6)
95%-CI	[51,8-76,1]
TEAE in months [95%-CI]	
Median	1,38 [0,49-2,07]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,0 [17,6-43,3]
Month 6	21,0 [9,0-36,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	41 (69,5)
95%-CI	[56,1-80,8]
TEAE in months [95%-CI]	
Median	1,41 [0,95-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,3 [25,2-51,2]
Month 6	22,8 [10,4-38,1]
Month 12	5,7 [0,5-21,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	13 (61,9)
95%-CI	[38,4-81,9]
TEAE in months [95%-CI]	
Median	1,38[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,8 [19,4-61,3]
Month 6	32,7 [12,4-54,8]
Month 12	32,7 [12,4-54,8]
Month 18	32,7 [12,4-54,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	21 (32,3)
95%-CI	[21,2-45,1]
TEAE in months [95%-CI]	
Median	NE [2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,7 [47,7-74,6]
Month 6	62,7 [47,7-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]
TEAE in months [95%-CI]	
Median	NE[4,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,2 [58,4-83,5]
Month 6	67,1 [48,2-80,4]
Month 12	67,1 [48,2-80,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [56,3-92,3]
Month 6	80,7 [56,3-92,3]
Month 12	80,7 [56,3-92,3]
Month 18	80,7 [56,3-92,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	11 (16,9)
95%-CI	[8,8-28,3]
TEAE in months [95%-CI]	
Median	NE [4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [67,4-91,5]
Month 6	68,5 [46,8-82,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	14 (23,7)
95%-CI	[13,6-36,6]
TEAE in months [95%-CI]	
Median	9,10 [6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [67,0-89,4]
Month 6	75,8 [58,3-86,8]
Month 12	39,0 [11,1-66,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	55,4 [15,6-82,8]
Month 12	55,4 [15,6-82,8]
Month 18	55,4 [15,6-82,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	15 (23,1)
95%-CI	[13,5-35,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,3 [63,6-86,3]
Month 6	70,2 [54,0-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [66,8-89,2]
Month 6	75,7 [58,2-86,6]
Month 12	75,7 [58,2-86,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [59,9-97,0]
Month 6	88,2 [59,9-97,0]
Month 12	88,2 [59,9-97,0]
Month 18	88,2 [59,9-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	7 (10,8)
95%-CI	[4,4-20,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [76,8-96,1]
Month 6	81,2 [61,7-91,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [74,9-95,6]
Month 6	89,2 [74,9-95,6]
Month 12	89,2 [74,9-95,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [67,0-97,5]
Month 6	90,5 [67,0-97,5]
Month 12	90,5 [67,0-97,5]
Month 18	90,5 [67,0-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	46 (70,8)
95%-CI	[58,2-81,4]
TEAE in months [95%-CI]	
Median	0,69[0,49-0,95]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	23,4 [12,8-35,8]
Month 6	23,4 [12,8-35,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	28 (47,5)
95%-CI	[34,3-60,9]
TEAE in months [95%-CI]	
Median	5,39 [1,18-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,6 [44,3-70,3]
Month 6	44,3 [26,5-60,8]
Month 12	14,8 [1,1-44,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	9 (42,9)
95%-CI	[21,8-66,0]
TEAE in months [95%-CI]	
Median	NE[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,9 [25,2-71,8]
Month 6	50,9 [25,2-71,8]
Month 12	50,9 [25,2-71,8]
Month 18	50,9 [25,2-71,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	34 (52,3)
95%-CI	[39,5-64,9]
TEAE in months [95%-CI]	
Median	1,74 [1,18-3,71]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,1 [27,9-55,7]
Month 6	35,1 [20,9-49,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	20 (33,9)
95%-CI	[22,1-47,4]
TEAE in months [95%-CI]	
Median	7,62 [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,7 [53,6-79,8]
Month 6	54,3 [34,4-70,5]
Month 12	36,2 [9,1-64,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,4 [53,9-91,7]
Month 6	79,4 [53,9-91,7]
Month 12	79,4 [53,9-91,7]
Month 18	79,4 [53,9-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	28 (43,1)
95%-CI	[30,8-56,0]
TEAE in months [95%-CI]	
Median	7,92 [0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,6 [42,0-67,2]
Month 6	55,6 [42,0-67,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	17 (28,8)
95%-CI	[17,8-42,1]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,9 [61,1-84,3]
Month 6	71,5 [56,5-82,1]
Month 12	26,8 [1,6-65,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [60,6-95,0]
Month 6	85,2 [60,6-95,0]
Month 12	85,2 [60,6-95,0]
Month 18	85,2 [60,6-95,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	23 (35,4)
95%-CI	[23,9-48,2]
TEAE in months [95%-CI]	
Median	NE [1,77-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,2 [45,9-71,7]
Month 6	60,2 [45,9-71,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,4 [70,4-91,0]
Month 6	83,4 [70,4-91,0]
Month 12	83,4 [70,4-91,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
TEAE in months [95%-CI]	
Median	NE [2,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,7 [37,5-83,6]
Month 6	65,7 [37,5-83,6]
Month 12	65,7 [37,5-83,6]
Month 18	65,7 [37,5-83,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	9 (13,8)
95%-CI	[6,5-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [70,8-91,4]
Month 6	83,9 [70,8-91,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [5,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [72,5-92,4]
Month 6	69,4 [42,8-85,5]
Month 12	69,4 [42,8-85,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [65,3-97,4]
Month 6	90,0 [65,3-97,4]
Month 12	90,0 [65,3-97,4]
Month 18	90,0 [65,3-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	4 (6,2)
95%-CI	[1,7-15,0]
TEAE in months [95%-CI]	
Median	NE [8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [79,0-98,0]
Month 6	93,3 [79,0-98,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [80,7-96,4]
Month 6	91,5 [80,7-96,4]
Month 12	91,5 [80,7-96,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [67,0-97,5]
Month 6	90,5 [67,0-97,5]
Month 12	90,5 [67,0-97,5]
Month 18	90,5 [67,0-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	44 (67,7)
95%-CI	[54,9-78,8]
TEAE in months [95%-CI]	
Median	0,95 [0,49-1,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	28,4 [17,0-41,0]
Month 6	15,8 [4,4-33,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	32 (54,2)
95%-CI	[40,8-67,3]
TEAE in months [95%-CI]	
Median	2,10 [1,22-3,78]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,2 [28,3-57,4]
Month 6	30,6 [15,8-46,7]
Month 12	30,6 [15,8-46,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	7 (33,3)
95%-CI	[14,6-57,0]
TEAE in months [95%-CI]	
Median	19,38 [2,10-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [43,2-84,9]
Month 6	69,0 [43,2-84,9]
Month 12	69,0 [43,2-84,9]
Month 18	69,0 [43,2-84,9]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	33 (50,8)
95%-CI	[38,1-63,4]
TEAE in months [95%-CI]	
Median	3,48 [2,10-4,99]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,0 [36,2-64,0]
Month 6	27,9 [13,4-44,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	24 (40,7)
95%-CI	[28,1-54,3]
TEAE in months [95%-CI]	
Median	3,78 [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,1 [42,4-71,0]
Month 6	49,2 [31,8-64,5]
Month 12	39,4 [18,4-59,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	19,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [53,9-93,9]
Month 6	82,1 [53,9-93,9]
Month 12	82,1 [53,9-93,9]
Month 18	82,1 [53,9-93,9]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	18 (27,7)
95%-CI	[17,3-40,2]
TEAE in months [95%-CI]	
Median	NE [3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,3 [55,6-82,2]
Month 6	54,9 [36,0-70,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [5,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,1 [59,8-87,7]
Month 6	70,1 [48,0-84,2]
Month 12	70,1 [48,0-84,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	95,2 [70,7-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	19 (29,2)
95%-CI	[18,6-41,8]
TEAE in months [95%-CI]	
Median	7,56[2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [49,7-76,9]
Month 6	65,2 [49,7-76,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [82,8-98,9]
Month 6	85,5 [63,4-94,8]
Month 12	85,5 [63,4-94,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	15 (23,1)
95%-CI	[13,5-35,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,1 [58,7-83,2]
Month 6	73,1 [58,7-83,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [76,1-96,4]
Month 6	80,4 [59,1-91,4]
Month 12	80,4 [59,1-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE[4,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	79,0 [31,8-95,2]
Month 12	79,0 [31,8-95,2]
Month 18	79,0 [31,8-95,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [82,3-97,3]
Month 6	89,4 [75,1-95,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [76,3-96,4]
Month 6	86,4 [69,2-94,3]
Month 12	86,4 [69,2-94,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	39 (60,0)
95%-CI	[47,1-72,0]
TEAE in months [95%-CI]	
Median	0,82 [0,43-4,63]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,9 [25,5-50,3]
Month 6	30,4 [15,1-47,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
TEAE in months [95%-CI]	
Median	NE [0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,3 [37,0-63,8]
Month 6	51,3 [37,0-63,8]
Month 12	51,3 [37,0-63,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	11 (52,4)
95%-CI	[29,8-74,3]
TEAE in months [95%-CI]	
Median	2,76[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,2 [25,5-69,2]
Month 6	49,2 [25,5-69,2]
Month 12	24,6 [1,9-61,0]
Month 18	24,6 [1,9-61,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	17 (26,2)
95%-CI	[16,0-38,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,4 [54,7-80,2]
Month 6	69,4 [54,7-80,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [63,1-86,5]
Month 6	72,4 [55,3-83,8]
Month 12	72,4 [55,3-83,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,6 [53,9-91,9]
Month 6	79,6 [53,9-91,9]
Month 12	79,6 [53,9-91,9]
Month 18	79,6 [53,9-91,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	10 (15,4)
95%-CI	[7,6-26,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [69,8-91,2]
Month 6	76,9 [57,0-88,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,2 [68,3-91,5]
Month 6	77,7 [58,4-88,8]
Month 12	77,7 [58,4-88,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
TEAE in months [95%-CI]	
Median	11,30 [2,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,0 [42,5-87,2]
Month 6	71,0 [42,5-87,2]
Month 12	35,5 [1,7-76,9]
Month 18	35,5 [1,7-76,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	15 (23,1)
95%-CI	[13,5-35,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,2 [59,5-84,3]
Month 6	68,9 [51,1-81,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [84,8-98,3]
Month 6	94,8 [84,8-98,3]
Month 12	94,8 [84,8-98,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	93,8 [63,2-99,1]
Month 12	93,8 [63,2-99,1]
Month 18	93,8 [63,2-99,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	12 (18,5)
95%-CI	[9,9-30,0]
TEAE in months [95%-CI]	
Median	8,11[6,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [70,6-91,7]
Month 6	78,0 [58,8-89,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [80,3-97,1]
Month 6	92,3 [80,3-97,1]
Month 12	92,3 [80,3-97,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	95,2 [70,7-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	10 (15,4)
95%-CI	[7,6-26,5]
TEAE in months [95%-CI]	
Median	NE [5,42-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [67,6-90,5]
Month 6	72,9 [47,9-87,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [79,5-96,1]
Month 6	85,6 [67,3-94,1]
Month 12	85,6 [67,3-94,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE[4,96-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	83,3 [27,3-97,5]
Month 12	83,3 [27,3-97,5]
Month 18	83,3 [27,3-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	35 (53,8)
95%-CI	[41,0-66,3]
TEAE in months [95%-CI]	
Median	2,14 [1,25-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,7 [36,1-61,9]
Month 6	36,4 [21,5-51,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	30 (50,8)
95%-CI	[37,5-64,1]
TEAE in months [95%-CI]	
Median	3,52 [0,72-8,51]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,0 [43,2-68,6]
Month 6	42,9 [25,8-58,8]
Month 12	25,7 [8,4-47,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	12 (57,1)
95%-CI	[34,0-78,2]
TEAE in months [95%-CI]	
Median	2,53[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,5 [18,8-63,0]
Month 6	41,5 [18,8-63,0]
Month 12	27,7 [6,4-54,9]
Month 18	27,7 [6,4-54,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	11 (16,9)
95%-CI	[8,8-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [66,4-88,9]
Month 6	80,3 [66,4-88,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [71,0-91,2]
Month 6	83,7 [71,0-91,2]
Month 12	83,7 [71,0-91,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [56,4-96,8]
Month 6	87,3 [56,4-96,8]
Month 12	58,2 [8,4-88,9]
Month 18	58,2 [8,4-88,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	10 (15,4)
95%-CI	[7,6-26,5]
TEAE in months [95%-CI]	
Median	NE [5,75-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [71,7-93,0]
Month 6	67,1 [41,6-83,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [73,7-92,7]
Month 6	78,7 [57,5-90,2]
Month 12	65,6 [32,8-85,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE[4,96-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	76,9 [31,3-94,3]
Month 12	76,9 [31,3-94,3]
Month 18	76,9 [31,3-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	9 (13,8)
95%-CI	[6,5-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [76,5-94,2]
Month 6	83,9 [68,5-92,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [71,2-91,3]
Month 6	78,6 [61,2-88,9]
Month 12	78,6 [61,2-88,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE[4,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [58,5-97,0]
Month 6	75,4 [37,2-92,2]
Month 12	75,4 [37,2-92,2]
Month 18	75,4 [37,2-92,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	10 (15,4)
95%-CI	[7,6-26,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [76,7-94,2]
Month 6	76,7 [58,8-87,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [74,6-93,6]
Month 6	87,0 [74,6-93,6]
Month 12	87,0 [74,6-93,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [54,6-94,4]
Month 6	82,9 [54,6-94,4]
Month 12	82,9 [54,6-94,4]
Month 18	82,9 [54,6-94,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	6 (9,2)
95%-CI	[3,5-19,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,4 [79,8-95,6]
Month 6	90,4 [79,8-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [79,6-96,2]
Month 6	91,0 [79,6-96,2]
Month 12	91,0 [79,6-96,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	95,2 [70,7-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	2 (3,1)
95%-CI	[0,4-10,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,9 [88,3-99,2]
Month 6	96,9 [88,3-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [80,0-96,2]
Month 6	86,1 [68,5-94,2]
Month 12	71,7 [34,8-90,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [67,0-97,5]
Month 6	90,5 [67,0-97,5]
Month 12	90,5 [67,0-97,5]
Month 18	90,5 [67,0-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [81,1-96,5]
Month 6	91,7 [81,1-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [84,7-98,3]
Month 6	94,8 [84,7-98,3]
Month 12	94,8 [84,7-98,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [56,4-96,8]
Month 6	87,3 [56,4-96,8]
Month 12	87,3 [56,4-96,8]
Month 18	87,3 [56,4-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	33 (50,8)
95%-CI	[38,1-63,4]
TEAE in months [95%-CI]	
Median	2,07 [1,41-2,79]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,9 [18,4-48,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
TEAE in months [95%-CI]	
Median	3,06[1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,6 [35,7-63,7]
Month 6	22,1 [2,0-55,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	8 (38,1)
95%-CI	[18,1-61,6]
TEAE in months [95%-CI]	
Median	NE [1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,3 [39,2-81,2]
Month 6	51,5 [21,9-74,8]
Month 12	51,5 [21,9-74,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	10 (15,4)
95%-CI	[7,6-26,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,0 [63,2-88,6]
Month 6	79,0 [63,2-88,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [79,5-97,0]
Month 6	91,9 [79,5-97,0]
Month 12	91,9 [79,5-97,0]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [59,5-94,8]
Month 6	75,3 [44,4-90,5]
Month 12	75,3 [44,4-90,5]
Month 18	75,3 [44,4-90,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	8 (12,3)
95%-CI	[5,5-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [72,9-92,5]
Month 6	85,5 [72,9-92,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,5 [69,4-91,5]
Month 6	83,5 [69,4-91,5]
Month 12	83,5 [69,4-91,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	85,3 [50,5-96,4]
Month 12	56,8 [8,5-87,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	9 (13,8)
95%-CI	[6,5-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [66,0-89,9]
Month 6	81,0 [66,0-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [81,2-97,1]
Month 6	92,5 [81,2-97,1]
Month 12	77,1 [34,6-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	94,7 [68,1-99,2]
Month 18	94,7 [68,1-99,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	8 (12,3)
95%-CI	[5,5-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [67,6-92,1]
Month 6	77,1 [55,8-89,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [75,6-94,6]
Month 6	80,9 [58,3-92,0]
Month 12	80,9 [58,3-92,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	31 (47,7)
95%-CI	[35,1-60,5]
TEAE in months [95%-CI]	
Median	2,86[1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,4 [33,1-60,5]
Month 6	36,9 [20,7-53,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	23 (39,0)
95%-CI	[26,5-52,6]
TEAE in months [95%-CI]	
Median	4,34 [3,09-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [54,0-80,4]
Month 6	46,8 [27,6-63,9]
Month 12	31,2 [12,1-52,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	7 (33,3)
95%-CI	[14,6-57,0]
TEAE in months [95%-CI]	
Median	7,69[2,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [49,1-91,2]
Month 6	55,7 [22,3-79,6]
Month 12	37,2 [7,1-69,0]
Month 18	37,2 [7,1-69,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	19 (29,2)
95%-CI	[18,6-41,8]
TEAE in months [95%-CI]	
Median	NE [4,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,1 [52,1-78,4]
Month 6	62,0 [44,6-75,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [70,4-93,0]
Month 6	79,1 [58,7-90,2]
Month 12	65,9 [33,1-85,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE in months [95%-CI]	
Median	NE [2,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [49,1-91,2]
Month 6	77,4 [49,1-91,2]
Month 12	77,4 [49,1-91,2]
Month 18	77,4 [49,1-91,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	6 (9,2)
95%-CI	[3,5-19,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [75,2-94,9]
Month 6	88,5 [75,2-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [80,0-96,2]
Month 6	80,9 [59,1-91,8]
Month 12	64,7 [27,1-86,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE[4,90-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [67,0-97,5]
Month 6	75,4 [33,3-93,0]
Month 12	75,4 [33,3-93,0]
Month 18	75,4 [33,3-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [77,3-96,8]
Month 6	84,8 [62,4-94,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [75,5-94,7]
Month 6	76,4 [53,7-89,1]
Month 12	63,7 [31,6-83,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	63,2 [7,0-92,4]
Month 18	63,2 [7,0-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	18 (27,7)
95%-CI	[17,3-40,2]
TEAE in months [95%-CI]	
Median	NE [3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,2 [52,2-79,9]
Month 6	59,4 [41,0-73,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	22 (37,3)
95%-CI	[25,0-50,9]
TEAE in months [95%-CI]	
Median	4,83 [2,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,7 [45,4-74,4]
Month 6	42,3 [18,4-64,6]
Month 12	31,7 [9,7-56,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	8 (38,1)
95%-CI	[18,1-61,6]
TEAE in months [95%-CI]	
Median	NE [1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,5 [29,6-75,2]
Month 6	55,5 [29,6-75,2]
Month 12	55,5 [29,6-75,2]
Month 18	55,5 [29,6-75,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	25 (38,5)
95%-CI	[26,7-51,4]
TEAE in months [95%-CI]	
Median	5,22 [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,7 [40,6-70,0]
Month 6	37,8 [18,3-57,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	14 (23,7)
95%-CI	[13,6-36,6]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,6 [60,1-85,8]
Month 6	70,6 [52,4-82,9]
Month 12	58,8 [31,2-78,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	7 (33,3)
95%-CI	[14,6-57,0]
TEAE in months [95%-CI]	
Median	NE [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,8 [40,8-84,5]
Month 6	50,8 [17,0-77,3]
Month 12	50,8 [17,0-77,3]
Month 18	50,8 [17,0-77,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	22 (33,8)
95%-CI	[22,6-46,6]
TEAE in months [95%-CI]	
Median	5,29[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [58,2-81,5]
Month 6	47,3 [27,3-64,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	12 (20,3)
95%-CI	[11,0-32,8]
TEAE in months [95%-CI]	
Median	10,97[5,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [76,3-94,1]
Month 6	70,6 [45,1-85,9]
Month 12	26,5 [1,5-65,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	7 (33,3)
95%-CI	[14,6-57,0]
TEAE in months [95%-CI]	
Median	NE[0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,3 [38,5-81,5]
Month 6	64,3 [38,5-81,5]
Month 12	64,3 [38,5-81,5]
Month 18	64,3 [38,5-81,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	11 (16,9)
95%-CI	[8,8-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [74,0-92,3]
Month 6	73,7 [52,2-86,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [87,1-99,1]
Month 6	96,6 [87,1-99,1]
Month 12	96,6 [87,1-99,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [67,0-97,5]
Month 6	90,5 [67,0-97,5]
Month 12	90,5 [67,0-97,5]
Month 18	90,5 [67,0-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	14 (21,5)
95%-CI	[12,3-33,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [62,7-86,0]
Month 6	72,2 [55,7-83,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [68,2-89,7]
Month 6	77,0 [60,6-87,2]
Month 12	77,0 [60,6-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [62,0-95,2]
Month 6	85,7 [62,0-95,2]
Month 12	85,7 [62,0-95,2]
Month 18	85,7 [62,0-95,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	4 (6,2)
95%-CI	[1,7-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [82,5-97,4]
Month 6	93,1 [82,5-97,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [80,9-97,1]
Month 6	87,8 [70,8-95,2]
Month 12	87,8 [70,8-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	95,2 [70,7-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	15 (23,1)
95%-CI	[13,5-35,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [53,7-81,3]
Month 6	69,8 [53,7-81,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,9 [68,7-89,9]
Month 6	81,9 [68,7-89,9]
Month 12	81,9 [68,7-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [61,3-95,1]
Month 6	85,5 [61,3-95,1]
Month 12	85,5 [61,3-95,1]
Month 18	85,5 [61,3-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	9 (13,8)
95%-CI	[6,5-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [64,7-89,9]
Month 6	80,6 [64,7-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [75,6-94,7]
Month 6	88,3 [75,6-94,7]
Month 12	88,3 [75,6-94,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	95,2 [70,7-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	11 (16,9)
95%-CI	[8,8-28,3]
TEAE in months [95%-CI]	
Median	7,92 [4,14-8,11]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [68,6-93,0]
Month 6	69,4 [46,2-84,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [75,4-96,6]
Month 6	77,5 [56,1-89,4]
Month 12	77,5 [56,1-89,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [61,8-97,2]
Month 6	88,9 [61,8-97,2]
Month 12	88,9 [61,8-97,2]
Month 18	88,9 [61,8-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	9 (13,8)
95%-CI	[6,5-24,7]
TEAE in months [95%-CI]	
Median	NE [6,67-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [74,3-93,7]
Month 6	79,8 [57,8-91,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [71,1-92,1]
Month 6	78,9 [60,2-89,6]
Month 12	78,9 [60,2-89,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	95,2 [70,7-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	7 (10,8)
95%-CI	[4,4-20,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [74,3-93,7]
Month 6	87,0 [74,3-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [83,0-98,1]
Month 6	94,2 [83,0-98,1]
Month 12	94,2 [83,0-98,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	95,0 [69,5-99,3]
Month 12	95,0 [69,5-99,3]
Month 18	95,0 [69,5-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [79,2-96,1]
Month 6	90,8 [79,2-96,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	9,17[7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [77,8-95,1]
Month 6	89,4 [77,8-95,1]
Month 12	44,7 [11,2-74,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [62,0-95,2]
Month 6	85,7 [62,0-95,2]
Month 12	85,7 [62,0-95,2]
Month 18	85,7 [62,0-95,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	4 (6,2)
95%-CI	[1,7-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [80,9-97,2]
Month 6	92,5 [80,9-97,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [71,9-93,3]
Month 6	81,2 [63,5-90,9]
Month 12	81,2 [63,5-90,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	84,6 [51,2-95,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	3 (4,6)
95%-CI	[1,0-12,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [85,0-98,3]
Month 6	94,9 [85,0-98,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [73,2-94,4]
Month 6	87,4 [73,2-94,4]
Month 12	87,4 [73,2-94,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS01: Time to first TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [63,2-97,2]
Month 6	89,3 [63,2-97,2]
Month 12	89,3 [63,2-97,2]
Month 18	89,3 [63,2-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

4.10.2 Merkmal: Geschlecht

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	40 (66,7)
95%-CI	[53,3-78,3]
TEAE in months [95%-CI]	
Median	1,18 [0,72-2,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,3 [21,7-47,3]
Month 6	25,7 [14,0-39,2]
Month 12	21,4 [10,0-35,7]
Month 18	21,4 [10,0-35,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	56 (65,9)
95%-CI	[54,8-75,8]
TEAE in months [95%-CI]	
Median	1,41 [0,76-2,56]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,1 [24,9-47,3]
Month 6	18,8 [6,9-35,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	18 (30,0)
95%-CI	[18,8-43,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,8 [50,7-77,3]
Month 6	65,8 [50,7-77,3]
Month 12	65,8 [50,7-77,3]
Month 18	65,8 [50,7-77,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	22 (25,9)
95%-CI	[17,0-36,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,8 [61,0-81,6]
Month 6	67,2 [50,9-79,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	14 (23,3)
95%-CI	[13,4-36,0]
TEAE in months [95%-CI]	
Median	NE[4,90-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [69,4-90,9]
Month 6	66,0 [45,9-80,2]
Month 12	58,7 [35,9-75,8]
Month 18	58,7 [35,9-75,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	15 (17,6)
95%-CI	[10,2-27,4]
TEAE in months [95%-CI]	
Median	9,10[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [72,1-91,6]
Month 6	70,4 [48,8-84,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	12 (20,0)
95%-CI	[10,8-32,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [64,2-88,3]
Month 6	72,5 [55,8-83,8]
Month 12	72,5 [55,8-83,8]
Month 18	72,5 [55,8-83,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	16 (18,8)
95%-CI	[11,2-28,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [71,0-88,4]
Month 6	78,0 [65,3-86,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	5 (8,3)
95%-CI	[2,8-18,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [79,0-96,0]
Month 6	90,7 [79,0-96,0]
Month 12	90,7 [79,0-96,0]
Month 18	90,7 [79,0-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [78,4-95,1]
Month 6	81,7 [65,0-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	33 (55,0)
95%-CI	[41,6-67,9]
TEAE in months [95%-CI]	
Median	1,18 [0,49-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [30,6-57,2]
Month 6	39,4 [24,5-53,9]
Month 12	31,5 [14,8-49,8]
Month 18	31,5 [14,8-49,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	50 (58,8)
95%-CI	[47,6-69,4]
TEAE in months [95%-CI]	
Median	1,41 [0,72-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,2 [28,7-51,4]
Month 6	35,1 [23,4-47,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	26 (43,3)
95%-CI	[30,6-56,8]
TEAE in months [95%-CI]	
Median	5,39[1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,5 [39,0-65,9]
Month 6	48,6 [32,7-62,8]
Month 12	48,6 [32,7-62,8]
Month 18	48,6 [32,7-62,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	32 (37,6)
95%-CI	[27,4-48,8]
TEAE in months [95%-CI]	
Median	7,62 [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,0 [48,9-72,7]
Month 6	50,9 [36,2-63,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	22 (36,7)
95%-CI	[24,6-50,1]
TEAE in months [95%-CI]	
Median	9,23[3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [51,2-76,5]
Month 6	62,4 [47,4-74,2]
Month 12	44,5 [21,6-65,2]
Month 18	44,5 [21,6-65,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	26 (30,6)
95%-CI	[21,0-41,5]
TEAE in months [95%-CI]	
Median	6,93 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,4 [58,1-78,2]
Month 6	69,4 [58,1-78,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	21 (35,0)
95%-CI	[23,1-48,4]
TEAE in months [95%-CI]	
Median	NE [2,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,0 [43,3-71,7]
Month 6	59,0 [43,3-71,7]
Month 12	59,0 [43,3-71,7]
Month 18	59,0 [43,3-71,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	17 (20,0)
95%-CI	[12,1-30,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [66,5-85,7]
Month 6	77,8 [66,5-85,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	12 (20,0)
95%-CI	[10,8-32,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [68,3-89,7]
Month 6	71,0 [51,0-84,0]
Month 12	71,0 [51,0-84,0]
Month 18	71,0 [51,0-84,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [78,0-93,7]
Month 6	88,0 [78,0-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	5 (8,3)
95%-CI	[2,8-18,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [83,2-97,4]
Month 6	93,3 [83,2-97,4]
Month 12	84,0 [54,5-95,1]
Month 18	84,0 [54,5-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	6 (7,1)
95%-CI	[2,6-14,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [81,2-96,3]
Month 6	91,5 [81,2-96,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	31 (51,7)
95%-CI	[38,4-64,8]
TEAE in months [95%-CI]	
Median	2,10 [0,72-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,5 [30,0-58,1]
Month 6	41,3 [26,8-55,3]
Month 12	41,3 [26,8-55,3]
Month 18	41,3 [26,8-55,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	52 (61,2)
95%-CI	[50,0-71,6]
TEAE in months [95%-CI]	
Median	1,48 [0,95-2,83]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,6 [27,3-49,8]
Month 6	23,4 [10,8-38,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	25 (41,7)
95%-CI	[29,1-55,1]
TEAE in months [95%-CI]	
Median	8,05[2,10-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,7 [45,9-74,1]
Month 6	51,5 [34,8-66,0]
Month 12	38,7 [19,8-57,2]
Month 18	38,7 [19,8-57,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	36 (42,4)
95%-CI	[31,7-53,6]
TEAE in months [95%-CI]	
Median	4,14 [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,1 [43,1-67,3]
Month 6	36,3 [20,3-52,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	12 (20,0)
95%-CI	[10,8-32,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,3 [63,0-87,8]
Month 6	69,3 [50,4-82,2]
Month 12	69,3 [50,4-82,2]
Month 18	69,3 [50,4-82,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	17 (20,0)
95%-CI	[12,1-30,1]
TEAE in months [95%-CI]	
Median	NE[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,9 [63,4-86,0]
Month 6	66,6 [49,6-79,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	12 (20,0)
95%-CI	[10,8-32,3]
TEAE in months [95%-CI]	
Median	NE [7,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [67,8-90,4]
Month 6	75,3 [58,7-86,0]
Month 12	67,8 [45,6-82,5]
Month 18	67,8 [45,6-82,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	11 (12,9)
95%-CI	[6,6-22,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [70,9-90,5]
Month 6	83,1 [70,9-90,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	11 (18,3)
95%-CI	[9,5-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [70,9-92,0]
Month 6	72,4 [53,5-84,7]
Month 12	72,4 [53,5-84,7]
Month 18	72,4 [53,5-84,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	12 (14,1)
95%-CI	[7,5-23,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [71,4-90,1]
Month 6	82,9 [71,4-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	4 (6,7)
95%-CI	[1,8-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [81,2-97,1]
Month 6	92,5 [81,2-97,1]
Month 12	92,5 [81,2-97,1]
Month 18	92,5 [81,2-97,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	6 (7,1)
95%-CI	[2,6-14,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [82,8-97,5]
Month 6	87,7 [73,7-94,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	30 (50,0)
95%-CI	[36,8-63,2]
TEAE in months [95%-CI]	
Median	2,76[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,1 [31,6-59,4]
Month 6	46,1 [31,6-59,4]
Month 12	36,9 [18,2-55,8]
Month 18	36,9 [18,2-55,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	47 (55,3)
95%-CI	[44,1-66,1]
TEAE in months [95%-CI]	
Median	1,41[0,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,2 [33,1-54,7]
Month 6	38,6 [24,9-52,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	14 (23,3)
95%-CI	[13,4-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,6 [59,2-83,6]
Month 6	73,6 [59,2-83,6]
Month 12	73,6 [59,2-83,6]
Month 18	73,6 [59,2-83,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	20 (23,5)
95%-CI	[15,0-34,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,5 [62,4-83,2]
Month 6	69,8 [54,6-80,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [64,2-90,4]
Month 6	80,9 [64,2-90,4]
Month 12	69,4 [39,5-86,6]
Month 18	69,4 [39,5-86,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	16 (18,8)
95%-CI	[11,2-28,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [70,5-88,8]
Month 6	71,1 [52,0-83,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	12 (20,0)
95%-CI	[10,8-32,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [61,5-86,2]
Month 6	76,4 [61,5-86,2]
Month 12	76,4 [61,5-86,2]
Month 18	76,4 [61,5-86,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	7 (8,2)
95%-CI	[3,4-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [84,0-96,6]
Month 6	87,0 [69,4-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	5 (8,3)
95%-CI	[2,8-18,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [82,5-97,3]
Month 6	93,1 [82,5-97,3]
Month 12	83,8 [54,5-95,0]
Month 18	83,8 [54,5-95,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	12 (14,1)
95%-CI	[7,5-23,4]
TEAE in months [95%-CI]	
Median	NE[6,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [75,6-92,6]
Month 6	80,2 [61,6-90,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	7 (11,7)
95%-CI	[4,8-22,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [74,7-94,4]
Month 6	82,7 [64,5-92,1]
Month 12	82,7 [64,5-92,1]
Month 18	82,7 [64,5-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	10 (11,8)
95%-CI	[5,8-20,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [79,3-94,5]
Month 6	76,6 [51,9-89,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	36 (60,0)
95%-CI	[46,5-72,4]
TEAE in months [95%-CI]	
Median	3,38 [0,99-5,75]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,1 [36,1-62,6]
Month 6	35,3 [21,4-49,6]
Month 12	22,4 [9,7-38,4]
Month 18	22,4 [9,7-38,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	41 (48,2)
95%-CI	[37,3-59,3]
TEAE in months [95%-CI]	
Median	3,09[1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,0 [40,0-62,7]
Month 6	47,1 [34,5-58,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [72,3-92,3]
Month 6	85,1 [72,3-92,3]
Month 12	74,5 [46,1-89,4]
Month 18	74,5 [46,1-89,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	14 (16,5)
95%-CI	[9,3-26,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [69,0-88,5]
Month 6	80,8 [69,0-88,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	13 (21,7)
95%-CI	[12,1-34,2]
TEAE in months [95%-CI]	
Median	NE [5,75-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [66,6-90,1]
Month 6	67,5 [47,2-81,4]
Month 12	60,0 [36,8-77,1]
Month 18	60,0 [36,8-77,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [81,1-95,5]
Month 6	80,8 [60,7-91,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	8 (13,3)
95%-CI	[5,9-24,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [79,1-96,1]
Month 6	79,3 [61,0-89,7]
Month 12	79,3 [61,0-89,7]
Month 18	79,3 [61,0-89,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	14 (16,5)
95%-CI	[9,3-26,1]
TEAE in months [95%-CI]	
Median	NE [6,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [71,9-89,9]
Month 6	82,9 [71,9-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [75,5-93,9]
Month 6	80,5 [64,5-89,8]
Month 12	80,5 [64,5-89,8]
Month 18	80,5 [64,5-89,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	11 (12,9)
95%-CI	[6,6-22,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [75,7-92,6]
Month 6	83,8 [71,8-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	7 (11,7)
95%-CI	[4,8-22,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [75,6-93,9]
Month 6	87,6 [75,6-93,9]
Month 12	87,6 [75,6-93,9]
Month 18	87,6 [75,6-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [86,4-97,5]
Month 6	94,1 [86,4-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [81,1-96,4]
Month 6	91,7 [81,1-96,4]
Month 12	84,0 [60,1-94,2]
Month 18	84,0 [60,1-94,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [87,2-98,1]
Month 6	91,2 [77,3-96,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,6 [84,1-98,2]
Month 6	94,6 [84,1-98,2]
Month 12	94,6 [84,1-98,2]
Month 18	94,6 [84,1-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	7 (8,2)
95%-CI	[3,4-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,4 [80,4-95,5]
Month 6	90,4 [80,4-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	25 (41,7)
95%-CI	[29,1-55,1]
TEAE in months [95%-CI]	
Median	3,91[1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,7 [41,7-69,2]
Month 6	33,7 [12,5-56,5]
Month 12	33,7 [12,5-56,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	43 (50,6)
95%-CI	[39,5-61,6]
TEAE in months [95%-CI]	
Median	2,07[1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,2 [24,1-50,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [71,2-93,2]
Month 6	81,1 [63,6-90,8]
Month 12	81,1 [63,6-90,8]
Month 18	40,6 [1,5-82,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	10 (11,8)
95%-CI	[5,8-20,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [73,6-91,9]
Month 6	85,1 [73,6-91,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	10 (16,7)
95%-CI	[8,3-28,5]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [69,0-91,2]
Month 6	79,0 [62,4-88,9]
Month 12	69,1 [42,6-85,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [77,9-93,7]
Month 6	88,0 [77,9-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	4 (6,7)
95%-CI	[1,8-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [82,4-98,0]
Month 6	94,0 [82,4-98,0]
Month 12	85,4 [57,1-95,7]
Month 18	85,4 [57,1-95,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	11 (12,9)
95%-CI	[6,6-22,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [72,4-91,0]
Month 6	83,9 [72,4-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [82,8-98,9]
Month 6	90,7 [71,7-97,2]
Month 12	90,7 [71,7-97,2]
Month 18	90,7 [71,7-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	12 (14,1)
95%-CI	[7,5-23,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,2 [71,0-90,6]
Month 6	75,6 [54,2-88,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	21 (35,0)
95%-CI	[23,1-48,4]
TEAE in months [95%-CI]	
Median	7,69[3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,1 [53,0-80,6]
Month 6	50,8 [32,6-66,4]
Month 12	45,1 [26,3-62,2]
Month 18	45,1 [26,3-62,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	40 (47,1)
95%-CI	[36,1-58,2]
TEAE in months [95%-CI]	
Median	3,91 [2,27-6,01]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,6 [43,2-66,3]
Month 6	38,6 [22,7-54,4]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	12 (20,0)
95%-CI	[10,8-32,3]
TEAE in months [95%-CI]	
Median	NE[4,57-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [60,8-87,6]
Month 6	68,8 [49,5-81,9]
Month 12	68,8 [49,5-81,9]
Month 18	68,8 [49,5-81,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	20 (23,5)
95%-CI	[15,0-34,0]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,2 [63,6-83,6]
Month 6	75,2 [63,6-83,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [82,0-97,3]
Month 6	84,8 [66,9-93,5]
Month 12	84,8 [66,9-93,5]
Month 18	84,8 [66,9-93,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	11 (12,9)
95%-CI	[6,6-22,0]
TEAE in months [95%-CI]	
Median	7,62 [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [77,6-93,7]
Month 6	82,8 [66,2-91,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	4 (6,7)
95%-CI	[1,8-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [83,1-98,1]
Month 6	94,2 [83,1-98,1]
Month 12	86,4 [59,9-95,9]
Month 18	86,4 [59,9-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	12 (14,1)
95%-CI	[7,5-23,4]
TEAE in months [95%-CI]	
Median	7,26[4,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [76,7-94,0]
Month 6	71,8 [49,4-85,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	21 (35,0)
95%-CI	[23,1-48,4]
TEAE in months [95%-CI]	
Median	6,47 [2,99-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [49,2-77,3]
Month 6	50,7 [31,6-67,1]
Month 12	44,4 [24,6-62,5]
Month 18	44,4 [24,6-62,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	27 (31,8)
95%-CI	[22,1-42,8]
TEAE in months [95%-CI]	
Median	NE [2,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,0 [48,3-73,0]
Month 6	58,3 [43,6-70,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	19 (31,7)
95%-CI	[20,3-45,0]
TEAE in months [95%-CI]	
Median	7,10[4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,2 [54,4-81,5]
Month 6	55,2 [35,2-71,3]
Month 12	49,1 [28,4-66,9]
Month 18	49,1 [28,4-66,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	27 (31,8)
95%-CI	[22,1-42,8]
TEAE in months [95%-CI]	
Median	NE [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,1 [49,5-74,0]
Month 6	53,3 [35,6-68,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	19 (31,7)
95%-CI	[20,3-45,0]
TEAE in months [95%-CI]	
Median	10,97[5,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,1 [61,3-84,6]
Month 6	62,5 [43,6-76,6]
Month 12	41,6 [16,7-65,1]
Month 18	41,6 [16,7-65,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	22 (25,9)
95%-CI	[17,0-36,5]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,9 [68,2-86,4]
Month 6	52,7 [29,8-71,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [78,7-95,3]
Month 6	89,8 [78,7-95,3]
Month 12	89,8 [78,7-95,3]
Month 18	89,8 [78,7-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [83,1-95,9]
Month 6	81,0 [60,4-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	11 (18,3)
95%-CI	[9,5-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [70,6-91,2]
Month 6	76,3 [59,8-86,7]
Month 12	76,3 [59,8-86,7]
Month 18	76,3 [59,8-86,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	17 (20,0)
95%-CI	[12,1-30,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [66,4-85,7]
Month 6	77,8 [66,4-85,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	2 (3,3)
95%-CI	[0,4-11,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,9 [86,1-99,7]
Month 6	94,3 [78,0-98,6]
Month 12	94,3 [78,0-98,6]
Month 18	94,3 [78,0-98,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [80,8-94,9]
Month 6	90,0 [80,8-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [72,7-91,8]
Month 6	84,7 [72,7-91,8]
Month 12	84,7 [72,7-91,8]
Month 18	84,7 [72,7-91,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	19 (22,4)
95%-CI	[14,0-32,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [60,4-82,1]
Month 6	72,9 [60,4-82,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [77,8-95,1]
Month 6	89,4 [77,8-95,1]
Month 12	89,4 [77,8-95,1]
Month 18	89,4 [77,8-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	10 (11,8)
95%-CI	[5,8-20,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [71,7-91,3]
Month 6	84,0 [71,7-91,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [75,6-96,5]
Month 6	79,7 [60,9-90,1]
Month 12	59,8 [30,0-80,2]
Month 18	59,8 [30,0-80,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	11 (12,9)
95%-CI	[6,6-22,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [73,0-92,9]
Month 6	73,7 [53,7-86,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [79,7-96,2]
Month 6	91,0 [79,7-96,2]
Month 12	84,5 [63,5-94,0]
Month 18	84,5 [63,5-94,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	13 (15,3)
95%-CI	[8,4-24,7]
TEAE in months [95%-CI]	
Median	NE [5,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [74,0-91,5]
Month 6	72,2 [47,8-86,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [83,2-98,1]
Month 6	94,3 [83,2-98,1]
Month 12	94,3 [83,2-98,1]
Month 18	94,3 [83,2-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [79,2-94,5]
Month 6	89,1 [79,2-94,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE[8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [82,2-97,3]
Month 6	92,9 [82,2-97,3]
Month 12	76,7 [47,0-91,1]
Month 18	76,7 [47,0-91,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	11 (12,9)
95%-CI	[6,6-22,0]
TEAE in months [95%-CI]	
Median	9,17[9,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [77,5-93,0]
Month 6	87,2 [77,5-93,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [71,1-93,9]
Month 6	86,4 [71,1-93,9]
Month 12	86,4 [71,1-93,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [78,6-95,1]
Month 6	85,9 [71,5-93,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [82,6-98,1]
Month 6	94,1 [82,6-98,1]
Month 12	94,1 [82,6-98,1]
Month 18	94,1 [82,6-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS02: Time to first TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [78,5-94,4]
Month 6	88,9 [78,5-94,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

4.10.3 *Merkmal: Ethnie*

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	86 (66,2)
95%-CI	[57,3-74,2]
TEAE in months [95%-CI]	
Median	1,38 [0,85-1,77]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,1 [24,3-42,2]
Month 6	23,1 [14,1-33,5]
Month 12	16,9 [8,1-28,4]
Month 18	16,9 [8,1-28,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	10 (66,7)
95%-CI	[38,4-88,2]
TEAE in months [95%-CI]	
Median	3,32 [0,13-9,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,3 [26,3-74,4]
Month 6	26,7 [4,9-56,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	35 (26,9)
95%-CI	[19,5-35,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,2 [60,4-78,0]
Month 6	67,5 [56,5-76,3]
Month 12	67,5 [56,5-76,3]
Month 18	67,5 [56,5-76,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [37,5-84,6]
Month 6	66,7 [37,5-84,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	26 (20,0)
95%-CI	[13,5-27,9]
TEAE in months [95%-CI]	
Median	NE [6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,6 [72,0-88,1]
Month 6	67,6 [52,2-78,9]
Month 12	56,8 [37,1-72,3]
Month 18	56,8 [37,1-72,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	9,10 [3,32-9,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	76,2 [33,2-93,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	26 (20,0)
95%-CI	[13,5-27,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,5 [70,6-86,0]
Month 6	73,8 [63,0-82,0]
Month 12	73,8 [63,0-82,0]
Month 18	73,8 [63,0-82,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [82,7-94,6]
Month 6	85,6 [74,8-92,0]
Month 12	85,6 [74,8-92,0]
Month 18	85,6 [74,8-92,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	71 (54,6)
95%-CI	[45,7-63,4]
TEAE in months [95%-CI]	
Median	1,18 [0,72-3,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,7 [34,3-52,7]
Month 6	40,2 [30,5-49,7]
Month 12	32,2 [17,1-48,2]
Month 18	32,2 [17,1-48,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	12 (80,0)
95%-CI	[51,9-95,7]
TEAE in months [95%-CI]	
Median	1,45 [0,26-5,39]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	28,1 [7,9-53,1]
Month 6	14,1 [1,1-42,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	48 (36,9)
95%-CI	[28,6-45,8]
TEAE in months [95%-CI]	
Median	NE [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,7 [49,5-68,5]
Month 6	54,4 [43,4-64,2]
Month 12	54,4 [43,4-64,2]
Month 18	54,4 [43,4-64,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	10 (66,7)
95%-CI	[38,4-88,2]
TEAE in months [95%-CI]	
Median	1,64 [0,56-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,0 [20,5-71,2]
Month 6	25,6 [5,0-53,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	42 (32,3)
95%-CI	[24,4-41,1]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,2 [59,1-75,7]
Month 6	66,7 [57,3-74,6]
Month 12	50,0 [28,1-68,6]
Month 18	50,0 [28,1-68,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	6,93[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [35,1-84,0]
Month 6	65,2 [35,1-84,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	38 (29,2)
95%-CI	[21,6-37,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,4 [56,4-74,6]
Month 6	66,4 [56,4-74,6]
Month 12	66,4 [56,4-74,6]
Month 18	66,4 [56,4-74,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [78,0-90,9]
Month 6	82,4 [71,5-89,5]
Month 12	82,4 [71,5-89,5]
Month 18	82,4 [71,5-89,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	5,85 [5,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [51,2-96,0]
Month 6	42,4 [1,2-84,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [87,9-96,8]
Month 6	93,8 [87,9-96,8]
Month 12	85,2 [58,8-95,3]
Month 18	85,2 [58,8-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [48,7-95,9]
Month 6	84,0 [48,7-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	74 (56,9)
95%-CI	[48,0-65,6]
TEAE in months [95%-CI]	
Median	1,64 [1,18-2,83]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,6 [31,1-49,8]
Month 6	32,6 [22,5-43,1]
Month 12	32,6 [22,5-43,1]
Month 18	32,6 [22,5-43,1]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	9 (60,0)
95%-CI	[32,3-83,7]
TEAE in months [95%-CI]	
Median	2,83[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,8 [17,9-67,2]
Month 6	29,2 [6,2-58,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	55 (42,3)
95%-CI	[33,7-51,3]
TEAE in months [95%-CI]	
Median	4,14 [2,76-8,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,7 [47,2-66,9]
Month 6	43,8 [31,8-55,2]
Month 12	32,9 [17,9-48,6]
Month 18	32,9 [17,9-48,6]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	5,16[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,0 [31,9-83,0]
Month 6	47,3 [14,7-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	27 (20,8)
95%-CI	[14,2-28,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,3 [63,6-82,3]
Month 6	67,5 [54,9-77,4]
Month 12	67,5 [54,9-77,4]
Month 18	67,5 [54,9-77,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	74,1 [28,9-93,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	22 (16,9)
95%-CI	[10,9-24,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,4 [70,7-87,1]
Month 6	78,3 [67,9-85,7]
Month 12	71,2 [52,5-83,7]
Month 18	71,2 [52,5-83,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [3, 61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	22 (16,9)
95%-CI	[10,9-24,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [72,3-87,8]
Month 6	76,0 [63,8-84,6]
Month 12	76,0 [63,8-84,6]
Month 18	76,0 [63,8-84,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [85,7-96,7]
Month 6	89,4 [79,9-94,6]
Month 12	89,4 [79,9-94,6]
Month 18	89,4 [79,9-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	71 (54,6)
95%-CI	[45,7-63,4]
TEAE in months [95%-CI]	
Median	1,64 [0,82-11,30]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,1 [33,7-52,1]
Month 6	40,2 [30,0-50,2]
Month 12	32,2 [17,0-48,4]
Month 18	32,2 [17,0-48,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	NE[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,0 [31,8-79,7]
Month 6	60,0 [31,8-79,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	32 (24,6)
95%-CI	[17,5-32,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,6 [63,0-80,1]
Month 6	70,1 [59,4-78,5]
Month 12	70,1 [59,4-78,5]
Month 18	70,1 [59,4-78,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	23 (17,7)
95%-CI	[11,6-25,4]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [70,9-87,3]
Month 6	74,6 [61,7-83,7]
Month 12	64,0 [38,8-81,0]
Month 18	64,0 [38,8-81,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [76,0-90,3]
Month 6	81,6 [70,6-88,8]
Month 12	81,6 [70,6-88,8]
Month 18	81,6 [70,6-88,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [83,2-94,3]
Month 6	86,8 [75,8-93,0]
Month 12	74,5 [51,7-87,7]
Month 18	74,5 [51,7-87,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [48,7-95,9]
Month 6	84,0 [48,7-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [80,8-93,5]
Month 6	78,8 [63,5-88,3]
Month 12	78,8 [63,5-88,3]
Month 18	78,8 [63,5-88,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	69 (53,1)
95%-CI	[44,1-61,9]
TEAE in months [95%-CI]	
Median	3,09 [1,41-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,3 [41,7-60,1]
Month 6	40,4 [29,6-50,9]
Month 12	25,0 [12,4-39,8]
Month 18	25,0 [12,4-39,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]
TEAE in months [95%-CI]	
Median	2,81[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,0 [22,2-72,7]
Month 6	41,7 [16,1-65,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	21 (16,2)
95%-CI	[10,3-23,6]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [74,3-88,7]
Month 6	82,8 [74,3-88,7]
Month 12	72,4 [46,9-87,2]
Month 18	72,4 [46,9-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [45,7-95,6]
Month 6	83,0 [45,7-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	19 (14,6)
95%-CI	[9,0-21,9]
TEAE in months [95%-CI]	
Median	NE [8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [78,1-91,7]
Month 6	76,1 [60,9-86,0]
Month 12	68,5 [46,8-82,8]
Month 18	68,5 [46,8-82,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [3,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	67,9 [28,2-88,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [80,0-92,7]
Month 6	80,9 [69,2-88,5]
Month 12	76,9 [62,3-86,4]
Month 18	76,9 [62,3-86,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE [1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [36,8-87,5]
Month 6	69,3 [36,8-87,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	19 (14,6)
95%-CI	[9,0-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [76,9-90,6]
Month 6	81,3 [71,4-88,1]
Month 12	81,3 [71,4-88,1]
Month 18	81,3 [71,4-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [85,7-95,6]
Month 6	92,0 [85,7-95,6]
Month 12	92,0 [85,7-95,6]
Month 18	92,0 [85,7-95,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [51,2-96,0]
Month 6	84,9 [51,2-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [88,7-97,3]
Month 6	92,2 [83,7-96,4]
Month 12	85,6 [65,0-94,6]
Month 18	85,6 [65,0-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	8 (6,2)
95%-CI	[2,7-11,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [85,6-96,4]
Month 6	92,8 [85,6-96,4]
Month 12	92,8 [85,6-96,4]
Month 18	92,8 [85,6-96,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	60 (46,2)
95%-CI	[37,4-55,1]
TEAE in months [95%-CI]	
Median	2,30 [1,45-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,1 [37,9-57,6]
Month 6	31,2 [14,7-49,3]
Month 12	31,2 [14,7-49,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]
TEAE in months [95%-CI]	
Median	2,17[1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,7 [10,8-60,3]
Month 6	34,7 [10,8-60,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [79,0-92,8]
Month 6	84,6 [73,6-91,3]
Month 12	84,6 [73,6-91,3]
Month 18	42,3 [1,3-84,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE [1,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [35,0-86,7]
Month 6	67,9 [35,0-86,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [76,9-90,8]
Month 6	83,0 [73,2-89,4]
Month 12	72,6 [46,5-87,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [78,0-91,9]
Month 6	86,5 [78,0-91,9]
Month 12	78,6 [57,2-90,2]
Month 18	78,6 [57,2-90,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [81,4-94,1]
Month 6	82,8 [69,1-90,8]
Month 12	82,8 [69,1-90,8]
Month 18	82,8 [69,1-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [46,1-95,3]
Month 6	82,5 [46,1-95,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	53 (40,8)
95%-CI	[32,2-49,7]
TEAE in months [95%-CI]	
Median	4,44 [3,09-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,1 [51,7-70,8]
Month 6	42,9 [30,3-55,0]
Month 12	35,2 [21,5-49,3]
Month 18	35,2 [21,5-49,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]
TEAE in months [95%-CI]	
Median	1,41 [0,69-7,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,6 [19,4-71,5]
Month 6	47,6 [19,4-71,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	28 (21,5)
95%-CI	[14,8-29,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [65,5-83,0]
Month 6	70,5 [58,5-79,6]
Month 12	70,5 [58,5-79,6]
Month 18	70,5 [58,5-79,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	7,62 [1,41-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [45,5-92,5]
Month 6	78,0 [45,5-92,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [82,1-94,1]
Month 6	81,8 [68,8-89,8]
Month 12	81,8 [68,8-89,8]
Month 18	81,8 [68,8-89,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	7,62 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	14 (10,8)
95%-CI	[6,0-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [82,3-94,8]
Month 6	81,7 [67,8-90,0]
Month 12	75,4 [55,8-87,2]
Month 18	75,4 [55,8-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	7,26 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	43 (33,1)
95%-CI	[25,1-41,9]
TEAE in months [95%-CI]	
Median	6,47 [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,8 [50,7-71,1]
Month 6	52,8 [39,1-64,8]
Month 12	48,0 [32,7-61,8]
Month 18	48,0 [32,7-61,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE in months [95%-CI]	
Median	NE[0,99-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,0 [41,2-88,6]
Month 6	60,0 [26,7-82,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	42 (32,3)
95%-CI	[24,4-41,1]
TEAE in months [95%-CI]	
Median	7,10[4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,2 [55,6-74,9]
Month 6	50,1 [35,0-63,5]
Month 12	43,9 [26,7-59,8]
Month 18	43,9 [26,7-59,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE [2,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [36,8-87,5]
Month 6	69,3 [36,8-87,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	37 (28,5)
95%-CI	[20,9-37,0]
TEAE in months [95%-CI]	
Median	9,23[5,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [68,3-83,6]
Month 6	57,4 [41,7-70,3]
Month 12	38,2 [16,0-60,4]
Month 18	38,2 [16,0-60,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [50,0-93,1]
Month 6	64,0 [25,0-86,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [83,9-94,5]
Month 6	87,4 [77,1-93,3]
Month 12	87,4 [77,1-93,3]
Month 18	87,4 [77,1-93,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	74,7 [24,6-94,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	25 (19,2)
95%-CI	[12,8-27,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,4 [70,6-85,8]
Month 6	77,0 [67,0-84,4]
Month 12	77,0 [67,0-84,4]
Month 18	77,0 [67,0-84,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [3,32-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	77,0 [43,2-92,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	7 (5,4)
95%-CI	[2,2-10,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [88,1-97,2]
Month 6	94,1 [88,1-97,2]
Month 12	94,1 [88,1-97,2]
Month 18	94,1 [88,1-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [3,32-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [51,2-96,0]
Month 6	75,4 [40,8-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	25 (19,2)
95%-CI	[12,8-27,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [68,6-84,6]
Month 6	77,8 [68,6-84,6]
Month 12	77,8 [68,6-84,6]
Month 18	77,8 [68,6-84,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [45,5-92,5]
Month 6	78,0 [45,5-92,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	14 (10,8)
95%-CI	[6,0-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [78,2-92,1]
Month 6	86,7 [78,2-92,1]
Month 12	86,7 [78,2-92,1]
Month 18	86,7 [78,2-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [48,7-95,9]
Month 6	84,0 [48,7-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	20 (15,4)
95%-CI	[9,7-22,8]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [76,1-92,1]
Month 6	72,6 [58,2-82,7]
Month 12	54,4 [28,9-74,2]
Month 18	54,4 [28,9-74,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [81,4-93,4]
Month 6	85,3 [73,7-92,0]
Month 12	80,0 [62,9-89,8]
Month 18	80,0 [62,9-89,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE [2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [42,7-91,8]
Month 6	66,8 [33,2-86,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [85,8-96,0]
Month 6	92,4 [85,8-96,0]
Month 12	92,4 [85,8-96,0]
Month 18	92,4 [85,8-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [48,2-95,6]
Month 6	83,3 [48,2-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	16 (12,3)
95%-CI	[7,2-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [81,1-93,0]
Month 6	88,4 [81,1-93,0]
Month 12	74,6 [50,8-88,1]
Month 18	74,6 [50,8-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	9,17 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [79,7-93,4]
Month 6	86,0 [76,0-92,1]
Month 12	86,0 [76,0-92,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [2,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	11 (8,5)
95%-CI	[4,3-14,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [82,0-94,4]
Month 6	89,8 [82,0-94,4]
Month 12	89,8 [82,0-94,4]
Month 18	89,8 [82,0-94,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS03: Time to first TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

4.10.4 Merkmal: Region-1

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	46 (78,0)
95%-CI	[65,3-87,7]
TEAE in months [95%-CI]	
Median	0,76 [0,43-1,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	20,6 [10,1-33,7]
Month 6	8,6 [1,8-22,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	18 (58,1)
95%-CI	[39,1-75,5]
TEAE in months [95%-CI]	
Median	3,29[0,49-6,01]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,1 [29,4-67,7]
Month 6	28,2 [9,3-51,0]
Month 12	14,1 [1,2-42,1]
Month 18	14,1 [1,2-42,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	30 (56,6)
95%-CI	[42,3-70,2]
TEAE in months [95%-CI]	
Median	1,77 [0,89-7,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,7 [30,6-57,9]
Month 6	39,1 [23,5-54,5]
Month 12	31,3 [14,3-50,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	22 (37,3)
95%-CI	[25,0-50,9]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,3 [44,7-71,2]
Month 6	59,3 [44,7-71,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	11 (35,5)
95%-CI	[19,2-54,6]
TEAE in months [95%-CI]	
Median	NE [2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,1 [40,3-79,2]
Month 6	50,5 [22,2-73,3]
Month 12	50,5 [22,2-73,3]
Month 18	50,5 [22,2-73,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [74,1-95,3]
Month 6	88,6 [74,1-95,3]
Month 12	88,6 [74,1-95,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
TEAE in months [95%-CI]	
Median	9,10 [3,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [61,7-87,1]
Month 6	51,9 [27,5-71,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	5 (16,1)
95%-CI	[5,5-33,7]
TEAE in months [95%-CI]	
Median	NE[6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [64,7-96,1]
Month 6	79,6 [51,4-92,5]
Month 12	59,7 [18,2-85,6]
Month 18	59,7 [18,2-85,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	8 (15,1)
95%-CI	[6,7-27,6]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [73,2-95,1]
Month 6	77,5 [54,4-89,9]
Month 12	64,6 [31,8-84,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [70,0-91,7]
Month 6	83,9 [70,0-91,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]
TEAE in months [95%-CI]	
Median	NE [3,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [62,7-92,4]
Month 6	75,0 [50,0-88,7]
Month 12	75,0 [50,0-88,7]
Month 18	75,0 [50,0-88,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	13 (24,5)
95%-CI	[13,8-38,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,1 [60,0-85,2]
Month 6	70,7 [53,5-82,5]
Month 12	70,7 [53,5-82,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,3 [88,6-99,8]
Month 6	93,6 [73,6-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	12 (22,6)
95%-CI	[12,3-36,2]
TEAE in months [95%-CI]	
Median	NE [3,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [58,8-86,0]
Month 6	69,6 [49,7-82,8]
Month 12	69,6 [49,7-82,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	34 (57,6)
95%-CI	[44,1-70,4]
TEAE in months [95%-CI]	
Median	1,41 [0,62-6,93]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,6 [27,3-55,3]
Month 6	33,3 [16,1-51,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]
TEAE in months [95%-CI]	
Median	NE [3,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,5 [54,9-91,6]
Month 6	72,3 [45,3-87,5]
Month 12	72,3 [45,3-87,5]
Month 18	72,3 [45,3-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	43 (81,1)
95%-CI	[68,0-90,6]
TEAE in months [95%-CI]	
Median	0,49 [0,49-0,72]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	18,4 [9,0-30,5]
Month 6	15,8 [7,1-27,7]
Month 12	15,8 [7,1-27,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	21 (35,6)
95%-CI	[23,6-49,1]
TEAE in months [95%-CI]	
Median	5,39[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [48,1-76,3]
Month 6	46,0 [24,2-65,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [64,2-94,3]
Month 6	85,1 [64,2-94,3]
Month 12	85,1 [64,2-94,3]
Month 18	85,1 [64,2-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	33 (62,3)
95%-CI	[47,9-75,2]
TEAE in months [95%-CI]	
Median	1,41 [0,72-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,9 [24,1-51,6]
Month 6	30,9 [17,3-45,5]
Month 12	30,9 [17,3-45,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	18 (30,5)
95%-CI	[19,2-43,9]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,3 [56,0-80,8]
Month 6	70,3 [56,0-80,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [76,6-98,4]
Month 6	93,6 [76,6-98,4]
Month 12	93,6 [76,6-98,4]
Month 18	93,6 [76,6-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	28 (52,8)
95%-CI	[38,6-66,7]
TEAE in months [95%-CI]	
Median	1,25[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,4 [35,0-62,2]
Month 6	46,6 [32,2-59,8]
Month 12	31,1 [8,8-57,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [55,4-81,7]
Month 6	70,8 [55,4-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [66,5-96,1]
Month 6	88,0 [66,5-96,1]
Month 12	88,0 [66,5-96,1]
Month 18	88,0 [66,5-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	20 (37,7)
95%-CI	[24,8-52,1]
TEAE in months [95%-CI]	
Median	NE [1,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,4 [44,2-71,8]
Month 6	59,4 [44,2-71,8]
Month 12	59,4 [44,2-71,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	14 (23,7)
95%-CI	[13,6-36,6]
TEAE in months [95%-CI]	
Median	NE [5,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,2 [59,3-84,4]
Month 6	63,6 [37,9-81,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	7 (13,2)
95%-CI	[5,5-25,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [75,4-94,5]
Month 6	80,7 [58,2-91,9]
Month 12	80,7 [58,2-91,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [72,0-91,5]
Month 6	84,3 [72,0-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	92,3 [56,6-98,9]
Month 18	92,3 [56,6-98,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	29 (49,2)
95%-CI	[35,9-62,5]
TEAE in months [95%-CI]	
Median	2,10[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,4 [29,7-58,0]
Month 6	44,4 [29,7-58,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	10 (32,3)
95%-CI	[16,7-51,4]
TEAE in months [95%-CI]	
Median	19,38 [3,78-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [55,7-87,8]
Month 6	58,5 [30,9-78,4]
Month 12	58,5 [30,9-78,4]
Month 18	58,5 [30,9-78,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	43 (81,1)
95%-CI	[68,0-90,6]
TEAE in months [95%-CI]	
Median	0,95 [0,49-1,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	19,7 [9,7-32,2]
Month 6	9,0 [2,1-22,1]
Month 12	9,0 [2,1-22,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [52,9-81,0]
Month 6	65,0 [47,2-78,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	9 (29,0)
95%-CI	[14,2-48,0]
TEAE in months [95%-CI]	
Median	19,38 [3,78-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,5 [58,1-89,8]
Month 6	60,6 [31,7-80,4]
Month 12	60,6 [31,7-80,4]
Month 18	60,6 [31,7-80,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	35 (66,0)
95%-CI	[51,7-78,5]
TEAE in months [95%-CI]	
Median	2,10 [1,38-3,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [24,3-52,6]
Month 6	20,1 [8,3-35,5]
Month 12	10,0 [1,1-31,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [69,4-93,3]
Month 6	76,8 [51,3-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	96,8 [79,2-99,5]
Month 12	96,8 [79,2-99,5]
Month 18	96,8 [79,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	21 (39,6)
95%-CI	[26,5-54,0]
TEAE in months [95%-CI]	
Median	4,14 [2,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,5 [43,6-73,7]
Month 6	44,4 [26,6-60,8]
Month 12	44,4 [26,6-60,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [76,8-96,7]
Month 6	86,5 [68,4-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [73,7-98,2]
Month 6	92,7 [73,7-98,2]
Month 12	92,7 [73,7-98,2]
Month 18	92,7 [73,7-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	16 (30,2)
95%-CI	[18,3-44,3]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [52,8-80,6]
Month 6	64,7 [47,1-77,7]
Month 12	51,8 [24,6-73,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [80,2-97,0]
Month 6	79,3 [53,6-91,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [73,7-98,2]
Month 6	92,7 [73,7-98,2]
Month 12	92,7 [73,7-98,2]
Month 18	92,7 [73,7-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	15 (28,3)
95%-CI	[16,8-42,3]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [54,1-81,3]
Month 6	65,6 [48,2-78,4]
Month 12	65,6 [48,2-78,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [79,9-97,8]
Month 6	93,2 [79,9-97,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	96,8 [79,2-99,5]
Month 12	96,8 [79,2-99,5]
Month 18	96,8 [79,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	6 (11,3)
95%-CI	[4,3-23,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [77,6-96,6]
Month 6	83,4 [65,7-92,5]
Month 12	83,4 [65,7-92,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	34 (57,6)
95%-CI	[44,1-70,4]
TEAE in months [95%-CI]	
Median	1,02[0,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,5 [22,9-50,2]
Month 6	36,5 [22,9-50,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	17 (54,8)
95%-CI	[36,0-72,7]
TEAE in months [95%-CI]	
Median	1,64 [0,36-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,9 [23,6-59,2]
Month 6	41,9 [23,6-59,2]
Month 12	41,9 [23,6-59,2]
Month 18	41,9 [23,6-59,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	24 (45,3)
95%-CI	[31,6-59,6]
TEAE in months [95%-CI]	
Median	4,63 [1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,0 [42,3-69,4]
Month 6	49,9 [31,4-65,9]
Month 12	37,4 [14,4-60,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [55,7-81,6]
Month 6	70,8 [55,7-81,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	8 (25,8)
95%-CI	[11,9-44,6]
TEAE in months [95%-CI]	
Median	NE [2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [45,5-84,0]
Month 6	69,0 [45,5-84,0]
Month 12	69,0 [45,5-84,0]
Month 18	69,0 [45,5-84,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	10 (18,9)
95%-CI	[9,4-32,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,1 [66,7-89,8]
Month 6	74,9 [55,1-86,9]
Month 12	74,9 [55,1-86,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [55,2-83,0]
Month 6	71,7 [55,2-83,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]
TEAE in months [95%-CI]	
Median	NE [5,32-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [62,1-92,3]
Month 6	68,6 [33,8-87,7]
Month 12	68,6 [33,8-87,7]
Month 18	68,6 [33,8-87,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [78,4-97,6]
Month 6	86,0 [62,7-95,2]
Month 12	68,8 [26,9-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [78,5-96,0]
Month 6	90,5 [78,5-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [64,7-94,3]
Month 6	85,2 [64,7-94,3]
Month 12	85,2 [64,7-94,3]
Month 18	85,2 [64,7-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	8 (15,1)
95%-CI	[6,7-27,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [68,8-92,3]
Month 6	77,1 [55,0-89,3]
Month 12	77,1 [55,0-89,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [78,0-95,1]
Month 6	89,5 [78,0-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
TEAE in months [95%-CI]	
Median	NE [6,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [68,5-97,9]
Month 6	91,4 [68,5-97,9]
Month 12	73,1 [26,0-93,0]
Month 18	73,1 [26,0-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	7 (13,2)
95%-CI	[5,5-25,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [72,7-94,2]
Month 6	80,8 [60,1-91,5]
Month 12	80,8 [60,1-91,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE[4,96-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [70,3-92,7]
Month 6	69,6 [42,0-86,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
TEAE in months [95%-CI]	
Median	NE [5,42-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [76,2-98,3]
Month 6	80,1 [39,7-94,8]
Month 12	80,1 [39,7-94,8]
Month 18	80,1 [39,7-94,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [80,6-97,8]
Month 6	93,4 [80,6-97,8]
Month 12	93,4 [80,6-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	33 (55,9)
95%-CI	[42,4-68,8]
TEAE in months [95%-CI]	
Median	2,14 [0,72-4,86]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,3 [27,6-56,3]
Month 6	32,0 [16,2-49,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	10 (32,3)
95%-CI	[16,7-51,4]
TEAE in months [95%-CI]	
Median	NE [3,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [57,1-88,2]
Month 6	62,7 [37,9-80,0]
Month 12	50,2 [21,4-73,5]
Month 18	50,2 [21,4-73,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	32 (60,4)
95%-CI	[46,0-73,5]
TEAE in months [95%-CI]	
Median	1,38 [0,53-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,6 [31,6-58,6]
Month 6	38,6 [24,0-53,0]
Month 12	24,8 [9,2-44,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [66,6-90,2]
Month 6	81,5 [66,6-90,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	14 (26,4)
95%-CI	[15,3-40,3]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [58,0-83,8]
Month 6	73,3 [58,0-83,8]
Month 12	58,7 [27,5-80,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	8,51[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,4 [64,9-89,6]
Month 6	58,5 [32,9-77,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [76,6-98,4]
Month 6	93,6 [76,6-98,4]
Month 12	93,6 [76,6-98,4]
Month 18	93,6 [76,6-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	6 (11,3)
95%-CI	[4,3-23,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [78,6-96,7]
Month 6	79,4 [55,0-91,5]
Month 12	79,4 [55,0-91,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,1 [65,5-89,0]
Month 6	74,8 [56,4-86,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE in months [95%-CI]	
Median	NE[6,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [75,9-98,3]
Month 6	84,9 [55,5-95,5]
Month 12	67,9 [25,7-89,5]
Month 18	67,9 [25,7-89,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [77,7-95,8]
Month 6	90,1 [77,7-95,8]
Month 12	90,1 [77,7-95,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [76,2-96,5]
Month 6	86,1 [68,0-94,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,7 [78,6-99,5]
Month 6	96,7 [78,6-99,5]
Month 12	96,7 [78,6-99,5]
Month 18	96,7 [78,6-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	13 (24,5)
95%-CI	[13,8-38,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [62,2-85,9]
Month 6	73,0 [57,4-83,6]
Month 12	73,0 [57,4-83,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [85,4-99,0]
Month 6	96,2 [85,4-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	96,8 [79,2-99,5]
Month 12	96,8 [79,2-99,5]
Month 18	96,8 [79,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	9 (17,0)
95%-CI	[8,1-29,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,7 [69,3-90,6]
Month 6	82,7 [69,3-90,6]
Month 12	82,7 [69,3-90,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [71,9-91,5]
Month 6	84,3 [71,9-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	91,7 [53,9-98,8]
Month 12	91,7 [53,9-98,8]
Month 18	91,7 [53,9-98,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	1 (1,9)
95%-CI	[0,0-10,1]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	85,7 [33,4-97,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [76,7-96,7]
Month 6	91,0 [76,7-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	96,8 [79,2-99,5]
Month 12	96,8 [79,2-99,5]
Month 18	96,8 [79,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,4 [78,4-95,9]
Month 6	90,4 [78,4-95,9]
Month 12	90,4 [78,4-95,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
TEAE in months [95%-CI]	
Median	2,79[1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,8 [29,2-60,9]
Month 6	33,9 [16,4-52,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	16 (51,6)
95%-CI	[33,1-69,8]
TEAE in months [95%-CI]	
Median	1,38 [0,95-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,2 [23,4-61,6]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	25 (47,2)
95%-CI	[33,3-61,4]
TEAE in months [95%-CI]	
Median	2,30 [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,2 [30,7-60,3]
Month 6	46,2 [30,7-60,3]
Month 12	46,2 [30,7-60,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [66,1-90,9]
Month 6	76,5 [57,0-88,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	5 (16,1)
95%-CI	[5,5-33,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,3 [55,3-91,3]
Month 6	79,3 [55,3-91,3]
Month 12	79,3 [55,3-91,3]
Month 18	79,3 [55,3-91,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [78,4-96,8]
Month 6	91,4 [78,4-96,8]
Month 12	91,4 [78,4-96,8]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [73,1-93,3]
Month 6	86,3 [73,1-93,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE in months [95%-CI]	
Median	8,84 [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [68,6-96,2]
Month 6	88,6 [68,6-96,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	8 (15,1)
95%-CI	[6,7-27,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [69,4-92,2]
Month 6	78,6 [59,2-89,5]
Month 12	78,6 [59,2-89,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [82,0-98,8]
Month 6	95,2 [82,0-98,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [75,9-98,3]
Month 6	93,3 [75,9-98,3]
Month 12	93,3 [75,9-98,3]
Month 18	93,3 [75,9-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	11 (20,8)
95%-CI	[10,8-34,1]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [62,5-87,7]
Month 6	77,9 [62,5-87,7]
Month 12	58,5 [20,1-83,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [77,9-98,6]
Month 6	94,3 [77,9-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	8 (25,8)
95%-CI	[11,9-44,6]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [55,8-89,2]
Month 6	51,5 [19,2-76,5]
Month 12	51,5 [19,2-76,5]
Month 18	51,5 [19,2-76,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [73,8-95,0]
Month 6	88,3 [73,8-95,0]
Month 12	88,3 [73,8-95,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	33 (55,9)
95%-CI	[42,4-68,8]
TEAE in months [95%-CI]	
Median	2,66 [1,41-4,34]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [29,3-58,4]
Month 6	24,8 [10,0-43,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	11 (35,5)
95%-CI	[19,2-54,6]
TEAE in months [95%-CI]	
Median	6,01[2,27-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,2 [49,0-86,2]
Month 6	57,8 [32,0-76,8]
Month 12	21,7 [1,5-57,4]
Month 18	21,7 [1,5-57,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	16 (30,2)
95%-CI	[18,3-44,3]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,2 [58,0-83,7]
Month 6	56,3 [35,1-73,0]
Month 12	56,3 [35,1-73,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	19 (32,2)
95%-CI	[20,6-45,6]
TEAE in months [95%-CI]	
Median	7,62 [2,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,8 [45,3-74,6]
Month 6	61,8 [45,3-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE in months [95%-CI]	
Median	NE[4,57-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [64,9-96,1]
Month 6	76,7 [43,2-92,0]
Month 12	76,7 [43,2-92,0]
Month 18	76,7 [43,2-92,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	8 (15,1)
95%-CI	[6,7-27,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [73,3-93,2]
Month 6	80,1 [60,4-90,7]
Month 12	80,1 [60,4-90,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	NE [4,90-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [68,1-90,7]
Month 6	66,9 [44,6-81,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [76,6-98,4]
Month 6	93,6 [76,6-98,4]
Month 12	93,6 [76,6-98,4]
Month 18	93,6 [76,6-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	2 (3,8)
95%-CI	[0,5-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,9 [84,6-99,0]
Month 6	95,9 [84,6-99,0]
Month 12	95,9 [84,6-99,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [74,3-93,6]
Month 6	81,1 [62,2-91,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	7,69 [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	93,8 [63,2-99,1]
Month 12	46,9 [0,9-88,6]
Month 18	46,9 [0,9-88,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [76,9-97,5]
Month 6	78,0 [50,6-91,4]
Month 12	78,0 [50,6-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	20 (33,9)
95%-CI	[22,1-47,4]
TEAE in months [95%-CI]	
Median	6,47 [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,7 [43,7-74,0]
Month 6	52,0 [30,3-69,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	16 (51,6)
95%-CI	[33,1-69,8]
TEAE in months [95%-CI]	
Median	1,84[0,99-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,4 [19,9-60,2]
Month 6	32,4 [12,7-54,0]
Month 12	32,4 [12,7-54,0]
Month 18	32,4 [12,7-54,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	11 (20,8)
95%-CI	[10,8-34,1]
TEAE in months [95%-CI]	
Median	NE[4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [59,3-87,0]
Month 6	69,4 [47,7-83,6]
Month 12	69,4 [47,7-83,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	26 (44,1)
95%-CI	[31,2-57,6]
TEAE in months [95%-CI]	
Median	2,76 [2,04-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,6 [29,5-60,4]
Month 6	40,6 [23,9-56,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [75,8-98,3]
Month 6	93,3 [75,8-98,3]
Month 12	93,3 [75,8-98,3]
Month 18	93,3 [75,8-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	17 (32,1)
95%-CI	[19,9-46,3]
TEAE in months [95%-CI]	
Median	5,82 [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,5 [58,7-84,9]
Month 6	45,7 [21,9-66,7]
Month 12	36,6 [13,9-59,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	22 (37,3)
95%-CI	[25,0-50,9]
TEAE in months [95%-CI]	
Median	9,23[3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [53,8-78,5]
Month 6	53,6 [34,6-69,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	7 (22,6)
95%-CI	[9,6-41,1]
TEAE in months [95%-CI]	
Median	NE [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [61,9-90,8]
Month 6	73,3 [49,5-87,2]
Month 12	73,3 [49,5-87,2]
Month 18	73,3 [49,5-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	12 (22,6)
95%-CI	[12,3-36,2]
TEAE in months [95%-CI]	
Median	10,97[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [71,7-92,8]
Month 6	57,3 [31,2-76,7]
Month 12	43,0 [14,5-69,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [71,4-91,4]
Month 6	78,0 [59,3-88,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [76,6-98,4]
Month 6	93,6 [76,6-98,4]
Month 12	93,6 [76,6-98,4]
Month 18	93,6 [76,6-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [85,7-99,0]
Month 6	89,4 [64,1-97,2]
Month 12	89,4 [64,1-97,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,9 [57,2-82,3]
Month 6	67,9 [51,7-79,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	7 (22,6)
95%-CI	[9,6-41,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,6 [52,2-86,6]
Month 6	73,6 [52,2-86,6]
Month 12	73,6 [52,2-86,6]
Month 18	73,6 [52,2-86,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [80,0-96,9]
Month 6	85,8 [65,0-94,7]
Month 12	85,8 [65,0-94,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [76,3-94,8]
Month 6	84,6 [69,0-92,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [82,4-98,0]
Month 6	94,0 [82,4-98,0]
Month 12	94,0 [82,4-98,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	18 (30,5)
95%-CI	[19,2-43,9]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,9 [49,4-76,7]
Month 6	64,9 [49,4-76,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	5 (16,1)
95%-CI	[5,5-33,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [52,7-90,4]
Month 6	77,6 [52,7-90,4]
Month 12	77,6 [52,7-90,4]
Month 18	77,6 [52,7-90,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	4 (7,5)
95%-CI	[2,1-18,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [80,3-97,0]
Month 6	92,1 [80,3-97,0]
Month 12	92,1 [80,3-97,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,1 [60,1-86,4]
Month 6	76,1 [60,1-86,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	93,8 [63,2-99,1]
Month 12	93,8 [63,2-99,1]
Month 18	93,8 [63,2-99,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [82,8-98,1]
Month 6	94,1 [82,8-98,1]
Month 12	94,1 [82,8-98,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE[8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [70,8-93,8]
Month 6	77,1 [57,1-88,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE in months [95%-CI]	
Median	NE [2,99-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [46,1-90,3]
Month 6	75,5 [46,1-90,3]
Month 12	75,5 [46,1-90,3]
Month 18	75,5 [46,1-90,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	7 (13,2)
95%-CI	[5,5-25,3]
TEAE in months [95%-CI]	
Median	NE[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [82,1-98,8]
Month 6	74,4 [47,8-88,9]
Month 12	55,8 [18,1-82,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [70,8-92,0]
Month 6	80,0 [63,3-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [64,9-96,1]
Month 6	87,7 [64,9-96,1]
Month 12	87,7 [64,9-96,1]
Month 18	87,7 [64,9-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	7 (13,2)
95%-CI	[5,5-25,3]
TEAE in months [95%-CI]	
Median	NE[6,67-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [77,3-95,7]
Month 6	82,4 [58,9-93,2]
Month 12	72,1 [41,2-88,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [75,9-95,5]
Month 6	89,3 [75,9-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [76,6-98,4]
Month 6	93,6 [76,6-98,4]
Month 12	93,6 [76,6-98,4]
Month 18	93,6 [76,6-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	4 (7,5)
95%-CI	[2,1-18,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [79,6-96,9]
Month 6	91,8 [79,6-96,9]
Month 12	91,8 [79,6-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	12 (20,3)
95%-CI	[11,0-32,8]
TEAE in months [95%-CI]	
Median	NE [7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [69,1-90,0]
Month 6	82,1 [69,1-90,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [70,6-97,9]
Month 6	91,7 [70,6-97,9]
Month 12	91,7 [70,6-97,9]
Month 18	91,7 [70,6-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE in months [95%-CI]	
Median	NE[8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,0 [85,1-99,0]
Month 6	96,0 [85,1-99,0]
Month 12	76,8 [24,4-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [65,5-90,9]
Month 6	77,5 [59,3-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [57,8-97,4]
Month 6	88,7 [57,8-97,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,9 [82,1-98,0]
Month 6	93,9 [82,1-98,0]
Month 12	93,9 [82,1-98,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [81,2-97,9]
Month 6	93,6 [81,2-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	7 (22,6)
95%-CI	[9,6-41,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [55,0-87,6]
Month 6	75,5 [55,0-87,6]
Month 12	75,5 [55,0-87,6]
Month 18	75,5 [55,0-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS04: Time to first TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	1 (1,9)
95%-CI	[0,0-10,1]
TEAE in months [95%-CI]	
Median	NE[NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [77,2-99,5]
Month 6	96,4 [77,2-99,5]
Month 12	96,4 [77,2-99,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

4.10.5 *Merkmal: Region-2*

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	46 (78,0)
95%-CI	[65,3-87,7]
TEAE in months [95%-CI]	
Median	0,76 [0,43-1,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	20,6 [10,1-33,7]
Month 6	8,6 [1,8-22,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	50 (58,1)
95%-CI	[47,0-68,7]
TEAE in months [95%-CI]	
Median	1,77 [0,95-4,37]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,6 [33,0-55,6]
Month 6	32,7 [20,1-46,0]
Month 12	23,9 [11,3-39,0]
Month 18	23,9 [11,3-39,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	22 (37,3)
95%-CI	[25,0-50,9]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,3 [44,7-71,2]
Month 6	59,3 [44,7-71,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	18 (20,9)
95%-CI	[12,9-31,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [65,0-85,3]
Month 6	72,7 [57,9-83,1]
Month 12	72,7 [57,9-83,1]
Month 18	72,7 [57,9-83,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
TEAE in months [95%-CI]	
Median	9,10 [3,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [61,7-87,1]
Month 6	51,9 [27,5-71,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	13 (15,1)
95%-CI	[8,3-24,5]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [77,1-94,1]
Month 6	78,3 [61,4-88,4]
Month 12	61,5 [34,1-80,3]
Month 18	61,5 [34,1-80,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [70,0-91,7]
Month 6	83,9 [70,0-91,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	20 (23,3)
95%-CI	[14,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [66,8-85,9]
Month 6	70,2 [56,5-80,4]
Month 12	70,2 [56,5-80,4]
Month 18	70,2 [56,5-80,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,3 [88,6-99,8]
Month 6	93,6 [73,6-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	12 (14,0)
95%-CI	[7,4-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [72,8-91,4]
Month 6	81,2 [67,6-89,5]
Month 12	81,2 [67,6-89,5]
Month 18	81,2 [67,6-89,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	34 (57,6)
95%-CI	[44,1-70,4]
TEAE in months [95%-CI]	
Median	1,41 [0,62-6,93]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,6 [27,3-55,3]
Month 6	33,3 [16,1-51,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	49 (57,0)
95%-CI	[45,8-67,6]
TEAE in months [95%-CI]	
Median	1,18 [0,69-3,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,8 [30,5-52,8]
Month 6	37,3 [25,8-48,8]
Month 12	37,3 [25,8-48,8]
Month 18	37,3 [25,8-48,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	21 (35,6)
95%-CI	[23,6-49,1]
TEAE in months [95%-CI]	
Median	5,39[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [48,1-76,3]
Month 6	46,0 [24,2-65,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	37 (43,0)
95%-CI	[32,4-54,2]
TEAE in months [95%-CI]	
Median	NE [1,64-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,4 [43,2-66,0]
Month 6	50,8 [38,0-62,1]
Month 12	50,8 [38,0-62,1]
Month 18	50,8 [38,0-62,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	18 (30,5)
95%-CI	[19,2-43,9]
TEAE in months [95%-CI]	
Median	9,23[6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,3 [56,0-80,8]
Month 6	70,3 [56,0-80,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	30 (34,9)
95%-CI	[24,9-45,9]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [54,9-75,4]
Month 6	64,2 [52,5-73,8]
Month 12	51,4 [26,0-71,9]
Month 18	51,4 [26,0-71,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [55,4-81,7]
Month 6	70,8 [55,4-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	23 (26,7)
95%-CI	[17,8-37,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [57,9-79,0]
Month 6	69,8 [57,9-79,0]
Month 12	69,8 [57,9-79,0]
Month 18	69,8 [57,9-79,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	14 (23,7)
95%-CI	[13,6-36,6]
TEAE in months [95%-CI]	
Median	NE [5,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,2 [59,3-84,4]
Month 6	63,6 [37,9-81,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	7 (8,1)
95%-CI	[3,3-16,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [84,2-96,6]
Month 6	88,0 [72,5-95,0]
Month 12	88,0 [72,5-95,0]
Month 18	88,0 [72,5-95,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [72,0-91,5]
Month 6	84,3 [72,0-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	1 (1,2)
95%-CI	[0,0-6,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,6 [84,3-99,7]
Month 6	97,6 [84,3-99,7]
Month 12	97,6 [84,3-99,7]
Month 18	97,6 [84,3-99,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	29 (49,2)
95%-CI	[35,9-62,5]
TEAE in months [95%-CI]	
Median	2,10[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,4 [29,7-58,0]
Month 6	44,4 [29,7-58,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	54 (62,8)
95%-CI	[51,7-73,0]
TEAE in months [95%-CI]	
Median	1,48 [0,95-2,83]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [27,1-49,6]
Month 6	25,6 [14,5-38,3]
Month 12	25,6 [14,5-38,3]
Month 18	25,6 [14,5-38,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [52,9-81,0]
Month 6	65,0 [47,2-78,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	45 (52,3)
95%-CI	[41,3-63,2]
TEAE in months [95%-CI]	
Median	3,48 [2,10-4,99]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,1 [38,6-62,4]
Month 6	32,7 [19,9-46,2]
Month 12	24,6 [9,9-42,6]
Month 18	24,6 [9,9-42,6]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [69,4-93,3]
Month 6	76,8 [51,3-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	22 (25,6)
95%-CI	[16,8-36,1]
TEAE in months [95%-CI]	
Median	NE[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,5 [59,4-82,0]
Month 6	61,2 [45,7-73,6]
Month 12	61,2 [45,7-73,6]
Month 18	61,2 [45,7-73,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [76,8-96,7]
Month 6	86,5 [68,4-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	18 (20,9)
95%-CI	[12,9-31,0]
TEAE in months [95%-CI]	
Median	NE [7,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [65,0-85,6]
Month 6	74,5 [61,4-83,8]
Month 12	63,9 [38,6-81,0]
Month 18	63,9 [38,6-81,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [80,2-97,0]
Month 6	79,3 [53,6-91,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	17 (19,8)
95%-CI	[12,0-29,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [66,3-86,2]
Month 6	75,4 [62,6-84,4]
Month 12	75,4 [62,6-84,4]
Month 18	75,4 [62,6-84,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [79,9-97,8]
Month 6	93,2 [79,9-97,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	7 (8,1)
95%-CI	[3,3-16,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [83,7-97,1]
Month 6	88,1 [75,8-94,4]
Month 12	88,1 [75,8-94,4]
Month 18	88,1 [75,8-94,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	34 (57,6)
95%-CI	[44,1-70,4]
TEAE in months [95%-CI]	
Median	1,02[0,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,5 [22,9-50,2]
Month 6	36,5 [22,9-50,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	43 (50,0)
95%-CI	[39,0-61,0]
TEAE in months [95%-CI]	
Median	4,63[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,4 [39,1-60,8]
Month 6	46,6 [33,8-58,4]
Month 12	37,2 [19,0-55,6]
Month 18	37,2 [19,0-55,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	15 (25,4)
95%-CI	[15,0-38,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [55,7-81,6]
Month 6	70,8 [55,7-81,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	19 (22,1)
95%-CI	[13,9-32,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,5 [65,1-84,7]
Month 6	72,9 [59,3-82,6]
Month 12	72,9 [59,3-82,6]
Month 18	72,9 [59,3-82,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [55,2-83,0]
Month 6	71,7 [55,2-83,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	12 (14,0)
95%-CI	[7,4-23,1]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [77,3-93,5]
Month 6	79,6 [63,0-89,4]
Month 12	66,3 [34,4-85,4]
Month 18	66,3 [34,4-85,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [78,5-96,0]
Month 6	90,5 [78,5-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	14 (16,3)
95%-CI	[9,2-25,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [71,1-89,6]
Month 6	78,1 [63,2-87,5]
Month 12	78,1 [63,2-87,5]
Month 18	78,1 [63,2-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [78,0-95,1]
Month 6	89,5 [78,0-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	10 (11,6)
95%-CI	[5,7-20,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [78,7-94,5]
Month 6	84,8 [70,0-92,6]
Month 12	78,7 [58,5-89,9]
Month 18	78,7 [58,5-89,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE[4,96-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [70,3-92,7]
Month 6	69,6 [42,0-86,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	8 (9,3)
95%-CI	[4,1-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [81,8-95,7]
Month 6	86,4 [71,2-93,9]
Month 12	86,4 [71,2-93,9]
Month 18	86,4 [71,2-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	33 (55,9)
95%-CI	[42,4-68,8]
TEAE in months [95%-CI]	
Median	2,14 [0,72-4,86]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,3 [27,6-56,3]
Month 6	32,0 [16,2-49,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	44 (51,2)
95%-CI	[40,1-62,1]
TEAE in months [95%-CI]	
Median	3,52[1,38-10,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,5 [45,0-66,5]
Month 6	44,8 [31,9-56,9]
Month 12	30,7 [15,6-47,1]
Month 18	30,7 [15,6-47,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [66,6-90,2]
Month 6	81,5 [66,6-90,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	14 (16,3)
95%-CI	[9,2-25,8]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [72,1-90,0]
Month 6	83,0 [72,1-90,0]
Month 12	71,2 [41,8-87,6]
Month 18	71,2 [41,8-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	8,51[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,4 [64,9-89,6]
Month 6	58,5 [32,9-77,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	9 (10,5)
95%-CI	[4,9-18,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [81,7-95,6]
Month 6	83,1 [66,3-92,0]
Month 12	83,1 [66,3-92,0]
Month 18	83,1 [66,3-92,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,1 [65,5-89,0]
Month 6	74,8 [56,4-86,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	11 (12,8)
95%-CI	[6,6-21,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [81,5-95,0]
Month 6	84,1 [70,5-91,8]
Month 12	78,5 [59,8-89,2]
Month 18	78,5 [59,8-89,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [76,2-96,5]
Month 6	86,1 [68,0-94,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	15 (17,4)
95%-CI	[10,1-27,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,1 [74,2-90,5]
Month 6	79,0 [66,5-87,3]
Month 12	79,0 [66,5-87,3]
Month 18	79,0 [66,5-87,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [85,4-99,0]
Month 6	96,2 [85,4-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	10 (11,6)
95%-CI	[5,7-20,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [79,1-93,4]
Month 6	88,1 [79,1-93,4]
Month 12	88,1 [79,1-93,4]
Month 18	88,1 [79,1-93,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [71,9-91,5]
Month 6	84,3 [71,9-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	2 (2,3)
95%-CI	[0,3-8,1]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	96,9 [79,8-99,6]
Month 12	86,1 [47,7-97,0]
Month 18	86,1 [47,7-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [76,7-96,7]
Month 6	91,0 [76,7-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	6 (7,0)
95%-CI	[2,6-14,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [84,6-96,7]
Month 6	92,8 [84,6-96,7]
Month 12	92,8 [84,6-96,7]
Month 18	92,8 [84,6-96,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	27 (45,8)
95%-CI	[32,7-59,2]
TEAE in months [95%-CI]	
Median	2,79 [1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,8 [29,2-60,9]
Month 6	33,9 [16,4-52,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	41 (47,7)
95%-CI	[36,8-58,7]
TEAE in months [95%-CI]	
Median	2,07 [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,7 [33,4-57,2]
Month 6	30,5 [8,9-55,7]
Month 12	30,5 [8,9-55,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [66,1-90,9]
Month 6	76,5 [57,0-88,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	10 (11,6)
95%-CI	[5,7-20,3]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [77,4-93,5]
Month 6	87,7 [77,4-93,5]
Month 12	87,7 [77,4-93,5]
Month 18	43,9 [1,2-85,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [73,1-93,3]
Month 6	86,3 [73,1-93,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	12 (14,0)
95%-CI	[7,4-23,1]
TEAE in months [95%-CI]	
Median	NE[8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [75,1-92,2]
Month 6	82,7 [69,8-90,5]
Month 12	66,2 [28,9-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [82,0-98,8]
Month 6	95,2 [82,0-98,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	13 (15,1)
95%-CI	[8,3-24,5]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,4 [72,3-90,4]
Month 6	83,4 [72,3-90,4]
Month 12	69,5 [36,3-87,8]
Month 18	69,5 [36,3-87,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [77,9-98,6]
Month 6	94,3 [77,9-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	13 (15,1)
95%-CI	[8,3-24,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [73,4-91,2]
Month 6	75,1 [57,0-86,4]
Month 12	75,1 [57,0-86,4]
Month 18	75,1 [57,0-86,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	33 (55,9)
95%-CI	[42,4-68,8]
TEAE in months [95%-CI]	
Median	2,66 [1,41-4,34]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [29,3-58,4]
Month 6	24,8 [10,0-43,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	28 (32,6)
95%-CI	[22,8-43,5]
TEAE in months [95%-CI]	
Median	7,69[3,94-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,8 [59,5-80,9]
Month 6	55,7 [39,6-69,1]
Month 12	43,4 [24,1-61,3]
Month 18	43,4 [24,1-61,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	19 (32,2)
95%-CI	[20,6-45,6]
TEAE in months [95%-CI]	
Median	7,62 [2,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,8 [45,3-74,6]
Month 6	61,8 [45,3-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	13 (15,1)
95%-CI	[8,3-24,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [74,5-91,7]
Month 6	77,5 [61,5-87,5]
Month 12	77,5 [61,5-87,5]
Month 18	77,5 [61,5-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	13 (22,0)
95%-CI	[12,3-34,7]
TEAE in months [95%-CI]	
Median	NE [4,90-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [68,1-90,7]
Month 6	66,9 [44,6-81,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	4 (4,7)
95%-CI	[1,3-11,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [87,5-98,2]
Month 6	95,1 [87,5-98,2]
Month 12	95,1 [87,5-98,2]
Month 18	95,1 [87,5-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [74,3-93,6]
Month 6	81,1 [62,2-91,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	7 (8,1)
95%-CI	[3,3-16,1]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [82,0-97,4]
Month 6	84,7 [66,5-93,5]
Month 12	74,2 [44,0-89,7]
Month 18	74,2 [44,0-89,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	20 (33,9)
95%-CI	[22,1-47,4]
TEAE in months [95%-CI]	
Median	6,47 [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,7 [43,7-74,0]
Month 6	52,0 [30,3-69,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	28 (32,6)
95%-CI	[22,8-43,5]
TEAE in months [95%-CI]	
Median	NE [3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,0 [51,8-75,4]
Month 6	53,9 [37,7-67,6]
Month 12	53,9 [37,7-67,6]
Month 18	53,9 [37,7-67,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	26 (44,1)
95%-CI	[31,2-57,6]
TEAE in months [95%-CI]	
Median	2,76[2,04-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,6 [29,5-60,4]
Month 6	40,6 [23,9-56,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	20 (23,3)
95%-CI	[14,8-33,6]
TEAE in months [95%-CI]	
Median	NE [5,78-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [68,5-87,7]
Month 6	60,5 [39,8-76,0]
Month 12	50,4 [25,7-70,8]
Month 18	50,4 [25,7-70,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	22 (37,3)
95%-CI	[25,0-50,9]
TEAE in months [95%-CI]	
Median	9,23[3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [53,8-78,5]
Month 6	53,6 [34,6-69,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	19 (22,1)
95%-CI	[13,9-32,3]
TEAE in months [95%-CI]	
Median	10,97 [5,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [73,4-90,3]
Month 6	62,1 [41,9-77,0]
Month 12	49,7 [22,8-71,8]
Month 18	49,7 [22,8-71,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [71,4-91,4]
Month 6	78,0 [59,3-88,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [88,1-98,2]
Month 6	91,0 [75,6-96,9]
Month 12	91,0 [75,6-96,9]
Month 18	91,0 [75,6-96,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	16 (27,1)
95%-CI	[16,4-40,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,9 [57,2-82,3]
Month 6	67,9 [51,7-79,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	12 (14,0)
95%-CI	[7,4-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [75,8-91,9]
Month 6	82,4 [69,6-90,2]
Month 12	82,4 [69,6-90,2]
Month 18	82,4 [69,6-90,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [76,3-94,8]
Month 6	84,6 [69,0-92,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	3 (3,5)
95%-CI	[0,7-9,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [88,7-98,8]
Month 6	96,2 [88,7-98,8]
Month 12	96,2 [88,7-98,8]
Month 18	96,2 [88,7-98,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	18 (30,5)
95%-CI	[19,2-43,9]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,9 [49,4-76,7]
Month 6	64,9 [49,4-76,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	10 (11,6)
95%-CI	[5,7-20,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [76,3-92,7]
Month 6	86,6 [76,3-92,7]
Month 12	86,6 [76,3-92,7]
Month 18	86,6 [76,3-92,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,1 [60,1-86,4]
Month 6	76,1 [60,1-86,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [84,3-97,2]
Month 6	93,3 [84,3-97,2]
Month 12	93,3 [84,3-97,2]
Month 18	93,3 [84,3-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE[8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [70,8-93,8]
Month 6	77,1 [57,1-88,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	11 (12,8)
95%-CI	[6,6-21,7]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [76,9-95,1]
Month 6	76,1 [57,7-87,3]
Month 12	63,4 [33,0-82,9]
Month 18	63,4 [33,0-82,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [70,8-92,0]
Month 6	80,0 [63,3-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	10 (11,6)
95%-CI	[5,7-20,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [79,8-94,7]
Month 6	84,5 [68,4-92,8]
Month 12	76,8 [53,0-89,6]
Month 18	76,8 [53,0-89,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [75,9-95,5]
Month 6	89,3 [75,9-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	6 (7,0)
95%-CI	[2,6-14,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [84,0-96,6]
Month 6	92,5 [84,0-96,6]
Month 12	92,5 [84,0-96,6]
Month 18	92,5 [84,0-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	12 (20,3)
95%-CI	[11,0-32,8]
TEAE in months [95%-CI]	
Median	NE [7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [69,1-90,0]
Month 6	82,1 [69,1-90,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [86,5-98,0]
Month 6	94,7 [86,5-98,0]
Month 12	81,2 [40,3-95,4]
Month 18	81,2 [40,3-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [65,5-90,9]
Month 6	77,5 [59,3-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [82,4-97,0]
Month 6	92,6 [82,4-97,0]
Month 12	92,6 [82,4-97,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [81,2-97,9]
Month 6	93,6 [81,2-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS05: Time to first TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	8 (9,3)
95%-CI	[4,1-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [78,9-94,6]
Month 6	89,1 [78,9-94,6]
Month 12	89,1 [78,9-94,6]
Month 18	89,1 [78,9-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

4.10.6 Merkmal: Krankheitsstadium nach Ann-Arbor

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	6 (60,0)
95%-CI	[26,2-87,8]
TEAE in months [95%-CI]	
Median	1,77 [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,0 [8,5-64,0]
Month 6	35,0 [8,5-64,0]
Month 12	35,0 [8,5-64,0]
Month 18	35,0 [8,5-64,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]
TEAE in months [95%-CI]	
Median	4,86[0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,2 [27,5-72,1]
Month 6	39,1 [13,2-64,7]
Month 12	39,1 [13,2-64,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	11 (57,9)
95%-CI	[33,5-79,7]
TEAE in months [95%-CI]	
Median	1,51[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,9 [22,8-66,4]
Month 6	45,9 [22,8-66,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	68 (73,1)
95%-CI	[62,9-81,8]
TEAE in months [95%-CI]	
Median	0,99[0,76-1,61]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	29,0 [19,2-39,6]
Month 6	14,7 [6,6-26,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,0 [22,6-87,5]
Month 6	64,0 [22,6-87,5]
Month 12	64,0 [22,6-87,5]
Month 18	64,0 [22,6-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	91,3 [69,5-97,8]
Month 12	91,3 [69,5-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	6 (31,6)
95%-CI	[12,6-56,6]
TEAE in months [95%-CI]	
Median	NE [0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [38,0-82,8]
Month 6	65,2 [38,0-82,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	29 (31,2)
95%-CI	[22,0-41,6]
TEAE in months [95%-CI]	
Median	NE [4,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,4 [54,7-75,8]
Month 6	62,9 [49,6-73,6]
Month 12	62,9 [49,6-73,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	85,7 [33,4-97,9]
Month 12	85,7 [33,4-97,9]
Month 18	85,7 [33,4-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [51,4-92,0]
Month 6	63,2 [25,4-85,8]
Month 12	63,2 [25,4-85,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE[6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	21 (22,6)
95%-CI	[14,6-32,4]
TEAE in months [95%-CI]	
Median	9,10[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [70,8-89,7]
Month 6	60,5 [41,1-75,2]
Month 12	41,5 [17,4-64,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE[1,64-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [36,5-93,9]
Month 6	77,8 [36,5-93,9]
Month 12	77,8 [36,5-93,9]
Month 18	77,8 [36,5-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [2,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,0 [46,3-88,9]
Month 6	74,0 [46,3-88,9]
Month 12	74,0 [46,3-88,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	93,8 [63,2-99,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	20 (21,5)
95%-CI	[13,7-31,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [69,0-87,0]
Month 6	71,5 [57,7-81,5]
Month 12	71,5 [57,7-81,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [2,60-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	83,3 [27,3-97,5]
Month 18	83,3 [27,3-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [50,5-94,3]
Month 6	81,8 [50,5-94,3]
Month 12	81,8 [50,5-94,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [64,1-97,3]
Month 6	89,5 [64,1-97,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	8 (8,6)
95%-CI	[3,8-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [85,2-96,8]
Month 6	86,8 [72,9-93,8]
Month 12	86,8 [72,9-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	7 (70,0)
95%-CI	[34,8-93,3]
TEAE in months [95%-CI]	
Median	1,07[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,0 [12,3-67,0]
Month 6	40,0 [12,3-67,0]
Month 12	20,0 [1,4-54,7]
Month 18	20,0 [1,4-54,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	10 (43,5)
95%-CI	[23,2-65,5]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,7 [32,1-72,6]
Month 6	54,7 [32,1-72,6]
Month 12	54,7 [32,1-72,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	13 (68,4)
95%-CI	[43,4-87,4]
TEAE in months [95%-CI]	
Median	1,38 [0,69-2,86]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	24,8 [7,0-48,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	53 (57,0)
95%-CI	[46,3-67,2]
TEAE in months [95%-CI]	
Median	1,18 [0,62-5,39]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,3 [31,1-52,9]
Month 6	34,1 [20,5-48,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,3 [20,9-80,9]
Month 6	56,3 [20,9-80,9]
Month 12	56,3 [20,9-80,9]
Month 18	56,3 [20,9-80,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	9 (39,1)
95%-CI	[19,7-61,5]
TEAE in months [95%-CI]	
Median	NE[0,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,7 [33,4-78,4]
Month 6	51,1 [24,7-72,5]
Month 12	51,1 [24,7-72,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	9 (47,4)
95%-CI	[24,4-71,1]
TEAE in months [95%-CI]	
Median	2,10[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,4 [14,5-63,8]
Month 6	39,4 [14,5-63,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	36 (38,7)
95%-CI	[28,8-49,4]
TEAE in months [95%-CI]	
Median	5,39[3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,4 [50,7-72,0]
Month 6	49,2 [33,5-63,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	9,23[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,0 [25,3-82,7]
Month 6	60,0 [25,3-82,7]
Month 12	30,0 [1,7-70,2]
Month 18	30,0 [1,7-70,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,0 [49,5-86,9]
Month 6	73,0 [49,5-86,9]
Month 12	73,0 [49,5-86,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]
TEAE in months [95%-CI]	
Median	NE [0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [42,6-86,6]
Month 6	70,4 [42,6-86,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	32 (34,4)
95%-CI	[24,9-45,0]
TEAE in months [95%-CI]	
Median	7,92 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,9 [55,9-75,8]
Month 6	64,7 [53,1-74,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE[0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [32,9-89,2]
Month 6	70,0 [32,9-89,2]
Month 12	70,0 [32,9-89,2]
Month 18	70,0 [32,9-89,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [65,6-97,4]
Month 6	90,0 [65,6-97,4]
Month 12	90,0 [65,6-97,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	4 (21,1)
95%-CI	[6,1-45,6]
TEAE in months [95%-CI]	
Median	NE [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [46,1-90,1]
Month 6	75,3 [46,1-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	29 (31,2)
95%-CI	[22,0-41,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,2 [52,1-74,0]
Month 6	64,2 [52,1-74,0]
Month 12	64,2 [52,1-74,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	88,9 [43,3-98,4]
Month 18	88,9 [43,3-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [63,8-95,5]
Month 6	86,5 [63,8-95,5]
Month 12	86,5 [63,8-95,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,2 [51,7-93,6]
Month 6	81,2 [51,7-93,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	14 (15,1)
95%-CI	[8,5-24,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [75,8-91,6]
Month 6	74,8 [55,0-86,9]
Month 12	74,8 [55,0-86,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	9 (9,7)
95%-CI	[4,5-17,6]
TEAE in months [95%-CI]	
Median	NE [8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [83,2-95,5]
Month 6	91,3 [83,2-95,5]
Month 12	78,2 [42,1-93,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	7 (70,0)
95%-CI	[34,8-93,3]
TEAE in months [95%-CI]	
Median	2,10 [0,23-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,0 [9,0-64,8]
Month 6	36,0 [9,0-64,8]
Month 12	36,0 [9,0-64,8]
Month 18	36,0 [9,0-64,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	16 (69,6)
95%-CI	[47,1-86,8]
TEAE in months [95%-CI]	
Median	1,18 [0,46-3,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	31,0 [11,8-52,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	12 (63,2)
95%-CI	[38,4-83,7]
TEAE in months [95%-CI]	
Median	1,84 [0,49-5,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,0 [17,0-62,3]
Month 6	16,0 [1,3-46,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	48 (51,6)
95%-CI	[41,0-62,1]
TEAE in months [95%-CI]	
Median	2,04 [0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,8 [33,4-55,6]
Month 6	40,8 [28,1-53,0]
Month 12	40,8 [28,1-53,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	6 (60,0)
95%-CI	[26,2-87,8]
TEAE in months [95%-CI]	
Median	2,83[1,18-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,0 [9,8-69,7]
Month 6	40,0 [9,8-69,7]
Month 12	40,0 [9,8-69,7]
Month 18	40,0 [9,8-69,7]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	14 (60,9)
95%-CI	[38,5-80,3]
TEAE in months [95%-CI]	
Median	2,40 [1,18-3,78]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,2 [18,4-62,9]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	8 (42,1)
95%-CI	[20,3-66,5]
TEAE in months [95%-CI]	
Median	5,16[1,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,4 [25,8-74,8]
Month 6	40,1 [12,7-66,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	33 (35,5)
95%-CI	[25,8-46,1]
TEAE in months [95%-CI]	
Median	8,05[3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,0 [55,2-76,4]
Month 6	55,4 [40,7-67,7]
Month 12	36,9 [15,7-58,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE[1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,1 [28,9-93,0]
Month 6	74,1 [28,9-93,0]
Month 12	74,1 [28,9-93,0]
Month 18	74,1 [28,9-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2, 63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,0 [42,7-87,1]
Month 6	63,1 [34,4-82,0]
Month 12	63,1 [34,4-82,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]
TEAE in months [95%-CI]	
Median	NE [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [38,0-85,3]
Month 6	67,5 [38,0-85,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	16 (17,2)
95%-CI	[10,2-26,4]
TEAE in months [95%-CI]	
Median	NE [5,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [70,1-89,8]
Month 6	66,4 [47,4-79,9]
Month 12	66,4 [47,4-79,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [27,2-88,2]
Month 6	66,7 [27,2-88,2]
Month 12	66,7 [27,2-88,2]
Month 18	66,7 [27,2-88,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [46,2-88,2]
Month 6	65,1 [36,6-83,3]
Month 12	65,1 [36,6-83,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	4 (21,1)
95%-CI	[6,1-45,6]
TEAE in months [95%-CI]	
Median	NE [2,33-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [46,1-90,1]
Month 6	75,3 [46,1-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	10 (10,8)
95%-CI	[5,3-18,9]
TEAE in months [95%-CI]	
Median	NE [7,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [78,1-94,4]
Month 6	85,7 [72,9-92,8]
Month 12	75,0 [46,2-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE[0,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,1 [28,9-93,0]
Month 6	74,1 [28,9-93,0]
Month 12	74,1 [28,9-93,0]
Month 18	74,1 [28,9-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,7 [51,6-91,7]
Month 6	70,8 [41,9-87,2]
Month 12	70,8 [41,9-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [54,9-94,0]
Month 6	82,5 [54,9-94,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	13 (14,0)
95%-CI	[7,7-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [76,3-92,3]
Month 6	78,2 [61,7-88,3]
Month 12	78,2 [61,7-88,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	94,7 [68,1-99,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [3,09-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	8 (8,6)
95%-CI	[3,8-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,4 [80,6-95,4]
Month 6	87,8 [76,3-94,0]
Month 12	87,8 [76,3-94,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE in months [95%-CI]	
Median	NE[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,4 [14,4-79,6]
Month 6	51,4 [14,4-79,6]
Month 12	51,4 [14,4-79,6]
Month 18	51,4 [14,4-79,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]
TEAE in months [95%-CI]	
Median	4,63 [0,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,5 [30,4-74,7]
Month 6	37,0 [8,5-66,9]
Month 12	18,5 [1,1-53,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	11 (57,9)
95%-CI	[33,5-79,7]
TEAE in months [95%-CI]	
Median	0,59[0,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,9 [19,1-61,8]
Month 6	40,9 [19,1-61,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	51 (54,8)
95%-CI	[44,2-65,2]
TEAE in months [95%-CI]	
Median	1,18[0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,9 [32,2-53,1]
Month 6	42,9 [32,2-53,1]
Month 12	42,9 [32,2-53,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	75,0 [12,8-96,1]
Month 12	75,0 [12,8-96,1]
Month 18	75,0 [12,8-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [2,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [49,1-91,2]
Month 6	77,4 [49,1-91,2]
Month 12	77,4 [49,1-91,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [46,4-87,8]
Month 6	72,9 [46,4-87,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	24 (25,8)
95%-CI	[17,3-35,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [58,9-79,5]
Month 6	70,6 [58,9-79,5]
Month 12	70,6 [58,9-79,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	55,6 [7,3-87,6]
Month 12	55,6 [7,3-87,6]
Month 18	55,6 [7,3-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	11,30 [2,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [47,8-93,3]
Month 6	79,7 [47,8-93,3]
Month 12	39,9 [1,4-82,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [57,3-96,6]
Month 6	87,1 [57,3-96,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	17 (18,3)
95%-CI	[11,0-27,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [69,7-87,8]
Month 6	75,8 [60,8-85,7]
Month 12	75,8 [60,8-85,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	79,7 [31,7-95,6]
Month 12	79,7 [31,7-95,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	4 (21,1)
95%-CI	[6,1-45,6]
TEAE in months [95%-CI]	
Median	NE [2,04-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,5 [48,7-90,5]
Month 6	76,5 [48,7-90,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	13 (14,0)
95%-CI	[7,7-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [73,3-90,5]
Month 6	83,9 [73,3-90,5]
Month 12	83,9 [73,3-90,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	78,8 [38,1-94,3]
Month 18	78,8 [38,1-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [54,3-96,9]
Month 6	87,0 [54,3-96,9]
Month 12	87,0 [54,3-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	8,11 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	11 (11,8)
95%-CI	[6,1-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [81,6-94,7]
Month 6	85,0 [69,4-93,0]
Month 12	77,2 [53,5-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [55,1-94,6]
Month 6	83,3 [55,1-94,6]
Month 12	83,3 [55,1-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,8-97,0]
Month 6	88,4 [60,8-97,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	12 (12,9)
95%-CI	[6,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [79,0-94,0]
Month 6	74,6 [54,1-87,0]
Month 12	74,6 [54,1-87,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	8,51[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [32,9-89,2]
Month 6	52,5 [15,0-80,4]
Month 12	26,3 [1,4-65,7]
Month 18	26,3 [1,4-65,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	12 (52,2)
95%-CI	[30,6-73,2]
TEAE in months [95%-CI]	
Median	10,15[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,8 [30,0-69,8]
Month 6	51,8 [30,0-69,8]
Month 12	25,9 [2,0-62,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	8 (42,1)
95%-CI	[20,3-66,5]
TEAE in months [95%-CI]	
Median	5,75 [1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [31,5-77,8]
Month 6	38,9 [8,6-69,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	52 (55,9)
95%-CI	[45,2-66,2]
TEAE in months [95%-CI]	
Median	2,53 [1,18-4,86]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,7 [36,3-58,1]
Month 6	35,6 [23,5-47,9]
Month 12	27,7 [15,2-41,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	10,15[2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [45,9-91,3]
Month 6	76,7 [45,9-91,3]
Month 12	38,3 [1,5-80,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [55,9-94,3]
Month 6	83,1 [55,9-94,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	14 (15,1)
95%-CI	[8,5-24,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [72,6-89,7]
Month 6	83,0 [72,6-89,7]
Month 12	83,0 [72,6-89,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	50,0 [0,6-91,0]
Month 18	50,0 [0,6-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	68,9 [24,8-90,5]
Month 12	68,9 [24,8-90,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [5,75-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	62,5 [7,2-92,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	16 (17,2)
95%-CI	[10,2-26,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [70,6-89,0]
Month 6	73,1 [56,3-84,3]
Month 12	73,1 [56,3-84,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [61,8-95,2]
Month 6	85,7 [61,8-95,2]
Month 12	85,7 [61,8-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,8-97,0]
Month 6	88,4 [60,8-97,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	16 (17,2)
95%-CI	[10,2-26,4]
TEAE in months [95%-CI]	
Median	NE [6,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [75,2-91,6]
Month 6	75,9 [60,7-85,8]
Month 12	69,5 [49,8-82,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	59,1 [16,0-86,0]
Month 12	59,1 [16,0-86,0]
Month 18	59,1 [16,0-86,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [68,1-97,6]
Month 6	90,9 [68,1-97,6]
Month 12	90,9 [68,1-97,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	14 (15,1)
95%-CI	[8,5-24,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [75,0-91,5]
Month 6	79,5 [66,3-88,0]
Month 12	79,5 [66,3-88,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	91,3 [69,5-97,8]
Month 12	91,3 [69,5-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,8-97,0]
Month 6	88,4 [60,8-97,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	7 (7,5)
95%-CI	[3,1-14,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [83,8-96,1]
Month 6	92,0 [83,8-96,1]
Month 12	92,0 [83,8-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [64,8-95,6]
Month 6	87,0 [64,8-95,6]
Month 12	87,0 [64,8-95,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	6 (6,5)
95%-CI	[2,4-13,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [88,1-98,3]
Month 6	92,2 [80,2-97,1]
Month 12	83,0 [54,2-94,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	9 (9,7)
95%-CI	[4,5-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [79,2-94,2]
Month 6	88,9 [79,2-94,2]
Month 12	88,9 [79,2-94,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	7 (70,0)
95%-CI	[34,8-93,3]
TEAE in months [95%-CI]	
Median	1,18 [0,26-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,8 [8,0-62,7]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	8 (34,8)
95%-CI	[16,4-57,3]
TEAE in months [95%-CI]	
Median	2,79[2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,2 [16,8-70,3]
Month 6	45,2 [16,8-70,3]
Month 12	45,2 [16,8-70,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	11 (57,9)
95%-CI	[33,5-79,7]
TEAE in months [95%-CI]	
Median	1,51[0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	42 (45,2)
95%-CI	[34,8-55,8]
TEAE in months [95%-CI]	
Median	2,30 [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,7 [37,8-60,6]
Month 6	40,8 [25,7-55,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	6 (31,6)
95%-CI	[12,6-56,6]
TEAE in months [95%-CI]	
Median	NE [1,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,5 [25,3-78,9]
Month 6	56,5 [25,3-78,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	12 (12,9)
95%-CI	[6,8-21,5]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [77,8-93,3]
Month 6	83,4 [69,3-91,4]
Month 12	83,4 [69,3-91,4]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	8,84 [0,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [36,5-93,9]
Month 6	77,8 [36,5-93,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [65,6-97,4]
Month 6	90,0 [65,6-97,4]
Month 12	90,0 [65,6-97,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [58,6-96,7]
Month 6	87,5 [58,6-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	12 (12,9)
95%-CI	[6,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [74,9-91,7]
Month 6	82,2 [69,6-90,0]
Month 12	82,2 [69,6-90,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [2,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,1 [48,8-93,4]
Month 6	80,1 [48,8-93,4]
Month 12	80,1 [48,8-93,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	4 (21,1)
95%-CI	[6,1-45,6]
TEAE in months [95%-CI]	
Median	NE [1,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [47,7-90,2]
Month 6	75,9 [47,7-90,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	8 (8,6)
95%-CI	[3,8-16,2]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [81,2-95,5]
Month 6	90,7 [81,2-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [1,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	59,3 [7,7-89,9]
Month 12	59,3 [7,7-89,9]
Month 18	59,3 [7,7-89,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [37,9-88,1]
Month 6	70,4 [37,9-88,1]
Month 12	70,4 [37,9-88,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [59,5-96,8]
Month 6	87,8 [59,5-96,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	7 (7,5)
95%-CI	[3,1-14,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [84,4-96,7]
Month 6	87,6 [70,7-95,0]
Month 12	87,6 [70,7-95,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE in months [95%-CI]	
Median	3,91[0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	24,0 [1,0-64,3]
Month 12	24,0 [1,0-64,3]
Month 18	24,0 [1,0-64,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	9 (39,1)
95%-CI	[19,7-61,5]
TEAE in months [95%-CI]	
Median	NE [1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,6 [30,9-74,6]
Month 6	55,6 [30,9-74,6]
Month 12	55,6 [30,9-74,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	8 (42,1)
95%-CI	[20,3-66,5]
TEAE in months [95%-CI]	
Median	6,01[1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,0 [36,3-79,8]
Month 6	62,0 [36,3-79,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	40 (43,0)
95%-CI	[32,8-53,7]
TEAE in months [95%-CI]	
Median	4,34 [2,79-7,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,5 [45,8-69,3]
Month 6	37,6 [22,2-52,9]
Month 12	25,1 [10,0-43,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	60,0 [7,6-90,4]
Month 12	60,0 [7,6-90,4]
Month 18	60,0 [7,6-90,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [56,4-92,4]
Month 6	80,8 [56,4-92,4]
Month 12	80,8 [56,4-92,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [55,7-94,2]
Month 6	82,9 [55,7-94,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	23 (24,7)
95%-CI	[16,4-34,8]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [58,9-81,0]
Month 6	67,9 [53,4-78,7]
Month 12	59,4 [38,1-75,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [3,09-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	83,3 [27,3-97,5]
Month 12	83,3 [27,3-97,5]
Month 18	83,3 [27,3-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	14 (15,1)
95%-CI	[8,5-24,0]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [76,4-92,4]
Month 6	78,3 [62,0-88,3]
Month 12	69,6 [45,3-84,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [3,94-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	75,0 [12,8-96,1]
Month 12	75,0 [12,8-96,1]
Month 18	75,0 [12,8-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [53,5-94,6]
Month 6	83,0 [53,5-94,6]
Month 12	83,0 [53,5-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	12 (12,9)
95%-CI	[6,8-21,5]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [79,7-94,6]
Month 6	80,7 [63,2-90,4]
Month 12	62,7 [34,4-81,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	6,47[0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	45,0 [1,0-87,1]
Month 18	45,0 [1,0-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,7 [48,0-89,0]
Month 6	62,2 [29,5-83,1]
Month 12	62,2 [29,5-83,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	6 (31,6)
95%-CI	[12,6-56,6]
TEAE in months [95%-CI]	
Median	3,55[2,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,9 [28,2-82,4]
Month 6	45,7 [13,6-73,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	34 (36,6)
95%-CI	[26,8-47,2]
TEAE in months [95%-CI]	
Median	4,83 [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,5 [44,4-68,5]
Month 6	48,5 [32,3-62,9]
Month 12	48,5 [32,3-62,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	53,3 [8,5-85,2]
Month 12	53,3 [8,5-85,2]
Month 18	53,3 [8,5-85,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	7 (30,4)
95%-CI	[13,2-52,9]
TEAE in months [95%-CI]	
Median	NE[1,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,0 [40,9-82,5]
Month 6	66,0 [40,9-82,5]
Month 12	66,0 [40,9-82,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	6 (31,6)
95%-CI	[12,6-56,6]
TEAE in months [95%-CI]	
Median	NE [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,7 [26,2-78,6]
Month 6	56,7 [26,2-78,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	30 (32,3)
95%-CI	[22,9-42,7]
TEAE in months [95%-CI]	
Median	5,82 [4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [53,1-76,6]
Month 6	46,9 [28,3-63,5]
Month 12	39,1 [19,3-58,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	9,23[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	45,0 [1,0-87,1]
Month 18	45,0 [1,0-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [65,9-97,5]
Month 6	60,1 [20,1-85,1]
Month 12	60,1 [20,1-85,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	7 (36,8)
95%-CI	[16,3-61,6]
TEAE in months [95%-CI]	
Median	5,29[3,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [53,9-93,9]
Month 6	22,0 [1,3-58,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	28 (30,1)
95%-CI	[21,0-40,5]
TEAE in months [95%-CI]	
Median	10,97[10,97-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [60,9-80,1]
Month 6	66,0 [52,9-76,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	63,6 [20,1-88,1]
Month 12	63,6 [20,1-88,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	93,8 [63,2-99,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	11 (11,8)
95%-CI	[6,1-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [79,6-93,3]
Month 6	88,2 [79,6-93,3]
Month 12	88,2 [79,6-93,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE[1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [36,5-93,9]
Month 6	77,8 [36,5-93,9]
Month 12	77,8 [36,5-93,9]
Month 18	77,8 [36,5-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [54,3-96,9]
Month 6	87,0 [54,3-96,9]
Month 12	87,0 [54,3-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	6 (31,6)
95%-CI	[12,6-56,6]
TEAE in months [95%-CI]	
Median	NE[0,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,5 [39,9-83,5]
Month 6	66,5 [39,9-83,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	18 (19,4)
95%-CI	[11,9-28,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [71,2-88,2]
Month 6	75,5 [62,3-84,6]
Month 12	75,5 [62,3-84,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	4 (21,1)
95%-CI	[6,1-45,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [51,1-91,1]
Month 6	77,9 [51,1-91,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	6 (6,5)
95%-CI	[2,4-13,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,9 [85,9-97,4]
Month 6	91,1 [80,1-96,2]
Month 12	91,1 [80,1-96,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [48,8-91,7]
Month 6	77,9 [48,8-91,7]
Month 12	77,9 [48,8-91,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	4 (21,1)
95%-CI	[6,1-45,6]
TEAE in months [95%-CI]	
Median	NE [1,97-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,6 [46,9-90,2]
Month 6	75,6 [46,9-90,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	20 (21,5)
95%-CI	[13,7-31,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [64,2-83,7]
Month 6	75,5 [64,2-83,7]
Month 12	75,5 [64,2-83,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [53,9-96,7]
Month 6	86,6 [53,9-96,7]
Month 12	86,6 [53,9-96,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,8-97,0]
Month 6	88,4 [60,8-97,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	12 (12,9)
95%-CI	[6,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [72,9-90,8]
Month 6	84,0 [72,9-90,8]
Month 12	84,0 [72,9-90,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	88,9 [43,3-98,4]
Month 18	88,9 [43,3-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	7 (36,8)
95%-CI	[16,3-61,6]
TEAE in months [95%-CI]	
Median	4,14 [2,99-8,11]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [39,4-91,5]
Month 6	34,3 [6,3-66,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	11 (11,8)
95%-CI	[6,1-20,2]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [76,9-94,1]
Month 6	82,3 [68,0-90,6]
Month 12	61,7 [20,0-86,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [68,8-97,7]
Month 6	91,1 [68,8-97,7]
Month 12	91,1 [68,8-97,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]
TEAE in months [95%-CI]	
Median	NE [2,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [46,1-89,9]
Month 6	75,0 [46,1-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	11 (11,8)
95%-CI	[6,1-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [79,6-94,2]
Month 6	79,8 [60,7-90,3]
Month 12	79,8 [60,7-90,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [51,4-93,4]
Month 6	80,8 [51,4-93,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	7 (7,5)
95%-CI	[3,1-14,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [83,4-96,0]
Month 6	91,8 [83,4-96,0]
Month 12	91,8 [83,4-96,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	50,0 [0,6-91,0]
Month 18	50,0 [0,6-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [63,7-95,5]
Month 6	86,5 [63,7-95,5]
Month 12	86,5 [63,7-95,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [62,1-97,1]
Month 6	88,8 [62,1-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	11 (11,8)
95%-CI	[6,1-20,2]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [80,7-94,4]
Month 6	89,5 [80,7-94,4]
Month 12	67,1 [33,1-86,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [53,6-92,0]
Month 6	79,7 [53,6-92,0]
Month 12	79,7 [53,6-92,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE in months [95%-CI]	
Median	NE [2,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	8 (8,6)
95%-CI	[3,8-16,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [81,3-95,8]
Month 6	87,9 [75,7-94,3]
Month 12	87,9 [75,7-94,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	95,0 [69,5-99,3]
Month 12	95,0 [69,5-99,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS06: Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	10 (10,8)
95%-CI	[5,3-18,9]
TEAE in months [95%-CI]	
Median	NE[NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [76,7-93,0]
Month 6	87,0 [76,7-93,0]
Month 12	87,0 [76,7-93,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

4.10.7 Merkmal: Bulky Erkrankung

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	92 (67,2)
95%-CI	[58,6-74,9]
TEAE in months [95%-CI]	
Median	1,38 [0,85-2,00]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,2 [26,6-44,0]
Month 6	23,2 [14,5-33,1]
Month 12	14,1 [6,0-25,6]
Month 18	14,1 [6,0-25,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	38 (27,7)
95%-CI	[20,4-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [60,7-77,5]
Month 6	67,6 [57,3-76,0]
Month 12	67,6 [57,3-76,0]
Month 18	67,6 [57,3-76,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	28 (20,4)
95%-CI	[14,0-28,2]
TEAE in months [95%-CI]	
Median	NE[6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [75,2-89,7]
Month 6	68,3 [54,3-78,9]
Month 12	52,0 [31,8-68,8]
Month 18	52,0 [31,8-68,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	26 (19,0)
95%-CI	[12,8-26,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [72,6-87,0]
Month 6	76,0 [66,1-83,4]
Month 12	76,0 [66,1-83,4]
Month 18	76,0 [66,1-83,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	14 (10,2)
95%-CI	[5,7-16,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [82,0-94,1]
Month 6	85,7 [76,0-91,7]
Month 12	85,7 [76,0-91,7]
Month 18	85,7 [76,0-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	79 (57,7)
95%-CI	[48,9-66,1]
TEAE in months [95%-CI]	
Median	1,38 [0,72-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,8 [32,7-50,6]
Month 6	36,0 [26,1-46,0]
Month 12	24,0 [10,9-40,0]
Month 18	24,0 [10,9-40,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	55 (40,1)
95%-CI	[31,9-48,9]
TEAE in months [95%-CI]	
Median	7,62 [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,3 [49,6-67,7]
Month 6	50,3 [39,0-60,5]
Month 12	44,0 [28,9-58,1]
Month 18	44,0 [28,9-58,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	45 (32,8)
95%-CI	[25,1-41,4]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,4 [59,6-75,7]
Month 6	67,0 [57,9-74,6]
Month 12	45,7 [24,5-64,7]
Month 18	45,7 [24,5-64,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	36 (26,3)
95%-CI	[19,1-34,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [61,1-77,9]
Month 6	70,4 [61,1-77,9]
Month 12	70,4 [61,1-77,9]
Month 18	70,4 [61,1-77,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	21 (15,3)
95%-CI	[9,7-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [76,9-90,0]
Month 6	78,2 [65,4-86,8]
Month 12	78,2 [65,4-86,8]
Month 18	78,2 [65,4-86,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [85,0-95,6]
Month 6	91,9 [85,0-95,6]
Month 12	84,2 [61,4-94,1]
Month 18	84,2 [61,4-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	78 (56,9)
95%-CI	[48,2-65,4]
TEAE in months [95%-CI]	
Median	1,84 [1,22-3,09]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,6 [32,3-50,6]
Month 6	32,1 [22,1-42,6]
Month 12	32,1 [22,1-42,6]
Month 18	32,1 [22,1-42,6]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	56 (40,9)
95%-CI	[32,6-49,6]
TEAE in months [95%-CI]	
Median	4,99 [2,83-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,0 [49,8-68,8]
Month 6	45,3 [33,4-56,4]
Month 12	35,2 [20,6-50,2]
Month 18	35,2 [20,6-50,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	27 (19,7)
95%-CI	[13,4-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [68,6-85,4]
Month 6	68,1 [55,4-77,9]
Month 12	68,1 [55,4-77,9]
Month 18	68,1 [55,4-77,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	22 (16,1)
95%-CI	[10,3-23,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [74,1-88,9]
Month 6	79,4 [69,4-86,4]
Month 12	72,8 [55,0-84,4]
Month 18	72,8 [55,0-84,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	21 (15,3)
95%-CI	[9,7-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [76,1-90,0]
Month 6	78,1 [66,7-86,0]
Month 12	78,1 [66,7-86,0]
Month 18	78,1 [66,7-86,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	9 (6,6)
95%-CI	[3,0-12,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [86,9-96,9]
Month 6	90,5 [82,0-95,1]
Month 12	90,5 [82,0-95,1]
Month 18	90,5 [82,0-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	72 (52,6)
95%-CI	[43,9-61,1]
TEAE in months [95%-CI]	
Median	1,84[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,7 [36,6-54,4]
Month 6	43,5 [33,8-52,7]
Month 12	34,8 [18,6-51,5]
Month 18	34,8 [18,6-51,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	31 (22,6)
95%-CI	[15,9-30,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [66,5-82,3]
Month 6	73,4 [63,6-80,9]
Month 12	73,4 [63,6-80,9]
Month 18	73,4 [63,6-80,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	25 (18,2)
95%-CI	[12,2-25,7]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [71,7-87,0]
Month 6	75,8 [64,4-84,0]
Month 12	65,0 [39,7-81,7]
Month 18	65,0 [39,7-81,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	17 (12,4)
95%-CI	[7,4-19,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [78,8-91,7]
Month 6	84,0 [74,3-90,4]
Month 12	84,0 [74,3-90,4]
Month 18	84,0 [74,3-90,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	17 (12,4)
95%-CI	[7,4-19,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [81,3-93,2]
Month 6	85,9 [76,0-91,9]
Month 12	75,0 [54,4-87,3]
Month 18	75,0 [54,4-87,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	15 (10,9)
95%-CI	[6,3-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [82,4-94,1]
Month 6	81,1 [67,4-89,5]
Month 12	81,1 [67,4-89,5]
Month 18	81,1 [67,4-89,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	70 (51,1)
95%-CI	[42,4-59,7]
TEAE in months [95%-CI]	
Median	3,48 [2,04-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,7 [44,4-62,2]
Month 6	42,3 [31,7-52,5]
Month 12	26,9 [13,9-41,9]
Month 18	26,9 [13,9-41,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	22 (16,1)
95%-CI	[10,3-23,3]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,6 [74,2-88,5]
Month 6	82,6 [74,2-88,5]
Month 12	72,3 [46,9-87,0]
Month 18	72,3 [46,9-87,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	20 (14,6)
95%-CI	[9,2-21,6]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [79,9-92,7]
Month 6	74,6 [60,2-84,5]
Month 12	67,8 [48,0-81,4]
Month 18	67,8 [48,0-81,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	19 (13,9)
95%-CI	[8,6-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [80,3-92,6]
Month 6	81,9 [71,4-88,8]
Month 12	78,1 [64,9-86,9]
Month 18	78,1 [64,9-86,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	19 (13,9)
95%-CI	[8,6-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [79,3-91,9]
Month 6	82,0 [72,3-88,5]
Month 12	82,0 [72,3-88,5]
Month 18	82,0 [72,3-88,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [85,5-95,3]
Month 6	91,7 [85,5-95,3]
Month 12	91,7 [85,5-95,3]
Month 18	91,7 [85,5-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [87,5-96,5]
Month 6	91,4 [83,9-95,5]
Month 12	85,3 [66,8-94,0]
Month 18	85,3 [66,8-94,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	8 (5,8)
95%-CI	[2,6-11,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [86,6-96,6]
Month 6	93,2 [86,6-96,6]
Month 12	93,2 [86,6-96,6]
Month 18	93,2 [86,6-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	68 (49,6)
95%-CI	[41,0-58,3]
TEAE in months [95%-CI]	
Median	2,07 [1,45-3,91]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,7 [33,8-53,2]
Month 6	32,1 [18,8-46,2]
Month 12	32,1 [18,8-46,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	19 (13,9)
95%-CI	[8,6-20,8]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [76,5-90,5]
Month 6	82,5 [72,5-89,1]
Month 12	82,5 [72,5-89,1]
Month 18	41,3 [1,4-83,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	19 (13,9)
95%-CI	[8,6-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [77,6-90,8]
Month 6	83,5 [74,6-89,6]
Month 12	74,3 [50,5-87,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	15 (10,9)
95%-CI	[6,3-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [79,8-92,6]
Month 6	87,6 [79,8-92,6]
Month 12	80,9 [62,0-91,0]
Month 18	80,9 [62,0-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	15 (10,9)
95%-CI	[6,3-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [79,7-92,9]
Month 6	82,4 [70,5-89,9]
Month 12	82,4 [70,5-89,9]
Month 18	82,4 [70,5-89,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	57 (41,6)
95%-CI	[33,3-50,3]
TEAE in months [95%-CI]	
Median	4,44 [3,09-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,1 [52,2-70,5]
Month 6	44,6 [32,5-56,1]
Month 12	33,2 [19,5-47,5]
Month 18	33,2 [19,5-47,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	29 (21,2)
95%-CI	[14,7-29,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,3 [68,0-84,2]
Month 6	72,6 [61,3-81,1]
Month 12	67,0 [51,1-78,8]
Month 18	67,0 [51,1-78,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	16 (11,7)
95%-CI	[6,8-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [83,3-94,4]
Month 6	83,7 [72,4-90,7]
Month 12	77,3 [58,4-88,4]
Month 18	77,3 [58,4-88,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	15 (10,9)
95%-CI	[6,3-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [83,6-95,1]
Month 6	83,6 [71,3-90,9]
Month 12	71,6 [50,2-85,1]
Month 18	71,6 [50,2-85,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	46 (33,6)
95%-CI	[25,7-42,1]
TEAE in months [95%-CI]	
Median	6,47 [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,8 [53,5-72,3]
Month 6	54,1 [41,4-65,1]
Month 12	49,6 [35,1-62,4]
Month 18	49,6 [35,1-62,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	43 (31,4)
95%-CI	[23,7-39,9]
TEAE in months [95%-CI]	
Median	7,10[5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [56,5-75,1]
Month 6	53,3 [39,4-65,3]
Month 12	47,9 [32,0-62,2]
Month 18	47,9 [32,0-62,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	40 (29,2)
95%-CI	[21,7-37,6]
TEAE in months [95%-CI]	
Median	9,23[5,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [68,7-83,4]
Month 6	58,1 [43,8-70,0]
Month 12	39,9 [17,8-61,3]
Month 18	39,9 [17,8-61,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	15 (10,9)
95%-CI	[6,3-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [83,9-94,3]
Month 6	85,3 [74,6-91,7]
Month 12	85,3 [74,6-91,7]
Month 18	85,3 [74,6-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	28 (20,4)
95%-CI	[14,0-28,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [70,8-85,4]
Month 6	75,7 [66,1-83,0]
Month 12	75,7 [66,1-83,0]
Month 18	75,7 [66,1-83,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	10 (7,3)
95%-CI	[3,6-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [86,7-96,2]
Month 6	91,2 [83,8-95,3]
Month 12	91,2 [83,8-95,3]
Month 18	91,2 [83,8-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	27 (19,7)
95%-CI	[13,4-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,5 [68,6-84,2]
Month 6	77,5 [68,6-84,2]
Month 12	77,5 [68,6-84,2]
Month 18	77,5 [68,6-84,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	15 (10,9)
95%-CI	[6,3-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [78,2-91,8]
Month 6	86,5 [78,2-91,8]
Month 12	86,5 [78,2-91,8]
Month 18	86,5 [78,2-91,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	20 (14,6)
95%-CI	[9,2-21,6]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [78,7-92,9]
Month 6	76,3 [63,8-85,0]
Month 12	59,4 [34,3-77,6]
Month 18	59,4 [34,3-77,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	19 (13,9)
95%-CI	[8,6-20,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [79,3-91,8]
Month 6	81,8 [70,4-89,1]
Month 12	77,0 [61,4-86,9]
Month 18	77,0 [61,4-86,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [84,0-94,9]
Month 6	90,9 [84,0-94,9]
Month 12	90,9 [84,0-94,9]
Month 18	90,9 [84,0-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	17 (12,4)
95%-CI	[7,4-19,1]
TEAE in months [95%-CI]	
Median	NE[9,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [82,2-93,4]
Month 6	89,1 [82,2-93,4]
Month 12	69,3 [44,2-84,8]
Month 18	69,3 [44,2-84,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	13 (9,5)
95%-CI	[5,1-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [80,4-93,6]
Month 6	86,8 [77,5-92,4]
Month 12	86,8 [77,5-92,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS07: Time to first TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	9 (6,6)
95%-CI	[3,0-12,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [85,3-96,0]
Month 6	92,2 [85,3-96,0]
Month 12	92,2 [85,3-96,0]
Month 18	92,2 [85,3-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

4.10.8 *Merkmal: Double/Triple-Hit*

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	12 (80,0)
95%-CI	[51,9-95,7]
TEAE in months [95%-CI]	
Median	0,85 [0,07-1,77]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	10,2 [0,7-35,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	84 (64,6)
95%-CI	[55,8-72,8]
TEAE in months [95%-CI]	
Median	1,48 [0,89-2,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,0 [28,9-47,1]
Month 6	24,7 [15,3-35,3]
Month 12	15,1 [6,4-27,3]
Month 18	15,1 [6,4-27,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	NE[0,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,2 [20,4-76,6]
Month 6	52,2 [20,4-76,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	34 (26,2)
95%-CI	[18,8-34,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,0 [62,6-79,4]
Month 6	69,3 [58,6-77,7]
Month 12	69,3 [58,6-77,7]
Month 18	69,3 [58,6-77,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	4,90 [4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	32,5 [1,4-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	25 (19,2)
95%-CI	[12,8-27,1]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,5 [74,3-89,7]
Month 6	72,1 [58,5-81,9]
Month 12	53,2 [30,9-71,3]
Month 18	53,2 [30,9-71,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,9 [24,6-80,9]
Month 6	57,9 [24,6-80,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	23 (17,7)
95%-CI	[11,6-25,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [74,5-88,7]
Month 6	77,2 [66,7-84,8]
Month 12	77,2 [66,7-84,8]
Month 18	77,2 [66,7-84,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [3,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	80,0 [37,4-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	12 (9,2)
95%-CI	[4,9-15,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [81,4-94,3]
Month 6	87,3 [77,6-93,0]
Month 12	87,3 [77,6-93,0]
Month 18	87,3 [77,6-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	9 (60,0)
95%-CI	[32,3-83,7]
TEAE in months [95%-CI]	
Median	0,49[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,3 [13,6-61,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	74 (56,9)
95%-CI	[48,0-65,6]
TEAE in months [95%-CI]	
Median	1,41[0,82-3,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,3 [32,9-51,4]
Month 6	36,1 [25,7-46,5]
Month 12	24,0 [10,8-40,2]
Month 18	24,0 [10,8-40,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,7 [29,1-81,7]
Month 6	60,7 [29,1-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	53 (40,8)
95%-CI	[32,2-49,7]
TEAE in months [95%-CI]	
Median	5,39[2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,6 [48,5-67,3]
Month 6	48,6 [36,8-59,5]
Month 12	41,7 [25,8-56,9]
Month 18	41,7 [25,8-56,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	NE [0,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [29,3-78,9]
Month 6	58,3 [29,3-78,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	42 (32,3)
95%-CI	[24,4-41,1]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,1 [60,0-76,5]
Month 6	67,6 [58,2-75,3]
Month 12	43,4 [20,8-64,2]
Month 18	43,4 [20,8-64,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	NE [0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,3 [30,7-79,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	32 (24,6)
95%-CI	[17,5-32,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [61,9-79,2]
Month 6	71,6 [61,9-79,2]
Month 12	71,6 [61,9-79,2]
Month 18	71,6 [61,9-79,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [43,9-92,0]
Month 6	77,0 [43,9-92,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [78,6-91,5]
Month 6	79,2 [65,2-88,1]
Month 12	79,2 [65,2-88,1]
Month 18	79,2 [65,2-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	8,05[8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	8 (6,2)
95%-CI	[2,7-11,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [85,7-96,5]
Month 6	92,8 [85,7-96,5]
Month 12	92,8 [85,7-96,5]
Month 18	92,8 [85,7-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	8 (53,3)
95%-CI	[26,6-78,7]
TEAE in months [95%-CI]	
Median	2,10[0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,7 [16,3-67,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	75 (57,7)
95%-CI	[48,7-66,3]
TEAE in months [95%-CI]	
Median	1,51 [1,18-2,83]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,4 [30,9-49,7]
Month 6	30,1 [19,9-41,0]
Month 12	30,1 [19,9-41,0]
Month 18	30,1 [19,9-41,0]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	8,05 [1,15-8,05]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,6 [22,4-79,4]
Month 6	55,6 [22,4-79,4]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	55 (42,3)
95%-CI	[33,7-51,3]
TEAE in months [95%-CI]	
Median	4,14 [2,83-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [47,9-67,4]
Month 6	42,4 [30,3-54,0]
Month 12	37,1 [23,2-51,1]
Month 18	37,1 [23,2-51,1]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	79,1 [36,7-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	27 (20,8)
95%-CI	[14,2-28,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [67,3-84,7]
Month 6	66,3 [53,0-76,6]
Month 12	66,3 [53,0-76,6]
Month 18	66,3 [53,0-76,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [42,0-95,4]
Month 6	81,7 [42,0-95,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	21 (16,2)
95%-CI	[10,3-23,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [73,9-89,1]
Month 6	79,0 [68,4-86,4]
Month 12	71,8 [52,7-84,2]
Month 18	71,8 [52,7-84,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [4,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	57,8 [8,5-88,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	20 (15,4)
95%-CI	[9,7-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,2 [74,3-89,2]
Month 6	79,1 [68,5-86,5]
Month 12	79,1 [68,5-86,5]
Month 18	79,1 [68,5-86,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [85,1-96,2]
Month 6	88,8 [79,6-94,1]
Month 12	88,8 [79,6-94,1]
Month 18	88,8 [79,6-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	10 (66,7)
95%-CI	[38,4-88,2]
TEAE in months [95%-CI]	
Median	0,89[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	23,7 [4,7-50,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	67 (51,5)
95%-CI	[42,6-60,4]
TEAE in months [95%-CI]	
Median	1,84[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,4 [38,1-56,1]
Month 6	44,9 [34,9-54,3]
Month 12	35,9 [19,2-53,0]
Month 18	35,9 [19,2-53,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE in months [95%-CI]	
Median	NE [0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,8 [28,8-82,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	29 (22,3)
95%-CI	[15,5-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,0 [66,9-82,9]
Month 6	73,6 [63,4-81,4]
Month 12	73,6 [63,4-81,4]
Month 18	73,6 [63,4-81,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE [1,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,2 [28,1-85,7]
Month 6	64,2 [28,1-85,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	21 (16,2)
95%-CI	[10,3-23,6]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [74,4-89,4]
Month 6	77,7 [65,4-86,1]
Month 12	64,8 [35,2-83,5]
Month 18	64,8 [35,2-83,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [76,3-90,4]
Month 6	82,0 [71,4-88,9]
Month 12	82,0 [71,4-88,9]
Month 18	82,0 [71,4-88,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [81,8-94,0]
Month 6	86,4 [75,6-92,6]
Month 12	74,6 [52,3-87,6]
Month 18	74,6 [52,3-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	4,96[2,33-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,5 [34,9-90,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [83,0-94,6]
Month 6	84,3 [71,4-91,7]
Month 12	84,3 [71,4-91,7]
Month 18	84,3 [71,4-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	9 (60,0)
95%-CI	[32,3-83,7]
TEAE in months [95%-CI]	
Median	1,58[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,3 [13,6-61,5]
Month 6	37,3 [13,6-61,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	68 (52,3)
95%-CI	[43,4-61,1]
TEAE in months [95%-CI]	
Median	3,48 [1,48-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,1 [43,6-61,8]
Month 6	40,7 [29,7-51,3]
Month 12	25,2 [12,5-40,1]
Month 18	25,2 [12,5-40,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [45,5-92,3]
Month 6	77,8 [45,5-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	20 (15,4)
95%-CI	[9,7-22,8]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [74,2-89,0]
Month 6	83,0 [74,2-89,0]
Month 12	71,1 [42,4-87,4]
Month 18	71,1 [42,4-87,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	4,96[2,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,0 [35,3-90,9]
Month 6	48,6 [8,6-81,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [81,0-93,3]
Month 6	76,9 [62,0-86,6]
Month 12	69,2 [47,5-83,4]
Month 18	69,2 [47,5-83,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE[0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [50,0-93,1]
Month 6	64,0 [25,0-86,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [78,7-91,9]
Month 6	82,6 [72,2-89,3]
Month 12	78,4 [64,6-87,4]
Month 18	78,4 [64,6-87,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [53,3-96,2]
Month 6	85,6 [53,3-96,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	18 (13,8)
95%-CI	[8,4-21,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [78,9-92,0]
Month 6	81,2 [70,7-88,2]
Month 12	81,2 [70,7-88,2]
Month 18	81,2 [70,7-88,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	11 (8,5)
95%-CI	[4,3-14,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [84,5-95,0]
Month 6	91,1 [84,5-95,0]
Month 12	91,1 [84,5-95,0]
Month 18	91,1 [84,5-95,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [88,7-97,3]
Month 6	92,3 [84,1-96,4]
Month 12	85,2 [63,2-94,6]
Month 18	85,2 [63,2-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [84,8-95,9]
Month 6	92,0 [84,8-95,9]
Month 12	92,0 [84,8-95,9]
Month 18	92,0 [84,8-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	7 (46,7)
95%-CI	[21,3-73,4]
TEAE in months [95%-CI]	
Median	3,91[0,33-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [27,3-77,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	61 (46,9)
95%-CI	[38,1-55,9]
TEAE in months [95%-CI]	
Median	2,17 [1,48-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,2 [33,7-54,3]
Month 6	34,8 [20,1-50,0]
Month 12	34,8 [20,1-50,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [51,2-96,0]
Month 6	67,9 [24,9-89,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	16 (12,3)
95%-CI	[7,2-19,2]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [76,8-91,3]
Month 6	85,6 [76,8-91,3]
Month 12	85,6 [76,8-91,3]
Month 18	42,8 [1,3-84,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [51,2-96,0]
Month 6	84,9 [51,2-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	17 (13,1)
95%-CI	[7,8-20,1]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [78,1-91,5]
Month 6	84,0 [74,5-90,2]
Month 12	73,5 [46,9-88,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [59,1-99,0]
Month 6	92,9 [59,1-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	14 (10,8)
95%-CI	[6,0-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [79,3-92,7]
Month 6	87,6 [79,3-92,7]
Month 12	79,6 [57,7-91,0]
Month 18	79,6 [57,7-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [78,2-92,4]
Month 6	80,7 [67,4-89,0]
Month 12	80,7 [67,4-89,0]
Month 18	80,7 [67,4-89,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	3,02 [2,46-4,90]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [24,8-84,5]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	55 (42,3)
95%-CI	[33,7-51,3]
TEAE in months [95%-CI]	
Median	4,44 [3,09-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,8 [50,8-69,4]
Month 6	46,2 [34,0-57,5]
Month 12	34,3 [20,3-48,9]
Month 18	34,3 [20,3-48,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [2,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [31,2-89,7]
Month 6	70,0 [31,2-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	29 (22,3)
95%-CI	[15,5-30,4]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [67,4-83,8]
Month 6	71,7 [60,0-80,5]
Month 12	65,7 [49,0-78,1]
Month 18	65,7 [49,0-78,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	58,3 [7,7-89,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [83,6-94,4]
Month 6	86,0 [76,0-92,1]
Month 12	78,9 [58,5-90,0]
Month 18	78,9 [58,5-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	16 (12,3)
95%-CI	[7,2-19,2]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [81,5-94,2]
Month 6	81,1 [67,5-89,4]
Month 12	67,5 [44,4-82,7]
Month 18	67,5 [44,4-82,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE in months [95%-CI]	
Median	2,99[0,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,7 [16,1-72,8]
Month 6	46,7 [16,1-72,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	42 (32,3)
95%-CI	[24,4-41,1]
TEAE in months [95%-CI]	
Median	6,47 [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,3 [54,7-74,0]
Month 6	54,4 [40,7-66,1]
Month 12	49,4 [33,9-63,1]
Month 18	49,4 [33,9-63,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	7 (46,7)
95%-CI	[21,3-73,4]
TEAE in months [95%-CI]	
Median	4,40[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,3 [23,7-77,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	39 (30,0)
95%-CI	[22,3-38,7]
TEAE in months [95%-CI]	
Median	7,10[5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,6 [57,0-76,2]
Month 6	55,4 [40,9-67,7]
Month 12	49,9 [33,2-64,4]
Month 18	49,9 [33,2-64,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,0 [41,2-88,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	37 (28,5)
95%-CI	[20,9-37,0]
TEAE in months [95%-CI]	
Median	9,23[5,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [69,4-84,4]
Month 6	57,7 [42,7-70,1]
Month 12	39,6 [17,5-61,0]
Month 18	39,6 [17,5-61,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [50,0-93,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	12 (9,2)
95%-CI	[4,9-15,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [85,8-95,7]
Month 6	86,6 [75,0-93,1]
Month 12	86,6 [75,0-93,1]
Month 18	86,6 [75,0-93,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [42,5-88,8]
Month 6	72,7 [42,5-88,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	24 (18,5)
95%-CI	[12,2-26,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [72,4-87,2]
Month 6	76,9 [66,5-84,5]
Month 12	76,9 [66,5-84,5]
Month 18	76,9 [66,5-84,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [85,9-96,0]
Month 6	90,5 [82,5-95,0]
Month 12	90,5 [82,5-95,0]
Month 18	90,5 [82,5-95,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE in months [95%-CI]	
Median	NE [1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [37,9-87,8]
Month 6	70,0 [37,9-87,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	24 (18,5)
95%-CI	[12,2-26,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [69,1-85,2]
Month 6	78,4 [69,1-85,2]
Month 12	78,4 [69,1-85,2]
Month 18	78,4 [69,1-85,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [51,2-96,0]
Month 6	84,9 [51,2-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	14 (10,8)
95%-CI	[6,0-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [77,5-91,9]
Month 6	86,3 [77,5-91,9]
Month 12	86,3 [77,5-91,9]
Month 18	86,3 [77,5-91,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE in months [95%-CI]	
Median	NE [2,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,9 [25,6-88,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	17 (13,1)
95%-CI	[7,8-20,1]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [81,7-95,0]
Month 6	77,7 [64,3-86,6]
Month 12	60,5 [34,5-78,8]
Month 18	60,5 [34,5-78,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	19 (14,6)
95%-CI	[9,0-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [78,0-91,3]
Month 6	80,3 [67,8-88,3]
Month 12	74,9 [57,9-85,8]
Month 18	74,9 [57,9-85,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	11 (8,5)
95%-CI	[4,3-14,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [83,0-94,5]
Month 6	90,3 [83,0-94,5]
Month 12	90,3 [83,0-94,5]
Month 18	90,3 [83,0-94,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [83,0-94,2]
Month 6	90,0 [83,0-94,2]
Month 12	66,4 [38,0-84,2]
Month 18	66,4 [38,0-84,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [80,0-93,5]
Month 6	86,3 [76,5-92,2]
Month 12	86,3 [76,5-92,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE in months [95%-CI]	
Median	NE [1,81-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS08: Time to first TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [83,7-95,2]
Month 6	91,0 [83,7-95,2]
Month 12	91,0 [83,7-95,2]
Month 18	91,0 [83,7-95,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

4.10.9 Merkmal: Transformation des DLBCL

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	21 (72,4)
95%-CI	[52,8-87,3]
TEAE in months [95%-CI]	
Median	0,85 [0,23-1,61]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	24,4 [9,8-42,5]
Month 6	18,3 [5,6-36,9]
Month 12	18,3 [5,6-36,9]
Month 18	18,3 [5,6-36,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	75 (64,7)
95%-CI	[55,2-73,3]
TEAE in months [95%-CI]	
Median	1,51 [0,89-2,56]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,8 [28,1-47,5]
Month 6	23,9 [13,8-35,6]
Month 12	11,0 [2,8-25,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	14 (48,3)
95%-CI	[29,4-67,5]
TEAE in months [95%-CI]	
Median	2,07[0,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,6 [27,4-65,4]
Month 6	47,6 [27,4-65,4]
Month 12	47,6 [27,4-65,4]
Month 18	47,6 [27,4-65,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	26 (22,4)
95%-CI	[15,2-31,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [65,3-83,0]
Month 6	72,3 [60,4-81,1]
Month 12	72,3 [60,4-81,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [69,2-96,3]
Month 6	88,8 [69,2-96,3]
Month 12	88,8 [69,2-96,3]
Month 18	88,8 [69,2-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	26 (22,4)
95%-CI	[15,2-31,1]
TEAE in months [95%-CI]	
Median	9,10[4,90-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [72,2-89,1]
Month 6	62,5 [46,0-75,2]
Month 12	42,1 [20,4-62,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	NE [3,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [63,2-93,8]
Month 6	69,0 [40,9-85,7]
Month 12	69,0 [40,9-85,7]
Month 18	69,0 [40,9-85,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	22 (19,0)
95%-CI	[12,3-27,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [69,7-86,1]
Month 6	77,1 [66,6-84,6]
Month 12	77,1 [66,6-84,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [56,6-95,1]
Month 6	84,5 [56,6-95,1]
Month 12	84,5 [56,6-95,1]
Month 18	84,5 [56,6-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	11 (9,5)
95%-CI	[4,8-16,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [83,4-95,5]
Month 6	86,5 [75,4-92,8]
Month 12	86,5 [75,4-92,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	17 (58,6)
95%-CI	[38,9-76,5]
TEAE in months [95%-CI]	
Median	0,72[0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,8 [22,9-57,9]
Month 6	40,8 [22,9-57,9]
Month 12	40,8 [22,9-57,9]
Month 18	40,8 [22,9-57,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	66 (56,9)
95%-CI	[47,4-66,1]
TEAE in months [95%-CI]	
Median	1,41[0,82-3,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,1 [32,0-51,8]
Month 6	35,2 [24,2-46,3]
Month 12	21,1 [7,6-39,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	15 (51,7)
95%-CI	[32,5-70,6]
TEAE in months [95%-CI]	
Median	2,10[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,7 [17,3-58,1]
Month 6	37,7 [17,3-58,1]
Month 12	37,7 [17,3-58,1]
Month 18	37,7 [17,3-58,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	43 (37,1)
95%-CI	[28,3-46,5]
TEAE in months [95%-CI]	
Median	7,62 [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,9 [53,5-72,6]
Month 6	52,9 [40,1-64,1]
Month 12	45,3 [27,8-61,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	12 (41,4)
95%-CI	[23,5-61,1]
TEAE in months [95%-CI]	
Median	7,92 [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,9 [43,1-78,8]
Month 6	58,1 [36,3-74,7]
Month 12	29,0 [2,0-67,7]
Month 18	29,0 [2,0-67,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	36 (31,0)
95%-CI	[22,8-40,3]
TEAE in months [95%-CI]	
Median	NE [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [59,3-76,8]
Month 6	69,0 [59,3-76,8]
Month 12	51,1 [27,2-70,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	NE [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,1 [48,3-87,4]
Month 6	73,1 [48,3-87,4]
Month 12	73,1 [48,3-87,4]
Month 18	73,1 [48,3-87,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	32 (27,6)
95%-CI	[19,7-36,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,6 [59,6-77,6]
Month 6	69,6 [59,6-77,6]
Month 12	69,6 [59,6-77,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	NE [4,70-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,6 [52,2-86,6]
Month 6	58,9 [25,9-81,3]
Month 12	58,9 [25,9-81,3]
Month 18	58,9 [25,9-81,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	13 (11,2)
95%-CI	[6,1-18,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [80,1-93,2]
Month 6	83,9 [70,1-91,6]
Month 12	83,9 [70,1-91,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [67,3-94,6]
Month 6	86,2 [67,3-94,6]
Month 12	86,2 [67,3-94,6]
Month 18	86,2 [67,3-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	7 (6,0)
95%-CI	[2,5-12,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [85,9-97,3]
Month 6	93,7 [85,9-97,3]
Month 12	83,3 [51,2-95,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	21 (72,4)
95%-CI	[52,8-87,3]
TEAE in months [95%-CI]	
Median	0,49[0,43-1,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,7 [16,5-49,9]
Month 6	26,1 [10,6-44,8]
Month 12	26,1 [10,6-44,8]
Month 18	26,1 [10,6-44,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	62 (53,4)
95%-CI	[44,0-62,8]
TEAE in months [95%-CI]	
Median	2,10 [1,25-3,78]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,8 [32,4-52,7]
Month 6	33,5 [22,3-45,0]
Month 12	33,5 [22,3-45,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	17 (58,6)
95%-CI	[38,9-76,5]
TEAE in months [95%-CI]	
Median	2,73 [1,18-8,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,8 [21,1-61,4]
Month 6	31,4 [10,8-54,7]
Month 12	15,7 [1,3-45,4]
Month 18	15,7 [1,3-45,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	44 (37,9)
95%-CI	[29,1-47,4]
TEAE in months [95%-CI]	
Median	4,99 [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,5 [51,4-71,7]
Month 6	46,7 [33,5-58,9]
Month 12	40,0 [23,9-55,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [63,8-95,8]
Month 6	74,6 [38,8-91,3]
Month 12	74,6 [38,8-91,3]
Month 18	74,6 [38,8-91,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	25 (21,6)
95%-CI	[14,5-30,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [64,1-83,4]
Month 6	65,6 [51,8-76,3]
Month 12	65,6 [51,8-76,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [56,0-91,0]
Month 6	79,1 [56,0-91,0]
Month 12	79,1 [56,0-91,0]
Month 18	79,1 [56,0-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	18 (15,5)
95%-CI	[9,5-23,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [73,8-90,0]
Month 6	79,3 [67,9-87,1]
Month 12	71,4 [50,5-84,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [58,1-93,1]
Month 6	82,1 [58,1-93,1]
Month 12	82,1 [58,1-93,1]
Month 18	82,1 [58,1-93,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	19 (16,4)
95%-CI	[10,2-24,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [74,8-90,0]
Month 6	76,2 [63,1-85,2]
Month 12	76,2 [63,1-85,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [78,0-99,5]
Month 6	88,5 [57,7-97,3]
Month 12	88,5 [57,7-97,3]
Month 18	88,5 [57,7-97,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [84,2-96,3]
Month 6	90,3 [81,0-95,2]
Month 12	90,3 [81,0-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	18 (62,1)
95%-CI	[42,3-79,3]
TEAE in months [95%-CI]	
Median	0,49[0,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,0 [18,9-53,5]
Month 6	36,0 [18,9-53,5]
Month 12	36,0 [18,9-53,5]
Month 18	36,0 [18,9-53,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	59 (50,9)
95%-CI	[41,4-60,3]
TEAE in months [95%-CI]	
Median	2,76 [1,12-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,3 [37,3-56,7]
Month 6	44,4 [33,4-54,7]
Month 12	29,6 [8,9-54,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,8 [54,1-87,1]
Month 6	66,4 [41,1-82,9]
Month 12	66,4 [41,1-82,9]
Month 18	66,4 [41,1-82,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	26 (22,4)
95%-CI	[15,2-31,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,2 [64,0-81,8]
Month 6	74,2 [64,0-81,8]
Month 12	74,2 [64,0-81,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [65,4-94,3]
Month 6	75,9 [46,9-90,4]
Month 12	75,9 [46,9-90,4]
Month 18	75,9 [46,9-90,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	20 (17,2)
95%-CI	[10,9-25,4]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,4 [70,2-87,4]
Month 6	76,9 [64,2-85,6]
Month 12	57,7 [20,5-82,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [66,3-94,4]
Month 6	85,8 [66,3-94,4]
Month 12	85,8 [66,3-94,4]
Month 18	85,8 [66,3-94,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	15 (12,9)
95%-CI	[7,4-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [76,5-91,4]
Month 6	82,4 [70,8-89,8]
Month 12	82,4 [70,8-89,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [71,3-96,5]
Month 6	89,7 [71,3-96,5]
Month 12	89,7 [71,3-96,5]
Month 18	89,7 [71,3-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	14 (12,1)
95%-CI	[6,8-19,4]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [80,8-93,9]
Month 6	85,7 [73,8-92,4]
Month 12	71,7 [46,2-86,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [65,4-94,3]
Month 6	85,3 [65,4-94,3]
Month 12	85,3 [65,4-94,3]
Month 18	85,3 [65,4-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	13 (11,2)
95%-CI	[6,1-18,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [80,9-94,2]
Month 6	78,8 [62,5-88,7]
Month 12	78,8 [62,5-88,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	16 (55,2)
95%-CI	[35,7-73,6]
TEAE in months [95%-CI]	
Median	3,38[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,5 [34,8-70,6]
Month 6	42,4 [22,1-61,4]
Month 12	28,3 [7,1-54,8]
Month 18	28,3 [7,1-54,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	61 (52,6)
95%-CI	[43,1-61,9]
TEAE in months [95%-CI]	
Median	3,09 [1,41-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,3 [40,0-59,7]
Month 6	39,9 [28,4-51,1]
Month 12	23,7 [9,3-41,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [67,7-96,1]
Month 6	88,3 [67,7-96,1]
Month 12	88,3 [67,7-96,1]
Month 18	88,3 [67,7-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	20 (17,2)
95%-CI	[10,9-25,4]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,1 [71,5-87,8]
Month 6	81,1 [71,5-87,8]
Month 12	64,9 [29,5-85,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [66,3-94,4]
Month 6	71,5 [34,4-90,0]
Month 12	71,5 [34,4-90,0]
Month 18	71,5 [34,4-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	17 (14,7)
95%-CI	[8,8-22,4]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [77,9-92,6]
Month 6	74,2 [58,1-84,9]
Month 12	65,0 [40,7-81,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [3,52-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [68,8-96,2]
Month 6	72,6 [43,0-88,5]
Month 12	72,6 [43,0-88,5]
Month 18	72,6 [43,0-88,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	17 (14,7)
95%-CI	[8,8-22,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [76,7-91,1]
Month 6	82,6 [71,7-89,6]
Month 12	78,0 [63,0-87,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [3,52-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [62,2-93,7]
Month 6	75,5 [47,9-89,8]
Month 12	75,5 [47,9-89,8]
Month 18	75,5 [47,9-89,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	15 (12,9)
95%-CI	[7,4-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [79,1-92,6]
Month 6	83,5 [73,1-90,1]
Month 12	83,5 [73,1-90,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	12 (10,3)
95%-CI	[5,5-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [81,8-93,8]
Month 6	89,2 [81,8-93,8]
Month 12	89,2 [81,8-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,9 [61,6-92,1]
Month 6	81,9 [61,6-92,1]
Month 12	54,6 [9,6-85,5]
Month 18	54,6 [9,6-85,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	5 (4,3)
95%-CI	[1,4-9,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [91,1-98,7]
Month 6	94,1 [84,9-97,8]
Month 12	94,1 [84,9-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [74,7-98,2]
Month 6	93,0 [74,7-98,2]
Month 12	93,0 [74,7-98,2]
Month 18	93,0 [74,7-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [84,1-96,0]
Month 6	91,9 [84,1-96,0]
Month 12	91,9 [84,1-96,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	12 (41,4)
95%-CI	[23,5-61,1]
TEAE in months [95%-CI]	
Median	2,79[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,9 [15,3-66,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	56 (48,3)
95%-CI	[38,9-57,7]
TEAE in months [95%-CI]	
Median	2,17 [1,45-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,8 [35,1-55,9]
Month 6	33,1 [18,8-48,1]
Month 12	33,1 [18,8-48,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [63,6-93,9]
Month 6	84,5 [63,6-93,9]
Month 12	84,5 [63,6-93,9]
Month 18	84,5 [63,6-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	15 (12,9)
95%-CI	[7,4-20,4]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [76,1-91,6]
Month 6	82,6 [70,8-90,0]
Month 12	82,6 [70,8-90,0]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [68,8-97,7]
Month 6	91,1 [68,8-97,7]
Month 12	60,7 [7,9-90,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	16 (13,8)
95%-CI	[8,1-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [75,6-90,5]
Month 6	82,2 [71,6-89,1]
Month 12	82,2 [71,6-89,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [64,5-94,0]
Month 6	84,9 [64,5-94,0]
Month 12	84,9 [64,5-94,0]
Month 18	84,9 [64,5-94,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	11 (9,5)
95%-CI	[4,8-16,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [80,2-94,0]
Month 6	88,9 [80,2-94,0]
Month 12	80,9 [57,8-92,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [47,7-89,7]
Month 6	75,3 [47,7-89,7]
Month 12	75,3 [47,7-89,7]
Month 18	75,3 [47,7-89,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	10 (8,6)
95%-CI	[4,2-15,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [83,0-95,6]
Month 6	84,8 [70,8-92,4]
Month 12	84,8 [70,8-92,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	12 (41,4)
95%-CI	[23,5-61,1]
TEAE in months [95%-CI]	
Median	3,91[1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,3 [31,6-72,4]
Month 6	47,5 [24,8-67,3]
Month 12	47,5 [24,8-67,3]
Month 18	47,5 [24,8-67,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	49 (42,2)
95%-CI	[33,1-51,8]
TEAE in months [95%-CI]	
Median	4,44 [3,02-7,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,5 [51,7-71,5]
Month 6	42,2 [28,4-55,3]
Month 12	27,4 [12,8-44,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	NE [2,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,0 [38,8-81,0]
Month 6	64,0 [38,8-81,0]
Month 12	64,0 [38,8-81,0]
Month 18	64,0 [38,8-81,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	24 (20,7)
95%-CI	[13,7-29,2]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,7 [68,8-85,8]
Month 6	72,9 [60,0-82,2]
Month 12	65,6 [46,1-79,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [68,0-96,2]
Month 6	88,4 [68,0-96,2]
Month 12	88,4 [68,0-96,2]
Month 18	88,4 [68,0-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	14 (12,1)
95%-CI	[6,8-19,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [82,4-94,8]
Month 6	82,3 [68,8-90,4]
Month 12	74,1 [51,0-87,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [72,5-98,1]
Month 6	83,1 [51,8-94,9]
Month 12	83,1 [51,8-94,9]
Month 18	83,1 [51,8-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	13 (11,2)
95%-CI	[6,1-18,4]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [81,4-94,9]
Month 6	83,4 [69,2-91,5]
Month 12	68,3 [42,6-84,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]
TEAE in months [95%-CI]	
Median	NE [1,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,4 [39,0-77,6]
Month 6	53,7 [29,8-72,6]
Month 12	53,7 [29,8-72,6]
Month 18	53,7 [29,8-72,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	37 (31,9)
95%-CI	[23,6-41,2]
TEAE in months [95%-CI]	
Median	6,47 [3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,6 [52,0-73,2]
Month 6	53,4 [38,5-66,2]
Month 12	46,7 [28,9-62,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]
TEAE in months [95%-CI]	
Median	5,78[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [40,9-80,2]
Month 6	42,7 [14,9-68,4]
Month 12	42,7 [14,9-68,4]
Month 18	42,7 [14,9-68,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	35 (30,2)
95%-CI	[22,0-39,4]
TEAE in months [95%-CI]	
Median	7,10[5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,4 [55,0-75,6]
Month 6	55,6 [40,4-68,4]
Month 12	48,7 [30,2-64,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	13 (44,8)
95%-CI	[26,4-64,3]
TEAE in months [95%-CI]	
Median	4,17[0,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [43,3-78,9]
Month 6	30,5 [6,8-59,2]
Month 12	30,5 [6,8-59,2]
Month 18	30,5 [6,8-59,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	28 (24,1)
95%-CI	[16,7-33,0]
TEAE in months [95%-CI]	
Median	10,97[9,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [71,6-86,9]
Month 6	66,6 [51,4-78,0]
Month 12	35,5 [7,8-65,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [70,9-97,9]
Month 6	80,3 [44,3-94,3]
Month 12	80,3 [44,3-94,3]
Month 18	80,3 [44,3-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	12 (10,3)
95%-CI	[5,5-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [83,5-94,6]
Month 6	87,1 [76,0-93,3]
Month 12	87,1 [76,0-93,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [62,9-93,9]
Month 6	84,2 [62,9-93,9]
Month 12	84,2 [62,9-93,9]
Month 18	84,2 [62,9-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	24 (20,7)
95%-CI	[13,7-29,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [69,8-85,9]
Month 6	74,5 [63,1-82,8]
Month 12	74,5 [63,1-82,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [71,8-98,0]
Month 6	92,2 [71,8-98,0]
Month 12	92,2 [71,8-98,0]
Month 18	92,2 [71,8-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,5 [86,7-96,8]
Month 6	91,3 [82,6-95,8]
Month 12	91,3 [82,6-95,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,6 [49,3-89,5]
Month 6	75,6 [49,3-89,5]
Month 12	75,6 [49,3-89,5]
Month 18	75,6 [49,3-89,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	23 (19,8)
95%-CI	[13,0-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [68,6-85,0]
Month 6	78,1 [68,6-85,0]
Month 12	78,1 [68,6-85,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [53,4-92,6]
Month 6	80,3 [53,4-92,6]
Month 12	80,3 [53,4-92,6]
Month 18	80,3 [53,4-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	12 (10,3)
95%-CI	[5,5-17,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [78,9-92,9]
Month 6	87,7 [78,9-92,9]
Month 12	87,7 [78,9-92,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	7,92 [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [59,6-93,3]
Month 6	54,6 [22,4-78,3]
Month 12	27,3 [1,7-66,3]
Month 18	27,3 [1,7-66,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	12 (10,3)
95%-CI	[5,5-17,4]
TEAE in months [95%-CI]	
Median	NE[8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [78,9-94,6]
Month 6	82,1 [69,0-90,1]
Month 12	70,4 [41,0-87,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [64,4-94,1]
Month 6	84,9 [64,4-94,1]
Month 12	84,9 [64,4-94,1]
Month 18	84,9 [64,4-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	15 (12,9)
95%-CI	[7,4-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [79,7-93,1]
Month 6	81,7 [67,9-90,0]
Month 12	75,4 [55,9-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [71,5-98,0]
Month 6	92,1 [71,5-98,0]
Month 12	92,1 [71,5-98,0]
Month 18	92,1 [71,5-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	9 (7,8)
95%-CI	[3,6-14,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [83,3-95,3]
Month 6	91,0 [83,3-95,3]
Month 12	91,0 [83,3-95,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	95,5 [71,9-99,4]
Month 18	95,5 [71,9-99,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	16 (13,8)
95%-CI	[8,1-21,4]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [80,4-93,0]
Month 6	88,1 [80,4-93,0]
Month 12	62,8 [33,7-82,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [56,6-93,1]
Month 6	81,7 [56,6-93,1]
Month 12	81,7 [56,6-93,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	10 (8,6)
95%-CI	[4,2-15,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [80,8-94,8]
Month 6	87,4 [76,7-93,4]
Month 12	87,4 [76,7-93,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [68,5-96,3]
Month 6	88,7 [68,5-96,3]
Month 12	88,7 [68,5-96,3]
Month 18	88,7 [68,5-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSS09: Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [83,4-95,8]
Month 6	91,5 [83,4-95,8]
Month 12	91,5 [83,4-95,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

4.10.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	36 (75,0)
95%-CI	[60,4-86,4]
TEAE in months [95%-CI]	
Median	0,89[0,26-2,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,6 [17,1-45,1]
Month 6	15,3 [5,1-30,7]
Month 12	7,6 [0,8-25,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	16 (69,6)
95%-CI	[47,1-86,8]
TEAE in months [95%-CI]	
Median	0,99[0,49-3,71]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,9 [14,8-54,2]
Month 6	12,7 [1,1-39,0]
Month 12	12,7 [1,1-39,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	20 (41,7)
95%-CI	[27,6-56,8]
TEAE in months [95%-CI]	
Median	NE [1,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,2 [39,0-68,7]
Month 6	55,2 [39,0-68,7]
Month 12	55,2 [39,0-68,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE[4,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [68,1-97,6]
Month 6	77,9 [39,2-93,6]
Month 12	77,9 [39,2-93,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	10 (20,8)
95%-CI	[10,5-35,0]
TEAE in months [95%-CI]	
Median	9,10[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [73,5-95,0]
Month 6	66,1 [41,0-82,5]
Month 12	44,0 [9,6-75,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,9 [48,0-91,0]
Month 6	57,7 [26,0-79,9]
Month 12	57,7 [26,0-79,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [69,6-92,2]
Month 6	80,4 [63,8-89,9]
Month 12	80,4 [63,8-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [52,8-89,7]
Month 6	65,8 [35,2-84,6]
Month 12	65,8 [35,2-84,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	3 (6,3)
95%-CI	[1,3-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [81,7-97,9]
Month 6	93,7 [81,7-97,9]
Month 12	93,7 [81,7-97,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [3,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [54,3-96,9]
Month 6	77,3 [42,4-92,6]
Month 12	77,3 [42,4-92,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	24 (50,0)
95%-CI	[35,2-64,8]
TEAE in months [95%-CI]	
Median	5,39 [1,18-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,6 [38,2-68,4]
Month 6	45,1 [27,2-61,4]
Month 12	22,5 [4,9-48,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]
TEAE in months [95%-CI]	
Median	2,56[0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,2 [17,0-64,2]
Month 6	41,2 [17,0-64,2]
Month 12	41,2 [17,0-64,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	16 (33,3)
95%-CI	[20,4-48,4]
TEAE in months [95%-CI]	
Median	7,62 [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,6 [51,9-81,8]
Month 6	55,7 [35,1-72,0]
Month 12	41,7 [15,6-66,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	8 (34,8)
95%-CI	[16,4-57,3]
TEAE in months [95%-CI]	
Median	NE [1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,2 [33,5-80,2]
Month 6	51,0 [22,7-73,7]
Month 12	51,0 [22,7-73,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [72,6-93,8]
Month 6	86,7 [72,6-93,8]
Month 12	54,2 [15,6-81,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [54,6-90,1]
Month 6	77,8 [54,6-90,1]
Month 12	77,8 [54,6-90,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	11 (22,9)
95%-CI	[12,0-37,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,7 [58,4-85,3]
Month 6	74,7 [58,4-85,3]
Month 12	74,7 [58,4-85,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,8 [47,7-88,3]
Month 6	73,8 [47,7-88,3]
Month 12	73,8 [47,7-88,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	9 (18,8)
95%-CI	[8,9-32,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,7 [68,2-91,0]
Month 6	74,4 [50,7-87,9]
Month 12	74,4 [50,7-87,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	4 (8,3)
95%-CI	[2,3-20,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [74,0-96,2]
Month 6	89,8 [74,0-96,2]
Month 12	89,8 [74,0-96,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [68,8-97,7]
Month 6	91,1 [68,8-97,7]
Month 12	91,1 [68,8-97,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	23 (47,9)
95%-CI	[33,3-62,8]
TEAE in months [95%-CI]	
Median	3,78 [1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,1 [33,5-64,7]
Month 6	39,1 [21,0-56,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	14 (60,9)
95%-CI	[38,5-80,3]
TEAE in months [95%-CI]	
Median	1,22 [0,72-4,14]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,6 [21,3-62,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	18 (37,5)
95%-CI	[24,0-52,6]
TEAE in months [95%-CI]	
Median	5,16[2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [43,7-75,2]
Month 6	46,1 [26,2-64,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	8 (34,8)
95%-CI	[16,4-57,3]
TEAE in months [95%-CI]	
Median	NE [2,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,3 [43,0-85,2]
Month 6	51,3 [23,1-73,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [68,5-91,8]
Month 6	76,6 [54,8-88,9]
Month 12	76,6 [54,8-88,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [3,25-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [50,4-95,9]
Month 6	52,5 [19,1-77,9]
Month 12	52,5 [19,1-77,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [75,0-96,1]
Month 6	85,4 [67,1-93,9]
Month 12	85,4 [67,1-93,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	86,8 [54,1-96,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	6 (12,5)
95%-CI	[4,7-25,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [73,9-95,0]
Month 6	83,6 [65,6-92,7]
Month 12	83,6 [65,6-92,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [79,2-98,6]
Month 6	94,4 [79,2-98,6]
Month 12	94,4 [79,2-98,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	86,8 [54,1-96,8]
Month 12	86,8 [54,1-96,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	32 (66,7)
95%-CI	[51,6-79,6]
TEAE in months [95%-CI]	
Median	0,89[0,53-2,07]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	31,7 [18,5-45,7]
Month 6	31,7 [18,5-45,7]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	12 (52,2)
95%-CI	[30,6-73,2]
TEAE in months [95%-CI]	
Median	1,41[0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,5 [24,2-64,6]
Month 6	45,5 [24,2-64,6]
Month 12	45,5 [24,2-64,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	15 (31,3)
95%-CI	[18,7-46,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [50,2-78,3]
Month 6	66,3 [50,2-78,3]
Month 12	66,3 [50,2-78,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [42,1-85,3]
Month 6	69,0 [42,1-85,3]
Month 12	69,0 [42,1-85,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	11 (22,9)
95%-CI	[12,0-37,3]
TEAE in months [95%-CI]	
Median	11,30 [5,32-11,30]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,3 [58,8-87,1]
Month 6	69,4 [47,4-83,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,1 [57,1-94,8]
Month 6	84,1 [57,1-94,8]
Month 12	84,1 [57,1-94,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	7 (14,6)
95%-CI	[6,1-27,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [65,0-91,0]
Month 6	81,8 [65,0-91,0]
Month 12	81,8 [65,0-91,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [64,3-95,5]
Month 6	86,7 [64,3-95,5]
Month 12	86,7 [64,3-95,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [72,3-93,8]
Month 6	86,6 [72,3-93,8]
Month 12	63,0 [26,3-85,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [55,6-94,7]
Month 6	69,8 [31,9-89,3]
Month 12	69,8 [31,9-89,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	7 (14,6)
95%-CI	[6,1-27,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [72,7-94,8]
Month 6	75,3 [50,8-88,8]
Month 12	75,3 [50,8-88,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [65,2-97,5]
Month 6	90,0 [65,2-97,5]
Month 12	90,0 [65,2-97,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	18 (37,5)
95%-CI	[24,0-52,6]
TEAE in months [95%-CI]	
Median	6,44 [3,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,1 [52,0-81,1]
Month 6	58,3 [37,6-74,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	14 (60,9)
95%-CI	[38,5-80,3]
TEAE in months [95%-CI]	
Median	1,58[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,4 [19,6-60,4]
Month 6	33,6 [14,0-54,7]
Month 12	33,6 [14,0-54,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	3 (6,3)
95%-CI	[1,3-17,2]
TEAE in months [95%-CI]	
Median	10,15[10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [83,4-98,9]
Month 6	95,6 [83,4-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,5 [43,4-90,2]
Month 6	74,5 [43,4-90,2]
Month 12	74,5 [43,4-90,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [5,75-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [68,3-93,8]
Month 6	71,8 [46,1-86,8]
Month 12	53,9 [18,0-80,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [68,1-97,6]
Month 6	81,8 [50,5-94,3]
Month 12	81,8 [50,5-94,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [80,6-97,8]
Month 6	88,6 [70,6-95,9]
Month 12	79,8 [51,6-92,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,1 [39,2-85,4]
Month 6	68,1 [39,2-85,4]
Month 12	68,1 [39,2-85,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [83,5-98,9]
Month 6	95,6 [83,5-98,9]
Month 12	95,6 [83,5-98,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	91,7 [53,9-98,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [83,2-98,9]
Month 6	95,5 [83,2-98,9]
Month 12	95,5 [83,2-98,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	91,3 [69,5-97,8]
Month 12	91,3 [69,5-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	4 (8,3)
95%-CI	[2,3-20,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [79,3-96,8]
Month 6	91,7 [79,3-96,8]
Month 12	91,7 [79,3-96,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	87,0 [54,3-96,9]
Month 12	87,0 [54,3-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	1 (2,1)
95%-CI	[0,1-11,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,8 [85,6-99,7]
Month 6	97,8 [85,6-99,7]
Month 12	97,8 [85,6-99,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [2,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [49,5-91,4]
Month 6	77,8 [49,5-91,4]
Month 12	77,8 [49,5-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	29 (60,4)
95%-CI	[45,3-74,2]
TEAE in months [95%-CI]	
Median	1,51 [1,18-2,79]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,1 [19,2-49,7]
Month 6	18,2 [4,5-39,3]
Month 12	18,2 [4,5-39,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	8 (34,8)
95%-CI	[16,4-57,3]
TEAE in months [95%-CI]	
Median	NE [1,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,5 [38,9-81,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	10 (20,8)
95%-CI	[10,5-35,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [61,1-88,0]
Month 6	72,6 [53,2-85,0]
Month 12	72,6 [53,2-85,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [55,0-96,4]
Month 6	86,2 [55,0-96,4]
Month 12	86,2 [55,0-96,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [72,0-94,6]
Month 6	87,4 [72,0-94,6]
Month 12	87,4 [72,0-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [61,3-95,1]
Month 6	85,5 [61,3-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	3 (6,3)
95%-CI	[1,3-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [80,0-97,7]
Month 6	93,1 [80,0-97,7]
Month 12	93,1 [80,0-97,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [60,7-97,1]
Month 6	88,6 [60,7-97,1]
Month 12	88,6 [60,7-97,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	9 (18,8)
95%-CI	[8,9-32,6]
TEAE in months [95%-CI]	
Median	NE[4,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [65,0-91,0]
Month 6	69,0 [45,2-84,1]
Month 12	69,0 [45,2-84,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [66,6-99,2]
Month 6	94,4 [66,6-99,2]
Month 12	94,4 [66,6-99,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	20 (41,7)
95%-CI	[27,6-56,8]
TEAE in months [95%-CI]	
Median	4,34 [2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [49,7-79,0]
Month 6	49,1 [29,4-66,1]
Month 12	24,5 [5,1-51,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	10 (43,5)
95%-CI	[23,2-65,5]
TEAE in months [95%-CI]	
Median	4,76 [1,68-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,2 [35,0-78,2]
Month 6	33,4 [7,4-63,1]
Month 12	33,4 [7,4-63,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	9 (18,8)
95%-CI	[8,9-32,6]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [66,4-91,4]
Month 6	76,6 [56,2-88,4]
Month 12	61,3 [26,8-83,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [56,0-92,4]
Month 6	80,7 [56,0-92,4]
Month 12	80,7 [56,0-92,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	7 (14,6)
95%-CI	[6,1-27,8]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [78,9-96,7]
Month 6	82,1 [61,5-92,4]
Month 12	61,6 [19,2-86,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	7 (14,6)
95%-CI	[6,1-27,8]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [74,9-96,3]
Month 6	83,6 [61,3-93,7]
Month 12	50,2 [13,4-78,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [2,27-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [49,3-91,0]
Month 6	61,8 [25,0-84,6]
Month 12	61,8 [25,0-84,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	21 (43,8)
95%-CI	[29,5-58,8]
TEAE in months [95%-CI]	
Median	6,47[1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,0 [38,4-68,9]
Month 6	50,0 [32,4-65,4]
Month 12	40,0 [18,7-60,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	11 (47,8)
95%-CI	[26,8-69,4]
TEAE in months [95%-CI]	
Median	2,50 [0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,1 [23,7-69,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	17 (35,4)
95%-CI	[22,2-50,5]
TEAE in months [95%-CI]	
Median	NE [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,5 [40,0-71,6]
Month 6	57,5 [40,0-71,6]
Month 12	57,5 [40,0-71,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [2,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,9 [46,2-88,8]
Month 6	59,1 [24,2-82,3]
Month 12	59,1 [24,2-82,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	13 (27,1)
95%-CI	[15,3-41,8]
TEAE in months [95%-CI]	
Median	9,23[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [68,9-91,1]
Month 6	61,8 [38,7-78,4]
Month 12	41,2 [9,5-71,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE in months [95%-CI]	
Median	NE [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [59,0-92,9]
Month 6	65,3 [35,7-83,9]
Month 12	65,3 [35,7-83,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [78,5-96,7]
Month 6	86,0 [66,8-94,5]
Month 12	86,0 [66,8-94,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [64,8-95,6]
Month 6	87,0 [64,8-95,6]
Month 12	87,0 [64,8-95,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	9 (18,8)
95%-CI	[8,9-32,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [67,6-90,8]
Month 6	78,4 [61,8-88,4]
Month 12	78,4 [61,8-88,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	7 (30,4)
95%-CI	[13,2-52,9]
TEAE in months [95%-CI]	
Median	NE[0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,9 [42,5-82,8]
Month 6	66,9 [42,5-82,8]
Month 12	66,9 [42,5-82,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,9 [86,1-99,7]
Month 6	93,8 [76,0-98,5]
Month 12	93,8 [76,0-98,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [61,0-95,1]
Month 6	85,4 [61,0-95,1]
Month 12	85,4 [61,0-95,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	13 (27,1)
95%-CI	[15,3-41,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,9 [52,0-80,9]
Month 6	68,9 [52,0-80,9]
Month 12	68,9 [52,0-80,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,9 [53,0-89,7]
Month 6	76,9 [53,0-89,7]
Month 12	76,9 [53,0-89,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	10 (20,8)
95%-CI	[10,5-35,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [58,4-86,1]
Month 6	75,3 [58,4-86,1]
Month 12	75,3 [58,4-86,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [69,0-94,0]
Month 6	75,7 [53,4-88,4]
Month 12	60,6 [26,2-82,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	84,0 [48,7-95,9]
Month 12	84,0 [48,7-95,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [6,67-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [80,2-97,7]
Month 6	88,5 [70,4-95,8]
Month 12	73,7 [34,6-91,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	5 (21,7)
95%-CI	[7,5-43,7]
TEAE in months [95%-CI]	
Median	NE [5,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [54,6-92,3]
Month 6	60,2 [18,6-85,8]
Month 12	60,2 [18,6-85,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [81,9-98,8]
Month 6	95,1 [81,9-98,8]
Month 12	95,1 [81,9-98,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	91,3 [69,5-97,8]
Month 12	91,3 [69,5-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE in months [95%-CI]	
Median	NE [7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [72,9-93,9]
Month 6	86,8 [72,9-93,9]
Month 12	52,1 [13,8-80,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	95,5 [71,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [79,3-96,8]
Month 6	87,3 [70,6-94,9]
Month 12	87,3 [70,6-94,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	91,7 [53,9-98,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [75,3-95,2]
Month 6	88,9 [75,3-95,2]
Month 12	88,9 [75,3-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS10: Time to first TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

4.10.11 Merkmal: Maximaler längster Durchmesser

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	54 (65,9)
95%-CI	[54,6-76,0]
TEAE in months [95%-CI]	
Median	1,51 [0,95-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,3 [28,2-50,2]
Month 6	31,1 [20,3-42,6]
Month 12	19,0 [8,1-33,3]
Month 18	19,0 [8,1-33,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	25 (69,4)
95%-CI	[51,9-83,7]
TEAE in months [95%-CI]	
Median	0,99 [0,43-2,86]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	27,6 [11,6-46,2]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	7 (70,0)
95%-CI	[34,8-93,3]
TEAE in months [95%-CI]	
Median	0,53[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	26,7 [4,8-56,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
TEAE in months [95%-CI]	
Median	0,85[0,13-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	21 (25,6)
95%-CI	[16,6-36,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [61,4-81,5]
Month 6	72,9 [61,4-81,5]
Month 12	72,9 [61,4-81,5]
Month 18	72,9 [61,4-81,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	13 (36,1)
95%-CI	[20,8-53,8]
TEAE in months [95%-CI]	
Median	4,37[2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,6 [39,3-76,4]
Month 6	48,5 [21,8-70,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [23,0-82,1]
Month 6	58,3 [23,0-82,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [27,6-92,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	16 (19,5)
95%-CI	[11,6-29,7]
TEAE in months [95%-CI]	
Median	NE [6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [74,4-92,6]
Month 6	72,7 [55,2-84,3]
Month 12	52,9 [29,3-71,8]
Month 18	52,9 [29,3-71,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE in months [95%-CI]	
Median	NE[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [69,4-96,7]
Month 6	71,6 [37,8-89,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE in months [95%-CI]	
Median	NE [0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,0 [19,7-81,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	14 (17,1)
95%-CI	[9,7-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [72,7-90,4]
Month 6	78,8 [66,1-87,2]
Month 12	78,8 [66,1-87,2]
Month 18	78,8 [66,1-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	9 (25,0)
95%-CI	[12,1-42,2]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [56,3-87,2]
Month 6	67,1 [42,4-83,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,5 [30,6-90,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	11 (13,4)
95%-CI	[6,9-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [77,7-93,6]
Month 6	82,3 [69,0-90,3]
Month 12	82,3 [69,0-90,3]
Month 18	82,3 [69,0-90,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [79,6-98,6]
Month 6	94,4 [79,6-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [2, 63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,0 [0,6-91,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	50 (61,0)
95%-CI	[49,6-71,6]
TEAE in months [95%-CI]	
Median	1,18 [0,69-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,8 [29,5-51,8]
Month 6	32,5 [20,4-45,3]
Month 12	26,0 [12,5-41,9]
Month 18	26,0 [12,5-41,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	19 (52,8)
95%-CI	[35,5-69,6]
TEAE in months [95%-CI]	
Median	1,45[0,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,2 [26,6-60,5]
Month 6	44,2 [26,6-60,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	9,23 [0,03-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [23,0-82,1]
Month 6	58,3 [23,0-82,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]
TEAE in months [95%-CI]	
Median	1,41[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	35 (42,7)
95%-CI	[31,8-54,1]
TEAE in months [95%-CI]	
Median	5,39[2,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,4 [46,9-69,9]
Month 6	48,6 [34,3-61,5]
Month 12	41,7 [24,5-58,0]
Month 18	41,7 [24,5-58,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	13 (36,1)
95%-CI	[20,8-53,8]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,1 [42,3-75,4]
Month 6	61,1 [42,3-75,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,1 [16,0-86,0]
Month 6	59,1 [16,0-86,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	1,41[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	26 (31,7)
95%-CI	[21,9-42,9]
TEAE in months [95%-CI]	
Median	NE [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [59,1-79,4]
Month 6	68,6 [56,6-77,9]
Month 12	52,9 [30,5-71,1]
Month 18	52,9 [30,5-71,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	11 (30,6)
95%-CI	[16,3-48,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,9 [50,9-81,5]
Month 6	68,9 [50,9-81,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	9,23 [0,33-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	NE [0,33-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,6 [29,4-81,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	21 (25,6)
95%-CI	[16,6-36,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,8 [61,2-81,4]
Month 6	72,8 [61,2-81,4]
Month 12	72,8 [61,2-81,4]
Month 18	72,8 [61,2-81,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	12 (33,3)
95%-CI	[18,6-51,0]
TEAE in months [95%-CI]	
Median	NE [1,77-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,8 [43,0-77,3]
Month 6	62,8 [43,0-77,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,3 [7,7-89,9]
Month 6	59,3 [7,7-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	15 (18,3)
95%-CI	[10,6-28,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [72,1-89,7]
Month 6	73,9 [56,8-85,1]
Month 12	73,9 [56,8-85,1]
Month 18	73,9 [56,8-85,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [75,3-97,1]
Month 6	91,3 [75,3-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [81,5-96,2]
Month 6	91,5 [81,5-96,2]
Month 12	91,5 [81,5-96,2]
Month 18	91,5 [81,5-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [79,6-98,6]
Month 6	94,4 [79,6-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	49 (59,8)
95%-CI	[48,3-70,4]
TEAE in months [95%-CI]	
Median	2,10 [1,22-3,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,4 [30,6-53,8]
Month 6	27,3 [14,8-41,3]
Month 12	27,3 [14,8-41,3]
Month 18	27,3 [14,8-41,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	18 (50,0)
95%-CI	[32,9-67,1]
TEAE in months [95%-CI]	
Median	2,10[1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,9 [27,7-62,3]
Month 6	45,9 [27,7-62,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	6 (60,0)
95%-CI	[26,2-87,8]
TEAE in months [95%-CI]	
Median	0,85 [0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,3 [8,2-63,3]
Month 6	34,3 [8,2-63,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
TEAE in months [95%-CI]	
Median	0,62 [0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,9 [6,6-63,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	35 (42,7)
95%-CI	[31,8-54,1]
TEAE in months [95%-CI]	
Median	4,14 [2,83-8,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,2 [47,9-72,1]
Month 6	39,0 [23,4-54,3]
Month 12	32,5 [16,2-50,0]
Month 18	32,5 [16,2-50,0]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	13 (36,1)
95%-CI	[20,8-53,8]
TEAE in months [95%-CI]	
Median	NE [1,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,7 [44,3-77,9]
Month 6	57,9 [37,1-74,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	2,07[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,3 [5,8-66,8]
Month 6	34,3 [5,8-66,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]
TEAE in months [95%-CI]	
Median	1,18[0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,6 [7,4-69,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	17 (20,7)
95%-CI	[12,6-31,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,5 [64,5-86,2]
Month 6	66,9 [50,0-79,2]
Month 12	66,9 [50,0-79,2]
Month 18	66,9 [50,0-79,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	7 (19,4)
95%-CI	[8,2-36,0]
TEAE in months [95%-CI]	
Median	NE [3,25-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,1 [60,0-90,9]
Month 6	72,9 [48,4-87,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [22,5-91,8]
Month 6	70,0 [22,5-91,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	3,55 [1,41-3,55]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	15 (18,3)
95%-CI	[10,6-28,4]
TEAE in months [95%-CI]	
Median	NE [7,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [70,6-89,8]
Month 6	77,2 [63,5-86,3]
Month 12	68,6 [45,9-83,3]
Month 18	68,6 [45,9-83,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [69,1-96,4]
Month 6	89,0 [69,1-96,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,7 [20,7-86,3]
Month 6	61,7 [20,7-86,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [0,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	14 (17,1)
95%-CI	[9,7-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [73,4-91,3]
Month 6	74,4 [57,7-85,3]
Month 12	74,4 [57,7-85,3]
Month 18	74,4 [57,7-85,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	4 (11,1)
95%-CI	[3,1-26,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [69,6-95,1]
Month 6	87,4 [69,6-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,0 [21,8-86,9]
Month 6	63,0 [21,8-86,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	5 (6,1)
95%-CI	[2,0-13,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [84,3-97,7]
Month 6	91,4 [80,0-96,4]
Month 12	91,4 [80,0-96,4]
Month 18	91,4 [80,0-96,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [77,9-98,5]
Month 6	88,1 [65,4-96,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	37 (45,1)
95%-CI	[34,1-56,5]
TEAE in months [95%-CI]	
Median	11,30[1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,3 [43,4-65,8]
Month 6	51,6 [38,4-63,4]
Month 12	41,3 [21,0-60,6]
Month 18	41,3 [21,0-60,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	24 (66,7)
95%-CI	[49,0-81,4]
TEAE in months [95%-CI]	
Median	1,00 [0,46-1,84]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,5 [15,9-46,4]
Month 6	30,5 [15,9-46,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	6 (60,0)
95%-CI	[26,2-87,8]
TEAE in months [95%-CI]	
Median	1,69[0,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,3 [6,3-64,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	8 (61,5)
95%-CI	[31,6-86,1]
TEAE in months [95%-CI]	
Median	1,02 [0,33-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	19,2 [1,3-53,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	15 (18,3)
95%-CI	[10,6-28,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [68,5-88,0]
Month 6	77,1 [63,9-86,0]
Month 12	77,1 [63,9-86,0]
Month 18	77,1 [63,9-86,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	11 (30,6)
95%-CI	[16,3-48,1]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,8 [49,3-80,8]
Month 6	67,8 [49,3-80,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [27,2-88,2]
Month 6	66,7 [27,2-88,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,1 [24,6-89,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	13 (15,9)
95%-CI	[8,7-25,6]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [73,4-91,1]
Month 6	81,2 [68,1-89,3]
Month 12	67,7 [35,6-86,3]
Month 18	67,7 [35,6-86,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	8 (22,2)
95%-CI	[10,1-39,2]
TEAE in months [95%-CI]	
Median	NE [5,32-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [57,7-89,1]
Month 6	66,6 [37,3-84,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,1 [16,0-86,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	9 (11,0)
95%-CI	[5,1-19,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [79,1-94,4]
Month 6	85,2 [71,4-92,6]
Month 12	85,2 [71,4-92,6]
Month 18	85,2 [71,4-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [66,0-96,5]
Month 6	88,5 [66,0-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,33-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE [0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,9 [14,4-81,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	8 (9,8)
95%-CI	[4,3-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [84,4-96,6]
Month 6	88,6 [74,7-95,1]
Month 12	79,8 [53,2-92,2]
Month 18	79,8 [53,2-92,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE in months [95%-CI]	
Median	NE [6,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [69,2-95,1]
Month 6	87,3 [69,2-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	2,50 [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,3 [1,2-84,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	8 (9,8)
95%-CI	[4,3-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [83,2-96,4]
Month 6	84,6 [68,3-92,9]
Month 12	84,6 [68,3-92,9]
Month 18	84,6 [68,3-92,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	6 (16,7)
95%-CI	[6,4-32,8]
TEAE in months [95%-CI]	
Median	NE [5,42-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [64,6-93,2]
Month 6	67,1 [27,7-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [31,5-93,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	40 (48,8)
95%-CI	[37,6-60,1]
TEAE in months [95%-CI]	
Median	4,86[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,8 [44,7-67,3]
Month 6	44,4 [31,0-57,1]
Month 12	33,7 [17,8-50,3]
Month 18	33,7 [17,8-50,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	18 (50,0)
95%-CI	[32,9-67,1]
TEAE in months [95%-CI]	
Median	3,48[0,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,7 [34,0-69,9]
Month 6	40,3 [19,7-60,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	8 (80,0)
95%-CI	[44,4-97,5]
TEAE in months [95%-CI]	
Median	0,43 [0,03-8,51]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	25,0 [4,1-54,9]
Month 6	25,0 [4,1-54,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	9 (69,2)
95%-CI	[38,6-90,9]
TEAE in months [95%-CI]	
Median	0,49[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	25,6 [5,2-53,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	14 (17,1)
95%-CI	[9,7-27,0]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,7 [71,7-89,7]
Month 6	82,7 [71,7-89,7]
Month 12	70,9 [41,8-87,3]
Month 18	70,9 [41,8-87,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	6 (16,7)
95%-CI	[6,4-32,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,2 [66,4-92,1]
Month 6	83,2 [66,4-92,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	85,7 [33,4-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	2,83 [1,64-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,0 [1,1-82,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	10 (12,2)
95%-CI	[6,0-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [82,5-96,3]
Month 6	74,6 [54,3-86,9]
Month 12	74,6 [54,3-86,9]
Month 18	74,6 [54,3-86,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	6 (16,7)
95%-CI	[6,4-32,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,5 [56,6-90,2]
Month 6	78,5 [56,6-90,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	8,51 [0,33-8,51]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	3,38 [0,66-3,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	10 (12,2)
95%-CI	[6,0-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [79,7-95,2]
Month 6	81,0 [65,7-89,9]
Month 12	81,0 [65,7-89,9]
Month 18	81,0 [65,7-89,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	6 (16,7)
95%-CI	[6,4-32,8]
TEAE in months [95%-CI]	
Median	NE [6,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [69,8-94,0]
Month 6	86,1 [69,8-94,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,8 [9,0-82,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	11 (13,4)
95%-CI	[6,9-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [77,0-93,4]
Month 6	82,4 [69,6-90,2]
Month 12	82,4 [69,6-90,2]
Month 18	82,4 [69,6-90,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	6 (16,7)
95%-CI	[6,4-32,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [68,8-93,8]
Month 6	78,5 [55,0-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [0,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [83,7-96,5]
Month 6	92,4 [83,7-96,5]
Month 12	92,4 [83,7-96,5]
Month 18	92,4 [83,7-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	1 (2,8)
95%-CI	[0,1-14,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,2 [81,9-99,6]
Month 6	97,2 [81,9-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE [0,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,5 [27,6-85,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	7 (8,5)
95%-CI	[3,5-16,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [84,0-96,6]
Month 6	92,5 [84,0-96,6]
Month 12	84,8 [60,9-94,7]
Month 18	84,8 [60,9-94,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,2 [81,9-99,6]
Month 6	89,1 [57,9-97,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [81,7-96,2]
Month 6	91,5 [81,7-96,2]
Month 12	91,5 [81,7-96,2]
Month 18	91,5 [81,7-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-9,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,7 [34,9-86,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	42 (51,2)
95%-CI	[39,9-62,4]
TEAE in months [95%-CI]	
Median	1,74 [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,7 [26,9-52,2]
Month 6	39,7 [26,9-52,2]
Month 12	39,7 [26,9-52,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	20 (55,6)
95%-CI	[38,1-72,1]
TEAE in months [95%-CI]	
Median	2,07 [1,18-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,3 [27,6-63,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,0 [18,1-80,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	11 (13,4)
95%-CI	[6,9-22,7]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [74,0-92,0]
Month 6	85,3 [74,0-92,0]
Month 12	85,3 [74,0-92,0]
Month 18	42,7 [1,3-84,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	7 (19,4)
95%-CI	[8,2-36,0]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [61,5-91,2]
Month 6	69,4 [38,6-86,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	12 (14,6)
95%-CI	[7,8-24,2]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [73,8-91,2]
Month 6	84,6 [73,8-91,2]
Month 12	70,5 [36,4-88,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [69,8-95,1]
Month 6	79,5 [53,7-91,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	12 (14,6)
95%-CI	[7,8-24,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [73,1-91,0]
Month 6	84,2 [73,1-91,0]
Month 12	75,8 [52,8-88,6]
Month 18	75,8 [52,8-88,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [78,3-98,5]
Month 6	94,1 [78,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	8 (9,8)
95%-CI	[4,3-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [76,6-93,8]
Month 6	87,8 [76,6-93,8]
Month 12	87,8 [76,6-93,8]
Month 18	87,8 [76,6-93,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	6 (16,7)
95%-CI	[6,4-32,8]
TEAE in months [95%-CI]	
Median	NE [4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [66,3-94,7]
Month 6	59,1 [22,2-83,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	35 (42,7)
95%-CI	[31,8-54,1]
TEAE in months [95%-CI]	
Median	4,90 [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [53,0-75,0]
Month 6	48,3 [33,5-61,7]
Month 12	34,2 [18,2-50,8]
Month 18	34,2 [18,2-50,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	12 (33,3)
95%-CI	[18,6-51,0]
TEAE in months [95%-CI]	
Median	3,94 [2,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,9 [40,0-79,1]
Month 6	43,1 [17,3-66,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	3,09[0,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,0 [25,3-82,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
TEAE in months [95%-CI]	
Median	2,66[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	26,4 [1,7-64,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	20 (24,4)
95%-CI	[15,6-35,1]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,8 [64,1-84,2]
Month 6	72,6 [59,4-82,2]
Month 12	66,0 [47,4-79,4]
Month 18	66,0 [47,4-79,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	4 (11,1)
95%-CI	[3,1-26,1]
TEAE in months [95%-CI]	
Median	NE[4,57-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [67,3-96,6]
Month 6	76,2 [39,4-92,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,39-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,2 [33,2-93,5]
Month 6	76,2 [33,2-93,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	2,66[0,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,2 [1,6-77,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	12 (14,6)
95%-CI	[7,8-24,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [77,8-93,6]
Month 6	80,6 [65,0-89,7]
Month 12	73,2 [51,1-86,5]
Month 18	73,2 [51,1-86,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	1 (2,8)
95%-CI	[0,1-14,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	96,8 [79,2-99,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	9 (11,0)
95%-CI	[5,1-19,8]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [86,1-97,9]
Month 6	83,6 [66,0-92,6]
Month 12	68,4 [41,7-84,8]
Month 18	68,4 [41,7-84,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [60,1-95,2]
Month 6	85,4 [60,1-95,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,2 [42,7-91,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	25 (30,5)
95%-CI	[20,8-41,6]
TEAE in months [95%-CI]	
Median	NE [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,0 [55,8-78,9]
Month 6	54,8 [37,9-68,9]
Month 12	54,8 [37,9-68,9]
Month 18	54,8 [37,9-68,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	13 (36,1)
95%-CI	[20,8-53,8]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,7 [39,8-74,9]
Month 6	59,7 [39,8-74,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	6,47 [0,13-6,47]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,6 [14,0-79,0]
Month 6	50,6 [14,0-79,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	2,33[0,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,9 [1,5-78,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	29 (35,4)
95%-CI	[25,1-46,7]
TEAE in months [95%-CI]	
Median	7,10[3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,7 [51,9-75,0]
Month 6	54,2 [38,5-67,5]
Month 12	48,2 [30,4-63,9]
Month 18	48,2 [30,4-63,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	9 (25,0)
95%-CI	[12,1-42,2]
TEAE in months [95%-CI]	
Median	NE [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,2 [40,4-83,0]
Month 6	53,0 [22,3-76,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,6 [30,5-88,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE [0,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [37,3-87,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	24 (29,3)
95%-CI	[19,7-40,4]
TEAE in months [95%-CI]	
Median	10,97[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [67,8-86,1]
Month 6	56,3 [38,0-71,2]
Month 12	45,1 [21,2-66,4]
Month 18	45,1 [21,2-66,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	9 (25,0)
95%-CI	[12,1-42,2]
TEAE in months [95%-CI]	
Median	NE [3, 61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [59,6-89,4]
Month 6	65,2 [40,1-81,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
TEAE in months [95%-CI]	
Median	9,23 [0,10-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,3 [23,0-82,1]
Month 6	58,3 [23,0-82,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [20,4-96,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	9 (11,0)
95%-CI	[5,1-19,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [82,4-95,7]
Month 6	84,0 [68,8-92,2]
Month 12	84,0 [68,8-92,2]
Month 18	84,0 [68,8-92,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [76,4-97,2]
Month 6	91,7 [76,4-97,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	14 (17,1)
95%-CI	[9,7-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [73,6-90,8]
Month 6	79,1 [66,3-87,5]
Month 12	79,1 [66,3-87,5]
Month 18	79,1 [66,3-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	10 (27,8)
95%-CI	[14,2-45,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,7 [50,8-82,5]
Month 6	69,7 [50,8-82,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [29,1-88,3]
Month 6	67,5 [29,1-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [85,4-97,3]
Month 6	91,2 [80,7-96,1]
Month 12	91,2 [80,7-96,1]
Month 18	91,2 [80,7-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [76,6-98,4]
Month 6	93,6 [76,6-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE in months [95%-CI]	
Median	NE [0,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	12 (14,6)
95%-CI	[7,8-24,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [72,5-90,5]
Month 6	83,6 [72,5-90,5]
Month 12	83,6 [72,5-90,5]
Month 18	83,6 [72,5-90,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	10 (27,8)
95%-CI	[14,2-45,2]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [47,7-81,7]
Month 6	67,9 [47,7-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [36,5-93,9]
Month 6	77,8 [36,5-93,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [0,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [30,6-89,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	10 (12,2)
95%-CI	[6,0-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [75,4-92,4]
Month 6	86,2 [75,4-92,4]
Month 12	86,2 [75,4-92,4]
Month 18	86,2 [75,4-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,2 [59,1-92,1]
Month 6	81,2 [59,1-92,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	16 (19,5)
95%-CI	[11,6-29,7]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [74,0-92,6]
Month 6	71,7 [55,2-83,0]
Month 12	53,8 [28,1-73,9]
Month 18	53,8 [28,1-73,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [70,6-98,0]
Month 6	83,6 [53,9-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	11 (13,4)
95%-CI	[6,9-22,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [79,1-94,4]
Month 6	81,4 [65,0-90,7]
Month 12	75,2 [54,1-87,6]
Month 18	75,2 [54,1-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	4 (11,1)
95%-CI	[3,1-26,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [66,7-94,9]
Month 6	86,4 [66,7-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Maximal longest diameter: > 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	80,0 [40,9-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [81,8-96,1]
Month 6	91,4 [81,8-96,1]
Month 12	91,4 [81,8-96,1]
Month 18	91,4 [81,8-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [77,9-98,5]
Month 6	94,0 [77,9-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	80,0 [40,9-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	11 (13,4)
95%-CI	[6,9-22,7]
TEAE in months [95%-CI]	
Median	NE [9,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [78,6-93,7]
Month 6	88,2 [78,6-93,7]
Month 12	70,6 [41,7-87,1]
Month 18	70,6 [41,7-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [77,9-98,5]
Month 6	94,0 [77,9-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE in months [95%-CI]	
Median	7,16[0,23-7,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	80,0 [40,9-94,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	7 (8,5)
95%-CI	[3,5-16,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [79,0-95,7]
Month 6	87,4 [74,2-94,1]
Month 12	87,4 [74,2-94,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [66,8-96,4]
Month 6	88,6 [66,8-96,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [29,8-93,4]
Month 6	75,0 [29,8-93,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	3 (3,7)
95%-CI	[0,8-10,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,9 [87,7-98,7]
Month 6	95,9 [87,7-98,7]
Month 12	95,9 [87,7-98,7]
Month 18	95,9 [87,7-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	4 (11,1)
95%-CI	[3,1-26,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [65,2-94,8]
Month 6	85,9 [65,2-94,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE in months [95%-CI]	
Median	NE [0,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [29,8-93,4]
Month 6	75,0 [29,8-93,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS11: Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [30,9-94,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

4.10.12 Merkmal: Primärdiagnose

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	84 (66,1)
95%-CI	[57,2-74,3]
TEAE in months [95%-CI]	
Median	1,48 [0,89-2,07]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,8 [27,7-45,8]
Month 6	24,2 [15,1-34,5]
Month 12	14,8 [6,2-26,7]
Month 18	14,8 [6,2-26,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	9 (81,8)
95%-CI	[48,2-97,7]
TEAE in months [95%-CI]	
Median	0,85 [0,07-2,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	35 (27,6)
95%-CI	[20,0-36,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,9 [60,1-77,7]
Month 6	67,3 [56,4-76,0]
Month 12	67,3 [56,4-76,0]
Month 18	67,3 [56,4-76,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	NE[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,6 [22,9-78,0]
Month 6	54,6 [22,9-78,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	26 (20,5)
95%-CI	[13,8-28,5]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,6 [73,4-88,9]
Month 6	71,5 [58,1-81,2]
Month 12	52,8 [30,8-70,7]
Month 18	52,8 [30,8-70,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	4,90 [4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	34,1 [1,3-76,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	23 (18,1)
95%-CI	[11,8-25,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [73,6-88,2]
Month 6	76,7 [66,2-84,4]
Month 12	76,7 [66,2-84,4]
Month 18	76,7 [66,2-84,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE [0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [23,6-88,3]
Month 6	65,5 [23,6-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	13 (10,2)
95%-CI	[5,6-16,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [80,4-93,6]
Month 6	86,5 [76,9-92,3]
Month 12	86,5 [76,9-92,3]
Month 18	86,5 [76,9-92,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [3,71-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	71 (55,9)
95%-CI	[46,8-64,7]
TEAE in months [95%-CI]	
Median	1,41 [0,89-3,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,7 [34,1-52,8]
Month 6	37,3 [26,7-47,9]
Month 12	24,9 [11,1-41,4]
Month 18	24,9 [11,1-41,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	7 (63,6)
95%-CI	[30,8-89,1]
TEAE in months [95%-CI]	
Median	0,49[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,1 [9,1-61,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	51 (40,2)
95%-CI	[31,6-49,2]
TEAE in months [95%-CI]	
Median	5,39[2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,2 [49,0-68,0]
Month 6	49,3 [37,4-60,2]
Month 12	42,3 [26,1-57,6]
Month 18	42,3 [26,1-57,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,6 [25,8-83,1]
Month 6	60,6 [25,8-83,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	40 (31,5)
95%-CI	[23,5-40,3]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,1 [61,0-77,5]
Month 6	68,7 [59,2-76,4]
Month 12	44,1 [21,1-65,1]
Month 18	44,1 [21,1-65,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE in months [95%-CI]	
Median	NE [0,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,3 [27,8-84,0]
Month 6	62,3 [27,8-84,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	33 (26,0)
95%-CI	[18,6-34,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,2 [60,4-78,0]
Month 6	70,2 [60,4-78,0]
Month 12	70,2 [60,4-78,0]
Month 18	70,2 [60,4-78,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE in months [95%-CI]	
Median	NE [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,6 [29,7-84,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	18 (14,2)
95%-CI	[8,6-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [78,1-91,3]
Month 6	78,9 [64,9-87,9]
Month 12	78,9 [64,9-87,9]
Month 18	78,9 [64,9-87,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE [0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [35,0-89,9]
Month 6	71,6 [35,0-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	9 (7,1)
95%-CI	[3,3-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [84,7-95,9]
Month 6	92,0 [84,7-95,9]
Month 12	92,0 [84,7-95,9]
Month 18	92,0 [84,7-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	8,05[8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	74 (58,3)
95%-CI	[49,2-67,0]
TEAE in months [95%-CI]	
Median	1,64 [1,18-2,83]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,9 [30,3-49,3]
Month 6	29,9 [19,7-40,7]
Month 12	29,9 [19,7-40,7]
Month 18	29,9 [19,7-40,7]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	NE [0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,6 [22,9-78,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	53 (41,7)
95%-CI	[33,0-50,8]
TEAE in months [95%-CI]	
Median	4,14 [2,83-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,7 [48,1-67,9]
Month 6	42,8 [30,7-54,5]
Month 12	37,5 [23,4-51,5]
Month 18	37,5 [23,4-51,5]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	8,05 [0,82-8,05]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,2 [21,3-82,7]
Month 6	58,2 [21,3-82,7]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	24 (18,9)
95%-CI	[12,5-26,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,4 [69,3-86,5]
Month 6	68,1 [54,5-78,4]
Month 12	68,1 [54,5-78,4]
Month 18	68,1 [54,5-78,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [24,1-93,1]
Month 6	72,7 [24,1-93,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	19 (15,0)
95%-CI	[9,3-22,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,3 [75,3-90,2]
Month 6	80,4 [69,8-87,6]
Month 12	73,1 [53,5-85,4]
Month 18	73,1 [53,5-85,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	19 (15,0)
95%-CI	[9,3-22,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,8 [74,9-89,8]
Month 6	79,8 [69,2-87,1]
Month 12	79,8 [69,2-87,1]
Month 18	79,8 [69,2-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE[4,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	60,6 [7,6-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	10 (7,9)
95%-CI	[3,8-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [84,8-96,1]
Month 6	88,7 [79,5-94,0]
Month 12	88,7 [79,5-94,0]
Month 18	88,7 [79,5-94,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	66 (52,0)
95%-CI	[42,9-60,9]
TEAE in months [95%-CI]	
Median	1,84 [0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,0 [37,6-55,8]
Month 6	44,5 [34,5-54,1]
Month 12	35,6 [19,0-52,7]
Month 18	35,6 [19,0-52,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	9 (81,8)
95%-CI	[48,2-97,7]
TEAE in months [95%-CI]	
Median	0,89[0,43-2,76]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	12,1 [0,7-40,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	28 (22,0)
95%-CI	[15,2-30,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [67,3-83,3]
Month 6	74,1 [63,9-81,8]
Month 12	74,1 [63,9-81,8]
Month 18	74,1 [63,9-81,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,9 [18,2-76,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	20 (15,7)
95%-CI	[9,9-23,3]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [75,0-89,8]
Month 6	78,3 [66,0-86,6]
Month 12	65,2 [35,3-83,9]
Month 18	65,2 [35,3-83,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	2,63[0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,8 [13,5-74,9]
Month 6	46,8 [13,5-74,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	18 (14,2)
95%-CI	[8,6-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [76,0-90,2]
Month 6	81,7 [71,1-88,7]
Month 12	81,7 [71,1-88,7]
Month 18	81,7 [71,1-88,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [81,6-93,9]
Month 6	86,2 [75,4-92,5]
Month 12	74,5 [52,2-87,5]
Month 18	74,5 [52,2-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	13 (10,2)
95%-CI	[5,6-16,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [82,7-94,4]
Month 6	84,1 [71,3-91,5]
Month 12	84,1 [71,3-91,5]
Month 18	84,1 [71,3-91,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE in months [95%-CI]	
Median	4,96[0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [23,6-88,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	67 (52,8)
95%-CI	[43,7-61,7]
TEAE in months [95%-CI]	
Median	3,48 [1,58-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,1 [43,5-61,8]
Month 6	40,8 [29,9-51,4]
Month 12	25,3 [12,5-40,2]
Month 18	25,3 [12,5-40,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	2,53[0,36-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,7 [14,1-75,7]
Month 6	47,7 [14,1-75,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	18 (14,2)
95%-CI	[8,6-21,5]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [75,4-90,1]
Month 6	84,2 [75,4-90,1]
Month 12	72,2 [42,5-88,3]
Month 18	72,2 [42,5-88,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE[0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	81,8 [44,7-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	17 (13,4)
95%-CI	[8,0-20,6]
TEAE in months [95%-CI]	
Median	NE [8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [81,5-93,7]
Month 6	77,4 [62,4-87,0]
Month 12	69,7 [47,7-83,8]
Month 18	69,7 [47,7-83,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE in months [95%-CI]	
Median	4,96[1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [23,6-88,3]
Month 6	43,6 [7,3-76,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	19 (15,0)
95%-CI	[9,3-22,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [77,6-91,1]
Month 6	81,7 [71,5-88,5]
Month 12	77,6 [64,0-86,6]
Month 18	77,6 [64,0-86,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	65,5 [23,6-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	17 (13,4)
95%-CI	[8,0-20,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [79,7-92,6]
Month 6	82,0 [71,5-88,9]
Month 12	82,0 [71,5-88,9]
Month 18	82,0 [71,5-88,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	11 (8,7)
95%-CI	[4,4-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [84,2-94,9]
Month 6	90,9 [84,2-94,9]
Month 12	90,9 [84,2-94,9]
Month 18	90,9 [84,2-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	10 (7,9)
95%-CI	[3,8-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,5 [87,4-96,7]
Month 6	91,5 [83,3-95,7]
Month 12	84,4 [63,1-94,0]
Month 18	84,4 [63,1-94,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	9 (7,1)
95%-CI	[3,3-13,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [84,7-95,8]
Month 6	91,9 [84,7-95,8]
Month 12	91,9 [84,7-95,8]
Month 18	91,9 [84,7-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	60 (47,2)
95%-CI	[38,3-56,3]
TEAE in months [95%-CI]	
Median	2,17[1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [33,7-54,3]
Month 6	35,0 [20,2-50,1]
Month 12	35,0 [20,2-50,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	3,91[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,4 [26,6-83,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [77,3-91,7]
Month 6	86,1 [77,3-91,7]
Month 12	86,1 [77,3-91,7]
Month 18	43,1 [1,3-85,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [42,4-94,9]
Month 6	60,6 [16,6-87,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [79,7-92,7]
Month 6	85,5 [76,0-91,5]
Month 12	74,8 [47,2-89,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE [1,64-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [42,4-94,9]
Month 6	80,8 [42,4-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [78,1-91,9]
Month 6	86,5 [78,1-91,9]
Month 12	78,6 [57,2-90,2]
Month 18	78,6 [57,2-90,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [77,9-92,2]
Month 6	80,5 [67,2-88,8]
Month 12	80,5 [67,2-88,8]
Month 18	80,5 [67,2-88,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	55 (43,3)
95%-CI	[34,5-52,4]
TEAE in months [95%-CI]	
Median	4,44 [3,09-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,4 [50,4-69,0]
Month 6	46,1 [34,0-57,3]
Month 12	34,2 [20,2-48,7]
Month 18	34,2 [20,2-48,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	3,02 [2,46-4,90]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,6 [12,8-83,6]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	29 (22,8)
95%-CI	[15,9-31,1]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,6 [67,2-83,6]
Month 6	71,5 [59,8-80,3]
Month 12	65,5 [48,9-77,9]
Month 18	65,5 [48,9-77,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE [2,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [19,5-90,4]
Month 6	66,7 [19,5-90,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [83,2-94,3]
Month 6	85,8 [75,7-92,0]
Month 12	78,7 [58,4-89,9]
Month 18	78,7 [58,4-89,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE [2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	55,6 [7,3-87,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	16 (12,6)
95%-CI	[7,4-19,7]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [81,2-94,1]
Month 6	81,0 [67,5-89,3]
Month 12	67,5 [44,4-82,7]
Month 18	67,5 [44,4-82,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	43 (33,9)
95%-CI	[25,7-42,8]
TEAE in months [95%-CI]	
Median	6,47 [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [53,6-72,9]
Month 6	53,5 [40,1-65,2]
Month 12	48,6 [33,4-62,2]
Month 18	48,6 [33,4-62,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	5 (45,5)
95%-CI	[16,7-76,6]
TEAE in months [95%-CI]	
Median	2,99[0,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,4 [5,8-69,8]
Month 6	36,4 [5,8-69,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	38 (29,9)
95%-CI	[22,1-38,7]
TEAE in months [95%-CI]	
Median	NE [5,78-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,0 [57,3-76,5]
Month 6	55,7 [41,2-68,0]
Month 12	50,2 [33,4-64,8]
Month 18	50,2 [33,4-64,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	6 (54,5)
95%-CI	[23,4-83,3]
TEAE in months [95%-CI]	
Median	2,73[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,8 [13,5-74,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	37 (29,1)
95%-CI	[21,4-37,9]
TEAE in months [95%-CI]	
Median	9,23[5,29-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [68,7-84,0]
Month 6	57,3 [42,4-69,7]
Month 12	39,3 [17,5-60,7]
Month 18	39,3 [17,5-60,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [37,1-90,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	13 (10,2)
95%-CI	[5,6-16,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [84,5-95,0]
Month 6	85,7 [74,2-92,3]
Month 12	85,7 [74,2-92,3]
Month 18	85,7 [74,2-92,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE [0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	24 (18,9)
95%-CI	[12,5-26,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,4 [71,6-86,8]
Month 6	76,4 [66,0-84,0]
Month 12	76,4 [66,0-84,0]
Month 18	76,4 [66,0-84,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [37,1-90,3]
Month 6	72,7 [37,1-90,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	10 (7,9)
95%-CI	[3,8-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [85,5-95,9]
Month 6	90,4 [82,3-94,9]
Month 12	90,4 [82,3-94,9]
Month 18	90,4 [82,3-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	25 (19,7)
95%-CI	[13,2-27,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [67,8-84,2]
Month 6	77,2 [67,8-84,2]
Month 12	77,2 [67,8-84,2]
Month 18	77,2 [67,8-84,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [35,0-89,9]
Month 6	71,6 [35,0-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	14 (11,0)
95%-CI	[6,2-17,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [77,3-91,8]
Month 6	86,2 [77,3-91,8]
Month 12	86,2 [77,3-91,8]
Month 18	86,2 [77,3-91,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE [1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [42,4-94,9]
Month 6	80,8 [42,4-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	17 (13,4)
95%-CI	[8,0-20,6]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [81,5-94,9]
Month 6	77,8 [64,4-86,6]
Month 12	60,5 [34,5-78,8]
Month 18	60,5 [34,5-78,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE in months [95%-CI]	
Median	NE [2,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,6 [12,8-83,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	19 (15,0)
95%-CI	[9,3-22,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [77,6-91,1]
Month 6	80,1 [67,6-88,1]
Month 12	74,7 [57,8-85,7]
Month 18	74,7 [57,8-85,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	11 (8,7)
95%-CI	[4,4-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [82,6-94,4]
Month 6	90,0 [82,6-94,4]
Month 12	90,0 [82,6-94,4]
Month 18	90,0 [82,6-94,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	15 (11,8)
95%-CI	[6,8-18,7]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [82,5-94,0]
Month 6	89,7 [82,5-94,0]
Month 12	66,3 [37,9-84,0]
Month 18	66,3 [37,9-84,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE in months [95%-CI]	
Median	NE[0,03-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	81,8 [44,7-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	13 (10,2)
95%-CI	[5,6-16,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [79,8-93,4]
Month 6	86,2 [76,5-92,1]
Month 12	86,2 [76,5-92,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	10 (7,9)
95%-CI	[3,8-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [83,4-95,1]
Month 6	90,9 [83,4-95,1]
Month 12	90,9 [83,4-95,1]
Month 18	90,9 [83,4-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS12: Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE in months [95%-CI]	
Median	NE [1,81-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	85,7 [33,4-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

4.10.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	37 (58,7)
95%-CI	[45,6-71,0]
TEAE in months [95%-CI]	
Median	2,56 [0,85-3,71]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,2 [31,6-57,8]
Month 6	35,5 [21,7-49,6]
Month 12	24,3 [10,4-41,4]
Month 18	24,3 [10,4-41,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	24 (68,6)
95%-CI	[50,7-83,1]
TEAE in months [95%-CI]	
Median	1,61 [0,72-4,37]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,4 [21,5-55,2]
Month 6	12,0 [1,1-37,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	35 (74,5)
95%-CI	[59,7-86,1]
TEAE in months [95%-CI]	
Median	0,85 [0,43-1,61]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	19,0 [8,3-33,2]
Month 6	12,7 [3,2-28,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	14 (22,2)
95%-CI	[12,7-34,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,2 [61,1-84,8]
Month 6	75,2 [61,1-84,8]
Month 12	75,2 [61,1-84,8]
Month 18	75,2 [61,1-84,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	10 (28,6)
95%-CI	[14,6-46,3]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [49,5-84,1]
Month 6	58,8 [30,1-79,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	16 (34,0)
95%-CI	[20,9-49,3]
TEAE in months [95%-CI]	
Median	NE [1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,3 [44,2-74,6]
Month 6	61,3 [44,2-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	12 (19,0)
95%-CI	[10,2-30,9]
TEAE in months [95%-CI]	
Median	NE [6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [71,8-92,5]
Month 6	77,1 [59,3-87,8]
Month 12	58,4 [29,4-79,0]
Month 18	58,4 [29,4-79,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	9,10 [4,86-9,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [63,0-94,6]
Month 6	51,2 [13,4-80,0]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	10 (21,3)
95%-CI	[10,7-35,7]
TEAE in months [95%-CI]	
Median	NE [3,32-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [61,7-90,2]
Month 6	62,9 [38,4-79,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	7 (11,1)
95%-CI	[4,6-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [78,7-95,3]
Month 6	86,1 [71,6-93,5]
Month 12	86,1 [71,6-93,5]
Month 18	86,1 [71,6-93,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	10 (28,6)
95%-CI	[14,6-46,3]
TEAE in months [95%-CI]	
Median	NE [2,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [44,3-80,3]
Month 6	65,5 [44,3-80,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	11 (23,4)
95%-CI	[12,3-38,0]
TEAE in months [95%-CI]	
Median	NE[3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [61,8-88,1]
Month 6	69,1 [49,5-82,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [80,9-96,4]
Month 6	91,6 [80,9-96,4]
Month 12	91,6 [80,9-96,4]
Month 18	91,6 [80,9-96,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [3,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [65,6-96,4]
Month 6	78,4 [46,9-92,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [73,8-96,2]
Month 6	84,1 [63,2-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	25 (39,7)
95%-CI	[27,6-52,8]
TEAE in months [95%-CI]	
Median	3,15[2,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,6 [42,2-70,3]
Month 6	49,9 [33,4-64,4]
Month 12	49,9 [33,4-64,4]
Month 18	49,9 [33,4-64,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	22 (62,9)
95%-CI	[44,9-78,5]
TEAE in months [95%-CI]	
Median	0,95 [0,49-6,93]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,4 [21,3-53,5]
Month 6	37,4 [21,3-53,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	36 (76,6)
95%-CI	[62,0-87,7]
TEAE in months [95%-CI]	
Median	0,49 [0,33-0,95]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	23,9 [12,3-37,6]
Month 6	17,9 [6,6-33,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	18 (28,6)
95%-CI	[17,9-41,3]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,3 [57,5-82,7]
Month 6	61,4 [44,1-74,8]
Month 12	61,4 [44,1-74,8]
Month 18	61,4 [44,1-74,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	19 (54,3)
95%-CI	[36,6-71,2]
TEAE in months [95%-CI]	
Median	1,64 [0,69-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,8 [24,8-59,7]
Month 6	42,8 [24,8-59,7]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	21 (44,7)
95%-CI	[30,2-59,9]
TEAE in months [95%-CI]	
Median	3,02 [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,8 [34,7-66,5]
Month 6	40,1 [20,7-58,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	13 (20,6)
95%-CI	[11,5-32,7]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [68,0-89,0]
Month 6	77,4 [62,7-86,9]
Month 12	61,9 [28,3-83,3]
Month 18	61,9 [28,3-83,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	6,93[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,6 [46,0-78,2]
Month 6	64,6 [46,0-78,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	22 (46,8)
95%-CI	[32,1-61,9]
TEAE in months [95%-CI]	
Median	9,23[0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,6 [36,7-66,2]
Month 6	52,6 [36,7-66,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Number prior lines: 2 lines	
Patients in analysis set	63
Patients with events - n(%)	10 (15,9)
95%-CI	[7,9-27,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,2 [67,4-89,6]
Month 6	81,2 [67,4-89,6]
Month 12	81,2 [67,4-89,6]
Month 18	81,2 [67,4-89,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,6 [56,9-87,0]
Month 6	75,6 [56,9-87,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	20 (42,6)
95%-CI	[28,3-57,8]
TEAE in months [95%-CI]	
Median	NE [1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,4 [35,8-66,6]
Month 6	52,4 [35,8-66,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [85,5-98,4]
Month 6	89,1 [68,1-96,6]
Month 12	89,1 [68,1-96,6]
Month 18	89,1 [68,1-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,9 [50,8-83,9]
Month 6	70,9 [50,8-83,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	8 (17,0)
95%-CI	[7,6-30,8]
TEAE in months [95%-CI]	
Median	NE [5,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [67,8-91,7]
Month 6	69,4 [35,2-88,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	1 (1,6)
95%-CI	[0,0-8,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [77,2-99,5]
Month 6	96,4 [77,2-99,5]
Month 12	96,4 [77,2-99,5]
Month 18	96,4 [77,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [71,7-95,4]
Month 6	88,3 [71,7-95,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE in months [95%-CI]	
Median	NE [8,05-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [76,3-95,4]
Month 6	89,4 [76,3-95,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	31 (49,2)
95%-CI	[36,4-62,1]
TEAE in months [95%-CI]	
Median	2,83[1,38-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,7 [33,9-61,9]
Month 6	39,5 [23,3-55,4]
Month 12	39,5 [23,3-55,4]
Month 18	39,5 [23,3-55,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	21 (60,0)
95%-CI	[42,1-76,1]
TEAE in months [95%-CI]	
Median	2,10 [0,49-4,14]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,5 [25,2-58,8]
Month 6	22,7 [5,4-46,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	31 (66,0)
95%-CI	[50,7-79,1]
TEAE in months [95%-CI]	
Median	0,82 [0,56-2,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	29,5 [16,1-44,2]
Month 6	26,2 [13,4-41,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	23 (36,5)
95%-CI	[24,7-49,6]
TEAE in months [95%-CI]	
Median	5,16[2,83-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,9 [49,9-77,8]
Month 6	47,9 [28,8-64,7]
Month 12	35,9 [13,5-59,2]
Month 18	35,9 [13,5-59,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	18 (51,4)
95%-CI	[34,0-68,6]
TEAE in months [95%-CI]	
Median	2,79 [1,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,9 [29,6-65,7]
Month 6	26,1 [6,1-52,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	20 (42,6)
95%-CI	[28,3-57,8]
TEAE in months [95%-CI]	
Median	3,48[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,8 [37,1-69,4]
Month 6	47,5 [29,9-63,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	7 (11,1)
95%-CI	[4,6-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [71,7-94,1]
Month 6	82,1 [64,1-91,7]
Month 12	82,1 [64,1-91,7]
Month 18	82,1 [64,1-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	NE [3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [62,8-92,6]
Month 6	61,3 [28,7-82,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	15 (31,9)
95%-CI	[19,1-47,1]
TEAE in months [95%-CI]	
Median	NE [2, 63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,2 [43,3-76,3]
Month 6	51,2 [30,0-68,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	9 (14,3)
95%-CI	[6,7-25,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [70,2-92,3]
Month 6	80,5 [63,9-90,0]
Month 12	80,5 [63,9-90,0]
Month 18	80,5 [63,9-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [64,9-94,4]
Month 6	85,4 [64,9-94,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	10 (21,3)
95%-CI	[10,7-35,7]
TEAE in months [95%-CI]	
Median	NE [7,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,7 [61,4-88,9]
Month 6	74,1 [54,9-86,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	9 (14,3)
95%-CI	[6,7-25,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [70,5-92,2]
Month 6	80,7 [64,5-90,0]
Month 12	80,7 [64,5-90,0]
Month 18	80,7 [64,5-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE[4,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [66,9-94,8]
Month 6	74,0 [39,8-90,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	9 (19,1)
95%-CI	[9,1-33,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,9 [63,2-89,6]
Month 6	74,5 [54,9-86,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [80,4-97,1]
Month 6	92,3 [80,4-97,1]
Month 12	92,3 [80,4-97,1]
Month 18	92,3 [80,4-97,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [69,9-96,5]
Month 6	89,4 [69,9-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,0 [80,4-99,6]
Month 6	88,3 [67,6-96,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	32 (50,8)
95%-CI	[37,9-63,6]
TEAE in months [95%-CI]	
Median	4,63[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,4 [37,1-62,3]
Month 6	46,2 [31,7-59,4]
Month 12	36,9 [18,2-55,9]
Month 18	36,9 [18,2-55,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	19 (54,3)
95%-CI	[36,6-71,2]
TEAE in months [95%-CI]	
Median	1,38[0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,8 [20,3-57,0]
Month 6	38,8 [20,3-57,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	26 (55,3)
95%-CI	[40,1-69,8]
TEAE in months [95%-CI]	
Median	1,41[0,43-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,8 [26,8-56,1]
Month 6	41,8 [26,8-56,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	13 (20,6)
95%-CI	[11,5-32,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [64,4-86,6]
Month 6	77,7 [64,4-86,6]
Month 12	77,7 [64,4-86,6]
Month 18	77,7 [64,4-86,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,8 [54,1-84,9]
Month 6	72,8 [54,1-84,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	12 (25,5)
95%-CI	[13,9-40,3]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [52,3-82,7]
Month 6	64,0 [42,9-79,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	13 (20,6)
95%-CI	[11,5-32,7]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,5 [63,8-87,8]
Month 6	73,3 [55,1-85,0]
Month 12	61,1 [32,2-80,7]
Month 18	61,1 [32,2-80,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [70,4-95,2]
Month 6	87,7 [70,4-95,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	8 (17,0)
95%-CI	[7,6-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [63,7-91,0]
Month 6	74,0 [50,4-87,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	7 (11,1)
95%-CI	[4,6-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [76,3-94,9]
Month 6	83,2 [64,5-92,6]
Month 12	83,2 [64,5-92,6]
Month 18	83,2 [64,5-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Number prior lines: 3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [59,0-92,4]
Month 6	81,5 [59,0-92,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	7 (14,9)
95%-CI	[6,2-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [69,4-92,2]
Month 6	84,2 [69,4-92,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [83,4-98,2]
Month 6	94,5 [83,4-98,2]
Month 12	86,6 [59,9-96,0]
Month 18	86,6 [59,9-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [66,9-96,4]
Month 6	73,8 [33,8-91,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	9 (19,1)
95%-CI	[9,1-33,3]
TEAE in months [95%-CI]	
Median	NE[8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [67,4-90,7]
Month 6	82,2 [67,4-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	7 (11,1)
95%-CI	[4,6-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [79,0-95,4]
Month 6	84,3 [65,9-93,3]
Month 12	84,3 [65,9-93,3]
Month 18	84,3 [65,9-93,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Number prior lines: 3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE[4,96-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [69,3-96,5]
Month 6	66,9 [18,1-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [68,5-93,9]
Month 6	78,6 [54,9-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	30 (47,6)
95%-CI	[34,9-60,6]
TEAE in months [95%-CI]	
Median	5,75 [2,14-10,15]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,6 [46,5-72,1]
Month 6	47,0 [30,9-61,6]
Month 12	30,2 [13,6-48,8]
Month 18	30,2 [13,6-48,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	21 (60,0)
95%-CI	[42,1-76,1]
TEAE in months [95%-CI]	
Median	1,25[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,6 [22,6-56,2]
Month 6	33,9 [17,0-51,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	26 (55,3)
95%-CI	[40,1-69,8]
TEAE in months [95%-CI]	
Median	2,56[0,53-8,51]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,0 [31,1-61,4]
Month 6	36,6 [19,8-53,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [82,9-97,4]
Month 6	93,2 [82,9-97,4]
Month 12	79,9 [40,9-94,5]
Month 18	79,9 [40,9-94,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,6 [47,9-83,7]
Month 6	69,6 [47,9-83,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	9 (19,1)
95%-CI	[9,1-33,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [61,8-88,2]
Month 6	78,2 [61,8-88,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	9 (14,3)
95%-CI	[6,7-25,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [72,3-93,4]
Month 6	75,3 [53,9-87,8]
Month 12	75,3 [53,9-87,8]
Month 18	75,3 [53,9-87,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	57,4 [19,0-83,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	9 (19,1)
95%-CI	[9,1-33,3]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [63,8-89,7]
Month 6	80,2 [63,8-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	8 (12,7)
95%-CI	[5,6-23,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [79,0-95,4]
Month 6	86,2 [71,9-93,6]
Month 12	79,1 [56,6-90,8]
Month 18	79,1 [56,6-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE[4,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [68,0-93,6]
Month 6	73,0 [40,3-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	8 (17,0)
95%-CI	[7,6-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,5 [64,4-91,0]
Month 6	76,1 [55,8-88,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [82,4-97,3]
Month 6	89,5 [75,2-95,7]
Month 12	89,5 [75,2-95,7]
Month 18	89,5 [75,2-95,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [68,5-93,7]
Month 6	85,5 [68,5-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	10 (21,3)
95%-CI	[10,7-35,7]
TEAE in months [95%-CI]	
Median	NE [3,52-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [61,9-89,2]
Month 6	69,3 [48,4-83,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	3 (4,8)
95%-CI	[1,0-13,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [85,4-98,4]
Month 6	95,0 [85,4-98,4]
Month 12	95,0 [85,4-98,4]
Month 18	95,0 [85,4-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [75,5-97,1]
Month 6	91,3 [75,5-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [71,8-93,7]
Month 6	86,3 [71,8-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [86,0-98,4]
Month 6	95,2 [86,0-98,4]
Month 12	81,6 [39,7-95,6]
Month 18	81,6 [39,7-95,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [3,52-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [74,6-97,0]
Month 6	79,7 [45,5-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [81,5-97,9]
Month 6	93,6 [81,5-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	3 (4,8)
95%-CI	[1,0-13,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [84,8-98,3]
Month 6	94,8 [84,8-98,3]
Month 12	94,8 [84,8-98,3]
Month 18	94,8 [84,8-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	94,3 [79,0-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [71,2-94,7]
Month 6	87,2 [71,2-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	34 (54,0)
95%-CI	[40,9-66,6]
TEAE in months [95%-CI]	
Median	1,51 [1,15-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,6 [26,7-54,0]
Month 6	22,5 [6,1-45,3]
Month 12	22,5 [6,1-45,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	14 (40,0)
95%-CI	[23,9-57,9]
TEAE in months [95%-CI]	
Median	2,79 [1,68-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,4 [23,2-65,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	20 (42,6)
95%-CI	[28,3-57,8]
TEAE in months [95%-CI]	
Median	3,06[1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,0 [35,0-66,6]
Month 6	46,8 [28,9-62,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	10 (15,9)
95%-CI	[7,9-27,3]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [71,1-92,1]
Month 6	79,9 [62,8-89,7]
Month 12	79,9 [62,8-89,7]
Month 18	39,9 [1,5-81,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [66,3-94,7]
Month 6	86,2 [66,3-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [70,7-94,7]
Month 6	87,2 [70,7-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	13 (20,6)
95%-CI	[11,5-32,7]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [65,2-88,0]
Month 6	75,2 [59,2-85,6]
Month 12	60,2 [27,7-81,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [73,5-96,9]
Month 6	90,6 [73,5-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [77,6-97,5]
Month 6	92,2 [77,6-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	11 (17,5)
95%-CI	[9,1-29,1]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [67,0-89,4]
Month 6	80,9 [67,0-89,4]
Month 12	67,5 [35,3-86,2]
Month 18	67,5 [35,3-86,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [77,3-97,4]
Month 6	92,1 [77,3-97,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	7 (11,1)
95%-CI	[4,6-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [79,8-96,2]
Month 6	80,5 [59,3-91,4]
Month 12	80,5 [59,3-91,4]
Month 18	80,5 [59,3-91,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,4 [49,6-88,3]
Month 6	74,4 [49,6-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	2 (4,3)
95%-CI	[0,5-14,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [79,4-98,6]
Month 6	94,5 [79,4-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	22 (34,9)
95%-CI	[23,3-48,0]
TEAE in months [95%-CI]	
Median	7,69[3,94-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,8 [50,9-77,2]
Month 6	62,2 [46,3-74,6]
Month 12	48,4 [27,3-66,7]
Month 18	48,4 [27,3-66,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	4,76 [3,61-7,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [50,2-83,9]
Month 6	22,7 [1,5-59,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	26 (55,3)
95%-CI	[40,1-69,8]
TEAE in months [95%-CI]	
Median	2,86 [1,68-4,34]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,5 [32,0-63,3]
Month 6	20,7 [6,2-40,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	11 (17,5)
95%-CI	[9,1-29,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,1 [66,8-89,7]
Month 6	76,3 [58,9-87,1]
Month 12	76,3 [58,9-87,1]
Month 18	76,3 [58,9-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	7,62 [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,9 [64,0-91,5]
Month 6	81,9 [64,0-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	14 (29,8)
95%-CI	[17,3-44,9]
TEAE in months [95%-CI]	
Median	NE [2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,8 [47,7-78,9]
Month 6	59,2 [38,4-75,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	6 (9,5)
95%-CI	[3,6-19,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [79,0-95,4]
Month 6	90,0 [79,0-95,4]
Month 12	90,0 [79,0-95,4]
Month 18	90,0 [79,0-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	7,62 [4,90-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	78,6 [33,1-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	7 (14,9)
95%-CI	[6,2-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [70,8-94,5]
Month 6	75,5 [51,3-88,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [85,8-98,4]
Month 6	95,2 [85,8-98,4]
Month 12	81,6 [39,8-95,6]
Month 18	81,6 [39,8-95,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	7,26 [4,76-7,26]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	78,1 [31,7-94,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	9 (19,1)
95%-CI	[9,1-33,3]
TEAE in months [95%-CI]	
Median	NE [4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [63,6-90,5]
Month 6	66,2 [40,7-82,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	18 (28,6)
95%-CI	[17,9-41,3]
TEAE in months [95%-CI]	
Median	NE [4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,0 [58,4-83,1]
Month 6	58,8 [39,3-74,0]
Month 12	58,8 [39,3-74,0]
Month 18	58,8 [39,3-74,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	NE [1,74-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,0 [35,2-72,5]
Month 6	56,0 [35,2-72,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	17 (36,2)
95%-CI	[22,7-51,5]
TEAE in months [95%-CI]	
Median	3,61[2,50-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,9 [35,0-70,9]
Month 6	48,0 [27,0-66,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	16 (25,4)
95%-CI	[15,3-37,9]
TEAE in months [95%-CI]	
Median	7,10[5,78-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [56,5-84,0]
Month 6	59,7 [37,2-76,4]
Month 12	47,7 [21,0-70,4]
Month 18	47,7 [21,0-70,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	5,22[2,04-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,2 [38,4-75,1]
Month 6	44,4 [16,5-69,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	17 (36,2)
95%-CI	[22,7-51,5]
TEAE in months [95%-CI]	
Median	4,40 [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,0 [45,1-76,6]
Month 6	49,0 [27,1-67,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	19 (30,2)
95%-CI	[19,2-43,0]
TEAE in months [95%-CI]	
Median	10,97[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,7 [61,3-84,0]
Month 6	59,9 [40,2-74,9]
Month 12	47,9 [22,1-69,8]
Month 18	47,9 [22,1-69,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	NE [3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [68,7-93,7]
Month 6	59,9 [23,8-83,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	15 (31,9)
95%-CI	[19,1-47,1]
TEAE in months [95%-CI]	
Median	9,23 [3,29-9,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,0 [57,5-84,9]
Month 6	54,1 [28,3-74,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [83,9-97,6]
Month 6	88,4 [70,3-95,8]
Month 12	88,4 [70,3-95,8]
Month 18	88,4 [70,3-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [75,5-97,1]
Month 6	78,3 [40,6-93,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [72,3-93,8]
Month 6	86,5 [72,3-93,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	12 (19,0)
95%-CI	[10,2-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [64,0-87,2]
Month 6	78,1 [64,0-87,2]
Month 12	78,1 [64,0-87,2]
Month 18	78,1 [64,0-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [58,9-87,7]
Month 6	76,8 [58,9-87,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	8 (17,0)
95%-CI	[7,6-30,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [69,2-93,1]
Month 6	74,1 [52,0-87,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	3 (4,8)
95%-CI	[1,0-13,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [85,0-98,3]
Month 6	94,9 [85,0-98,3]
Month 12	94,9 [85,0-98,3]
Month 18	94,9 [85,0-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [78,7-98,5]
Month 6	94,2 [78,7-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [73,9-95,9]
Month 6	84,9 [66,4-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	12 (19,0)
95%-CI	[10,2-30,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,3 [64,5-87,2]
Month 6	78,3 [64,5-87,2]
Month 12	78,3 [64,5-87,2]
Month 18	78,3 [64,5-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,1 [51,0-84,1]
Month 6	71,1 [51,0-84,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	7 (14,9)
95%-CI	[6,2-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [66,0-91,5]
Month 6	82,5 [66,0-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [78,2-96,1]
Month 6	90,5 [78,2-96,1]
Month 12	90,5 [78,2-96,1]
Month 18	90,5 [78,2-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Number prior lines: 3 lines	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,1 [55,2-88,2]
Month 6	76,1 [55,2-88,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	4 (8,5)
95%-CI	[2,4-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [71,8-95,8]
Month 6	88,8 [71,8-95,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	10 (15,9)
95%-CI	[7,9-27,3]
TEAE in months [95%-CI]	
Median	NE[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [71,1-94,7]
Month 6	70,6 [49,5-84,2]
Month 12	58,9 [30,1-79,1]
Month 18	58,9 [30,1-79,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [70,8-96,7]
Month 6	89,8 [70,8-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	7 (14,9)
95%-CI	[6,2-28,3]
TEAE in months [95%-CI]	
Median	8,11[8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [68,3-95,0]
Month 6	76,5 [53,4-89,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	8 (12,7)
95%-CI	[5,6-23,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [78,0-94,5]
Month 6	88,8 [78,0-94,5]
Month 12	80,0 [54,3-92,1]
Month 18	80,0 [54,3-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [5,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [69,9-96,5]
Month 6	60,3 [18,1-86,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [66,1-92,3]
Month 6	83,3 [66,1-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,5 [83,5-97,5]
Month 6	93,5 [83,5-97,5]
Month 12	93,5 [83,5-97,5]
Month 18	93,5 [83,5-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [69,9-96,5]
Month 6	89,4 [69,9-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	4 (8,5)
95%-CI	[2,4-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [73,1-95,8]
Month 6	89,0 [73,1-95,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	8 (12,7)
95%-CI	[5,6-23,5]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [75,8-94,0]
Month 6	87,7 [75,8-94,0]
Month 12	75,2 [41,9-91,1]
Month 18	75,2 [41,9-91,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	9,17 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [75,3-97,1]
Month 6	91,3 [75,3-97,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
TEAE in months [95%-CI]	
Median	NE [7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [78,1-96,6]
Month 6	91,2 [78,1-96,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	7 (11,1)
95%-CI	[4,6-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [69,4-92,8]
Month 6	84,8 [69,4-92,8]
Month 12	84,8 [69,4-92,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [61,2-94,4]
Month 6	84,5 [61,2-94,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [81,4-98,8]
Month 6	89,4 [68,0-96,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [81,1-96,5]
Month 6	91,7 [81,1-96,5]
Month 12	91,7 [81,1-96,5]
Month 18	91,7 [81,1-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [70,7-96,6]
Month 6	89,6 [70,7-96,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS13: Time to first TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [74,6-97,2]
Month 6	91,3 [74,6-97,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

4.10.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	73 (73,7)
95%-CI	[63,9-82,1]
TEAE in months [95%-CI]	
Median	0,99 [0,72-1,64]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,8 [25,3-44,4]
Month 6	20,1 [11,0-31,2]
Month 12	8,4 [1,9-21,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	13 (44,8)
95%-CI	[26,4-64,3]
TEAE in months [95%-CI]	
Median	2,56[0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,4 [16,0-60,7]
Month 6	38,4 [16,0-60,7]
Month 12	38,4 [16,0-60,7]
Month 18	38,4 [16,0-60,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	34 (34,3)
95%-CI	[25,1-44,6]
TEAE in months [95%-CI]	
Median	NE[4,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,6 [53,7-73,6]
Month 6	61,5 [49,4-71,6]
Month 12	61,5 [49,4-71,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: Fatigue	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [51,3-93,0]
Month 6	80,3 [51,3-93,0]
Month 12	80,3 [51,3-93,0]
Month 18	80,3 [51,3-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	21 (21,2)
95%-CI	[13,6-30,6]
TEAE in months [95%-CI]	
Median	9,10[6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [74,7-91,0]
Month 6	69,8 [53,7-81,3]
Month 12	45,7 [21,2-67,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [3,06-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,4 [50,2-92,6]
Month 6	69,5 [37,2-87,4]
Month 12	69,5 [37,2-87,4]
Month 18	69,5 [37,2-87,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

SOC: General disorders and administration site conditions	
PT: Pyrexia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	19 (19,2)
95%-CI	[12,0-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [72,3-88,3]
Month 6	77,4 [66,0-85,3]
Month 12	77,4 [66,0-85,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

SOC: General disorders and administration site conditions	
PT: Pyrexia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [71,5-98,0]
Month 6	78,9 [39,5-94,1]
Month 12	78,9 [39,5-94,1]
Month 18	78,9 [39,5-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: Asthenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	10 (10,1)
95%-CI	[5,0-17,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [79,4-94,3]
Month 6	86,3 [74,8-92,8]
Month 12	86,3 [74,8-92,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [75,7-99,5]
Month 6	96,2 [75,7-99,5]
Month 12	96,2 [75,7-99,5]
Month 18	96,2 [75,7-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	58 (58,6)
95%-CI	[48,2-68,4]
TEAE in months [95%-CI]	
Median	1,41 [0,69-5,39]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	43,7 [33,2-53,8]
Month 6	36,1 [24,5-47,9]
Month 12	18,1 [4,4-39,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	15 (51,7)
95%-CI	[32,5-70,6]
TEAE in months [95%-CI]	
Median	1,18[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,0 [22,1-60,8]
Month 6	42,0 [22,1-60,8]
Month 12	42,0 [22,1-60,8]
Month 18	42,0 [22,1-60,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	42 (42,4)
95%-CI	[32,5-52,8]
TEAE in months [95%-CI]	
Median	5,39[2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,5 [48,1-69,2]
Month 6	47,3 [33,9-59,6]
Month 12	35,5 [14,9-56,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	9 (31,0)
95%-CI	[15,3-50,8]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,8 [37,0-77,9]
Month 6	60,8 [37,0-77,9]
Month 12	60,8 [37,0-77,9]
Month 18	60,8 [37,0-77,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	33 (33,3)
95%-CI	[24,2-43,5]
TEAE in months [95%-CI]	
Median	7,92 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,8 [59,5-78,0]
Month 6	68,1 [57,4-76,6]
Month 12	35,8 [11,3-61,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	9 (31,0)
95%-CI	[15,3-50,8]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [43,4-80,7]
Month 6	65,5 [43,4-80,7]
Month 12	65,5 [43,4-80,7]
Month 18	65,5 [43,4-80,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	24 (24,2)
95%-CI	[16,2-33,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,0 [62,1-81,2]
Month 6	73,0 [62,1-81,2]
Month 12	73,0 [62,1-81,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	9 (31,0)
95%-CI	[15,3-50,8]
TEAE in months [95%-CI]	
Median	NE [1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,5 [39,3-78,9]
Month 6	62,5 [39,3-78,9]
Month 12	62,5 [39,3-78,9]
Month 18	62,5 [39,3-78,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	16 (16,2)
95%-CI	[9,5-24,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [75,9-90,9]
Month 6	76,5 [60,3-86,8]
Month 12	76,5 [60,3-86,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [67,9-97,8]
Month 6	91,1 [67,9-97,8]
Month 12	91,1 [67,9-97,8]
Month 18	91,1 [67,9-97,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [83,2-96,2]
Month 6	91,9 [83,2-96,2]
Month 12	91,9 [83,2-96,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [75,1-98,2]
Month 6	93,1 [75,1-98,2]
Month 12	93,1 [75,1-98,2]
Month 18	93,1 [75,1-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	55 (55,6)
95%-CI	[45,2-65,5]
TEAE in months [95%-CI]	
Median	2,10 [1,22-4,14]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,8 [35,0-55,9]
Month 6	32,8 [20,8-45,3]
Month 12	32,8 [20,8-45,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Investigations	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	16 (55,2)
95%-CI	[35,7-73,6]
TEAE in months [95%-CI]	
Median	1,41 [0,49-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,4 [18,7-59,7]
Month 6	39,4 [18,7-59,7]
Month 12	39,4 [18,7-59,7]
Month 18	39,4 [18,7-59,7]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	41 (41,4)
95%-CI	[31,6-51,8]
TEAE in months [95%-CI]	
Median	4,14 [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [49,8-71,2]
Month 6	43,8 [30,0-56,7]
Month 12	37,5 [21,7-53,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	12 (41,4)
95%-CI	[23,5-61,1]
TEAE in months [95%-CI]	
Median	3,48 [1,41-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,0 [30,6-74,0]
Month 6	47,1 [22,8-68,2]
Month 12	47,1 [22,8-68,2]
Month 18	47,1 [22,8-68,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	21 (21,2)
95%-CI	[13,6-30,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [67,8-86,4]
Month 6	67,2 [52,2-78,5]
Month 12	67,2 [52,2-78,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [49,1-93,6]
Month 6	69,0 [33,9-88,1]
Month 12	69,0 [33,9-88,1]
Month 18	69,0 [33,9-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [78,9-93,5]
Month 6	83,3 [71,3-90,6]
Month 12	83,3 [71,3-90,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	7,56[2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,7 [44,6-89,1]
Month 6	73,7 [44,6-89,1]
Month 12	36,9 [1,6-78,6]
Month 18	36,9 [1,6-78,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	15 (15,2)
95%-CI	[8,7-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [75,9-91,3]
Month 6	80,4 [68,6-88,2]
Month 12	80,4 [68,6-88,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,5 [45,4-89,7]
Month 6	74,5 [45,4-89,7]
Month 12	74,5 [45,4-89,7]
Month 18	74,5 [45,4-89,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [84,7-96,8]
Month 6	90,7 [80,9-95,6]
Month 12	90,7 [80,9-95,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [75,7-99,5]
Month 6	86,5 [51,5-96,9]
Month 12	86,5 [51,5-96,9]
Month 18	86,5 [51,5-96,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	48 (48,5)
95%-CI	[38,3-58,7]
TEAE in months [95%-CI]	
Median	4,63 [1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,0 [40,4-60,7]
Month 6	47,9 [36,2-58,6]
Month 12	47,9 [36,2-58,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	19 (65,5)
95%-CI	[45,7-82,1]
TEAE in months [95%-CI]	
Median	0,89[0,43-1,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	25,5 [10,0-44,4]
Month 6	25,5 [10,0-44,4]
Month 12	25,5 [10,0-44,4]
Month 18	25,5 [10,0-44,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	21 (21,2)
95%-CI	[13,6-30,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [68,2-85,5]
Month 6	75,4 [63,9-83,8]
Month 12	75,4 [63,9-83,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,9 [42,1-81,8]
Month 6	65,9 [42,1-81,8]
Month 12	65,9 [42,1-81,8]
Month 18	65,9 [42,1-81,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	13 (13,1)
95%-CI	[7,2-21,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [75,9-91,8]
Month 6	82,9 [70,9-90,2]
Month 12	82,9 [70,9-90,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	5,32[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,7 [35,7-82,1]
Month 6	47,8 [15,8-74,4]
Month 12	47,8 [15,8-74,4]
Month 18	47,8 [15,8-74,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [79,4-93,3]
Month 6	84,6 [72,4-91,7]
Month 12	84,6 [72,4-91,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,4 [44,8-86,8]
Month 6	71,4 [44,8-86,8]
Month 12	71,4 [44,8-86,8]
Month 18	71,4 [44,8-86,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [79,7-93,9]
Month 6	85,2 [72,6-92,2]
Month 12	75,7 [49,7-89,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [6,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [75,1-98,2]
Month 6	93,1 [75,1-98,2]
Month 12	62,1 [7,5-91,6]
Month 18	62,1 [7,5-91,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	11 (11,1)
95%-CI	[5,7-19,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [80,4-93,9]
Month 6	86,1 [75,1-92,5]
Month 12	86,1 [75,1-92,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: Constipation	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [5,42-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [74,7-98,2]
Month 6	69,7 [16,9-92,9]
Month 12	69,7 [16,9-92,9]
Month 18	69,7 [16,9-92,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	53 (53,5)
95%-CI	[43,2-63,6]
TEAE in months [95%-CI]	
Median	3,48 [1,18-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,2 [42,6-62,7]
Month 6	39,7 [27,6-51,6]
Month 12	29,0 [14,7-44,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	17 (58,6)
95%-CI	[38,9-76,5]
TEAE in months [95%-CI]	
Median	2,04 [0,36-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,6 [19,8-60,5]
Month 6	33,8 [14,2-54,8]
Month 12	22,6 [5,2-47,3]
Month 18	22,6 [5,2-47,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	15 (15,2)
95%-CI	[8,7-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [74,0-89,9]
Month 6	83,6 [74,0-89,9]
Month 12	83,6 [74,0-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [56,0-92,6]
Month 6	81,0 [56,0-92,6]
Month 12	81,0 [56,0-92,6]
Month 18	81,0 [56,0-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	18 (18,2)
95%-CI	[11,1-27,2]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [77,3-91,8]
Month 6	73,0 [56,7-84,0]
Month 12	63,9 [40,0-80,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [2,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	81,8 [44,7-95,1]
Month 12	81,8 [44,7-95,1]
Month 18	81,8 [44,7-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	14 (14,1)
95%-CI	[8,0-22,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [78,6-92,6]
Month 6	82,3 [70,7-89,6]
Month 12	82,3 [70,7-89,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	NE [6,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,1 [62,1-92,1]
Month 6	82,1 [62,1-92,1]
Month 12	54,7 [9,6-85,6]
Month 18	54,7 [9,6-85,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	15 (15,2)
95%-CI	[8,7-23,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [77,6-91,8]
Month 6	81,5 [70,1-88,9]
Month 12	81,5 [70,1-88,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [71,2-97,9]
Month 6	82,7 [51,5-94,7]
Month 12	82,7 [51,5-94,7]
Month 18	82,7 [51,5-94,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [85,3-96,5]
Month 6	92,7 [85,3-96,5]
Month 12	92,7 [85,3-96,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [64,4-94,1]
Month 6	84,9 [64,4-94,1]
Month 12	84,9 [64,4-94,1]
Month 18	84,9 [64,4-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [87,9-97,8]
Month 6	92,2 [82,3-96,7]
Month 12	83,0 [54,8-94,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [71,3-96,5]
Month 6	89,7 [71,3-96,5]
Month 12	89,7 [71,3-96,5]
Month 18	89,7 [71,3-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	3 (3,0)
95%-CI	[0,6-8,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,0 [90,8-99,0]
Month 6	97,0 [90,8-99,0]
Month 12	97,0 [90,8-99,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [59,0-91,6]
Month 6	80,6 [59,0-91,6]
Month 12	80,6 [59,0-91,6]
Month 18	80,6 [59,0-91,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	52 (52,5)
95%-CI	[42,2-62,7]
TEAE in months [95%-CI]	
Median	1,74 [1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,8 [31,5-53,6]
Month 6	26,8 [8,1-50,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	10 (34,5)
95%-CI	[17,9-54,3]
TEAE in months [95%-CI]	
Median	3,91[1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,5 [35,5-77,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [77,1-92,6]
Month 6	86,8 [77,1-92,6]
Month 12	86,8 [77,1-92,6]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [51,1-94,5]
Month 6	65,8 [25,1-88,1]
Month 12	65,8 [25,1-88,1]
Month 18	65,8 [25,1-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	14 (14,1)
95%-CI	[8,0-22,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [76,1-91,3]
Month 6	82,7 [71,7-89,8]
Month 12	82,7 [71,7-89,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	8,84 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [75,7-99,5]
Month 6	96,2 [75,7-99,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	10 (10,1)
95%-CI	[5,0-17,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [81,5-94,7]
Month 6	90,0 [81,5-94,7]
Month 12	80,0 [51,8-92,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [1,87-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [48,2-91,5]
Month 6	77,6 [48,2-91,5]
Month 12	77,6 [48,2-91,5]
Month 18	77,6 [48,2-91,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,6 [76,6-92,5]
Month 6	82,8 [69,5-90,7]
Month 12	82,8 [69,5-90,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line Loncastuximab tesirine
 Data-cut 3

SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [4,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,0 [74,8-99,4]
Month 6	72,0 [15,4-94,4]
Month 12	72,0 [15,4-94,4]
Month 18	72,0 [15,4-94,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	40 (40,4)
95%-CI	[30,7-50,7]
TEAE in months [95%-CI]	
Median	4,76[3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,4 [55,2-75,4]
Month 6	49,6 [35,7-62,1]
Month 12	33,8 [17,4-51,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	14 (48,3)
95%-CI	[29,4-67,5]
TEAE in months [95%-CI]	
Median	2,46[0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,3 [19,0-64,2]
Month 6	28,2 [6,4-55,9]
Month 12	28,2 [6,4-55,9]
Month 18	28,2 [6,4-55,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	21 (21,2)
95%-CI	[13,6-30,6]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [67,9-85,9]
Month 6	75,3 [62,9-84,0]
Month 12	67,8 [47,8-81,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	7 (24,1)
95%-CI	[10,3-43,5]
TEAE in months [95%-CI]	
Median	NE [2,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,3 [43,6-87,1]
Month 6	57,0 [23,4-80,5]
Month 12	57,0 [23,4-80,5]
Month 18	57,0 [23,4-80,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [82,7-95,0]
Month 6	85,5 [73,4-92,3]
Month 12	76,0 [50,0-89,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [71,3-96,5]
Month 6	89,7 [71,3-96,5]
Month 12	89,7 [71,3-96,5]
Month 18	89,7 [71,3-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [82,3-95,9]
Month 6	81,6 [65,9-90,6]
Month 12	63,5 [35,2-82,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [66,3-96,1]
Month 6	87,9 [66,3-96,1]
Month 12	87,9 [66,3-96,1]
Month 18	87,9 [66,3-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	34 (34,3)
95%-CI	[25,1-44,6]
TEAE in months [95%-CI]	
Median	6,47[3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,9 [55,6-76,0]
Month 6	53,4 [37,9-66,7]
Month 12	47,5 [29,9-63,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

SOC: Infections and infestations	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,3 [35,6-80,5]
Month 6	62,3 [35,6-80,5]
Month 12	62,3 [35,6-80,5]
Month 18	62,3 [35,6-80,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	28 (28,3)
95%-CI	[19,7-38,2]
TEAE in months [95%-CI]	
Median	7,10[5,78-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,9 [60,1-80,8]
Month 6	56,8 [39,7-70,7]
Month 12	48,7 [28,0-66,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	10 (34,5)
95%-CI	[17,9-54,3]
TEAE in months [95%-CI]	
Median	NE [1,87-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,3 [30,6-75,7]
Month 6	56,3 [30,6-75,7]
Month 12	56,3 [30,6-75,7]
Month 18	56,3 [30,6-75,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Nervous system disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	32 (32,3)
95%-CI	[23,3-42,5]
TEAE in months [95%-CI]	
Median	9,23[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [66,8-84,1]
Month 6	52,8 [36,1-67,1]
Month 12	28,2 [6,7-55,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [63,4-92,4]
Month 6	82,8 [63,4-92,4]
Month 12	82,8 [63,4-92,4]
Month 18	82,8 [63,4-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	8 (8,1)
95%-CI	[3,6-15,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [86,7-97,2]
Month 6	87,1 [72,7-94,2]
Month 12	87,1 [72,7-94,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [67,3-94,6]
Month 6	86,2 [67,3-94,6]
Month 12	86,2 [67,3-94,6]
Month 18	86,2 [67,3-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	17 (17,2)
95%-CI	[10,3-26,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [73,7-89,3]
Month 6	80,8 [70,5-87,9]
Month 12	80,8 [70,5-87,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE in months [95%-CI]	
Median	3,81[2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,1 [38,2-83,7]
Month 6	49,6 [16,4-76,2]
Month 12	49,6 [16,4-76,2]
Month 18	49,6 [16,4-76,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Vascular disorders	
PT: Hypotension	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [86,3-97,1]
Month 6	91,3 [81,9-96,0]
Month 12	91,3 [81,9-96,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [66,3-97,5]
Month 6	90,3 [66,3-97,5]
Month 12	90,3 [66,3-97,5]
Month 18	90,3 [66,3-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	20 (20,2)
95%-CI	[12,8-29,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [67,1-85,1]
Month 6	77,6 [67,1-85,1]
Month 12	77,6 [67,1-85,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [2,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,5 [46,7-89,3]
Month 6	74,5 [46,7-89,3]
Month 12	74,5 [46,7-89,3]
Month 18	74,5 [46,7-89,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Psychiatric disorders	
PT: Insomnia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [75,5-91,7]
Month 6	85,6 [75,5-91,7]
Month 12	85,6 [75,5-91,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Psychiatric disorders	
PT: Insomnia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [52,9-96,4]
Month 6	85,9 [52,9-96,4]
Month 12	85,9 [52,9-96,4]
Month 18	85,9 [52,9-96,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	16 (16,2)
95%-CI	[9,5-24,9]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [77,7-93,7]
Month 6	75,3 [60,0-85,4]
Month 12	53,8 [25,1-75,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Eye disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE in months [95%-CI]	
Median	NE [3,25-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [66,6-99,2]
Month 6	81,0 [37,8-95,5]
Month 12	81,0 [37,8-95,5]
Month 18	81,0 [37,8-95,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	12 (12,1)
95%-CI	[6,4-20,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [80,9-94,5]
Month 6	82,7 [67,8-91,2]
Month 12	75,8 [54,4-88,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [63,4-92,4]
Month 6	82,8 [63,4-92,4]
Month 12	82,8 [63,4-92,4]
Month 18	82,8 [63,4-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	6 (6,1)
95%-CI	[2,3-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [85,3-96,9]
Month 6	93,1 [85,3-96,9]
Month 12	93,1 [85,3-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Cardiac disorders	
PT: Tachycardia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [68,3-96,2]
Month 6	88,6 [68,3-96,2]
Month 12	88,6 [68,3-96,2]
Month 18	88,6 [68,3-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	13 (13,1)
95%-CI	[7,2-21,4]
TEAE in months [95%-CI]	
Median	NE [8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [81,5-94,3]
Month 6	89,6 [81,5-94,3]
Month 12	60,5 [28,8-81,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,4 [58,7-93,2]
Month 6	82,4 [58,7-93,2]
Month 12	82,4 [58,7-93,2]
Month 18	82,4 [58,7-93,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [86,3-97,1]
Month 6	91,0 [80,9-95,9]
Month 12	91,0 [80,9-95,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Renal and urinary disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE in months [95%-CI]	
Median	NE [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,2 [36,5-84,5]
Month 6	66,2 [36,5-84,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	7 (7,1)
95%-CI	[2,9-14,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [83,3-96,1]
Month 6	91,9 [83,3-96,1]
Month 12	91,9 [83,3-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS14: Time to first TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - Loncastuximab tesirine
 first line Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [66,0-96,0]
Month 6	87,8 [66,0-96,0]
Month 12	87,8 [66,0-96,0]
Month 18	87,8 [66,0-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

4.10.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	32 (72,7)
95%-CI	[57,2-85,0]
TEAE in months [95%-CI]	
Median	1,48 [0,43-2,23]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,3 [19,5-47,7]
Month 6	25,9 [13,0-40,9]
Month 12	9,7 [1,0-30,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	57 (64,8)
95%-CI	[53,9-74,7]
TEAE in months [95%-CI]	
Median	1,22 [0,76-2,07]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,1 [25,0-47,3]
Month 6	18,4 [7,5-33,0]
Month 12	13,8 [4,3-28,7]
Month 18	13,8 [4,3-28,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: General disorders and administration site conditions	
PT: Fatigue	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	15 (34,1)
95%-CI	[20,5-49,9]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,0 [47,3-76,7]
Month 6	64,0 [47,3-76,7]
Month 12	64,0 [47,3-76,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	23 (26,1)
95%-CI	[17,3-36,6]
TEAE in months [95%-CI]	
Median	NE [4,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,5 [57,7-80,1]
Month 6	64,1 [46,2-77,4]
Month 12	64,1 [46,2-77,4]
Month 18	64,1 [46,2-77,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	12 (27,3)
95%-CI	[15,0-42,8]
TEAE in months [95%-CI]	
Median	9,10[4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [68,0-92,8]
Month 6	62,0 [37,8-79,0]
Month 12	38,7 [12,3-65,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	13 (14,8)
95%-CI	[8,1-23,9]
TEAE in months [95%-CI]	
Median	NE [6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [76,1-93,3]
Month 6	74,4 [54,4-86,6]
Month 12	65,1 [39,0-82,3]
Month 18	65,1 [39,0-82,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: General disorders and administration site conditions	
PT: Pyrexia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	13 (29,5)
95%-CI	[16,8-45,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,3 [51,6-80,3]
Month 6	68,3 [51,6-80,3]
Month 12	68,3 [51,6-80,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: General disorders and administration site conditions	
PT: Pyrexia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	14 (15,9)
95%-CI	[9,0-25,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [76,1-92,2]
Month 6	75,8 [59,8-86,1]
Month 12	75,8 [59,8-86,1]
Month 18	75,8 [59,8-86,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [71,1-94,5]
Month 6	81,2 [60,4-91,8]
Month 12	81,2 [60,4-91,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: General disorders and administration site conditions	
PT: Asthenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	6 (6,8)
95%-CI	[2,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [85,1-96,8]
Month 6	93,0 [85,1-96,8]
Month 12	93,0 [85,1-96,8]
Month 18	93,0 [85,1-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	33 (75,0)
95%-CI	[59,7-86,8]
TEAE in months [95%-CI]	
Median	0,82 [0,49-1,64]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	27,6 [14,7-42,3]
Month 6	24,2 [11,9-38,9]
Month 12	12,1 [2,7-29,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	43 (48,9)
95%-CI	[38,1-59,8]
TEAE in months [95%-CI]	
Median	2,56[1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,7 [37,9-60,4]
Month 6	41,5 [27,2-55,3]
Month 12	41,5 [27,2-55,3]
Month 18	41,5 [27,2-55,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	27 (61,4)
95%-CI	[45,5-75,6]
TEAE in months [95%-CI]	
Median	2,10 [0,95-3,71]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,5 [28,9-59,0]
Month 6	34,5 [19,6-49,8]
Month 12	27,6 [12,2-45,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	27 (30,7)
95%-CI	[21,3-41,4]
TEAE in months [95%-CI]	
Median	NE [5,39-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,8 [51,9-75,0]
Month 6	58,3 [40,8-72,3]
Month 12	58,3 [40,8-72,3]
Month 18	58,3 [40,8-72,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	20 (45,5)
95%-CI	[30,4-61,2]
TEAE in months [95%-CI]	
Median	6,93[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,6 [43,1-72,7]
Month 6	55,8 [38,9-69,8]
Month 12	29,8 [7,0-57,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	25 (28,4)
95%-CI	[19,3-39,0]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,0 [59,8-79,6]
Month 6	71,0 [59,8-79,6]
Month 12	53,3 [20,4-77,9]
Month 18	53,3 [20,4-77,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	14 (31,8)
95%-CI	[18,6-47,6]
TEAE in months [95%-CI]	
Median	NE [2,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [48,6-78,0]
Month 6	65,5 [48,6-78,0]
Month 12	65,5 [48,6-78,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	19 (21,6)
95%-CI	[13,5-31,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,4 [62,0-83,2]
Month 6	74,4 [62,0-83,2]
Month 12	74,4 [62,0-83,2]
Month 18	74,4 [62,0-83,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	11 (25,0)
95%-CI	[13,2-40,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [59,0-86,0]
Month 6	70,0 [50,8-82,9]
Month 12	70,0 [50,8-82,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [84,4-96,7]
Month 6	84,3 [58,3-94,7]
Month 12	84,3 [58,3-94,7]
Month 18	84,3 [58,3-94,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [71,0-94,5]
Month 6	87,0 [71,0-94,5]
Month 12	87,0 [71,0-94,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	4 (4,5)
95%-CI	[1,3-11,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [88,3-98,3]
Month 6	95,4 [88,3-98,3]
Month 12	95,4 [88,3-98,3]
Month 18	95,4 [88,3-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	26 (59,1)
95%-CI	[43,2-73,7]
TEAE in months [95%-CI]	
Median	2,04 [0,85-5,16]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,0 [26,7-56,5]
Month 6	32,0 [16,4-48,7]
Month 12	32,0 [16,4-48,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	49 (55,7)
95%-CI	[44,7-66,3]
TEAE in months [95%-CI]	
Median	1,64 [0,95-3,09]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,2 [27,9-52,0]
Month 6	34,6 [22,3-47,2]
Month 12	34,6 [22,3-47,2]
Month 18	34,6 [22,3-47,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	22 (50,0)
95%-CI	[34,6-65,4]
TEAE in months [95%-CI]	
Median	4,14 [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,1 [40,1-70,9]
Month 6	40,0 [22,6-56,9]
Month 12	33,3 [15,8-52,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	32 (36,4)
95%-CI	[26,4-47,3]
TEAE in months [95%-CI]	
Median	4,14 [2,83-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,5 [45,5-70,9]
Month 6	49,0 [33,2-63,1]
Month 12	49,0 [33,2-63,1]
Month 18	49,0 [33,2-63,1]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	10 (22,7)
95%-CI	[11,5-37,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [58,5-86,8]
Month 6	71,2 [52,0-83,8]
Month 12	71,2 [52,0-83,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	13 (14,8)
95%-CI	[8,1-23,9]
TEAE in months [95%-CI]	
Median	NE [5,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [69,6-90,8]
Month 6	69,0 [48,4-82,7]
Month 12	69,0 [48,4-82,7]
Month 18	69,0 [48,4-82,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
TEAE in months [95%-CI]	
Median	NE [7,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [75,2-96,1]
Month 6	89,9 [75,2-96,1]
Month 12	79,9 [49,9-93,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	15 (17,0)
95%-CI	[9,9-26,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,9 [66,6-88,3]
Month 6	72,8 [56,5-83,8]
Month 12	72,8 [56,5-83,8]
Month 18	72,8 [56,5-83,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [79,1-97,6]
Month 6	86,5 [64,6-95,3]
Month 12	86,5 [64,6-95,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	15 (17,0)
95%-CI	[9,9-26,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,3 [67,4-88,6]
Month 6	73,5 [57,7-84,2]
Month 12	73,5 [57,7-84,2]
Month 18	73,5 [57,7-84,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [74,7-96,0]
Month 6	89,7 [74,7-96,0]
Month 12	89,7 [74,7-96,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	6 (6,8)
95%-CI	[2,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [84,6-97,9]
Month 6	88,0 [73,5-94,8]
Month 12	88,0 [73,5-94,8]
Month 18	88,0 [73,5-94,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	24 (54,5)
95%-CI	[38,8-69,6]
TEAE in months [95%-CI]	
Median	2,83[0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,2 [31,3-61,6]
Month 6	42,9 [26,7-58,2]
Month 12	28,6 [7,9-54,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	43 (48,9)
95%-CI	[38,1-59,8]
TEAE in months [95%-CI]	
Median	2,07[0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,6 [37,3-59,0]
Month 6	48,6 [37,3-59,0]
Month 12	48,6 [37,3-59,0]
Month 18	48,6 [37,3-59,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	9 (20,5)
95%-CI	[9,8-35,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [63,8-89,5]
Month 6	75,0 [56,1-86,7]
Month 12	75,0 [56,1-86,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	21 (23,9)
95%-CI	[15,4-34,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,0 [62,8-82,3]
Month 6	74,0 [62,8-82,3]
Month 12	74,0 [62,8-82,3]
Month 18	74,0 [62,8-82,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [67,9-92,7]
Month 6	79,0 [59,2-89,9]
Month 12	52,6 [9,9-83,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	11 (12,5)
95%-CI	[6,4-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [78,6-93,3]
Month 6	82,0 [64,5-91,4]
Month 12	82,0 [64,5-91,4]
Month 18	82,0 [64,5-91,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [76,1-96,3]
Month 6	84,3 [63,3-93,8]
Month 12	84,3 [63,3-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	11 (12,5)
95%-CI	[6,4-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [73,4-91,7]
Month 6	84,9 [73,4-91,7]
Month 12	84,9 [73,4-91,7]
Month 18	84,9 [73,4-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [76,6-96,4]
Month 6	84,5 [63,5-93,9]
Month 12	84,5 [63,5-93,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	10 (11,4)
95%-CI	[5,6-19,9]
TEAE in months [95%-CI]	
Median	NE [8,11-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [81,8-95,1]
Month 6	90,5 [81,8-95,1]
Month 12	61,1 [18,5-86,6]
Month 18	61,1 [18,5-86,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [81,0-98,7]
Month 6	88,1 [63,3-96,6]
Month 12	88,1 [63,3-96,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	11 (12,5)
95%-CI	[6,4-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [76,2-92,8]
Month 6	79,5 [58,6-90,6]
Month 12	79,5 [58,6-90,6]
Month 18	79,5 [58,6-90,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	20 (45,5)
95%-CI	[30,4-61,2]
TEAE in months [95%-CI]	
Median	8,51[1,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,1 [43,8-73,1]
Month 6	60,1 [43,8-73,1]
Month 12	28,1 [6,4-55,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	49 (55,7)
95%-CI	[44,7-66,3]
TEAE in months [95%-CI]	
Median	2,56 [0,99-3,52]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,6 [36,8-59,4]
Month 6	33,2 [20,8-46,2]
Month 12	28,5 [15,5-42,8]
Month 18	28,5 [15,5-42,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	10 (22,7)
95%-CI	[11,5-37,8]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [63,1-88,4]
Month 6	78,8 [63,1-88,4]
Month 12	59,1 [20,1-84,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	12 (13,6)
95%-CI	[7,2-22,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [72,1-90,7]
Month 6	83,6 [72,1-90,7]
Month 12	83,6 [72,1-90,7]
Month 18	83,6 [72,1-90,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [80,0-97,7]
Month 6	86,9 [64,9-95,5]
Month 12	74,5 [39,2-91,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	11 (12,5)
95%-CI	[6,4-21,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [75,8-93,2]
Month 6	75,3 [54,0-87,8]
Month 12	75,3 [54,0-87,8]
Month 18	75,3 [54,0-87,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [73,4-94,8]
Month 6	82,4 [62,8-92,3]
Month 12	82,4 [62,8-92,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	15 (17,0)
95%-CI	[9,9-26,6]
TEAE in months [95%-CI]	
Median	NE [6,44-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [72,2-90,8]
Month 6	76,5 [60,8-86,5]
Month 12	68,0 [44,6-83,1]
Month 18	68,0 [44,6-83,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [70,2-93,2]
Month 6	85,4 [70,2-93,2]
Month 12	85,4 [70,2-93,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	14 (15,9)
95%-CI	[9,0-25,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [74,5-91,9]
Month 6	75,7 [60,0-86,0]
Month 12	75,7 [60,0-86,0]
Month 18	75,7 [60,0-86,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	2 (4,5)
95%-CI	[0,6-15,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [82,8-98,8]
Month 6	95,4 [82,8-98,8]
Month 12	95,4 [82,8-98,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	9 (10,2)
95%-CI	[4,8-18,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [80,1-94,2]
Month 6	89,2 [80,1-94,2]
Month 12	89,2 [80,1-94,2]
Month 18	89,2 [80,1-94,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [81,9-98,8]
Month 6	95,2 [81,9-98,8]
Month 12	84,6 [49,3-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [85,5-96,9]
Month 6	89,5 [76,5-95,5]
Month 12	89,5 [76,5-95,5]
Month 18	89,5 [76,5-95,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	1 (2,3)
95%-CI	[0,1-12,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,6 [84,3-99,7]
Month 6	97,6 [84,3-99,7]
Month 12	97,6 [84,3-99,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [78,8-95,4]
Month 6	89,9 [78,8-95,4]
Month 12	89,9 [78,8-95,4]
Month 18	89,9 [78,8-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	26 (59,1)
95%-CI	[43,2-73,7]
TEAE in months [95%-CI]	
Median	1,61 [1,12-3,06]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [23,5-53,4]
Month 6	33,7 [18,5-49,6]
Month 12	33,7 [18,5-49,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	35 (39,8)
95%-CI	[29,5-50,8]
TEAE in months [95%-CI]	
Median	2,79[1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,7 [35,3-62,5]
Month 6	37,3 [15,4-59,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	9 (20,5)
95%-CI	[9,8-35,3]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [64,1-89,6]
Month 6	80,2 [64,1-89,6]
Month 12	80,2 [64,1-89,6]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	8 (9,1)
95%-CI	[4,0-17,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [74,6-93,8]
Month 6	87,2 [74,6-93,8]
Month 12	87,2 [74,6-93,8]
Month 18	87,2 [74,6-93,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	7 (15,9)
95%-CI	[6,6-30,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [69,7-93,1]
Month 6	80,4 [62,0-90,5]
Month 12	80,4 [62,0-90,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	11 (12,5)
95%-CI	[6,4-21,3]
TEAE in months [95%-CI]	
Median	8,84 [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [75,5-92,3]
Month 6	86,1 [75,5-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [71,9-94,5]
Month 6	87,3 [71,9-94,5]
Month 12	72,7 [35,3-90,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [79,8-95,3]
Month 6	90,1 [79,8-95,3]
Month 12	90,1 [79,8-95,3]
Month 18	90,1 [79,8-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [69,0-92,9]
Month 6	84,8 [69,0-92,9]
Month 12	84,8 [69,0-92,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	8 (9,1)
95%-CI	[4,0-17,1]
TEAE in months [95%-CI]	
Median	NE [4,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [76,4-95,3]
Month 6	75,3 [49,7-89,2]
Month 12	75,3 [49,7-89,2]
Month 18	75,3 [49,7-89,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	23 (52,3)
95%-CI	[36,7-67,5]
TEAE in months [95%-CI]	
Median	4,76 [2,66-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,7 [48,3-77,1]
Month 6	41,6 [23,9-58,4]
Month 12	27,7 [10,8-47,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	31 (35,2)
95%-CI	[25,3-46,1]
TEAE in months [95%-CI]	
Median	6,01[2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,6 [46,8-71,9]
Month 6	51,8 [35,4-66,0]
Month 12	43,2 [23,1-61,8]
Month 18	43,2 [23,1-61,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	11 (25,0)
95%-CI	[13,2-40,3]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [61,8-88,0]
Month 6	72,9 [53,8-85,1]
Month 12	63,7 [38,6-80,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	18 (20,5)
95%-CI	[12,6-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [63,7-85,2]
Month 6	70,9 [54,0-82,6]
Month 12	70,9 [54,0-82,6]
Month 18	70,9 [54,0-82,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	7 (15,9)
95%-CI	[6,6-30,1]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [76,7-96,4]
Month 6	80,7 [59,1-91,7]
Month 12	70,6 [41,3-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [83,0-95,9]
Month 6	91,5 [83,0-95,9]
Month 12	91,5 [83,0-95,9]
Month 18	91,5 [83,0-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [7,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [81,8-98,8]
Month 6	84,2 [60,8-94,2]
Month 12	63,2 [30,2-83,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	9 (10,2)
95%-CI	[4,8-18,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [72,8-92,6]
Month 6	85,6 [72,8-92,6]
Month 12	85,6 [72,8-92,6]
Month 18	85,6 [72,8-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	22 (50,0)
95%-CI	[34,6-65,4]
TEAE in months [95%-CI]	
Median	3,55[1,74-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,2 [33,5-64,7]
Month 6	45,1 [27,8-61,1]
Month 12	36,1 [16,5-56,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	22 (25,0)
95%-CI	[16,4-35,4]
TEAE in months [95%-CI]	
Median	NE [4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,2 [58,4-82,1]
Month 6	54,2 [32,4-71,6]
Month 12	54,2 [32,4-71,6]
Month 18	54,2 [32,4-71,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	18 (40,9)
95%-CI	[26,3-56,8]
TEAE in months [95%-CI]	
Median	5,82 [2,73-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,2 [48,2-77,9]
Month 6	49,6 [29,4-67,0]
Month 12	41,3 [20,0-61,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	22 (25,0)
95%-CI	[16,4-35,4]
TEAE in months [95%-CI]	
Median	NE [5,78-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [52,5-78,7]
Month 6	60,7 [41,5-75,4]
Month 12	60,7 [41,5-75,4]
Month 18	60,7 [41,5-75,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	15 (34,1)
95%-CI	[20,5-49,9]
TEAE in months [95%-CI]	
Median	9,23[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,8 [57,6-84,6]
Month 6	63,8 [43,3-78,5]
Month 12	23,9 [1,6-61,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	23 (26,1)
95%-CI	[17,3-36,6]
TEAE in months [95%-CI]	
Median	NE [4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [67,4-85,7]
Month 6	55,0 [34,6-71,4]
Month 12	55,0 [34,6-71,4]
Month 18	55,0 [34,6-71,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [81,6-98,7]
Month 6	89,1 [66,7-96,8]
Month 12	89,1 [66,7-96,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	10 (11,4)
95%-CI	[5,6-19,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [81,2-94,5]
Month 6	84,2 [67,1-92,8]
Month 12	84,2 [67,1-92,8]
Month 18	84,2 [67,1-92,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	9 (20,5)
95%-CI	[9,8-35,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [65,5-90,0]
Month 6	76,2 [58,0-87,3]
Month 12	76,2 [58,0-87,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	17 (19,3)
95%-CI	[11,7-29,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [69,3-87,3]
Month 6	76,7 [63,9-85,4]
Month 12	76,7 [63,9-85,4]
Month 18	76,7 [63,9-85,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [76,6-96,3]
Month 6	90,5 [76,6-96,3]
Month 12	90,5 [76,6-96,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	6 (6,8)
95%-CI	[2,5-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,5 [84,9-97,3]
Month 6	90,0 [77,1-95,8]
Month 12	90,0 [77,1-95,8]
Month 18	90,0 [77,1-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	6 (13,6)
95%-CI	[5,2-27,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [70,3-93,2]
Month 6	85,4 [70,3-93,2]
Month 12	85,4 [70,3-93,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	20 (22,7)
95%-CI	[14,5-32,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,3 [59,2-81,7]
Month 6	72,3 [59,2-81,7]
Month 12	72,3 [59,2-81,7]
Month 18	72,3 [59,2-81,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [79,0-97,6]
Month 6	92,7 [79,0-97,6]
Month 12	92,7 [79,0-97,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	13 (14,8)
95%-CI	[8,1-23,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,4 [65,8-88,1]
Month 6	79,4 [65,8-88,1]
Month 12	79,4 [65,8-88,1]
Month 18	79,4 [65,8-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Eye disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	9 (20,5)
95%-CI	[9,8-35,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [64,5-90,7]
Month 6	71,9 [51,3-85,0]
Month 12	71,9 [51,3-85,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	8,11[7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [81,6-98,3]
Month 6	85,1 [63,4-94,4]
Month 12	42,5 [6,5-76,6]
Month 18	42,5 [6,5-76,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE in months [95%-CI]	
Median	NE [5,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [70,4-93,2]
Month 6	73,4 [49,7-87,2]
Month 12	73,4 [49,7-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	10 (11,4)
95%-CI	[5,6-19,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [75,9-92,7]
Month 6	86,5 [75,9-92,7]
Month 12	86,5 [75,9-92,7]
Month 18	86,5 [75,9-92,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [75,7-96,2]
Month 6	90,1 [75,7-96,2]
Month 12	90,1 [75,7-96,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [81,6-95,6]
Month 6	90,8 [81,6-95,6]
Month 12	90,8 [81,6-95,6]
Month 18	90,8 [81,6-95,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE in months [95%-CI]	
Median	NE [7,16-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [73,3-94,8]
Month 6	87,9 [73,3-94,8]
Month 12	52,1 [18,4-77,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [83,1-95,9]
Month 6	91,6 [83,1-95,9]
Month 12	91,6 [83,1-95,9]
Month 18	91,6 [83,1-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [75,9-97,4]
Month 6	91,8 [75,9-97,4]
Month 12	91,8 [75,9-97,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	9 (10,2)
95%-CI	[4,8-18,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [73,3-92,9]
Month 6	85,9 [73,3-92,9]
Month 12	85,9 [73,3-92,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [78,5-97,5]
Month 6	92,5 [78,5-97,5]
Month 12	92,5 [78,5-97,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS15: Time to first TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - last line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [78,8-95,3]
Month 6	89,8 [78,8-95,3]
Month 12	89,8 [78,8-95,3]
Month 18	89,8 [78,8-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

4.10.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	14 (58,3)
95%-CI	[36,6-77,9]
TEAE in months [95%-CI]	
Median	2,00 [0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	26,1 [7,3-50,1]
Month 6	26,1 [7,3-50,1]
Month 12	26,1 [7,3-50,1]
Month 18	26,1 [7,3-50,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	80 (69,6)
95%-CI	[60,3-77,8]
TEAE in months [95%-CI]	
Median	1,22 [0,76-1,77]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,7 [26,6-44,9]
Month 6	22,4 [13,4-32,9]
Month 12	12,3 [4,3-24,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: Fatigue	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE[2,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [46,7-91,8]
Month 6	77,4 [46,7-91,8]
Month 12	77,4 [46,7-91,8]
Month 18	77,4 [46,7-91,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	35 (30,4)
95%-CI	[22,2-39,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,0 [57,9-76,1]
Month 6	65,2 [54,0-74,4]
Month 12	65,2 [54,0-74,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE in months [95%-CI]	
Median	NE [2,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [45,8-91,4]
Month 6	67,1 [34,8-86,0]
Month 12	67,1 [34,8-86,0]
Month 18	67,1 [34,8-86,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	24 (20,9)
95%-CI	[13,9-29,4]
TEAE in months [95%-CI]	
Median	9,10[6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [75,3-90,6]
Month 6	68,0 [52,3-79,5]
Month 12	48,1 [25,7-67,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: Pyrexia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [67,3-97,6]
Month 6	77,7 [39,0-93,4]
Month 12	77,7 [39,0-93,4]
Month 18	77,7 [39,0-93,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: Pyrexia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	25 (21,7)
95%-CI	[14,6-30,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [68,2-84,7]
Month 6	73,9 [63,1-81,9]
Month 12	73,9 [63,1-81,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: Asthenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,3-97,8]
Month 6	91,3 [69,3-97,8]
Month 12	91,3 [69,3-97,8]
Month 18	91,3 [69,3-97,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: General disorders and administration site conditions	
PT: Asthenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	11 (9,6)
95%-CI	[4,9-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [80,7-94,4]
Month 6	87,1 [76,8-93,0]
Month 12	87,1 [76,8-93,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	11 (45,8)
95%-CI	[25,6-67,2]
TEAE in months [95%-CI]	
Median	2,56[0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,2 [17,5-65,3]
Month 6	42,2 [17,5-65,3]
Month 12	42,2 [17,5-65,3]
Month 18	42,2 [17,5-65,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	70 (60,9)
95%-CI	[51,3-69,8]
TEAE in months [95%-CI]	
Median	1,05 [0,69-2,86]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	40,5 [30,9-49,8]
Month 6	33,9 [23,4-44,6]
Month 12	20,3 [7,4-37,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,7 [41,1-84,3]
Month 6	67,7 [41,1-84,3]
Month 12	67,7 [41,1-84,3]
Month 18	67,7 [41,1-84,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	51 (44,3)
95%-CI	[35,1-53,9]
TEAE in months [95%-CI]	
Median	3,71[2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,2 [45,6-65,5]
Month 6	45,7 [33,6-57,0]
Month 12	38,1 [21,7-54,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,2 [53,0-90,0]
Month 6	77,2 [53,0-90,0]
Month 12	77,2 [53,0-90,0]
Month 18	77,2 [53,0-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	42 (36,5)
95%-CI	[27,7-46,0]
TEAE in months [95%-CI]	
Median	7,92 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,5 [55,8-73,6]
Month 6	63,9 [53,9-72,4]
Month 12	37,9 [15,7-60,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	8 (33,3)
95%-CI	[15,6-55,3]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [36,9-78,9]
Month 6	61,5 [36,9-78,9]
Month 12	61,5 [36,9-78,9]
Month 18	61,5 [36,9-78,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	29 (25,2)
95%-CI	[17,6-34,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [61,4-79,5]
Month 6	71,6 [61,4-79,5]
Month 12	71,6 [61,4-79,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	1 (4,2)
95%-CI	[0,1-21,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [65,0-99,2]
Month 6	94,1 [65,0-99,2]
Month 12	94,1 [65,0-99,2]
Month 18	94,1 [65,0-99,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	19 (16,5)
95%-CI	[10,3-24,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [75,3-89,7]
Month 6	76,3 [61,6-86,0]
Month 12	76,3 [61,6-86,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	1 (4,2)
95%-CI	[0,1-21,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [73,9-99,4]
Month 6	95,8 [73,9-99,4]
Month 12	95,8 [73,9-99,4]
Month 18	95,8 [73,9-99,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	10 (8,7)
95%-CI	[4,2-15,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [83,2-95,4]
Month 6	91,2 [83,2-95,4]
Month 12	82,0 [55,4-93,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	14 (58,3)
95%-CI	[36,6-77,9]
TEAE in months [95%-CI]	
Median	1,41 [0,62-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [17,3-59,4]
Month 6	38,5 [17,3-59,4]
Month 12	38,5 [17,3-59,4]
Month 18	38,5 [17,3-59,4]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	66 (57,4)
95%-CI	[47,8-66,6]
TEAE in months [95%-CI]	
Median	1,84 [1,18-3,48]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,1 [32,1-51,7]
Month 6	30,4 [19,5-42,1]
Month 12	30,4 [19,5-42,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	10 (41,7)
95%-CI	[22,1-63,4]
TEAE in months [95%-CI]	
Median	19,38 [0,95-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [32,0-75,2]
Month 6	56,6 [32,0-75,2]
Month 12	56,6 [32,0-75,2]
Month 18	56,6 [32,0-75,2]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	50 (43,5)
95%-CI	[34,3-53,0]
TEAE in months [95%-CI]	
Median	4,14 [2,79-8,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	58,5 [47,5-68,0]
Month 6	41,1 [28,5-53,3]
Month 12	30,8 [16,4-46,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [45,0-92,9]
Month 6	67,2 [32,0-87,1]
Month 12	67,2 [32,0-87,1]
Month 18	67,2 [32,0-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	24 (20,9)
95%-CI	[13,9-29,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [67,9-85,5]
Month 6	67,9 [54,1-78,4]
Month 12	67,9 [54,1-78,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Alanine aminotransferase increased	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE in months [95%-CI]	
Median	NE[2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [40,2-87,5]
Month 6	70,6 [40,2-87,5]
Month 12	70,6 [40,2-87,5]
Month 18	70,6 [40,2-87,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Investigations	
PT: Alanine aminotransferase increased	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	16 (13,9)
95%-CI	[8,2-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [78,2-92,2]
Month 6	82,6 [71,9-89,5]
Month 12	75,1 [54,6-87,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE [2,83-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,1 [45,1-91,0]
Month 6	76,1 [45,1-91,0]
Month 12	76,1 [45,1-91,0]
Month 18	76,1 [45,1-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Aspartate aminotransferase increased	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	18 (15,7)
95%-CI	[9,5-23,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [76,4-90,8]
Month 6	77,7 [65,0-86,2]
Month 12	77,7 [65,0-86,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	85,9 [51,1-96,6]
Month 12	85,9 [51,1-96,6]
Month 18	85,9 [51,1-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Weight increased	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [84,9-96,4]
Month 6	90,6 [81,6-95,4]
Month 12	90,6 [81,6-95,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	16 (66,7)
95%-CI	[44,7-84,4]
TEAE in months [95%-CI]	
Median	1,02 [0,33-1,74]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	27,0 [10,4-46,9]
Month 6	27,0 [10,4-46,9]
Month 12	27,0 [10,4-46,9]
Month 18	27,0 [10,4-46,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	58 (50,4)
95%-CI	[41,0-59,9]
TEAE in months [95%-CI]	
Median	2,83[0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,6 [38,5-57,9]
Month 6	45,9 [35,1-56,0]
Month 12	34,4 [15,1-54,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	8 (33,3)
95%-CI	[15,6-55,3]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,8 [38,5-79,7]
Month 6	62,8 [38,5-79,7]
Month 12	62,8 [38,5-79,7]
Month 18	62,8 [38,5-79,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	24 (20,9)
95%-CI	[13,9-29,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [68,6-84,9]
Month 6	75,6 [65,0-83,4]
Month 12	75,6 [65,0-83,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	7 (29,2)
95%-CI	[12,6-51,1]
TEAE in months [95%-CI]	
Median	5,32 [2,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [33,7-83,4]
Month 6	42,8 [8,8-74,3]
Month 12	42,8 [8,8-74,3]
Month 18	42,8 [8,8-74,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	16 (13,9)
95%-CI	[8,2-21,6]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [76,4-91,3]
Month 6	82,9 [72,1-89,8]
Month 12	69,1 [36,3-87,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [40,0-84,9]
Month 6	67,9 [40,0-84,9]
Month 12	67,9 [40,0-84,9]
Month 18	67,9 [40,0-84,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: Vomiting	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	13 (11,3)
95%-CI	[6,2-18,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [80,6-93,4]
Month 6	85,5 [74,6-92,0]
Month 12	85,5 [74,6-92,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	6,37[6,37-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [70,6-97,9]
Month 6	91,7 [70,6-97,9]
Month 12	45,8 [1,0-87,7]
Month 18	45,8 [1,0-87,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	14 (12,2)
95%-CI	[6,8-19,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [80,0-93,3]
Month 6	85,2 [73,9-91,8]
Month 12	76,6 [53,1-89,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: Constipation	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [5,42-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [70,0-97,8]
Month 6	61,0 [7,9-90,8]
Month 12	61,0 [7,9-90,8]
Month 18	61,0 [7,9-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: Constipation	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	13 (11,3)
95%-CI	[6,2-18,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [80,6-93,7]
Month 6	82,9 [69,9-90,6]
Month 12	82,9 [69,9-90,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	14 (58,3)
95%-CI	[36,6-77,9]
TEAE in months [95%-CI]	
Median	2,53 [0,33-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,1 [16,2-61,5]
Month 6	31,3 [10,7-54,6]
Month 12	15,6 [1,3-45,3]
Month 18	15,6 [1,3-45,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	60 (52,2)
95%-CI	[42,7-61,6]
TEAE in months [95%-CI]	
Median	3,48 [1,41-7,62]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,5 [43,6-62,5]
Month 6	41,3 [29,8-52,5]
Month 12	25,5 [11,4-42,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [2,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [48,6-93,7]
Month 6	80,5 [48,6-93,7]
Month 12	80,5 [48,6-93,7]
Month 18	80,5 [48,6-93,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	19 (16,5)
95%-CI	[10,3-24,6]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,8 [73,8-89,0]
Month 6	82,8 [73,8-89,0]
Month 12	71,0 [42,3-87,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE [2,04-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [40,9-94,6]
Month 6	80,0 [40,9-94,6]
Month 12	80,0 [40,9-94,6]
Month 18	80,0 [40,9-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	20 (17,4)
95%-CI	[11,0-25,6]
TEAE in months [95%-CI]	
Median	NE [8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [78,6-92,0]
Month 6	72,0 [56,3-82,8]
Month 12	64,0 [42,1-79,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
TEAE in months [95%-CI]	
Median	6,44 [2,66-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,7 [44,8-89,1]
Month 6	73,7 [44,8-89,1]
Month 12	36,9 [1,6-78,6]
Month 18	36,9 [1,6-78,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	15 (13,0)
95%-CI	[7,5-20,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [81,1-93,5]
Month 6	81,6 [69,6-89,2]
Month 12	81,6 [69,6-89,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [3,09-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [51,2-96,7]
Month 6	76,5 [41,0-92,3]
Month 12	76,5 [41,0-92,3]
Month 18	76,5 [41,0-92,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	16 (13,9)
95%-CI	[8,2-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [79,1-92,2]
Month 6	82,9 [72,5-89,6]
Month 12	82,9 [72,5-89,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,6 [60,0-93,1]
Month 6	82,6 [60,0-93,1]
Month 12	82,6 [60,0-93,1]
Month 18	82,6 [60,0-93,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [86,1-96,3]
Month 6	92,8 [86,1-96,3]
Month 12	92,8 [86,1-96,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [66,1-95,8]
Month 6	87,5 [66,1-95,8]
Month 12	87,5 [66,1-95,8]
Month 18	87,5 [66,1-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,6 [88,4-97,6]
Month 6	92,3 [83,4-96,5]
Month 12	85,2 [62,9-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE [2,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,7 [44,6-90,9]
Month 6	75,7 [44,6-90,9]
Month 12	75,7 [44,6-90,9]
Month 18	75,7 [44,6-90,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	5 (4,3)
95%-CI	[1,4-9,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [89,7-98,1]
Month 6	95,6 [89,7-98,1]
Month 12	95,6 [89,7-98,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]
TEAE in months [95%-CI]	
Median	3,91[0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,0 [35,0-78,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	57 (49,6)
95%-CI	[40,1-59,0]
TEAE in months [95%-CI]	
Median	2,07[1,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [33,6-54,5]
Month 6	33,5 [17,5-50,4]
Month 12	33,5 [17,5-50,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE[1,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [47,0-93,8]
Month 6	64,2 [24,2-87,0]
Month 12	64,2 [24,2-87,0]
Month 18	64,2 [24,2-87,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	15 (13,0)
95%-CI	[7,5-20,6]
TEAE in months [95%-CI]	
Median	15,38 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [76,4-91,4]
Month 6	85,6 [76,4-91,4]
Month 12	85,6 [76,4-91,4]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	8,84 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	16 (13,9)
95%-CI	[8,2-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [76,0-90,6]
Month 6	82,5 [72,3-89,2]
Month 12	82,5 [72,3-89,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [50,1-94,1]
Month 6	81,4 [50,1-94,1]
Month 12	81,4 [50,1-94,1]
Month 18	81,4 [50,1-94,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	11 (9,6)
95%-CI	[4,9-16,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [82,2-94,6]
Month 6	90,1 [82,2-94,6]
Month 12	81,9 [58,4-92,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE[4,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	63,5 [6,9-92,6]
Month 12	63,5 [6,9-92,6]
Month 18	63,5 [6,9-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	13 (11,3)
95%-CI	[6,2-18,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [77,4-92,4]
Month 6	83,5 [71,5-90,7]
Month 12	83,5 [71,5-90,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	11 (45,8)
95%-CI	[25,6-67,2]
TEAE in months [95%-CI]	
Median	1,87[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,0 [10,0-60,3]
Month 6	34,0 [10,0-60,3]
Month 12	34,0 [10,0-60,3]
Month 18	34,0 [10,0-60,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	49 (42,6)
95%-CI	[33,4-52,2]
TEAE in months [95%-CI]	
Median	4,44 [3,61-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [53,6-72,8]
Month 6	44,7 [31,7-56,9]
Month 12	31,9 [17,5-47,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	7 (29,2)
95%-CI	[12,6-51,1]
TEAE in months [95%-CI]	
Median	NE [1,68-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,4 [31,5-80,3]
Month 6	60,4 [31,5-80,3]
Month 12	60,4 [31,5-80,3]
Month 18	60,4 [31,5-80,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	25 (21,7)
95%-CI	[14,6-30,4]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [67,6-84,9]
Month 6	72,1 [59,5-81,3]
Month 12	65,5 [47,4-78,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [70,6-97,9]
Month 6	91,7 [70,6-97,9]
Month 12	91,7 [70,6-97,9]
Month 18	91,7 [70,6-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	14 (12,2)
95%-CI	[6,8-19,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [83,8-95,0]
Month 6	83,4 [70,7-90,9]
Month 12	76,4 [56,0-88,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [57,2-94,6]
Month 6	83,9 [57,2-94,6]
Month 12	83,9 [57,2-94,6]
Month 18	83,9 [57,2-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	13 (11,3)
95%-CI	[6,2-18,6]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [83,3-95,8]
Month 6	83,0 [69,1-91,0]
Month 12	69,2 [45,2-84,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	7 (29,2)
95%-CI	[12,6-51,1]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,4 [35,8-81,7]
Month 6	63,4 [35,8-81,7]
Month 12	63,4 [35,8-81,7]
Month 18	63,4 [35,8-81,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Infections and infestations	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	41 (35,7)
95%-CI	[26,9-45,1]
TEAE in months [95%-CI]	
Median	6,47[3,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,1 [50,8-71,5]
Month 6	50,7 [36,8-63,1]
Month 12	45,7 [30,1-60,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	9 (37,5)
95%-CI	[18,8-59,4]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,4 [22,4-73,1]
Month 6	50,4 [22,4-73,1]
Month 12	50,4 [22,4-73,1]
Month 18	50,4 [22,4-73,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	35 (30,4)
95%-CI	[22,2-39,7]
TEAE in months [95%-CI]	
Median	7,10[5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [58,1-77,9]
Month 6	53,9 [38,6-66,9]
Month 12	47,9 [30,5-63,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [52,6-87,9]
Month 6	75,0 [52,6-87,9]
Month 12	75,0 [52,6-87,9]
Month 18	75,0 [52,6-87,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Nervous system disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	34 (29,6)
95%-CI	[21,4-38,8]
TEAE in months [95%-CI]	
Median	9,23[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [68,6-84,6]
Month 6	55,6 [39,6-68,9]
Month 12	34,8 [12,4-58,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [57,0-90,8]
Month 6	79,2 [57,0-90,8]
Month 12	79,2 [57,0-90,8]
Month 18	79,2 [57,0-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	9 (7,8)
95%-CI	[3,6-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [87,2-97,0]
Month 6	87,7 [74,7-94,2]
Month 12	87,7 [74,7-94,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Vascular disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	7 (29,2)
95%-CI	[12,6-51,1]
TEAE in months [95%-CI]	
Median	NE [1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,0 [33,0-81,3]
Month 6	62,0 [33,0-81,3]
Month 12	62,0 [33,0-81,3]
Month 18	62,0 [33,0-81,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	19 (16,5)
95%-CI	[10,3-24,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [75,5-89,8]
Month 6	79,8 [69,2-87,1]
Month 12	79,8 [69,2-87,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [60,7-95,1]
Month 6	85,4 [60,7-95,1]
Month 12	85,4 [60,7-95,1]
Month 18	85,4 [60,7-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	7 (6,1)
95%-CI	[2,5-12,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [87,9-97,4]
Month 6	92,3 [83,8-96,5]
Month 12	92,3 [83,8-96,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE [2,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [45,9-91,3]
Month 6	76,7 [45,9-91,3]
Month 12	76,7 [45,9-91,3]
Month 18	76,7 [45,9-91,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	23 (20,0)
95%-CI	[13,1-28,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,6 [67,8-84,7]
Month 6	77,6 [67,8-84,7]
Month 12	77,6 [67,8-84,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	1 (4,2)
95%-CI	[0,1-21,1]
TEAE in months [95%-CI]	
Median	NE [2,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Psychiatric disorders	
PT: Insomnia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	14 (12,2)
95%-CI	[6,8-19,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [76,4-91,4]
Month 6	85,6 [76,4-91,4]
Month 12	85,6 [76,4-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Eye disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE [3,25-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	80,4 [37,6-95,2]
Month 12	80,4 [37,6-95,2]
Month 18	80,4 [37,6-95,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	17 (14,8)
95%-CI	[8,9-22,6]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [77,6-93,3]
Month 6	76,1 [62,0-85,6]
Month 12	57,1 [30,0-77,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,2 [57,0-90,8]
Month 6	79,2 [57,0-90,8]
Month 12	79,2 [57,0-90,8]
Month 18	79,2 [57,0-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	14 (12,2)
95%-CI	[6,8-19,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [80,6-93,7]
Month 6	82,9 [69,7-90,7]
Month 12	77,4 [59,3-88,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [63,3-95,4]
Month 6	86,4 [63,3-95,4]
Month 12	86,4 [63,3-95,4]
Month 18	86,4 [63,3-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [84,5-95,9]
Month 6	92,0 [84,5-95,9]
Month 12	92,0 [84,5-95,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	4 (16,7)
95%-CI	[4,7-37,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,8 [53,9-92,1]
Month 6	79,8 [53,9-92,1]
Month 12	79,8 [53,9-92,1]
Month 18	79,8 [53,9-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	13 (11,3)
95%-CI	[6,2-18,6]
TEAE in months [95%-CI]	
Median	NE[8,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [83,7-95,0]
Month 6	90,9 [83,7-95,0]
Month 12	67,1 [38,1-84,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE in months [95%-CI]	
Median	NE [2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,4 [33,1-84,9]
Month 6	65,4 [33,1-84,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Renal and urinary disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	9 (7,8)
95%-CI	[3,6-14,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [84,0-95,9]
Month 6	89,6 [79,8-94,7]
Month 12	89,6 [79,8-94,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [64,4-97,4]
Month 6	89,8 [64,4-97,4]
Month 12	89,8 [64,4-97,4]
Month 18	89,8 [64,4-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS16: Time to first TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE by SOC/PT by subgroup: Response category - any line Loncastuximab tesirine
 Data-cut 3

SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
TEAE in months [95%-CI]	
Median	NE[NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [83,6-95,8]
Month 6	91,6 [83,6-95,8]
Month 12	91,6 [83,6-95,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

4.10.17 Merkmal: Vorherige CAR-T-Therapie

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	8 (61,5)
95%-CI	[31,6-86,1]
TEAE in months [95%-CI]	
Median	1,25 [0,23-1,41]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	88 (66,7)
95%-CI	[57,9-74,6]
TEAE in months [95%-CI]	
Median	1,48 [0,85-2,07]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,5 [27,7-45,4]
Month 6	24,1 [15,0-34,3]
Month 12	14,7 [6,2-26,5]
Month 18	14,7 [6,2-26,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
TEAE in months [95%-CI]	
Median	1,38[0,23-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	33 (25,0)
95%-CI	[17,9-33,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,0 [63,7-80,3]
Month 6	70,5 [60,0-78,7]
Month 12	70,5 [60,0-78,7]
Month 18	70,5 [60,0-78,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [4,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	66,7 [5,4-94,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	28 (21,2)
95%-CI	[14,6-29,2]
TEAE in months [95%-CI]	
Median	NE [6,01-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [73,5-88,7]
Month 6	68,4 [54,1-79,1]
Month 12	50,3 [29,0-68,2]
Month 18	50,3 [29,0-68,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	27 (20,5)
95%-CI	[13,9-28,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [71,0-86,0]
Month 6	74,4 [64,0-82,2]
Month 12	74,4 [64,0-82,2]
Month 18	74,4 [64,0-82,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	14 (10,6)
95%-CI	[5,9-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [81,2-93,9]
Month 6	85,1 [74,8-91,4]
Month 12	85,1 [74,8-91,4]
Month 18	85,1 [74,8-91,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	11 (84,6)
95%-CI	[54,6-98,1]
TEAE in months [95%-CI]	
Median	0,49[0,23-1,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	9,2 [0,6-33,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	72 (54,5)
95%-CI	[45,7-63,2]
TEAE in months [95%-CI]	
Median	1,64 [0,95-5,39]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,7 [35,2-53,8]
Month 6	38,2 [27,5-48,8]
Month 12	25,5 [11,4-42,3]
Month 18	25,5 [11,4-42,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]
TEAE in months [95%-CI]	
Median	1,48 [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	21,2 [1,2-57,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	52 (39,4)
95%-CI	[31,0-48,3]
TEAE in months [95%-CI]	
Median	7,62 [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,0 [51,2-69,4]
Month 6	51,4 [39,7-61,9]
Month 12	45,0 [29,4-59,4]
Month 18	45,0 [29,4-59,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	NE [0,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,1 [23,3-79,5]
Month 6	56,1 [23,3-79,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	43 (32,6)
95%-CI	[24,7-41,3]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,9 [59,9-76,3]
Month 6	67,4 [58,1-75,1]
Month 12	43,4 [20,8-64,1]
Month 18	43,4 [20,8-64,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	NE [0,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,4 [24,4-79,3]
Month 6	56,4 [24,4-79,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	33 (25,0)
95%-CI	[17,9-33,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,5 [61,9-79,0]
Month 6	71,5 [61,9-79,0]
Month 12	71,5 [61,9-79,0]
Month 18	71,5 [61,9-79,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE[0,49-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [23,6-85,0]
Month 6	61,5 [23,6-85,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	17 (12,9)
95%-CI	[7,7-19,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [79,9-92,3]
Month 6	80,2 [66,0-89,0]
Month 12	80,2 [66,0-89,0]
Month 18	80,2 [66,0-89,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	9 (6,8)
95%-CI	[3,2-12,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [86,0-96,6]
Month 6	93,0 [86,0-96,6]
Month 12	84,5 [58,6-94,9]
Month 18	84,5 [58,6-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	NE [0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	55,4 [21,3-79,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	78 (59,1)
95%-CI	[50,2-67,6]
TEAE in months [95%-CI]	
Median	1,48 [1,18-2,83]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	39,5 [30,3-48,7]
Month 6	30,1 [20,1-40,6]
Month 12	30,1 [20,1-40,6]
Month 18	30,1 [20,1-40,6]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [20,4-96,9]
Month 6	80,0 [20,4-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	60 (45,5)
95%-CI	[36,8-54,3]
TEAE in months [95%-CI]	
Median	4,14 [2,76-8,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,5 [46,4-65,4]
Month 6	41,7 [30,1-52,8]
Month 12	31,2 [17,1-46,5]
Month 18	31,2 [17,1-46,5]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	29 (22,0)
95%-CI	[15,2-30,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,8 [65,7-83,3]
Month 6	64,9 [51,7-75,3]
Month 12	64,9 [51,7-75,3]
Month 18	64,9 [51,7-75,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	22 (16,7)
95%-CI	[10,7-24,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [72,9-88,3]
Month 6	78,4 [68,0-85,7]
Month 12	71,2 [52,5-83,7]
Month 18	71,2 [52,5-83,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	23 (17,4)
95%-CI	[11,4-25,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [73,5-88,3]
Month 6	75,5 [63,6-84,0]
Month 12	75,5 [63,6-84,0]
Month 18	75,5 [63,6-84,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	10 (7,6)
95%-CI	[3,7-13,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [85,5-96,3]
Month 6	89,2 [80,3-94,3]
Month 12	89,2 [80,3-94,3]
Month 18	89,2 [80,3-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	7 (53,8)
95%-CI	[25,1-80,8]
TEAE in months [95%-CI]	
Median	1,41[0,07-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,5 [11,1-66,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	70 (53,0)
95%-CI	[44,2-61,8]
TEAE in months [95%-CI]	
Median	1,84[0,82-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	45,5 [36,2-54,3]
Month 6	43,1 [33,2-52,5]
Month 12	34,5 [18,4-51,2]
Month 18	34,5 [18,4-51,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [0,89-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,8 [25,3-87,2]
Month 6	64,8 [25,3-87,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	31 (23,5)
95%-CI	[16,5-31,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,6 [65,4-81,7]
Month 6	72,5 [62,4-80,3]
Month 12	72,5 [62,4-80,3]
Month 18	72,5 [62,4-80,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [1,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	79,1 [36,7-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	23 (17,4)
95%-CI	[11,4-25,0]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [72,2-87,9]
Month 6	76,0 [63,8-84,6]
Month 12	65,1 [39,5-82,1]
Month 18	65,1 [39,5-82,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	79,1 [36,7-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	17 (12,9)
95%-CI	[7,7-19,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [78,0-91,4]
Month 6	83,4 [73,2-90,0]
Month 12	83,4 [73,2-90,0]
Month 18	83,4 [73,2-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	8,11 [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	14 (10,6)
95%-CI	[5,9-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [82,3-94,1]
Month 6	86,6 [75,9-92,8]
Month 12	82,1 [66,8-90,8]
Month 18	82,1 [66,8-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [1,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	15 (11,4)
95%-CI	[6,5-18,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [82,0-93,9]
Month 6	80,6 [66,5-89,2]
Month 12	80,6 [66,5-89,2]
Month 18	80,6 [66,5-89,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]
TEAE in months [95%-CI]	
Median	1,48 [0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,2 [18,5-74,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	71 (53,8)
95%-CI	[44,9-62,5]
TEAE in months [95%-CI]	
Median	3,38 [1,41-6,44]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,5 [42,0-60,1]
Month 6	40,1 [29,6-50,4]
Month 12	25,5 [13,1-40,0]
Month 18	25,5 [13,1-40,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [0,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [36,5-93,9]
Month 6	77,8 [36,5-93,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	21 (15,9)
95%-CI	[10,1-23,3]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,7 [74,0-88,7]
Month 6	82,7 [74,0-88,7]
Month 12	72,4 [46,8-87,1]
Month 18	72,4 [46,8-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	4,86[1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	19 (14,4)
95%-CI	[8,9-21,6]
TEAE in months [95%-CI]	
Median	NE [8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [79,4-92,5]
Month 6	76,4 [62,0-85,9]
Month 12	69,4 [49,2-82,9]
Month 18	69,4 [49,2-82,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE[0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,2 [33,4-90,0]
Month 6	71,2 [33,4-90,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	19 (14,4)
95%-CI	[8,9-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [79,6-92,3]
Month 6	81,0 [69,9-88,3]
Month 12	76,9 [62,8-86,2]
Month 18	76,9 [62,8-86,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE[0,85-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,2 [33,2-93,5]
Month 6	76,2 [33,2-93,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	18 (13,6)
95%-CI	[8,3-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [79,7-92,3]
Month 6	82,1 [72,0-88,8]
Month 12	82,1 [72,0-88,8]
Month 18	82,1 [72,0-88,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	12 (9,1)
95%-CI	[4,8-15,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [84,0-94,6]
Month 6	90,6 [84,0-94,6]
Month 12	90,6 [84,0-94,6]
Month 18	90,6 [84,0-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	9 (6,8)
95%-CI	[3,2-12,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,6 [88,9-97,4]
Month 6	92,6 [84,8-96,5]
Month 12	86,0 [65,3-94,8]
Month 18	86,0 [65,3-94,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	9 (6,8)
95%-CI	[3,2-12,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [85,3-96,0]
Month 6	92,2 [85,3-96,0]
Month 12	92,2 [85,3-96,0]
Month 18	92,2 [85,3-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	2,79[1,12-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,2 [1,6-70,7]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	63 (47,7)
95%-CI	[39,0-56,6]
TEAE in months [95%-CI]	
Median	2,17 [1,45-4,17]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,8 [36,8-56,1]
Month 6	34,4 [20,2-49,0]
Month 12	34,4 [20,2-49,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [2,56-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [20,4-96,9]
Month 6	80,0 [20,4-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	18 (13,6)
95%-CI	[8,3-20,7]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [77,7-91,2]
Month 6	83,3 [73,2-89,8]
Month 12	83,3 [73,2-89,8]
Month 18	41,6 [1,4-83,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	18 (13,6)
95%-CI	[8,3-20,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [77,8-91,2]
Month 6	83,8 [74,6-89,9]
Month 12	74,5 [50,5-88,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	15 (11,4)
95%-CI	[6,5-18,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [79,1-92,3]
Month 6	87,2 [79,1-92,3]
Month 12	79,9 [59,9-90,7]
Month 18	79,9 [59,9-90,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [20,4-96,9]
Month 6	80,0 [20,4-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	14 (10,6)
95%-CI	[5,9-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,0 [81,2-93,6]
Month 6	83,1 [70,6-90,6]
Month 12	83,1 [70,6-90,6]
Month 18	83,1 [70,6-90,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	8 (61,5)
95%-CI	[31,6-86,1]
TEAE in months [95%-CI]	
Median	1,41 [0,26-3,02]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,0 [6,6-63,6]
Month 6	16,5 [1,0-49,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	53 (40,2)
95%-CI	[31,7-49,0]
TEAE in months [95%-CI]	
Median	4,76 [3,61-7,69]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,4 [53,4-71,8]
Month 6	46,1 [33,3-57,9]
Month 12	33,1 [18,5-48,5]
Month 18	33,1 [18,5-48,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]
TEAE in months [95%-CI]	
Median	2,66[0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,6 [7,1-68,3]
Month 6	36,6 [7,1-68,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	26 (19,7)
95%-CI	[13,3-27,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,3 [70,1-86,0]
Month 6	74,2 [62,5-82,8]
Month 12	68,0 [50,8-80,4]
Month 18	68,0 [50,8-80,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [0,59-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [47,2-95,5]
Month 6	83,1 [47,2-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	15 (11,4)
95%-CI	[6,5-18,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [83,5-94,8]
Month 6	83,5 [71,3-90,8]
Month 12	76,5 [56,2-88,3]
Month 18	76,5 [56,2-88,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,0 [38,2-91,0]
Month 6	74,0 [38,2-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	13 (9,8)
95%-CI	[5,3-16,3]
TEAE in months [95%-CI]	
Median	NE [7,69-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [84,5-96,1]
Month 6	84,0 [70,5-91,6]
Month 12	71,1 [48,0-85,3]
Month 18	71,1 [48,0-85,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	2,33[1,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,7 [7,1-80,3]
Month 6	46,7 [7,1-80,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	45 (34,1)
95%-CI	[26,1-42,8]
TEAE in months [95%-CI]	
Median	6,47[3,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,8 [53,4-72,5]
Month 6	53,7 [40,7-65,1]
Month 12	48,8 [33,8-62,2]
Month 18	48,8 [33,8-62,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE in months [95%-CI]	
Median	NE[0,46-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,8 [19,0-78,2]
Month 6	52,8 [19,0-78,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	41 (31,1)
95%-CI	[23,3-39,7]
TEAE in months [95%-CI]	
Median	7,10[4,40-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,2 [56,6-75,7]
Month 6	51,6 [36,6-64,8]
Month 12	45,9 [29,0-61,3]
Month 18	45,9 [29,0-61,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	4,17[0,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,6 [39,3-94,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	37 (28,0)
95%-CI	[20,6-36,5]
TEAE in months [95%-CI]	
Median	10,97[5,55-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,9 [68,4-83,4]
Month 6	60,7 [45,8-72,7]
Month 12	41,6 [18,4-63,5]
Month 18	41,6 [18,4-63,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [1,08-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	58,3 [7,7-89,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	13 (9,8)
95%-CI	[5,3-16,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [84,4-94,7]
Month 6	87,9 [78,1-93,5]
Month 12	87,9 [78,1-93,5]
Month 18	87,9 [78,1-93,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	4 (30,8)
95%-CI	[9,1-61,4]
TEAE in months [95%-CI]	
Median	NE[0,26-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,5 [23,6-85,0]
Month 6	61,5 [23,6-85,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	24 (18,2)
95%-CI	[12,0-25,8]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [73,3-87,6]
Month 6	77,9 [67,9-85,1]
Month 12	77,9 [67,9-85,1]
Month 18	77,9 [67,9-85,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [1,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	9 (6,8)
95%-CI	[3,2-12,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,5 [87,5-96,7]
Month 6	91,7 [84,1-95,8]
Month 12	91,7 [84,1-95,8]
Month 18	91,7 [84,1-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [0,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,1 [15,1-84,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	25 (18,9)
95%-CI	[12,6-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,9 [70,2-85,4]
Month 6	78,9 [70,2-85,4]
Month 12	78,9 [70,2-85,4]
Month 18	78,9 [70,2-85,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE in months [95%-CI]	
Median	NE [1,41-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,3 [14,7-84,2]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	13 (9,8)
95%-CI	[5,3-16,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [80,5-93,2]
Month 6	88,4 [80,5-93,2]
Month 12	88,4 [80,5-93,2]
Month 18	88,4 [80,5-93,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	8,11 [2,14-8,11]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	18 (13,6)
95%-CI	[8,3-20,7]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [79,2-93,5]
Month 6	76,1 [62,9-85,2]
Month 12	66,6 [42,8-82,3]
Month 18	66,6 [42,8-82,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	19 (14,4)
95%-CI	[8,9-21,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [78,5-91,5]
Month 6	80,8 [68,5-88,6]
Month 12	75,4 [58,4-86,2]
Month 18	75,4 [58,4-86,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	11 (8,3)
95%-CI	[4,2-14,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [83,4-94,7]
Month 6	90,5 [83,4-94,7]
Month 12	90,5 [83,4-94,7]
Month 18	90,5 [83,4-94,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	15 (11,4)
95%-CI	[6,5-18,0]
TEAE in months [95%-CI]	
Median	NE [9,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [83,4-94,4]
Month 6	90,2 [83,4-94,4]
Month 12	68,6 [41,5-85,1]
Month 18	68,6 [41,5-85,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	13 (9,8)
95%-CI	[5,3-16,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [79,3-93,2]
Month 6	86,0 [76,2-92,0]
Month 12	86,0 [76,2-92,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS17: Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	10 (7,6)
95%-CI	[3,7-13,5]
TEAE in months [95%-CI]	
Median	NE[NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [83,5-95,1]
Month 6	91,0 [83,5-95,1]
Month 12	91,0 [83,5-95,1]
Month 18	91,0 [83,5-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

4.10.18 Merkmal: Arzneimittelformulierung

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	24 (68,6)
95%-CI	[50,7-83,1]
TEAE in months [95%-CI]	
Median	1,61 [0,43-3,29]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,6 [18,1-51,7]
Month 6	18,4 [4,4-40,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	72 (65,5)
95%-CI	[55,8-74,3]
TEAE in months [95%-CI]	
Median	1,38 [0,76-2,10]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,0 [25,2-44,9]
Month 6	24,5 [14,8-35,5]
Month 12	16,8 [7,3-29,7]
Month 18	16,8 [7,3-29,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,7 [60,1-92,3]
Month 6	81,7 [60,1-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Fatigue	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	35 (31,8)
95%-CI	[23,3-41,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,0 [55,5-74,7]
Month 6	63,2 [51,4-72,8]
Month 12	63,2 [51,4-72,8]
Month 18	63,2 [51,4-72,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	6,01[4,86-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [70,2-98,1]
Month 6	64,7 [18,3-89,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Oedema peripheral	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	24 (21,8)
95%-CI	[14,5-30,7]
TEAE in months [95%-CI]	
Median	NE [7,10-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [71,1-88,2]
Month 6	67,8 [53,0-78,9]
Month 12	54,8 [33,9-71,6]
Month 18	54,8 [33,9-71,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	NE [3,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [51,0-82,7]
Month 6	50,1 [26,9-69,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Pyrexia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,8 [74,3-90,0]
Month 6	83,8 [74,3-90,0]
Month 12	83,8 [74,3-90,0]
Month 18	83,8 [74,3-90,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	NE [3,45-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,5 [54,6-89,8]
Month 6	67,8 [39,2-85,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: Asthenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	7 (6,4)
95%-CI	[2,6-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [87,4-97,3]
Month 6	91,7 [82,1-96,2]
Month 12	91,7 [82,1-96,2]
Month 18	91,7 [82,1-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	24 (68,6)
95%-CI	[50,7-83,1]
TEAE in months [95%-CI]	
Median	1,05 [0,69-1,41]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,1 [17,4-49,6]
Month 6	22,0 [8,2-40,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	59 (53,6)
95%-CI	[43,9-63,2]
TEAE in months [95%-CI]	
Median	1,64 [0,72-6,93]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	44,3 [33,8-54,3]
Month 6	40,9 [29,4-52,0]
Month 12	27,3 [12,1-45,0]
Month 18	27,3 [12,1-45,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	18 (51,4)
95%-CI	[34,0-68,6]
TEAE in months [95%-CI]	
Median	2,40[0,95-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,9 [21,7-60,9]
Month 6	34,9 [15,4-55,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	40 (36,4)
95%-CI	[27,4-46,1]
TEAE in months [95%-CI]	
Median	7,62 [3,48-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,6 [52,9-72,5]
Month 6	54,2 [41,2-65,4]
Month 12	47,4 [30,5-62,5]
Month 18	47,4 [30,5-62,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	NE [1,18-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,2 [42,5-75,5]
Month 6	61,2 [42,5-75,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	35 (31,8)
95%-CI	[23,3-41,4]
TEAE in months [95%-CI]	
Median	9,23 [6,93-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [60,1-78,0]
Month 6	68,2 [57,8-76,6]
Month 12	46,0 [24,1-65,5]
Month 18	46,0 [24,1-65,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	10 (28,6)
95%-CI	[14,6-46,3]
TEAE in months [95%-CI]	
Median	NE [1,61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,9 [49,6-82,0]
Month 6	68,9 [49,6-82,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	28 (25,5)
95%-CI	[17,6-34,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,6 [59,8-79,0]
Month 6	70,6 [59,8-79,0]
Month 12	70,6 [59,8-79,0]
Month 18	70,6 [59,8-79,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [70,8-95,3]
Month 6	87,9 [70,8-95,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	17 (15,5)
95%-CI	[9,3-23,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [75,6-90,5]
Month 6	77,2 [62,4-86,8]
Month 12	77,2 [62,4-86,8]
Month 18	77,2 [62,4-86,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [80,9-94,5]
Month 6	89,6 [80,9-94,5]
Month 12	82,1 [60,4-92,6]
Month 18	82,1 [60,4-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	27 (77,1)
95%-CI	[59,9-89,6]
TEAE in months [95%-CI]	
Median	0,72 [0,49-1,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	19,5 [7,3-36,1]
Month 6	9,8 [1,0-30,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	56 (50,9)
95%-CI	[41,2-60,6]
TEAE in months [95%-CI]	
Median	2,10 [1,41-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,1 [37,4-58,0]
Month 6	38,4 [26,4-50,3]
Month 12	38,4 [26,4-50,3]
Month 18	38,4 [26,4-50,3]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	24 (68,6)
95%-CI	[50,7-83,1]
TEAE in months [95%-CI]	
Median	1,41 [0,95-2,76]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	27,8 [13,1-44,6]
Month 6	18,5 [4,8-39,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	37 (33,6)
95%-CI	[24,9-43,3]
TEAE in months [95%-CI]	
Median	8,05 [3,78-19,38]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,5 [58,2-78,2]
Month 6	52,7 [38,4-65,1]
Month 12	41,0 [23,5-57,8]
Month 18	41,0 [23,5-57,8]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	14 (40,0)
95%-CI	[23,9-57,9]
TEAE in months [95%-CI]	
Median	3,55[2,53-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,4 [39,0-76,3]
Month 6	35,6 [12,4-60,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Blood alkaline phosphatase increased	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [73,1-90,3]
Month 6	77,6 [63,8-86,7]
Month 12	77,6 [63,8-86,7]
Month 18	77,6 [63,8-86,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [50,5-84,0]
Month 6	70,8 [50,5-84,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Alanine aminotransferase increased	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	14 (12,7)
95%-CI	[7,1-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [77,0-92,6]
Month 6	82,3 [70,4-89,7]
Month 12	74,8 [53,9-87,2]
Month 18	74,8 [53,9-87,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,4 [52,9-86,0]
Month 6	73,4 [52,9-86,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Aspartate aminotransferase increased	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [78,5-92,7]
Month 6	79,1 [65,5-87,8]
Month 12	79,1 [65,5-87,8]
Month 18	79,1 [65,5-87,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [72,3-98,2]
Month 6	86,7 [62,8-95,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Weight increased	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	7 (6,4)
95%-CI	[2,6-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [85,5-97,0]
Month 6	91,2 [81,7-95,8]
Month 12	91,2 [81,7-95,8]
Month 18	91,2 [81,7-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	23 (65,7)
95%-CI	[47,8-80,9]
TEAE in months [95%-CI]	
Median	0,69[0,33-2,07]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,1 [17,0-48,3]
Month 6	32,1 [17,0-48,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	54 (49,1)
95%-CI	[39,4-58,8]
TEAE in months [95%-CI]	
Median	2,83[1,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,9 [38,4-58,6]
Month 6	46,4 [35,3-56,7]
Month 12	37,1 [19,5-54,8]
Month 18	37,1 [19,5-54,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	11 (31,4)
95%-CI	[16,9-49,3]
TEAE in months [95%-CI]	
Median	NE [2,20-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [50,0-82,3]
Month 6	57,7 [30,2-77,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Nausea	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	23 (20,9)
95%-CI	[13,7-29,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,8 [65,5-83,5]
Month 6	75,8 [65,5-83,5]
Month 12	75,8 [65,5-83,5]
Month 18	75,8 [65,5-83,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE [3,91-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [60,4-92,3]
Month 6	70,1 [38,2-87,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Diarrhoea	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	19 (17,3)
95%-CI	[10,7-25,7]
TEAE in months [95%-CI]	
Median	NE [11,30-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,9 [70,4-87,9]
Month 6	77,5 [64,8-86,1]
Month 12	66,4 [39,9-83,3]
Month 18	66,4 [39,9-83,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	10 (28,6)
95%-CI	[14,6-46,3]
TEAE in months [95%-CI]	
Median	NE [2,79-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,5 [47,1-81,5]
Month 6	67,5 [47,1-81,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Vomiting	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	9 (8,2)
95%-CI	[3,8-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [84,3-95,9]
Month 6	88,8 [77,7-94,6]
Month 12	88,8 [77,7-94,6]
Month 18	88,8 [77,7-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE [5,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,7 [64,0-93,1]
Month 6	69,7 [34,2-88,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Abdominal pain	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [83,3-95,3]
Month 6	91,0 [83,3-95,3]
Month 12	78,8 [55,8-90,7]
Month 18	78,8 [55,8-90,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [61,9-91,2]
Month 6	81,0 [61,9-91,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: Constipation	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [83,1-95,6]
Month 6	80,6 [63,8-90,1]
Month 12	80,6 [63,8-90,1]
Month 18	80,6 [63,8-90,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	22 (62,9)
95%-CI	[44,9-78,5]
TEAE in months [95%-CI]	
Median	2,04 [0,53-5,75]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,4 [29,9-62,9]
Month 6	26,8 [10,8-45,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	55 (50,0)
95%-CI	[40,3-59,7]
TEAE in months [95%-CI]	
Median	3,52 [1,48-8,51]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,4 [41,7-62,0]
Month 6	45,8 [34,2-56,7]
Month 12	28,5 [14,3-44,5]
Month 18	28,5 [14,3-44,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,6 [59,1-90,5]
Month 6	79,6 [59,1-90,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	17 (15,5)
95%-CI	[9,3-23,6]
TEAE in months [95%-CI]	
Median	NE [10,15-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [74,2-89,8]
Month 6	83,6 [74,2-89,8]
Month 12	73,1 [46,8-87,9]
Month 18	73,1 [46,8-87,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [5,75-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [70,8-96,7]
Month 6	65,9 [26,2-87,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Decreased appetite	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	17 (15,5)
95%-CI	[9,3-23,6]
TEAE in months [95%-CI]	
Median	NE[8,51-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [76,3-91,6]
Month 6	75,9 [60,7-85,8]
Month 12	69,0 [48,4-82,7]
Month 18	69,0 [48,4-82,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE in months [95%-CI]	
Median	NE [3,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [64,6-91,7]
Month 6	65,8 [38,3-83,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypokalaemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	14 (12,7)
95%-CI	[7,1-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [78,4-92,8]
Month 6	84,5 [73,4-91,3]
Month 12	79,8 [64,3-89,1]
Month 18	79,8 [64,3-89,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE in months [95%-CI]	
Median	NE [3,52-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [64,5-91,6]
Month 6	69,7 [45,7-84,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypomagnesaemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	12 (10,9)
95%-CI	[5,8-18,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [79,5-93,5]
Month 6	86,0 [75,7-92,1]
Month 12	86,0 [75,7-92,1]
Month 18	86,0 [75,7-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,9 [62,4-89,9]
Month 6	79,9 [62,4-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypocalcaemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	5 (4,5)
95%-CI	[1,5-10,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [88,6-98,0]
Month 6	95,1 [88,6-98,0]
Month 12	95,1 [88,6-98,0]
Month 18	95,1 [88,6-98,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyperglycaemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [84,5-95,6]
Month 6	89,2 [79,8-94,4]
Month 12	82,8 [63,7-92,4]
Month 18	82,8 [63,7-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [71,1-95,4]
Month 6	88,0 [71,1-95,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hyponatraemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	6 (5,5)
95%-CI	[2,0-11,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [85,3-97,1]
Month 6	93,4 [85,3-97,1]
Month 12	93,4 [85,3-97,1]
Month 18	93,4 [85,3-97,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	NE [1, 61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	54,2 [33,1-71,1]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	55 (50,0)
95%-CI	[40,3-59,7]
TEAE in months [95%-CI]	
Median	1,68 [1,38-3,91]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,8 [31,3-53,8]
Month 6	29,0 [14,8-44,8]
Month 12	29,0 [14,8-44,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [72,3-98,2]
Month 6	92,5 [72,3-98,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Pruritus	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	17 (15,5)
95%-CI	[9,3-23,6]
TEAE in months [95%-CI]	
Median	15,38 [15,38-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,0 [72,8-89,6]
Month 6	80,0 [68,0-87,9]
Month 12	80,0 [68,0-87,9]
Month 18	40,0 [1,5-81,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [67,0-94,9]
Month 6	86,5 [67,0-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Rash	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [8,84-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [76,9-91,6]
Month 6	83,4 [72,8-90,2]
Month 12	74,1 [49,9-87,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [61,2-93,7]
Month 6	83,6 [61,2-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Erythema	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [81,1-94,2]
Month 6	89,4 [81,1-94,2]
Month 12	82,5 [62,5-92,5]
Month 18	82,5 [62,5-92,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [65,5-94,6]
Month 6	85,7 [65,5-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Skin and subcutaneous tissue disorders	
PT: Photosensitivity reaction	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,1 [79,5-94,3]
Month 6	82,5 [68,2-90,8]
Month 12	82,5 [68,2-90,8]
Month 18	82,5 [68,2-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	16 (45,7)
95%-CI	[28,8-63,4]
TEAE in months [95%-CI]	
Median	3,91 [2,20-6,01]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,2 [37,0-73,1]
Month 6	34,3 [10,8-59,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	45 (40,9)
95%-CI	[31,6-50,7]
TEAE in months [95%-CI]	
Median	4,44 [3,02-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,3 [51,2-71,6]
Month 6	46,0 [32,6-58,4]
Month 12	36,8 [21,8-51,9]
Month 18	36,8 [21,8-51,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,4 [50,1-83,7]
Month 6	70,4 [50,1-83,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Cough	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	23 (20,9)
95%-CI	[13,7-29,7]
TEAE in months [95%-CI]	
Median	NE [7,62-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,9 [67,2-85,5]
Month 6	72,1 [58,9-81,8]
Month 12	66,1 [48,4-79,0]
Month 18	66,1 [48,4-79,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	94,3 [79,0-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Dyspnoea	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [79,9-93,6]
Month 6	80,6 [67,2-89,0]
Month 12	73,9 [53,9-86,2]
Month 18	73,9 [53,9-86,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [3,94-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [66,9-96,3]
Month 6	55,2 [15,2-82,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: Pleural effusion	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	11 (10,0)
95%-CI	[5,1-17,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [83,6-95,7]
Month 6	88,6 [77,6-94,4]
Month 12	75,9 [52,8-88,8]
Month 18	75,9 [52,8-88,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE in months [95%-CI]	
Median	NE [3, 61-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [53,8-87,8]
Month 6	66,9 [41,0-83,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	40 (36,4)
95%-CI	[27,4-46,1]
TEAE in months [95%-CI]	
Median	4,83 [2,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,2 [47,3-69,3]
Month 6	49,5 [35,1-62,3]
Month 12	44,0 [27,9-59,0]
Month 18	44,0 [27,9-59,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE in months [95%-CI]	
Median	3,91[2,76-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,9 [44,6-79,4]
Month 6	24,4 [1,6-61,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Musculoskeletal and connective tissue disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	33 (30,0)
95%-CI	[21,6-39,5]
TEAE in months [95%-CI]	
Median	NE [5,78-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,3 [54,3-75,8]
Month 6	56,5 [41,6-68,9]
Month 12	50,8 [33,7-65,6]
Month 18	50,8 [33,7-65,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE in months [95%-CI]	
Median	NE[4,14-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [70,8-95,3]
Month 6	60,3 [22,5-84,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	35 (31,8)
95%-CI	[23,3-41,4]
TEAE in months [95%-CI]	
Median	9,23[4,63-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,8 [64,0-81,3]
Month 6	56,7 [41,2-69,5]
Month 12	38,9 [17,2-60,3]
Month 18	38,9 [17,2-60,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	94,3 [79,0-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Nervous system disorders	
PT: Headache	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	13 (11,8)
95%-CI	[6,4-19,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [82,1-94,2]
Month 6	83,6 [70,8-91,1]
Month 12	83,6 [70,8-91,1]
Month 18	83,6 [70,8-91,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [78,7-98,5]
Month 6	94,2 [78,7-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	26 (23,6)
95%-CI	[16,1-32,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [65,4-83,0]
Month 6	71,1 [59,6-79,9]
Month 12	71,1 [59,6-79,9]
Month 18	71,1 [59,6-79,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [80,9-99,6]
Month 6	97,1 [80,9-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Vascular disorders	
PT: Hypotension	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	9 (8,2)
95%-CI	[3,8-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [84,5-95,9]
Month 6	89,8 [80,6-94,8]
Month 12	89,8 [80,6-94,8]
Month 18	89,8 [80,6-94,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [71,8-95,5]
Month 6	88,3 [71,8-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	24 (21,8)
95%-CI	[14,5-30,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,3 [63,6-82,3]
Month 6	74,3 [63,6-82,3]
Month 12	74,3 [63,6-82,3]
Month 18	74,3 [63,6-82,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [75,3-97,1]
Month 6	91,3 [75,3-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Psychiatric disorders	
PT: Insomnia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	13 (11,8)
95%-CI	[6,4-19,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [74,4-91,1]
Month 6	84,7 [74,4-91,1]
Month 12	84,7 [74,4-91,1]
Month 18	84,7 [74,4-91,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	NE [3,22-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [61,4-95,5]
Month 6	52,1 [9,4-83,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Eye disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [7,92-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [78,5-94,0]
Month 6	79,7 [66,5-88,1]
Month 12	62,0 [35,2-80,3]
Month 18	62,0 [35,2-80,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE in months [95%-CI]	
Median	6,67 [5,72-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [75,7-97,2]
Month 6	73,1 [26,8-92,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	14 (12,7)
95%-CI	[7,1-20,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [77,0-91,8]
Month 6	83,8 [73,3-90,4]
Month 12	83,8 [73,3-90,4]
Month 18	83,8 [73,3-90,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	94,3 [79,0-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Cardiac disorders	
PT: Tachycardia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	9 (8,2)
95%-CI	[3,8-15,0]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [81,9-94,8]
Month 6	90,2 [81,9-94,8]
Month 12	90,2 [81,9-94,8]
Month 18	90,2 [81,9-94,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [78,7-98,5]
Month 6	94,2 [78,7-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Injury, poisoning and procedural complications	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	15 (13,6)
95%-CI	[7,8-21,5]
TEAE in months [95%-CI]	
Median	NE [9,17-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,3 [80,2-93,2]
Month 6	88,3 [80,2-93,2]
Month 12	68,3 [43,2-84,1]
Month 18	68,3 [43,2-84,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [81,4-99,6]
Month 6	97,1 [81,4-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Renal and urinary disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	13 (11,8)
95%-CI	[6,4-19,4]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,4 [74,9-91,7]
Month 6	83,0 [71,5-90,2]
Month 12	83,0 [71,5-90,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [69,4-95,1]
Month 6	87,3 [69,4-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3A_TSSS18: Time to first TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	7 (6,4)
95%-CI	[2,6-12,7]
TEAE in months [95%-CI]	
Median	NE [NE-NE]
TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [83,5-96,3]
Month 6	92,0 [83,5-96,3]
Month 12	92,0 [83,5-96,3]
Month 18	92,0 [83,5-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

4.11 Subgruppenanalysen zum Endpunkt: Schwere unerwünschte Ereignisse nach SOC und PT

4.11.1 Merkmal Alter

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	6 (9,2)
95%-CI	[3,5-19,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [75,4-95,7]
Month 6	89,4 [75,4-95,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,1 [85,4-99,0]
Month 6	91,1 [71,5-97,4]
Month 12	91,1 [71,5-97,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,90-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	79,2 [31,8-95,4]
Month 12	79,2 [31,8-95,4]
Month 18	79,2 [31,8-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	29 (44,6)
95%-CI	[32,3-57,5]
TEAE graded >= 3 in months [95%-CI]	
Median	3,71[1,74-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,3 [41,7-68,6]
Month 6	42,9 [25,5-59,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	23 (39,0)
95%-CI	[26,5-52,6]
TEAE graded >= 3 in months [95%-CI]	
Median	5,39 [3,02-9,23]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,9 [53,7-80,0]
Month 6	45,8 [25,9-63,6]
Month 12	15,3 [1,1-45,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	6 (28,6)
95%-CI	[11,3-52,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[2,56-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,2 [39,4-84,4]
Month 6	67,2 [39,4-84,4]
Month 12	67,2 [39,4-84,4]
Month 18	67,2 [39,4-84,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	19 (29,2)
95%-CI	[18,6-41,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,4 [52,7-78,4]
Month 6	63,2 [47,0-75,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	17 (28,8)
95%-CI	[17,8-42,1]
TEAE graded >= 3 in months [95%-CI]	
Median	7,62 [3,29-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,4 [64,6-88,5]
Month 6	51,5 [30,1-69,4]
Month 12	34,4 [8,5-62,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,8-97,0]
Month 6	88,4 [60,8-97,0]
Month 12	88,4 [60,8-97,0]
Month 18	88,4 [60,8-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	13 (20,0)
95%-CI	[11,1-31,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [7,79-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [72,6-91,8]
Month 6	71,7 [51,4-84,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [68,2-90,5]
Month 6	82,2 [68,2-90,5]
Month 12	65,8 [28,7-86,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	3 (14,3)
95%-CI	[3,0-36,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [60,1-94,9]
Month 6	84,9 [60,1-94,9]
Month 12	84,9 [60,1-94,9]
Month 18	84,9 [60,1-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	7 (10,8)
95%-CI	[4,4-20,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [74,4-93,7]
Month 6	87,0 [74,4-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [75,2-95,6]
Month 6	85,8 [69,6-93,7]
Month 12	85,8 [69,6-93,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,3 [56,4-96,8]
Month 6	87,3 [56,4-96,8]
Month 12	87,3 [56,4-96,8]
Month 18	87,3 [56,4-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [78,4-96,1]
Month 6	90,6 [78,4-96,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,85-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [79,7-97,0]
Month 6	76,9 [48,5-90,9]
Month 12	76,9 [48,5-90,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,8-97,0]
Month 6	88,4 [60,8-97,0]
Month 12	88,4 [60,8-97,0]
Month 18	88,4 [60,8-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	3 (4,6)
95%-CI	[1,0-12,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [79,0-98,0]
Month 6	93,3 [79,0-98,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [85,1-98,3]
Month 6	94,9 [85,1-98,3]
Month 12	94,9 [85,1-98,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [67,0-97,5]
Month 6	90,5 [67,0-97,5]
Month 12	90,5 [67,0-97,5]
Month 18	90,5 [67,0-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	20 (30,8)
95%-CI	[19,9-43,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,4 [45,1-72,7]
Month 6	60,4 [45,1-72,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	10 (16,9)
95%-CI	[8,4-29,0]
TEAE graded >= 3 in months [95%-CI]	
Median	12,45 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [68,5-93,2]
Month 6	73,8 [51,2-87,1]
Month 12	73,8 [51,2-87,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	17 (26,2)
95%-CI	[16,0-38,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,96-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,6 [48,8-76,6]
Month 6	64,6 [48,8-76,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [70,4-94,5]
Month 6	76,2 [53,8-88,8]
Month 12	76,2 [53,8-88,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	7 (10,8)
95%-CI	[4,4-20,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [79,6-95,5]
Month 6	90,3 [79,6-95,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [77,9-95,9]
Month 6	85,5 [68,2-93,8]
Month 12	85,5 [68,2-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	1 (4,8)
95%-CI	[0,1-23,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	66,7 [5,4-94,5]
Month 18	66,7 [5,4-94,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	10 (15,4)
95%-CI	[7,6-26,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [72,7-91,8]
Month 6	84,8 [72,7-91,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,1 [71,6-91,4]
Month 6	84,1 [71,6-91,4]
Month 12	84,1 [71,6-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	4 (19,0)
95%-CI	[5,4-41,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [62,0-95,2]
Month 6	85,7 [62,0-95,2]
Month 12	57,1 [8,9-87,9]
Month 18	57,1 [8,9-87,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	1 (1,5)
95%-CI	[0,0-8,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,3 [88,6-99,8]
Month 6	98,3 [88,6-99,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [79,1-96,1]
Month 6	90,7 [79,1-96,1]
Month 12	90,7 [79,1-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	63,5 [6,9-92,6]
Month 18	63,5 [6,9-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	4 (6,2)
95%-CI	[1,7-15,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [80,2-97,1]
Month 6	92,3 [80,2-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [82,9-98,9]
Month 6	78,5 [52,9-91,2]
Month 12	78,5 [52,9-91,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	4 (6,2)
95%-CI	[1,7-15,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [76,1-96,7]
Month 6	90,8 [76,1-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,9 [69,8-93,8]
Month 6	77,3 [51,4-90,5]
Month 12	77,3 [51,4-90,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS01: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [56,1-96,8]
Month 6	87,1 [56,1-96,8]
Month 12	87,1 [56,1-96,8]
Month 18	87,1 [56,1-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Sex
 ITT set

4.11.2 Merkmal: Geschlecht

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	5 (8,3)
95%-CI	[2,8-18,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [83,1-98,1]
Month 6	89,5 [71,9-96,4]
Month 12	83,9 [62,1-93,8]
Month 18	83,9 [62,1-93,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	6 (7,1)
95%-CI	[2,6-14,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [81,7-96,8]
Month 6	88,5 [74,2-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	25 (41,7)
95%-CI	[29,1-55,1]
TEAE graded >= 3 in months [95%-CI]	
Median	7,79[1,48-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [49,8-75,2]
Month 6	51,7 [34,3-66,5]
Month 12	36,9 [17,2-56,8]
Month 18	36,9 [17,2-56,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	33 (38,8)
95%-CI	[28,4-50,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	5,68 [2,86-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,4 [49,3-73,0]
Month 6	45,2 [28,1-60,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	18 (30,0)
95%-CI	[18,8-43,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,17-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,2 [60,8-84,9]
Month 6	54,0 [34,4-70,0]
Month 12	54,0 [34,4-70,0]
Month 18	54,0 [34,4-70,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	20 (23,5)
95%-CI	[15,0-34,0]
TEAE graded >= 3 in months [95%-CI]	
Median	7,62 [7,62-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,7 [63,4-84,3]
Month 6	70,0 [55,9-80,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	13 (21,7)
95%-CI	[12,1-34,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [7,79-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,2 [67,8-89,5]
Month 6	78,0 [63,2-87,4]
Month 12	63,8 [40,2-80,1]
Month 18	63,8 [40,2-80,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	13 (15,3)
95%-CI	[8,4-24,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [75,1-91,8]
Month 6	74,5 [52,0-87,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	7 (11,7)
95%-CI	[4,8-22,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [72,5-94,1]
Month 6	83,6 [67,7-92,2]
Month 12	83,6 [67,7-92,2]
Month 18	83,6 [67,7-92,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [77,7-94,3]
Month 6	88,5 [77,7-94,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	8 (13,3)
95%-CI	[5,9-24,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [75,2-94,5]
Month 6	77,4 [56,2-89,2]
Month 12	77,4 [56,2-89,2]
Month 18	77,4 [56,2-89,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [82,7-96,9]
Month 6	92,5 [82,7-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [85,3-98,4]
Month 6	95,0 [85,3-98,4]
Month 12	95,0 [85,3-98,4]
Month 18	95,0 [85,3-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [82,3-97,1]
Month 6	92,7 [82,3-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	10 (16,7)
95%-CI	[8,3-28,5]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [65,6-90,3]
Month 6	81,3 [65,6-90,3]
Month 12	81,3 [65,6-90,3]
Month 18	43,4 [8,0-75,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	20 (23,5)
95%-CI	[15,0-34,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [4,47-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,8 [59,8-82,2]
Month 6	65,7 [49,9-77,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [65,6-90,3]
Month 6	81,3 [65,6-90,3]
Month 12	81,3 [65,6-90,3]
Month 18	54,2 [9,9-85,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	16 (18,8)
95%-CI	[11,2-28,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [64,4-86,2]
Month 6	70,2 [54,1-81,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	7 (11,7)
95%-CI	[4,8-22,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [78,6-95,3]
Month 6	89,8 [78,6-95,3]
Month 12	78,5 [46,9-92,6]
Month 18	78,5 [46,9-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	7 (8,2)
95%-CI	[3,4-16,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [83,9-97,1]
Month 6	89,6 [76,5-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	9 (15,0)
95%-CI	[7,1-26,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [74,3-92,9]
Month 6	86,2 [74,3-92,9]
Month 12	75,4 [46,5-90,1]
Month 18	75,4 [46,5-90,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	14 (16,5)
95%-CI	[9,3-26,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,5 [73,2-90,1]
Month 6	83,5 [73,2-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,3 [86,1-99,1]
Month 6	96,3 [86,1-99,1]
Month 12	84,3 [44,3-96,5]
Month 18	84,3 [44,3-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [85,4-97,3]
Month 6	93,7 [85,4-97,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [81,3-96,1]
Month 6	78,0 [57,8-89,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	4 (6,7)
95%-CI	[1,8-16,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [73,4-96,2]
Month 6	89,6 [73,4-96,2]
Month 12	89,6 [73,4-96,2]
Month 18	89,6 [73,4-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS02: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	9 (10,6)
95%-CI	[5,0-19,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [74,9-93,6]
Month 6	79,2 [55,9-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Race group
 ITT set

4.11.3 Merkmal: Ethnie

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [85,4-96,7]
Month 6	87,3 [74,3-94,0]
Month 12	82,7 [65,8-91,7]
Month 18	82,7 [65,8-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	93,3 [61,3-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	47 (36,2)
95%-CI	[27,9-45,0]
TEAE graded >= 3 in months [95%-CI]	
Median	7,79[3,29-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,1 [56,2-74,3]
Month 6	53,8 [41,2-64,8]
Month 12	41,0 [23,2-58,0]
Month 18	41,0 [23,2-58,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	11 (73,3)
95%-CI	[44,9-92,2]
TEAE graded >= 3 in months [95%-CI]	
Median	1,64 [0,39-5,39]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	38,4 [13,2-63,6]
Month 6	14,4 [1,0-43,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	28 (21,5)
95%-CI	[14,8-29,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,7 [69,3-85,5]
Month 6	68,2 [55,6-77,9]
Month 12	68,2 [55,6-77,9]
Month 18	68,2 [55,6-77,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	10 (66,7)
95%-CI	[38,4-88,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,64 [0,56-7,62]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	48,0 [20,5-71,2]
Month 6	25,6 [5,0-53,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	24 (18,5)
95%-CI	[12,2-26,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,5 [75,2-89,2]
Month 6	76,7 [64,8-85,1]
Month 12	64,4 [43,8-79,1]
Month 18	64,4 [43,8-79,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [53,3-96,2]
Month 6	85,6 [53,3-96,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	15 (11,5)
95%-CI	[6,6-18,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [77,4-91,8]
Month 6	84,6 [75,1-90,7]
Month 12	84,6 [75,1-90,7]
Month 18	84,6 [75,1-90,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	11 (8,5)
95%-CI	[4,3-14,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [83,5-95,0]
Month 6	87,7 [76,8-93,7]
Month 12	87,7 [76,8-93,7]
Month 18	87,7 [76,8-93,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [5,85-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	61,1 [7,5-91,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	7 (5,4)
95%-CI	[2,2-10,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [88,8-97,4]
Month 6	94,5 [88,8-97,4]
Month 12	94,5 [88,8-97,4]
Month 18	94,5 [88,8-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[2,86-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	27 (20,8)
95%-CI	[14,2-28,8]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,0 [65,7-83,6]
Month 6	71,6 [59,9-80,5]
Month 12	71,6 [59,9-80,5]
Month 18	38,2 [8,1-69,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,83-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [45,5-92,5]
Month 6	78,0 [45,5-92,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	23 (17,7)
95%-CI	[11,6-25,4]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [67,9-85,6]
Month 6	73,9 [62,1-82,5]
Month 12	73,9 [62,1-82,5]
Month 18	49,2 [10,8-79,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,83-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [48,7-95,9]
Month 6	84,0 [48,7-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	14 (10,8)
95%-CI	[6,0-17,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [83,8-94,8]
Month 6	88,7 [80,1-93,7]
Month 12	73,7 [45,4-88,9]
Month 18	73,7 [45,4-88,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	21 (16,2)
95%-CI	[10,3-23,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,5 [76,8-89,9]
Month 6	84,5 [76,8-89,9]
Month 12	70,3 [44,7-85,6]
Month 18	70,3 [44,7-85,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [53,3-96,2]
Month 6	85,6 [53,3-96,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	8 (6,2)
95%-CI	[2,7-11,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [88,0-97,1]
Month 6	94,1 [88,0-97,1]
Month 12	82,3 [46,6-95,2]
Month 18	82,3 [46,6-95,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [87,3-97,4]
Month 6	86,3 [73,1-93,3]
Month 12	86,3 [73,1-93,3]
Month 18	86,3 [73,1-93,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [80,3-94,7]
Month 6	86,1 [73,1-93,1]
Month 12	86,1 [73,1-93,1]
Month 18	86,1 [73,1-93,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS03: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[2,83-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [43,2-92,2]
Month 6	77,0 [43,2-92,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

4.11.4 Merkmal: Region-1

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [6,01-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [76,0-96,5]
Month 6	83,0 [58,3-93,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,7 [78,6-99,5]
Month 6	88,6 [57,7-97,4]
Month 12	88,6 [57,7-97,4]
Month 18	88,6 [57,7-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [81,2-97,9]
Month 6	93,6 [81,2-97,9]
Month 12	93,6 [81,2-97,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	29 (49,2)
95%-CI	[35,9-62,5]
TEAE graded >= 3 in months [95%-CI]	
Median	3,71 [1,41-9,23]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,0 [35,6-64,5]
Month 6	39,0 [20,5-57,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [52,7-90,9]
Month 6	71,0 [43,9-86,7]
Month 12	71,0 [43,9-86,7]
Month 18	71,0 [43,9-86,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	23 (43,4)
95%-CI	[29,8-57,7]
TEAE graded >= 3 in months [95%-CI]	
Median	5,68 [3,02-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,9 [50,7-77,4]
Month 6	44,8 [26,3-61,7]
Month 12	35,9 [15,9-56,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	19 (32,2)
95%-CI	[20,6-45,6]
TEAE graded >= 3 in months [95%-CI]	
Median	5,39[3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,0 [50,6-79,0]
Month 6	46,9 [23,8-67,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,1 [64,2-94,3]
Month 6	85,1 [64,2-94,3]
Month 12	85,1 [64,2-94,3]
Month 18	85,1 [64,2-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	15 (28,3)
95%-CI	[16,8-42,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,29-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [63,1-87,1]
Month 6	61,1 [41,5-75,8]
Month 12	61,1 [41,5-75,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [66,8-89,2]
Month 6	80,6 [66,8-89,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [73,5-98,1]
Month 6	92,6 [73,5-98,1]
Month 12	92,6 [73,5-98,1]
Month 18	92,6 [73,5-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	13 (24,5)
95%-CI	[13,8-38,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,68-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,6 [67,5-90,0]
Month 6	68,6 [48,3-82,3]
Month 12	58,8 [33,0-77,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [66,6-91,1]
Month 6	82,3 [66,6-91,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [62,2-95,5]
Month 6	86,2 [62,2-95,5]
Month 12	86,2 [62,2-95,5]
Month 18	86,2 [62,2-95,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	4 (7,5)
95%-CI	[2,1-18,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [82,6-98,0]
Month 6	90,3 [74,9-96,4]
Month 12	90,3 [74,9-96,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,85-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [62,8-87,9]
Month 6	69,6 [45,7-84,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	2 (3,8)
95%-CI	[0,5-13,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,1 [87,1-99,7]
Month 6	90,5 [60,4-98,1]
Month 12	90,5 [60,4-98,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [76,1-94,0]
Month 6	87,8 [76,1-94,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	1 (3,2)
95%-CI	[0,1-16,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	92,3 [56,6-98,9]
Month 18	92,3 [56,6-98,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,8 [63,8-89,3]
Month 6	79,8 [63,8-89,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,47-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,9 [62,9-95,8]
Month 6	77,2 [45,8-91,8]
Month 12	77,2 [45,8-91,8]
Month 18	77,2 [45,8-91,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	17 (32,1)
95%-CI	[19,9-46,3]
TEAE graded >= 3 in months [95%-CI]	
Median	12,45[3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,2 [50,5-79,3]
Month 6	63,0 [45,2-76,3]
Month 12	63,0 [45,2-76,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [70,9-94,7]
Month 6	87,2 [70,9-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,47-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [62,1-95,6]
Month 6	76,8 [45,5-91,5]
Month 12	76,8 [45,5-91,5]
Month 18	76,8 [45,5-91,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	16 (30,2)
95%-CI	[18,3-44,3]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,2 [50,5-79,3]
Month 6	63,0 [45,2-76,3]
Month 12	63,0 [45,2-76,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [79,3-96,1]
Month 6	90,9 [79,3-96,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [63,8-94,3]
Month 6	77,9 [52,4-90,8]
Month 12	62,3 [25,7-84,8]
Month 18	62,3 [25,7-84,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,0 [84,8-99,0]
Month 6	96,0 [84,8-99,0]
Month 12	76,8 [24,5-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	12 (20,3)
95%-CI	[11,0-32,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [65,0-87,1]
Month 6	78,4 [65,0-87,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [70,6-96,5]
Month 6	89,5 [70,6-96,5]
Month 12	71,6 [27,0-91,8]
Month 18	71,6 [27,0-91,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	7 (13,2)
95%-CI	[5,5-25,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [75,4-94,5]
Month 6	88,1 [75,4-94,5]
Month 12	70,5 [28,2-90,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [75,9-94,6]
Month 6	88,4 [75,9-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	2 (3,8)
95%-CI	[0,5-13,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,0 [86,9-99,7]
Month 6	98,0 [86,9-99,7]
Month 12	78,4 [22,6-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,2 [87,8-99,7]
Month 6	91,6 [64,8-98,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	88,7 [57,8-97,4]
Month 12	88,7 [57,8-97,4]
Month 18	88,7 [57,8-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	5 (9,4)
95%-CI	[3,1-20,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [77,1-96,5]
Month 6	84,3 [62,3-94,0]
Month 12	84,3 [62,3-94,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [71,7-96,0]
Month 6	88,9 [71,7-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	6 (19,4)
95%-CI	[7,5-37,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,52-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [60,2-91,9]
Month 6	67,8 [33,4-87,1]
Month 12	67,8 [33,4-87,1]
Month 18	67,8 [33,4-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS04: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [73,2-97,1]
Month 6	90,8 [73,2-97,1]
Month 12	90,8 [73,2-97,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

4.11.5 *Merkmal: Region-2*

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [6,01-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,5 [76,0-96,5]
Month 6	83,0 [58,3-93,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [86,1-98,0]
Month 6	91,6 [79,5-96,7]
Month 12	91,6 [79,5-96,7]
Month 18	91,6 [79,5-96,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	29 (49,2)
95%-CI	[35,9-62,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	3,71 [1,41-9,23]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,0 [35,6-64,5]
Month 6	39,0 [20,5-57,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	29 (33,7)
95%-CI	[23,9-44,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	7,79[3,29-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,2 [59,1-80,3]
Month 6	54,3 [38,6-67,7]
Month 12	46,6 [27,2-63,8]
Month 18	46,6 [27,2-63,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	19 (32,2)
95%-CI	[20,6-45,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	5,39[3,71-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,0 [50,6-79,0]
Month 6	46,9 [23,8-67,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	19 (22,1)
95%-CI	[13,9-32,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [69,9-88,1]
Month 6	70,1 [55,6-80,7]
Month 12	70,1 [55,6-80,7]
Month 18	70,1 [55,6-80,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,6 [66,8-89,2]
Month 6	80,6 [66,8-89,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	15 (17,4)
95%-CI	[10,1-27,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [7,79-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [75,7-91,9]
Month 6	76,7 [61,1-86,7]
Month 12	68,2 [44,8-83,3]
Month 18	68,2 [44,8-83,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	8 (13,6)
95%-CI	[6,0-25,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,3 [66,6-91,1]
Month 6	82,3 [66,6-91,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	7 (8,1)
95%-CI	[3,3-16,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [82,2-96,2]
Month 6	89,3 [78,2-94,9]
Month 12	89,3 [78,2-94,9]
Month 18	89,3 [78,2-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	11 (18,6)
95%-CI	[9,7-30,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [5,85-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,2 [62,8-87,9]
Month 6	69,6 [45,7-84,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	2 (2,3)
95%-CI	[0,3-8,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,8 [91,9-99,8]
Month 6	94,1 [73,5-98,8]
Month 12	94,1 [73,5-98,8]
Month 18	94,1 [73,5-98,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	7 (11,9)
95%-CI	[4,9-22,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,8 [76,1-94,0]
Month 6	87,8 [76,1-94,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	1 (1,2)
95%-CI	[0,0-6,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,6 [84,3-99,7]
Month 6	97,6 [84,3-99,7]
Month 12	97,6 [84,3-99,7]
Month 18	97,6 [84,3-99,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	9 (15,3)
95%-CI	[7,2-27,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,8 [63,8-89,3]
Month 6	79,8 [63,8-89,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	21 (24,4)
95%-CI	[15,8-34,9]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,9 [60,9-83,1]
Month 6	68,1 [53,4-79,0]
Month 12	68,1 [53,4-79,0]
Month 18	36,3 [7,9-66,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [70,9-94,7]
Month 6	87,2 [70,9-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	20 (23,3)
95%-CI	[14,8-33,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	14,13 [14,13-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,7 [60,8-83,0]
Month 6	68,0 [53,3-78,9]
Month 12	68,0 [53,3-78,9]
Month 18	45,3 [10,7-75,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [79,3-96,1]
Month 6	90,9 [79,3-96,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	9 (10,5)
95%-CI	[4,9-18,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [83,5-96,5]
Month 6	89,4 [77,9-95,1]
Month 12	71,5 [39,3-88,7]
Month 18	71,5 [39,3-88,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	12 (20,3)
95%-CI	[11,0-32,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [65,0-87,1]
Month 6	78,4 [65,0-87,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	11 (12,8)
95%-CI	[6,6-21,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [79,7-94,1]
Month 6	88,9 [79,7-94,1]
Month 12	71,1 [39,7-88,2]
Month 18	71,1 [39,7-88,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [75,9-94,6]
Month 6	88,4 [75,9-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	2 (2,3)
95%-CI	[0,3-8,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,8 [91,8-99,8]
Month 6	98,8 [91,8-99,8]
Month 12	84,7 [35,7-97,4]
Month 18	84,7 [35,7-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,2 [87,8-99,7]
Month 6	91,6 [64,8-98,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	7 (8,1)
95%-CI	[3,3-16,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [83,2-97,0]
Month 6	85,8 [70,3-93,6]
Month 12	85,8 [70,3-93,6]
Month 18	85,8 [70,3-93,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [71,7-96,0]
Month 6	88,9 [71,7-96,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS05: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	9 (10,5)
95%-CI	[4,9-18,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,6 [75,8-93,8]
Month 6	82,9 [66,8-91,7]
Month 12	82,9 [66,8-91,7]
Month 18	82,9 [66,8-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

4.11.6 Merkmal: Krankheitsstadium nach Ann-Arbor

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	95,0 [69,5-99,3]
Month 12	95,0 [69,5-99,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [66,6-99,2]
Month 6	94,4 [66,6-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	9 (9,7)
95%-CI	[4,5-17,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [81,5-96,3]
Month 6	83,5 [65,9-92,5]
Month 12	76,5 [53,4-89,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	9,23[0,03-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [32,9-89,2]
Month 6	70,0 [32,9-89,2]
Month 12	35,0 [1,6-76,7]
Month 18	35,0 [1,6-76,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	7 (30,4)
95%-CI	[13,2-52,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[2,40-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,1 [40,4-85,0]
Month 6	51,1 [16,9-77,6]
Month 12	51,1 [16,9-77,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	9 (47,4)
95%-CI	[24,4-71,1]
TEAE graded >= 3 in months [95%-CI]	
Median	2,86[1,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,6 [20,1-69,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	38 (40,9)
95%-CI	[30,8-51,5]
TEAE graded >= 3 in months [95%-CI]	
Median	5,39[3,25-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,5 [52,8-74,0]
Month 6	47,1 [31,9-60,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [0,49-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,8 [38,1-94,3]
Month 6	78,8 [38,1-94,3]
Month 12	78,8 [38,1-94,3]
Month 18	78,8 [38,1-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[2,40-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [45,5-88,5]
Month 6	64,1 [34,3-83,2]
Month 12	64,1 [34,3-83,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	6 (31,6)
95%-CI	[12,6-56,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [1,48-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,6 [33,2-80,8]
Month 6	61,6 [33,2-80,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	24 (25,8)
95%-CI	[17,3-35,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	7,62 [4,67-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,7 [67,7-86,3]
Month 6	58,5 [40,7-72,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded >= 3 in months [95%-CI]	
Median	9,23[0,49-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	45,0 [1,0-87,1]
Month 18	45,0 [1,0-87,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [5,68-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,7 [67,6-97,6]
Month 6	72,6 [26,2-92,6]
Month 12	72,6 [26,2-92,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [63,2-99,1]
Month 6	93,8 [63,2-99,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	20 (21,5)
95%-CI	[13,7-31,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [7,79-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [68,3-86,6]
Month 6	74,5 [62,1-83,3]
Month 12	66,2 [45,1-80,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [0,69-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	74,1 [28,9-93,0]
Month 12	74,1 [28,9-93,0]
Month 18	74,1 [28,9-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-17,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	13 (14,0)
95%-CI	[7, 7-22, 7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,0 [70, 3-89, 4]
Month 6	82,0 [70, 3-89, 4]
Month 12	82,0 [70, 3-89, 4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	95,5 [71,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,2 [57,2-96,7]
Month 6	87,2 [57,2-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	10 (10,8)
95%-CI	[5,3-18,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [79,4-94,6]
Month 6	78,9 [58,8-90,0]
Month 12	78,9 [58,8-90,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[0,03-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,86-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	6 (6,5)
95%-CI	[2,4-13,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [85,9-97,0]
Month 6	93,4 [85,9-97,0]
Month 12	93,4 [85,9-97,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [1,18-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,1 [28,9-93,0]
Month 6	74,1 [28,9-93,0]
Month 12	74,1 [28,9-93,0]
Month 18	74,1 [28,9-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	7 (30,4)
95%-CI	[13,2-52,9]
TEAE graded >= 3 in months [95%-CI]	
Median	12,45[3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [50,1-91,2]
Month 6	59,2 [28,5-80,3]
Month 12	59,2 [28,5-80,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[2,33-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,6 [37,2-84,7]
Month 6	66,6 [37,2-84,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	16 (17,2)
95%-CI	[10,2-26,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [66,3-86,8]
Month 6	78,6 [66,3-86,8]
Month 12	78,6 [66,3-86,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,96-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	83,3 [27,3-97,5]
Month 18	83,3 [27,3-97,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,7 [50,1-91,2]
Month 6	59,2 [28,5-80,3]
Month 12	59,2 [28,5-80,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	5 (26,3)
95%-CI	[9,1-51,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[2,33-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,6 [37,2-84,7]
Month 6	66,6 [37,2-84,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	13 (14,0)
95%-CI	[7,7-22,7]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [69,5-89,5]
Month 6	81,8 [69,5-89,5]
Month 12	81,8 [69,5-89,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,84-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	88,9 [43,3-98,4]
Month 18	88,9 [43,3-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	50,0 [0,6-91,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	11 (11,8)
95%-CI	[6,1-20,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [81,0-94,5]
Month 6	86,9 [75,8-93,1]
Month 12	80,2 [60,2-90,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [0,59-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	10,15 [10,15-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [63,2-95,4]
Month 6	86,3 [63,2-95,4]
Month 12	43,2 [1,2-85,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [65,0-99,2]
Month 6	94,1 [65,0-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	17 (18,3)
95%-CI	[11,0-27,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [71,9-88,4]
Month 6	81,8 [71,9-88,4]
Month 12	75,5 [58,0-86,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	50,0 [0,6-91,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [65,0-99,2]
Month 6	94,1 [65,0-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	6 (6,5)
95%-CI	[2,4-13,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [84,9-96,8]
Month 6	92,9 [84,9-96,8]
Month 12	92,9 [84,9-96,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,27-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	75,0 [12,8-96,1]
Month 12	75,0 [12,8-96,1]
Month 18	75,0 [12,8-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	95,5 [71,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	6 (6,5)
95%-CI	[2,4-13,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [84,5-97,7]
Month 6	86,8 [70,6-94,4]
Month 12	86,8 [70,6-94,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [2,89-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [35,9-90,7]
Month 6	72,9 [35,9-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS06: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	9 (9,7)
95%-CI	[4,5-17,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [76,4-94,1]
Month 6	82,1 [63,4-91,8]
Month 12	82,1 [63,4-91,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Bulky disease
 ITT set

4.11.7 *Merkmal: Bulky Erkrankung*

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [85,9-96,4]
Month 6	88,1 [77,1-94,0]
Month 12	84,1 [69,5-92,1]
Month 18	84,1 [69,5-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	56 (40,9)
95%-CI	[32,6-49,6]
TEAE graded >= 3 in months [95%-CI]	
Median	5,68 [3,25-9,23]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,3 [53,7-71,4]
Month 6	48,5 [36,5-59,5]
Month 12	33,2 [17,8-49,5]
Month 18	33,2 [17,8-49,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	37 (27,0)
95%-CI	[19,8-35,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,39-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,7 [66,7-82,5]
Month 6	62,3 [49,8-72,4]
Month 12	56,0 [39,4-69,8]
Month 18	56,0 [39,4-69,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	25 (18,2)
95%-CI	[12,2-25,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,8 [75,9-89,2]
Month 6	77,8 [66,9-85,5]
Month 12	66,2 [46,7-80,1]
Month 18	66,2 [46,7-80,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	14 (10,2)
95%-CI	[5,7-16,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [80,6-93,3]
Month 6	87,1 [78,7-92,3]
Month 12	87,1 [78,7-92,3]
Month 18	87,1 [78,7-92,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	13 (9,5)
95%-CI	[5,1-15,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,4 [83,3-94,6]
Month 6	84,3 [71,5-91,7]
Month 12	84,3 [71,5-91,7]
Month 18	84,3 [71,5-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	8 (5,8)
95%-CI	[2,6-11,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [86,7-96,7]
Month 6	93,3 [86,7-96,7]
Month 12	93,3 [86,7-96,7]
Month 18	93,3 [86,7-96,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	27 (19,7)
95%-CI	[13,4-27,4]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [68,5-85,0]
Month 6	74,2 [63,4-82,3]
Month 12	74,2 [63,4-82,3]
Month 18	39,6 [8,2-71,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	22 (16,1)
95%-CI	[10,3-23,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [71,5-87,6]
Month 6	77,1 [66,2-84,9]
Month 12	77,1 [66,2-84,9]
Month 18	51,4 [10,6-82,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	13 (9,5)
95%-CI	[5,1-15,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,1 [85,7-95,7]
Month 6	90,3 [82,6-94,7]
Month 12	75,6 [46,3-90,3]
Month 18	75,6 [46,3-90,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	19 (13,9)
95%-CI	[8,6-20,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,8 [79,7-91,6]
Month 6	86,8 [79,7-91,6]
Month 12	72,7 [46,0-87,7]
Month 18	72,7 [46,0-87,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	8 (5,8)
95%-CI	[2,6-11,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [88,7-97,3]
Month 6	94,5 [88,7-97,3]
Month 12	82,6 [46,5-95,4]
Month 18	82,6 [46,5-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	8 (5,8)
95%-CI	[2,6-11,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [89,3-98,1]
Month 6	88,7 [77,1-94,7]
Month 12	88,7 [77,1-94,7]
Month 18	88,7 [77,1-94,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS07: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [80,8-94,4]
Month 6	86,2 [74,2-92,9]
Month 12	86,2 [74,2-92,9]
Month 18	86,2 [74,2-92,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

4.11.8 *Merkmal: Double/Triple-Hit*

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	4,90 [2,50-6,01]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,5 [35,9-91,1]
Month 6	49,0 [8,6-81,3]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	6 (4,6)
95%-CI	[1,7-9,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [89,3-98,1]
Month 6	93,3 [84,7-97,2]
Month 12	93,3 [84,7-97,2]
Month 18	93,3 [84,7-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	6 (40,0)
95%-CI	[16,3-67,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[0,30-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,0 [27,7-78,2]
Month 6	57,0 [27,7-78,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	52 (40,0)
95%-CI	[31,5-49,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	5,68 [3,25-9,23]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,8 [53,8-72,3]
Month 6	47,4 [34,7-59,1]
Month 12	30,7 [14,9-48,1]
Month 18	30,7 [14,9-48,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	5 (33,3)
95%-CI	[11,8-61,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,18-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,4 [27,3-81,2]
Month 6	59,4 [27,3-81,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	33 (25,4)
95%-CI	[18,2-33,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [5,39-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [68,2-84,3]
Month 6	62,6 [49,2-73,3]
Month 12	55,6 [37,5-70,4]
Month 18	55,6 [37,5-70,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [0,95-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [37,9-87,8]
Month 6	70,0 [37,9-87,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	22 (16,9)
95%-CI	[10,9-24,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [77,3-90,7]
Month 6	78,6 [66,7-86,7]
Month 12	64,9 [42,4-80,4]
Month 18	64,9 [42,4-80,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	75,0 [31,5-93,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	13 (10,0)
95%-CI	[5,4-16,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [79,9-93,0]
Month 6	88,0 [79,9-93,0]
Month 12	88,0 [79,9-93,0]
Month 18	88,0 [79,9-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [1,77-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [40,8-91,5]
Month 6	75,4 [40,8-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [85,6-96,3]
Month 6	85,9 [71,7-93,3]
Month 12	85,9 [71,7-93,3]
Month 18	85,9 [71,7-93,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,7 [56,4-96,5]
Month 6	86,7 [56,4-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	6 (4,6)
95%-CI	[1,7-9,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [87,4-97,6]
Month 6	94,4 [87,4-97,6]
Month 12	94,4 [87,4-97,6]
Month 18	94,4 [87,4-97,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	29 (22,3)
95%-CI	[15,5-30,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,0 [64,9-82,6]
Month 6	70,9 [59,5-79,6]
Month 12	70,9 [59,5-79,6]
Month 18	37,8 [8,1-68,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	24 (18,5)
95%-CI	[12,2-26,2]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [68,0-85,3]
Month 6	73,9 [62,5-82,3]
Month 12	73,9 [62,5-82,3]
Month 18	49,3 [10,8-79,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [50,4-95,9]
Month 6	84,4 [50,4-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	12 (9,2)
95%-CI	[4,9-15,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [86,0-96,1]
Month 6	90,5 [82,3-95,0]
Month 12	73,9 [41,3-90,2]
Month 18	73,9 [41,3-90,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [0,72-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,5 [40,4-88,3]
Month 6	71,5 [40,4-88,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	19 (14,6)
95%-CI	[9,0-21,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,3 [78,8-91,2]
Month 6	86,3 [78,8-91,2]
Month 12	70,4 [41,2-87,0]
Month 18	70,4 [41,2-87,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	6 (4,6)
95%-CI	[1,7-9,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [90,2-98,2]
Month 6	95,8 [90,2-98,2]
Month 12	82,1 [39,6-95,9]
Month 18	82,1 [39,6-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [87,6-97,5]
Month 6	86,8 [74,1-93,5]
Month 12	86,8 [74,1-93,5]
Month 18	86,8 [74,1-93,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,92-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [36,7-94,7]
Month 6	79,1 [36,7-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS08: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Infections and infestations	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	11 (8,5)
95%-CI	[4,3-14,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [80,2-94,3]
Month 6	85,6 [73,0-92,7]
Month 12	85,6 [73,0-92,7]
Month 18	85,6 [73,0-92,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

4.11.9 *Merkmal: Transformation des DLBCL*

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [66,9-96,0]
Month 6	87,9 [66,9-96,0]
Month 12	87,9 [66,9-96,0]
Month 18	87,9 [66,9-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [86,2-97,7]
Month 6	88,4 [74,7-94,9]
Month 12	83,4 [65,4-92,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	14 (48,3)
95%-CI	[29,4-67,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	3,29[0,49-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,0 [32,7-69,7]
Month 6	47,1 [26,5-65,3]
Month 12	47,1 [26,5-65,3]
Month 18	47,1 [26,5-65,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	44 (37,9)
95%-CI	[29,1-47,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	5,68 [3,25-9,23]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,6 [54,7-74,4]
Month 6	48,5 [34,6-61,1]
Month 12	29,1 [12,3-48,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	11 (37,9)
95%-CI	[20,7-57,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,77-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,7 [42,5-80,2]
Month 6	51,8 [28,4-70,9]
Month 12	51,8 [28,4-70,9]
Month 18	51,8 [28,4-70,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	27 (23,3)
95%-CI	[15,9-32,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [7,62-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,4 [68,6-85,5]
Month 6	65,2 [50,7-76,4]
Month 12	57,1 [36,5-73,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [1,51-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,2 [47,5-83,3]
Month 6	69,2 [47,5-83,3]
Month 12	69,2 [47,5-83,3]
Month 18	69,2 [47,5-83,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	18 (15,5)
95%-CI	[9,5-23,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [79,3-92,6]
Month 6	79,9 [66,7-88,3]
Month 12	64,6 [39,8-81,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [58,2-94,8]
Month 6	84,4 [58,2-94,8]
Month 12	84,4 [58,2-94,8]
Month 18	84,4 [58,2-94,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	12 (10,3)
95%-CI	[5,5-17,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [80,4-93,8]
Month 6	87,1 [77,7-92,7]
Month 12	87,1 [77,7-92,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [4,70-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,6 [61,5-93,6]
Month 6	71,7 [38,4-89,1]
Month 12	71,7 [38,4-89,1]
Month 18	71,7 [38,4-89,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [84,9-96,4]
Month 6	88,2 [73,6-95,0]
Month 12	88,2 [73,6-95,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [67,3-94,6]
Month 6	86,2 [67,3-94,6]
Month 12	86,2 [67,3-94,6]
Month 18	86,2 [67,3-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	4 (3,4)
95%-CI	[0,9-8,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [87,6-98,4]
Month 6	95,5 [87,6-98,4]
Month 12	95,5 [87,6-98,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Transformed DLBCL: Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded ≥ 3 : Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [63,4-97,5]
Month 6	89,7 [63,4-97,5]
Month 12	89,7 [63,4-97,5]
Month 18	44,9 [1,0-86,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	27 (23,3)
95%-CI	[15,9-32,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	12,45 [12,45-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [62,0-81,2]
Month 6	68,4 [56,1-77,9]
Month 12	68,4 [56,1-77,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [63,4-97,5]
Month 6	89,7 [63,4-97,5]
Month 12	89,7 [63,4-97,5]
Month 18	44,9 [1,0-86,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	22 (19,0)
95%-CI	[12,3-27,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,4 [65,4-84,3]
Month 6	71,7 [59,3-81,0]
Month 12	71,7 [59,3-81,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [70,1-96,4]
Month 6	89,2 [70,1-96,4]
Month 12	89,2 [70,1-96,4]
Month 18	89,2 [70,1-96,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	11 (9,5)
95%-CI	[4,8-16,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [85,1-96,1]
Month 6	90,1 [81,0-95,0]
Month 12	68,3 [28,3-89,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [68,1-96,1]
Month 6	88,4 [68,1-96,1]
Month 12	88,4 [68,1-96,1]
Month 18	88,4 [68,1-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	20 (17,2)
95%-CI	[10,9-25,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,8 [75,4-89,5]
Month 6	83,8 [75,4-89,5]
Month 12	63,5 [28,8-84,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [70,9-97,9]
Month 6	91,8 [70,9-97,9]
Month 12	91,8 [70,9-97,9]
Month 18	91,8 [70,9-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	6 (5,2)
95%-CI	[1,9-10,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [89,4-98,1]
Month 6	95,5 [89,4-98,1]
Month 12	76,4 [25,2-94,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[4,27-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	87,5 [38,7-98,1]
Month 12	87,5 [38,7-98,1]
Month 18	87,5 [38,7-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [86,1-97,1]
Month 6	88,2 [75,7-94,5]
Month 12	88,2 [75,7-94,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,4 [55,4-93,1]
Month 6	81,4 [55,4-93,1]
Month 12	81,4 [55,4-93,1]
Month 18	81,4 [55,4-93,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS09: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Infections and infestations	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	9 (7,8)
95%-CI	[3,6-14,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [79,8-94,9]
Month 6	85,6 [71,3-93,1]
Month 12	85,6 [71,3-93,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type
 ITT set

4.11.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	1 (2,1)
95%-CI	[0,1-11,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [84,9-99,7]
Month 6	97,7 [84,9-99,7]
Month 12	97,7 [84,9-99,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[3,48-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [60,3-97,1]
Month 6	79,6 [47,5-93,3]
Month 12	79,6 [47,5-93,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	19 (39,6)
95%-CI	[25,8-54,7]
TEAE graded >= 3 in months [95%-CI]	
Median	7,62 [2,86-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,3 [47,3-77,1]
Month 6	54,7 [35,2-70,6]
Month 12	27,3 [5,6-55,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	8 (34,8)
95%-CI	[16,4-57,3]
TEAE graded >= 3 in months [95%-CI]	
Median	3,71[2,40-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,8 [33,9-82,9]
Month 6	45,5 [18,0-69,7]
Month 12	45,5 [18,0-69,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	12 (25,0)
95%-CI	[13,6-39,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [5,39-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,0 [61,5-88,0]
Month 6	67,5 [46,0-82,0]
Month 12	50,6 [18,1-76,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[2,40-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,7 [48,1-90,9]
Month 6	56,8 [25,2-79,3]
Month 12	56,8 [25,2-79,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,0 [77,7-96,5]
Month 6	91,0 [77,7-96,5]
Month 12	72,8 [27,2-92,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [68,8-97,7]
Month 6	82,0 [50,8-94,4]
Month 12	82,0 [50,8-94,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [74,7-95,2]
Month 6	88,7 [74,7-95,2]
Month 12	88,7 [74,7-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [78,1-96,6]
Month 6	83,6 [59,1-94,1]
Month 12	83,6 [59,1-94,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	4 (8,3)
95%-CI	[2,3-20,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [74,0-96,2]
Month 6	89,8 [74,0-96,2]
Month 12	89,8 [74,0-96,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	11 (22,9)
95%-CI	[12,0-37,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,47-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [58,7-86,1]
Month 6	69,6 [49,7-82,9]
Month 12	69,6 [49,7-82,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
TEAE graded >= 3 in months [95%-CI]	
Median	12,45 [3,71-12,45]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,6 [64,9-90,9]
Month 6	75,8 [55,2-87,9]
Month 12	75,8 [55,2-87,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[3,71-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	7 (14,6)
95%-CI	[6,1-27,8]
TEAE graded >= 3 in months [95%-CI]	
Median	11,30 [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,5 [74,4-95,1]
Month 6	88,5 [74,4-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	83,0 [53,5-94,6]
Month 12	83,0 [53,5-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
TEAE graded >= 3 in months [95%-CI]	
Median	10,15[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [81,9-97,9]
Month 6	93,8 [81,9-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	6 (26,1)
95%-CI	[10,2-48,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[1,58-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,9 [49,3-86,9]
Month 6	72,9 [49,3-86,9]
Month 12	72,9 [49,3-86,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
TEAE graded >= 3 in months [95%-CI]	
Median	10,15[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,7 [84,9-99,7]
Month 6	97,7 [84,9-99,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	1 (2,1)
95%-CI	[0,1-11,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	93,3 [61,3-99,0]
Month 12	93,3 [61,3-99,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,48-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [58,9-95,0]
Month 6	76,3 [46,4-90,9]
Month 12	76,3 [46,4-90,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	8 (16,7)
95%-CI	[7,5-30,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,3 [62,1-89,3]
Month 6	79,3 [62,1-89,3]
Month 12	79,3 [62,1-89,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS10: Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,52-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	80,0 [20,4-96,9]
Month 12	80,0 [20,4-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

4.11.11 Merkmal: Maximaler längster Durchmesser

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
\leq 5 cm	
Patients in analysis set	82
Patients with events - n(%)	5 (6,1)
95%-CI	[2,0-13,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [84,6-97,8]
Month 6	89,8 [74,1-96,2]
Month 12	89,8 [74,1-96,2]
Month 18	89,8 [74,1-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	4 (11,1)
95%-CI	[3,1-26,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,6 [70,1-96,7]
Month 6	80,7 [51,3-93,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	34 (41,5)
95%-CI	[30,7-52,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	5,68 [3,02-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,5 [52,0-74,6]
Month 6	47,3 [31,9-61,2]
Month 12	36,8 [20,2-53,5]
Month 18	36,8 [20,2-53,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - \leq 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	13 (36,1)
95%-CI	[20,8-53,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [1,45-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,9 [47,8-79,1]
Month 6	60,0 [39,6-75,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	4 (40,0)
95%-CI	[12,2-73,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	9,23 [0,03-9,23]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	57,9 [15,3-85,2]
Month 6	57,9 [15,3-85,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,41[0,43-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	22 (26,8)
95%-CI	[17,6-37,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [5,39-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,5 [64,7-84,8]
Month 6	64,8 [49,2-76,7]
Month 12	57,6 [37,7-73,2]
Month 18	57,6 [37,7-73,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	9 (25,0)
95%-CI	[12,1-42,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE[4,67-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,8 [58,7-87,7]
Month 6	65,8 [37,7-83,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,74-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	55,6 [7,3-87,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,18-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	13 (15,9)
95%-CI	[8,7-25,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,5 [76,3-92,5]
Month 6	80,1 [65,3-89,1]
Month 12	73,4 [52,9-86,1]
Month 18	73,4 [52,9-86,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
>5 - \leq 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	8 (22,2)
95%-CI	[10,1-39,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,0 [60,8-89,5]
Month 6	72,4 [50,1-86,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	9,23 [0,92-9,23]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,66-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,3 [37,9-90,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	7 (8,5)
95%-CI	[3,5-16,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [78,3-94,9]
Month 6	89,3 [78,3-94,9]
Month 12	89,3 [78,3-94,9]
Month 18	89,3 [78,3-94,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	7 (19,4)
95%-CI	[8,2-36,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,9 [63,7-91,6]
Month 6	76,8 [56,2-88,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,81-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	9 (11,0)
95%-CI	[5,1-19,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,1 [80,2-95,2]
Month 6	81,6 [64,0-91,1]
Month 12	81,6 [64,0-91,1]
Month 18	81,6 [64,0-91,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
>5 - \leq 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	1 (2,8)
95%-CI	[0,1-14,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,2 [81,9-99,6]
Month 6	97,2 [81,9-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,38-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [33,4-97,9]
Month 6	85,7 [33,4-97,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,41-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [81,5-96,2]
Month 6	91,5 [81,5-96,2]
Month 12	91,5 [81,5-96,2]
Month 18	91,5 [81,5-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-9,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,03-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
\leq 5 cm	
Patients in analysis set	82
Patients with events - n(%)	20 (24,4)
95%-CI	[15,6-35,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,3 [62,4-84,3]
Month 6	69,7 [55,2-80,3]
Month 12	69,7 [55,2-80,3]
Month 18	37,2 [8,0-67,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [60,6-92,3]
Month 6	81,8 [60,6-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,59-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,1 [23,3-92,3]
Month 6	71,1 [23,3-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,38-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [19,5-90,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	16 (19,5)
95%-CI	[11,6-29,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,9 [66,1-87,4]
Month 6	73,3 [58,6-83,5]
Month 12	73,3 [58,6-83,5]
Month 18	48,9 [10,6-79,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [60,6-92,3]
Month 6	81,8 [60,6-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	2 (20,0)
95%-CI	[2,5-55,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,12-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [22,5-91,8]
Month 6	70,0 [22,5-91,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,38-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,7 [19,5-90,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	3 (3,7)
95%-CI	[0,8-10,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,5 [90,5-99,4]
Month 6	97,5 [90,5-99,4]
Month 12	83,6 [37,5-96,8]
Month 18	83,6 [37,5-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	7 (19,4)
95%-CI	[8,2-36,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [6,44-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [65,2-93,1]
Month 6	76,9 [53,1-89,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,20-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,43-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [48,2-95,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	10 (12,2)
95%-CI	[6,0-21,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [78,8-93,8]
Month 6	88,4 [78,8-93,8]
Month 12	75,8 [42,4-91,4]
Month 18	75,8 [42,4-91,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	5 (13,9)
95%-CI	[4,7-29,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [6,44-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [73,1-95,7]
Month 6	88,9 [73,1-95,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,26-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,6 [26,0-87,7]
Month 6	65,6 [26,0-87,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	5 (38,5)
95%-CI	[13,9-68,4]
TEAE graded >= 3 in months [95%-CI]	
Median	1,18[0,49-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	49,5 [14,6-77,3]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	6 (7,3)
95%-CI	[2,7-15,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [84,8-97,2]
Month 6	93,4 [84,8-97,2]
Month 12	80,0 [41,1-94,6]
Month 18	80,0 [41,1-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [79,3-98,6]
Month 6	94,4 [79,3-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
≤ 5 cm	
Patients in analysis set	82
Patients with events - n(%)	3 (3,7)
95%-CI	[0,8-10,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,4 [88,9-99,8]
Month 6	91,1 [73,4-97,2]
Month 12	91,1 [73,4-97,2]
Month 18	91,1 [73,4-97,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - \leq 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [71,5-98,0]
Month 6	83,8 [54,2-95,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,56-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,72-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [47,2-95,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
\leq 5 cm	
Patients in analysis set	82
Patients with events - n(%)	7 (8,5)
95%-CI	[3,5-16,8]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,1 [74,2-93,9]
Month 6	87,1 [74,2-93,9]
Month 12	87,1 [74,2-93,9]
Month 18	87,1 [74,2-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
>5 - $\leq 7,5$ cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [5,52-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [78,1-98,5]
Month 6	80,6 [39,6-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - \leq 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [1,74-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS11: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [0,66-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [47,2-95,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

4.11.12 Merkmal: Primärdiagnose

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	7 (5,5)
95%-CI	[2,2-11,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [88,1-97,5]
Month 6	92,5 [84,0-96,6]
Month 12	92,5 [84,0-96,6]
Month 18	92,5 [84,0-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE graded >= 3 in months [95%-CI]	
Median	4,90 [2,50-6,01]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [24,1-93,1]
Month 6	48,5 [7,3-81,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	52 (40,9)
95%-CI	[32,3-50,0]
TEAE graded >= 3 in months [95%-CI]	
Median	5,68 [3,15-9,23]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	63,3 [53,2-71,8]
Month 6	47,2 [34,5-58,9]
Month 12	30,6 [14,9-47,9]
Month 18	30,6 [14,9-47,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE[0,30-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,4 [26,6-83,5]
Month 6	61,4 [26,6-83,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	33 (26,0)
95%-CI	[18,6-34,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [5,39-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,0 [67,6-84,0]
Month 6	62,4 [49,1-73,1]
Month 12	55,4 [37,4-70,2]
Month 18	55,4 [37,4-70,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	4 (36,4)
95%-CI	[10,9-69,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [1,18-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,6 [20,1-81,7]
Month 6	56,6 [20,1-81,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	22 (17,3)
95%-CI	[11,2-25,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,9 [76,7-90,4]
Month 6	78,2 [66,2-86,4]
Month 12	64,5 [42,2-80,1]
Month 18	64,5 [42,2-80,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE[0,95-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [35,0-89,9]
Month 6	71,6 [35,0-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	13 (10,2)
95%-CI	[5,6-16,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [80,5-93,5]
Month 6	87,0 [78,2-92,4]
Month 12	87,0 [78,2-92,4]
Month 18	87,0 [78,2-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	10 (7,9)
95%-CI	[3,8-14,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [85,3-96,2]
Month 6	85,8 [71,6-93,2]
Month 12	85,8 [71,6-93,2]
Month 18	85,8 [71,6-93,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,18-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,3 [27,8-88,5]
Month 6	67,3 [27,8-88,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	7 (5,5)
95%-CI	[2,2-11,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [86,5-97,0]
Month 6	93,6 [86,5-97,0]
Month 12	93,6 [86,5-97,0]
Month 18	93,6 [86,5-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	26 (20,5)
95%-CI	[13,8-28,5]
TEAE graded ≥ 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,4 [67,3-84,6]
Month 6	73,2 [61,7-81,7]
Month 12	73,2 [61,7-81,7]
Month 18	39,0 [8,2-70,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	22 (17,3)
95%-CI	[11,2-25,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,7 [69,7-86,7]
Month 6	75,5 [64,0-83,7]
Month 12	75,5 [64,0-83,7]
Month 18	50,3 [10,7-81,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	12 (9,4)
95%-CI	[5,0-15,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [85,8-96,0]
Month 6	90,4 [82,2-95,0]
Month 12	73,8 [41,3-90,1]
Month 18	73,8 [41,3-90,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [1,51-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [42,4-94,9]
Month 6	80,8 [42,4-94,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	20 (15,7)
95%-CI	[9,9-23,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,0 [77,2-90,3]
Month 6	85,0 [77,2-90,3]
Month 12	69,4 [41,0-86,1]
Month 18	69,4 [41,0-86,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,72-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	81,8 [44,7-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	6 (4,7)
95%-CI	[1,8-10,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [89,9-98,2]
Month 6	95,7 [89,9-98,2]
Month 12	82,0 [39,7-95,8]
Month 18	82,0 [39,7-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [0,79-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,8 [44,7-95,1]
Month 6	81,8 [44,7-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	9 (7,1)
95%-CI	[3,3-13,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [87,5-97,4]
Month 6	86,8 [74,1-93,5]
Month 12	86,8 [74,1-93,5]
Month 18	86,8 [74,1-93,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	11 (8,7)
95%-CI	[4,4-15,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,2 [80,2-94,2]
Month 6	85,6 [73,0-92,6]
Month 12	85,6 [73,0-92,6]
Month 18	85,6 [73,0-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS12: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,92-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,7 [24,1-93,1]
Month 6	72,7 [24,1-93,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

4.11.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	3 (4,8)
95%-CI	[1,0-13,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [84,5-98,3]
Month 6	94,7 [84,5-98,3]
Month 12	94,7 [84,5-98,3]
Month 18	94,7 [84,5-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[4,90-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [80,9-99,6]
Month 6	80,9 [31,0-96,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[6,01-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [71,1-95,6]
Month 6	83,2 [62,4-93,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	14 (22,2)
95%-CI	[12,7-34,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[4,17-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [70,8-92,4]
Month 6	59,8 [38,6-75,7]
Month 12	59,8 [38,6-75,7]
Month 18	59,8 [38,6-75,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Number prior lines: 3 lines	
Patients in analysis set	35
Patients with events - n(%)	16 (45,7)
95%-CI	[28,8-63,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	7,62 [0,95-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	53,4 [34,4-69,2]
Month 6	53,4 [34,4-69,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	28 (59,6)
95%-CI	[44,3-73,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	2,40 [0,92-5,39]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	42,5 [26,8-57,4]
Month 6	32,5 [16,2-49,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	10 (15,9)
95%-CI	[7,9-27,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [78,5-95,3]
Month 6	74,3 [55,2-86,2]
Month 12	74,3 [55,2-86,2]
Month 18	74,3 [55,2-86,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	14 (40,0)
95%-CI	[23,9-57,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	7,62 [1,74-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	59,0 [38,2-74,8]
Month 6	51,6 [29,2-70,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	14 (29,8)
95%-CI	[17,3-44,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [2,40-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,0 [50,0-80,7]
Month 6	52,4 [28,4-71,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	3 (4,8)
95%-CI	[1,0-13,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [86,4-99,1]
Month 6	90,0 [66,0-97,4]
Month 12	90,0 [66,0-97,4]
Month 18	90,0 [66,0-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	10 (28,6)
95%-CI	[14,6-46,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [51,2-82,6]
Month 6	70,0 [51,2-82,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	13 (27,7)
95%-CI	[15,6-42,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	9,23[7,79-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,5 [60,8-87,7]
Month 6	70,4 [52,3-82,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Number prior lines: 2 lines	
Patients in analysis set	63
Patients with events - n(%)	2 (3,2)
95%-CI	[0,4-11,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,1 [84,9-99,0]
Month 6	96,1 [84,9-99,0]
Month 12	96,1 [84,9-99,0]
Month 18	96,1 [84,9-99,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [3,02-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,5 [54,4-92,6]
Month 6	74,3 [47,4-88,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	8 (17,0)
95%-CI	[7,6-30,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,0 [65,4-90,1]
Month 6	81,0 [65,4-90,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	2 (3,2)
95%-CI	[0,4-11,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,4 [88,9-99,8]
Month 6	92,6 [68,3-98,5]
Month 12	92,6 [68,3-98,5]
Month 18	92,6 [68,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [57,7-90,0]
Month 6	78,6 [57,7-90,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [5,85-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [73,8-95,9]
Month 6	76,6 [40,9-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	1 (1,6)
95%-CI	[0,0-8,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [77,2-99,5]
Month 6	96,4 [77,2-99,5]
Month 12	96,4 [77,2-99,5]
Month 18	96,4 [77,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [75,2-97,1]
Month 6	91,2 [75,2-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	4 (8,5)
95%-CI	[2,4-20,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [78,9-96,7]
Month 6	91,5 [78,9-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	11 (17,5)
95%-CI	[9,1-29,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [65,3-89,8]
Month 6	80,7 [65,3-89,8]
Month 12	80,7 [65,3-89,8]
Month 18	43,1 [8,0-75,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[4,47-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [67,1-94,6]
Month 6	75,4 [44,1-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	14 (29,8)
95%-CI	[17,3-44,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,79-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,4 [46,3-77,7]
Month 6	60,1 [41,3-74,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Number prior lines: 2 lines	
Patients in analysis set	63
Patients with events - n(%)	8 (12,7)
95%-CI	[5,6-23,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [14,13-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,0 [68,3-92,3]
Month 6	84,0 [68,3-92,3]
Month 12	84,0 [68,3-92,3]
Month 18	56,0 [9,5-86,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	5 (14,3)
95%-CI	[4,8-30,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[4,47-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [67,1-94,6]
Month 6	75,4 [44,1-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	12 (25,5)
95%-CI	[13,9-40,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [3,71-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,4 [50,0-81,3]
Month 6	64,2 [45,0-78,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	6 (9,5)
95%-CI	[3,6-19,6]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [81,8-97,3]
Month 6	92,8 [81,8-97,3]
Month 12	72,9 [37,8-90,3]
Month 18	72,9 [37,8-90,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines: 3 lines	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3: Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [77,4-98,4]
Month 6	93,8 [77,4-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [74,6-95,2]
Month 6	84,0 [66,1-92,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	8 (12,7)
95%-CI	[5,6-23,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,9 [78,9-95,4]
Month 6	89,9 [78,9-95,4]
Month 12	70,7 [37,8-88,3]
Month 18	70,7 [37,8-88,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	9 (25,7)
95%-CI	[12,5-43,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,6 [55,3-85,3]
Month 6	73,6 [55,3-85,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,0 [71,4-93,5]
Month 6	86,0 [71,4-93,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	1 (1,6)
95%-CI	[0,0-8,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	85,7 [33,4-97,9]
Month 18	85,7 [33,4-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [70,9-95,3]
Month 6	87,9 [70,9-95,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	3 (6,4)
95%-CI	[1,3-17,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [79,5-97,7]
Month 6	92,9 [79,5-97,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	2 (3,2)
95%-CI	[0,4-11,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [83,9-99,0]
Month 6	95,8 [83,9-99,0]
Month 12	95,8 [83,9-99,0]
Month 18	95,8 [83,9-99,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	7 (14,9)
95%-CI	[6,2-28,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE[4,73-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [73,8-96,0]
Month 6	71,4 [46,1-86,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	5 (7,9)
95%-CI	[2,6-17,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,8 [76,0-95,9]
Month 6	89,8 [76,0-95,9]
Month 12	89,8 [76,0-95,9]
Month 18	89,8 [76,0-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines: 3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [5,52-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [71,7-96,7]
Month 6	72,0 [26,9-92,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS13: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	4 (8,5)
95%-CI	[2,4-20,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,8 [65,6-94,6]
Month 6	85,8 [65,6-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Response category - first line
 ITT set

4.11.14 Merkmal: *Ansprechkategorie auf die vorherige systemische Erstlinientherapie*

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	6 (6,1)
95%-CI	[2,3-12,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [87,9-97,8]
Month 6	92,3 [82,7-96,7]
Month 12	92,3 [82,7-96,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	90,9 [50,8-98,7]
Month 18	90,9 [50,8-98,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	43 (43,4)
95%-CI	[33,5-53,8]
TEAE graded >= 3 in months [95%-CI]	
Median	5,39 [3,02-9,23]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	62,2 [50,9-71,6]
Month 6	44,8 [30,9-57,8]
Month 12	28,0 [10,3-49,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	8 (27,6)
95%-CI	[12,7-47,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	7,79 [3,25-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,3 [55,7-89,3]
Month 6	67,7 [39,7-84,8]
Month 12	33,8 [1,8-74,8]
Month 18	33,8 [1,8-74,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	31 (31,3)
95%-CI	[22,4-41,4]
TEAE graded >= 3 in months [95%-CI]	
Median	7,62 [4,17-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	74,2 [63,6-82,2]
Month 6	56,8 [42,1-69,1]
Month 12	47,4 [26,4-65,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [61,3-95,3]
Month 6	85,7 [61,3-95,3]
Month 12	85,7 [61,3-95,3]
Month 18	85,7 [61,3-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	16 (16,2)
95%-CI	[9,5-24,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,6 [76,5-91,4]
Month 6	79,7 [66,2-88,3]
Month 12	69,7 [44,2-85,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	6 (20,7)
95%-CI	[8,0-39,7]
TEAE graded >= 3 in months [95%-CI]	
Median	7,79 [3,25-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [65,9-94,3]
Month 6	74,9 [43,8-90,3]
Month 12	37,4 [1,6-79,3]
Month 18	37,4 [1,6-79,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	13 (13,1)
95%-CI	[7,2-21,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,2 [76,7-92,0]
Month 6	84,3 [74,1-90,8]
Month 12	84,3 [74,1-90,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	10 (10,1)
95%-CI	[5,0-17,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [82,5-95,4]
Month 6	83,2 [67,2-91,8]
Month 12	83,2 [67,2-91,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [77,2-99,5]
Month 6	96,4 [77,2-99,5]
Month 12	96,4 [77,2-99,5]
Month 18	96,4 [77,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	5 (5,1)
95%-CI	[1,7-11,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,9 [85,3-97,5]
Month 6	93,9 [85,3-97,5]
Month 12	93,9 [85,3-97,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [75,1-98,2]
Month 6	93,1 [75,1-98,2]
Month 12	93,1 [75,1-98,2]
Month 18	93,1 [75,1-98,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	21 (21,2)
95%-CI	[13,6-30,6]
TEAE graded >= 3 in months [95%-CI]	
Median	12,45 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,6 [67,5-86,3]
Month 6	73,4 [60,3-82,8]
Month 12	73,4 [60,3-82,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: Investigations	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,96-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,7 [41,5-88,1]
Month 6	71,7 [41,5-88,1]
Month 12	71,7 [41,5-88,1]
Month 18	71,7 [41,5-88,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	16 (16,2)
95%-CI	[9,5-24,9]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,6 [71,7-89,6]
Month 6	77,3 [64,0-86,2]
Month 12	77,3 [64,0-86,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	5 (17,2)
95%-CI	[5,8-35,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,96-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,8 [40,8-87,6]
Month 6	70,8 [40,8-87,6]
Month 12	70,8 [40,8-87,6]
Month 18	70,8 [40,8-87,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	8 (8,1)
95%-CI	[3,6-15,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [84,9-96,4]
Month 6	90,1 [80,4-95,2]
Month 12	90,1 [80,4-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [6,44-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,7 [65,8-96,0]
Month 6	87,7 [65,8-96,0]
Month 12	58,5 [8,7-88,9]
Month 18	58,5 [8,7-88,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	13 (13,1)
95%-CI	[7,2-21,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,4 [77,6-91,8]
Month 6	86,4 [77,6-91,8]
Month 12	86,4 [77,6-91,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	7 (24,1)
95%-CI	[10,3-43,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,9 [58,9-89,9]
Month 6	78,9 [58,9-89,9]
Month 12	52,6 [9,9-83,6]
Month 18	52,6 [9,9-83,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	5 (5,1)
95%-CI	[1,7-11,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [87,8-97,8]
Month 6	94,7 [87,8-97,8]
Month 12	94,7 [87,8-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	95,7 [72,9-99,4]
Month 18	95,7 [72,9-99,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	6 (6,1)
95%-CI	[2,3-12,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [89,3-98,9]
Month 6	87,6 [72,5-94,7]
Month 12	87,6 [72,5-94,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [54,7-97,1]
Month 6	87,4 [54,7-97,1]
Month 12	87,4 [54,7-97,1]
Month 18	87,4 [54,7-97,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	8 (8,1)
95%-CI	[3,6-15,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [78,9-95,1]
Month 6	85,2 [69,5-93,2]
Month 12	85,2 [69,5-93,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS14: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [52,3-92,6]
Month 6	80,0 [52,3-92,6]
Month 12	80,0 [52,3-92,6]
Month 18	80,0 [52,3-92,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

4.11.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	2 (4,5)
95%-CI	[0,6-15,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,6 [84,3-99,7]
Month 6	91,1 [64,8-98,0]
Month 12	91,1 [64,8-98,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,6 [81,7-96,2]
Month 6	87,8 [73,7-94,6]
Month 12	87,8 [73,7-94,6]
Month 18	87,8 [73,7-94,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	26 (59,1)
95%-CI	[43,2-73,7]
TEAE graded >= 3 in months [95%-CI]	
Median	3,29[1,74-7,62]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	56,4 [39,8-70,1]
Month 6	37,8 [21,2-54,3]
Month 12	16,8 [3,8-37,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	28 (31,8)
95%-CI	[22,3-42,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,25-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,1 [54,5-77,0]
Month 6	55,2 [38,2-69,3]
Month 12	55,2 [38,2-69,3]
Month 18	55,2 [38,2-69,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	20 (45,5)
95%-CI	[30,4-61,2]
TEAE graded >= 3 in months [95%-CI]	
Median	4,67[2,40-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,4 [48,5-78,0]
Month 6	46,8 [28,9-62,9]
Month 12	39,0 [19,6-58,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	15 (17,0)
95%-CI	[9,9-26,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,9 [72,2-89,8]
Month 6	73,3 [54,8-85,2]
Month 12	73,3 [54,8-85,2]
Month 18	73,3 [54,8-85,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	13 (29,5)
95%-CI	[16,8-45,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,68-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,8 [59,6-86,2]
Month 6	68,9 [47,8-82,9]
Month 12	50,2 [23,5-72,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	13 (14,8)
95%-CI	[8,1-23,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [74,5-91,7]
Month 6	79,1 [65,1-88,0]
Month 12	79,1 [65,1-88,0]
Month 18	79,1 [65,1-88,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	9 (20,5)
95%-CI	[9,8-35,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,0 [62,0-89,1]
Month 6	75,4 [57,5-86,6]
Month 12	75,4 [57,5-86,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	6 (6,8)
95%-CI	[2,5-14,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [82,6-96,4]
Month 6	91,9 [82,6-96,4]
Month 12	91,9 [82,6-96,4]
Month 18	91,9 [82,6-96,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,5 [66,6-91,3]
Month 6	77,0 [57,3-88,4]
Month 12	77,0 [57,3-88,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	3 (3,4)
95%-CI	[0,7-9,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,4 [89,8-99,3]
Month 6	89,9 [61,7-97,7]
Month 12	89,9 [61,7-97,7]
Month 18	89,9 [61,7-97,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,4 [73,5-96,0]
Month 6	89,4 [73,5-96,0]
Month 12	89,4 [73,5-96,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	3 (3,4)
95%-CI	[0,7-9,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [89,8-98,9]
Month 6	96,6 [89,8-98,9]
Month 12	96,6 [89,8-98,9]
Month 18	96,6 [89,8-98,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [67,4-92,5]
Month 6	79,5 [60,8-89,9]
Month 12	79,5 [60,8-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	16 (18,2)
95%-CI	[10,8-27,8]
TEAE graded >= 3 in months [95%-CI]	
Median	12,45 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,9 [62,3-85,2]
Month 6	75,9 [62,3-85,2]
Month 12	75,9 [62,3-85,2]
Month 18	37,9 [1,7-79,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,9 [67,4-92,5]
Month 6	79,5 [60,8-89,9]
Month 12	79,5 [60,8-89,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	12 (13,6)
95%-CI	[7,2-22,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [65,3-87,9]
Month 6	79,1 [65,3-87,9]
Month 12	79,1 [65,3-87,9]
Month 18	79,1 [65,3-87,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [79,0-97,6]
Month 6	92,7 [79,0-97,6]
Month 12	69,5 [17,3-92,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	8 (9,1)
95%-CI	[4,0-17,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [83,9-96,6]
Month 6	88,9 [76,0-95,1]
Month 12	80,0 [53,6-92,3]
Month 18	80,0 [53,6-92,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	8 (18,2)
95%-CI	[8,2-32,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [68,1-91,7]
Month 6	83,3 [68,1-91,7]
Month 12	62,5 [19,8-87,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	13 (14,8)
95%-CI	[8,1-23,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [76,1-91,6]
Month 6	85,7 [76,1-91,6]
Month 12	77,1 [54,0-89,6]
Month 18	77,1 [54,0-89,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [75,8-96,2]
Month 6	90,2 [75,8-96,2]
Month 12	67,6 [18,3-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	3 (3,4)
95%-CI	[0,7-9,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [89,2-98,8]
Month 6	96,4 [89,2-98,8]
Month 12	96,4 [89,2-98,8]
Month 18	96,4 [89,2-98,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [82,8-98,8]
Month 6	90,1 [69,7-97,0]
Month 12	90,1 [69,7-97,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	5 (5,7)
95%-CI	[1,9-12,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [81,9-97,4]
Month 6	89,3 [74,4-95,7]
Month 12	89,3 [74,4-95,7]
Month 18	89,3 [74,4-95,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [69,1-95,2]
Month 6	87,4 [69,1-95,2]
Month 12	87,4 [69,1-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS15: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	9 (10,2)
95%-CI	[4,8-18,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,0 [73,9-93,8]
Month 6	80,3 [59,3-91,2]
Month 12	80,3 [59,3-91,2]
Month 18	80,3 [59,3-91,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - any line
 ITT set

4.11.16 Merkmal: *Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	1 (4,2)
95%-CI	[0,1-21,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [2,00-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	9 (7,8)
95%-CI	[3,6-14,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [88,1-97,5]
Month 6	89,2 [77,3-95,0]
Month 12	84,7 [68,5-93,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	6 (25,0)
95%-CI	[9,8-46,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,56-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,3 [43,0-88,3]
Month 6	62,0 [30,6-82,4]
Month 12	62,0 [30,6-82,4]
Month 18	62,0 [30,6-82,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	51 (44,3)
95%-CI	[35,1-53,9]
TEAE graded >= 3 in months [95%-CI]	
Median	5,39[3,02-9,23]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	60,7 [50,2-69,6]
Month 6	45,0 [32,2-57,1]
Month 12	27,0 [11,5-45,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,2 [60,6-96,9]
Month 6	88,2 [60,6-96,9]
Month 12	88,2 [60,6-96,9]
Month 18	88,2 [60,6-96,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	35 (30,4)
95%-CI	[22,2-39,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,67-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,2 [63,1-80,9]
Month 6	57,2 [43,4-68,8]
Month 12	50,0 [32,0-65,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [3,25-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [68,8-97,7]
Month 6	79,7 [43,9-93,9]
Month 12	79,7 [43,9-93,9]
Month 18	79,7 [43,9-93,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	22 (19,1)
95%-CI	[12,4-27,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,7 [73,9-88,8]
Month 6	77,6 [65,6-85,8]
Month 12	64,0 [42,0-79,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	15 (13,0)
95%-CI	[7,5-20,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [76,0-91,2]
Month 6	83,6 [73,7-90,0]
Month 12	83,6 [73,7-90,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	12 (10,4)
95%-CI	[5,5-17,5]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,7 [81,5-94,4]
Month 6	82,7 [68,2-91,0]
Month 12	82,7 [68,2-91,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	1 (4,2)
95%-CI	[0,1-21,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [73,9-99,4]
Month 6	95,8 [73,9-99,4]
Month 12	95,8 [73,9-99,4]
Month 18	95,8 [73,9-99,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	7 (6,1)
95%-CI	[2,5-12,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [85,2-96,7]
Month 6	92,9 [85,2-96,7]
Month 12	92,9 [85,2-96,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,96-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	69,6 [39,3-86,9]
Month 6	69,6 [39,3-86,9]
Month 12	69,6 [39,3-86,9]
Month 18	69,6 [39,3-86,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	24 (20,9)
95%-CI	[13,9-29,4]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13 [12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	78,1 [67,8-85,4]
Month 6	73,5 [61,6-82,3]
Month 12	73,5 [61,6-82,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [1,94-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	68,8 [38,6-86,4]
Month 6	68,8 [38,6-86,4]
Month 12	68,8 [38,6-86,4]
Month 18	68,8 [38,6-86,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	19 (16,5)
95%-CI	[10,3-24,6]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[14,13-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,6 [71,4-88,4]
Month 6	77,0 [65,0-85,3]
Month 12	77,0 [65,0-85,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
TEAE graded >= 3 in months [95%-CI]	
Median	6,44 [6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	47,8 [0,8-89,4]
Month 18	47,8 [0,8-89,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	10 (8,7)
95%-CI	[4,2-15,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [85,6-96,2]
Month 6	90,4 [81,7-95,1]
Month 12	77,5 [42,2-92,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	5 (20,8)
95%-CI	[7,1-42,2]
TEAE graded >= 3 in months [95%-CI]	
Median	6,44 [6,44-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [61,5-93,4]
Month 6	83,3 [61,5-93,4]
Month 12	41,7 [1,3-83,7]
Month 18	41,7 [1,3-83,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	16 (13,9)
95%-CI	[8,2-21,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [78,0-91,4]
Month 6	86,1 [78,0-91,4]
Month 12	73,8 [42,8-89,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	7 (6,1)
95%-CI	[2,5-12,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [88,0-97,5]
Month 6	94,4 [88,0-97,5]
Month 12	80,9 [40,7-95,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	1 (4,2)
95%-CI	[0,1-21,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,00-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [88,5-97,9]
Month 6	87,4 [74,3-94,0]
Month 12	87,4 [74,3-94,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	3 (12,5)
95%-CI	[2,7-32,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [62,5-95,4]
Month 6	86,1 [62,5-95,4]
Month 12	86,1 [62,5-95,4]
Month 18	86,1 [62,5-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS16: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	10 (8,7)
95%-CI	[4,2-15,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [77,6-93,8]
Month 6	84,2 [70,2-92,0]
Month 12	84,2 [70,2-92,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

4.11.17 Merkmal: Vorherige CAR-T-Therapie

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	11 (8,3)
95%-CI	[4,2-14,4]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [85,3-96,3]
Month 6	87,5 [75,7-93,8]
Month 12	83,1 [67,4-91,7]
Month 18	83,1 [67,4-91,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	10 (76,9)
95%-CI	[46,2-95,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	1,18 [0,26-2,10]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	13,0 [0,9-41,0]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	48 (36,4)
95%-CI	[28,2-45,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	7,62 [3,71-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	67,9 [58,1-75,9]
Month 6	51,5 [38,5-63,1]
Month 12	35,3 [18,7-52,4]
Month 18	35,3 [18,7-52,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	6 (46,2)
95%-CI	[19,2-74,9]
TEAE graded ≥ 3 in months [95%-CI]	
Median	1,48 [1,18-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	21,2 [1,2-57,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	32 (24,2)
95%-CI	[17,2-32,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [7,62-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	79,1 [70,2-85,6]
Month 6	64,7 [51,6-75,1]
Month 12	58,2 [40,6-72,2]
Month 18	58,2 [40,6-72,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE[0,66-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,2 [33,4-90,0]
Month 6	71,2 [33,4-90,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	23 (17,4)
95%-CI	[11,4-25,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [76,8-90,2]
Month 6	78,1 [66,3-86,2]
Month 12	65,6 [44,5-80,2]
Month 18	65,6 [44,5-80,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [0,62-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,0 [32,9-89,2]
Month 6	70,0 [32,9-89,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	12 (9,1)
95%-CI	[4,8-15,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [81,0-94,1]
Month 6	87,7 [78,8-93,0]
Month 12	87,7 [78,8-93,0]
Month 18	87,7 [78,8-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[1,41-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	70,5 [30,6-90,2]
Month 6	70,5 [30,6-90,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	10 (7,6)
95%-CI	[3,7-13,5]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [85,3-96,2]
Month 6	85,5 [70,9-93,1]
Month 12	85,5 [70,9-93,1]
Month 18	85,5 [70,9-93,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,6 [51,2-95,9]
Month 6	84,6 [51,2-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	6 (4,5)
95%-CI	[1,7-9,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [87,7-97,6]
Month 6	94,5 [87,7-97,6]
Month 12	94,5 [87,7-97,6]
Month 18	94,5 [87,7-97,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	29 (22,0)
95%-CI	[15,2-30,0]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,1 [65,0-82,6]
Month 6	71,1 [59,8-79,7]
Month 12	71,1 [59,8-79,7]
Month 18	37,9 [8,1-68,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	25 (18,9)
95%-CI	[12,6-26,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	14,13 [14,13-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,5 [67,5-84,7]
Month 6	73,5 [62,2-81,9]
Month 12	73,5 [62,2-81,9]
Month 18	49,0 [10,8-79,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [1,51-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	72,5 [34,9-90,7]
Month 6	72,5 [34,9-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	11 (8,3)
95%-CI	[4,2-14,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [87,2-96,7]
Month 6	91,6 [83,7-95,7]
Month 12	76,3 [46,0-91,0]
Month 18	76,3 [46,0-91,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	3 (23,1)
95%-CI	[5,0-53,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [0,66-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	71,6 [35,0-89,9]
Month 6	71,6 [35,0-89,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	20 (15,2)
95%-CI	[9,5-22,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,7 [78,3-90,8]
Month 6	85,7 [78,3-90,8]
Month 12	71,5 [45,3-86,7]
Month 18	71,5 [45,3-86,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [0,79-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	77,8 [36,5-93,9]
Month 6	77,8 [36,5-93,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	6 (4,5)
95%-CI	[1,7-9,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,0 [90,6-98,3]
Month 6	96,0 [90,6-98,3]
Month 12	84,0 [45,2-96,2]
Month 18	84,0 [45,2-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	8 (6,1)
95%-CI	[2,7-11,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [88,7-98,0]
Month 6	88,0 [75,6-94,3]
Month 12	88,0 [75,6-94,3]
Month 18	88,0 [75,6-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,92-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,0 [20,4-96,9]
Month 6	80,0 [20,4-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS17: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	12 (9,1)
95%-CI	[4,8-15,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [80,0-93,8]
Month 6	85,2 [72,8-92,2]
Month 12	85,2 [72,8-92,2]
Month 18	85,2 [72,8-92,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

4.11.18 Merkmal: Arzneimittelformulierung

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	10 (9,1)
95%-CI	[4,4-16,1]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,2 [83,9-96,3]
Month 6	86,5 [73,5-93,4]
Month 12	81,7 [64,5-91,1]
Month 18	81,7 [64,5-91,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	13 (37,1)
95%-CI	[21,5-55,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	3,25[2,40-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	66,2 [45,2-80,8]
Month 6	48,6 [26,2-67,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	45 (40,9)
95%-CI	[31,6-50,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	5,68 [3,29-9,23]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,9 [50,9-71,1]
Month 6	49,0 [35,4-61,3]
Month 12	32,7 [16,5-50,0]
Month 18	32,7 [16,5-50,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	8 (22,9)
95%-CI	[10,4-40,1]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [3,02-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,4 [54,2-87,9]
Month 6	69,2 [45,7-84,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Neutropenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	30 (27,3)
95%-CI	[19,2-36,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [5,39-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,5 [65,2-83,1]
Month 6	60,6 [46,2-72,2]
Month 12	53,9 [35,6-69,0]
Month 18	53,9 [35,6-69,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	7 (20,0)
95%-CI	[8,4-36,9]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,7 [61,3-91,0]
Month 6	74,9 [52,8-87,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Thrombocytopenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	19 (17,3)
95%-CI	[10,7-25,7]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [9,23-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,7 [75,9-90,5]
Month 6	79,0 [66,1-87,4]
Month 12	66,8 [45,8-81,2]
Month 18	66,8 [45,8-81,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [73,9-98,2]
Month 6	87,1 [63,6-95,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Anaemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	12 (10,9)
95%-CI	[5,8-18,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	86,1 [76,3-92,1]
Month 6	86,1 [76,3-92,1]
Month 12	86,1 [76,3-92,1]
Month 18	86,1 [76,3-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [81,4-99,6]
Month 6	97,1 [81,4-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Leukopenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	12 (10,9)
95%-CI	[5,8-18,3]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,7 [79,8-93,8]
Month 6	81,7 [66,9-90,3]
Month 12	81,7 [66,9-90,3]
Month 18	81,7 [66,9-90,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Blood and lymphatic system disorders	
PT: Lymphopenia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	8 (7,3)
95%-CI	[3,2-13,8]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [83,0-95,8]
Month 6	91,5 [83,0-95,8]
Month 12	91,5 [83,0-95,8]
Month 18	91,5 [83,0-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	12 (34,3)
95%-CI	[19,1-52,2]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [2,53-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	61,7 [40,9-77,0]
Month 6	55,5 [33,7-72,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	18 (16,4)
95%-CI	[10,0-24,6]
TEAE graded >= 3 in months [95%-CI]	
Median	14,13[12,45-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [70,5-88,5]
Month 6	78,6 [66,5-86,8]
Month 12	78,6 [66,5-86,8]
Month 18	41,9 [8,1-74,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	11 (31,4)
95%-CI	[16,9-49,3]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [2,53-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	64,1 [42,9-79,2]
Month 6	57,7 [35,2-74,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Investigations	
PT: Gamma-glutamyltransferase increased	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	14 (12,7)
95%-CI	[7,1-20,4]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [14,13-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,2 [73,5-90,9]
Month 6	81,5 [69,3-89,2]
Month 12	81,5 [69,3-89,2]
Month 18	54,3 [10,1-85,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	94,3 [79,0-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	12 (10,9)
95%-CI	[5,8-18,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [11,30-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [83,1-95,2]
Month 6	88,7 [79,2-94,0]
Month 12	73,5 [45,0-88,8]
Month 18	73,5 [45,0-88,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	6 (17,1)
95%-CI	[6,6-33,6]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	82,2 [64,5-91,6]
Month 6	82,2 [64,5-91,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	17 (15,5)
95%-CI	[9,3-23,6]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,5 [77,1-91,0]
Month 6	85,5 [77,1-91,0]
Month 12	70,9 [44,6-86,4]
Month 18	70,9 [44,6-86,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-10,0]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: Hypophosphataemia	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	8 (7,3)
95%-CI	[3,2-13,8]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [10,15-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [85,7-96,6]
Month 6	92,9 [85,7-96,6]
Month 12	81,3 [47,1-94,5]
Month 18	81,3 [47,1-94,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE graded >= 3 in months [95%-CI]	
Median	NE[4,27-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,1 [66,7-96,1]
Month 6	73,4 [33,9-91,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded \geq 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	5 (4,5)
95%-CI	[1,5-10,3]
TEAE graded \geq 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded \geq 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,0 [91,0-99,0]
Month 6	91,6 [78,8-96,8]
Month 12	91,6 [78,8-96,8]
Month 18	91,6 [78,8-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded ≥ 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
TEAE graded ≥ 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded ≥ 3 :	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [62,6-94,1]
Month 6	84,4 [62,6-94,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AC_TSSS18: Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first TEAE graded >= 3 by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Infections and infestations	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	9 (8,2)
95%-CI	[3,8-15,0]
TEAE graded >= 3 in months [95%-CI]	
Median	NE [NE-NE]
TEAE graded >= 3:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,3 [78,7-94,8]
Month 6	85,1 [70,0-92,9]
Month 12	85,1 [70,0-92,9]
Month 18	85,1 [70,0-92,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

4.12 Subgruppenanalysen zum Endpunkt: Schwerwiegende unerwünschte Ereignisse nach SOC und PT

4.12.1 Merkmal Alter

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [78,9-97,1]
Month 6	92,0 [78,9-97,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [84,4-98,9]
Month 6	87,3 [67,6-95,4]
Month 12	87,3 [67,6-95,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
serious TEAE in months [95%-CI]	
Median	NE[4,90-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	79,2 [31,8-95,4]
Month 12	79,2 [31,8-95,4]
Month 18	79,2 [31,8-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [84,2-97,6]
Month 6	93,8 [84,2-97,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [79,6-97,0]
Month 6	91,9 [79,6-97,0]
Month 12	91,9 [79,6-97,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	4 (6,2)
95%-CI	[1,7-15,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,1 [82,6-97,4]
Month 6	93,1 [82,6-97,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	2 (3,4)
95%-CI	[0,4-11,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [86,3-99,1]
Month 6	96,4 [86,3-99,1]
Month 12	96,4 [86,3-99,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,9 [58,5-97,0]
Month 6	87,9 [58,5-97,0]
Month 12	87,9 [58,5-97,0]
Month 18	87,9 [58,5-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	3 (4,6)
95%-CI	[1,0-12,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [82,1-98,1]
Month 6	94,1 [82,1-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [82,9-98,9]
Month 6	79,1 [54,2-91,4]
Month 12	79,1 [54,2-91,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-16,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
< 65 years	
Patients in analysis set	65
Patients with events - n(%)	5 (7,7)
95%-CI	[2,5-17,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,8 [74,0-95,4]
Month 6	88,8 [74,0-95,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
65 to < 75 years	
Patients in analysis set	59
Patients with events - n(%)	5 (8,5)
95%-CI	[2,8-18,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [84,9-98,3]
Month 6	83,6 [58,5-94,2]
Month 12	83,6 [58,5-94,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS01: Time to first serious TEAE by SOC/PT by subgroup: Age group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Age group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Age group:	
>= 75 years	
Patients in analysis set	21
Patients with events - n(%)	2 (9,5)
95%-CI	[1,2-30,4]
serious TEAE in months [95%-CI]	
Median	NE [3,32-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	83,9 [49,4-95,7]
Month 12	83,9 [49,4-95,7]
Month 18	83,9 [49,4-95,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

4.12.2 Merkmal: Geschlecht

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	6 (10,0)
95%-CI	[3,8-20,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [82,5-98,0]
Month 6	86,0 [67,7-94,3]
Month 12	80,6 [59,3-91,5]
Month 18	80,6 [59,3-91,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [84,2-97,8]
Month 6	91,4 [79,3-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	5 (8,3)
95%-CI	[2,8-18,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [79,9-96,2]
Month 6	91,1 [79,9-96,2]
Month 12	91,1 [79,9-96,2]
Month 18	91,1 [79,9-96,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	4 (4,7)
95%-CI	[1,3-11,6]
serious TEAE in months [95%-CI]	
Median	NE[6,44-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [87,3-98,7]
Month 6	95,8 [87,3-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	3 (5,0)
95%-CI	[1,0-13,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [79,2-97,9]
Month 6	93,2 [79,2-97,9]
Month 12	93,2 [79,2-97,9]
Month 18	93,2 [79,2-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	5 (5,9)
95%-CI	[1,9-13,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,6 [85,2-97,3]
Month 6	93,6 [85,2-97,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-6,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [82,8-97,0]
Month 6	80,1 [60,6-90,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Sex:	
Female	
Patients in analysis set	60
Patients with events - n(%)	4 (6,7)
95%-CI	[1,8-16,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [78,3-97,8]
Month 6	89,1 [72,3-96,0]
Month 12	89,1 [72,3-96,0]
Month 18	89,1 [72,3-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS02: Time to first serious TEAE by SOC/PT by subgroup: Sex
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Sex	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Sex:	
Male	
Patients in analysis set	85
Patients with events - n(%)	8 (9,4)
95%-CI	[4,2-17,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [80,0-96,0]
Month 6	80,9 [58,4-92,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

4.12.3 Merkmal: Ethnie

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	11 (8,5)
95%-CI	[4,3-14,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [86,0-96,8]
Month 6	86,2 [73,6-93,1]
Month 12	81,7 [65,2-90,8]
Month 18	81,7 [65,2-90,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	9 (6,9)
95%-CI	[3,2-12,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [86,8-96,6]
Month 6	93,2 [86,8-96,6]
Month 12	88,6 [73,7-95,3]
Month 18	88,6 [73,7-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	8 (6,2)
95%-CI	[2,7-11,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [85,3-96,3]
Month 6	92,6 [85,3-96,3]
Month 12	92,6 [85,3-96,3]
Month 18	92,6 [85,3-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	7 (5,4)
95%-CI	[2,2-10,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [90,4-98,7]
Month 6	88,8 [75,7-95,0]
Month 12	88,8 [75,7-95,0]
Month 18	88,8 [75,7-95,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [53,9-98,8]
Month 6	91,7 [53,9-98,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Race group:	
White	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [82,6-95,8]
Month 6	86,0 [72,9-93,0]
Month 12	86,0 [72,9-93,0]
Month 18	86,0 [72,9-93,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS03: Time to first serious TEAE by SOC/PT by subgroup: Race group
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Race group	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
serious TEAE in months [95%-CI]	
Median	NE [3,32-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,3 [61,3-99,0]
Month 6	83,0 [45,7-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

4.12.4 Merkmal: Region-1

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
serious TEAE in months [95%-CI]	
Median	NE [6,01-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [75,5-96,4]
Month 6	82,8 [58,1-93,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,4 [76,2-98,3]
Month 6	85,7 [58,0-95,7]
Month 12	85,7 [58,0-95,7]
Month 18	85,7 [58,0-95,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	2 (3,8)
95%-CI	[0,5-13,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,1 [87,1-99,7]
Month 6	94,3 [77,6-98,7]
Month 12	94,3 [77,6-98,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [81,4-97,2]
Month 6	92,6 [81,4-97,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	4 (12,9)
95%-CI	[3,6-29,8]
serious TEAE in months [95%-CI]	
Median	NE [6,44-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,4 [67,0-96,2]
Month 6	88,4 [67,0-96,2]
Month 12	70,7 [26,9-91,2]
Month 18	70,7 [26,9-91,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	1 (1,9)
95%-CI	[0,0-10,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,1 [87,4-99,7]
Month 6	98,1 [87,4-99,7]
Month 12	98,1 [87,4-99,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [77,0-96,7]
Month 6	91,1 [77,0-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	3 (9,7)
95%-CI	[2,0-25,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	89,5 [70,6-96,5]
Month 6	89,5 [70,6-96,5]
Month 12	89,5 [70,6-96,5]
Month 18	89,5 [70,6-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	1 (1,9)
95%-CI	[0,0-10,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	98,0 [86,6-99,7]
Month 6	98,0 [86,6-99,7]
Month 12	98,0 [86,6-99,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,3 [81,8-98,9]
Month 6	88,9 [65,2-96,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	2 (6,5)
95%-CI	[0,8-21,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,8 [79,2-99,5]
Month 6	88,7 [57,8-97,4]
Month 12	88,7 [57,8-97,4]
Month 18	88,7 [57,8-97,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [82,8-98,9]
Month 6	89,1 [65,5-96,9]
Month 12	89,1 [65,5-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [77,0-97,7]
Month 6	87,9 [68,7-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
UK	
Patients in analysis set	31
Patients with events - n(%)	5 (16,1)
95%-CI	[5,5-33,7]
serious TEAE in months [95%-CI]	
Median	NE [5,52-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,2 [64,4-94,3]
Month 6	71,0 [34,0-89,7]
Month 12	71,0 [34,0-89,7]
Month 18	71,0 [34,0-89,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS04: Time to first serious TEAE by SOC/PT by subgroup: Country
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Country	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Country:	
Italy	
Patients in analysis set	53
Patients with events - n(%)	3 (5,7)
95%-CI	[1,2-15,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [78,3-98,7]
Month 6	90,8 [73,2-97,1]
Month 12	90,8 [73,2-97,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

4.12.5 *Merkmal: Region 2*

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	6 (10,2)
95%-CI	[3,8-20,8]
serious TEAE in months [95%-CI]	
Median	NE [6,01-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,3 [75,5-96,4]
Month 6	82,8 [58,1-93,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [89,4-98,8]
Month 6	91,3 [78,9-96,5]
Month 12	91,3 [78,9-96,5]
Month 18	91,3 [78,9-96,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [81,4-97,2]
Month 6	92,6 [81,4-97,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [86,5-98,1]
Month 6	94,8 [86,5-98,1]
Month 12	88,5 [66,9-96,3]
Month 18	88,5 [66,9-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,1 [77,0-96,7]
Month 6	91,1 [77,0-96,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	4 (4,7)
95%-CI	[1,3-11,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [87,3-98,1]
Month 6	95,0 [87,3-98,1]
Month 12	95,0 [87,3-98,1]
Month 18	95,0 [87,3-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	3 (5,1)
95%-CI	[1,1-14,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,3 [81,8-98,9]
Month 6	88,9 [65,2-96,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	5 (5,8)
95%-CI	[1,9-13,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,9 [87,4-98,7]
Month 6	89,3 [74,1-95,8]
Month 12	89,3 [74,1-95,8]
Month 18	89,3 [74,1-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Region:	
USA	
Patients in analysis set	59
Patients with events - n(%)	4 (6,8)
95%-CI	[1,9-16,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [77,0-97,7]
Month 6	87,9 [68,7-95,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS05: Time to first serious TEAE by SOC/PT by subgroup: Region
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Region	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Region:	
Non-USA	
Patients in analysis set	86
Patients with events - n(%)	8 (9,3)
95%-CI	[4,1-17,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,2 [80,8-96,1]
Month 6	84,4 [68,3-92,7]
Month 12	84,4 [68,3-92,7]
Month 18	84,4 [68,3-92,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

4.12.6 Merkmal: Krankheitsstadium nach Ann-Arbor

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,0 [69,5-99,3]
Month 6	86,4 [53,6-96,6]
Month 12	86,4 [53,6-96,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-17,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	9 (9,7)
95%-CI	[4,5-17,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,0 [82,6-96,5]
Month 6	84,5 [67,7-93,0]
Month 12	77,4 [54,5-89,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
serious TEAE in months [95%-CI]	
Median	NE[1,84-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	88,9 [43,3-98,4]
Month 18	88,9 [43,3-98,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	1 (5,3)
95%-CI	[0,1-26,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [68,1-99,2]
Month 6	94,7 [68,1-99,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	7 (7,5)
95%-CI	[3,1-14,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [85,5-96,9]
Month 6	93,2 [85,5-96,9]
Month 12	86,0 [63,4-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	95,2 [70,7-99,3]
Month 12	95,2 [70,7-99,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-17,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	7 (7,5)
95%-CI	[3,1-14,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [81,2-95,7]
Month 6	90,9 [81,2-95,7]
Month 12	90,9 [81,2-95,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
serious TEAE in months [95%-CI]	
Median	NE[3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	75,0 [12,8-96,1]
Month 12	75,0 [12,8-96,1]
Month 18	75,0 [12,8-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	1 (4,3)
95%-CI	[0,1-21,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	95,5 [71,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	2 (10,5)
95%-CI	[1,3-33,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,0 [59,4-96,9]
Month 6	88,0 [59,4-96,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	4 (4,3)
95%-CI	[1,2-10,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [88,6-99,3]
Month 6	90,0 [73,1-96,5]
Month 12	90,0 [73,1-96,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-30,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage II	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	87,0 [54,3-96,9]
Month 12	87,0 [54,3-96,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage III	
Patients in analysis set	19
Patients with events - n(%)	3 (15,8)
95%-CI	[3,4-39,6]
serious TEAE in months [95%-CI]	
Median	NE [2,89-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	76,6 [41,2-92,3]
Month 6	76,6 [41,2-92,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS06: Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Ann Arbor stage:	
Stage IV	
Patients in analysis set	93
Patients with events - n(%)	7 (7,5)
95%-CI	[3,1-14,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,8 [82,6-97,1]
Month 6	84,3 [65,2-93,4]
Month 12	84,3 [65,2-93,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS07: Time to first serious TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

4.12.7 *Merkmal: Bulky Erkrankung*

Time to first serious TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	11 (8,0)
95%-CI	[4,1-13,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [87,2-97,1]
Month 6	87,9 [77,0-93,8]
Month 12	83,9 [69,3-91,9]
Month 18	83,9 [69,3-91,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS07: Time to first serious TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	8 (5,8)
95%-CI	[2,6-11,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [88,5-97,3]
Month 6	94,4 [88,5-97,3]
Month 12	90,3 [76,7-96,1]
Month 18	90,3 [76,7-96,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS07: Time to first serious TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	5 (3,6)
95%-CI	[1,2-8,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,4 [89,0-98,1]
Month 6	95,4 [89,0-98,1]
Month 12	95,4 [89,0-98,1]
Month 18	95,4 [89,0-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS07: Time to first serious TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	7 (5,1)
95%-CI	[2,1-10,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,3 [90,2-98,6]
Month 6	89,9 [78,6-95,4]
Month 12	89,9 [78,6-95,4]
Month 18	89,9 [78,6-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT1AS_TSSS07: Time to first serious TEAE by SOC/PT by subgroup: Bulky disease
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Bulky disease:	
No	
Patients in analysis set	137
Patients with events - n(%)	10 (7,3)
95%-CI	[3,6-13,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [85,7-96,8]
Month 6	86,7 [74,6-93,3]
Month 12	86,7 [74,6-93,3]
Month 18	86,7 [74,6-93,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

4.12.8 *Merkmal: Double/Triple-Hit*

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	4 (26,7)
95%-CI	[7,8-55,1]
serious TEAE in months [95%-CI]	
Median	6,01 [2,50-6,01]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,3 [41,5-95,2]
Month 6	54,2 [8,5-85,9]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	7 (5,4)
95%-CI	[2,2-10,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [89,9-98,2]
Month 6	92,0 [83,1-96,3]
Month 12	92,0 [83,1-96,3]
Month 18	92,0 [83,1-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	1 (6,7)
95%-CI	[0,2-31,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [59,1-99,0]
Month 6	92,9 [59,1-99,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	8 (6,2)
95%-CI	[2,7-11,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,1 [87,9-97,2]
Month 6	94,1 [87,9-97,2]
Month 12	89,6 [74,9-95,9]
Month 18	89,6 [74,9-95,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	3 (20,0)
95%-CI	[4,3-48,1]
serious TEAE in months [95%-CI]	
Median	NE [2,73-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	73,9 [37,9-91,0]
Month 6	73,9 [37,9-91,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	5 (3,8)
95%-CI	[1,3-8,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,0 [90,6-98,3]
Month 6	96,0 [90,6-98,3]
Month 12	96,0 [90,6-98,3]
Month 18	96,0 [90,6-98,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-21,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	8 (6,2)
95%-CI	[2,7-11,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [88,6-98,0]
Month 6	88,0 [75,6-94,3]
Month 12	88,0 [75,6-94,3]
Month 18	88,0 [75,6-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Double/Triple hit:	
Yes	
Patients in analysis set	15
Patients with events - n(%)	2 (13,3)
95%-CI	[1,7-40,5]
serious TEAE in months [95%-CI]	
Median	NE [2,92-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	72,9 [27,6-92,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS08: Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Double/Triple hit:	
No	
Patients in analysis set	130
Patients with events - n(%)	10 (7,7)
95%-CI	[3,8-13,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [84,9-96,3]
Month 6	87,2 [74,8-93,7]
Month 12	87,2 [74,8-93,7]
Month 18	87,2 [74,8-93,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

4.12.9 *Merkmal: Transformation des DLBCL*

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	4 (13,8)
95%-CI	[3,9-31,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [65,8-95,8]
Month 6	80,1 [53,6-92,4]
Month 12	80,1 [53,6-92,4]
Month 18	80,1 [53,6-92,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	7 (6,0)
95%-CI	[2,5-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,6 [88,1-98,4]
Month 6	90,2 [77,1-96,0]
Month 12	85,2 [66,9-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [70,9-97,9]
Month 6	91,8 [70,9-97,9]
Month 12	91,8 [70,9-97,9]
Month 18	91,8 [70,9-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	7 (6,0)
95%-CI	[2,5-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [87,7-97,5]
Month 6	94,4 [87,7-97,5]
Month 12	89,4 [72,9-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-11,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	8 (6,9)
95%-CI	[3,0-13,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,9 [84,1-96,0]
Month 6	91,9 [84,1-96,0]
Month 12	91,9 [84,1-96,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
serious TEAE in months [95%-CI]	
Median	NE [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	90,0 [47,3-98,5]
Month 12	90,0 [47,3-98,5]
Month 18	90,0 [47,3-98,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	7 (6,0)
95%-CI	[2,5-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,6 [87,2-97,8]
Month 6	89,3 [76,8-95,2]
Month 12	89,3 [76,8-95,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Transformed DLBCL:	
Transformed	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [73,7-98,1]
Month 6	85,0 [57,2-95,4]
Month 12	85,0 [57,2-95,4]
Month 18	85,0 [57,2-95,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS09: Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Transformed DLBCL:	
De novo	
Patients in analysis set	116
Patients with events - n(%)	9 (7,8)
95%-CI	[3,6-14,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,4 [82,0-96,0]
Month 6	85,4 [71,0-93,0]
Month 12	85,4 [71,0-93,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term. DLBCL = Diffuse large B-Cell Lymphoma.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

4.12.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	1 (2,1)
95%-CI	[0,1-11,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	95,8 [73,9-99,4]
Month 12	95,8 [73,9-99,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [70,7-99,3]
Month 6	86,6 [53,9-96,7]
Month 12	86,6 [53,9-96,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	5 (10,4)
95%-CI	[3,5-22,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,8 [77,0-96,5]
Month 6	90,8 [77,0-96,5]
Month 12	82,5 [56,4-93,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	91,3 [69,5-97,8]
Month 12	91,3 [69,5-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	2 (4,2)
95%-CI	[0,5-14,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [84,2-98,9]
Month 6	95,8 [84,2-98,9]
Month 12	95,8 [84,2-98,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	4 (17,4)
95%-CI	[5,0-38,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	81,6 [58,0-92,7]
Month 6	81,6 [58,0-92,7]
Month 12	81,6 [58,0-92,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	1 (2,1)
95%-CI	[0,1-11,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	93,3 [61,3-99,0]
Month 12	93,3 [61,3-99,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	3 (13,0)
95%-CI	[2,8-33,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,3 [69,5-97,8]
Month 6	83,0 [53,5-94,6]
Month 12	83,0 [53,5-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
B-cell type:	
Germinal center B-cell	
Patients in analysis set	48
Patients with events - n(%)	7 (14,6)
95%-CI	[6,1-27,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,8 [68,6-93,0]
Month 6	80,7 [62,7-90,7]
Month 12	80,7 [62,7-90,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS10: Time to first serious TEAE by SOC/PT by subgroup: B-Cell type
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
B-cell type:	
Activated B-cell	
Patients in analysis set	23
Patients with events - n(%)	2 (8,7)
95%-CI	[1,1-28,0]
serious TEAE in months [95%-CI]	
Median	NE [5,52-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	73,3 [24,3-93,4]
Month 12	73,3 [24,3-93,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

4.12.11 Merkmal: Maximaler längster Durchmesser

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	8 (9,8)
95%-CI	[4,3-18,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [82,8-96,9]
Month 6	83,7 [68,1-92,1]
Month 12	83,7 [68,1-92,1]
Month 18	83,7 [68,1-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	1 (2,8)
95%-CI	[0,1-14,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,2 [81,9-99,6]
Month 6	97,2 [81,9-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
serious TEAE in months [95%-CI]	
Median	NE [0,49-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-24,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	2 (2,4)
95%-CI	[0,3-8,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,4 [89,8-99,3]
Month 6	97,4 [89,8-99,3]
Month 12	97,4 [89,8-99,3]
Month 18	97,4 [89,8-99,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	3 (8,3)
95%-CI	[1,8-22,5]
serious TEAE in months [95%-CI]	
Median	NE [6,44-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [74,0-98,3]
Month 6	93,0 [74,0-98,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
serious TEAE in months [95%-CI]	
Median	NE [0,20-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
serious TEAE in months [95%-CI]	
Median	NE [0,43-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [48,2-95,6]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	1 (1,2)
95%-CI	[0,0-6,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,8 [85,3-99,7]
Month 6	97,8 [85,3-99,7]
Month 12	97,8 [85,3-99,7]
Month 18	97,8 [85,3-99,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [79,6-98,6]
Month 6	94,4 [79,6-98,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	3 (30,0)
95%-CI	[6,7-65,2]
serious TEAE in months [95%-CI]	
Median	NE [0,26-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,6 [26,0-87,7]
Month 6	65,6 [26,0-87,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
serious TEAE in months [95%-CI]	
Median	NE [0,99-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,2 [40,3-94,8]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	4 (4,9)
95%-CI	[1,3-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [87,2-99,2]
Month 6	89,9 [73,7-96,3]
Month 12	89,9 [73,7-96,3]
Month 18	89,9 [73,7-96,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	1 (2,8)
95%-CI	[0,1-14,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	91,7 [53,9-98,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
serious TEAE in months [95%-CI]	
Median	NE [0,56-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,9 [43,3-98,4]
Month 6	88,9 [43,3-98,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
serious TEAE in months [95%-CI]	
Median	NE [0,72-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [47,2-95,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	82
Patients with events - n(%)	7 (8,5)
95%-CI	[3,5-16,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,2 [78,8-95,7]
Month 6	87,9 [75,4-94,2]
Month 12	87,9 [75,4-94,2]
Month 18	87,9 [75,4-94,2]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	36
Patients with events - n(%)	2 (5,6)
95%-CI	[0,7-18,7]
serious TEAE in months [95%-CI]	
Median	NE [5,52-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	79,1 [36,7-94,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	10
Patients with events - n(%)	1 (10,0)
95%-CI	[0,3-44,5]
serious TEAE in months [95%-CI]	
Median	NE [1,74-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS11: Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
serious TEAE in months [95%-CI]	
Median	NE [0,66-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,1 [47,2-95,5]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

4.12.12 Merkmal: Primärdiagnose

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	8 (6,3)
95%-CI	[2,8-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [88,6-97,6]
Month 6	91,2 [82,3-95,7]
Month 12	91,2 [82,3-95,7]
Month 18	91,2 [82,3-95,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: General disorders and administration site conditions	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	3 (27,3)
95%-CI	[6,0-61,0]
serious TEAE in months [95%-CI]	
Median	6,01 [2,50-6,01]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	55,6 [7,3-87,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	8 (6,3)
95%-CI	[2,8-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [87,6-97,1]
Month 6	94,0 [87,6-97,1]
Month 12	89,5 [74,9-95,8]
Month 18	89,5 [74,9-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Gastrointestinal disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	1 (9,1)
95%-CI	[0,2-41,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [50,8-98,7]
Month 6	90,9 [50,8-98,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	6 (4,7)
95%-CI	[1,8-10,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [89,0-97,7]
Month 6	94,9 [89,0-97,7]
Month 12	94,9 [89,0-97,7]
Month 18	94,9 [89,0-97,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Metabolism and nutrition disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
serious TEAE in months [95%-CI]	
Median	NE [2,73-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	75,8 [30,5-93,7]
Month 6	75,8 [30,5-93,7]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	8 (6,3)
95%-CI	[2,8-12,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,2 [88,5-98,0]
Month 6	88,1 [75,8-94,3]
Month 12	88,1 [75,8-94,3]
Month 18	88,1 [75,8-94,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-28,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	127
Patients with events - n(%)	10 (7,9)
95%-CI	[3,8-14,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [84,7-96,2]
Month 6	87,2 [74,8-93,7]
Month 12	87,2 [74,8-93,7]
Month 18	87,2 [74,8-93,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS12: Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

SOC: Infections and infestations	
PT: All PTs	
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	2 (18,2)
95%-CI	[2,3-51,8]
serious TEAE in months [95%-CI]	
Median	NE [2,92-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	83,3 [27,3-97,5]
Month 6	66,7 [19,5-90,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

4.12.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [84,8-98,3]
Month 6	91,0 [76,1-96,8]
Month 12	91,0 [76,1-96,8]
Month 18	91,0 [76,1-96,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
serious TEAE in months [95%-CI]	
Median	NE[4,90-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	83,3 [27,3-97,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	6 (12,8)
95%-CI	[4,8-25,7]
serious TEAE in months [95%-CI]	
Median	NE [6,01-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	88,6 [71,7-95,7]
Month 6	84,6 [65,9-93,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,4 [83,5-98,2]
Month 6	94,4 [83,5-98,2]
Month 12	86,6 [59,9-96,0]
Month 18	86,6 [59,9-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [80,9-99,6]
Month 6	97,1 [80,9-99,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	4 (8,5)
95%-CI	[2,4-20,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [77,3-96,5]
Month 6	90,9 [77,3-96,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [82,5-97,3]
Month 6	93,0 [82,5-97,3]
Month 12	93,0 [82,5-97,3]
Month 18	93,0 [82,5-97,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	85,3 [63,0-94,6]
Month 6	85,3 [63,0-94,6]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-7,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	2 (3,2)
95%-CI	[0,4-11,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,8 [83,9-99,0]
Month 6	95,8 [83,9-99,0]
Month 12	95,8 [83,9-99,0]
Month 18	95,8 [83,9-99,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	1 (2,9)
95%-CI	[0,1-14,9]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [71,9-99,4]
Month 6	95,5 [71,9-99,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	5 (10,6)
95%-CI	[3,5-23,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,5 [83,1-98,9]
Month 6	77,5 [51,1-90,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
2 lines	
Patients in analysis set	63
Patients with events - n(%)	4 (6,3)
95%-CI	[1,8-15,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,7 [77,7-97,0]
Month 6	91,7 [77,7-97,0]
Month 12	91,7 [77,7-97,0]
Month 18	91,7 [77,7-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
3 lines	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
serious TEAE in months [95%-CI]	
Median	NE [5,52-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [74,4-98,2]
Month 6	67,7 [25,7-89,4]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS13: Time to first serious TEAE by SOC/PT by subgroup: Number prior lines
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Number prior lines:	
> 3 lines	
Patients in analysis set	47
Patients with events - n(%)	4 (8,5)
95%-CI	[2,4-20,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,9 [73,4-97,1]
Month 6	86,8 [67,5-95,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

4.12.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	6 (6,1)
95%-CI	[2,3-12,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [88,8-98,4]
Month 6	91,4 [81,0-96,3]
Month 12	91,4 [81,0-96,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,4 [77,2-99,5]
Month 6	96,4 [77,2-99,5]
Month 12	96,4 [77,2-99,5]
Month 18	96,4 [77,2-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	5 (5,1)
95%-CI	[1,7-11,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [87,3-97,7]
Month 6	94,5 [87,3-97,7]
Month 12	94,5 [87,3-97,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
serious TEAE in months [95%-CI]	
Median	NE [6,44-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,9 [74,4-98,2]
Month 6	92,9 [74,4-98,2]
Month 12	61,9 [7,6-91,5]
Month 18	61,9 [7,6-91,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	5 (5,1)
95%-CI	[1,7-11,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,7 [87,8-97,8]
Month 6	94,7 [87,8-97,8]
Month 12	94,7 [87,8-97,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	2 (6,9)
95%-CI	[0,8-22,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [73,4-98,1]
Month 6	92,6 [73,4-98,1]
Month 12	92,6 [73,4-98,1]
Month 18	92,6 [73,4-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	6 (6,1)
95%-CI	[2,3-12,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,1 [88,3-98,8]
Month 6	87,6 [72,8-94,6]
Month 12	87,6 [72,8-94,6]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	1 (3,4)
95%-CI	[0,1-17,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,2 [75,7-99,5]
Month 6	96,2 [75,7-99,5]
Month 12	96,2 [75,7-99,5]
Month 18	96,2 [75,7-99,5]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - first line:	
Relapse	
Patients in analysis set	99
Patients with events - n(%)	8 (8,1)
95%-CI	[3,6-15,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,5 [83,5-96,7]
Month 6	86,1 [71,0-93,7]
Month 12	86,1 [71,0-93,7]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS14: Time to first serious TEAE by SOC/PT by subgroup: Response category - first line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - first line:	
Refractory	
Patients in analysis set	29
Patients with events - n(%)	3 (10,3)
95%-CI	[2,2-27,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	84,4 [55,0-95,3]
Month 6	84,4 [55,0-95,3]
Month 12	84,4 [55,0-95,3]
Month 18	84,4 [55,0-95,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

4.12.15 Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,4 [83,2-99,6]
Month 6	87,3 [63,2-96,1]
Month 12	87,3 [63,2-96,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	6 (6,8)
95%-CI	[2,5-14,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [85,5-97,4]
Month 6	90,2 [77,5-96,0]
Month 12	90,2 [77,5-96,0]
Month 18	90,2 [77,5-96,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,4 [78,3-97,5]
Month 6	92,4 [78,3-97,5]
Month 12	92,4 [78,3-97,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	4 (4,5)
95%-CI	[1,3-11,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,5 [89,6-98,9]
Month 6	96,5 [89,6-98,9]
Month 12	86,9 [53,4-96,9]
Month 18	86,9 [53,4-96,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	3 (6,8)
95%-CI	[1,4-18,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,8 [76,1-97,4]
Month 6	91,8 [76,1-97,4]
Month 12	91,8 [76,1-97,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	4 (4,5)
95%-CI	[1,3-11,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,9 [86,8-98,1]
Month 6	94,9 [86,8-98,1]
Month 12	94,9 [86,8-98,1]
Month 18	94,9 [86,8-98,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	4 (9,1)
95%-CI	[2,5-21,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,6 [78,6-97,6]
Month 6	87,5 [67,9-95,5]
Month 12	87,5 [67,9-95,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	3 (3,4)
95%-CI	[0,7-9,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,6 [86,5-99,2]
Month 6	92,9 [77,5-97,9]
Month 12	92,9 [77,5-97,9]
Month 18	92,9 [77,5-97,9]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - last line:	
Relapse	
Patients in analysis set	44
Patients with events - n(%)	5 (11,4)
95%-CI	[3,8-24,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,4 [69,1-95,2]
Month 6	83,4 [63,9-92,9]
Month 12	83,4 [63,9-92,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS15: Time to first serious TEAE by SOC/PT by subgroup: Response category - last line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - last line:	
Refractory	
Patients in analysis set	88
Patients with events - n(%)	7 (8,0)
95%-CI	[3,3-15,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,0 [86,1-97,5]
Month 6	83,9 [62,4-93,7]
Month 12	83,9 [62,4-93,7]
Month 18	83,9 [62,4-93,7]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

4.12.16 Merkmal: *Ansprechkategorie auf eine beliebige vorherige systemische Therapie*

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,6 [67,3-97,6]
Month 6	90,6 [67,3-97,6]
Month 12	90,6 [67,3-97,6]
Month 18	90,6 [67,3-97,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,1 [90,0-98,5]
Month 6	89,2 [76,9-95,2]
Month 12	84,8 [68,2-93,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
serious TEAE in months [95%-CI]	
Median	6,44 [6,44-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,7 [72,9-99,4]
Month 6	95,7 [72,9-99,4]
Month 12	47,8 [0,8-89,4]
Month 18	47,8 [0,8-89,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	6 (5,2)
95%-CI	[1,9-11,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [87,6-97,4]
Month 6	94,3 [87,6-97,4]
Month 12	94,3 [87,6-97,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	6 (5,2)
95%-CI	[1,9-11,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [86,1-97,2]
Month 6	93,7 [86,1-97,2]
Month 12	93,7 [86,1-97,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	0 (0,0)
95%-CI	[0,0-14,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	8 (7,0)
95%-CI	[3,1-13,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,8 [87,7-97,8]
Month 6	87,4 [74,6-94,0]
Month 12	87,4 [74,6-94,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - any line:	
Relapse	
Patients in analysis set	24
Patients with events - n(%)	2 (8,3)
95%-CI	[1,0-27,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [70,0-97,8]
Month 6	91,5 [70,0-97,8]
Month 12	91,5 [70,0-97,8]
Month 18	91,5 [70,0-97,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS16: Time to first serious TEAE by SOC/PT by subgroup: Response category - any line
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Response category - any line:	
Refractory	
Patients in analysis set	115
Patients with events - n(%)	10 (8,7)
95%-CI	[4,2-15,4]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	91,5 [82,4-96,0]
Month 6	83,9 [70,0-91,8]
Month 12	83,9 [70,0-91,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

4.12.17 Merkmal: Vorherige CAR-T-Therapie

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
serious TEAE in months [95%-CI]	
Median	NE [1,38-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [38,7-98,1]
Month 6	87,5 [38,7-98,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	10 (7,6)
95%-CI	[3,7-13,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,5 [87,8-97,6]
Month 6	88,0 [76,2-94,2]
Month 12	83,6 [67,7-92,1]
Month 18	83,6 [67,7-92,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
serious TEAE in months [95%-CI]	
Median	NE [1,38-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	80,8 [41,0-95,0]
Month 6	80,8 [41,0-95,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	7 (5,3)
95%-CI	[2,2-10,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	95,1 [89,3-97,8]
Month 6	95,1 [89,3-97,8]
Month 12	90,5 [75,3-96,6]
Month 18	90,5 [75,3-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
serious TEAE in months [95%-CI]	
Median	NE [0,66-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	90,0 [47,3-98,5]
Month 6	90,0 [47,3-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	7 (5,3)
95%-CI	[2,2-10,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,7 [86,8-97,0]
Month 6	93,7 [86,8-97,0]
Month 12	93,7 [86,8-97,0]
Month 18	93,7 [86,8-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	1 (7,7)
95%-CI	[0,2-36,0]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,3 [56,6-98,9]
Month 6	92,3 [56,6-98,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	7 (5,3)
95%-CI	[2,2-10,6]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,1 [89,7-98,5]
Month 6	89,3 [77,2-95,1]
Month 12	89,3 [77,2-95,1]
Month 18	89,3 [77,2-95,1]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	13
Patients with events - n(%)	2 (15,4)
95%-CI	[1,9-45,4]
serious TEAE in months [95%-CI]	
Median	NE [1,38-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	65,6 [15,7-90,9]
Month 6	65,6 [15,7-90,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS17: Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Prior use of T-CART therapy:	
No	
Patients in analysis set	132
Patients with events - n(%)	10 (7,6)
95%-CI	[3,7-13,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,5 [86,4-97,0]
Month 6	86,8 [74,4-93,4]
Month 12	86,8 [74,4-93,4]
Month 18	86,8 [74,4-93,4]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

4.12.18 Merkmal: Arzneimittelformulierung

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	97,1 [81,4-99,6]
Month 6	84,4 [56,7-95,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: General disorders and administration site conditions	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	8 (7,3)
95%-CI	[3,2-13,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,0 [84,6-96,9]
Month 6	89,5 [76,9-95,5]
Month 12	84,6 [66,8-93,3]
Month 18	84,6 [66,8-93,3]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,3 [79,0-98,5]
Month 6	94,3 [79,0-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Gastrointestinal disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	7 (6,4)
95%-CI	[2,6-12,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,8 [86,6-97,2]
Month 6	93,8 [86,6-97,2]
Month 12	88,9 [72,6-95,8]
Month 18	88,9 [72,6-95,8]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	2 (5,7)
95%-CI	[0,7-19,2]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	94,2 [78,7-98,5]
Month 6	94,2 [78,7-98,5]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Metabolism and nutrition disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	6 (5,5)
95%-CI	[2,0-11,5]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [84,9-97,0]
Month 6	93,2 [84,9-97,0]
Month 12	93,2 [84,9-97,0]
Month 18	93,2 [84,9-97,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	3 (8,6)
95%-CI	[1,8-23,1]
serious TEAE in months [95%-CI]	
Median	NE [3,94-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	92,7 [73,1-98,2]
Month 6	81,1 [44,5-94,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Respiratory, thoracic and mediastinal disorders	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	5 (4,5)
95%-CI	[1,5-10,3]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	96,7 [89,7-98,9]
Month 6	91,3 [78,4-96,6]
Month 12	91,3 [78,4-96,6]
Month 18	91,3 [78,4-96,6]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Drug formulation:	
Frozen liquid	
Patients in analysis set	35
Patients with events - n(%)	4 (11,4)
95%-CI	[3,2-26,7]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	87,5 [64,7-96,0]
Month 6	82,0 [57,7-93,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3AS_TSSS18: Time to first serious TEAE by SOC/PT by subgroup: Drug formulation
 ITT set

Time to first serious TEAE by SOC/PT by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
SOC: Infections and infestations	
PT: All PTs	
Drug formulation:	
Lyophilized	
Patients in analysis set	110
Patients with events - n(%)	8 (7,3)
95%-CI	[3,2-13,8]
serious TEAE in months [95%-CI]	
Median	NE [NE-NE]
serious TEAE:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	93,2 [84,8-97,0]
Month 6	86,7 [71,8-94,0]
Month 12	86,7 [71,8-94,0]
Month 18	86,7 [71,8-94,0]
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. TEAE = Treatment-emergent adverse event.

ITT set = Intent to Treat set. SOC= System organ class. PT=Preferred term.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aae_tte, created on: 10JAN2023

Table LT3FAD_PSTS01: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Age group
 PRO set

4.13 Subgruppenanalysen zum FACT-G GP5 (Zeit bis zur Verschlechterung)

4.13.1 Merkmal Alter

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
Patients with events - n(%)	31 (54,4)
95%-CI	[40,7-67,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,68 [1,08-2,83]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	31,8 [17,6-47,0]
Month 6	20,5 [7,2-38,3]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS01: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Age group
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
Patients with events - n(%)	32 (60,4)
95%-CI	[46,0-73,5]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,04 [1,45-2,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	29,7 [15,9-44,9]
Month 6	16,5 [6,3-30,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS01: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Age group
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: >= 75 years	
Patients in analysis set	20
Patients with events - n(%)	11 (55,0)
95%-CI	[31,5-76,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,79[1,15-11,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	47,6 [21,3-70,0]
Month 6	35,7 [11,0-61,9]
Month 12	11,9 [0,7-39,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS02: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Sex
 PRO set

4.13.2 *Merkmal: Geschlecht*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
Patients with events - n(%)	28 (52,8)
95%-CI	[38,6-66,7]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,41-3,32]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,3 [21,8-52,9]
Month 6	25,6 [11,9-41,9]
Month 12	8,5 [0,7-29,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS02: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Sex
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
Patients with events - n(%)	46 (59,7)
95%-CI	[47,9-70,8]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,71 [1,41-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,6 [18,4-43,7]
Month 6	17,5 [7,4-31,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS03: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Race group
 PRO set

4.13.3 *Merkmal: Ethnie*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
Patients with events - n(%)	67 (58,3)
95%-CI	[48,7-67,4]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,68 [1,41-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	30,5 [20,5-41,1]
Month 6	17,0 [8,7-27,6]
Month 12	5,7 [0,6-20,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS03: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Race group
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
Patients with events - n(%)	7 (46,7)
95%-CI	[21,3-73,4]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	6,08 [0,76-NE]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	51,0 [20,6-75,1]
Month 6	51,0 [20,6-75,1]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS04: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Country
 PRO set

4.13.4 *Merkmal: Region-1*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
Patients with events - n(%)	26 (51,0)
95%-CI	[36,6-65,2]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,48 [0,95-3,02]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,3 [21,1-53,5]
Month 6	18,7 [5,5-37,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS04: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Country
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
Patients with events - n(%)	16 (55,2)
95%-CI	[35,7-73,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	3,32 [1,71-10,12]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,1 [27,6-69,0]
Month 6	39,0 [18,3-59,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS04: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Country
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
Patients with events - n(%)	30 (62,5)
95%-CI	[47,4-76,0]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,48 [1,18-2,30]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	21,8 [9,7-37,1]
Month 6	11,6 [2,7-27,9]
Month 12	11,6 [2,7-27,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS05: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Region
 PRO set

4.13.5 *Merkmal: Region-2*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
Patients with events - n(%)	26 (51,0)
95%-CI	[36,6-65,2]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,48 [0,95-3,02]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,3 [21,1-53,5]
Month 6	18,7 [5,5-37,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS05: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Region
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
Patients with events - n(%)	48 (60,8)
95%-CI	[49,1-71,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,48-2,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	31,7 [20,0-44,1]
Month 6	21,6 [11,2-34,3]
Month 12	5,8 [0,5-21,3]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS06: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage
 PRO set

4.13.6 Merkmal: Krankheitsstadium nach Ann-Arbor

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Ann Arbor stage:	
Stage I	
Patients in analysis set	10
Patients with events - n(%)	5 (50,0)
95%-CI	[18,7-81,3]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,71[0,95-11,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	50,0 [11,1-80,4]
Month 6	33,3 [4,6-67,6]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS06: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
Patients with events - n(%)	8 (38,1)
95%-CI	[18,1-61,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	3,02 [1,41-NE]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	52,6 [24,3-74,7]
Month 6	42,1 [15,3-67,1]
Month 12	42,1 [15,3-67,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS06: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
Patients with events - n(%)	12 (70,6)
95%-CI	[44,0-89,7]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,08 [0,72-4,40]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	25,0 [6,2-50,1]
Month 6	12,5 [0,9-39,7]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS06: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
Patients with events - n(%)	49 (59,8)
95%-CI	[48,3-70,4]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,64 [1,41-2,14]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	27,7 [16,3-40,3]
Month 6	15,4 [6,3-28,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS07: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Bulky disease
 PRO set

4.13.7 *Merkmal: Bulky Erkrankung*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Bulky disease:	
No	
Patients in analysis set	126
Patients with events - n(%)	73 (57,9)
95%-CI	[48,8-66,7]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,04 [1,48-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,9 [23,2-43,0]
Month 6	20,7 [12,1-31,0]
Month 12	6,0 [0,6-21,5]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS08: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup:
 Double/Triple hit
 PRO set

4.13.8 *Merkmal: Double/Triple-Hit*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
Patients with events - n(%)	7 (50,0)
95%-CI	[23,0-77,0]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,64[0,72-NE]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	NE
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS08: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup:
 Double/Triple hit
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
Patients with events - n(%)	67 (57,8)
95%-CI	[48,2-66,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,48-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,6 [24,3-45,1]
Month 6	21,8 [12,7-32,5]
Month 12	6,4 [0,6-22,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS09: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Transformed DLBCL PRO set

4.13.9 Merkmal: Transformation des DLBCL

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
---	-----------------------------------

Transformed DLBCL:	
Transformed	
Patients in analysis set	24
Patients with events - n(%)	16 (66,7)
95%-CI	[44,7-84,4]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,64 [0,92-2,30]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	18,6 [4,7-39,5]
Month 6	18,6 [4,7-39,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS09: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Transformed DLBCL PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
Patients with events - n(%)	58 (54,7)
95%-CI	[44,8-64,4]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,45-2,99]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,9 [25,7-48,2]
Month 6	20,9 [11,1-32,8]
Month 12	8,7 [1,0-27,1]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable. DLBCL = Diffuse large B-Cell Lymphoma.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS10: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: B-Cell type
 PRO set

4.13.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
Patients with events - n(%)	24 (55,8)
95%-CI	[39,9-70,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,14 [1,41-6,08]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	41,0 [24,5-56,9]
Month 6	35,9 [19,3-52,8]
Month 12	15,0 [1,5-42,4]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS10: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: B-Cell type
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
Patients with events - n(%)	12 (57,1)
95%-CI	[34,0-78,2]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,79 [1,38-3,75]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	46,7 [22,1-68,1]
Month 6	18,7 [3,3-43,9]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS11: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter
 PRO set

4.13.11 Merkmal: Maximaler längster Durchmesser

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
Patients with events - n(%)	43 (56,6)
95%-CI	[44,7-67,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,33 [1,45-3,02]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,2 [24,2-50,1]
Month 6	25,3 [13,3-39,2]
Month 12	7,0 [0,6-24,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS11: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
Patients with events - n(%)	23 (67,6)
95%-CI	[49,5-82,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,48 [1,38-2,17]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	29,6 [13,9-47,3]
Month 6	14,8 [4,0-32,2]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS11: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter
PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:

> 7,5 cm - <= 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS11: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter
PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:
> 10 cm

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS12: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Primary disease diagnosis
 PRO set

4.13.12 Merkmal: Primärdiagnose

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Primary disease diagnosis

Loncastuximab tesirine
 Data-cut 3

Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
Patients with events - n(%)	63 (56,3)
95%-CI	[46,6-65,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,58-2,83]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	37,1 [26,4-47,9]
Month 6	23,4 [13,7-34,6]
Month 12	6,8 [0,7-23,8]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS12: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Primary disease diagnosis
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
Patients with events - n(%)	8 (72,7)
95%-CI	[39,0-94,0]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,38 [0,72-2,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	[NE-NE]
Month 6	[NE-NE]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS13: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Number prior lines
 PRO set

4.13.13 Merkmal: Anzahl der vorherigen systemischen Therapien

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Number prior lines:	
2 lines	
Patients in analysis set	59
Patients with events - n(%)	39 (66,1)
95%-CI	[52,6-77,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,64 [1,41-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,5 [20,1-47,4]
Month 6	20,7 [9,3-35,2]
Month 12	5,5 [0,5-20,9]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS13: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Number prior lines
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Number prior lines
 Loncastuximab tesirine
 Data-cut 3

Number prior lines:	
3 lines	
Patients in analysis set	32
Patients with events - n(%)	14 (43,8)
95%-CI	[26,4-62,3]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10[1,41-NE]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,8 [14,1-55,0]
Month 6	33,8 [14,1-55,0]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS13: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Number prior lines
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Number prior lines:	
> 3 lines	
Patients in analysis set	39
Patients with events - n(%)	21 (53,8)
95%-CI	[37,2-69,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,33 [0,82-3,35]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,6 [15,4-51,0]
Month 6	16,3 [4,4-34,8]
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS14: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - first line
 PRO set

4.13.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - first line

Loncastuximab tesirine
 Data-cut 3

Response category - first line:	
Relapse	
Patients in analysis set	92
Patients with events - n(%)	50 (54,3)
95%-CI	[43,6-64,8]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,14 [1,48-2,83]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	35,6 [23,6-47,7]
Month 6	22,2 [11,5-35,1]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS14: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - first line
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
Patients with events - n(%)	17 (77,3)
95%-CI	[54,6-92,2]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,45 [0,72-2,10]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	19,7 [5,2-40,9]
Month 6	13,1 [2,3-33,5]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS15: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - last line
 PRO set

4.13.15 *Merkmal: Ansprechkategorie auf die letzte vorherige systemische Therapie*

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - last line

	Loncastuximab tesirine
	Data-cut 3

Response category - last line:

Relapse

Patients in analysis set

40

Patients with events - n(%)

24 (60,0)

95%-CI

[43,3-75,1]

FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]

Median

1,48 [0,95-2,79]

FACT-Lym question bothered by side effects - Time to increase by at least 1 point:

Status at specific timepoints KM-estimate [95%-CI]

Month 3

24,3 [10,1-41,9]

Month 6

24,3 [10,1-41,9]

Month 12

9,1 [0,9-30,0]

Month 18

NE

Month 24

NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS15: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - last line
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - last line

Loncastuximab tesirine
 Data-cut 3

Response category - last line:	
Refractory	
Patients in analysis set	79
Patients with events - n(%)	45 (57,0)
95%-CI	[45,3-68,1]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,71 [1,48-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	32,5 [20,2-45,3]
Month 6	18,0 [8,1-31,2]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS16: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - any line
 PRO set

4.13.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
Patients with events - n(%)	17 (81,0)
95%-CI	[58,1-94,6]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	1,58 [0,72-2,17]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	25,4 [8,4-46,8]
Month 6	12,7 [2,2-32,8]
Month 12	[NE-NE]
Month 18	[NE-NE]
Month 24	[NE-NE]

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS16: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - any line
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Response category - any line

	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Response category - any line:	
Refractory	
Patients in analysis set	104
Patients with events - n(%)	55 (52,9)
95%-CI	[42,8-62,8]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,48-2,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	34,4 [23,1-46,0]
Month 6	22,4 [12,2-34,6]
Month 12	9,6 [1,2-29,2]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS17: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Prior use of T-CART therapy
PRO set

4.13.17 Merkmal: Vorherige CAR-T-Therapie

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Prior use of T-CART therapy:

Yes

Patients in analysis set

<10

Subgroup level is not displayed due to few patients

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.

PRO = patient reported outcome.

Confidence interval for event rate: exact Clopper-Pearson method.

Confidence interval for Median: Brookmeyer Crowley.

Confidence interval for time point estimates: via log-log transformation of rates.

Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS17: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Prior use of T-CART therapy
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
Patients with events - n(%)	70 (57,4)
95%-CI	[48,1-66,3]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,04 [1,48-2,33]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	33,6 [23,6-44,0]
Month 6	20,5 [11,6-31,1]
Month 12	5,8 [0,6-21,0]
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS18: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Drug formulation
 PRO set

4.13.18 Merkmal: Arzneimittelformulierung

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Drug formulation:	
Frozen liquid	
Patients in analysis set	32
Patients with events - n(%)	20 (62,5)
95%-CI	[43,7-78,9]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,04 [1,41-2,99]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	24,9 [9,2-44,4]
Month 6	NE
Month 12	NE
Month 18	NE
Month 24	NE

Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAD_PSTS18: Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Drug formulation
 PRO set

Time to first increase in FACT-Lym question bothered by side effects by at least 1 point by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
Patients with events - n(%)	54 (55,1)
95%-CI	[44,7-65,2]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point in months [95%-CI]	
Median	2,10 [1,45-2,79]
FACT-Lym question bothered by side effects - Time to increase by at least 1 point:	
Status at specific timepoints KM-estimate [95%-CI]	
Month 3	36,1 [24,6-47,8]
Month 6	22,7 [12,5-34,6]
Month 12	6,6 [0,6-23,4]
Month 18	NE
Month 24	NE

 Note: n = number of patients with events. 95% CI = 95% confidence intervals. NE = Not evaluable.
 PRO = patient reported outcome.
 Confidence interval for event rate: exact Clopper-Pearson method.
 Confidence interval for Median: Brookmeyer Crowley.
 Confidence interval for time point estimates: via log-log transformation of rates.
 Source Data: aqs_tte, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

4.14 Subgruppenanalysen zum FACT-G GP5 (Veränderung gegenüber Studienbeginn)

4.14.1 Merkmal Alter

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
Patients in analysis set	57
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	57
Treated patients with non-missing values - n(%)	50 (87,7)
Mean (SD)	0,76 (1,06)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	40 (81,6)
Mean (SD)	0,30 (1,09)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	37
Treated patients with non-missing values - n(%)	28 (75,7)
Mean (SD)	0,43 (0,96)
Median (Min - Max)	0,50 [-2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	22 (78,6)

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Mean (SD)	0,77 (1,15)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	1,00 (1,14)
Median (Min - Max)	1,00 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	1,23 (1,42)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	1,17 (1,19)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	1,11 (1,36)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	1,33 (1,21)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	1,50 (1,00)
Median (Min - Max)	1,00 [1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
< 65 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	0,67 (0,58)
Median (Min - Max)	1,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

Age group:

< 65 years

FACT-Lym question bothered by side effects - Change from
baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

39 (68,4)

Mean (SD)

0,79 (1,56)

Median (Min - Max)

1,00 [-4,00-3,00]

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
Patients in analysis set	53
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	49 (92,5)
Mean (SD)	0,53 (0,94)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	48
Treated patients with non-missing values - n(%)	41 (85,4)
Mean (SD)	0,02 (0,99)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	27 (79,4)
Mean (SD)	0,44 (1,25)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	22 (84,6)
Mean (SD)	0,73 (1,24)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	17

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	15 (88,2)
Mean (SD)	0,40 (0,63)
Median (Min - Max)	0,00 [-1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,50 (0,97)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,13 (0,83)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,83 (1,17)
Median (Min - Max)	0,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,17 (1,17)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (1,53)
Median (Min - Max)	0,00 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (1,29)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (1,15)
Median (Min - Max)	1,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
65 to < 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: 65 to < 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	39 (73,6)
Mean (SD)	0,72 (1,02)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
Patients in analysis set	20
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	0,39 (0,70)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	0,31 (0,79)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	11 (73,3)
Mean (SD)	-0,09 (0,83)
Median (Min - Max)	0,00 [-2,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	8 (61,5)
Mean (SD)	0,63 (1,19)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,88 (0,99)
Median (Min - Max)	0,50 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,83 (1,17)
Median (Min - Max)	0,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,20 (0,84)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,50 (0,58)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,00 (0,82)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	0,00 (0,00)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	0,00 (0,00)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group:	
>= 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS01: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Age group	Loncastuximab tesirine Data-cut 3
Age group: >= 75 years	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	12 (60,0)
Mean (SD)	0,50 (1,38)
Median (Min - Max)	0,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

4.14.2 Merkmal: Geschlecht

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
Patients in analysis set	53
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	53
Treated patients with non-missing values - n(%)	43 (81,1)
Mean (SD)	0,74 (1,05)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	33 (71,7)
Mean (SD)	0,06 (1,03)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	25 (69,4)
Mean (SD)	0,28 (1,17)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	28
Treated patients with non-missing values - n(%)	17 (60,7)
Mean (SD)	0,53 (1,07)
Median (Min - Max)	0,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	23
Treated patients with non-missing values - n(%)	18 (78,3)
Mean (SD)	0,78 (0,94)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	15 (71,4)
Mean (SD)	0,67 (1,23)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	15 (78,9)
Mean (SD)	0,47 (1,13)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	10 (62,5)
Mean (SD)	0,90 (1,20)
Median (Min - Max)	0,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	10 (71,4)
Mean (SD)	0,40 (1,35)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	6 (50,0)
Mean (SD)	0,50 (1,05)
Median (Min - Max)	0,50 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	0,43 (0,98)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	5 (45,5)
Mean (SD)	0,40 (1,14)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	0,40 (0,55)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Female	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	35 (66,0)
Mean (SD)	0,63 (1,21)
Median (Min - Max)	1,00 [-2,00-3,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
Patients in analysis set	77
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	77
Treated patients with non-missing values - n(%)	74 (96,1)
Mean (SD)	0,53 (0,91)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	70
Treated patients with non-missing values - n(%)	64 (91,4)
Mean (SD)	0,25 (0,99)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	50
Treated patients with non-missing values - n(%)	41 (82,0)
Mean (SD)	0,39 (1,02)
Median (Min - Max)	0,00 [-2,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	39
Treated patients with non-missing values - n(%)	35 (89,7)
Mean (SD)	0,83 (1,22)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	26

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	0,74 (1,01)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	1,14 (1,23)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	0,90 (1,10)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,89 (1,17)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,83 (0,98)
Median (Min - Max)	0,50 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (1,53)
Median (Min - Max)	1,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS02: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Sex	Loncastuximab tesirine Data-cut 3
Sex:	
Male	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	55 (71,4)
Mean (SD)	0,78 (1,38)
Median (Min - Max)	1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

4.14.3 Merkmal: Ethnie

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
Patients in analysis set	115
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	115
Treated patients with non-missing values - n(%)	103 (89,6)
Mean (SD)	0,56 (0,89)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	104
Treated patients with non-missing values - n(%)	86 (82,7)
Mean (SD)	0,17 (0,95)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	74
Treated patients with non-missing values - n(%)	57 (77,0)
Mean (SD)	0,35 (1,09)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	56
Treated patients with non-missing values - n(%)	42 (75,0)
Mean (SD)	0,64 (1,06)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	41
Treated patients with non-missing values - n(%)	34 (82,9)
Mean (SD)	0,79 (0,95)
Median (Min - Max)	1,00 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	24 (80,0)
Mean (SD)	0,96 (1,23)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	0,75 (1,12)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	16 (72,7)
Mean (SD)	1,13 (1,09)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	15 (78,9)
Mean (SD)	0,60 (1,24)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	14

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (57,1)
Mean (SD)	0,88 (1,25)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	0,50 (0,93)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	6 (50,0)
Mean (SD)	0,33 (1,03)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	0,40 (0,55)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
White	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	79 (68,7)
Mean (SD)	0,72 (1,20)
Median (Min - Max)	1,00 [-2,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
Patients in analysis set	15
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	0,93 (1,38)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	11 (91,7)
Mean (SD)	0,27 (1,42)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	0,33 (1,00)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	1,10 (1,60)
Median (Min - Max)	0,50 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	8

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	0,57 (1,13)
Median (Min - Max)	0,00 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,60 (1,34)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,20 (1,10)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	-0,33 (0,58)
Median (Min - Max)	0,00 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS03: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Race group	Loncastuximab tesirine Data-cut 3
Race group:	
Non-white	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	11 (73,3)
Mean (SD)	0,73 (2,05)
Median (Min - Max)	1,00 [-4,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

4.14.4 Merkmal: Region-1

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
Patients in analysis set	51
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	46 (90,2)
Mean (SD)	0,72 (1,09)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	39 (86,7)
Mean (SD)	0,26 (1,33)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	25 (75,8)
Mean (SD)	0,48 (1,23)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	21 (77,8)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	15 (75,0)
Mean (SD)	0,93 (0,96)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	13 (76,5)
Mean (SD)	1,15 (1,41)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	0,67 (1,32)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,43 (1,27)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (1,73)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,25 (0,96)
Median (Min - Max)	0,50 [-1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,25 (0,96)
Median (Min - Max)	0,50 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (1,29)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	31 (60,8)
Mean (SD)	0,77 (1,28)
Median (Min - Max)	1,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
Patients in analysis set	29
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	29
Treated patients with non-missing values - n(%)	29 (100,0)
Mean (SD)	0,76 (1,09)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	24
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	0,00 (0,56)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	9 (56,3)
Mean (SD)	-0,33 (1,12)
Median (Min - Max)	0,00 [-2,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,30 (0,82)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	9 (90,0)
Mean (SD)	0,22 (0,67)
Median (Min - Max)	0,00 [-1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	6 (85,7)
Mean (SD)	0,33 (0,82)
Median (Min - Max)	0,50 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,17 (1,17)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,67 (0,58)
Median (Min - Max)	1,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	-0,20 (0,84)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
UK	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	25 (86,2)
Mean (SD)	0,32 (1,57)
Median (Min - Max)	0,00 [-4,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
Patients in analysis set	48
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	48
Treated patients with non-missing values - n(%)	40 (83,3)
Mean (SD)	0,38 (0,67)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	46
Treated patients with non-missing values - n(%)	37 (80,4)
Mean (SD)	0,22 (0,79)
Median (Min - Max)	0,00 [-2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	31 (86,1)
Mean (SD)	0,45 (0,89)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	21 (80,8)
Mean (SD)	0,67 (1,02)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	18

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	0,88 (1,09)
Median (Min - Max)	1,00 [0,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,90 (1,20)
Median (Min - Max)	1,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,90 (0,88)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	1,33 (1,12)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	1,14 (0,90)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	1,50 (1,29)
Median (Min - Max)	1,50 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	0,75 (0,96)
Median (Min - Max)	0,50 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	4

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,33 (1,15)
Median (Min - Max)	2,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS04: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Country	Loncastuximab tesirine Data-cut 3
Country:	
Italy	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	32 (66,7)
Mean (SD)	1,00 (1,11)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

4.14.5 *Merkmal: Region-2*

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
Patients in analysis set	51
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	51
Treated patients with non-missing values - n(%)	46 (90,2)
Mean (SD)	0,72 (1,09)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	45
Treated patients with non-missing values - n(%)	39 (86,7)
Mean (SD)	0,26 (1,33)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	25 (75,8)
Mean (SD)	0,48 (1,23)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	27
Treated patients with non-missing values - n(%)	21 (77,8)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	20
Treated patients with non-missing values - n(%)	15 (75,0)
Mean (SD)	0,93 (0,96)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	17
Treated patients with non-missing values - n(%)	13 (76,5)
Mean (SD)	1,15 (1,41)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	9 (81,8)
Mean (SD)	0,67 (1,32)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	7 (77,8)
Mean (SD)	0,43 (1,27)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (1,73)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,25 (0,96)
Median (Min - Max)	0,50 [-1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,25 (0,96)
Median (Min - Max)	0,50 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (1,29)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	31 (60,8)
Mean (SD)	0,77 (1,28)
Median (Min - Max)	1,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
Patients in analysis set	79
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	71 (89,9)
Mean (SD)	0,54 (0,88)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	71
Treated patients with non-missing values - n(%)	58 (81,7)
Mean (SD)	0,14 (0,71)
Median (Min - Max)	0,00 [-2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	53
Treated patients with non-missing values - n(%)	41 (77,4)
Mean (SD)	0,27 (0,98)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	31 (77,5)
Mean (SD)	0,55 (0,96)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	26 (89,7)
Mean (SD)	0,65 (0,98)
Median (Min - Max)	0,50 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	0,69 (1,08)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	16 (88,9)
Mean (SD)	0,63 (1,02)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	1,17 (1,03)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	0,58 (1,08)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	9

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	1,20 (1,30)
Median (Min - Max)	1,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	0,60 (0,89)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	0,40 (0,55)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS05: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Region	Loncastuximab tesirine Data-cut 3
Region:	
Non-USA	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	59 (74,7)
Mean (SD)	0,69 (1,34)
Median (Min - Max)	1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

4.14.6 Merkmal: Krankheitsstadium nach Ann-Arbor

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
Patients in analysis set	10
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,75 (1,04)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,33 (1,03)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	1,00 (0,00)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	0,00 (1,00)
Median (Min - Max)	0,00 [-1,00-1,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-0,50 (0,71)
Median (Min - Max)	-0,50 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-0,50 (0,71)
Median (Min - Max)	-0,50 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	-0,50 (0,71)
Median (Min - Max)	-0,50 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage I	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	5 (50,0)
Mean (SD)	1,00 (1,87)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
Patients in analysis set	21
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,68 (1,06)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	20
Treated patients with non-missing values - n(%)	18 (90,0)
Mean (SD)	-0,11 (0,96)
Median (Min - Max)	0,00 [-2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,36 (1,21)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,50 (1,35)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	9

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,67 (1,41)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,17 (1,94)
Median (Min - Max)	0,50 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,80 (1,48)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,80 (1,48)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,00 (1,00)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage II	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	15 (71,4)
Mean (SD)	0,53 (0,92)
Median (Min - Max)	0,00 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
Patients in analysis set	17
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,50 (0,82)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	14 (93,3)
Mean (SD)	0,43 (0,76)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,50 (1,08)
Median (Min - Max)	1,00 [-2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	9 (100,0)
Mean (SD)	0,56 (0,88)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	7

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	0,86 (0,69)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,20 (1,10)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,20 (1,10)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,67 (1,15)
Median (Min - Max)	1,00 [1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage III	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	12 (70,6)
Mean (SD)	1,33 (1,56)
Median (Min - Max)	2,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
Patients in analysis set	82
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	82
Treated patients with non-missing values - n(%)	74 (90,2)
Mean (SD)	0,59 (0,98)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	72
Treated patients with non-missing values - n(%)	59 (81,9)
Mean (SD)	0,20 (1,06)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	54
Treated patients with non-missing values - n(%)	42 (77,8)
Mean (SD)	0,31 (1,09)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	42
Treated patients with non-missing values - n(%)	31 (73,8)
Mean (SD)	0,84 (1,24)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	29

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	22 (75,9)
Mean (SD)	0,86 (0,83)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	16 (72,7)
Mean (SD)	0,88 (0,96)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	0,54 (0,97)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	14
Treated patients with non-missing values - n(%)	10 (71,4)
Mean (SD)	0,80 (1,03)
Median (Min - Max)	0,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	0,44 (1,13)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	10

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	5 (62,5)
Mean (SD)	0,40 (1,14)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	5 (62,5)
Mean (SD)	0,20 (0,84)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (0,58)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	1 (20,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS06: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Ann Arbor stage	Loncastuximab tesirine Data-cut 3
Ann Arbor stage:	
Stage IV	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	58 (70,7)
Mean (SD)	0,62 (1,30)
Median (Min - Max)	1,00 [-4,00-3,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

4.14.7 *Merkmal: Bulky Erkrankung*

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
Patients in analysis set	126
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	126
Treated patients with non-missing values - n(%)	114 (90,5)
Mean (SD)	0,61 (0,97)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	113
Treated patients with non-missing values - n(%)	95 (84,1)
Mean (SD)	0,19 (1,01)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	85
Treated patients with non-missing values - n(%)	66 (77,6)
Mean (SD)	0,35 (1,07)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	51 (77,3)
Mean (SD)	0,75 (1,18)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	49
Treated patients with non-missing values - n(%)	41 (83,7)
Mean (SD)	0,76 (0,97)
Median (Min - Max)	1,00 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	36
Treated patients with non-missing values - n(%)	29 (80,6)
Mean (SD)	0,90 (1,23)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	29
Mean (SD)	25 (86,2)
Median (Min - Max)	0,64 (1,11)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	25
Mean (SD)	19 (76,0)
Median (Min - Max)	0,89 (1,15)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	16 (80,0)
Median (Min - Max)	0,56 (1,21)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
	15

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	9 (60,0)
Mean (SD)	0,78 (1,20)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	0,44 (0,88)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	7 (53,8)
Mean (SD)	0,43 (0,98)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	0,33 (0,52)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS07: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Bulky disease	Loncastuximab tesirine Data-cut 3
Bulky disease:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	89 (70,6)
Mean (SD)	0,72 (1,32)
Median (Min - Max)	1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

4.14.8 *Merkmal: Double/Triple-Hit*

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
Patients in analysis set	14
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	0,58 (0,79)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	0,50 (1,35)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,33 (0,82)
Median (Min - Max)	0,50 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,75 (1,50)
Median (Min - Max)	0,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	1,75 (0,50)
Median (Min - Max)	2,00 [1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	1,33 (1,53)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	1,00 (0,00)
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	0,50 (0,71)
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	2
Mean (SD)	1 (50,0)
Median (Min - Max)	0,00 (NE)
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
Treated patients with non-missing values - n(%)	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
Yes	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	7 (50,0)
Mean (SD)	1,00 (1,00)
Median (Min - Max)	1,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
Patients in analysis set	116
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	116
Treated patients with non-missing values - n(%)	105 (90,5)
Mean (SD)	0,61 (0,99)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	104
Mean (SD)	87 (83,7)
Median (Min - Max)	0,15 (0,96)
	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	78
Mean (SD)	60 (76,9)
Median (Min - Max)	0,35 (1,10)
	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	60
Mean (SD)	48 (80,0)
Median (Min - Max)	0,73 (1,16)
	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	43

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	37 (86,0)
Mean (SD)	0,65 (0,95)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	26 (83,9)
Mean (SD)	0,85 (1,22)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	23 (88,5)
Median (Min - Max)	0,61 (1,16)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	17 (77,3)
Median (Min - Max)	0,94 (1,20)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	15 (83,3)
Median (Min - Max)	0,60 (1,24)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
	13

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (61,5)
Mean (SD)	0,75 (1,28)
Median (Min - Max)	0,50 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,38 (0,92)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	6 (54,5)
Mean (SD)	0,50 (1,05)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,33 (0,52)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS08: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Double/Triple hit	Loncastuximab tesirine Data-cut 3
Double/Triple hit:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	83 (71,6)
Mean (SD)	0,70 (1,34)
Median (Min - Max)	1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

4.14.9 *Merkmal: Transformation des DLBCL*

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
Patients in analysis set	24
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	24
Treated patients with non-missing values - n(%)	23 (95,8)
Mean (SD)	0,57 (1,12)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,11 (0,88)
Median (Min - Max)	0,00 [-2,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	16
Treated patients with non-missing values - n(%)	14 (87,5)
Mean (SD)	0,71 (1,20)
Median (Min - Max)	0,50 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	1,30 (1,34)
Median (Min - Max)	1,00 [0,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	0,50 (0,85)
Median (Min - Max)	0,50 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,00 (0,71)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,00 (0,71)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,60 (1,52)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,00 (1,00)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	0,00 (0,00)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (0,71)
Median (Min - Max)	1,50 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
Transformed	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (79,2)
Mean (SD)	0,63 (1,61)
Median (Min - Max)	0,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
Patients in analysis set	106
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	106
Treated patients with non-missing values - n(%)	94 (88,7)
Mean (SD)	0,62 (0,93)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	95
Mean (SD)	78 (82,1)
Median (Min - Max)	0,21 (1,04)
	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	70
Mean (SD)	52 (74,3)
Median (Min - Max)	0,25 (1,03)
	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	54
Mean (SD)	42 (77,8)
Median (Min - Max)	0,60 (1,11)
	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	39

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	31 (79,5)
Mean (SD)	0,84 (1,00)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	24 (77,4)
Mean (SD)	1,08 (1,25)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	24
Mean (SD)	20 (83,3)
Median (Min - Max)	0,80 (1,15)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	20
Mean (SD)	14 (70,0)
Median (Min - Max)	1,00 (1,04)
	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	13 (76,5)
Median (Min - Max)	0,54 (1,27)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
	12

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	6 (50,0)
Mean (SD)	0,67 (1,37)
Median (Min - Max)	0,50 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	0,33 (0,82)
Median (Min - Max)	0,50 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	10
Treated patients with non-missing values - n(%)	4 (40,0)
Mean (SD)	0,50 (1,29)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	1 (25,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS09: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Transformed DLBCL	Loncastuximab tesirine Data-cut 3
Transformed DLBCL:	
De novo	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	71 (67,0)
Mean (SD)	0,75 (1,24)
Median (Min - Max)	1,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment. DLBCL = Diffuse large B-Cell Lymphoma.
 PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

4.14.10 Merkmal: Keimfähige B-Zellen und aktivierte B-Zellen

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
Patients in analysis set	43
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	43
Treated patients with non-missing values - n(%)	40 (93,0)
Mean (SD)	0,50 (0,78)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	40
Treated patients with non-missing values - n(%)	34 (85,0)
Mean (SD)	0,18 (0,76)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	30
Treated patients with non-missing values - n(%)	23 (76,7)
Mean (SD)	0,26 (0,96)
Median (Min - Max)	0,00 [-2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	21 (77,8)
Mean (SD)	1,00 (1,38)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	0,69 (1,25)
Median (Min - Max)	0,50 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	13 (81,3)
Mean (SD)	0,85 (1,46)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	13 (92,9)
Mean (SD)	0,62 (1,39)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	12
Treated patients with non-missing values - n(%)	9 (75,0)
Mean (SD)	0,89 (1,36)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	0,57 (1,51)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Germinal center B-cell	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	1,50 (0,71)
Median (Min - Max)	1,50 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	EOT
Treated patients with non-missing values - n(%)	NE
Mean (SD)	32 (74,4)
Median (Min - Max)	0,72 (1,35)
	1,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
Patients in analysis set	21
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	20 (95,2)
Mean (SD)	0,65 (0,88)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	16 (88,9)
Median (Min - Max)	0,00 (0,89)
	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	16
Mean (SD)	13 (81,3)
Median (Min - Max)	0,46 (1,05)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	11 (91,7)
Median (Min - Max)	0,18 (0,60)
	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	9

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (88,9)
Mean (SD)	0,50 (0,76)
Median (Min - Max)	0,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	5 (83,3)
Mean (SD)	0,60 (0,89)
Median (Min - Max)	1,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,33 (1,15)
Median (Min - Max)	1,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,00 (1,00)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (1,53)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,00 (2,83)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
B-cell type:	
Activated B-cell	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,00 (1,41)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS10: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: B-Cell type	Loncastuximab tesirine Data-cut 3
---	--------------------------------------

B-cell type:	
Activated B-cell	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	15 (71,4)
Mean (SD)	0,67 (0,98)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

4.14.11 Merkmal: Maximaler längster Durchmesser

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
Patients in analysis set	76
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	76
Treated patients with non-missing values - n(%)	69 (90,8)
Mean (SD)	0,62 (1,09)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	69
Treated patients with non-missing values - n(%)	59 (85,5)
Mean (SD)	0,19 (0,99)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	57
Treated patients with non-missing values - n(%)	46 (80,7)
Mean (SD)	0,33 (1,16)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	36 (83,7)
Mean (SD)	0,64 (1,10)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	0,66 (0,77)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	25
Treated patients with non-missing values - n(%)	22 (88,0)
Mean (SD)	0,86 (1,08)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,53 (0,90)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	15 (83,3)
Mean (SD)	0,80 (1,15)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	11 (84,6)
Mean (SD)	0,64 (1,21)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	12

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	1,00 (1,07)
Median (Min - Max)	1,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,63 (0,74)
Median (Min - Max)	0,50 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	0,67 (0,82)
Median (Min - Max)	0,50 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,33 (0,52)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
<= 5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 23 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 24 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 25 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: <= 5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	54 (71,1)
Mean (SD)	0,69 (1,50)
Median (Min - Max)	0,50 [-4,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
>5 - <= 7,5 cm	
Patients in analysis set	34
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	34
Treated patients with non-missing values - n(%)	33 (97,1)
Mean (SD)	0,61 (0,79)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	32
Treated patients with non-missing values - n(%)	29 (90,6)
Mean (SD)	0,17 (1,07)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	16 (84,2)
Mean (SD)	0,63 (0,81)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	12 (75,0)
Mean (SD)	1,17 (1,34)
Median (Min - Max)	1,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	12

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	10 (83,3)
Mean (SD)	1,10 (1,45)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: >5 - <= 7,5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	7 (87,5)
Mean (SD)	1,00 (1,73)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,00 (1,67)
Median (Min - Max)	1,50 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,25 (1,26)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,40 (1,34)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: >5 - <= 7,5 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	-1,00 (NE)
Median (Min - Max)	-1,00 [-1,00--1,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	27 (79,4)
Mean (SD)	0,85 (1,06)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 7,5 cm - <= 10 cm	
Patients in analysis set	9
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,17 (0,41)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	-0,33 (0,58)
Median (Min - Max)	0,00 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	2 (33,3)
Mean (SD)	-0,50 (0,71)
Median (Min - Max)	-0,50 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter: > 7,5 cm - <= 10 cm	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	3 (33,3)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Maximal longest diameter:	
> 10 cm	
Patients in analysis set	7
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	7
Treated patients with non-missing values - n(%)	7 (100,0)
Mean (SD)	0,86 (0,90)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	0,20 (0,84)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (0,71)
Median (Min - Max)	-0,50 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	-0,50 (0,71)
Median (Min - Max)	-0,50 [-1,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS11: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Maximal longest diameter	Loncastuximab tesirine Data-cut 3
--	--------------------------------------

Maximal longest diameter:
> 10 cm

FACT-Lym question bothered by side effects - Change from
baseline

EOT

Treated patients at visit

NE

Treated patients with non-missing values - n(%)

5 (71,4)

Mean (SD)

0,60 (0,55)

Median (Min - Max)

1,00 [0,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.

Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

4.14.12 Merkmal: Primärdiagnose

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
Patients in analysis set	112
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	112
Treated patients with non-missing values - n(%)	102 (91,1)
Mean (SD)	0,62 (0,98)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	101
Treated patients with non-missing values - n(%)	86 (85,1)
Mean (SD)	0,12 (0,95)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	78
Treated patients with non-missing values - n(%)	60 (76,9)
Mean (SD)	0,32 (1,11)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	60
Treated patients with non-missing values - n(%)	49 (81,7)
Mean (SD)	0,71 (1,15)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	43
Treated patients with non-missing values - n(%)	37 (86,0)
Mean (SD)	0,65 (0,95)
Median (Min - Max)	1,00 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	26 (83,9)
Mean (SD)	0,85 (1,22)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	26
Treated patients with non-missing values - n(%)	23 (88,5)
Mean (SD)	0,61 (1,16)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	22
Treated patients with non-missing values - n(%)	17 (77,3)
Mean (SD)	0,94 (1,20)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	18
Treated patients with non-missing values - n(%)	15 (83,3)
Mean (SD)	0,60 (1,24)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	13

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (61,5)
Mean (SD)	0,75 (1,28)
Median (Min - Max)	0,50 [-1,00-3,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,38 (0,92)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	6 (54,5)
Mean (SD)	0,50 (1,05)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,33 (0,52)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
DBLCL NOS	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	79 (70,5)
Mean (SD)	0,68 (1,31)
Median (Min - Max)	1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
Patients in analysis set	11
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,40 (0,70)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	9 (90,0)
Median (Min - Max)	0,67 (1,32)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	5 (83,3)
Median (Min - Max)	0,60 (0,55)
	1,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	6
Mean (SD)	3 (50,0)
Median (Min - Max)	1,00 (1,73)
	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	6

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	1,75 (0,50)
Median (Min - Max)	2,00 [1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	1,33 (1,53)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,00 (0,00)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Primary disease diagnosis:	
HGBL	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS12: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Primary disease diagnosis	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	1,00 (0,93)
Median (Min - Max)	1,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

4.14.13 Merkmal: Anzahl der vorherigen systemischen Therapien

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
Patients in analysis set	59
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	59
Treated patients with non-missing values - n(%)	56 (94,9)
Mean (SD)	0,55 (0,89)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	52
Treated patients with non-missing values - n(%)	45 (86,5)
Mean (SD)	0,16 (0,98)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	38
Treated patients with non-missing values - n(%)	27 (71,1)
Mean (SD)	0,11 (1,12)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	29
Treated patients with non-missing values - n(%)	22 (75,9)
Mean (SD)	0,45 (0,80)
Median (Min - Max)	0,00 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	17 (77,3)
Mean (SD)	0,53 (0,72)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	15 (78,9)
Mean (SD)	0,60 (0,91)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	15 (93,8)
Mean (SD)	0,47 (0,83)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	10 (76,9)
Mean (SD)	0,90 (0,88)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,30 (0,95)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	7

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,75 (0,96)
Median (Min - Max)	0,50 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	0,60 (0,89)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	5 (71,4)
Mean (SD)	0,40 (0,55)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 17 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 18 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 19 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 20 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
2 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	44 (74,6)
Mean (SD)	0,95 (1,24)
Median (Min - Max)	1,00 [-2,00-3,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
Patients in analysis set	32
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	28 (87,5)
Mean (SD)	0,50 (0,92)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	30
Mean (SD)	24 (80,0)
Median (Min - Max)	0,21 (1,02)
	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	21
Mean (SD)	17 (81,0)
Median (Min - Max)	0,59 (1,18)
	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	15
Mean (SD)	14 (93,3)
Median (Min - Max)	1,36 (1,78)
	0,50 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	10

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	10 (100,0)
Mean (SD)	1,20 (1,40)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	1,67 (1,75)
Median (Min - Max)	1,50 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,75 (1,71)
Median (Min - Max)	0,50 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,00 (1,83)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (1,15)
Median (Min - Max)	2,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
3 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (59,4)
Mean (SD)	0,47 (1,12)
Median (Min - Max)	0,00 [-2,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
Patients in analysis set	39
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	39
Treated patients with non-missing values - n(%)	33 (84,6)
Mean (SD)	0,79 (1,11)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	28 (82,4)
Mean (SD)	0,21 (1,07)
Median (Min - Max)	0,00 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	27
Treated patients with non-missing values - n(%)	22 (81,5)
Mean (SD)	0,45 (0,91)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	16 (69,6)
Mean (SD)	0,56 (0,73)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	17

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	14 (82,4)
Mean (SD)	0,71 (0,83)
Median (Min - Max)	0,50 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,88 (1,25)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	8
Treated patients with non-missing values - n(%)	5 (62,5)
Mean (SD)	0,80 (1,30)
Median (Min - Max)	0,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,67 (2,08)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	6

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (50,0)
Mean (SD)	0,33 (1,15)
Median (Min - Max)	1,00 [-1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Number prior lines:	
> 3 lines	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,33 (1,15)
Median (Min - Max)	1,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	0,33 (1,53)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS13: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Number prior lines	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	27 (69,2)
Mean (SD)	0,52 (1,53)
Median (Min - Max)	0,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

4.14.14 Merkmal: Ansprechkategorie auf die vorherige systemische Erstlinientherapie

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
Patients in analysis set	92
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	92
Treated patients with non-missing values - n(%)	82 (89,1)
Mean (SD)	0,65 (1,02)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	86
Treated patients with non-missing values - n(%)	70 (81,4)
Mean (SD)	0,09 (0,99)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	66
Treated patients with non-missing values - n(%)	51 (77,3)
Mean (SD)	0,27 (1,17)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	49
Treated patients with non-missing values - n(%)	39 (79,6)
Mean (SD)	0,72 (1,23)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	34
Treated patients with non-missing values - n(%)	31 (91,2)
Mean (SD)	0,74 (1,00)
Median (Min - Max)	1,00 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	22 (84,6)
Mean (SD)	0,77 (1,23)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	23
Treated patients with non-missing values - n(%)	21 (91,3)
Mean (SD)	0,62 (1,16)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	19
Treated patients with non-missing values - n(%)	15 (78,9)
Mean (SD)	1,07 (1,22)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	14
Treated patients with non-missing values - n(%)	12 (85,7)
Mean (SD)	0,67 (1,37)
Median (Min - Max)	0,50 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	10

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [-1,00-3,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	9
Treated patients with non-missing values - n(%)	6 (66,7)
Mean (SD)	0,50 (1,05)
Median (Min - Max)	0,50 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	0,60 (1,14)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,50 (0,58)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	2 (40,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,33 (1,15)
Median (Min - Max)	2,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	61 (66,3)
Mean (SD)	0,57 (1,32)
Median (Min - Max)	0,00 [-4,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
Patients in analysis set	22
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	22
Treated patients with non-missing values - n(%)	21 (95,5)
Mean (SD)	0,48 (0,75)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	18
Mean (SD)	17 (94,4)
Median (Min - Max)	0,41 (1,12)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	8 (66,7)
Median (Min - Max)	0,63 (0,52)
	1,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	11
Mean (SD)	8 (72,7)
Median (Min - Max)	0,88 (0,83)
	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	8

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (50,0)
Mean (SD)	0,50 (0,58)
Median (Min - Max)	0,50 [0,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	3 (60,0)
Mean (SD)	1,33 (1,53)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	1,00 (1,41)
	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	0,50 (0,71)
	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	3
Mean (SD)	2 (66,7)
Median (Min - Max)	0,50 (0,71)
	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS14: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - first line	Loncastuximab tesirine Data-cut 3
Response category - first line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	18 (81,8)
Mean (SD)	1,22 (1,11)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

4.14.15 Merkmal: *Ansprechkategorie auf die letzte vorherige systemische Therapie*

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
Patients in analysis set	40
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	40
Treated patients with non-missing values - n(%)	35 (87,5)
Mean (SD)	0,40 (0,74)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	37
Treated patients with non-missing values - n(%)	29 (78,4)
Mean (SD)	0,52 (0,69)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	32
Treated patients with non-missing values - n(%)	25 (78,1)
Mean (SD)	0,56 (1,33)
Median (Min - Max)	0,00 [-2,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	25
Treated patients with non-missing values - n(%)	18 (72,0)
Mean (SD)	0,78 (1,35)
Median (Min - Max)	0,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	18
Treated patients with non-missing values - n(%)	14 (77,8)
Mean (SD)	0,86 (0,77)
Median (Min - Max)	1,00 [0,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	10 (66,7)
Mean (SD)	0,60 (1,17)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	13
Mean (SD)	10 (76,9)
Median (Min - Max)	0,20 (0,79)
	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	12
Mean (SD)	8 (66,7)
Median (Min - Max)	1,00 (1,07)
	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	10
Mean (SD)	7 (70,0)
Median (Min - Max)	0,43 (1,27)
	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
	9

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	0,80 (1,64)
Median (Min - Max)	0,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,25 (1,26)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (1,15)
Median (Min - Max)	1,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	4 (66,7)
Mean (SD)	0,50 (0,58)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	25 (62,5)
Mean (SD)	0,72 (1,54)
Median (Min - Max)	0,00 [-2,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
Patients in analysis set	79
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	79
Treated patients with non-missing values - n(%)	73 (92,4)
Mean (SD)	0,71 (1,07)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	68
Treated patients with non-missing values - n(%)	59 (86,8)
Mean (SD)	0,03 (1,11)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	45
Treated patients with non-missing values - n(%)	34 (75,6)
Mean (SD)	0,24 (0,92)
Median (Min - Max)	0,00 [-3,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	34
Treated patients with non-missing values - n(%)	29 (85,3)
Mean (SD)	0,83 (1,10)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	23

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	21 (91,3)
Mean (SD)	0,71 (1,15)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	15
Treated patients with non-missing values - n(%)	15 (100,0)
Mean (SD)	0,93 (1,33)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	13
Treated patients with non-missing values - n(%)	13 (100,0)
Mean (SD)	0,92 (1,32)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	10 (90,9)
Mean (SD)	0,90 (1,29)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	0,75 (1,28)
Median (Min - Max)	0,50 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	0,67 (0,58)
Median (Min - Max)	1,00 [0,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,50 (0,58)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	0,00 (0,00)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (1,15)
Median (Min - Max)	0,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,50 (0,71)
Median (Min - Max)	1,50 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS15: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - last line	Loncastuximab tesirine Data-cut 3
Response category - last line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	60 (75,9)
Mean (SD)	0,70 (1,25)
Median (Min - Max)	1,00 [-4,00-3,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

4.14.16 Merkmal: Ansprechkategorie auf eine beliebige vorherige systemische Therapie

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
Patients in analysis set	21
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	21
Treated patients with non-missing values - n(%)	21 (100,0)
Mean (SD)	0,48 (0,75)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	16
Treated patients with non-missing values - n(%)	16 (100,0)
Mean (SD)	0,19 (0,91)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	8 (72,7)
Mean (SD)	0,50 (0,53)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	8 (80,0)
Mean (SD)	0,88 (0,83)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	4 (57,1)
Mean (SD)	0,25 (0,50)
Median (Min - Max)	0,00 [0,00-1,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,25 (1,26)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	2 (100,0)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Relapse	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	1,16 (1,12)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
Patients in analysis set	104
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	104
Treated patients with non-missing values - n(%)	91 (87,5)
Mean (SD)	0,63 (1,00)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 2 Day 1
Treated patients with non-missing values - n(%)	96
Mean (SD)	77 (80,2)
Median (Min - Max)	0,13 (0,98)
	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 3 Day 1
Treated patients with non-missing values - n(%)	73
Mean (SD)	56 (76,7)
Median (Min - Max)	0,32 (1,15)
	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 4 Day 1
Treated patients with non-missing values - n(%)	55
Mean (SD)	43 (78,2)
Median (Min - Max)	0,72 (1,24)
	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 5 Day 1
	40

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	35 (87,5)
Mean (SD)	0,80 (0,99)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	30
Treated patients with non-missing values - n(%)	24 (80,0)
Mean (SD)	0,83 (1,27)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 7 Day 1
Treated patients with non-missing values - n(%)	26
Mean (SD)	22 (84,6)
Median (Min - Max)	0,59 (1,14)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 8 Day 1
Treated patients with non-missing values - n(%)	22
Mean (SD)	16 (72,7)
Median (Min - Max)	1,00 (1,21)
	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 9 Day 1
Treated patients with non-missing values - n(%)	17
Mean (SD)	13 (76,5)
Median (Min - Max)	0,62 (1,33)
	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	Cycle 10 Day 1
	13

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	7 (53,8)
Mean (SD)	0,86 (1,35)
Median (Min - Max)	1,00 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	7 (63,6)
Mean (SD)	0,43 (0,98)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	11
Treated patients with non-missing values - n(%)	5 (45,5)
Mean (SD)	0,60 (1,14)
Median (Min - Max)	1,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	9
Treated patients with non-missing values - n(%)	5 (55,6)
Mean (SD)	0,40 (0,55)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	6
Treated patients with non-missing values - n(%)	2 (33,3)
Mean (SD)	0,50 (0,71)
Median (Min - Max)	0,50 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,33 (1,15)
Median (Min - Max)	2,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	2,00 (0,00)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	1 (33,3)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS16: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Response category - any line	Loncastuximab tesirine Data-cut 3
Response category - any line:	
Refractory	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 22 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	0 (0,0)
Mean (SD)	
Median (Min - Max)	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	67 (64,4)
Mean (SD)	0,61 (1,31)
Median (Min - Max)	0,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

4.14.17 Merkmal: Vorherige CAR-T-Therapie

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
Patients in analysis set	8
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	8
Treated patients with non-missing values - n(%)	8 (100,0)
Mean (SD)	0,75 (0,89)
Median (Min - Max)	0,50 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 2 Day 1
Treated patients at visit	6
Treated patients with non-missing values - n(%)	6 (100,0)
Mean (SD)	0,50 (1,64)
Median (Min - Max)	0,50 [-2,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 3 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,25 (1,26)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 4 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	0,50 (1,00)
Median (Min - Max)	0,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (1,53)
Median (Min - Max)	1,00 [-1,00-2,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	0,67 (2,08)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,00 (2,00)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,00 (2,00)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
Yes	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	1,00 (NE)
Median (Min - Max)	1,00 [1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	2,00 (NE)
Median (Min - Max)	2,00 [2,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	6 (75,0)
Mean (SD)	0,67 (1,21)
Median (Min - Max)	0,00 [0,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
Patients in analysis set	122
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	122
Treated patients with non-missing values - n(%)	109 (89,3)
Mean (SD)	0,60 (0,97)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	110
Treated patients with non-missing values - n(%)	91 (82,7)
Mean (SD)	0,16 (0,96)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	82
Treated patients with non-missing values - n(%)	62 (75,6)
Mean (SD)	0,35 (1,07)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	63
Treated patients with non-missing values - n(%)	48 (76,2)
Mean (SD)	0,75 (1,19)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 5 Day 1	
Treated patients at visit	46

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	38 (82,6)
Mean (SD)	0,76 (0,94)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	33
Treated patients with non-missing values - n(%)	26 (78,8)
Mean (SD)	0,92 (1,16)
Median (Min - Max)	1,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 7 Day 1
Treated patients at visit	26
Treated patients with non-missing values - n(%)	22 (84,6)
Mean (SD)	0,59 (1,01)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 8 Day 1
Treated patients at visit	22
Treated patients with non-missing values - n(%)	16 (72,7)
Mean (SD)	0,88 (1,02)
Median (Min - Max)	1,00 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 9 Day 1
Treated patients at visit	19
Treated patients with non-missing values - n(%)	15 (78,9)
Mean (SD)	0,40 (1,06)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 10 Day 1
Treated patients at visit	14

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (57,1)
Mean (SD)	0,75 (1,28)
Median (Min - Max)	0,50 [-1,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	8 (66,7)
Mean (SD)	0,38 (0,92)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	12
Treated patients with non-missing values - n(%)	6 (50,0)
Mean (SD)	0,17 (0,75)
Median (Min - Max)	0,00 [-1,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	0,33 (0,52)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS17: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Prior use of T-CART therapy	Loncastuximab tesirine Data-cut 3
Prior use of T-CART therapy:	
No	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	84 (68,9)
Mean (SD)	0,73 (1,33)
Median (Min - Max)	1,00 [-4,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

4.14.18 Merkmal: Arzneimittelformulierung

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
Patients in analysis set	32
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	32
Treated patients with non-missing values - n(%)	30 (93,8)
Mean (SD)	0,27 (0,58)
Median (Min - Max)	0,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 2 Day 1	
Treated patients at visit	28
Treated patients with non-missing values - n(%)	26 (92,9)
Mean (SD)	0,23 (0,71)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 3 Day 1	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	19 (90,5)
Mean (SD)	0,53 (0,84)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Cycle 4 Day 1	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	16 (94,1)
Mean (SD)	0,75 (1,13)
Median (Min - Max)	1,00 [-1,00-4,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
FACT-Lym question bothered by side effects - Change from baseline	Cycle 5 Day 1
Treated patients at visit	11
Treated patients with non-missing values - n(%)	11 (100,0)
Mean (SD)	1,09 (1,14)
Median (Min - Max)	1,00 [0,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,60 (1,34)
Median (Min - Max)	1,00 [1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	5
Treated patients with non-missing values - n(%)	5 (100,0)
Mean (SD)	1,40 (0,89)
Median (Min - Max)	1,00 [1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	4 (100,0)
Mean (SD)	1,75 (0,96)
Median (Min - Max)	1,50 [1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	3 (100,0)
Mean (SD)	1,33 (1,15)
Median (Min - Max)	2,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	3,00 (NE)
Median (Min - Max)	3,00 [3,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Frozen liquid	
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	22 (68,8)
Mean (SD)	1,09 (1,11)
Median (Min - Max)	1,00 [-1,00-4,00]

 Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
Patients in analysis set	98
FACT-Lym question bothered by side effects	Baseline
Treated patients at visit	98
Treated patients with non-missing values - n(%)	87 (88,8)
Mean (SD)	0,72 (1,04)
Median (Min - Max)	0,00 [0,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	88
Treated patients with non-missing values - n(%)	71 (80,7)
Mean (SD)	0,17 (1,10)
Median (Min - Max)	0,00 [-3,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	65
Treated patients with non-missing values - n(%)	47 (72,3)
Mean (SD)	0,28 (1,16)
Median (Min - Max)	0,00 [-3,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	50
Treated patients with non-missing values - n(%)	36 (72,0)
Mean (SD)	0,72 (1,21)
Median (Min - Max)	0,00 [-1,00-4,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	38

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	30 (78,9)
Mean (SD)	0,63 (0,89)
Median (Min - Max)	0,50 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 6 Day 1
Treated patients at visit	31
Treated patients with non-missing values - n(%)	24 (77,4)
Mean (SD)	0,75 (1,19)
Median (Min - Max)	1,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	24
Treated patients with non-missing values - n(%)	20 (83,3)
Mean (SD)	0,45 (1,10)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	21
Treated patients with non-missing values - n(%)	15 (71,4)
Mean (SD)	0,67 (1,11)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	17
Treated patients with non-missing values - n(%)	13 (76,5)
Mean (SD)	0,38 (1,19)
Median (Min - Max)	0,00 [-1,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	14

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	8 (57,1)
Mean (SD)	0,50 (0,93)
Median (Min - Max)	0,50 [-1,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 11 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	9 (69,2)
Mean (SD)	0,44 (0,88)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 12 Day 1
Treated patients at visit	13
Treated patients with non-missing values - n(%)	7 (53,8)
Mean (SD)	0,43 (0,98)
Median (Min - Max)	0,00 [-1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 13 Day 1
Treated patients at visit	10
Treated patients with non-missing values - n(%)	6 (60,0)
Mean (SD)	0,33 (0,52)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 14 Day 1
Treated patients at visit	7
Treated patients with non-missing values - n(%)	3 (42,9)
Mean (SD)	0,33 (0,58)
Median (Min - Max)	0,00 [0,00-1,00]
FACT-Lym question bothered by side effects - Change from baseline	Cycle 15 Day 1
Treated patients at visit	5

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	4 (80,0)
Mean (SD)	1,00 (1,15)
Median (Min - Max)	1,00 [0,00-2,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 16 Day 1
Treated patients at visit	4
Treated patients with non-missing values - n(%)	3 (75,0)
Mean (SD)	1,67 (0,58)
Median (Min - Max)	2,00 [1,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	4
Treated patients with non-missing values - n(%)	2 (50,0)
Mean (SD)	1,00 (1,41)
Median (Min - Max)	1,00 [0,00-2,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	3
Treated patients with non-missing values - n(%)	2 (66,7)
Mean (SD)	1,50 (2,12)
Median (Min - Max)	1,50 [0,00-3,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 21 Day 1
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	2
Treated patients with non-missing values - n(%)	1 (50,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	
Treated patients at visit	1

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
PRO = patient reported outcome.
Source Data: aqs, created on: 10JAN2023

Table LT3FAC_PSHS18: FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation
 PRO set

FACT-Lym question bothered by side effects - Change from Baseline by subgroup: Drug formulation	Loncastuximab tesirine Data-cut 3
Drug formulation:	
Lyophilized	
FACT-Lym question bothered by side effects - Change from baseline	Cycle 26 Day 1
Treated patients at visit	1
Treated patients with non-missing values - n(%)	1 (100,0)
Mean (SD)	0,00 (NE)
Median (Min - Max)	0,00 [0,00-0,00]
FACT-Lym question bothered by side effects - Change from baseline	EOT
Treated patients at visit	NE
Treated patients with non-missing values - n(%)	68 (69,4)
Mean (SD)	0,60 (1,36)
Median (Min - Max)	0,00 [-4,00-3,00]

Note: SD = Standard deviation. NE = Not evaluable. EoT = End of treatment.
 PRO = patient reported outcome.
 Source Data: aqs, created on: 10JAN2023